<SEC-DOCUMENT>0001384101-20-000015.txt : 20200225
<SEC-HEADER>0001384101-20-000015.hdr.sgml : 20200225
<ACCEPTANCE-DATETIME>20200225162929
ACCESSION NUMBER:		0001384101-20-000015
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200225
DATE AS OF CHANGE:		20200225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VERACYTE, INC.
		CENTRAL INDEX KEY:			0001384101
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				205455398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36156
		FILM NUMBER:		20651079

	BUSINESS ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 243-6300

	MAIL ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALDEROME INC
		DATE OF NAME CHANGE:	20061219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vcyt-12312019x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:1cc053bb2e7b4a868f17d605d9c2ff47,x:b0c5f1e435cb4a4ea4ea3268f56fa29f-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:vcyt="http://www.veracyte.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:AmendmentFlag" id="Fact-C7EA9DFA9C8BE8590193C7EB69C80BAB-wk-Fact-C7EA9DFA9C8BE8590193C7EB69C80BAB" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-380BBE08AF5DD2F1D519C7EB69D986BB-wk-Fact-380BBE08AF5DD2F1D519C7EB69D986BB">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-EDFA1D3C675E6D54DB37C7EB69E2C3A7-wk-Fact-EDFA1D3C675E6D54DB37C7EB69E2C3A7">FY</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalYearFocus" id="Fact-83D83527B2B33180D8E5C7EB69E6045D-wk-Fact-83D83527B2B33180D8E5C7EB69E6045D">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:EntityCentralIndexKey" id="Fact-514BC3B61EB72EA0C76EC7EB69CF072B-wk-Fact-514BC3B61EB72EA0C76EC7EB69CF072B">0001384101</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" id="Fact-BB4577F093D304D63008E7D6651DAD6A-wk-Fact-BB4577F093D304D63008E7D6651DAD6A">3890000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q4YTD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" id="Fact-C97A52A613BE38A64032C7EB69DC5FC2-wk-Fact-C97A52A613BE38A64032C7EB69DC5FC2">9208000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-1F3F9FDD8ED170D3A3D6C7EB69EC5991-wk-Fact-1F3F9FDD8ED170D3A3D6C7EB69EC5991">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-72B62572941C0B0AE68DC7EB69E72C8B-wk-Fact-72B62572941C0B0AE68DC7EB69E72C8B">125000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-C5239A8A8FC0DA2B15107BCC65802ED0-wk-Fact-C5239A8A8FC0DA2B15107BCC65802ED0">40863202</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-722F3348297ADD6EE30E7BCC657024CD-wk-Fact-722F3348297ADD6EE30E7BCC657024CD">49625341</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-4902A9021E862852F2747BCC658D02D6-wk-Fact-4902A9021E862852F2747BCC658D02D6">40863202</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-7FE8575D8AD272FA79E57BCC6587B8DA-wk-Fact-7FE8575D8AD272FA79E57BCC6587B8DA">49625341</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-62BF053D1FD67F1D53FC5397047267C4-wk-Fact-62BF053D1FD67F1D53FC5397047267C4">P5Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2017Q4YTD" name="us-gaap:GoodwillImpairmentLoss" id="Fact-DDE0194F530D9E849A5AC7EB69CD07D6-wk-Fact-DDE0194F530D9E849A5AC7EB69CD07D6">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:GoodwillImpairmentLoss" id="Fact-90948CB52A7F288E93BAC7EB69C60A5D-wk-Fact-90948CB52A7F288E93BAC7EB69C60A5D">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2017Q4YTD" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" id="Fact-228AC9F46CDCD8B88DEAC7EB69D0D4DB-wk-Fact-228AC9F46CDCD8B88DEAC7EB69D0D4DB">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" id="Fact-806EC5A991D9C6F510A8C7EB69C19174-wk-Fact-806EC5A991D9C6F510A8C7EB69C19174">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2017Q4YTD" name="us-gaap:IncomeTaxExpenseBenefit" id="Fact-E712606F0D6A842AD3B1C7EB69D9A019-wk-Fact-E712606F0D6A842AD3B1C7EB69D9A019">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:IncomeTaxExpenseBenefit" id="Fact-478657FB290362098FB7C7EB69D83CF9-wk-Fact-478657FB290362098FB7C7EB69D83CF9">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2016Q3QTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" name="us-gaap:PaidInKindInterest" id="Fact-5ABC214C47CA6D157180C7EB6A16DE91-wk-Fact-5ABC214C47CA6D157180C7EB6A16DE91">385000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-7942ED17154389051FBAC7EB69F0EA1A-wk-Fact-7942ED17154389051FBAC7EB69F0EA1A">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-1A77A9339CC21D1A8AB9C7EB69F39E28-wk-Fact-1A77A9339CC21D1A8AB9C7EB69F39E28">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-CF6EDC76A3930D2C8B20C7EB69EEC456-wk-Fact-CF6EDC76A3930D2C8B20C7EB69EEC456">5000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-6DA7D367331ECDD6A7CDC7EB69EB7424-wk-Fact-6DA7D367331ECDD6A7CDC7EB69EB7424">5000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-2DE4E8A7F6F6F713FACFC7EB69EDB582-wk-Fact-2DE4E8A7F6F6F713FACFC7EB69EDB582">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-EBB545C5209BB9582E04C7EB69F0F0D2-wk-Fact-EBB545C5209BB9582E04C7EB69F0F0D2">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-E56FA1E4000E91FFEF99C7EB69EA6CD1-wk-Fact-E56FA1E4000E91FFEF99C7EB69EA6CD1">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-9188E838628B9591FD21C7EB69E93329-wk-Fact-9188E838628B9591FD21C7EB69E93329">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-A20863AEBA0936AEBC60C802D4007815-wk-Fact-A20863AEBA0936AEBC60C802D4007815">P3Y</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" name="us-gaap:SecurityDeposit" id="Fact-5123A7D92BA0BB51327CC7EB69D08693-wk-Fact-5123A7D92BA0BB51327CC7EB69D08693">603000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_LaboratoryFacilitiesAustinTexasMember" name="us-gaap:SecurityDeposit" id="Fact-8FC288A6C3FCD991044EC7EB69D4E961-wk-Fact-8FC288A6C3FCD991044EC7EB69D4E961">139000</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-E72EE3BE20076D6D5068C7EB69C91AD7-wk-Fact-E72EE3BE20076D6D5068C7EB69C91AD7">0.4386</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-37BD2986117B8A7E0B40C7EB69DFBDF3-wk-Fact-37BD2986117B8A7E0B40C7EB69DFBDF3">0.5240</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-7B2A83E32CAE36EA7232C7EB69F3A8EC-wk-Fact-7B2A83E32CAE36EA7232C7EB69F3A8EC">0.5110</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-54D4A630D5E82B822D57C7EB69CEC98C-wk-Fact-54D4A630D5E82B822D57C7EB69CEC98C">0.4774</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-D012DEB4490BE2619736C7EB69DF410E-wk-Fact-D012DEB4490BE2619736C7EB69DF410E">0.5270</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-21E63619C61E27C8DC71C7EB69E5E81E-wk-Fact-21E63619C61E27C8DC71C7EB69E5E81E">0.5050</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-03E19714845A995BED77C7EB69D10A68-wk-Fact-03E19714845A995BED77C7EB69D10A68">0.7177</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-5D2050442196E735D5DBC7EB69DF5342-wk-Fact-5D2050442196E735D5DBC7EB69DF5342">0.5340</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-B79456F34F80AC0288EAC7EB69E090F0-wk-Fact-B79456F34F80AC0288EAC7EB69E090F0">0.0000</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-42B327FD81544C355C46C7EB69C77BEF-wk-Fact-42B327FD81544C355C46C7EB69C77BEF">0.3700</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-2595332A975F3CFEE5F3C7EB69E02806-wk-Fact-2595332A975F3CFEE5F3C7EB69E02806">0.5040</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-3B071F91C7D2AD6D06AFC7EB69ED055C-wk-Fact-3B071F91C7D2AD6D06AFC7EB69ED055C">0.5040</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-39738B14B4D76E4DF22EC7EB69D3C43E-wk-Fact-39738B14B4D76E4DF22EC7EB69D3C43E">0.4288</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-95D70EB55CDCC51A618CC7EB69DD5F18-wk-Fact-95D70EB55CDCC51A618CC7EB69DD5F18">0.5040</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-9808A69AD09E59281B91C7EB69E228F9-wk-Fact-9808A69AD09E59281B91C7EB69E228F9">0.4360</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-F72F98B0F6F747B6FEE5C7EB69CC15CC-wk-Fact-F72F98B0F6F747B6FEE5C7EB69CC15CC">0.5338</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-C9857DA5A7867ED7EB23C7EB69DE899D-wk-Fact-C9857DA5A7867ED7EB23C7EB69DE899D">0.5290</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-0119050365A363787CA2C7EB69E6213C-wk-Fact-0119050365A363787CA2C7EB69E6213C">0.0000</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-0DE3C0F2BF7062A1387BC7EB69D0A070-wk-Fact-0DE3C0F2BF7062A1387BC7EB69D0A070">0.0122</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-B0D42CDE0C3B6D52E001C7EB69DDFC36-wk-Fact-B0D42CDE0C3B6D52E001C7EB69DDFC36">0.0233</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-F4F0F104CBF0922B1982C7EB69E577B0-wk-Fact-F4F0F104CBF0922B1982C7EB69E577B0">0.0237</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-2D80B360E1876AB5E601C7EB69CAF349-wk-Fact-2D80B360E1876AB5E601C7EB69CAF349">0.0245</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-72AE6C6BC89952195926C7EB69DD8C4B-wk-Fact-72AE6C6BC89952195926C7EB69DD8C4B">0.0310</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-FAC98266426F800F35DDC7EB69EC3AFE-wk-Fact-FAC98266426F800F35DDC7EB69EC3AFE">0.0287</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-E345FC6D1897A2342CEBC7EB69CED2AB-wk-Fact-E345FC6D1897A2342CEBC7EB69CED2AB">0.0256</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-35FFE1675CC9C9414BD8C7EB69DD9D92-wk-Fact-35FFE1675CC9C9414BD8C7EB69DD9D92">0.0260</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-FE3F4421651C416BDBB5C7EB69ED9E61-wk-Fact-FE3F4421651C416BDBB5C7EB69ED9E61">0.0000</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-1833961D76C5434DD449C7EB69CA6C25-wk-Fact-1833961D76C5434DD449C7EB69CA6C25">0.0065</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-1BB9EAC36F08484908C8C7EB69DF88E9-wk-Fact-1BB9EAC36F08484908C8C7EB69DF88E9">0.0180</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-3A44D78F3875DC03402AC7EB69EA8B29-wk-Fact-3A44D78F3875DC03402AC7EB69EA8B29">0.0216</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-4AA548C01CA48B727EF8C7EB69C99B9A-wk-Fact-4AA548C01CA48B727EF8C7EB69C99B9A">0.0164</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-CA607BB5AF5B897D2A8EC7EB69DC4614-wk-Fact-CA607BB5AF5B897D2A8EC7EB69DC4614">0.0240</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-E3E5DC2EF42B4B17088CC7EB69EA14F9-wk-Fact-E3E5DC2EF42B4B17088CC7EB69EA14F9">0.0184</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-8481D96329510AC93043C7EB69C90ED8-wk-Fact-8481D96329510AC93043C7EB69C90ED8">0.0188</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-058E4679E5F3BE02BBF3C7EB69E0B042-wk-Fact-058E4679E5F3BE02BBF3C7EB69E0B042">0.0190</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-3F6D304D1E4B6FFB5A4CC7EB69E15600-wk-Fact-3F6D304D1E4B6FFB5A4CC7EB69E15600">0.0000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-28CCB9A9E9DC1E513C28C7EB69DFFAE2-wk-Fact-28CCB9A9E9DC1E513C28C7EB69DFFAE2">0.33</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-5664806DF8EC3A69CE4DC7EB69E1746C-wk-Fact-5664806DF8EC3A69CE4DC7EB69E1746C">0.33</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-F79C2EE0FCDF6C522413C7EB69DFC730-wk-Fact-F79C2EE0FCDF6C522413C7EB69DFC730">0.33</ix:nonFraction><ix:nonNumeric contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-7C1AB79275FB505CBC22C7EB69CFBF2E-wk-Fact-7C1AB79275FB505CBC22C7EB69CFBF2E">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-5FB4686527A5FEA19D88C7EB69E138FF-wk-Fact-5FB4686527A5FEA19D88C7EB69E138FF">P6Y29D</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-A25842AB400DF5F15E5DC7EB69EFAAB2-wk-Fact-A25842AB400DF5F15E5DC7EB69EFAAB2">P7Y9M</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-5DF1CB35A5228C3ABFE0C7EB69CBB886-wk-Fact-5DF1CB35A5228C3ABFE0C7EB69CBB886">P6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-951D35523C019B6123B6C7EB69DD02CC-wk-Fact-951D35523C019B6123B6C7EB69DD02CC">P5Y6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-C7CC70CDEBEC81946E4DC7EB69EBD230-wk-Fact-C7CC70CDEBEC81946E4DC7EB69EBD230">P6Y9M18D</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-22234B2CC7C92795CFFEC7EB69CD8BD7-wk-Fact-22234B2CC7C92795CFFEC7EB69CD8BD7">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-A115A1D1361912B43287C7EB69E0254E-wk-Fact-A115A1D1361912B43287C7EB69E0254E">P6Y29D</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-D4C0CC99C38484E58BB0C7EB69E0792A-wk-Fact-D4C0CC99C38484E58BB0C7EB69E0792A">P6Y9M</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-5E0867889770575BCF05C7EB69C91C6C-wk-Fact-5E0867889770575BCF05C7EB69C91C6C">P6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-F8373E9A0E584BA22CD8C7EB69DFE9F8-wk-Fact-F8373E9A0E584BA22CD8C7EB69DFE9F8">P5Y6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-6358043445D40868313AC7EB69E5F55A-wk-Fact-6358043445D40868313AC7EB69E5F55A">P3M</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-63F83846DEA9D693DF1EC7EB69CDA0E9-wk-Fact-63F83846DEA9D693DF1EC7EB69CDA0E9">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-9F4DA860C72A2EF27BC9C7EB69DC8AE1-wk-Fact-9F4DA860C72A2EF27BC9C7EB69DC8AE1">P6Y29D</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-FFC946AA97E2E941C295C7EB69E70A14-wk-Fact-FFC946AA97E2E941C295C7EB69E70A14">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-DBFA6CDAB2FEE0C53F9CC7EB69CC94D7-wk-Fact-DBFA6CDAB2FEE0C53F9CC7EB69CC94D7">P6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-7EDA898231FB57D8D2B7C7EB69DCA758-wk-Fact-7EDA898231FB57D8D2B7C7EB69DCA758">P5Y6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-11FB1F608F962657D0F0C7EB69EC7AE8-wk-Fact-11FB1F608F962657D0F0C7EB69EC7AE8">P0Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" id="Fact-4B88507127CB42F9473FC7EB69E13E42-wk-Fact-4B88507127CB42F9473FC7EB69E13E42">1</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" name="vcyt:IncomeTaxExaminationPeriod" id="Fact-2EF8D3875E6527A08C57C808C5DCE0DC-wk-Fact-2EF8D3875E6527A08C57C808C5DCE0DC">P3Y</ix:nonNumeric><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" name="vcyt:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne" id="Fact-3F32EE6829DD01E7ABD9C7EB69E1F42B-wk-Fact-3F32EE6829DD01E7ABD9C7EB69E1F42B">0.25</ix:nonFraction><ix:nonNumeric contextRef="D2018Q2Apr09_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember" name="vcyt:TermContractAgreement" id="Fact-0809570B5CBA5DC81C01C80CAA02A78B-wk-Fact-0809570B5CBA5DC81C01C80CAA02A78B">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="vcyt-20191231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_vcyt_SalesRevenueGrossMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">vcyt:SalesRevenueGrossMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Feb20">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2May07">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-05-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3July">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_MajorCustomersAxis_vcyt_Perceptav.2andNassaRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:Perceptav.2andNassaRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May07">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-07</xbrli:startDate>
			<xbrli:endDate>2019-05-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_srt_ProductOrServiceAxis_vcyt_ProvisionofDataMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:ProvisionofDataMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-28</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_srt_ProductOrServiceAxis_vcyt_FulfillmentofObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:FulfillmentofObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Jul31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr09_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-09</xbrli:startDate>
			<xbrli:endDate>2018-04-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May07_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-07</xbrli:startDate>
			<xbrli:endDate>2019-05-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Dec28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-28</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-03</xbrli:startDate>
			<xbrli:endDate>2019-12-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-03</xbrli:startDate>
			<xbrli:endDate>2019-12-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-03</xbrli:startDate>
			<xbrli:endDate>2019-12-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-03</xbrli:startDate>
			<xbrli:endDate>2019-12-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-03</xbrli:startDate>
			<xbrli:endDate>2019-12-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-03</xbrli:startDate>
			<xbrli:endDate>2019-12-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsLeasedToOthersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsLeasedToOthersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsLeasedToOthersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsLeasedToOthersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_vcyt_OvernightRepurchaseAgreementsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_vcyt_OvernightRepurchaseAgreementsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_LaboratoryFacilitiesAustinTexasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:LaboratoryFacilitiesAustinTexasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_LaboratoryFacilitiesAustinTexasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:LaboratoryFacilitiesAustinTexasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-03</xbrli:startDate>
			<xbrli:endDate>2017-11-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan01-Jan31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May2019_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Nov3_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-03</xbrli:startDate>
			<xbrli:endDate>2017-11-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Nov3_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-03</xbrli:startDate>
			<xbrli:endDate>2017-11-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Mar30-Mar30_us-gaap_DebtInstrumentAxis_vcyt_InitialTermLoanMember_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vcyt:InitialTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-03-30</xbrli:startDate>
			<xbrli:endDate>2016-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2QTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorWhoWasNotPreviouslyEmployeeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonStatutoryStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockPlan2008Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-02-01</xbrli:startDate>
			<xbrli:endDate>2008-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2013Q4Oct31_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockPlan2008Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-02-01</xbrli:startDate>
			<xbrli:endDate>2008-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockPlan2008Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-02-01</xbrli:startDate>
			<xbrli:endDate>2008-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockPlan2008Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-02-01</xbrli:startDate>
			<xbrli:endDate>2008-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonStatutoryStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_stpr_CA_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_vcyt_OtherStatesNotSeparatelyDisclosedMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:OtherStatesNotSeparatelyDisclosedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="term_loan">
		<xbrli:measure>vcyt:term_loan</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="financial_institution">
		<xbrli:measure>vcyt:financial_institution</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>vcyt:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="installment">
		<xbrli:measure>vcyt:installment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="program">
		<xbrli:measure>vcyt:program</xbrli:measure>
	</xbrli:unit><xbrli:unit id="vote">
		<xbrli:measure>vcyt:vote</xbrli:measure>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s876F5D903AB04F3803A9428AFA00F069"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;font-weight:bold;">Form&#160;</span><span><ix:nonNumeric id="d32763161e726-wk-Fact-E619E94F65725AB5DA87C8143D3546CB" name="dei:DocumentType" contextRef="FD2019Q4YTD"><span style="font-size:14pt;font-weight:bold;">10-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:14pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:0px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Mark&#160;One)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;"><span><ix:nonNumeric id="d32763161e748-wk-Fact-18FA9A33AB647F334279C814EBADDB31" name="dei:DocumentAnnualReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the fiscal year ended </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d32763161e760-wk-Fact-142D2631C617238DFE5BC89C58F6F353" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q4YTD" format="ixt:datemonthdayyearen">December 31, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> or</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;"><span><ix:nonNumeric id="d32763161e777-wk-Fact-5C34545CB0D36C518CC8C8170C9FEF57" name="dei:DocumentTransitionReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commission File Number&#160;</span><span><ix:nonNumeric id="d32763161e796-wk-Fact-1BF3FEFDB2AB73D67BC8C8182D67B293" name="dei:EntityFileNumber" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">001-36156</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><span><ix:nonNumeric id="d32763161e804-wk-Fact-909AAA00504913C9C1D0C8189C73CCFF" name="dei:EntityRegistrantName" contextRef="FD2019Q4YTD"><span style="font-size:16pt;font-weight:bold;">VERACYTE,&#160;INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:16pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:15%;"></td><td style="width:34%;"></td><td style="width:3%;"></td><td style="width:34%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d32763161e833-wk-Fact-61B39289A743983F7C01C82137D539AD" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d32763161e843-wk-Fact-D70F937AC9AA7F971F6FC8215F19FA62" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q4YTD">20-5455398</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(State or Other Jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Incorporation or Organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Identification Number)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span><ix:nonNumeric id="d32763161e885-wk-Fact-FD4F7CA128ADE150852AC821C44981EB" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">6000 Shoreline Court,</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d32763161e890-wk-Fact-E8FA9EDE4E7BD9E7BB32C822159D6D54" name="dei:EntityAddressAddressLine2" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">Suite&#160;300</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span><ix:nonNumeric id="d32763161e896-wk-Fact-15A7EBB5394894D0C476C8226A746CDC" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">South San Francisco,</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d32763161e901-wk-Fact-F2DBBE8A4ABC9B3CDF7AC8229D3CB902" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen"><span style="font-size:8pt;font-weight:bold;">California</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d32763161e906-wk-Fact-F04F79C08EFCFCF42810C822EC2C8CE6" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">94080</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Address of Principal Executive Offices, Including Zip Code)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d32763161e920-wk-Fact-3C78E465746CD6FAF38EC8234BD41A91" name="dei:CityAreaCode" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">650</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">)&#160;</span><span><ix:nonNumeric id="d32763161e925-wk-Fact-A92FD40BD36F3CBD29FEC8238F0C14AA" name="dei:LocalPhoneNumber" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">243-6300</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Registrant's Telephone Number, Including Area Code)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Securities Registered Pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32763161e982-wk-Fact-758044072AF54820B50FC8243506D695" name="dei:Security12bTitle" contextRef="FD2019Q4YTD">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32763161e992-wk-Fact-4D57BF2179693589BB0DC8246173BE53" name="dei:TradingSymbol" contextRef="FD2019Q4YTD">VCYT</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32763161e1002-wk-Fact-3F31642CA396FFEE51E8C824835AEB8C" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:36px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Securities Registered Pursuant to Section&#160;12(g) of the Act: </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">None</span></div><div style="line-height:120%;text-align:center;text-indent:36px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;</span><span><ix:nonNumeric id="d32763161e1016-wk-Fact-A95D3A237053ABF080F8C82E3782EB3A" name="dei:EntityWellKnownSeasonedIssuer" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;Yes&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d32763161e1037-wk-Fact-1D805A960BA4A992313BC8320E8B45CD" name="dei:EntityVoluntaryFilers" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">No</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><span><ix:nonNumeric id="d32763161e1049-wk-Fact-5F19ADBAA4D5296AE4C5C833930E0496" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;</span><span><ix:nonNumeric id="d32763161e1065-wk-Fact-F6600292B03DD7A51214C834CC76629D" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:31%;"></td><td style="width:3%;"></td><td style="width:30%;"></td><td style="width:3%;"></td><td style="width:30%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonNumeric id="d32763161e1097-wk-Fact-F56B5E7EAF700409F7B8C837FD32F5D8" name="dei:EntityFilerCategory" contextRef="FD2019Q4YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated&#160;filer&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;font-weight:bold;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-accelerated&#160;filer&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;font-weight:bold;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d32763161e1153-wk-Fact-8B0575252897F2621396C83BA52598CB" name="dei:EntitySmallBusiness" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d32763161e1184-wk-Fact-3E3177F1656528BE796BC83BCFF357CF" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;</span><span><ix:nonNumeric id="d32763161e1199-wk-Fact-169CCC5237C389837BE6C83CB04667AE" name="dei:EntityShellCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:8pt;">, the aggregate market value of common stock held by non-affiliates of the registrant was approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d32763161e1216-wk-Fact-67348B753E31A73577BDC7EB69D6F7E2" name="dei:EntityPublicFloat" contextRef="FI2019Q2" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;">, based on the closing price of the common stock as reported on the Nasdaq Global Market for that date.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The number of shares of the registrant's Common Stock outstanding as of </span><span style="font-family:inherit;font-size:8pt;">February&#160;20, 2020</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32763161e1229-wk-Fact-26FDF92B768DB3E7249FC7EB69E7C3CB" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q1Feb20" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">49,738,822</ix:nonFraction></span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="TextSelection-C8A953BBB8E4B67A855DC83FD76C3AE9-0-wk-Fact-8F6F501386931F13507BC83FE8A3911C" continuedAt="TextSelection-C8A953BBB8E4B67A855DC83FD76C3AE9-1" escape="true"><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></ix:nonNumeric><div><br/></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-C8A953BBB8E4B67A855DC83FD76C3AE9-1"><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Portions of the registrant's proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for the registrant's 2020 Annual Meeting of Stockholders to be held on or about June 5, 2020 are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2019.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sEFDB29A731B62A077FF4428B070FCFF4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:87%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Item No.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Page No.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6F58CC469B0C494B78D1428B0741631C"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0DBC7C8878DCE993036B428B07639C81"><span style="font-family:inherit;font-size:10pt;">Item&#160;1. Business</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0DBC7C8878DCE993036B428B07639C81">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s56DE957E174475B6100E428B0795CC56"><span style="font-family:inherit;font-size:10pt;">Item&#160;1A. Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s56DE957E174475B6100E428B0795CC56">26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s916413EAA5B188F3A489428B07B7D9C6"><span style="font-family:inherit;font-size:10pt;">Item&#160;1B. Unresolved Staff Comments</span></a><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s916413EAA5B188F3A489428B07B7D9C6">51</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s46EF60DFEEA94DE1D371428B07E762F2"><span style="font-family:inherit;font-size:10pt;">Item&#160;2. Properties</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s46EF60DFEEA94DE1D371428B07E762F2">51</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2D35C462BA3E42B5E4AB428B08086768"><span style="font-family:inherit;font-size:10pt;">Item&#160;3. Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2D35C462BA3E42B5E4AB428B08086768">52</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA85903A8D1716D30D85F428B083BE56B"><span style="font-family:inherit;font-size:10pt;">Item&#160;4. Mine Safety Disclosure</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA85903A8D1716D30D85F428B083BE56B">52</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s816D613C06678C2588DF428B085DBF1D"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2F014EBF55B684F90AA1428AFF97FEA9"><span style="font-family:inherit;font-size:10pt;">Item&#160;5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2F014EBF55B684F90AA1428AFF97FEA9">52</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF747408585A999B7C4E2428AFA1B0B21"><span style="font-family:inherit;font-size:10pt;">Item&#160;6. Selected Financial Data</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF747408585A999B7C4E2428AFA1B0B21">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB94196C0F8241CCFB6C6428AFE50B99B"><span style="font-family:inherit;font-size:10pt;">Item&#160;7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB94196C0F8241CCFB6C6428AFE50B99B">56</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2F57DC36EFF9B6A98088428B095524EF"><span style="font-family:inherit;font-size:10pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2F57DC36EFF9B6A98088428B095524EF">73</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1837B6F1B0F8DCBCDABB428B095B6AFE"><span style="font-family:inherit;font-size:10pt;">Item&#160;8. Financial Statements and Supplementary Data</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1837B6F1B0F8DCBCDABB428B095B6AFE">74</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s625A924426068315B080428B0E8C728B"><span style="font-family:inherit;font-size:10pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s625A924426068315B080428B0E8C728B">108</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8CAEE5D98F0AD75DEBB3428B0EBF2FD5"><span style="font-family:inherit;font-size:10pt;">Item&#160;9A. Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8CAEE5D98F0AD75DEBB3428B0EBF2FD5">108</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE602F25C2B72CFF3E9B6428B0EDF801E"><span style="font-family:inherit;font-size:10pt;">Item&#160;9B. Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE602F25C2B72CFF3E9B6428B0EDF801E">110</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s1191F7D3C499A5756101428B0F137650"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s17735FADC8734C128EBF428B0F33F4C3"><span style="font-family:inherit;font-size:10pt;">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s17735FADC8734C128EBF428B0F33F4C3">111</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDC37643363C871A7D934428B0F64BC47"><span style="font-family:inherit;font-size:10pt;">Item&#160;11. Executive Compensation</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDC37643363C871A7D934428B0F64BC47">111</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s074085FFCCDDCD29AC6C428B0F850D86"><span style="font-family:inherit;font-size:10pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s074085FFCCDDCD29AC6C428B0F850D86">111</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAF474B99CD13CE3FDE3A428B0FC6C2F2"><span style="font-family:inherit;font-size:10pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAF474B99CD13CE3FDE3A428B0FC6C2F2">111</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6A444EBE1E84C2362F9D428B0FD9C1A1"><span style="font-family:inherit;font-size:10pt;">Item&#160;14. Principal Accountant Fees and Services</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6A444EBE1E84C2362F9D428B0FD9C1A1">111</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s3273C41ACFE1B54CF3DE428B100976A8"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s59B4F7AD48DCE2DF52F4428B102D13A6"><span style="font-family:inherit;font-size:10pt;">Item&#160;15. Exhibits, Financial Statement Schedules</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s59B4F7AD48DCE2DF52F4428B102D13A6">112</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0CF504962AE5827E5F42428B105F93F4"><span style="font-family:inherit;font-size:10pt;">Item 16. Form 10-K Summary</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0CF504962AE5827E5F42428B105F93F4">115</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sCEB843679FBE48109975428B10815692"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCEB843679FBE48109975428B10815692">115</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s6F58CC469B0C494B78D1428B0741631C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0DBC7C8878DCE993036B428B07639C81"></a></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;color:#0000ff;text-decoration:underline;">Table of Contents</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="line-height:120%;text-align:justify;padding-left:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this report, the words "expects," "anticipates," "intends," "estimates," "plans," "believes," "continuing," "ongoing," and similar expressions are intended to identify forward-looking statements. These are statements that relate to future events and include, but are not limited to, the factors that may impact our financial results; our expectations regarding revenue; our expectations with respect to our future research and development, general and administrative and selling and marketing expenses and our anticipated uses of our funds; our beliefs with respect to the optimization of our processes for the analysis of ribonucleic acid, or RNA, samples; our integration of the assets acquired from NanoString Technologies, Inc.; our ability to deploy the nCounter FLEX Analysis System successfully and run our tests on this platform worldwide; our collaboration with Johnson &amp; Johnson Services, Inc., or Johnson &amp; Johnson; our belief in the importance of maintaining libraries of clinical evidence; our expectations regarding capital expenditures; our anticipated cash needs and our estimates regarding our capital requirements; the timing and success of our transition to a single platform for all of our classifiers and tests; our ability to obtain Medicare coverage for our tests; our need for additional financing; potential future sources of cash; our business strategy and our ability to execute our strategy; our ability to achieve and maintain reimbursement from third-party payers at acceptable levels and our expectations regarding the timing of reimbursement; the estimated size of the global markets for our tests; the estimated number of patients who receive uncertain diagnoses who are candidates for our test; the attributes and potential benefits of our tests and any future tests we may develop to patients, physicians and payers; the factors we believe drive demand for and reimbursement of our tests; our ability to sustain or increase demand for our tests; our intent to expand into other clinical areas; our ability to develop new tests, and the timeframes for development or commercialization; our ability to get our data and clinical studies accepted in peer-reviewed publications; our dependence on and the terms of our strategic relationships, and the success of those relationships; our beliefs regarding our laboratory capacity; the applicability of clinical results to actual outcomes; our expectations regarding our international expansion; the occurrence, timing, outcome or success of clinical trials or studies; the ability of our tests to impact treatment decisions; our beliefs regarding our competitive position; our compliance with federal, state and international regulations; the potential impact of regulation of our tests by the Food and Drug Administration, or FDA, or other regulatory bodies; the impact of new or changing policies, regulation or legislation, or of judicial decisions, on our business; the impact of seasonal fluctuations and economic conditions on our business; our belief that we have taken reasonable steps to protect our intellectual property; our belief that our intellectual property will develop and maintain our competitive position; the impact of accounting pronouncements and our critical accounting policies, judgments, estimates, models and assumptions on our financial results; and anticipated trends and challenges in our business and the markets in which we operate.  We caution you that the foregoing list does not contain all of the forward-looking statements made in this report.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward-looking statements are based on our current plans and expectations and involve risks and uncertainties which could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those risks discussed in Part&#160;I, Item&#160;1A of this report. These forward-looking statements speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When used in this report, all references to "Veracyte," the "company," "we," "our" and "us" refer to Veracyte,&#160;Inc.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and Know by Design, and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are our trademarks. We also refer to trademarks of other corporations or organizations in this report that are the property of their respective owners.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This annual report contains statistical data and estimates that we obtained from industry publications and reports. These publications typically indicate that they have obtained their information from sources they believe to be reliable, but do not guarantee the accuracy and completeness of their information. Some data contained in this annual report is also based on our internal estimates. Although we have not independently verified the third-party data, we are responsible for its inclusion in the annual report and believe it to be reasonable.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">General</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a leading genomic diagnostics company that is creating value through innovation. We were founded in 2008 with a mission of improving diagnostic accuracy. Today, our growing menu of tests leverage advances in genomic science and technology to improve care throughout the patient journey, enabling more confident diagnostic, prognostic and treatment decisions in cancer and other challenging diseases. We are creating new standards of care by enabling more patients to avoid risks of unnecessary invasive procedures and removing costs from the healthcare system, while expediting the time to diagnosis and treatment decisions.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We perform our genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in our CLIA-certified laboratory in South San Francisco, California. In December 2019, we announced our acquisition from NanoString Technologies, Inc., or NanoString, of an exclusive global diagnostics license to the nCounter</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> FLEX Analysis System, as well as the Prosigna&#174; breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark&#8482; lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system. We believe this strategic transaction positions us to expand our business globally with a broad menu of advanced genomic tests that may be offered as distributed kits and performed in local laboratories worldwide. We believe our current and pipeline products address a collective $40 billion global market.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We develop our genomic tests to answer specific clinical questions, providing patients and physicians with a clear path forward in their diagnostic and treatment journey. We use advanced scientific methods, such as RNA whole-transcriptome sequencing and machine learning, to develop our tests and optimize the assay and classifier results for the platform on which the test will be performed. Historically, that platform has been RNA sequencing, performed in our CLIA lab. In the future, we expect this to also include the nCounter platform for international distribution of our tests.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our classifiers are designed to improve diagnostic and prognostic clarity for cancer and other diseases. In its 2015 report, &#8220;Improving Diagnostic Errors in Medicine,&#8221; the Institute of Medicine concluded that most people will experience at least one diagnostic error in their lifetime, sometimes with devastating consequences. Annually, of the hundreds of thousands of patients who are evaluated for suspected disease in our thyroid and lung indications, diagnosis can be ambiguous in 15-70% of cases. This diagnostic uncertainty can lead to additional, invasive procedures that are often unnecessary, delayed or incorrect treatment, increased healthcare costs and patient anxiety.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We position our tests to fit into the way physicians currently evaluate patients in order to facilitate adoption. We also design our tests to improve patient care and outcomes, while delivering clinical and economic utility to physicians, payers and the healthcare system in general.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our powerful scientific platform provides multiple vectors to create value for patients, providers and payers, as well as stockholders, and to help advance precision medicine:</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unique Biorepositories - When we develop new tests, we build extensive, robust biorepositories of patient-consented samples and well-curated clinical, radiological, outcome and other information from Institutional Review Board-approved clinical trials to inform our discovery efforts. Our biorepositories are designed to encompass the broad spectrum of disease that our tests may encounter when used in clinical practice, as well as the wide range of conditions associated with patients who are suspected of having a particular disease. We extract extensive genomic information from these patient samples using our RNA whole-transcriptome sequencing platform. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proprietary Technology and Bioinformatics - For biomarker discovery and product development, we utilize machine learning to select the genomic, clinical or other features from our biorepository that best distinguish the condition we are trying to identify. This enables us to develop high-performing genomic classifiers that can answer specific clinical questions. In addition, our bioinformatics pipelines are built to extract genomic variant content from the same assay to inform therapeutic selection.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">High-Performing Commercial Genomic Tests - With the exception of Prosigna, which competes with a first-to-market test in a highly competitive environment, our genomic tests generally serve large, untapped markets where they are changing the diagnostic and treatment paradigm for patients. We believe the nCounter platform affords us the opportunity to extend our business model on a global basis by enabling the development of a broad menu of tests. The platform is expected to be applicable to laboratories worldwide. Separately, we expect the nCounter platform may provide increased efficiency in our United States-based CLIA lab.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;"><img src="businessone.jpg" alt="businessone.jpg" style="height:450px;width:684px;"></img></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently offer five commercialized genomic tests that are changing disease diagnosis and patient care. All five tests are available in the United States and one is available internationally. These include the Afirma</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Genomic Sequencing Classifier, or GSC (its predecessor was the Afirma Gene Expression Classifier, or GEC) for thyroid cancer; the Percepta</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> GSC (its predecessor was the Percepta Bronchial Genomic Classifier) for lung cancer; the Envisia</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Genomic Classifier for IPF; the Afirma Xpression Atlas, which provides information on the most common and emerging gene alterations associated with thyroid cancer, enabling physicians to confidently tailor surgical and treatment decisions at time of diagnosis; and the Prosigna breast cancer test for assessing risk of distant recurrence, which is available for use on the nCounter platform in the United States and internationally.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We further believe our ability to leverage RNA whole-transcriptome sequencing data in large biorepositories of patient-consented samples in oncology and other indications presents an opportunity for biopharmaceutical companies to enhance their research and development capabilities. In April 2018, we announced a collaboration with Loxo Oncology (now a wholly owned subsidiary of Eli Lilly and Company) to advance its development of highly selective medicines for patients with genetically defined cancers, including thyroid cancer. In December 2018, we entered into a long-term strategic collaboration with Johnson &amp; Johnson Innovation and the Lung Cancer Initiative at Johnson &amp; Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. The collaboration builds upon foundational "field of injury" science whereby genomic changes associated with lung cancer can be identified with a simple brushing of a person's airway to develop new interventions that can save lives. Additionally, in January 2020, we announced an agreement with Acerta Pharma, the hematology research and development arm of AstraZeneca, to provide genomic information that will support its development of oncology therapeutics in lymphoma.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our collaboration with the Lung Cancer Initiative at Johnson &amp; Johnson has helped accelerate two of our key lung cancer programs: (i) commercialization of the Percepta GSC on our RNA whole-transcriptome sequencing platform, and (ii) development of the first non-invasive nasal swab test for early lung cancer detection. We began making the Percepta GSC available to customers in June 2019. In October 2019, we announced preliminary data for our nasal swab classifier, which demonstrated the test&#8217;s potential to identify patients at low risk of lung cancer so they can potentially avoid unnecessary procedures and those at high risk so they can receive prompt diagnosis and treatment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The published evidence supporting our tests demonstrates the robustness of our science and clinical studies, which we believe is key to driving adoption and reimbursement. Patients and physicians can access our full list of publications on our website. Over 45 clinical studies covering our products have been published, including three landmark clinical validation papers published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The New England Journal of Medicine</span><span style="font-family:inherit;font-size:10pt;"> for the Afirma and Percepta classifiers, respectively, and in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Lancet Respiratory Medicine</span><span style="font-family:inherit;font-size:10pt;"> for the Envisia classifier. We continue to build upon our extensive library of clinical evidence.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our focus on developing clinically useful tests that change patient care is enabling the company to set new standards in genomic test reimbursement. Our genomic classifiers in thyroid cancer, lung cancer and IPF, as well as the Prosigna breast cancer assay are covered by Medicare. Our Afirma classifier, for use in thyroid cancer diagnosis, is now covered by every major health plan in the United States, which collectively insure more than 275 million people. We are contracted as an in-network service provider to health plans representing over 225 million people in the United States. We believe that our in-network status with private payers will help facilitate private insurer reimbursement for our Percepta and Envisia classifiers. The Prosigna test is covered by leading private payers in the United States and is widely reimbursed by government and private payers in the countries where it is available.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also expect to continue expanding our offerings in thyroid cancer, lung cancer, interstitial lung diseases such as IPF, breast cancer and lymphoma, as well as other indications that we believe will benefit from our technology and approach.  Our product development pipelines address what we believe to be significant market opportunities for addressing clinical questions in early detection, diagnosis, staging/prognosis, therapy selection/surgery and disease monitoring across the aforementioned indications.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patients access our tests through their physician. Our Afirma, Percepta and Envisia tests are used as part of the diagnostic process and genomic testing services are performed in our CLIA laboratory located in San Francisco, California. We perform slide preparation and staining for cytopathology on fine needle aspiration samples, for use with Afirma testing, in our reference laboratory in Austin, Texas. The Prosigna test is an </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> diagnostic test that is performed on the nCounter FLEX Analysis System in laboratories worldwide, as well as in the United States.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Company Background</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We were incorporated in Delaware as Calderome,&#160;Inc. in August 2006. Calderome operated as an incubator until early 2008. We changed our name to Veracyte,&#160;Inc. in March 2008. Our principal executive offices are located at 6000 Shoreline Court, Suite&#160;300, South San Francisco, California 94080 and our telephone number is (650)&#160;243-6300. Our website address is www.veracyte.com. Our website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form 10-K.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We make available free of charge on our website our annual report on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission, or SEC. The reports are also available at www.sec.gov.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth Quarter and Full-Year 2019 Financial Results&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended December 31, 2019, compared to the prior year:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Total Revenue </span><span style="font-family:inherit;font-size:10pt;">was $29.7 million, an increase of 15%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Margin </span><span style="font-family:inherit;font-size:10pt;">was 66%, unchanged;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Expenses, Excluding Cost of Revenue, </span><span style="font-family:inherit;font-size:10pt;">were $27.8 million, an increase of 38%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss and Comprehensive Loss</span><span style="font-family:inherit;font-size:10pt;"> was ($7.5) million, an increase of 140%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basic and Diluted Net Loss Per Common Share </span><span style="font-family:inherit;font-size:10pt;">was ($0.15), an increase of 88%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Cash Provided by Operating Activities </span><span style="font-family:inherit;font-size:10pt;">was $1.8 million, compared to $1.2 million used; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents </span><span style="font-family:inherit;font-size:10pt;">was $159.3 million at December 31, 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2019, compared to the prior year:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Total Revenue </span><span style="font-family:inherit;font-size:10pt;">was $120.4 million, an increase of 31%; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Margin </span><span style="font-family:inherit;font-size:10pt;">was 70%, an increase of six percentage points; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Expenses, Excluding Cost of Revenue, </span><span style="font-family:inherit;font-size:10pt;">were $99.0 million, an increase of 22%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss and Comprehensive Loss </span><span style="font-family:inherit;font-size:10pt;">was ($12.6) million, an improvement of 45%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basic and Diluted Net Loss Per Common Share </span><span style="font-family:inherit;font-size:10pt;">was ($0.27), an improvement of 56%; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Cash Used in Operating Activities </span><span style="font-family:inherit;font-size:10pt;">was $3.2 million, an improvement of 76%.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019 Full-Year and Recent Business Highlights</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial Growth:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Achieved strong total revenue growth across our testing and product portfolio delivering $29.5 million in the fourth quarter and $108.3 million for 2019, an increase of 16% and 19%, respectively, compared to the prior year. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated pulmonology testing revenue to $2.0 million and $5.5 million for the fourth quarter and full year, respectively, a 123% and 174% increase compared to prior year. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grew total genomic volume (Afirma, Percepta and Envisia) by 18% to 10,846 tests in the fourth quarter of 2019 and by 25% to 39,612 tests in 2019, compared to prior year.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increased genomic volume for our pulmonology products by 136% in 2019 compared to prior year, achieving growth targets for both the Percepta and Envisia classifiers.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Received final Medicare coverage in March 2019 for the Envisia classifier and published strong clinical validation and clinical utility data in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Lancet Respiratory Medicine</span><span style="font-family:inherit;font-size:10pt;">, propelling nationwide commercial expansion of the test in the second half of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expanded payer contracts by 14.4 million lives, making Veracyte an in-network genomic testing provider to health plans representing over 225 million members.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Continued to build an extensive library of clinical data across our portfolio in 2019, including 8 publications and 11 presentations at leading medical meetings, demonstrating our Afirma and pulmonology tests&#8217; performance and clinical utility. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eleven abstracts were presented at the San Antonio Breast Cancer Symposium in December 2019, including data showing a benefit of Prosigna</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> over other genomic testing to identify patients&#8217; long-term risk of developing distant metastases. In addition, data were presented showing the test&#8217;s ability to identify patients with intrinsic breast cancer subtypes that may potentially benefit from CDK4/6 inhibitors in place of standard chemotherapy. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Biopharmaceutical Collaborations/Pipeline Advancement:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2019, announced a long-term strategic collaboration with Johnson &amp; Johnson Innovation LLC to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Presented preliminary data at the American College of Chest Physicians (CHEST) annual meeting for our first-of-its-kind noninvasive nasal swab classifier for improved lung cancer diagnosis. The test, being developed through our Johnson &amp; Johnson collaboration, is expected to launch in early 2021.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Launched the second-generation Percepta GSC, completing the transition of our core classifiers to our RNA whole-transcriptome sequencing platform.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Announced a multi-year collaboration with Acerta Pharma, the hematology research and development arm of AstraZeneca plc, to provide genomic information that will support the biopharmaceutical company&#8217;s development of oncology therapeutics in lymphoma. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Global Expansion:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired the exclusive global diagnostic rights to the NanoString nCounter FLEX Analysis System, as well as the Prosigna breast cancer assay and the in-development LymphMark lymphoma subtyping test. We believe this transaction positions us to access a $40 billion global market for our current and pipeline products, by offering a broad menu of advanced genomic tests in oncology and other indications using a distributed-kit model.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Products</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our focus on answering clinical questions that produce actionable results; our comprehensive scientific approach to product development, including our use of RNA whole-transcriptome sequencing; and our development of rigorous clinical evidence to establish our tests&#8217; performance and facilitate their reimbursement play critical roles in our ability to develop diagnostic tests that change clinical care. We offer genomic tests in thyroid cancer, lung cancer, IPF and breast cancer:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Afirma Genomic Sequencing Classifier and Xpression Atlas.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Our Afirma offerings include the Afirma GSC and Xpression Atlas.  Our offerings are intended to provide physicians with clinically actionable results from a single fine needle aspiration, or FNA, biopsy. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning, and is used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:29px;text-align:justify;"><span style="font-family:inherit;font-size:10pt;">out unnecessary thyroid surgery. The Afirma product is the first of its kind to market, and we believe the market leader. Since Afirma testing became available in 2011, we estimate that we have helped more than 75,000 patients avoid having all or part of their thyroids removed.</span></div><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We commercially launched the Afirma Xpression Atlas in 2018 to complement the Afirma GSC. The Xpression Atlas provides physicians with genomic alteration content from the same FNA samples that are used in Afirma GSC testing and may help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. The Afirma Xpression Atlas includes 761 DNA variants and 130 RNA fusion partners in over 500 genes that are associated with thyroid cancer.</span></div><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Percepta Genomic Sequencing Classifier.  </span><span style="font-family:inherit;font-size:10pt;">The Percepta classifier improves lung cancer diagnosis by enhancing the performance of diagnostic bronchoscopies, thus identifying more patients with lung nodules who are at low risk of cancer and may avoid further, invasive procedures. This second-generation test, developed on our RNA whole-transcriptome sequencing platform and commercially introduced in June 2019, provides expanded clinical utility by identifying not only low risk patients, but also those with a high risk of lung cancer, so they may obtain faster diagnosis and treatment. The test is built upon foundational "field of injury" science - through which genomic changes associated with lung cancer in current and former smokers can be identified with a simple brushing of a person's airway - without the need to sample the often hard-to-reach nodule directly.&#160;The Percepta classifier is the first product of its kind to be available commercially and the first to obtain Medicare coverage for improved lung cancer diagnosis.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Envisia Genomic Classifier.  </span><span style="font-family:inherit;font-size:10pt;">The Envisia classifier improves diagnosis of IPF by helping physicians better differentiate IPF from other interstitial lung diseases, or ILDs, without the need for surgery. The test identifies the genomic pattern of usual interstitial pneumonia, or UIP, a hallmark of IPF, with high accuracy on patient samples that are obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation. Obtaining an accurate, timely IPF diagnosis is important given the availability of drugs that can slow the progression of this debilitating disease, as well as the need to avoid inappropriate and potentially harmful treatment. IPF is often difficult to distinguish from other ILDs, even with the most advanced imaging technologies. Further, diagnostic surgery is risky, expensive and may not be viable for some patients. The Envisia classifier is the first product of its kind to market. We announced a final Medicare coverage policy for the Envisia classifier in March 2019, which was followed by the online publication of positive clinical validation and clinical utility data in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Lancet Respiratory Medicine</span><span style="font-family:inherit;font-size:10pt;"> in May 2019. Following these milestones, we initiated nationwide expansion for the test, beyond the limited Early Access Program begun in 2018.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prosigna Breast Cancer Prognostic Gene Signature Assay</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span><span style="font-family:inherit;font-size:10pt;"> The Prosigna test uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test leverages a collection of 50 genes known as the PAM50 gene signature, and can provide a breast cancer patient and physician with prognostic score indicating the probability of cancer recurrence during the next ten years. Outside of the United States, it is also utilized to provide cancer subtype classification information.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Physicians can use Prosigna to help guide therapeutic decisions so that patients receive therapeutic interventions, such as chemotherapy, only if clinically warranted. The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> diagnostic test is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care, either as:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A prognostic indicator for distant recurrence&#8208;free survival at ten years in post&#8208;menopausal women with Hormone Receptor&#8208;Positive (HR+), lymph node&#8208;negative, Stage I or II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A prognostic indicator for distant recurrence&#8208;free survival at ten years in post&#8208;menopausal women with Hormone Receptor&#8208;Positive (HR+), lymph node&#8208;positive (1&#8208;3 positive nodes), Stage II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. The device is not intended for patients with 4 or more positive nodes.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Prosigna test is cleared by the FDA for marketing in the United States for use on the nCounter</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span><span style="font-family:inherit;font-size:10pt;">Dx Analysis System and is available for use when ordered by a physician. The test is performed on formalin-fixed and paraffin-embedded, or FFPE, tissue. The Prosigna test has been CE-marked, and is available for use by healthcare professionals in the European Union and other countries that recognize the CE mark, as well as in Canada, Israel, Australia, New Zealand and Hong Kong. The test is covered by Medicare and leading private payers in the United States and is widely covered by government and private payers in the countries where it is available.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Pipeline</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product pipeline reflects our strategy of answering clinical questions in our indications across the clinical care continuum. We develop new products using our RNA whole-transcriptome sequencing and machine learning platform and also strategically acquire complementary products through collaborations and acquisitions. In December 2019, we acquired the exclusive global rights to the nCounter</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">diagnostics platform, positioning us to make our genomic tests available to physicians and patients worldwide through a distributed platform in which customers perform the tests in their local laboratories. This transaction also expands our existing genomic test offerings into new oncology indications of breast cancer and lymphoma. We believe the global market opportunity for our current and future pipeline products is over $40 billion annually.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nasal Swab Test for Early Lung Cancer Detection </span><span style="font-family:inherit;font-size:10pt;">- In October 2019, we announced preliminary clinical data showing that our noninvasive nasal swab test - the first of its kind - may enable early lung cancer detection and diagnosis. The preliminary findings specifically show that our novel genomic test has the potential to accurately classify lung cancer risk in patients with lung nodules so that these patients may obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively. The in-development test uses &#8220;field of injury&#8221; technology to determine the likelihood that a lung nodule is cancerous by measuring gene expression patterns in cells collected from the nose. We plan to introduce the nasal swab test commercially in the United States in early 2021 and internationally on the nCounter platform in 2022.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LymphMark Lymphoma Subtyping Test </span><span style="font-family:inherit;font-size:10pt;">- The LymphMark test is in development for use on the nCounter platform. The test uses the gene expression profile of cells found in Diffuse Large B-cell Lymphoma, or DLBCL, FFPE tissue for the classification of Cell-of-Origin subtype of DLBCL into Activated B-Cell-like or Germinal Center B-Cell-like or an unclassified result. DLBCL is a heterogeneous group of cancers that represents the most common and one of the most aggressive forms of Non-Hodgkin Lymphoma. According to the National Cancer Institute, there were approximately 70,000 new cases of Non-Hodgkin Lymphoma in the United States in 2015.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Extensions</span><span style="font-family:inherit;font-size:10pt;"> - We are expanding our portfolio of tests across our indications - lung cancer, IPF, breast cancer and lymphoma - to inform treatment decisions at the time of diagnosis, similar to what we have done with the Afirma Xpression Atlas in thyroid cancer. Because our diagnostic and prognostic tests are positioned early in the clinical care continuum, we have a unique opportunity to inform downstream decisions without the patient having to undergo further procedures to obtain additional tissue samples.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;"><img src="businessthree.jpg" alt="businessthree.jpg" style="height:381px;width:684px;"></img></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Platform for Global Expansion</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, we acquired from NanoString an exclusive worldwide license to the nCounter FLEX Analysis System for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> diagnostic use and for the development and commercialization of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> diagnostic tests. We expect this instrument platform to enable a broad range of testing through its ability to simultaneous conduct multiplex testing of up to 800 RNA, DNA </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and protein targets. The nCounter system is simple to use and requires less than two hours of hands-on time, which is an up to 80 percent reduction compared to sequencing technology, making advanced genomic testing more accessible to patients through laboratories that previously may not have had the resources or expertise to perform such complex testing.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019, several hundred nCounter instruments have been installed in more than 20 countries where they are used for research as well as diagnostic testing in clinical laboratories and medical centers. The Prosigna breast cancer prognostic gene signature assay is already offered on the system internationally and in the United States. We plan to begin offering the Envisia classifier, for use in IPF diagnosis, to international customers in 2021 as a kit-based test that runs on the nCounter system. We expect our in-development nasal swab classifier, for use in lung cancer diagnosis, to follow on the nCounter system in 2022, after the test becomes available in our CLIA laboratory in the United States in early 2021. Over time, we plan to offer additional genomic tests on the nCounter platform, including tests developed by potential diagnostics or biopharmaceutical partners seeking access to global markets. For testing in the United States, we plan to incorporate the nCounter FLEX Analysis System into our CLIA lab, as appropriate, to realize increased efficiency and margin expansion.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Biopharmaceutical Collaborations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe the powerful clinical and scientific platform we use in the discovery and development of new products also provides multiple opportunities to monetize our assets through collaborations with biopharmaceutical companies. In developing our products, we have built or gained access to unique biorepositories that include extensive clinical cohorts and whole genome RNA sequencing data, which we believe are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. Further, we believe our expanded global footprint and move into new clinical areas in oncology, enabled by the nCounter FLEX Analysis System acquired from NanoString, will prove highly attractive to biopharmaceutical companies, which need access to patients worldwide for their targeted therapies.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019, we had established biopharmaceutical collaborations with Loxo Oncology, Inc., or Loxo, a wholly-owned subsidiary of Eli Lilly and Company, and Johnson &amp; Johnson. In January 2020, we announced a new collaboration with Acerta Pharma, the hematology research and development arm of AstraZeneca plc.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through the research collaboration with Loxo Oncology, the biopharmaceutical company gained access to data derived from our Afirma Xpression Atlas platform for use in its development of highly selective medicines for patients with genetically defined cancers, including thyroid cancer.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also collaborate with the Lung Cancer Initiative at Johnson &amp; Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. The collaboration with Johnson &amp; Johnson, announced in January 2019, was formed to accelerate two key lung cancer programs for us: the commercialization of our Percepta GSC on our RNA whole-transcriptome sequencing platform, which was achieved in June 2019, and the development of the first noninvasive nasal swab test for early lung cancer detection. Under terms of the agreement, we and Johnson &amp; Johnson have combined clinical study cohorts involving more than 5,000 patients with multiple years of clinical outcome data.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through our collaboration with Acerta Pharma, we will provide genomic information that will support the biopharmaceutical company&#8217;s development of oncology therapeutics in lymphoma. The Acerta Pharma collaboration followed the announcement of our expansion into new oncology indications and global markets through our strategic transaction with NanoString.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Opportunity</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of our current business is focused on developing and commercializing genomic classifiers that help resolve diagnostic uncertainty. We believe this is a critical healthcare issue that leads to hundreds of thousands of unnecessary surgeries, delayed or potentially harmful treatments and billions of wasted healthcare dollars each year. We also offer genomic tests designed to answer important questions at other points along the care continuum - often from the same patient samples used in diagnosis - to further help improve patient outcomes and the use of healthcare resources. We believe the total addressable market for our current tests - in thyroid cancer, lung cancer, IPF and breast cancer - is over $3.4 billion in the United States and Europe. We believe the global market opportunity for our current and pipeline products is over $40 billion annually.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Thyroid Market Opportunity for Our Afirma Solution</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each year in the United States, we estimate that more than 525,000 FNA biopsies are performed to assess patients with potentially cancerous thyroid nodules. Cytopathology is performed on each biopsy and we estimate that up to 30 percent of the results are indeterminate (not clearly benign or malignant). Physicians have traditionally recommended thyroid surgery to obtain a more definitive diagnosis. Following surgery, however, 70% to 80% of patients' nodules are diagnosed as benign, meaning the surgery was unnecessary. Such surgery is invasive, costly and often leads to the need for lifelong daily thyroid hormone replacement drugs. The Afirma classifier is included in most leading medical guidelines.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe the addressable market opportunity for our Afirma solution is $720 million in the United States and approximately $100 million in the European Union.  We currently do not have meaningful operations or sales outside the United States.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2012, we obtained Medicare coverage for our Afirma classifier. The test is covered by every major health plan in the United States, which collectively insure more than 275 million people. We are contracted as an in-network service provider to health plans representing over 225 million people in the United States. We estimate that approximately 20% of patients evaluated for thyroid cancer in the United States are covered by Medicare and the remaining 80% are covered by commercial plans or Medicaid or they are self-insured.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Lung Cancer Market Opportunity for Our Percepta Classifier</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lung cancer is often difficult to diagnose without invasive, risky and costly surgeries.  Nearly 230,000 people are diagnosed with lung cancer each year in the United States and more than 140,000 people die annually from the disease. We estimate that approximately 1.8 million to 2.0 million lung nodules are identified in patients in the United States each year and that doctors perform approximately 545,000 bronchoscopies on these patients in order to obtain a diagnosis. A bronchoscopy is a non-surgical procedure that is often used to evaluate patients with potentially cancerous lung nodules, but produces inconclusive results in up to 70% of cases. We estimate that the number of bronchoscopies performed would potentially increase - in lieu of more invasive procedures - if physicians had more confidence in the bronchoscopy procedure&#8217;s ability to provide clear results. Currently, we estimate that approximately 230,000 patients undergoing bronchoscopy have inconclusive results and could potentially benefit from our test.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe the addressable market opportunity for our Percepta product is approximately $490 million in the United States and over $200 million in Europe. We anticipate the market will expand significantly over the coming years as lung cancer screening programs are implemented in the United States and physicians embrace bronchoscopy as a standard, less-invasive diagnostic modality for evaluating lung nodules and lesions.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, we obtained Medicare coverage for Percepta, making it the first genomic test to be covered for use in lung cancer screening and diagnosis. The test is available to nearly 60 million Medicare enrollees. We estimate that half of the patients evaluated for lung cancer in the United States are covered by Medicare.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPF Market Opportunity for Our Envisia Classifier</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each year in&#160;the United States&#160;and&#160;Europe, up to 220,000 patients are suspected of having an ILD, including IPF, which is among the most common and deadly of these lung-scarring diseases. IPF is notoriously difficult to diagnose, often leading to treatment delays, repeated misdiagnoses, patient distress and added healthcare expense. Physicians routinely use high-resolution computed tomography imaging to identify UIP, the pattern whose presence is essential to IPF diagnosis. This approach, however, frequently provides inconclusive results, leading many patients to require surgery to secure a more definitive diagnosis using surgical histopathology. These surgeries are risky and expensive, and many patients are too frail to undergo the procedure. Of the approximate 250,000 patients evaluated for ILD annually, we estimate that approximately 87%, or 191,000 patients receive an uncertain diagnosis and are candidates for our Envisia test.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe the addressable market opportunity for our Envisia product is approximately $435 million in the United States and up to $300 million in Europe.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, we obtained final Medicare coverage for the Envisia classifier through the MolDX program, administered by Palmetto GBA. The Envisia classifier is the first genomic test to be covered by Medicare for use in IPF diagnosis, with the test available to the government health program&#8217;s nearly 60 million Medicare enrollees. We estimate that half of the patients evaluated for ILDs/IPF in the United States are covered by Medicare.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Breast Cancer Market Opportunity for Our Prosigna Test</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide. It impacts 2.1 million women and causes 627,000 deaths each year. Following diagnosis, physicians have traditionally used clinical factors - tumor size, grade and nodal status - to help determine the risk of cancer recurrence and thus to help inform whether adjuvant chemotherapy should be added to endocrine treatment. We believe that historically this subjective approach led to women unnecessarily being exposed to toxic chemotherapy or to being undertreated.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Prosigna assay measures RNA expression levels of 50 genes that provide a breast cancer patient and physician with a prognostic score indicating the probability of cancer recurrence over ten years, as well as information on the patient&#8217;s breast cancer genetic subtypes [Luminal A and B, Basal and HER2-Enriched (in ex-United States markets and CLIA)], which can further inform treatment.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate that the global early stage breast cancer recurrence market is significant, with over 500,000 patients potentially eligible for Prosigna annually. This is comprised of approximately 115,000 patients in the United States and 400,000 in the  rest of the world. The Prosigna test is clinically validated in studies published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Annals of Oncology</span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Journal of Clinical Oncology. </span><span style="font-family:inherit;font-size:10pt;">The test is recommended in guidelines from the National Comprehensive Cancer Network and the American Society of Clinical Oncology in the United States. Medicare coverage for Prosigna through the MolDX program has been in effect since October 2015. Outside of the United States, the test is included in leading medical guidelines, including from the National Institute for Health and Care Excellence in the United Kingdom, which in 2019 recommended use of the test. We estimate that the addressable market for Prosigna is approximately $700 million in the United States and $500 million in the European Union.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Scientific Background</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the past, clinicians made diagnoses from biopsy samples by looking at them under a microscope. Technology has advanced far beyond this, and scientists now have the ability to decipher genomic patterns that reside in the DNA and RNA of such biopsies. We search for patterns that tell us whether or not the biopsy contains the disease in question. We do this by using a whole-genome approach. This means we look at all of the human genes, including their expression patterns and their variants and mutations, rather than just looking at a few selected genes that we think may be important. This comprehensive measurement of the human genome allows us to detect signals from genes we may not have previously suspected to be involved in disease.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use machine learning-based algorithms to match genomic patterns with clinical truth, or the true diagnosis. For example, when we train an algorithm on RNA sequencing data, we teach it to associate a set of expression patterns with disease and a different set of patterns with lack of disease. When algorithms are trained on enough examples with clinical truth, they learn to find that pattern in samples they have never encountered, thus allowing the algorithm to predict disease in a clinical setting.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our core products are built around algorithms that help either rule in or rule out disease. Due to the complex, sometimes rare, subtypes of various diseases like cancer, we develop and train our machine learning algorithms using a diverse set of patient samples so that they are equipped to recognize patterns across the whole spectrum of conditions that may be encountered in the clinic.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our process uses commercially available reagents and instruments with our own proprietary process and protocols, which results in RNA extraction from the range of small, minimally invasive biopsies used in our clinical development studies and our commercial laboratory tests.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our recently-acquired Prosigna breast cancer prognostic test similarly utilizes machine learning-based algorithms to provide prognostic information for certain early-stage breast cancer patients. The RNA-based test uses a &#8220;PAM50&#8221; signature, comprised of 50 genes, to compare the gene expression profile of a patient&#8217;s tumor - from a surgically removed sample - with each of four intrinsic tumor subtypes to determine the degree of similarity. The results, in combination with a proliferation score and tumor size, produce an individualized Prosigna risk-of-recurrence score. The Prosigna test was adapted to be performed using the nCounter Analysis System so that it can be performed in local laboratories.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our primary tests in each of our clinical indications, our RNA sequencing platform also enables us to identify gene alterations such as variants and fusions, copy number and other information - from samples utilized in initial testing - that may inform next steps in patient care. We currently offer this capability in our thyroid cancer offerings as the Afirma Xpression Atlas, which is used to help inform surgical strategy and treatment options for patients whose thyroid nodules are confirmed or suspicious for cancer. We believe this capability may be especially useful in oncology and other diseases that are increasingly treated using therapies that target specific gene alterations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Technology</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Genomic Testing</span></div><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our technology approach for our genomic tests is comprised of a number of key attributes:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Core Expertise in Broad-based Genomic Analysis</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">.  </span><span style="font-family:inherit;font-size:10pt;">Our team of bioinformatics and computational scientists possess extensive knowledge of both existing computational methods as well as the capacity to develop proprietary methods as needed for algorithm design. We demonstrated our ability to utilize large amounts of genomic data with machine learning algorithms in the development of the Afirma GEC on microarrays and substantially extended this capability in the development of the Afirma GSC by accessing genomic features through deep RNA sequencing. Our expertise allows us to use a combination of expression analysis as well as mutations and variants to build our sophisticated machine learning algorithms, all on the same platform. Additionally, we believe our technological capabilities enable us to adapt our genomic tests to other platforms, including the nCounter FLEX Analysis System for distribution to global markets.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Platform-Agnostic Approach.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">  </span><span style="font-family:inherit;font-size:10pt;">We are not reliant on any one technology platform to measure genomic signals; in fact, we may take advantage of a multitude of genomic methodologies to develop future tests. When we developed the Afirma GEC in 2008, microarray technologies were a cost-effective discovery technology compared to other approaches that were nascent at the time. More recently, the rapid cost reductions achieved in next generation sequencing platforms have allowed us to pursue our whole genome approach to biomarker discovery using a range of genomic features obtained through both DNA and RNA sequencing. From this vast array of sequence data, our algorithms select those genomic signals that inform on the disease in question, in the relevant biopsy sample. We continue to evaluate potential opportunities to use new genomic discoveries and technologies to further improve patient care.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Proprietary Capabilities in Analyzing Small, Heterogeneous Cytology Samples</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">.  </span><span style="font-family:inherit;font-size:10pt;">We have developed proprietary technology, intellectual property and know-how for optimized methods for extraction and analysis of nanogram quantities of RNA from small biopsy samples. Our focus is on redefining clinical truth, using patient samples obtained through less-invasive techniques, thereby increasing access to our technology by a larger patient population. While others can extract RNA from these small biopsies, we believe our process is optimized and scaled for high-throughput clinical testing and large-scale clinical development studies, such as those involving high-density microarrays and next-generation sequencing.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Precision and Reproducibility.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">  </span><span style="font-family:inherit;font-size:10pt;">We have in place standard operating procedures governing reagents, materials, instruments and controls and extensive experience from numerous verification studies performed for our tests. We apply the same high-quality control methods that were developed for our reagents and processes, along with our proprietary software for automation, sample tracking, data quality control and statistical analysis, to our development process.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">nCounter Platform</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, we acquired from NanoString an exclusive worldwide license to the nCounter FLEX Analysis System for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> diagnostic use and for the development and commercialization of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> diagnostic tests. Currently, the Prosigna breast cancer assay is the only commercially-available test on the platform.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The nCounter system can simultaneously analyze RNA, DNA or protein targets, as well as gene mutations, fusions and copy number variations, in up to 800 genes. The system utilizes proprietary chemistry that allows the measurement of subtle changes in the activity of multiple genes from minute amounts of a biological sample, with high sensitivity and precision. This chemistry also obviates the need for amplification or other steps that can be cumbersome and time-consuming or may introduce the possibility of measurement errors. As a result, the nCounter system enables easy-to-use genomic testing with simple workflow that requires less than two hours of hands-on time - an up to 80 percent reduction compared to sequencing technology - making advanced genomic testing more accessible to patients through laboratories that previously may not have had the resources or expertise to perform such complex testing.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe the nCounter system&#8217;s sensitivity and multiplexing capabilities will provide a robust platform for our genomic classifiers, enabling us to offer them in a kit format that can be performed locally in laboratories worldwide where the nCounter system is installed. Additionally, we believe that we can perform our genomic classifiers on the nCounter system in our own CLIA lab, enabling other, smaller-volume labs in the United States to offer our tests without the need to invest in an nCounter instrument, while also enabling us to enhance our margins.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to begin offering the Envisia classifier, for use in IPF diagnosis, to international customers in 2021 as a kit-based test that runs on the nCounter system. We expect our in-development nasal swab classifier, for use in lung cancer diagnosis, to follow on the nCounter system in 2022, after the test becomes available in our CLIA lab in the United States in early 2021. The nCounter system can also run additional tests developed by us, as well as by potential diagnostics or biopharmaceutical partners seeking access to global markets.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Studies Validating Test Performance and Clinical Utility</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2010, the Centers for Disease Control and Prevention published the &#8220;ACCE&#8221; model as a paradigm for establishing evidence to confirm the safety and effectiveness of molecular diagnostic tests. ACCE derives its name from the main criteria for evaluating such tests, including analytic validity, clinical validity and clinical utility. This model has been adopted by most technology assessment groups, professional societies and payers.  We fully embrace this paradigm of evidence development and we strive to provide the highest level of scientific evidence to support our test claims.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that developing an extensive library of rigorous clinical evidence to support our tests is critical to driving inclusion in clinical guidelines, securing reimbursement and gaining physician adoption.  We make our published research, abstracts from medical conferences and other product information available on our website at www.veracyte.com. Our website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form 10-K.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Afirma classifiers are supported by more than 30 published scientific studies. These include a prospective, multicenter clinical validation study published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The New England Journal of Medicine</span><span style="font-family:inherit;font-size:10pt;">, which suggested that the test can significantly reduce the number of unnecessary surgeries, compared to traditional diagnostic approaches. They also include a clinical validation study with patients from this same cohort, which was published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">JAMA Surgery</span><span style="font-family:inherit;font-size:10pt;"> and show that the next-generation Afirma GSC can identify 30 percent more patients who may potentially avoid unnecessary surgery. The Afirma classifier is recommended in leading practice guidelines and is covered for over 275 million lives in the United States, including through Medicare and all major commercial insurance plans in the United States.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Percepta test is supported by six published scientific studies, including data published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The New England Journal of Medicine</span><span style="font-family:inherit;font-size:10pt;">, which demonstrate the test&#8217;s accuracy in identifying patients who are at low risk of cancer following inconclusive results from bronchoscopy. These patients may then be monitored with CT scans in lieu of undergoing surgery - a frequent next step at this juncture of the clinical pathway. A clinical utility study published in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">CHEST </span><span style="font-family:inherit;font-size:10pt;">journal showed that use of the test reduced unnecessary surgeries in the target patient population, compared to physicians&#8217; plans prior to Percepta testing.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Envisia classifier is supported by clinical data published in six peer-reviewed journals. These include a prospective clinical validation study published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Lancet Respiratory Medicine</span><span style="font-family:inherit;font-size:10pt;">, which showed that the Envisia test achieved high specificity, meaning it would be expected to identify more than two-thirds of patients with usual interstitial pneumonia, or UIP, the hallmark of IPF, while minimizing the number of false positive results. In comparison, data show that high-resolution CT (HRCT) imaging, which is typically used in IPF diagnosis, has a sensitivity of just 43 percent for UIP.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Prosigna breast cancer prognostic test is supported by multiple clinical studies involving thousands of female patients with early-stage breast cancer. These include a large clinical validation study published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Annals of Oncology</span><span style="font-family:inherit;font-size:10pt;">. In this study of 1,478 patients, researchers found that the Prosigna risk of recurrence score added a &#8220;highly significant further increase in prognostic information&#8221; compared to a clinical linear predictor alone. Data demonstrating the test&#8217;s clinical performance, clinical utility, cost-effectiveness and analytical validation have been published in over a dozen peer-reviewed journals including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">the Journal of Clinical Oncology</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Journal of the National Cancer Institute</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">JAMA Oncology</span><span style="font-family:inherit;font-size:10pt;"> among others.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commercial Operations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial infrastructure, including our sales, marketing, managed care, and customer care functions, is critical to our ongoing success. We have built a strong domestic sales, marketing and reimbursement capability that interacts directly with users of our products, as well as payers and other stakeholders involved in the diagnostic workup of a patient.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our sales team is structured to sell all of our tests; we do not maintain a separate sales force for each product. Currently, our sales force is comprised of our product specialists, who are accountable for select geographic territories; pulmonary product specialists, who maintain and grow our relationships with key regional institutions; account managers, who manage existing client relationships; and medical science specialists, who focus on addressing medical and clinical education in the field.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continued to expand our domestic field sales team in 2019 and we expect to continue to invest in sales and marketing to support our commercial expansion efforts in the United States. Additionally, through the strategic transaction with NanoString, we hired a small number of personnel to support Prosigna laboratory customers in the United States.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, substantially all of our revenue has been derived from customers we serve in the United States. Through December 31, 2019, we derived most of our revenue from our Afirma solution, including cytopathology services and the Afirma assays.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to direct sales, industry trade shows or events provide us with an opportunity to share important product and research updates and to interact with key opinion leaders who impact our business. We typically have a presence at a number of select industry conferences, including the Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists, or AACE, and the Endocrine Society&#8217;s Annual Meeting, or ENDO; key pulmonology conferences such as the American Thoracic Society&#8217;s International Conference, or ATS, and the American College of Chest Physician&#8217;s CHEST Annual Meeting. With our expansion into breast cancer, we plan to also attend the annual San Antonio Breast Cancer Symposium.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our other marketing efforts encompass a range of tools and channels, including product websites, digital marketing tactics such as search engine optimization and online advertising, direct-to-customer communications and advertising in trade media outlets read by our customers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">International</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With our acquisition of the exclusive worldwide </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in </span><span style="font-family:inherit;font-size:10pt;">vitro diagnostic rights for the nCounter platform, we hired several key international members of NanoString&#8217;s global diagnostics sales, marketing, medical affairs and distribution teams, providing a foundation for our international expansion efforts.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna is currently our only product generating revenue in global markets. Commercialization efforts for Prosigna involve securing reimbursement, selling test kits to institutions and medical centers that already own or lease nCounter instruments, and driving physician demand for the test.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Laboratory Operations</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We perform all genomic testing in thyroid cancer, lung cancer and IPF in South San Francisco, California. For Afirma testing, we perform slide preparation and staining for cytopathology on FNA samples in Austin, Texas. Our South San Francisco facility is responsible for quality assurance oversight, licensing and regulatory compliance and maintenance for both of our laboratories to ensure data integrity and consistent, validated processes.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We receive samples for testing directly from the following sources:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FNAs for Afirma Genomic Testing Only.</span><span style="font-family:inherit;font-size:10pt;"> Institutions and other clients, such as laboratories, that perform their own cytopathology may send us FNA samples from indeterminate results to perform Afirma genomic testing. We receive over 70% of our Afirma test volume from this source and it is the fastest-growing segment of our business.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FNAs for Cytopathology and Reflexed Afirma Genomic Testing.  </span><span style="font-family:inherit;font-size:10pt;">We receive FNA samples from ordering physicians for cytopathology assessment and if results are indeterminate, Afirma genomic testing is to be performed. We partner with Thyroid Cytopathology Partners, or TCP, to perform the cytopathology review.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bronchoscopy Samples for Percepta Classifier.  </span><span style="font-family:inherit;font-size:10pt;">Institutions send us samples collected during the bronchoscopy procedure and order genomic testing with the Percepta classifier when bronchoscopy results are inconclusive.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bronchoscopy Samples for Envisia Classifier.  </span><span style="font-family:inherit;font-size:10pt;">Institutions send us samples to help better differentiate IPFs from other ILDs without the need for surgery. These samples are collected using transbronchial biopsy.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on TCP to provide professional cytopathology diagnoses on thyroid FNA samples pursuant to a pathology services agreement. Our agreement with TCP is effective until October&#160;31, 2022 and thereafter automatically renews every year unless either party provides notice of intent not to renew at least twelve months prior to the end of the then-current term.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Prosigna breast cancer test is performed on the nCounter FLEX Analysis System in laboratories internationally and in the United States. We believe that our state-of-the-art laboratory space in South San Francisco, California, has sufficient laboratory capacity to accommodate volume growth for our existing and pipeline products, as well as for Prosigna testing on the nCounter instrumentation system.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our quality assurance function oversees the quality of our laboratories as well as the quality systems used in research and development, client services, billing operations and sales and marketing. We have an established quality management system compliant with federal and state regulations and standards that we believe achieves excellence in operations across the entire business. We continuously monitor and strive to improve our quality program and believe our implementation of these processes has supported our achievement of product performance, customer satisfaction and retention and a philosophy of continuous improvement.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Reimbursement Strategy</span></div><div style="line-height:120%;text-align:justify;padding-left:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We employ a multi-pronged strategy designed to achieve broad coverage and reimbursement for our tests in the United States and internationally:</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compile a Growing Library of Peer-reviewed Studies that Demonstrate the Test Is Effective.  </span><span style="font-family:inherit;font-size:10pt;">To date, several peer-reviewed articles and review papers have been published and have helped support our efforts aimed at widespread adoption and reimbursement of our genomic tests. In each disease area we pursue, we intend to conduct studies in order to develop robust library of evidence.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Meet the Evidence Standards Necessary to Be Consistent with Leading Clinical Guidelines.  </span><span style="font-family:inherit;font-size:10pt;">We believe inclusion in leading clinical practice guidelines plays an important role in payers' coverage decisions. For example, the data published on Afirma to date is consistent with the recommendations of the widely-recognized American Thyroid Association and National Comprehensive Cancer Network clinical practice guidelines.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Execute an Internal Managed Care and Claims Adjudication Function as Part of Our Core Business Operations.  </span><span style="font-family:inherit;font-size:10pt;"> We believe that obtaining adequate and widespread reimbursement is a critical factor in our long-term success. We employ a team of in-house claims processing and reimbursement specialists who work with payers, physician practices and patients to obtain maximum reimbursement.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaborate with Network of Key Opinion Leaders.  </span><span style="font-family:inherit;font-size:10pt;">Key opinion leaders are able to impact clinical practice by publishing research and determining whether new tests should be integrated into practice guidelines. We collaborate with key opinion leaders early in the development process to ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our tests to patients, physicians and payers. Ongoing studies to support real world experience with our tests are also a key component of our efforts to collaborate with physician thought leaders.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:53px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Established Payer Relationships and In-network Contracts.  </span><span style="font-family:inherit;font-size:10pt;">We believe that positive engagement with payers leads to coverage decisions and facilitates our efforts on coverage and contract decisions for subsequent tests.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Coverage, Coding and Reimbursement</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from our tests comes from several sources, including commercial third-party payers, such as insurance companies and health maintenance organizations, government payers, such as Medicare and Medicaid, and patients.  The Centers for Medicare &amp; Medicaid Services, or CMS, administers the Medicare and Medicaid programs, which provide health care to almost one in every three Americans. For any particular geographic region, Medicare claims are processed at the local level by Medicare Administrative Contractors, or MACs.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare generally covers molecular diagnostic tests through the MolDX program, administered by the MAC, Palmetto GBA. Medicare has covered our Afirma classifier testing since 2012 and Percepta classifier testing since 2017. We received Medicare coverage for our Envisia classifier testing in 2019. The Prosigna test achieved Medicare coverage in 2015. We estimate that Medicare covers approximately 20% of patients evaluated for thyroid cancer and approximately 50% of patients evaluated for lung cancer, IPF and breast cancer, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since 1984, Medicare has paid for clinical diagnostic laboratory tests, or CDLTs, on the Clinical Laboratory Fee Schedule, or CLFS under section 1833(h) of the Social Security Act, or the SSA. Section 216(a) of the Protecting Access to Medicare Act of 2014, or PAMA, added section 1834A to the SSA. The statute required extensive revisions to the Medicare CLFS coding, rate setting processes, and laboratory payment reporting for CDLTs, and creates a new subcategory of CDLTs called Advanced Diagnostic Laboratory Tests, or ADLTs, with separate reporting and payment requirements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, CMS issued the final rule to implement the requirements of PAMA, which significantly revised the Medicare payment system for clinical diagnostic laboratory tests. The final rule was implemented on January 1, 2018 for the private payer rate-based fee schedule required by PAMA. Under the final rule, for CDLTs furnished on or after January 1, 2018, the amount Medicare pays is equal to the weighted median of private payer rates for the CDLT.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the implementation on January 1, 2018, the allowable Medicare rate for our Afirma GSC was $3,200. From January 1, 2018 through December 31, 2020, the allowable Medicare rate for our Afirma test under PAMA increased to $3,600.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, through the Further Consolidated Appropriations Act of 2020, Congress delayed the next data reporting period under PAMA from 2020 to 2021 for final payments made between January 1 and June 30, 2019, extending the applicability of the payment rates based on 2017 reporting by one year through December 31, 2021.  Afirma will continue to be paid at $3,600 through that date. The 2020 Medicare payment rate for Prosigna based on the volume-weighted median of private payer rates under PAMA will be $2,510.21. In 2021, Prosigna&#8217;s rate will decrease by 15% to approximately $2,134.  The volume-weighted median of these private payer rates for final payments made from January through June 2019 (and now reported January through March 2021) will now set the Medicare payment rate for the Afirma classifier and for Prosigna from January 1, 2022 through December 31, 2024.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We submit claims to payers directly for the Afirma GSC, using a unique American Medical Association Current Procedural Terminology code, or CPT code 81545. FNA samples are also received for cytopathology, for which we bill both the technical and professional component using established CPT codes.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We bill payers directly for the Percepta and Envisia classifiers using an &#8220;unlisted&#8221; CPT code until we obtain specific codes for the tests. Currently, labs in the United States that perform Prosigna testing on their own nCounter instruments bill payers directly using the CPT code that is specific to the Prosigna test, 81520. We expect that, when we perform Prosigna testing in our own CLIA certified lab that we will bill payers directly for Prosigna testing.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State Medicaid programs typically make their own decisions with respect to coverage for our tests, as do private payers. We rely on a small number of third-party payers for a significant portion of our revenue, the loss of one or more of which would have a negative effect on our business. For the years ended December 31, 2019, 2018, and 2017, respectively, revenue was represented by the indicated percent for each payer:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare accounted for 29%, 26% and 27% of our revenue; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UnitedHealthcare accounted for 12%, 14% and 12% of our revenue.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Outside the United States</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside of the United States, we bill hospital and laboratory customers directly for test kits they order, which currently consist of Prosigna test kits. Our customers subsequently bill third-party payers for reimbursement. Prosigna test marketing has initially targeted private and cash-pay markets in Europe. We will continue to drive reimbursement efforts in Europe and other global markets through the development of clinical and other evidence to support Prosigna&#8217;s inclusion in guidelines and coverage programs.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe the principal competitive factors in the markets we target with our advanced genomic tests include:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of the test to answer the appropriate clinical question at the right point in the clinical pathway;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the quality and strength of clinical validation and utility data;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">confidence in diagnostic results backed by analytical verification data;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent of reimbursement and in-network payer contracts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inclusion in practice guidelines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cost-effectiveness; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">local testing near the patient and ease of use.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe we compete favorably on the factors described above with our Afirma solution and are positioning ourselves to compete effectively on these factors with our first-to-market Percepta and Envisia classifiers. Another competitive factor that we believe will become increasingly important for advanced genomic tests offered within and outside of the United States is that they be  available as distributed kits on an instrument platform with broad functionality to justify the capital expense. We believe our plans to adapt our genomic tests to the nCounter platform, which already can run the Prosigna test, will further enhance our tests&#8217; attractiveness to hospitals and laboratories globally.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our principal competition for the Afirma solution comes from traditional methods used by physicians to diagnose thyroid cancer. Physicians in the United States have historically recommended that patients with indeterminate diagnoses from cytopathology results be considered for surgery to remove all or part of the thyroid to rule out cancer.  This practice has been the standard of care in the United States, as well as in many international markets, for many years, and we continue to educate physicians about the benefits of our test in order to change clinical practice.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also face competition from companies and academic institutions that use next generation sequencing technology or other methods to measure mutational markers such as BRAF and KRAS, along with numerous other mutations. These organizations include Interpace Diagnostics Group,&#160;Inc., CBLPath, Inc./University of Pittsburgh Medical Center, and others who are developing new products or technologies that may compete with our tests. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With the Percepta and Envisia tests, we believe our primary competition will similarly come from traditional methods used by physicians to diagnose the related diseases. For the Percepta test, we expect competition from companies focused on lung cancer such as Oncocyte Corporation and Biodesix, Inc. We also anticipate facing potential competition from companies offering or developing approaches for assessing malignancy risk in patients with lung nodules using alternative samples such as blood, urine or sputum, including Biodesix, Inc. and Guardant Health, Inc. However, such "liquid biopsies" are predominantly used later in the diagnostic paradigm; for example, to inform treatment decisions for cancer or to gauge risk of recurrence or response to treatment.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the breast cancer diagnostics market, the Prosigna test competes with Exact Sciences Corporation&#8217;s Oncotype Dx, a service for gene expression analysis performed in a central laboratory in Redwood City, California. We also face competition from companies such as Agendia, Inc. and bioTheranostics, Inc., which also offer centralized laboratories that profile gene or protein expression in breast cancer. Outside the United States, we also face regional competition from Myriad Genetics, Inc., and its product EndoPredict, a distributed test for breast cancer recurrence.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In general, we also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, and Sonic Healthcare USA with strong infrastructure to support the commercialization of diagnostic services. We face potential competition from companies such as Illumina,&#160;Inc. and Thermo Fisher Scientific&#160;Inc., both of which have entered the clinical diagnostics market. Other potential competitors include companies that develop diagnostic products, such as Roche Diagnostics, a division of Roche Holding&#160;Ltd, Siemens AG and Qiagen&#160;N.V.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competitors may develop their own versions of our solution in countries in which we do not have patents or where our intellectual property rights are not recognized and compete with us in those countries, including encouraging the use of their solution by physicians in other countries.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours, which could be viewed by physicians and payers as functionally equivalent to our solution, or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our solutions and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. As we add new tests and services, we will face many of these same competitive risks for these new tests.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Laboratory Improvement Amendments of 1988, or CLIA</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a clinical reference laboratory, we are required to hold certain federal, state and local licenses, certifications and permits to conduct our business. We are subject to CLIA, a federal law that regulates clinical laboratories that test specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease.  Under CLIA, which is administered by CMS, we are required to hold a certificate applicable to the type of laboratory examinations we perform and to comply with standards covering personnel qualifications, facilities administration, quality systems, inspections, and proficiency testing.  We must maintain CLIA compliance and certification to sell our tests and be eligible to bill for diagnostic services provided to Medicare beneficiaries.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, if one of our clinical reference laboratories is out of compliance with CLIA requirements, we may be subject to sanctions such as suspension, limitation or revocation of our CLIA certificate, as well as directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties. If we were to be found out of compliance with CLIA requirements and subjected to sanctions, our business could be harmed.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have historically held CLIA certifications to perform testing at our South San Francisco and Austin, Texas laboratory locations.&#160;To renew our CLIA certificates, we are subject to survey and inspection every two years to assess compliance with program standards.&#160; Moreover, CLIA inspectors may make random inspections of our clinical reference laboratories.  If we in the future fail to maintain CLIA certificates in our South San Francisco or Austin, Texas laboratory locations we would be unable to bill for services provided by state and federal healthcare programs, as well as many private third-party payers, which may have an adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">State Laboratory Licensing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">California Laboratory Licensing</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to federal certification requirements of laboratories under CLIA, licensure is required and maintained for our South San Francisco clinical reference laboratory under California law. Such laws establish standards for the day-to-day operation of a clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, California laws mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our clinical reference laboratory is out of compliance with California standards, the California Department of Public Health, or CDPH, may suspend, restrict or revoke our license to operate our clinical reference laboratory, assess substantial civil money penalties, or impose specific corrective action plans. Any such actions could materially affect our business. We maintain a current license in good standing with CDPH. However, we cannot provide assurance that CDPH will at all times in the future find us to be in compliance with all such laws.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New York Laboratory Licensing</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our clinical reference laboratories are required to be licensed by New York, under New York laws and regulations before we receive specimens from New York State. The license establishes standards for:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">quality management systems;</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">qualifications, responsibilities, and training;</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">facility design and resource management;</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">pre-analytic, analytic (including validation and quality control), and post-analytic systems; and</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">quality assessments and improvements.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether such laboratories are located in New York. If a laboratory is out of compliance with New York statutory or regulatory standards, the New York State Department of Health, or NYSDOH, may suspend, limit, revoke or annul the laboratory's New York license, censure the holder of the license or assess civil money penalties. Statutory or regulatory noncompliance may result in a laboratory's operator being found guilty of a misdemeanor under New York law. NYSDOH also must approve the laboratory developed tests, or LDTs, before the test is offered in New York; approval has been received for the Afirma GEC and the Percepta classifier. Should we be found out of compliance with New York laboratory standards of practice, we could be subject to such sanctions, which could harm our business. We maintain a current license in good standing with NYSDOH for our South San Francisco and Austin laboratories. We cannot provide assurance that the NYSDOH will at all times find us to be in compliance with applicable laws.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other States' Laboratory Licensing</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to New York and California, other states require licensing of out-of-state laboratories under certain circumstances. Pennsylvania, Maryland and Rhode Island require licenses to test specimens from patients in those states and Florida requires a license to receive specimens from a clinical laboratory in that state.  We have obtained licenses from states where we believe we are required to be licensed, and believe we are in compliance with applicable licensing laws.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states do have such requirements or will have such requirements in the future. If we identify any other state with such requirements or if we are contacted by any other state advising us of such requirements, we intend to comply with such requirements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States Regulation of Laboratory Testing</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Food and Drug Administration: Diagnostic Kits</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostic kits, including collection systems that are sold and distributed in the United States are regulated as medical devices by the FDA. Devices subject to FDA regulation must undergo premarket review prior to commercialization unless the device is of a type exempted from such review. In addition, manufacturers of medical devices must comply with various regulatory requirements under the Federal Food, Drug, and Cosmetic Act, or FDC Act, and implementing regulations promulgated under that Act. Entities that fail to comply with FDA requirements may be subject to issuance of inspectional observations on Form FDA-483, untitled or warning letters,  recalls, import detentions, seizures, or injunctions, including orders to cease manufacturing and can be liable for civil money penalties or criminal prosecution.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDC Act sets forth for the classifications of medical devices into one of three categories based on the risks associated with the device and prescribes the levels of controls appropriate for each of the three classes to help ensure reasonable assurance of safety and effectiveness. Class&#160;I devices are considered to be low risk and are exempt from FDA premarket notification requirements.  Class I devices are subject to general regulatory controls.  When general controls are considered insufficient to provide reasonable assurance of safety and effectiveness, but there is sufficient information to establish special controls to provide such assurance, FDA will classify the device as a Class II device.  For most Class&#160;II devices, the FDC Act requires the submission to FDA of a premarket notification, referred to as a &#8220;510(k),&#8221; which must provide data and information showing that the device is substantially equivalent to a legally marketed device, referred to as a predictive device, with respect to the indications for use and the product&#8217;s technological characteristics.  If the data and information are sufficient to show that the device is as safe and effective as the predicate device, FDA issues a Substantially Equivalent letter clearing the device for marketing. </span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If there is insufficient information to support classifying a device into Class I or Class II and the device is life-sustaining or life-supporting or is substantially important in preventing illness or injury or presents a potential unreasonable risk of illness or injury, FDA places the device into Class III.  Class&#160;III devices are considered the highest risk devices and generally require significant data and information, including testing data and data from nonclinical and clinical studies, to provide reasonable assurance of the device's safety and effectiveness. Class&#160;III devices require the submission and FDA approval of a premarket application, or PMA, before they can be marketed.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain devices are classified as Class III devices automatically, by operation of law, when the device does not have a predicate device or is found not to be substantially equivalent to a predicate device. If there is sufficient evidence to show that the device is a lower risk device, a manufacturer may ask FDA to reclassify the device into Class II or Class I by submitting a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">De Novo</span><span style="font-family:inherit;font-size:10pt;"> classification request. When FDA reclassifies a device through the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">De Novo</span><span style="font-family:inherit;font-size:10pt;"> process, other manufacturers of the same device type do not necessarily have to submit a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">De Novo</span><span style="font-family:inherit;font-size:10pt;"> request or a PMA in order to legally market the device. Instead, manufacturers can submit a 510(k), unless the device has been classified as 510(k) exempt, to legally market their device, because the device that was the subject of the original </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">De Novo</span><span style="font-family:inherit;font-size:10pt;"> request can serve as a predicate device for a substantial equivalence determination. If FDA does not issue an order granting the De Novo request for reclassification, the device will remain a Class III device and be subject to PMA requirements to obtain marketing authorization.  </span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Establishments that manufacture or distribute FDA-related medical devices, including manufacturers, repackagers and relabelers, specification developers, and initial importers, are required to register and list their device products with the FDA.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Devices that may be legally marketed are subject to numerous regulatory requirements. These include: good manufacturing practice for medical devices as set out in the Quality System Regulation, or QSR, labeling regulations, restrictions on promotion and advertising, the Medical Device Reporting, or MDR (which requires manufacturers to report to the FDA), and the Reports of Corrections and Removals regulation (which requires manufacturers to report certain recalls and field actions to the FDA). Certain corrections and market removals may also be subject to FDA&#8217;s recall regulation and procedures. </span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has issued a regulation outlining specific requirements for "specimen transport and storage containers." "Specimen transport and storage containers" are medical devices "intended to contain biological specimens, body waste, or body exudate during storage and transport" so that the specimen can be destroyed or used effectively for diagnostic examination. A specimen transport and storage container that is not labeled or otherwise represented as sterile is classified as a Class&#160;I exempt device, which means that the device is exempt from the 510(k) premarket notification requirement and the QSR, except for recordkeeping and complaint handling requirements.  These 510(k) exempt devices are still subject to MDR requirements, the reporting of corrections and removals, and establishment registration and product listing. </span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our FDA registration, we have registration, we have listed the containers we provide for collection and transport of Afirma GEC or GSC and Percepta samples from a physician to our clinical reference laboratory as Class&#160;I devices in accordance with the classification of regulation for the specimen transport and storage container . We also plan to list our sample collection containers for Envisia samples with the FDA as Class&#160;I devices. If the FDA were to determine that our sample collection containers are not Class&#160;I devices, we would be required to file&#160;510(k) applications and obtain FDA clearance to manufacture and market the containers, which could be time consuming and expensive.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA enforces the requirements described above by various means, including inspection and market surveillance. If the FDA finds a violation, it can institute a wide variety of enforcement actions, ranging from an Untitled Letter or Warning Letter to more severe sanctions such as:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">fines, injunctions, and civil money penalties;</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">recall or seizure of products;</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">operating restrictions, partial suspension or total shutdown of production; and</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">criminal prosecution.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Federal Oversight of Laboratory Developed Tests and Research Use Only Products</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical laboratory tests like our proprietary genomic tests are regulated under CLIA, as administered by CMS, as well as by applicable state laws. Clinical laboratory tests that are developed and validated by a laboratory are referred to as laboratory developed tests, or LDTs, by the FDA.  Currently, FDA believes these tests meet the definition of a device under the FDC Act; however, the FDA is currently exercising enforcement discretion for LDTs, meaning that FDA is not enforcing the device regulations that FDA has stated apply to clinical laboratories performing a LDT , although FDA may continue to enforce device regulations with respect to reagents, instruments, software or components provided by third parties and used to perform LDTs. We believe that the Afirma, Percepta and Envisia classifiers are LDTs for which FDA is currently exercising its enforcement discretion. In October 2014, the FDA published a draft guidance document proposing a framework for the regulation of LDTs.  In November 2016, the FDA announced that it would not finalize guidance and would instead work with the new Administration, Congress and stakeholders on an updated framework.  In January 2017, the FDA issued a discussion paper on LDTs in which it synthesized stakeholder feedback and outlined a substantially revised "possible approach" to the oversight of LDTs, which did not represent a formal position of the FDA, and is not enforceable.  In a December 2018 statement, FDA said that there is a need for &#8220;a unified approach to the regulation of in vitro clinical tests to protect patient safety, support innovation, and keep pace with the rapidly evolving technology that&#8217;s helping us find new treatments for disease,&#8221; and listed key principles of an approach it would support.  However, FDA&#8217;s enforcement discretion policy is expected to remain in place unless and until FDA announces and implements a different approach to the regulation of LDTs.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the materials we use for our tests and that we may use for future tests are in vitro diagnostic products intended and labeled for research use only, or RUO, or investigational use only, or IUO. An RUO product cannot be used for any human clinical purpose and must be labeled "For Research Use Only. Not for use in diagnostic procedures." RUOs are a separate regulatory category and include in vitro diagnostic devices that are in the laboratory research phase of development. They are therefore not subject to most FDA regulatory requirements so long as they are properly labeled and used in accordance with such labeling.  RUOs cannot be marketed with any claims that the device is safe, effective, or has diagnostic utility, or is intended for human clinical diagnostic or prognostic use. In November 2013, the FDA issued final guidance titled &#8220;Distribution of In-Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only&#8221; regarding the distribution, use, and labeling of in vitro diagnostic products labeled RUO or IUO. The FDA has advised that if evidence demonstrates that a product is inappropriately labeled for research or investigational use only, the device would be considered misbranded and adulterated within the meaning of the FDC Act. In the guidance, FDA stated that the manufacturer&#8217;s objective intent for an RUO or IUO product&#8217;s intended use will be determined by examining the totality of circumstances, including advertising, instructions for clinical interpretation, presentations that describe clinical use, and specialized technical support, surrounding the distribution of the product in question.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot predict the ultimate form or impact of any such RUO/IUO, LDT or other guidance and the potential effect on our solutions or materials used to perform our diagnostic services. While we qualify all materials used in our diagnostic services according to CLIA regulations, we cannot be certain that the FDA might not promulgate rules or issue guidance documents that could affect our ability to purchase materials necessary for the performance of our diagnostic services. Should any of the reagents obtained by us from vendors and used in conducting our diagnostic services be affected by future regulatory actions, our business could be adversely affected by those actions, including increasing the cost of service or delaying, limiting or prohibiting the purchase of reagents necessary to perform the service.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot provide any assurance that FDA premarket review or other requirements will not be imposed in the future for our diagnostic services, whether through additional guidance or regulations issued by the FDA, new enforcement policies adopted by </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or new legislation enacted by Congress. Legislative proposals addressing oversight of LDTs were introduced in recent years, most recently the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 in December 2018, and we expect that new legislative proposals will be introduced from time to time. It is possible that legislation could be enacted into law or regulations or guidance could be issued by the FDA which may result in new or increased regulatory requirements for us to continue to offer our tests or to develop and introduce new tests.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If premarket review, clearance, or approval, is required, our business could be negatively affected until such review is completed and clearance or approval to market is obtained, and the FDA could require that we stop selling our tests pending premarket clearance or approval. If our tests are allowed to remain on the market but there is uncertainty about the legal status of our services, if we are required by the FDA to label them investigational, or if FDA limits the use and corresponding labeling claims, order levels may decline and reimbursement may be adversely affected. The regulatory process may involve, among other things, successfully completing additional clinical studies and submitting to FDA a premarket notification to obtain clearance or a PMA to obtain approval to market the device. If clearance or approval is required by the FDA, there can be no assurance that our tests will be cleared or approved on a timely basis, if at all, nor can there be any assurance that approved labeling claims or labeling claims subject to cleared indications for use will be consistent with our current claims or adequate to support continued adoption of and reimbursement for our solutions. Ongoing compliance with FDA regulations would increase the cost of conducting our business, and subject us to heightened requirements of the FDA and penalties for failure to comply with these requirements. We may also decide voluntarily to pursue FDA premarket review of our tests to obtain marketing clearance or approval if we determine that doing so would be appropriate.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Privacy and Fraud and Abuse Compliance</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Health Insurance Portability and Accountability Act</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, the Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information used or disclosed by health care providers, such as us. HIPAA also regulates standardization of data content, codes and formats used in health care transactions and standardization of identifiers for health plans and providers. In 2009, Congress amended HIPAA through the Health Information Technology for Economic and Clinical Health Act, or HITECH. The implementing regulations of HIPAA, as amended by HITECH, were last modified in 2013 and resulted in significant changes to the privacy, security, breach notification, and enforcement requirements with which we must comply. Among these changes, covered entities are now vicariously liable for violations of HIPAA resulting from acts or omissions of their business associates where the business associate is an agent of the covered entity and was acting within the scope of its agency,&#160;regardless of whether the covered entity and business associate entered into a business associate agreement in compliance with HIPAA.  Penalties for violations of HIPAA regulations include civil and criminal penalties.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have developed and implemented policies and procedures designed to comply with HIPAA&#8217;s privacy, security, and breach notification requirements. We may not use or disclose protected health information in any form, including electronic, written, or oral, in a manner that is not permitted under HIPAA, and we are required to implement security measures to ensure the confidentiality, integrity, and availability of the electronic protected health information that we create, receive, maintain, or transmit. While we have some flexibility in determining which security safeguards are reasonable and appropriate to implement for our operations, it nonetheless requires significant effort and expense to ensure continuing compliance with the HIPAA security rule.&#160;We are also required to comply with the administrative simplification standards under HIPAA when we conduct the electronic transactions regulated by HIPAA, including by using standard code sets and formats and standardized identifiers for health plans and providers.  The requirements under HIPAA and its implementing regulations may change periodically and could have an effect on our business operations if compliance becomes substantially costlier than under current requirements.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to federal privacy regulations, there are a number of state laws governing confidentiality of health information that are applicable to our business.  In particular, we are subject to the California Consumer Privacy Act, or CCPA, which was enacted in California in 2018 and components of which went into effect on January 1, 2020.&#160; The CCPA, among other things, requires covered companies to provide disclosures to California consumers concerning the collection and sale of personal information, and gives such consumers the right to opt-out of certain sales of personal information. Amendments to the CCPA have been made since its enactment, and it remains unclear what, if any, further amendments will be made to this legislation or how it will be interpreted. </span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recent developments in Europe have created compliance uncertainty regarding the processing of personal data from Europe.  For example, the General Data Protection Regulation, or GDPR, which became effective in the European Union on May 25, 2018, applies to our activities conducted from an establishment in the EU or related to products and services that we offer to European Union users. The GDPR creates new compliance obligations applicable to our business, which could cause us to change our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">business practices, and increases financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher) for the most serious infringements).</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New laws governing privacy may be adopted in the future from time to time. We have taken steps to comply with health information privacy requirements to which we are aware that we are subject. However, we can provide no assurance that we are or will remain in compliance with diverse privacy requirements in all of the jurisdictions in which we do business. Failure to comply with privacy requirements could result in civil or criminal penalties, which could have a materially adverse effect on our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Practice of Medicine</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous states, including California and Texas, have enacted laws prohibiting corporations such as us from practicing medicine and employing or engaging physicians to practice medicine. These laws are designed to prevent interference in the medical decision-making process by anyone who is not a licensed physician. This prohibition is generally referred to as the prohibition against the corporate practice of medicine. Violation of this prohibition may result in civil or criminal fines, as well as sanctions imposed against us or the professional through licensing proceedings. The pathologists who review and classify thyroid FNA cytopathology results for Afirma are employed by TCP, a Texas professional association, pursuant to services agreement between us and TCP. Pursuant to the agreement, we pay TCP a monthly fee on a per FNA basis, and TCP manages and supervises the pathologists who perform the cytopathology services as a component of the Afirma solution.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Federal and State Physician Self-Referral Prohibitions</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar restrictions under the self-referral prohibitions of certain states in which we operate, including California's Physician Ownership and Referral Act, or PORA. Together these restrictions generally prohibit us from billing a patient or any governmental or private payer for any diagnostic services when the physician ordering the service, or any member of such physician's immediate family, has an investment interest in or compensation arrangement with us, unless the arrangement meets an exception to the prohibition.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Both the Stark Law and PORA contain an exception for compensation paid to a physician for personal services rendered by the physician meeting certain contractual requirements. We have compensation arrangements with a number of physicians for personal services, such as speaking engagements and consulting activities. We have structured these arrangements with terms intended to comply with the requirements of the personal services exception to Stark and PORA.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">However, we cannot be certain that regulators would find these arrangements to be in compliance with Stark, PORA or similar state laws. We would be required to refund any payments we receive pursuant to a referral prohibited by these laws to the patient, the payer or the Medicare program, as applicable.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sanctions for a violation of the Stark Law include the following:</span></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:17px;text-align:left;text-indent:12px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">denial of payment for the services provided in violation of the prohibition;</span></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">refunds of amounts collected by an entity in violation of the Stark Law;</span></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">a civil penalty of up to $15,000 for each service arising out of the prohibited referral;</span></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">possible exclusion from federal healthcare programs, including Medicare and Medicaid; and</span></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:29px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">a civil penalty of up to $100,000 against parties that enter into a scheme to circumvent the Stark Law's prohibition.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These prohibitions apply regardless of the reasons for the financial relationship and the referral. No finding of intent to violate the Stark Law is required for a violation. In addition, knowing violations of the Stark Law may also serve as the basis for liability under the Federal False Claims Act which prohibits knowingly presenting, or causing to be presented, a false, fictitious, or fraudulent claim for payment to the U.S. Government.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, a violation of PORA is a misdemeanor and could result in civil penalties and criminal fines. Finally, other states have self-referral restrictions with which we have to comply that differ from those imposed by federal and California law. While we have attempted to comply with the Stark Law, PORA and similar laws of other states, it is possible that some of our financial arrangements with physicians could be subject to regulatory scrutiny at some point in the future, and we cannot provide assurance that we will be found to be in compliance with these laws following any such regulatory review.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Federal and State Anti-Kickback Laws</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Anti-kickback Law makes it a felony for a person or entity, including a laboratory, to knowingly and willfully offer, pay, solicit or receive remuneration, directly or indirectly, in order to induce business that is reimbursable under any federal health care program. A violation of the Anti-kickback Law may result in imprisonment for up to five years and fines of up to $250,000 in the case of individuals and $500,000 in the case of organizations. Convictions under the Anti-kickback Law result in mandatory exclusion from federal health care programs for a minimum of five years. In addition, HHS has the authority to impose civil assessments and fines and to exclude health care providers and others engaged in prohibited activities from Medicare, Medicaid and other federal health care programs. Actions which violate the Anti-kickback Law also incur liability under the Federal False Claims Act, which prohibits knowingly presenting, or causing to be presented, a false, fictitious, or fraudulent claim for payment to the U.S. Government.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Anti-kickback Law applies only to federal health care programs, a number of states, including California, have passed statutes substantially similar to the Anti-kickback Law pursuant to which similar types of prohibitions are made applicable to all other health plans and third- party payers. California's fee-splitting and Anti-kickback statute, Business and Professions Code Section&#160;650, and its Medi-Cal Anti-kickback statute, Welfare and Institutions Code Section&#160;14107.2, have been interpreted by the California Attorney General and California courts in substantially the same way as HHS and the courts have interpreted the Anti-kickback Law. A violation of Section&#160;650 is punishable by imprisonment and fines of up to $50,000. A violation of Section&#160;14107.2 is punishable by imprisonment and fines of up to $10,000.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal and state law enforcement authorities scrutinize arrangements between health care providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to induce patient care referrals or induce the purchase or prescribing of particular products or services. The law enforcement authorities, the courts and Congress have also demonstrated a willingness to look behind the formalities of a transaction to determine the underlying purpose of payments between health care providers and actual or potential referral sources. Generally, courts have taken a broad interpretation of the scope of the Anti-kickback Law, holding that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals or purchases.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Anti-kickback Law includes statutory exceptions and provides for a number of safe harbors. If an arrangement meets the provisions of a safe harbor, it is deemed not to violate the Anti-kickback Law. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. Many state anti-kickback statutes have analogous exceptions or safe harbors to those of the federal Anti-kickback Law. These state anti-kickback statutes have generally been interpreted consistently with the Anti-kickback Law.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Among the safe harbors that may be relevant to us is the discount safe harbor. The discount safe harbor potentially applies to discounts provided by providers and suppliers, including laboratories, to physicians or institutions. If the terms of the discount safe harbor are met, the discounts will not be considered prohibited remuneration under the Anti-kickback Law. California does not have a discount safe harbor. However, as noted above, Section&#160;650 has generally been interpreted consistent with the Anti-kickback Law.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The personal services safe harbor to the Anti-kickback Law provides that remuneration paid to a referral source for personal services will not violate the Anti-kickback Law provided all of the elements of that safe harbor are met. One element is that if the agreement is intended to provide for the services of the physician on a periodic, sporadic or part-time basis, rather than on a full-time basis for the term of the agreement, the agreement specifies exactly the schedule of such intervals, their precise length, and the exact charge for such intervals. Our personal services arrangements with some physicians may not meet the specific requirement of this safe harbor that the agreement specify exactly the schedule of the intervals of time to be spent on the services because the nature of the services, such as speaking engagements, does not lend itself to exact scheduling and therefore meeting this element of the personal services safe harbor is impractical. Failure to meet the terms of the safe harbor does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis under the language of the statute, taking into account all facts and circumstances.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we believe that we are in compliance with the Anti-kickback Law, Section&#160;650, and Section 14107.2, there can be no assurance that our relationships with physicians, academic institutions and other customers will not be subject to investigation or challenge under such laws. If imposed for any reason, sanctions under the Anti-kickback Law, Section&#160;650, or Section 14107.2 could have a negative effect on our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Federal and State Fraud and Abuse Laws</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the requirements discussed above, several other health care fraud and abuse laws could have an effect on our business. For example, provisions of the Social Security Act permit Medicare and Medicaid to exclude an entity that charges the federal health care programs substantially in excess of its usual charges for its services. The terms "usual charge" and "substantially </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">in excess" are ambiguous and subject to varying interpretations, though the Department of Health and Human Services&#8217; Office of the Inspector General has provided some guidance on the topic.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, the federal False Claims Act prohibits a person from knowingly presenting or causing to be presented a false or fraudulent claim to, making a false record or statement in order to secure payment from or retaining an overpayment by the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the alleged fraud. Because the complaint is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. If the government is ultimately successful in obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government's involvement, then the plaintiff will receive a percentage of the recovery. Finally, the Social Security Act includes its own provisions that prohibit the filing of false claims or submitting false statements in order to obtain payment. Violation of these provisions may result in up to treble damages, substantial civil penalties, fines, imprisonment or combination of the above, and possible exclusion from Medicare or Medicaid programs. California has an analogous state false claims act applicable to all payers, as do many other states; however, we may not be aware of all such rules and statutes and cannot provide assurance that we will be in compliance with all such laws and regulations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In general, in recent years U.S. Attorneys&#8217; Offices have increased scrutiny of the healthcare industry, as have Congress, the Department of Justice, the Department of Health and Human Services&#8217; Office of the Inspector General and the Department of Defense. These bodies have all issued subpoenas and other requests for information to conduct investigations of, and commenced civil and criminal litigation against, healthcare companies based on financial arrangements with health care providers, regulatory compliance, product promotional practices and documentation, and coding and billing practices. Whistleblowers have filed numerous qui tam lawsuits against healthcare companies under the federal and state False Claims Acts in recent years, in part because the whistleblower can receive a portion of the government&#8217;s recovery under such suits.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, in October 2018, the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, was enacted as part of the SUPPORT for Patients and Communities Act (P.L 115-271).  This law prohibits the solicitation, receipt, payment or offering of any remuneration in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory for services covered by both government and private payers. EKRA also applies to the payment or offering of remuneration in exchange for an individual using the services of a recovery home, clinical treatment facility, or laboratory. To date, neither the Department of Justice nor the Department of Health and Human Services has issued guidance further interpreting or implementing EKRA.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finally, under PAMA, laboratories are required to report to CMS the private payer payment rates and test volumes paid by private payers based on final payments made during a specific &#8220;data collection period.&#8221; This data reporting requirement is triennial for most clinical diagnostic laboratory tests (annual for ADLTs), with the first data reporting period occurring in 2017 for final payments made in January through June 2016. The next data reporting period will be in 2021 for final payments made in January through June 2019.  When reporting data under PAMA, the President, CEO, or CFO of a reporting entity, or an individual who has been delegated authority to sign for, and who reports directly to, such an officer, must sign the certification statement and be responsible for assuring that the data provided are accurate, complete, and truthful, and meets all the required reporting parameters. Failure to report or misrepresentation or omission in reporting can result in civil penalties of up to $10,000 per day for each violation and other penalties. We believe we are in compliance with the PAMA reporting requirements, but there can be no assurance that our reporting practices will not be scrutinized under the PAMA regulations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">International</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many countries in which we may offer any of our tests in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national health care program. In situations involving physicians employed by state-funded institutions or national health care agencies, violation of the local anti-kickback law may also constitute a violation of the United States Foreign Corrupt Practices Act, or FCPA.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FCPA prohibits any U.S. individual, business entity or employee of a U.S. business entity to offer or provide, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors' activities that may fall within the purview of the FCPA, its books and records provisions and its anti-bribery provisions.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The standard of intent and knowledge in the Anti-Bribery cases is minimal-intent and knowledge are usually inferred from that fact that bribery took place. The accounting provisions do not require intent. Violations of the FCPA's anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2&#160;million and officers, directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption regulations, such as the United Kingdom Anti-bribery Act.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When marketing our tests outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our tests or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Patents and Proprietary Technology</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to remain competitive, we must develop and maintain protection of the proprietary aspects of our technologies. To that end, we rely on a combination of patents, copyrights and trademarks, as well as contracts, such as confidentiality, invention assignment and licensing agreements. We also rely upon trade secret laws to protect unpatented know-how and continuing technological innovation. In addition, we have what we consider to be reasonable security measures in place to maintain confidentiality. Our intellectual property strategy is intended to develop and maintain our competitive position.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We apply for and in-license patents covering our products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions.  Our issued patents expire between 2029 and 2035 and are related to methods used in the Afirma thyroid diagnostic platform, lung diagnostics, breast cancer diagnostics, and the nCounter analysis platform.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We intend to file additional patent applications in the United States and abroad to strengthen our intellectual property rights; however, our patent applications (including the patent applications listed above) may not result in issued patents in a timely fashion or at all, and we cannot assure investors that any patents that have issued or might issue will protect our technology. We may receive notices of claims of potential infringement from third parties in the future.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We hold registered trademarks in the United States for "Veracyte," "Afirma," "Percepta," "Know By Design," the Afirma logo, and the current and former Veracyte logos, and we have a pending federal trademark application for "Envisia". &#160;We also hold registered trademarks in various jurisdictions outside of the United States.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We require all employees and technical consultants working for us to execute confidentiality agreements, which provide that all confidential information received by them during the course of the employment, consulting or business relationship be kept confidential, except in specified circumstances. Our agreements with our research employees provide that all inventions, discoveries and other types of intellectual property, whether or not patentable or copyrightable, conceived by the individual while he or she is employed by us are assigned to us. We cannot provide any assurance, however, that employees and consultants will abide by the confidentiality or assignment terms of these agreements. Despite measures taken to protect our intellectual property, unauthorized parties might copy aspects of our technology or obtain and use information that we regard as proprietary.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At December&#160;31, 2019, we had 354 employees, of which 60 work in laboratory operations, 33 in research and development and clinical development, 175 in selling and marketing, and 86 in general and administrative, including 59 in billing and client services, 10 in information technology and 9 in finance. None of our employees are the subject of collective bargaining arrangements, and our management considers its relationships with employees to be good.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Environmental Matters</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations require the use of hazardous materials (including biological materials) which subject us to a variety of federal, state and local environmental and safety laws and regulations. Some of these regulations provide for strict liability, holding a party potentially liable without regard to fault or negligence. We could be held liable for damages and fines as a result of our, or others&#8217;, business operations should contamination of the environment or individual exposure to hazardous substances occur. We cannot predict how changes in laws or new regulations will affect our business, operations or the cost of compliance.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Raw Materials and Suppliers</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We procure reagents, equipment, chips and other materials that we use to perform our tests from sole suppliers. We also purchase components used in our collection kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. In addition, we utilize a sole source to assemble and distribute our sample collection kits. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. If these suppliers can no longer provide us with the materials we need to perform the tests and for our collection kits, if the materials do not meet our quality specifications or are otherwise unusable, if we cannot obtain acceptable substitute materials, or if we elect to change suppliers, an interruption in test processing could occur, we may not be able to deliver patient reports and we may incur higher one-time switching costs.  Any such interruption may significantly affect our future revenue, cause us to incur higher costs, and harm our customer relationships and reputation. In addition, in order to mitigate these risks, we maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. If our test volume decreases or we switch suppliers, we may hold excess inventory with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new test, we may experience supply issues as we ramp test volume.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we may be party to lawsuits in the ordinary course of business. We are currently not a party to any material legal proceedings.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><a id="s56DE957E174475B6100E428B0795CC56"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have a history of losses, and we expect to incur net losses for the foreseeable future and may never achieve or sustain profitability.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred net losses since our inception. For the year ended December 31, 2019, we had a net loss of $12.6 million and as of December 31, 2019, we had an accumulated deficit of $246.7 million.  We expect to incur additional losses in the future, and we may never achieve revenue sufficient to offset our expenses. Over the next couple of years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for our Afirma, Percepta and Envisia classifiers and Prosigna test, and the development of additional tests. We may never achieve or sustain profitability, and our failure to achieve and sustain profitability in the future could cause the market price of our common stock to decline.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our financial results currently depend mainly on sales of our Afirma tests, and we will need to generate sufficient revenue from this and other diagnostic solutions to grow our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most of our revenue to date has been derived from the sale of our Afirma tests, which are used in the diagnosis of thyroid cancer.  Over the next few years, we expect to continue to derive a substantial portion of our revenue from sales of our Afirma tests.  In the third quarter of 2017, we began recognizing revenue from the sale of our Percepta test, used in the diagnosis of lung cancer.  We also launched our Envisia test to help improve the diagnosis of interstitial lung disease, specifically IPF, and began recognizing revenue from Envisia in the second quarter of 2019. In December 2019, we acquired the rights to the Prosigna test from NanoString Technologies, Inc. and commenced marketing and selling Prosigna test kits to U.S. and international customers.  Once genomic tests are clinically validated and commercially available for patient testing, we must continue to develop and publish evidence that our tests are informing clinical decisions in order for them to receive positive coverage decisions by payers.  Without coverage policies, our tests may not be reimbursed and we will not be able to recognize revenue. We cannot guarantee that tests we commercialize will gain and maintain positive coverage decisions and therefore, we may never realize revenue from tests we commercialize.  In addition, we are in various stages of research and development for other diagnostic solutions that we may offer, but there can be no assurance that we will be able to identify other diseases that can be effectively addressed or, if we are able to identify such diseases, whether or when we will be able to successfully commercialize solutions for these diseases and obtain the evidence and coverage decisions from payers. If we are unable to increase sales and expand reimbursement for our Afirma, Percepta, Envisia and Prosigna tests, or develop and commercialize other solutions, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not able to successfully transition to our next-generation Percepta GSC, our business, operating results and competitive position could be harmed.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are in the process of transitioning our customers to our next-generation Percepta Genomic Sequencing Classifier, or GSC, that uses the same technology platform as the Afirma and Envisia classifiers. There are risks associated with this transition that include, but are not limited to, operational implementation, reimbursement, and customer adoption risks. If we are unable to effectively transition to the new platform, our business, financial condition and results of operations could be adversely effected and our reputation and competitive position could be harmed.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend on a few payers for a significant portion of our revenue and if one or more significant payers stops providing reimbursement or decreases the amount of reimbursement for our tests, our revenue could decline.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue for tests performed on patients covered by Medicare and UnitedHealthcare was 26% and 11%, respectively, of our revenue for the </span><span style="font-family:inherit;font-size:10pt;">twelve months ended December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared with 29% and 12%, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">twelve months ended December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The percentage of our revenue derived from significant payers is expected to fluctuate from period to period as our revenue fluctuates, as additional payers provide reimbursement for our tests or if one or more payers were to stop reimbursing for our tests or change their reimbursed amounts. Effective January 2012, Palmetto GBA, the regional Medicare Administrative Contractor, or MAC, that handled claims processing for Medicare services over our jurisdiction at that time, issued coverage and payment determinations for our Afirma Classifiers now covered by Noridian Healthcare Solutions, the current MAC for our jurisdiction, through the Molecular Diagnostics Services Program, or MolDX program, administered by Palmetto GBA, under a Local Coverage Determination, or LCD. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noridian Healthcare Solutions issued an LCD for Percepta effective for services performed on or after May 2017. This coverage policy requires us to establish and maintain a Certification and Training Registry program and make Percepta available only to certain Medicare patients through physicians who participate in this program. Failure by us or physicians to comply with the requirements of the Certification and Training Registry program could lead to loss of Medicare coverage for Percepta, which could have an adverse effect on our revenue. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We submitted the dossier of clinical evidence needed to obtain Medicare coverage for the Envisia Genomic Classifier through the MolDX technical assessment process in 2018, and received final Medicare coverage for the classifier in the first quarter of 2019, with an effective date of April 1, 2019. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An LCD was issued for Prosigna by Palmetto GBA in August 2015, which has been in effect since October 1, 2015.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a five-year rotational basis, Medicare requests bids for its regional MAC services. Any future changes in the MAC processing or coding for Medicare claims for the Afirma, Percepta or Envisia classifiers, or for Prosigna, could result in a change in the coverage or reimbursement rates for such products, or the loss of coverage, and could also result in increased difficulties in obtaining and maintaining coverage for future products. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 1, 2015, an American Medical Association Current Procedural Terminology code, or CPT code, 81545 for the Afirma GEC was issued. On January 1, 2018, the Medicare Clinical Laboratory Fee Schedule payment rate for the Afirma classifier increased from $3,220 to $3,600.  This rate is based on the volume-weighted median of private payer rates based on final payments made between January 1 and June 30, 2016, which we reported to the Centers for Medicare &amp; Medicaid Services, or CMS, in 2017 as required under the Protecting Access to Medicare Act of 2014, or PAMA. In December 2019, through the Further Consolidated Appropriations Act of 2020, Congress delayed the next data reporting period from 2020 to 2021 for final payments made between January 1 and June 30, 2019, extending the applicability of the payment rates based on 2017 reporting by one year through December 31, 2021.  Afirma will continue to be paid at $3,600 through that date. The volume-weighted median of private payer rates for final payments made from January through June 2019 (and now reported January through March 2021) will set the Medicare payment rate for the Afirma classifier from January 1, 2022 through December 31, 2024.  There can be no assurance that the Afirma or Prosigna rates will not decrease during this or a subsequent reporting cycle under PAMA.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We submit claims to Medicare for Percepta and Envisia using unlisted codes under the MolDX program. Specific CPT codes assigned to Percepta and Envisia may be required to go through the national payment determination process, and there can be no assurance that the Medicare payment rates the tests receive through this process will not be lower than their current payment rates. There can also be no assurance that the Medicare payment rates for the tests will not be reduced when they are set based on the volume-weighted medians of private payer rates when we are required to report those rates under PAMA. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If there is a decrease in the Medicare payment rate for our tests, our revenue from Medicare will decrease and the payment rates for some of our commercial payers may also decrease if they tie their allowable rates to the Medicare rates.  These changes could have an adverse effect on our business, financial condition and results of operations. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we have entered into contracts with certain third-party payers that establish in-network allowable rates of reimbursement for our Afirma tests, payers may suspend or discontinue reimbursement at any time, may require or increase co-payments from patients, or may reduce the reimbursement rates paid to us.  Reductions in private payer amounts could decrease the Medicare payment rates for our tests under PAMA.  In addition, private payers have begun requiring prior authorization for molecular diagnostic tests.  Potential reductions in reimbursement rates or increases in the difficulty of achieving payment could have a negative effect on our revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If payers do not provide reimbursement, rescind or modify their reimbursement policies, delay payments for our tests, recoup past payments, or if we are unable to successfully negotiate additional reimbursement contracts, our commercial success could be compromised.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Physicians might not order our tests unless payers reimburse a substantial portion of the test price. There is significant uncertainty concerning third-party reimbursement of any test incorporating new technology, including our tests. Reimbursement by a payer may depend on a number of factors, including a payer&#8217;s determination that these tests are:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">not experimental or investigational;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">pre-authorized and appropriate for the specific patient;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cost-effective;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">supported by peer-reviewed publications; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">included in clinical practice guidelines.</span></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since each payer makes its own decision as to whether to establish a coverage policy or enter into a contract to reimburse our tests, seeking these approvals is a time-consuming and costly process.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have a contracted rate of reimbursement with some payers for our tests. Without a contracted rate for reimbursement, our claims are often denied upon submission, and we must appeal the claims. The appeals process is time consuming and expensive, and may not result in payment. In cases where there is no contracted rate for reimbursement, there is typically a greater patient co-insurance or co-payment requirement which may result in further delay or decreased likelihood of collection. Payers may attempt to recoup prior payments after review, sometimes after significant time has passed, which would impact future revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to continue to focus substantial resources on increasing adoption, coverage and reimbursement for the Afirma, Percepta and Envisia classifiers, Prosigna, and any other future tests we may develop. We believe it will take several years to achieve coverage and contracted reimbursement with a majority of third-party payers. However, we cannot predict whether, under what circumstances, or at what payment levels payers will reimburse for our tests. Also, payer consolidation is underway and creates uncertainty as to whether coverage and contracts with existing payers will remain in effect. Finally, if there is a decrease in the Medicare payment rates for our tests, the payment rates for some of our commercial payers may also decrease if they tie their allowable rates to the Medicare rates. Reductions in private payer amounts could decrease the Medicare payment rates for our tests under PAMA.  Our failure to establish broad adoption of and reimbursement for our tests, or our inability to maintain existing reimbursement from payers, will negatively impact our ability to generate revenue and achieve profitability, as well as our future prospects and our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may experience limits on our revenue if physicians decide not to order our tests.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to create or maintain demand for our tests in sufficient volume, we may not become profitable. To generate demand, we will need to continue to educate physicians about the benefits and cost-effectiveness of our tests through published papers, presentations at scientific conferences, marketing campaigns and one-on-one education by our sales force. In addition, our ability to obtain and maintain adequate reimbursement from third-party payers will be critical to generating revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Afirma genomic classifier is included in most physician practice guidelines in the United States for the assessment of patients with thyroid nodules. However, historical practice recommended a full or partial thyroidectomy in cases where cytopathology results were indeterminate to confirm a diagnosis. Our lung products are not yet integrated into practice guidelines and physicians may be reluctant to order tests that are not recommended in these guidelines. The Prosigna test is included in practice guidelines in the United States and internationally but faces competition from other products.  Because our Afirma, Percepta and Envisia testing services are performed by our certified laboratory under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, rather than by the local laboratory or pathology practice, pathologists may be reluctant to support our testing services as well. Guidelines that include our tests currently may subsequently be revised to recommend another testing protocol, and these changes may result in physicians deciding not to use our tests. Lack of guideline inclusion could limit the adoption of our tests and our ability to generate revenue and achieve profitability. To the extent international markets have existing practices and standards of care that are different than those in the United States, we may face challenges with the adoption of our tests in international markets.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may experience limits on our revenue if patients decide not to use our tests.</span></div><div style="line-height:174%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some patients may decide not to use our tests because of price, all or part of which may be payable directly by the patient if the patient&#8217;s insurer denies reimbursement in full or in part. There is a growing trend among insurers to shift more of the cost of healthcare to patients in the form of higher co-payments or premiums, and this trend is accelerating which puts patients in the position of having to pay more for our tests. We expect to continue to see pressure from payers to limit the utilization of tests, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">generally, and we believe more payers are deploying costs containment tactics, such as pre-authorization and employing laboratory benefit managers to reduce utilization rates. Implementation of provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively the ACA, has also resulted in increases in premiums and reductions in coverage for some patients. In addition, Congressional efforts to repeal the ACA could result in an increase in uninsured patients. These events may result in patients delaying or forgoing medical checkups or treatment due to their inability to pay for our tests, which could have an adverse effect on our revenue.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with federal and state licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific personnel qualifications, facilities administration, quality systems, inspections, and proficiency testing. CLIA certification is also required for us to be eligible to bill state and federal healthcare programs, as well as many private third-party payers. To renew these certifications, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratories.  If we in the future fail to maintain CLIA certificates in our South San Francisco or Austin, Texas laboratory locations we would be unable to bill for services provided by state and federal healthcare programs, as well as many private third-party payers, which may have an adverse effect on our business, financial condition and results of operations.  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also required to maintain state licenses to conduct testing in our laboratories. California, New York, and Texas, among other states&#8217; laws, require that we maintain a license and comply with state regulation as a clinical laboratory. Other states may have similar requirements or may adopt similar requirements in the future. In addition, both of our clinical laboratories are required to be licensed on a test-specific basis by New York State. We have received approval for the Afirma, Percepta and Envisia tests. We will be required to obtain approval for other tests we may offer in the future. If we were to lose our CLIA certificate or California license for our South San Francisco laboratory, whether as a result of revocation, suspension or limitation, we would no longer be able to perform our molecular tests, which would eliminate our primary source of revenue and harm our business. If we fail to meet the state licensing requirements for our Austin laboratory, we would need to move the receipt and storage of FNAs, as well as the slide preparation for cytopathology, to South San Francisco, which could result in a delay in processing tests during that transition and increased costs. If we were to lose our licenses issued by New York or by other states where we are required to hold licenses, we would not be able to test specimens from those states. New tests we may develop may be subject to new approvals by regulatory bodies such as New York State, and we may not be able to offer our new tests until such approvals are received. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not successful in integrating the assets acquired from NanoString or if our general strategy of seeking growth through such acquisitions and collaborations is not successful, our prospects and financial condition will suffer.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have recently acquired assets, such as the nCounter FLEX Analysis System and Prosigna in December 2019, and we may pursue additional acquisitions of complementary businesses or assets as part of our business strategy. To date, we have limited experience with respect to acquisitions and the formation of strategic alliances and joint ventures. There can be no assurance that we will successfully integrate the assets acquired from NanoString successfully into our existing business, or that our exclusive worldwide license to the nCounter system for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> diagnostic use will allow us to expand our international reach as anticipated. This and any future acquisitions made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of acquired companies or businesses we may acquire in the future also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To finance any acquisitions or investments, we have previously and may choose in the future to issue shares of our stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all. If these funds are raised through the sale of equity or convertible debt securities, dilution to our stockholders could result. Our Loan and Security Agreement with Silicon Valley Bank contains covenants that could limit our ability to sell debt securities or obtain additional debt financing arrangements, which could affect our ability to finance acquisitions or investments other than through the issuance of stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not successful in advancing our collaborations with Johnson &amp; Johnson and others, or if our general strategy of seeking growth through such collaborations is not successful, our prospects and financial condition will suffer.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have previously entered into technology licensing and collaboration arrangements, such as our collaboration with Johnson &amp; Johnson in December 2018 and with Acerta Pharma, the hematology research and development arm of AstraZeneca, in December 2019, reflecting important elements of our business strategy. We also may pursue additional strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, or make investments in other companies. However, we have limited experience with respect to the formation of strategic alliances and joint ventures. There can be no assurance that we will successfully identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any technology license, strategic alliance, joint venture or investment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on sole suppliers for some of the reagents, equipment, chips and other materials used to perform our tests, and we may not be able to find replacements or transition to alternative suppliers.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on sole suppliers for critical supply of reagents, equipment, chips and other materials that we use to perform our tests and for the manufacture of the nCounter FLEX Dx systems and Prosigna test kits sold to customers. We also purchase components used in our collection kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. In addition, we utilize a sole source to assemble and distribute our sample collection kits. We rely on NanoString for the supply of the nCounter FLEX Dx System and Prosigna test kits. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. If these suppliers can no longer provide us with the materials we need to perform the tests and for our collection kits, if the materials do not meet our quality specifications or are otherwise unusable, if we cannot obtain acceptable substitute materials, or if we elect to change suppliers, an interruption in test processing or system and test kit deliveries could occur, we may not be able to deliver patient reports and we may incur higher one-time switching costs. Any such interruption may significantly affect our future revenue, cause us to incur higher costs, and harm our customer relationships and reputation. In addition, in order to mitigate these risks, we maintain inventories of these supplies at higher levels than would be the case if multiple sources of supplies were available. If our test volume decreases or we switch suppliers, we may hold excess supplies with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new test, we may experience supply issues as we ramp test volume.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend on a specialized cytopathology practice to perform the cytopathology component of our Afirma test, and our ability to perform our diagnostic solution would be harmed if we were required to secure a replacement.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on TCP to provide cytopathology professional diagnoses on thyroid FNA samples pursuant to a pathology services agreement. Pursuant to this agreement, as amended, TCP has the exclusive right to provide our cytopathology diagnoses on FNA samples at a fixed price per test.  Until February 2019, TCP also previously subleased a portion of our facility in Austin, Texas. Our agreement with TCP is effective through October 31, 2022, and thereafter automatically renews every year unless either party provides notice of intent not to renew at least 12 months prior to the end of the then-current term.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If TCP were not able to support our current test volume or future increases in test volume or to provide the quality of services we require, or if we were unable to agree on commercial terms and our relationship with TCP were to terminate, our business would be harmed until we were able to secure the services of another cytopathology provider. There can be no assurance that we would be successful in finding a replacement that would be able to conduct cytopathology diagnoses at the same volume or with the same high-quality results as TCP. Locating another suitable cytopathology provider could be time consuming and would result in delays in processing Afirma tests until a replacement was fully integrated with our test processing operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Due to how we recognize revenue, our quarterly operating results are likely to fluctuate.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize test revenue upon delivery of the patient report to the prescribing physician based on the amount we expect to ultimately realize. We determine the amount we expect to ultimately realize based on payer reimbursement history, contracts, and coverage. Upon ultimate collection, the amount received is compared to the estimates and the amount accrued is adjusted accordingly. We cannot be certain as to when we will receive payment for our diagnostic tests, and we must appeal negative payment decisions, which delays collections. Should judgments underlying estimated reimbursement change or were incorrect at the time we accrued such revenue, our financial results could be negatively impacted in future quarters. As a result, comparing our operating results on a period-to-period basis may not be meaningful. You should not rely on our past results as an indication of our future performance. In addition, these fluctuations in revenue may make it difficult for us, for research analysts and for investors to accurately forecast our revenue and operating results. If our revenue or operating results fall below expectations, the price of our common stock would likely decline.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the need to scale our testing capacity, future growth, including our transition to a multi-product company with international operations, will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees with the necessary skills to support the growing complexities of our business. Rapid and significant growth may place strain on our administrative, financial and operational infrastructure. Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We have implemented an internally-developed data warehouse, which is critical to our ability to track our diagnostic services and patient reports delivered to physicians, as well as to support our financial reporting systems. The time and resources required to optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to support demand for our commercial tests, our business could suffer.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As demand for our tests grows, we will need to continue to scale our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We will also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our tests. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs of processing tests, quality control issues or inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations will not negatively affect the quality of test results. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in healthcare policy, including legislation reforming the U.S. healthcare system, may have a material adverse effect on our financial condition and operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ACA, enacted in March 2010, made changes that significantly affected the pharmaceutical and medical device industries and clinical laboratories. Along with the now-repealed 2.3% excise tax on the sale of certain medical devices sold outside of the retail setting, other significant measures contained in the ACA include, for example, coordination and promotion of research on comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies. The ACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such violations. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the beginning of 2017, the U.S. Congress and the Administration took actions to repeal the ACA and indicated an intent to replace it with another act and efforts to repeal or amend the ACA are ongoing. We cannot predict if, or when, the ACA will be repealed or amended, and cannot predict the impact that an amendment or repeal of the ACA will have on our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the ACA, various healthcare reform proposals have also periodically emerged from federal and state governments. For example, in February 2012, Congress passed the Middle Class Tax Relief and Job Creation Act of 2012, which in part reset the clinical laboratory payment rates on the Medicare Clinical Laboratory Fee Schedule, or CLFS, by 2% in 2013. In addition, under the Budget Control Act of 2011, which is effective for dates of service on or after April 1, 2013, Medicare payments, including payments to clinical laboratories, are subject to a reduction of 2% due to the automatic expense reductions (sequester) until fiscal year 2024. Reductions resulting from the Congressional sequester are applied to total claims payment made; however, they do not currently result in a rebasing of the negotiated or established Medicare or Medicaid reimbursement rates.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State legislation on reimbursement applies to Medicaid reimbursement and managed Medicaid reimbursement rates within that state. Some states have passed or proposed legislation that would revise the reimbursement methodology for clinical laboratory payment rates under those Medicaid programs.  For example, effective July 2015, California&#8217;s Department of Health Care Services implemented a new rate methodology for clinical laboratories and laboratory services. This methodology involves the use of a range of rates that fell between zero and 80% of the calculated California-specific Medicare rate and the calculation of a weighted average (based on units billed) of such rates. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business, or the effect any future legislation or regulation will have on us. The taxes imposed by the new federal legislation, cost reduction measures and the expansion in the role of the U.S. government in the healthcare industry may result in decreased revenue, lower reimbursement by payers for our tests or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations. In addition, sales of our tests outside the United States subject our business to foreign regulatory requirements and cost-reduction measures, which may also change over time.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ongoing calls for deficit reduction at the federal government level and reforms to programs such as the Medicare program to pay for such reductions may affect the pharmaceutical, medical device and clinical laboratory industries. Currently, clinical laboratory services are excluded from the Medicare Part B co-insurance and co-payment as preventative services. Any requirement for clinical laboratories to collect co-payments from patients may increase our costs and reduce the amount ultimately collected.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CMS bundles payments for clinical laboratory diagnostic tests together with other services performed during hospital outpatient visits under the Hospital Outpatient Prospective Payment System. CMS currently maintains an exemption for molecular pathology tests from this bundling provision. It is possible that this exemption could be removed by CMS in future rule making, which might result in lower reimbursement for tests performed in this setting.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PAMA includes a substantial new payment system for clinical laboratory tests under the CLFS. Under PAMA, laboratories that receive the majority of their Medicare revenues from payments made under the CLFS and the Physician Fee Schedule would report on triennial bases (or annually for advanced diagnostic laboratory tests, or ADLTs), private payer rates and volumes for their tests with specific CPT codes based on final payments made during a set data collection period (the first of which was January 1 through June 30, 2016).  We believe that PAMA and its implementing regulations are generally favorable to us.&#160;We reported to CMS the data required under PAMA before the March 31, 2017 deadline. The new payment rate for the Afirma genomic classifier based on the volume-weighted median of private payer rates took effect January 1, 2018, increasing from $3,220 to $3,600 through December 31, 2020.  In December 2019, through the Further Consolidated Appropriations Act of 2020, Congress delayed the next data reporting period from 2020 to 2021 for final payments made between January 1 and June 30, 2019, extending the applicability of the current rate for Afirma through December 31, 2021. The volume-weighted median of the private payer rates between January 1 and June 30, 2019 will now set the Medicare payment rate for the Afirma classifier from January 1, 2022 through December 31, 2024.  There can be no assurance that the payment rate for Afirma or Prosigna will not decrease in the future or that the payment rates for Percepta or Envisia will not be adversely affected by the PAMA law and regulations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our Afirma genomic classifier as well as our Percepta and Envisia classifiers would be considered ADLTs under PAMA. The initial payment rate (for a period not to exceed nine months) under PAMA for a new ADLT (an ADLT for which payment has not been made under the CLFS prior to January 1, 2018) will be set at the &#8220;actual list charge&#8221; for the test as reported by the laboratory. Insofar as the actual list charge substantially exceeds private payer rates (by more than 30%), CMS will have the ability to recoup excess payments made during the initial nine-month payment period.&#160; We can determine whether to seek ADLT status for our tests, but there can be no assurance that our tests will be designated ADLTs or that the payment rates for our tests will not be adversely affected by such designation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have also been recent and substantial changes to the payment structure for physicians, including those passed as part of the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which was signed into law on April 16, 2015. MACRA created the Merit-Based Incentive Payment System which, beginning in 2019, more closely aligns physician payments with composite performance on performance metrics similar to three existing incentive programs (i.e., the Physician Quality Reporting System, the Value-based modifier program and the Electronic Health Record Meaningful Use program) and incentivizes physicians to enroll in alternative payment methods. At this time, we do not know whether these changes to the physician payment systems will have any impact on orders or payments for our tests.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, Congress passed the 21st Century Cures Act, which, among other things, revised the process for LCDs. Additionally, effective June 11, 2017, a MAC is required to, among other things, publish a summary of the evidence that it considered when developing an LCD, including a list of sources, and an explanation of the rationale that supports the MAC&#8217;s determinations. In October 2018, CMS issued additional guidance revising the requirements for the development of LCDs. We cannot predict whether these revisions will delay future LCDs and result in impeded coverage for our test products, which could have a material negative impact on revenue.  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Congress is considering legislation to limit balance billing of patients who receive services from out-of-network providers (including laboratories) at in-network facilities and to set a methodology for payment of the out-of-network provider in such circumstances. This legislation, if enacted, could limit our ability to achieve payment in full for our testing services.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because of Medicare billing rules, we may not receive reimbursement for all tests provided to Medicare patients. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under previous Medicare billing rules, hospitals were required to bill for our tests when performed on Medicare beneficiaries who were hospital outpatients at the time of tissue specimen collection when these tests were ordered less than 14 days following the date of the patient's discharge. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, CMS revised its billing rules to allow the performing laboratory to bill Medicare directly for molecular pathology tests performed on specimens collected from hospital outpatients, even when those tests are ordered less than 14 days after the date of discharge, if certain conditions are met. We believe that our Afirma, Percepta, and Envisia classifiers, along with Prosigna, should be covered by this policy.  Accordingly, we bill Medicare for these tests when we perform them on specimens collected from hospital outpatients and meet the conditions set forth in CMS's revised billing rules.  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This change does not apply to tests performed on specimens collected from hospital inpatients. We will continue to bill hospitals for tests performed on specimens collected from hospital inpatients when the test was ordered less than 14 days after the date of discharge.  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the CY 2020 Hospital Outpatient Prospective Payment System Proposed Rule, CMS solicited comments on potential revisions to these billing rules that could have impacted our ability to bill Medicare directly for our Afirma, Percepta, and Envisia classifiers, as well as for Prosigna, when performed on specimens collected from hospital outpatients.  Although these changes were not finalized, if CMS makes similar changes in the future, it could negatively impact our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we must maintain CLIA compliance and certification to sell our tests and be eligible to bill for diagnostic services provided to Medicare beneficiaries. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the FDA were to begin regulating those of our tests that are not currently regulated, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical laboratory tests have long been subject to comprehensive regulations under CLIA, as well as by applicable state laws. Most laboratory developed tests, or LDTs, are not currently subject to regulation under the FDA's enforcement discretion policy, although reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to regulation.  While the FDA maintains its authority to regulate LDTs, it has chosen to exercise its enforcement discretion not to enforce the premarket review and other applicable medical device requirements for LDTs. We believe that the Afirma, Percepta and Envisia classifiers are LDTs that fall under the FDA's enforcement discretion policy.  In October 2014, the FDA issued draft guidance, entitled "Framework for Regulatory Oversight of LDTs," proposing a risk-based framework of oversight and a phased-in enforcement of premarket review requirements for most LDTs. In 2016, the FDA announced that it would not be finalizing the guidance. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FDA issued a "Discussion Paper on Laboratory Developed Tests" following input it received from multiple stakeholders who had commented on its 2014 draft guidance. The FDA specifically states in its Discussion Paper that the proposals contained in the document do not represent a final version of the LDT draft guidance documents and are only designed to provide a possible approach to spark further dialogue. The suggested LDT framework could grandfather many types of LDTs without requiring new premarket review or quality management requirements. It also suggests a four-year phased implementation of the premarket review requirements for some types of tests.  In a December 2018 statement, the FDA said that there is a need for &#8220;a unified approach to the regulation of in vitro clinical tests to protect patient safety, support innovation, and keep pace with the rapidly evolving technology that&#8217;s helping us find new treatments for disease.&#8221; The FDA listed key principles of an approach it would support.  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2017, a draft bill on the regulation of LDTs, entitled "The Diagnostics Accuracy and Innovation Act", or DAIA, was released for discussion.  In December 2018, the sponsors of DAIA released a new version of the legislation called the &#8220;Verifying Accurate, Leading-edge IVCT Development Act, or VALID Act.  The VALID Act proposes a risk-based approach to regulate LDTs and creates a new in vitro clinical test category, which includes LDTs, and a regulatory structure under the FDA. As proposed, the bill would create a precertification program for lower risk tests not otherwise required to go through premarket review. It would grandfather existing tests but would allow the FDA to subject otherwise grandfathered tests to premarket review under certain conditions.  We cannot predict whether this draft bill will become legislation and cannot quantify the effect of this draft bill on our business.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the FDA were to require us to seek clearance or approval for our existing tests or any of our future products for clinical use, we may not be able to obtain such approvals on a timely basis, or at all. While we believe our Afirma, Percepta and Envisia classifiers would likely qualify for the &#8220;grandfathered&#8221; tests treatment, there can be no assurance of what the FDA might ultimately require if it issued final guidance. If premarket reviews were required, our business could be negatively impacted if we were required to stop selling our products pending their clearance or approval.  In addition, the launch of any new products that we develop could be delayed by the implementation of future FDA guidance. The cost of complying with premarket review requirements, including obtaining clinical data, could be significant. In addition, future regulation by the FDA could subject our business to further regulatory risks and costs. Failure to comply with applicable regulatory requirements of the FDA could result in enforcement action, including receiving untitled or warning letters, fines, injunctions, or civil or criminal penalties. Any such enforcement action would have a material adverse effect on our business, financial condition and operations. In addition, our sample collection containers are listed as Class I devices with the FDA. If the FDA were to determine that they are not Class I devices, we would be required to file 510(k) applications and obtain FDA clearance to use the containers, which could be time consuming and expensive.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the materials we use for our tests and that we may use for future tests are labeled for research use only, or RUO, or investigational use only, or IUO. In November 2013, the FDA finalized guidance regarding the sale and use of products labeled RUO or IUO. Among other things, the guidance advises that the FDA continues to be concerned about distribution of research or investigational use only products intended for clinical diagnostic use and that the manufacturer&#8217;s objective intent for the product&#8217;s intended use will be determined by examining the totality of circumstances, including advertising, instructions for clinical interpretation, presentations that describe clinical use, and specialized technical support, surrounding the distribution of the product in question. The FDA has advised that if evidence demonstrates that a product is inappropriately labeled for research or investigational-use only, the device would be considered misbranded and adulterated within the meaning of the Federal Food, Drug and Cosmetic Act. Some of the reagents, instruments, software or components obtained by us from suppliers for use in our products are currently labeled as RUO or IUO. If the FDA were to determine that any of these reagents, instruments, software or components are improperly labeled RUO or IUO and undertake enforcement actions, some of our suppliers might cease selling these reagents, instruments, software or components to us, and any failure to obtain an acceptable substitute could significantly and adversely affect our business, financial condition and results of operations, including increasing the cost of testing or delaying, limiting or prohibiting the purchase of reagents, instruments, software or components necessary to perform testing.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obtaining marketing authorization by the FDA and foreign regulatory authorities for our diagnostic tests will take significant time and require significant research, development and clinical study expenditures and ultimately may not succeed.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Before we begin to label and market some of our products for use as clinical diagnostics in the United States, unless an exemption applies, we are required to obtain clearance from FDA by submitting a premarket notification under section 510(k) of the FDC Act, or 510(k), or approval from FDA by submitting a PMA. We may also be able to obtain marketing authorization through a de novo classification process rather than through a PMA if the 510(k) pathway is not available.  In September 2013, Prosigna obtained FDA 510(k) clearance as a prognostic indicator for distant recurrence-free survival at ten years in post-menopausal </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">women with Stage I/II lymph node-negative or Stage&#160;II lymph node-positive (1-3 positive nodes), hormone receptor-positive breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors after they</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">have undergone surgery in conjunction with locoregional treatment and consistent with the standard of care. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2014, the FDA issued a final guidance document titled In Vitro Companion Diagnostic Devices. In the guidance, FDA defined an IVD companion diagnostic device as an in vitro diagnostic device that provides information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, including the labeling of any generic equivalents of the therapeutic product.  FDA stated that an IVD companion diagnostic should be submitted for review and approved or cleared through an appropriate device submission contemporaneously with the review and approval of the therapeutic product to facilitate concurrent review.   The FDA guidance also stated that while there may be cases when a companion diagnostic could come to market through the 510(k) pathway, FDA expects that most companion diagnostics will be Class III devices.  Class III devices generally require the approval of a PMA before they can be marketed. An IVD diagnostic device that is not a companion diagnostic device because it is not essential for the safe and effective use of a corresponding therapeutic product, may still be beneficial for use with a therapeutic product but may not be identified in the labeling of the therapeutic product.  It is possible that revenue from a cleared or approved beneficial or complementary IVD diagnostic device may be less than revenue from a cleared or approved IVD companion diagnostic device.   There is no assurance that we would be able to obtain clearance or approval for any of our diagnostic devices in development as a companion diagnostic device.   </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any marketing authorization we obtain for any future device product would be subject to regulatory requirements that would affect how we are able to market and sell the device. The FDC Act and FDA regulations place considerable requirements on our products, including, but not limited to, compliance with the QSR, establishment registration and product listing with the FDA, and compliance with labeling, marketing, complaint handling, medical device reporting requirements, and reporting certain corrections and removals. Obtaining FDA clearance or approval for diagnostics can be expensive and uncertain, generally may take several&#160;months to several years, and generally requires detailed and comprehensive scientific and clinical data, as well as compliance with FDA regulations for investigational devices. In addition, we have limited experience in obtaining PMA approval from the FDA and are therefore supplementing our operational capabilities to manage the more complex processes needed to obtain and maintain PMAs. Notwithstanding the expense, these efforts may never result in FDA clearance or approval. Even if we were to obtain marketing authorization, it may not be for the uses we believe are important or commercially attractive, in which case we would not market our product for those uses.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of our diagnostic products outside the United States are subject to foreign regulatory requirements governing clinical studies, vigilance reporting, marketing approval, manufacturing, regulatory inspections, product licensing, pricing and reimbursement. These regulatory requirements vary greatly from country to country. As a result, the time required to obtain approvals outside the United States may differ from that required to obtain FDA marketing authorization, and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. Marketing authorization from the FDA does not ensure approval by regulatory authorities in other countries, and approval by any foreign regulatory authority does not ensure marketing authorization by regulatory authorities in other countries or by the FDA. Foreign regulatory authorities could require additional testing beyond what the FDA requires. In addition, the FDC Act imposes requirements on the export of medical devices, such as labeling requirements, and foreign governments impose requirements on the import of medical devices from the United States. Failure to comply with these regulatory requirements or to obtain required approvals, clearances, and export certifications could impair our ability to commercialize our diagnostic products outside of the United States.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain marketing authorizations to market Prosigna in additional countries or if regulatory limitations are placed on our diagnostic kit products, our business and growth will be harmed.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FDA cleared the Prosigna test for marketing in the United States; Prosigna also has a CE mark which permits us to market the test in the European Union; and Prosigna received marketing authorizations in selected other jurisdictions. We intend to seek regulatory authorizations for Prosigna in other jurisdictions and, potentially, for other indications.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, pursuant to our collaborations with pharmaceutical companies for the development of companion diagnostic tests for use with their drugs, we are responsible for obtaining regulatory authorizations to use the companion diagnostic tests in clinical trials as well as the marketing authorizations to sell the companion diagnostic tests following completion of such trials. Some of the compensation we expect to receive pursuant to these collaborations is based on the receipt of marketing authorizations. Any failure to obtain marketing authorizations for our diagnostic kits in a particular jurisdiction may also reduce sales of our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter systems for clinical use in that jurisdiction, as the lack of a robust menu of available diagnostic tests would make those systems less attractive to testing laboratories.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot assure investors that we will be successful in obtaining regulatory clearances, approvals, or marketing authorizations. If we do not obtain regulatory clearances,&#160;approvals, or marketing authorizations for future kit products or expand future indications for diagnostic purposes, if additional regulatory limitations are placed on our kit products or if we fail to successfully commercialize such products, the market potential for our diagnostic kit products would be constrained, and our business and growth prospects would be adversely affected.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to ongoing and extensive regulatory requirements, and our failure to comply with these requirements could substantially harm our business.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our products are regulated as&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;">&#160;diagnostic medical devices, including Prosigna and the nCounter&#160;FLEX  Analysis System. Accordingly, we and certain of our contract manufacturers are subject to ongoing International Organization for Standardization, or ISO, obligations as well as requirements under the FDC Act and device regulations enforced by the FDA and other statutory and regulatory requirements enforced by other government authorities. These may include routine inspections by Notified Bodies, FDA, and other health authorities, of our manufacturing facilities and our records for compliance with standards  such as ISO 13485 and QSR regulations, which establish extensive requirements for quality assurance and control as well as manufacturing and change control procedures, among other things. We are also subject to other regulatory obligations, such as  registration of our company offices and facilities and the listing of our devices with the FDA; continued adverse event and malfunction reporting; reporting certain corrections and removals; and labeling and promotional requirements. Other regulatory bodies may also issue guidelines and regulations that could impact the development of our products, including companion diagnostic tests. For example, the European Medicines Agency, a European Union agency which is responsible for the scientific evaluation of medicines used in the European Union, recently launched an initiative to determine guidelines for the use of genomic biomarkers in the development and life-cycle of drugs. On April 5, 2017, the European Union Parliament passed Regulation (EU) 2017/746, referred to as the IVD Device Regulation, or IVDR, which increases the regulatory requirements applicable to&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;">&#160;diagnostics in the EU and would require that we re-classify and obtain approval, registration, or clearance for our existing CE-marked IVD products within a five-year grace period (by May 25, 2022).</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also be subject to additional FDA or global regulatory authority post-marketing obligations or requirements by the FDA or global regulatory authority to change our current product classifications which would impose additional regulatory obligations on us. The promotional claims we can make for Prosigna are limited to the indications for use in the United States as cleared by FDA or outside the United States as authorized by the applicable regulatory authority. If we are not able to maintain regulatory compliance, we may not be permitted to market our medical device products and/or may be subject to enforcement actions by the FDA or other governmental authorities such as the issuance of warning or untitled letters, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution. In addition, we may be subject to similar regulatory regimes of foreign jurisdictions as we continue to commercialize our products in new markets outside of the United States and Europe.  Adverse Notified Body, EU Competent Authority or FDA or global regulatory authority action in any of these areas could significantly increase our expenses and limit our revenue and profitability.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our principal competition for our tests comes from traditional methods used by physicians to diagnose and manage patient care decisions. For example, with our Afirma genomic classifier, practice guidelines in the United States have historically recommended that patients with indeterminate diagnoses from cytopathology results be considered for surgery to remove all or part of the thyroid to rule out cancer. This practice has been the standard of care in the United States for many years, and we need to continue to educate physicians about the benefits of the Afirma genomic classifier to change clinical practice.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also face competition from companies and academic institutions that use next generation sequencing technology or other methods to measure mutational markers such as BRAF and KRAS, along with numerous other mutations. These organizations include Interpace Diagnostics Group, Inc., CBLPath, Inc./University of Pittsburgh Medical Center and others who are developing new products or technologies that may compete with our tests. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our primary competition in pulmonology with our Percepta and Envisia classifiers will similarly come from traditional methods used by physicians to diagnose the related diseases. For the Percepta test, we expect competition from companies </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">focused on lung cancer such as Oncocyte Corporation and Biodesix, Inc.  We believe our principal competitor in the breast cancer diagnostics market is Exact Sciences, Inc. (having combined with Genomic Health, Inc.), which currently commands a substantial majority of the market. As we expand our portfolio of tests to address clinical questions across the clinical care continuum, we may also face competition from companies focused on screening at-risk patients for cancer or companies informing treatment decisions such as Guardant Health or GRAIL.  Competition could also emerge using alternative samples, such as blood, urine or sputum.  However, such &#8220;liquid biopsies&#8221; are currently being used to gauge risk of recurrence or response to treatment in patients already diagnosed with lung cancer.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In general, we also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings and Sonic Healthcare USA, with strong infrastructure to support the commercialization of diagnostic services. We face potential competition from companies such as Illumina,&#160;Inc. and Thermo Fisher Scientific&#160;Inc., both of which have entered the clinical diagnostics market. Other potential competitors include companies that develop diagnostic products, such as Roche Diagnostics, a division of Roche Holding&#160;Ltd, Siemens AG and Qiagen&#160;N.V.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, competitors may develop their own versions of our solutions in countries we may seek to enter where we do not have patents or where our intellectual property rights are not recognized and compete with us in those countries, including encouraging the use of their solutions by physicians in other countries.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To compete successfully, we must be able to demonstrate, among other things, that our diagnostic test results are accurate and cost effective, and we must secure a meaningful level of reimbursement for our products.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources, and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by physicians and payers as functionally equivalent to our solutions, or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our solutions and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. As we add new tests and services, we will face many of these same competitive risks for these new tests.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The loss of members of our senior management team or our inability to attract and retain key personnel could adversely affect our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends largely on the skills, experience and performance of key members of our executive management team and others in key management positions. The efforts of each of these persons together will be critical to us as we continue to develop our technologies and test processes and focus on our growth. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses, particularly in the San Francisco Bay Area. Our success in the development and commercialization of advanced diagnostics requires a significant medical and clinical staff to conduct studies and educate physicians and payers on the merits of our tests in order to achieve adoption and reimbursement. We are in a highly competitive industry to attract and retain this talent. Additionally, our success depends on our ability to attract and retain qualified sales people. We recently significantly expanded our sales force as we invest in our multi-product sales strategy, which includes assignment of a single contact to successfully develop and implement relationships with our customers. There can be no assurance that we will be successful in maintaining and growing our business. Additionally, as we increase our sales channels for new tests we commercialize, including the Percepta and Envisia tests, or acquire, such as Prosigna, we may have difficulties recruiting and training additional sales personnel or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our tests. As a public company located in the San Francisco Bay Area, we also face intense competition for highly skilled finance and accounting personnel. If we are unable to attract and retain finance and accounting personnel experienced in public company financial reporting, we risk being unable to close our books and file our public documents on a timely basis.  Finally, our business requires specialized capabilities in reimbursement, billing, and other areas and there may be a shortage of qualified individuals. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sales and reimbursement, billing and finance efforts. All of our employees are at will, which means that either we or the employee may terminate their employment at any time. We do not carry key man insurance for any of our employees.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Billing for our diagnostic tests is complex, and we must dedicate substantial time and resources to the billing process to be paid.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Billing for clinical laboratory testing services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, including Medicare, insurance companies and patients, all of which have different billing requirements. We generally bill third-party payers for our diagnostic tests and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also face increased risk in our collection efforts, including potential write-offs of accounts receivable and long collection cycles, which could adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Several factors make the billing process complex, including:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">differences between the list price for our tests and the reimbursement rates of payers;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:3pt;">&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;">compliance with complex federal and state regulations related to billing government payers, such as Medicare and Medicaid, including requirements to have an active CLIA certificate;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risk of government audits related to billing Medicare and other government payers;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disputes among payers as to which party is responsible for payment;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">differences in coverage and in information and billing requirements among payers, including the need for prior authorization and/or advanced notification;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effect of patient co-payments or co-insurance;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes to billing codes used for our tests;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incorrect or missing billing information; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the resources required to manage the billing and claims appeals process.</span></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use standard industry billing codes, known as CPT codes, to bill for cytopathology.  In addition, we use the CPT code 81545 to bill for our Afirma classifier.  CPT codes do not exist for our other proprietary molecular diagnostic tests. Therefore, until such time that we are assigned and are able to use a designated CPT code specific to Percepta and Envisia, we use &#8220;unlisted&#8221; codes for claim submissions, which can lead to delays in payers adjudicating our claims or denying payment altogether. Moreover, these codes can change over time. When codes change, there is a risk of an error being made in the claim adjudication process. These errors can occur with claims submission, third-party transmission or in the processing of the claim by the payer. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. Coding changes, therefore, may have an adverse effect on our revenues. Even when we receive a designated CPT code specific to our tests, such as the 81545 code for the Afirma GEC that became effective January 1, 2016, there can be no assurance that payers will recognize these codes in a timely manner or that the process of transitioning to such a code and updating their billing systems and ours will not result in errors, delays in payments and a related increase in accounts receivable balances.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we introduce new tests, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Correct coding is subject to the coding policies of the American Medical Association CPT Editorial Panel, or AMA CPT. With respect to claims submitted to Medicare and Medicaid, it is also subject to coding policies developed through the National Correct Coding Initiative, or NCCI. Other payers may develop their own payer-specific coding policies.  The broader coding policies of the AMA CPT, NCCI, and other payers are subject to change.  For instance, the NCCI recently adopted an update to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">its Coding Policy Manual effective January 1, 2019, to limit instances when multiple codes may be billed for molecular pathology testing.  Although the NCCI appears to have moderated this change in its updates effective January 1, 2020, such coding policy changes may negatively affect our revenues and cash flow.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, challenge coverage and payment denials, assist patients in appealing claims, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payers also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payer makes an overpayment determination, there is a risk that we may be required to return some portion of prior payments we have received.  Additionally, the ACA established a requirement for providers and suppliers to report and return any overpayments received from government payers under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws.  These billing complexities, and the related uncertainty in obtaining payment for our tests, could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on a third-party provider to transmit claims to payers, and any delay in transmitting claims could have an adverse effect on our revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we manage the overall processing of claims, we rely on a third-party provider to transmit the actual claims to payers based on the specific payer billing format. We have previously experienced delays in claims processing when our third-party provider made changes to its invoicing system, and again when it did not submit claims to payers within the timeframe we require. Additionally, coding for diagnostic tests may change, and such changes may cause short-term billing errors that may take significant time to resolve. If claims are not submitted to payers on a timely basis or are erroneously submitted, or if we are required to switch to a different provider to handle claim submissions, we may experience delays in our ability to process these claims and receipt of payments from payers, or possibly denial of claims for lack of timely submission, which would have an adverse effect on our revenue and our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our internal sales force is less successful than anticipated, our business expansion plans could suffer and our ability to generate revenues could be diminished. In addition, we have limited history selling our molecular diagnostics tests on a direct basis and our limited history makes forecasting difficult.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We acquired several international sales employees from NanoString, and expect to build upon this team as we offer additional tests internationally in the future.  If our internal sales force is not successful, however, or new additions to our sales team fail to gain traction among our customers, we may not be able to increase market awareness and sales of our molecular diagnostic tests. If we fail to establish our molecular diagnostic tests in the marketplace, it could have a negative effect on our ability to sell subsequent molecular diagnostic tests and hinder the desired expansion of our business. We have growing, however limited, historical experience forecasting the direct sales of our molecular diagnostics products. Our ability to produce test volumes that meet customer demand is dependent upon our ability to forecast accurately and plan production capacities accordingly.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Developing new products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other products we are developing.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continually seek to develop enhancements to our current test offerings and additional diagnostic solutions that requires us to devote considerable resources to research and development. There can be no assurance that we will be able to identify other diseases that can be effectively addressed with our molecular cytology platform. In addition, if we identify such diseases, we may not be able to develop products with the diagnostic accuracy necessary to be clinically useful and commercially successful. We may face challenges obtaining sufficient numbers of samples to validate a genomic signature for a molecular diagnostic product. After launching new products, we still must complete studies that meet the clinical evidence required to obtain reimbursement.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to develop and commercialize diagnostic tests, we need to:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expend significant funds to conduct substantial research and development;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conduct successful analytical and clinical studies;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">scale our laboratory processes to accommodate new tests; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">build the commercial infrastructure to market and sell new products.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product development process involves a high degree of risk and may take several years. Our product development efforts may fail for many reasons, including:</span></div><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure to identify a genomic signature in biomarker discovery;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inability to secure sufficient numbers of samples at an acceptable cost and on an acceptable timeframe to conduct analytical and clinical studies; or</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure of clinical validation studies to support the effectiveness of the test.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new product and our ability to invest in other products in our pipeline. If a clinical validation study fails to demonstrate the prospectively-defined endpoints of the study or if we fail to sufficiently demonstrate analytical validity, we might choose to abandon the development of the product, which could harm our business. In addition, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the past, we have entered into clinical study collaborations, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaboration with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Moreover, it may take longer to obtain the samples we need which could delay our trials, publications, and product launches and reimbursement. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in peer-reviewed journals is a crucial step in commercializing and obtaining reimbursement for our diagnostic tests, and our inability to control when and if results are published may delay or limit our ability to derive sufficient revenue from them.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to develop products to keep pace with rapid technological, medical and scientific change, our operating results and competitive position could be harmed.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In recent years, there have been numerous advances in technologies relating to diagnostics, particularly diagnostics that are based on genomic information. These advances require us to continuously develop our technology and to work to develop new solutions to keep pace with evolving standards of care. Our solutions could become obsolete unless we continually innovate and expand our product offerings to include new clinical applications. If we are unable to develop new products or to demonstrate the applicability of our products for other diseases, our sales could decline and our competitive position could be harmed.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Loan and Security Agreement provides our lenders with a first-priority lien against substantially all of our assets, excluding our intellectual property, and contains financial covenants and other restrictions on our actions, which could limit our operational flexibility and otherwise adversely affect our financial condition.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Loan and Security Agreement restricts our ability to, among other things,&#160;incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of its equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions.  It also requires us to achieve certain revenue levels tested quarterly on a trailing twelve-month basis. However, failure to maintain the revenue levels will not be considered a default if the sum of our unrestricted cash and cash equivalents maintained </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">with Silicon Valley Bank and amount available under the revolving line of credit is at least $40.0 million. Our ability to comply with these and other covenants is dependent upon a number of factors, some of which are beyond our control.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our failure to comply with the financial covenants, or the occurrence of other events specified in our Loan and Security Agreement, could result in an event of default under the Loan and Security Agreement, which would give our lenders the right to terminate their commitments to provide additional loans under the Loan and Security Agreement and to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, we have granted our lenders a first-priority lien against all of our assets, excluding our intellectual property, as collateral. Failure to comply with the covenants or other restrictions in the Loan and Security Agreement could result in a default. If the debt under our Loan and Security Agreement was to be accelerated, we may not have sufficient cash on hand or be able to sell sufficient collateral to repay it, which would have an immediate adverse effect on our business and operating results. This could potentially cause us to cease operations and result in a complete loss of your investment in our common stock.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Complying with numerous statutes and regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations are subject to other extensive federal, state, local, and foreign laws and regulations, all of which are subject to change. These laws and regulations currently include, among others:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which established comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions, and amendments made in 2013 to HIPAA under the Health Information Technology for Economic and Clinical Health Act, or HITECH, which strengthen and expand HIPAA privacy and security compliance requirements, increase penalties for violators, extend enforcement authority to state attorneys general, and impose requirements for breach notification;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare billing and payment regulations applicable to clinical laboratories, including requirements to have an active CLIA certificate;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Federal Anti-kickback Statute (and state equivalents), which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal healthcare program;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Eliminating Kickbacks in Recovery Act of 2018, which prohibits the solicitation, receipt, payment or offering of any remuneration in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory for services covered by both government and private payers;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Federal Stark physician self-referral law (and state equivalents), which prohibits a physician from making a referral for certain designated health services covered by the Medicare program, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services, unless the financial relationship falls within an applicable exception to the prohibition;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Federal False Claims Act, which imposes liability on any person or entity who knowingly presents, or causes to be presented, a false, fictitious, or fraudulent claim for payment to the federal government;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, prohibitions on the provision of products at no or discounted cost to induce physician or patient adoption, and false claims acts, which may extend to services reimbursable by any third-party payer, including private insurers;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Protecting Access to Medicare Act of 2014, which requires us to report private payer rates and test volumes for specific CPT codes on a triennial basis and imposes penalties for failures to report, omissions, or misrepresentations;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the rules&#160;regarding billing for diagnostic tests reimbursable by the Medicare program, which prohibit a physician or other supplier from marking up the price of the technical component or professional component of a diagnostic test ordered by the physician or other supplier and supervised or performed by a physician who does not &#8220;share a practice&#8221; with the billing physician or supplier;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">state laws that prohibit other specified practices related to billing such as billing physicians for testing that they order, waiving co-insurance, co-payments, deductibles, and other amounts owed by patients, and billing a state Medicaid program at a price that is higher than what is charged to other payers;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Foreign Corrupt Practices Act of 1977, and other similar laws, which apply to our international activities;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unclaimed property (escheat) laws and regulations, which may require us to turn over to governmental authorities the property of others held by us that has been unclaimed for a specified period of time; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">enforcing our intellectual property rights.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have adopted policies and procedures designed to comply with applicable laws and regulations. In the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance with some of these laws and regulations is also subject to governmental review. The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In recent years U.S. Attorneys&#8217; Offices have increased scrutiny of the healthcare industry, as have Congress, the Department of Justice, the Department of Health and Human Services&#8217; Office of the Inspector General and the Department of Defense. These bodies have all issued subpoenas and other requests for information to conduct investigations of, and commenced civil and criminal litigation against, healthcare companies based on financial arrangements with health care providers, regulatory compliance, product promotional practices and documentation, and coding and billing practices. Whistleblowers have filed numerous qui tam lawsuits against healthcare companies under the federal and state False Claims Acts in recent years, in part because the whistleblower can receive a portion of the government&#8217;s recovery under such suits. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. If one or more such agencies alleges that we may be in violation of any of these requirements, regardless of the outcome, it could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations and other commercial third-party payers. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty associated with the violation, including civil and criminal penalties, damages and fines, we could be required to refund payments received by us, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to federal, state and local laws, rules&#160;and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, and either could negatively affect our operating results.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business strategy includes international expansion in select countries, and may include developing and maintaining physician outreach and education capabilities outside of the United States, establishing agreements with laboratories, and expanding our relationships with international payers. Doing business internationally involves a number of risks, including:</span></div><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure by us to obtain regulatory approvals where required for the use of our solutions in various countries;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">logistics and regulations associated with shipping tissue samples, including infrastructure conditions and transportation delays;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">challenges associated with establishing laboratory partners, including proper sample collection techniques, management of supplies, sample logistics, billing and promotional activities;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limits on our ability to penetrate international markets if we are not able to process tests locally;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">financial risks, such as longer payment cycles, difficulty in collecting from payers, the effect of local and regional financial crises, and exposure to foreign currency exchange rate fluctuations;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the Foreign Corrupt Practices Act of 1977, including both its books and records provisions and its anti-bribery provisions.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our reliance on distributors for sales of our products outside of the United States, and on clinical laboratories for delivery of Prosigna testing services, could limit or prevent us from selling our products and impact our revenue.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have established distribution agreements for our nCounter FLEX Analysis System and related consumable products in certain countries where we do not sell directly. We intend to continue to grow our business internationally, and to do so we must attract additional distributors and retain existing distributors to maximize the commercial opportunity for our products. There is no guarantee that we will be successful in attracting or retaining desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations or may choose to favor marketing the products of our competitors. If current or future distributors do not perform adequately, or we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize long-term international revenue growth.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Similarly, we or our distributors have entered into agreements with clinical laboratories globally to provide Prosigna testing services. We do not provide testing services directly and, thus, we are reliant on these clinical laboratories to actively promote and sell Prosigna testing services. These clinical laboratories may take longer than anticipated to begin offering Prosigna testing services and may not commit the necessary resources to market and sell Prosigna testing services to the level of our expectations. Furthermore, we intend to contract with additional clinical laboratories to offer Prosigna testing services, including physician-owned laboratories, and we may be unsuccessful in attracting and contracting with new clinical laboratory providers. If current or future Prosigna testing service providers do not perform adequately, or we are unable to enter into contracts with </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additional clinical laboratories to provide Prosigna testing services, we may not be successful selling Prosigna and our future revenue prospects may be adversely affected.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are sued for product liability or errors and omissions liability, we could face substantial liabilities that exceed our resources.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The marketing, sale and use of our current or future tests could lead to product liability claims if someone were to allege that the tests failed to perform as they were designed. We may also be subject to liability for errors in the results we provide to physicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. Our Afirma classifiers are performed on FNA samples that are diagnosed as indeterminate by standard cytopathology review. We report results as benign or suspicious to the prescribing physician. Under certain circumstances, we might report a result as benign that later proves to have been malignant. This could be the result of the physician having poor nodule sampling in collecting the FNA, performing the FNA on a different nodule than the one that is malignant or failure of the classifier to perform as intended. We may also be subject to similar types of claims related to our Percepta, Envisia and Prosigna tests, as well as tests we may develop or acquire in the future. A product liability or errors and omissions liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain product liability and errors and omissions insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any product liability or errors and omissions liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our products and solutions. The occurrence of any of these events could have an adverse effect on our business and results of operations.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If a catastrophe strikes either of our laboratories or if either of our laboratories becomes inoperable for any other reason, we will be unable to perform our testing services and our business will be harmed.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We perform all of the Afirma, Percepta and Envisia genomic classifier testing at our laboratory in South San Francisco, California, near major earthquake faults known for seismic activity. Our laboratory in Austin, Texas accepts and stores the majority of our Afirma FNA samples pending transfer to our California laboratory for genomic test processing. The laboratories and equipment we use to perform our tests would be costly to replace and could require substantial lead time to replace and qualify for use if they became inoperable. Either of our facilities may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, flooding and power outages, which may render it difficult or impossible for us to perform our testing services for some period of time or to receive and store samples. The inability to perform our tests for even a short period of time may result in the loss of customers or harm our reputation, and we may be unable to regain those customers in the future. Although we maintain insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize new solutions and technologies and expand our operations.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect continued capital expenditures and operating losses over the next few years as we expand our infrastructure, commercial operations and research and development activities. We may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders could result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings could impose significant restrictions on our operations. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. Our Loan and Security Agreement imposes restrictions on our operations, increases our fixed payment obligations, and has restrictive covenants. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third-party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our products or development programs, which could lower the economic value of those programs to our company.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Security breaches, loss of data and other disruptions to us or our third-party service providers could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of our business, we and our third-party service providers collect and store sensitive data, including legally protected health information, personally identifiable information about our patients, credit card information, intellectual property, and our proprietary business and financial information. We manage and maintain our applications and data utilizing a combination of on-site systems, managed data center systems and cloud-based data center systems. We face a number of risks related to our protection of, and our service providers&#8217; protection of, this critical information, including loss of access, inappropriate disclosure and inappropriate access, as well as risks associated with our ability to identify and audit such events.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. While we are not aware of any such attack or breach, if such event would occur and cause interruptions in our operations, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under federal, state, and international laws that protect the privacy of personal information, such as HIPAA, and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payers or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, manage the administrative aspects of our business and damage our reputation, any of which could adversely affect our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the interpretation and application of consumer, health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business.  In addition, we are subject to various state laws, including the California Consumer Privacy Act, or CCPA, which was enacted in California in 2018 and components of which went into effect on January 1, 2020.&#160; The CCPA, among other things, requires covered companies to provide disclosures to California consumers concerning the collection and sale of personal information, and gives such consumers the right to opt-out of certain sales of personal information. Amendments to the CCPA have been made since its enactment, and it remains unclear what, if any, further amendments will be made to this legislation or how it will be interpreted. We cannot yet predict the impact of the CCPA on our business or operations, but it may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recent developments in Europe have created compliance uncertainty regarding the processing of personal data from Europe.  For example, the General Data Protection Regulation, or GDPR, which became effective in the European Union on May 25, 2018, applies to our activities conducted from an establishment in the EU or related to products and services that we offer to European Union users. The GDPR creates new compliance obligations applicable to our business, which could cause us to change our business practices, and increases financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher) for the most serious infringements). As a result, we may need to modify the way we treat such information. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we cannot license rights to use technologies on reasonable terms, we may not be able to commercialize new products in the future.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the future, we may license third-party technology to develop or commercialize new products. In return for the use of a third-party&#8217;s technology, we may agree to pay the licensor royalties based on sales of our solutions. Royalties are a component of cost of revenue and affect the margins on our solutions. We may also need to negotiate licenses to patents and patent applications after introducing a commercial product. Our business may suffer if we are unable to enter into the necessary licenses on acceptable terms, or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the license or fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect our intellectual property effectively, our business would be harmed.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We apply for and in-license patents covering our products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions.  Our issued patents expire between 2029 and 2035 and are related to methods used in thyroid diagnostics, lung diagnostics, breast cancer diagnostics, and the nCounter FLEX analysis platform. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. We may not be successful in defending any challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents and increased competition to our business. The outcome of patent litigation can be uncertain and any attempt by us to enforce our patent rights against others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods for analyzing or comparing nucleic acids.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In particular, the patent positions of companies engaged in the development and commercialization of genomic diagnostic tests are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related methods. These decisions state, among other things, that patent claims that recite laws of nature (for example, the relationship between blood levels of certain metabolites and the likelihood that a dosage of a specific drug will be ineffective or cause harm) are not themselves patentable. What constitutes a law of nature is uncertain, and it is possible that certain aspects of genomic diagnostics tests would be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our ability to obtain patents and may facilitate third-party challenges to any owned and licensed patents.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also be subject to claims that our employees have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential products, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, competitors could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. Others may independently develop similar or alternative products and technologies or replicate any of our products and technologies. If our intellectual property does not adequately protect us against competitors&#8217; products and methods, our competitive position could be adversely affected, as could our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not registered certain of our trademarks in all of our potential markets. If we apply to register these trademarks, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be involved in litigation related to intellectual property, which could be time-intensive and costly and may adversely affect our business, operating results or financial condition.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may receive notices of claims of direct or indirect infringement or misappropriation or misuse of other parties&#8217; proprietary rights from time to time. Some of these claims may lead to litigation. We cannot assure you that we will prevail in such actions, or that other actions alleging misappropriation or misuse by us of third-party trade secrets, infringement by us of third-party patents and trademarks or other rights, or the validity of our patents, trademarks or other rights, will not be asserted or prosecuted against us.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings, or other post-grant proceedings declared by the U.S. Patent and Trademark Office that could result in substantial cost to us. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, recent changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation may be necessary for us to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any litigation or other proceeding is inherently uncertain and might not be favorable to us, and we might not be able to obtain licenses to technology that we require on acceptable terms or at all. Further, we could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products. In addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we move into new markets and applications for our products, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success may depend in part on our non-infringement of the patents or proprietary rights of third parties. Numerous significant intellectual property issues have been litigated, and will likely continue to be litigated, between existing and new participants in our existing and targeted markets and competitors may assert that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets. Third parties may assert that we are employing their proprietary technology without authorization. In addition, our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our products infringes these patents. We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products, and could result in the award of substantial damages against us. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling certain products. We may not be able to obtain these licenses on acceptable terms, if at all. We could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our financial results. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products, and the prohibition of sale of any of our products could materially affect our business and our ability to gain market acceptance for our products.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards may be limited and may result in increased future tax liability to us.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred net losses since our inception and may never achieve profitability.  As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had net operating loss, or NOL, carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;">$236.9 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$58.3 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$45.2 million</span><span style="font-family:inherit;font-size:10pt;"> available to reduce future taxable income, if any, for federal, California and other state income tax purposes, respectively.  The U.S. federal NOL  carryforwards will begin to expire in 2026 while for state purposes, the NOL carryforwards begin to expire in 2028.  These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Cuts and Jobs Acts, or Tax Act, which was enacted in December 2017, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited.&#160; It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. We may be limited in the portion of NOL carryforwards that we can use in the future to offset taxable income for U.S. federal and state income tax purposes, and federal tax credits to offset federal tax liabilities.  Sections 382 and 383 of Internal Revenue Code limit the use of NOLs and tax credits after a cumulative change in corporate ownership of more than 50% occurs within a three-year period.  The limitation could prevent a corporation from using some or all its NOL and tax credits before they expire within their normal 20-year lifespan, as it places a formula limit of how much NOL and tax credits a loss corporation can use in a tax year.  In the event we have undergone an ownership change under Section 382 of the Internal Revenue Code, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability to us.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our goodwill or intangible assets become impaired, we may be required to record a significant charge to earnings.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We review our goodwill and intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable, such as declines in stock price, market capitalization, or cash flows and slower growth rates in our industry. Goodwill is required to be tested for impairment at least annually. If we are required to record a significant charge in our financial statements during the period in which any impairment of our goodwill or intangible assets is determined, that would negatively affect our operating results.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. GAAP is subject to interpretation by the Financial Accounting Standards Board, the Securities and Exchange Commission, or the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in accounting standards or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements and varying interpretations of accounting pronouncements have occurred and may occur in the future. Changes to existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our financial statements are subject to change and if our estimates or judgments relating to our critical accounting policies prove to be incorrect, our operating results could be adversely affected.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our financial statements and related notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, as provided in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Annual Report on Form 10-K.  The results of these estimates form the basis for making judgments about the carrying values of assets, liabilities, and equity, and the amount of revenue and expenses that are not readily apparent from other sources. Critical accounting policies and estimates used in preparing our financial statements include those related to revenue recognition, finite-lived intangible assets, goodwill, and stock-based compensation expense. Our operating results may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the price of our common stock.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Being a Public Company</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will continue to incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a public company, we will continue to incur significant legal, accounting, consulting and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. In addition, the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Act of 2010, as well as rules&#160;implemented by the SEC, and The Nasdaq Stock Market, impose a number of requirements on public companies, including with respect to corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance and disclosure obligations. Moreover, these rules&#160;and regulations have and will continue to increase our legal, accounting and financial compliance costs and make some activities more complex, time-consuming and costly. We also expect that it will continue to be expensive for us to maintain director and officer liability insurance.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal controls on an annual basis. If we have material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We have only recently compiled the systems, processes and documentation necessary to comply with Section&#160;404 of the Sarbanes-Oxley Act. We will need to maintain and enhance these processes and controls as we grow, and we will require additional management and staff resources to do so. Additionally, even if we conclude our internal controls are effective for a given period, we may in the future identify one or more material weaknesses in our internal </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">controls, in which case our management will be unable to conclude that our internal control over financial reporting is effective.  We are now required to include an attestation report from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting annually.  Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to conclude that our internal control over financial reporting is effective, or if our auditors were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Irrespective of compliance with Section&#160;404, any failure of our internal control over financial reporting could have a material adverse effect on our reported operating results and harm our reputation. Internal control deficiencies could also result in a restatement of our financial results.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading price of our common stock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include:</span></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actual or anticipated variations in our and our competitors&#8217; results of operations;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements by us or our competitors of new products, commercial relationships or capital commitments;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in reimbursement by current or potential payers, including governmental payers;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">issuance of new securities analysts&#8217; reports or changed recommendations for our stock;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuations in our revenue, due in part to the way in which we recognize revenue;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actual or anticipated changes in regulatory oversight of our products;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments or disputes concerning our intellectual property or other proprietary rights;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">commencement of, or our involvement in, litigation;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announced or completed acquisitions of businesses or technologies by us or our competitors;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any major change in our management; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general economic conditions and slow or negative growth of our markets.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the stock market in general, and the market for stock of life sciences companies and other emerging growth companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced if the trading volume of our stock remains low. In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading market for our common stock will depend in part on the research and reports that equity research analysts publish about us, our business and our competitors. We do not control these analysts or the content and opinions or financial models included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could discourage, delay or prevent a change in control and may affect the trading price of our common stock.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">authorize our board of directors to issue, without further action by the stockholders, up to 5.0&#160;million shares of undesignated preferred stock;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">specify that special meetings of our stockholders can be called only by our board of directors, our chairman of the board, or our chief executive officer;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish that our board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with each class serving staggered terms;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provide that our directors may be removed only for cause;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provide that vacancies on our board of directors may, except as otherwise required by law, be filled only by a majority of directors then in office, even if less than a quorum;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">specify that no stockholder is permitted to cumulate votes at any election of directors; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">require a super-majority of votes to amend certain of the above-mentioned provisions.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law regulating corporate takeovers. Section&#160;203 generally prohibits us from engaging in a business combination with an interested stockholder subject to certain exceptions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never paid dividends on any of our capital stock and currently intend to retain any future earnings to fund the growth of our business. In addition, our Loan and Security Agreement restricts our ability to pay cash dividends on our common stock and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s916413EAA5B188F3A489428B07B7D9C6"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s46EF60DFEEA94DE1D371428B07E762F2"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April&#160;29, 2015, we signed a non-cancelable lease agreement for approximately 59,000 square feet to serve as our South San Francisco, California headquarters and laboratory. The lease began in June 2015 and ends in March 2026, and contains extension of lease term and expansion options.  Certain expansion options were waived by us on February 8, 2017 in exchange for consideration of $500,000.  We also lease approximately 10,400 square feet of office and laboratory space in Austin, Texas, under a lease that expires in January 2029 and includes options for expansion and early termination in 2025. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s2D35C462BA3E42B5E4AB428B08086768"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are not currently a party to any material legal proceedings. We may from time to time become involved in legal proceedings arising in the ordinary course of business.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA85903A8D1716D30D85F428B083BE56B"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURE</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s816D613C06678C2588DF428B085DBF1D"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s2F014EBF55B684F90AA1428AFF97FEA9"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Information</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock is traded on the Nasdaq Global Market under the symbol "VCYT". </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividend Policy</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our earnings in the foreseeable future will be used for the operation and growth of our business. Any future determination to declare dividends will be subject to the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, and any other factors deemed relevant by our board of directors. In addition, the terms of our credit agreement restrict our ability to pay dividends on our common stock, and we may also enter into credit agreements or other borrowing arrangements in the future that will further restrict our ability to declare or pay dividends on our common stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Sale of Unregistered Securities and Use of Proceeds</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Sale of Unregistered Securities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 3, 2019, we issued 376,732 shares of our common stock as consideration to NanoString Technologies, Inc. in connection with our acquisition of certain of its assets. The sales of these securities were exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, in reliance upon Section 4(a)(2) of the Securities Act.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Performance Graph</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following information is not deemed to be "soliciting material" or to be "filed" with the Securities and Exchange Commission or subject to Regulation&#160;14A or 14C under the Securities Exchange Act of 1934, as amended, or the Exchange Act, or to the liabilities of Section&#160;18 of the Exchange Act, and will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent we specifically incorporate it by reference into such a filing.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The graph below shows the cumulative total stockholder return (change in stock price plus reinvested dividends) assuming the investment of $100.00 on the date specified in each of our common stock, the Nasdaq Global Market Index, and the Nasdaq Biotechnology Index for the period commencing on October&#160;30, 2013 (the first day of trading of our common stock) and ending on December&#160;31, 2019. The comparisons in the table are required by the SEC and are not intended to forecast or be indicative of future performance of our common stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;"><img src="chart-86950a12b9c0e735da0.jpg" alt="chart-86950a12b9c0e735da0.jpg" style="height:389px;width:684px;"></img></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Veracyte,&#160;Inc.&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">211.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nasdaq Global Market Index</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">121.00</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">128.00</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">137.00</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">176.00</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">169.00</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">229.00</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nasdaq Biotechnology Index</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">148.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">165.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">129.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">157.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">147.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">184.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sF747408585A999B7C4E2428AFA1B0B21"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.&#160;&#160;&#160;&#160;SELECTED FINANCIAL DATA</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information set forth below should be read in conjunction with "Item&#160;7. Management's Discussion and Analysis of Financial Condition and Results of Operations" and our audited consolidated financial statements and related notes included elsewhere in this annual report. The selected consolidated balance sheet data at December&#160;31, 2019 and 2018 and the selected consolidated statements of operations data for each of the years ended December&#160;31, 2019, 2018 and 2017 have been derived from our audited consolidated financial statements that are included elsewhere in this report. The selected consolidated balance sheet data at December&#160;31, 2017, 2016 and 2015 and the selected consolidated statements of operations data for the years ended December&#160;31, 2016 and 2015 have been derived from our audited consolidated financial statements not included in this report. The financial data are historical and are not necessarily indicative of results to be expected in any future period (in thousands, except share and per share data and genomic classifiers reported):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations Data:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">107,355</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91,058</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71,953</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65,085</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49,503</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">923</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharmaceutical revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,090</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">950</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">120,368</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92,008</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71,953</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65,085</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49,503</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,077</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,078</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,195</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,462</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,497</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">446</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,851</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,820</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,881</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,324</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,796</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53,691</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41,313</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32,260</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,248</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,293</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,029</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,963</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,088</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,787</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,583</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,401</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,067</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,067</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,067</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">800</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">135,495</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">114,241</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98,491</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">93,888</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82,969</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(15,127</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(22,233</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(26,538</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(28,803</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(33,466</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(677</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,963</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4,941</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,757</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(378</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,205</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,197</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">476</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">202</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">140</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss and comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12,599</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(22,999</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(31,003</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(31,358</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(33,704</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per common share, basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.27</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.62</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.91</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1.09</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1.30</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used in computing net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46,138,177</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37,020,246</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,925,617</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,830,472</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,994,193</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Operating Data:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reported genomic test volume</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,612</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31,710</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26,026</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,237</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,421</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:8pt;">_____________________________________________</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Includes stock-based compensation as follows:</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">277</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">130</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">133</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">126</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,856</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,495</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,322</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,178</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,938</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,866</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,899</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,594</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,326</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,736</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,944</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,090</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,336</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,998</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,807</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,958</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,617</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,378</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,602</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets Data:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">159,317</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77,995</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,891</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59,219</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,084</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Working capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">170,218</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83,893</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41,900</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62,093</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,192</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">275,212</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">120,638</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78,669</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101,034</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75,247</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(246,685</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(234,086</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(211,087</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(180,084</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(148,726</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders' equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">239,455</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79,755</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37,225</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59,581</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51,252</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB94196C0F8241CCFB6C6428AFE50B99B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion and analysis of financial condition and results of operations should be read together with the financial statements and the related notes included in Item&#160;8 of Part&#160;II of this Annual Report on Form&#160;10-K. This discussion and analysis contains certain forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section entitled "Risk Factors" in Item&#160;1A, and other documents we file with the Securities and Exchange Commission. Historical results are not necessarily indicative of future results.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a leading genomic diagnostics company that is creating value through innovation. We were founded in 2008 with a mission of improving diagnostic accuracy. Today, our growing menu of tests leverage advances in genomic science and technology to improve care throughout the patient journey, enabling more confident diagnostic, prognostic and treatment decisions in cancer and other challenging diseases. We are creating new standards of care by enabling more patients to avoid risks of unnecessary invasive procedures and removing costs from the healthcare system, while speeding the time to diagnosis and treatment decisions. </span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We perform our genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in our CLIA-certified laboratory in South San Francisco, California. In December 2019, we announced our acquisition from NanoString Technologies, Inc., or NanoString, of the exclusive global diagnostics license to the nCounter FLEX Analysis System, as well as the Prosigna breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system. We believe this strategic transaction positions us to expand our business globally with a broad menu of advanced genomic tests that may be offered as distributed kits and performed in local laboratories worldwide. We believe our current and pipeline products address a collective $40 billion global market.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently offer five commercialized genomic tests that are changing disease diagnosis and patient care. All five tests are available in the United States and one is available internationally. These include the Afirma Genomic Sequencing Classifier, or GSC (its predecessor was the Afirma Gene Expression Classifier, or GEC) for thyroid cancer; the Percepta GSC (its predecessor was the Percepta Bronchial Genomic Classifier) for lung cancer; the Envisia Genomic Classifier for IPF; the Afirma Xpression Atlas, which provides information on the most common and emerging gene alterations associated with thyroid cancer, enabling physicians to confidently tailor surgical and treatment decisions at time of diagnosis; and the Prosigna breast cancer test for assessing risk of distant recurrence, which is available for use on the nCounter platform in the United States and internationally.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to leverage RNA whole-transcriptome sequencing data in large biorepositories of patient-consented samples in oncology and other indications presents an opportunity for biopharmaceutical companies to enhance their research and development capabilities. In April 2018, we announced a collaboration with Loxo Oncology (now a wholly owned subsidiary of Eli Lilly and Company) to advance our development of highly selective medicines for patients with genetically defined cancers, including thyroid cancer. In December 2018, we entered into a long-term strategic collaboration with Johnson &amp; Johnson Innovation and the Lung Cancer Initiative at Johnson &amp; Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. The collaboration builds upon foundational "field of injury" science where genomic changes associated with lung cancer can be identified with a simple brushing of a person's airway to develop new interventions that can save lives. Additionally, in January 2020, we announced an agreement with Acerta Pharma, the hematology research and development arm of AstraZeneca, to provide genomic information that will support its development of oncology therapeutics in lymphoma. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patients access our tests through their physician. Our Afirma, Percepta and Envisia tests are used as part of the diagnostic process and genomic testing services are performed in our CLIA laboratory located in San Francisco, California. Cytopathology services for Afirma testing are performed in our reference laboratory in Austin, Texas. The Prosigna test is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care. This in vitro diagnostic test is performed on the nCounter Flex Analysis System in laboratories worldwide, as well as in the United States.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth Quarter and Full-Year 2019 Financial Results&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended December 31, 2019, compared to the prior year:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Total Revenue </span><span style="font-family:inherit;font-size:10pt;">was $29.7 million, an increase of 15%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Margin </span><span style="font-family:inherit;font-size:10pt;">was 66%, unchanged;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Expenses, Excluding Cost of Revenue, </span><span style="font-family:inherit;font-size:10pt;">were $27.8 million, an increase of 38%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss and Comprehensive Loss</span><span style="font-family:inherit;font-size:10pt;"> was ($7.5) million, an increase of 140%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basic and Diluted Net Loss Per Common Share </span><span style="font-family:inherit;font-size:10pt;">was ($0.15), an increase of 88%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Cash Provided by Operating Activities </span><span style="font-family:inherit;font-size:10pt;">was $1.8 million, compared to $1.2 million used; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents </span><span style="font-family:inherit;font-size:10pt;">was $159.3 million at December 31, 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2019, compared to the prior year:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Total Revenue </span><span style="font-family:inherit;font-size:10pt;">was $120.4 million, an increase of 31%; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Margin </span><span style="font-family:inherit;font-size:10pt;">was 70%, an increase of six percentage points; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Expenses, Excluding Cost of Revenue, </span><span style="font-family:inherit;font-size:10pt;">were $99.0 million, an increase of 22%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss and Comprehensive Loss </span><span style="font-family:inherit;font-size:10pt;">was ($12.6) million, an improvement of 45%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basic and Diluted Net Loss Per Common Share </span><span style="font-family:inherit;font-size:10pt;">was ($0.27), an improvement of 56%; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Cash Used in Operating Activities </span><span style="font-family:inherit;font-size:10pt;">was $3.2 million, an improvement of 76%.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019 Full-Year and Recent Business Highlights</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial Growth:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Achieved strong total revenue growth across our testing and product portfolio delivering $29.5 million in the fourth quarter and $108.3 million for 2019, an increase of 16% and 19%, respectively, compared to the prior year. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated pulmonology testing revenue to $2.0 million and $5.5 million for the fourth quarter and full year, respectively, a 123% and 174% increase compared to prior year. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grew total genomic volume (Afirma, Percepta and Envisia) by 18% to 10,846 tests in the fourth quarter of 2019 and by 25% to 39,612 tests in 2019, compared to prior year.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increased genomic volume for our pulmonology products by 136% in 2019 compared to prior year, achieving growth targets for both the Percepta and Envisia classifiers.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Received final Medicare coverage in March 2019 for the Envisia classifier and published strong clinical validation and clinical utility data in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Lancet Respiratory Medicine</span><span style="font-family:inherit;font-size:10pt;">, propelling nationwide commercial expansion of the test in the second half of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expanded payer contracts by 14.4 million lives, making Veracyte an in-network genomic testing provider to health plans representing over 225 million members.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Continued to build an extensive library of clinical data across our portfolio in 2019, including 8 publications and 11 presentations at leading medical meetings, demonstrating our Afirma and pulmonology tests&#8217; performance and clinical utility. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eleven abstracts were presented at the San Antonio Breast Cancer Symposium in December 2019, including data showing a benefit of Prosigna</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> over other genomic testing to identify patients&#8217; long-term risk of developing distant metastases. In addition, data were presented showing the test&#8217;s ability to identify patients with intrinsic breast cancer subtypes that may potentially benefit from CDK4/6 inhibitors in place of standard chemotherapy. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Biopharmaceutical Collaborations/Pipeline Advancement:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2019, announced a long-term strategic collaboration with Johnson &amp; Johnson Innovation LLC to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Presented preliminary data at the American College of Chest Physicians (CHEST) annual meeting for our first-of-its-kind noninvasive nasal swab classifier for improved lung cancer diagnosis. The test, being developed through our Johnson &amp; Johnson collaboration, is expected to launch in early 2021.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Launched the second-generation Percepta GSC, completing the transition of our core classifiers to our RNA whole-transcriptome sequencing platform.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Announced a multi-year collaboration with Acerta Pharma, the hematology research and development arm of AstraZeneca plc, to provide genomic information that will support the biopharmaceutical company&#8217;s development of oncology therapeutics in lymphoma. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Global Expansion:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired the exclusive global diagnostic rights to the NanoString nCounter FLEX Analysis System, as well as the Prosigna breast cancer assay and the in-development LymphMark lymphoma subtyping test. We believe this transaction positions us to access a $40 billion global market for our current and pipeline products, by offering a broad menu of advanced genomic tests in oncology and other indications using a distributed-kit model.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Factors Affecting Our Performance</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reported Genomic Test Volume</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our performance depends on the number of genomic tests that we perform and report as completed in our CLIA laboratories. Factors impacting the number of tests that we report as completed include, but are not limited to: </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of samples that we receive that meet the medical indication for each test performed; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the quantity and quality of the sample received; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">receipt of the necessary documentation, such as physician order and patient consent, required to perform, bill and collect for our tests; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the patient's ability to pay or provide necessary insurance coverage for the tests performed; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the time it takes us to perform our tests and report the results;  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the seasonality inherent in our business, such as the impact of work days per period, timing of industry conferences and the timing of when patient deductibles are exceeded, which also impacts the reimbursement we receive from insurers; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain prior authorization or meet other requirements instituted by payers, benefit managers, or regulators necessary to be paid for our tests.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate substantially all our revenue from genomic testing services, including the rendering of a cytopathology diagnosis as part of the Afirma solution.  For the Afirma classifier, we do not accrue revenue for approximately 5% - 10% of the tests that we perform and report as complete due principally to insufficient RNA from which to render a result and tests performed for which we do not reasonably expect to be paid.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Continued Adoption of and Reimbursement for our Products</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue growth depends on our ability to secure coverage decisions, achieve broader reimbursement at increased levels from third-party payers, expand our base of prescribing physicians and increase our penetration in existing accounts. Because some payers consider our products experimental and investigational, we may not receive payment for tests and payments we receive may not be at acceptable levels. We expect our revenue growth to increase if more payers make a positive coverage decision and as payers enter into contracts with us, which should enhance our revenue and cash collections. To drive increased adoption of our products, we increased our sales force and marketing efforts over the last several years.  Our sales team is structured to sell all of our products; we do not maintain a separate sales force for each product. If we are unable to expand the base of prescribing physicians and penetration within these accounts at an acceptable rate, or if we are not able to execute our strategy for increasing reimbursement, we may not be able to effectively increase our revenue.  We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying cost containment tactics, such as pre-authorization, reduction of the payer portion of reimbursement and employing laboratory benefit managers to reduce utilization rates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Integrating acquired assets and advances to our collaborations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue growth, operational results and advances to our business strategy depends on our ability to integrate the assets acquired into our existing business. The integration of acquired assets may impact our revenue growth, increase the cost of operations, cause significant write-offs of intangible assets, or may require management resources that otherwise would be available for ongoing development of our existing business.  The integration of assets acquired from NanoString in December 2019 may </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">impact our revenue and operating results through integration of a sales force, development of a product supply operation and the expansion of our business internationally with a broad menu of advanced genomic tests that may be offered.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue growth or reimbursement from our collaborations depends on our ability to deliver services or information and achieve milestones required from our collaborative partners.  Our collaboration parters pay us for the provision of data, other services and the achievement of milestones.  Under a collaboration with Johnson &amp; Johnson in 2018, we provided data services required under this agreement for $7.0 million in 2019, however, there remains $9.0 of revenue associated with development and commercialization milestones yet to be achieved.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">How We Recognize Revenue</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Testing Revenue</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We commenced recognizing revenue in accordance with the provisions of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> starting January 1, 2018.  Prior to January 1, 2018, we recognized revenue in accordance with the provisions of ASC 954-605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Health Care Entities - Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most of our revenue is generated from the provision of diagnostic services. These services are completed upon the delivery of test results to the prescribing physician, at which time we bill for the services. We recognize revenue related to billings on an accrual basis based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, we consider factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and us, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019, cumulative amounts billed at list price for tests processed which were not recognized as revenue upon delivery of a patient report because our accrual revenue recognition criteria were not met and for which we have not collected cash or written off as uncollectible, totaled approximately $159.3&#160;million.  Of this amount, we did not collect any amounts in the year ended December 31, 2019 and we have no expectation of future collection because we began accruing for substantially all revenue upon delivery of a patient report in the third quarter of 2016.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, cash we receive is collected within 12&#160;months of the date the test is billed. We cannot provide any assurance as to when, if ever, or to what extent any of these amounts will be collected. Notwithstanding our efforts to obtain payment for these tests, payers may deny our claims, in whole or in part, and we may never receive payment for these tests. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We bill list price regardless of contract rate, but only recognize revenue from amounts that we estimate are collectible and meet our revenue recognition criteria.&#160;Revenue may not be equal to the billed amount due to a number of factors that we consider when determining revenue accrual rates, including differences in reimbursement rates, the amounts of patient co-payments and co-insurance, the existence of secondary payers, claims denials and the amount we expect to ultimately collect. Finally, when we increase our list price, it will increase the cumulative amounts billed but may not positively impact accrued revenue.  In addition, payer contracts generally include the right of offset and payers may offset payments prior to resolving disputes over tests performed.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, we calculate the average reimbursement from our products from all payers, for tests that are on average a year old, since it can take a significant period of time to collect from some payers. Except in situations where we believe the rate we reasonably expect to collect to vary due to a coverage decision, contract, more recent reimbursement data or evidence to the contrary, we use an average of reimbursement for tests provided over four quarters as it reduces the effects of temporary volatility and seasonal effects. Thus, the average reimbursement per product represents the total cash collected to date against genomic classifier tests, including variants, performed during the relevant period divided by the number of these tests performed during that same period.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The average genomic classifier reimbursement rate will change over time due to a number of factors, including medical coverage decisions by payers, the effects of contracts signed with payers, changes in allowed amounts by payers, our ability to successfully win appeals for payment, and our ability to collect cash payments from third-party payers and individual patients. Historical average reimbursement is not necessarily indicative of future average reimbursement. For the year ended December 31, 2019, we accrued, on average, between $2,800 and $2,900 for the Afirma genomic classifier tests, including variants, that met our revenue recognition standard, which was between 90% - 95% of the reported Afirma classifier test volume.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From the fourth quarter of 2018 to the fourth quarter of 2019, we accrued between $1.0 million and $2.4 million in revenue per quarter from providing cytopathology services associated with our Afirma solution. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We incur expense for tests in the period in which the test is conducted and recognize revenue for tests in the period in which our revenue recognition criteria are met. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We began recognizing product revenue in December 2019 in accordance with the provisions of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers,</span><span style="font-family:inherit;font-size:10pt;"> when we executed an agreement with NanoString for the exclusive worldwide license to the nCounter platform for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> diagnostic use.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize product revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration expected to be received in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once we have transferred control of a product or service to the customer, meaning the customer has the ability to use and obtain the benefit of the product or service. We recognize product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to our customers and included in product revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our products consist of the nCounter Analysis System and related consumables. Services consist of instrument service contracts and service fees for assay processing. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Biopharmaceutical and Collaboration Revenues</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we enter into arrangements for research and development and/or commercialization services. Such arrangements may require us to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;D services, and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to us in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Arrangements with partners may fall under the scope of ASC Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC 808, we may analogize to ASC 606 for some aspects of these arrangements.  We analogize to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of our ongoing major or central operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">there be royalties, we utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue and collaboration revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  Payments made to us that are not net sales of data or other services to our customers are recorded as an offset against research and development expense in our consolidated statements of operations and comprehensive loss.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Development of Additional Tests</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to advance our portfolio of diagnostic tests that leverage innovations in genomic science, sequencing technology and machine learning methodologies to further improve patient care. In May 2017, we introduced the Afirma GSC, supported by rigorous clinical validation data showing that the RNA sequencing-based test can help significantly more patients avoid unnecessary surgery in thyroid cancer diagnosis, compared to the original Afirma classifier. In March 2018, we unveiled our Afirma Xpression Atlas, which uses the same RNA sequencing data from the platform as the Afirma GSC and enables us to extract rich genomic content - including gene expression, DNA variants and RNA fusions in over 500 genes that are associated with thyroid cancer - from thyroid FNA samples. We believe that this offering will provide clinicians with valuable genomic information that may inform surgery strategy and treatment options for patients with suspected thyroid cancer.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Together with our Afirma GSC and our tests for the BRAF v600E mutation and medullary thyroid cancer, or Malignancy Classifiers, the Afirma Xpression Atlas rounds out a comprehensive solution for physicians evaluating thyroid nodules. This innovation also enables us to enter into research collaboration with biopharmaceutical companies, which is intended to support their development of targeted therapies for genetically defined cancers, including thyroid cancer.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have also expanded our ability to provide important clinical answers - without the need for surgery - into pulmonology. Our Percepta Bronchial Genomic Classifier, introduced in April 2015, is the first genomic test to receive Medicare coverage for use in lung cancer diagnosis, where it improves the performance of diagnostic bronchoscopy. &#160;In June 2019, we began making our &#8220;next-generation&#8221; Percepta Genomic Sequencing Classifier available to physicians, providing them with expanded lung cancer risk information that can further guide next steps for patients with suspicious lung nodules, as compared to the Percepta Bronchial Genomic Classifier.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, our Envisia Genomic Classifier, launched in October 2016, is the first commercial test to improve the diagnosis of IPF among patients with a suspected interstitial lung disease.  In March 2019, we received final Medicare coverage for the Envisia classifier through the MolDX program, with an effective date of April 1, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also believe our Xpression Atlas platform can be transferred to our pulmonology indications, to further improve patient care and advance precision medicine in lung cancer and IPF.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently exploring opportunities to utilize the same &#8220;field of injury&#8221; technology that powers our Percepta classifier to develop a nasal swab test that can enable earlier lung cancer detection - and ultimately help reduce lung cancer deaths. In October 2019, we announced preliminary clinical data showing for our noninvasive nasal swab classifier - the first test of its kind. The findings show that the novel genomic test can accurately classify lung cancer risk in patients with lung nodules so that these patients can obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Timing of Our Research and Development Expenses</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We deploy state-of-the-art and costly genomic technologies in our biomarker discovery experiments, and our spending on these technologies may vary substantially from quarter to quarter. We also spend a significant amount to secure clinical samples that can be used in discovery and product development as well as clinical validation studies. The timing of these research and development activities is difficult to predict, as is the timing of sample acquisitions. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses can affect our financial results. We conduct clinical studies to validate our new products as well as on-going clinical studies to further the published evidence to support our commercialized tests. As these studies are initiated, start-up costs for each site can be significant and concentrated in a specific quarter. Spending on research and development, for both experiments and studies, may vary significantly by quarter depending on the timing of these various expenses.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Overview</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Testing Revenue</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through December&#160;31, 2019, we derived a substantial majority of our revenue from the sale of Afirma delivered primarily to physicians in the United States. We generally invoice third-party payers upon delivery of a patient report to the prescribing physician. As such, we take the assignment of benefits and the risk of cash collection from the third-party payer and individual patients. Third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UnitedHealthcare</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For tests performed, we recognize the related revenue upon delivery of a patient report to the prescribing physician based on the amount that we expect to ultimately receive. In determining the amount to accrue for a delivered test, we consider factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and us, payment as a percentage of agreed upon reimbursement rate (if applicable), amount paid per test and any current development or changes that could impact reimbursement.  Upon ultimate collection, the amount received is compared to previous estimates and the amount accrued is adjusted accordingly.  Our ability to increase our revenue will depend on our ability to penetrate the market, obtain positive coverage policies from additional third-party payers, obtain reimbursement and/or enter into contracts with additional third-party payers for our current and new tests, and increase reimbursement rates for tests performed. Finally, should the judgments underlying our estimated reimbursement change, our accrued revenue and financial results could be negatively impacted in future periods.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Testing Revenue</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of our cost of revenue are laboratory expenses, kit costs, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. As a result, our cost of revenue as a percentage of revenue may vary significantly from period to period because we may not recognize all revenue in the period in which the associated costs are incurred. We expect cost of revenue in absolute dollars to increase as the number of tests we perform increases. However, we expect that the cost per test will decrease over time due to leveraging fixed costs, efficiencies we may gain as test volume increases and from automation, process efficiencies and other cost reductions. As we introduce new tests, initially our cost of revenue will be high as we expect to run suboptimal batch sizes, run quality control batches, test batches, registry samples and generally incur costs that may suppress or reduce gross margins.  This will disproportionately increase our aggregate cost of revenue until we achieve efficiencies in processing these new tests.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Revenue</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in our products, provisions for slow-moving and obsolete inventory and stock-based compensation expense. Cost of product revenue for instruments and consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses include expenses incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products and pipeline. These expenses consist of compensation expenses, direct research and development expenses such as prototype materials, laboratory supplies and costs associated with setting up and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses. We expense all research and development costs in the periods in which they are incurred. We expect to incur significant research and development expenses as we continue to invest in research and development activities related to developing additional products and evaluating various platforms. We incurred research and development expenses on ongoing evidence development for our Afirma, Percepta and Envisia classifiers in 2019 . We believe a majority of our research and development expenses in and after 2020 will be predominantly in support of our pipeline products.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selling and Marketing</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing expenses consist of compensation expenses, direct marketing expenses, professional fees, other expenses such as travel and communications costs and allocation of facility and information technology expenses.  We have expanded our internal sales force as we invest in our multi-product sales strategy to assign a single point of contact to successfully develop and implement relationships with our customers and increased our marketing spending. We have also incurred increased selling and marketing expense as a result of investments in our lung product portfolio and believe total selling and marketing expenses will continue to increase as we launch and promote our new tests.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses include compensation expenses for executive officers and administrative, billing and client service personnel, professional fees for legal and audit services, occupancy costs, depreciation and amortization, and other expenses such as information technology and miscellaneous expenses offset by allocation of facility and information technology expenses to other functions.  For the year ended December 31, 2019, approximately 67% of the average headcount classified as general and administrative encompass our billing and customer care teams.  We expect general and administrative expenses to continue to increase as we build our general and administration infrastructure and to stabilize thereafter.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset Amortization</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our finite-lived intangible assets, acquired in business combinations, are being amortized over 5 to15 years, using the straight-line method.  Amortization expense is expected to be approximately $5.1 million per year through 2024 and decrease thereafter. </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense is attributable to our borrowings under debt agreements and capital leases as well as costs associated with the pre-payment of debt.  </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income, Net</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net consists primarily of sublease rental income and interest income from our cash held in interest bearing accounts.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management's discussion and analysis of our financial condition and results of operations is based on our audited financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S.&#160;GAAP. The preparation of the financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management's judgments and estimates.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Testing Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue related to billings on an accrual basis based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, we consider factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and us, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, we determine accrual rates based on the average reimbursement from payers for tests that are on average a year old, since it can take a significant period of time to collect from some payers. Except in situations where we believe the rate we reasonably expect to collect to vary due to a coverage decision, contract, more recent reimbursement data or evidence to the contrary, we use an average of reimbursement for tests provided over four quarters as it reduces the effects of temporary volatility and seasonal effects. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use judgment in determining accrual rates and our judgments will continue to evolve in the future as we continue to gain reimbursement experience.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Biopharmaceutical and Collaboration Revenue</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we enter into arrangements for the research and development and/or commercialization of services. Such arrangements may require us to deliver various rights, services and/or samples, including intellectual property rights/licenses, research and development services, and/or commercialization of services. The underlying terms of these arrangements generally provide for consideration to us in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments and/or profit sharing.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Arrangements with partners may fall under the scope of ASC Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC 808, we may analogize to ASC 606 for some aspects of these arrangements.  We analogize to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of our ongoing major or central operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, we utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue and collaboration revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  Payments made to us that are not net sales of data or other services to our customers are recorded as an offset against research and development expense in our consolidated statements of operations and comprehensive loss.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Significant Accounting Policies</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We first determine whether a set of assets acquired and liabilities assumed constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.&#160; </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration obligations incurred in connection with a business combination are recorded at fair value on the acquisition date and remeasured at each subsequent reporting period until the related contingencies are resolved, with the resulting changes in fair value recorded in earnings. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finite-lived Intangible Assets</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets consist of intangible assets acquired as part of business combinations. We amortize finite-lived intangible assets using the straight-line method over their estimated useful lives of five to 15 years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. We test these finite-lived intangible assets for impairment when events or circumstances indicate a reduction in the fair value below their carrying amounts. There was no impairment recognized during the years ended December&#160;31, 2019, 2018, or 2017.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired. Our goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. We have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of diagnostic products. In the event we determine that it is more likely than not the carrying value of the reporting unit is higher than its fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. We perform our annual evaluation of goodwill during the fourth quarter of each fiscal year. There was no impairment recognized during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, or 2017.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize stock-based compensation expense for only those shares underlying stock options and restricted stock units that we expect to vest on a straight-line basis over the requisite service period of the award. We estimate the fair value of stock options using a Black-Scholes option-pricing model, which requires the input of highly subjective assumptions, including the option's expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Years Ended December&#160;31, 2019 and 2018 (in thousands of dollars, except percentages)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">107,355</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,297</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91,058</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">923</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">923</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharmaceutical revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,090</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,140</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">752</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">950</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">120,368</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,360</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92,008</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expense:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,077</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,999</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,078</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">446</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">446</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,851</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,820</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53,691</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,378</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41,313</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,029</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,066</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,963</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,401</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">334</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,067</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">135,495</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,254</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">114,241</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(15,127</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,106</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(22,233</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(677</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,286</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(66</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,963</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,205</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,008</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">168</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,197</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss and comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12,599</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,400</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(22,999</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Operating Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Genomic classifiers reported</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,612</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,902</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31,710</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue increased $28.4 million, or 31%, for the year ended December 31, 2019 compared to 2018, primarily due to an increase in testing revenue from a 25% increase in genomic classifiers reported.  We had a $15.8 million increase in testing revenue for our Afirma, Percepta, and Envisia classifiers in the year ended December 31, 2019 compared to 2018. We also make adjustments, as necessary, for testing revenue accrued in prior periods as collections are made if the amount we expect to collect changes.  The adjustment for testing revenue accrued in prior periods was $1.0 million and $2.0 million for the years ended December 31, 2019 and 2018, respectively, a net decrease of $1.0 million between the years.  We also recognized $0.9 million from sales of Prosigna, a product that we acquired from NanoString in December 2019.  We recognized $8.1 million of biopharmaceutical revenue compared to $1.0 million in 2018 primarily due to the performance of data sequencing services for Johnson &amp; Johnson.  We also recognized $4.0 million of collaboration revenue in 2019 due to the achievements of milestones under the agreement we signed with Johnson &amp; Johnson in December 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of revenue for the years ending December 31, 2018 and 2017 are included in Item 8 of Part II of the Annual Report on Form 10-K filed with the Securities and Exchange Commission dated February 25, 2019.  There was no product revenue, biopharmaceutical revenue or collaboration revenue in 2017.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of the years ended December&#160;31, 2019 and 2018 was as follows (in thousands of dollars, except percentages):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,166</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,108</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,058</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sample collection expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,801</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">635</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,166</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,013</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,492</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,521</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License fees and royalties</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(795</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(99</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">805</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">220</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">800</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,749</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,731</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,318</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">321</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,997</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,077</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,999</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,078</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">446</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">446</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue increased $3.0 million, or 9%, for the year ended December 31, 2019 compared to 2018. The increase in laboratory costs was primarily due to a 25% increase in reported genomic classifiers volume, partially offset by lower pricing on supplies and improved efficiencies following the completion of the transition from the Afirma GEC to Afirma GSC in the third quarter of 2018. The increase in sample collection costs was primarily related to the increase in the overall volume of samples received, partially offset by lower shipping costs from modifications to our collection kits. The increase in compensation expense was primarily due to an average laboratory headcount increase of 16%. The decrease in license fees and royalties was due to the completed transition to the Afirma GSC in the third quarter of 2018, for which we do not pay license fees as we did in connection with the Afirma GEC. The increase in depreciation and amortization was from more equipment being placed into service. The increase in allocations was due to higher allocated costs from the increased headcount.  Cost of product revenue was $0.4 million from sales of Prosigna in 2019, a product that we acquired from NanoString in December 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of cost of testing revenue for the years ending December 31, 2018 and 2017 are included in Item 8 of Part II of the Annual Report on Form 10-K filed with the Securities and Exchange Commission dated February 25, 2019.  There was no cost of product revenue in 2017.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of the years ended December&#160;31, 2019 and 2018 was as follows (in thousands of dollars, except percentages):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,444</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,209</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,235</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Direct research and development expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,924</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(792</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(21</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,716</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">548</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(242</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(31</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">790</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">287</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(113</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(28</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">400</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">443</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">405</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,205</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(69</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,274</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,851</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,820</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense was flat in the year ended December 31, 2019 compared to 2018. Compensation expense increased $1.2 million, primarily due to higher stock-based compensation expense from the increase in our stock price and incentive compensation, partially offset by severance costs incurred in 2018 that were not incurred in 2019.  The decrease in direct research and development expense was due to one-time sequencing costs and materials and supplies purchased for research and development projects in 2018. The decrease in professional fees was due to lower consulting costs.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of research and development expense for the years ending December 31, 2018 and 2017 are included in Item 8 of Part II of the Annual Report on Form 10-K filed with the Securities and Exchange Commission dated February 25, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling and marketing</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of the years ended December&#160;31, 2019 and 2018 was as follows (in thousands of dollars, except percentages):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing expense:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,239</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,346</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,893</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Direct marketing expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,148</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,867</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,234</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">727</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,507</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,008</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,459</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,549</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,195</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">698</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,497</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53,691</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,378</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41,313</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing expense increased $12.4 million, or 30%, for the year ended December 31, 2019 compared to 2018.  The increase in compensation expense was due to a 41% increase in average headcount, higher incentive compensation and higher stock-based compensation expense.  The increase in direct marketing expense was due to higher general marketing expenditures.  The increase in professional fees was due to higher consulting expenses. The increase in other expenses was primarily due to higher travel and entertainment expenses related to the increase in headcount, which also increased allocated costs.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of selling and marketing expense for the years ending December 31, 2018 and 2017 are included in Item 8 of Part II of the Annual Report on Form 10-K filed with the Securities and Exchange Commission dated February 25, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of the years ended December&#160;31, 2019 and 2018 was as follows (in thousands of dollars, except percentages):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,537</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,479</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,058</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,854</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,652</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,202</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Occupancy costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,518</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">143</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,375</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,408</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(245</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(15</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,653</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,430</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">987</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,443</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6,718</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(950</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5,768</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,029</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,066</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,963</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense increased $5.1 million, or 21%, for the year ended December 31, 2019 compared to 2018.  The increase in compensation expense was primarily due to higher stock-based compensation expense from the increase in our stock price. The increase in professional fees was mainly due to $1.5 million of expenses associated with our acquisition of NanoString Technologies. Inc.'s diagnostics business, $0.6 million in other increases in legal spend, and $0.3 million higher investor relations costs.  The increase in other expenses was mainly from higher IT expenses to support the higher company headcount.  The increase in expenses allocated to other departments was due to higher headcount in departments associated with selling and marketing and cost of revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of general and administrative expense for the years ending December 31, 2018 and 2017 are included in Item 8 of Part II of the Annual Report on Form 10-K filed with the Securities and Exchange Commission dated February 25, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense decreased $1.3 million, or 66%, for the year ended December 31, 2019 compared to 2018, primarily due to the prepayments of $12.5 million and $12.4 million of the principal amount of our Term Loan Advance in January 2019 and May 2019, respectively. The average Term Loan Advance interest rate was 6.70% and 6.14% for the years ended December 31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of interest expense for the years ending December 31, 2018 and 2017 are included in Item 8 of Part II of the Annual Report on Form 10-K filed with the Securities and Exchange Commission dated February 25, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other income, net</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net, increased $2.0 million for the year ended December 31, 2019 compared to 2018, primarily due to higher interest income from our cash and cash equivalents, which had higher balances in 2019 following our public offering of common stock in July 2018 and May 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comparison of Other income, net, for the years ending December 31, 2018 and 2017 are included in Item 8 of Part II of the Annual Report on Form 10-K filed with the Securities and Exchange Commission dated February 25, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From inception through December 31, 2019, we have been financed primarily through net proceeds from the sale of our equity securities and borrowings under our credit facilities.  We have incurred net losses since our inception. For the years ended December&#160;31, 2019, 2018 and 2017, we had net losses of $12.6&#160;million, $23.0&#160;million and $31.0&#160;million, respectively, and we expect to incur additional losses in 2020 and potentially in future years. As of December&#160;31, 2019, we had an accumulated deficit of $246.7&#160;million. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our existing cash and cash equivalents of $159.3&#160;million as of December 31, 2019, our available revolving line of credit, and our revenue during the next 12 months will be sufficient to meet our anticipated cash requirements for at least the next 12 months.  We expect that our near- and longer-term liquidity requirements will continue to consist of costs to run our laboratories, research and development expenses, selling and marketing expenses, general and administrative expenses, working capital, costs to service our Loan and Security Agreement (See Note 8 to our audited consolidated financial statements included in this Annual Report on Form 10-K for more information about our Loan and Security Agreement), capital expenditures and general corporate expenses associated with the growth of our business. However, we may also use cash to acquire or invest in complementary businesses, technologies, services or products that would change our cash requirements. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives, or forgo potential acquisitions or investments.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public Offering of Common Stock</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 7, 2019, we issued and sold 6,325,000 shares of common stock in a registered public offering, including 825,000 shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;$23.25&#160;per share. Our net proceeds from the offering were approximately&#160;$137.8 million, after deducting underwriting discounts and commissions and offering expenses of $9.2 million.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 30, 2018, we issued and sold 5,750,000 shares of common stock in a registered public offering, including 750,000 shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;$10.25&#160;per share. Our net proceeds from the offering were approximately&#160;$55.0 million, after deducting underwriting discounts and commissions and estimated offering expenses of $3.9 million.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loan and Security Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 3, 2017, we entered into the Loan and Security Agreement with Silicon Valley Bank.  The Loan and Security Agreement allows us to borrow up to $35.0 million, with a $25.0 million term loan, or Term Loan, and a revolving line of credit of up to $10.0 million, or the Revolving Line of Credit, subject to, with respect to the Revolving Line of Credit, a borrowing base of 85% of eligible accounts receivable.  The Term Loan was advanced upon the closing of the Loan and Security Agreement. Borrowings under the Loan and Security Agreement mature in October 2022.  The Term Loan bears interest at a variable rate equal to (i) the thirty-day U.S. London Interbank Offer Rate, or LIBOR, plus (ii) 4.20%, with a minimum rate of 5.43% per annum.  Principal amounts outstanding under the Revolving Line of Credit bear interest at a variable rate equal to (i) LIBOR plus (ii) 3.50%, with a minimum rate of 4.70% per annum.  We are also required to pay an annual facility fee on the Revolving Line of Credit of $25,000.  The average Term Loan Advance interest rate for the&#160;year ended&#160;December&#160;31, 2019&#160;was&#160;6.70%.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may prepay the outstanding principal amount under the Term Loan plus accrued and unpaid interest and, if the Term Loan is repaid in full, a prepayment premium.  The prepayment premium will equal (i)&#160;$750,000, if the prepayment is made on or before November 3, 2018, (ii) $500,000, if the prepayment is made after November 3, 2018 and on or prior to November 3, 2019 and (iii)&#160;$250,000, if the prepayment is made after November 3, 2019.  In addition, a final payment on the Term Loan in the amount of $1.2 million is due upon the earlier of the maturity date of the Term Loan or its payment in full.  In January 2019 and May 2019, we prepaid $12.5 million and $12.4 million of the principal amount of the Term Loan Advance, respectively, and did not incur any prepayment premium as we did not repay the Term Loan Advance in full. These prepayments cover scheduled principal payments from November 2019 to September 2022.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Loan and Security Agreement contains customary representations, warranties, and events of default such as a material adverse change in our business, operations or financial conditions, as well as affirmative and negative covenants.  The negative covenants include, among other provisions, covenants that limit or restrict our ability to incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of our equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions.  As of December 31, 2019, the principal balance outstanding was $0.1 million and we were in compliance with debt covenants. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Loan and Security Agreement also requires us to comply with certain financial covenants, including achieving certain revenue levels tested quarterly on a trailing twelve-month basis.  However, failure to maintain the revenue levels will not be considered a default if the sum of our unrestricted cash and cash equivalents maintained with Silicon Valley Bank and amount available under the Revolving Line of Credit is at least $40.0 million.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our obligations under the Loan and Security Agreement are secured by substantially all of our assets (excluding intellectual property), subject to certain customary exceptions.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flows for the years ended December&#160;31, 2019, 2018 and 2017 (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3,232</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(13,521</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(23,915</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(42,733</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,874</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,315</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by (used in) financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">127,287</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59,499</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(218</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Operating Activities</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in operating activities for the year ended December 31, 2019 was $3.2 million. The net loss of $12.6 million includes non-cash charges of $9.8 million of stock-based compensation expense and $4.1 million of depreciation and amortization, which includes $1.4 million of intangible asset amortization, and $0.2 million of end-of-term debt obligation accruals.  Cash used as a result of changes in operating assets and liabilities was $4.8 million, primarily comprised of an increase in accounts receivable of $6.2 million, increase in supplies of $3.4 million and increase in other assets of $0.4 million, partially offset by an increase in accrued liabilities and deferred rent of $5.2 million.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in operating activities for the year ended December 31, 2018 was $13.5 million. The net loss of $23.0 million includes non-cash charges of $6.0 million of stock-based compensation expense and $3.9 million of depreciation and amortization, which includes $1.1 million of intangible asset amortization.  It also includes $0.3 million of end-of-term debt obligation accruals.  Cash used as a result of changes in operating assets and liabilities of $0.7 million was primarily due to a decrease in accounts payable of $1.6 million, an increase in other assets of $0.8 million and increases in prepaid expenses and other current assets and accounts receivable of $0.9 million, partially offset by a decrease in supplies of $1.9 million and an increase in accrued liabilities and deferred rent of $0.7 million.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in operating activities for the year ended December 31, 2017 was $23.9 million. The net loss of $31.0 million includes non-cash charges of $6.6 million of stock-based compensation expense and $3.8 million of depreciation and amortization, which includes $1.1 million of intangible asset amortization.  It also includes a $1.5 million prepayment penalty for exiting our previous credit agreement which is a financing cash flow, and the amortization and write-off of $0.5 million of debt issuance costs.  Cash used as a result of changes in operating assets and liabilities of $5.4 million was primarily due to an increase in accounts receivable of $4.0 million, an increase in supplies inventory of $1.8 million and a decrease in accrued liabilities and deferred rent of $1.2 million, partially offset by an increase in accounts payable of $1.7 million.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Investing Activities</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities for the year ended December 31, 2019 was $42.7 million, consisting of $40.0 million for the acquisition of NanoString Technologies, Inc.'s diagnostics business, and $2.7 million for the acquisition of property and equipment, net of proceeds from the disposal of property and equipment.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities for the year ended December 31, 2018 was $1.9 million for the acquisition of property and equipment.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities for the year ended December 31, 2017 was $1.2 million, mainly comprising $1.8 million for the acquisition of property and equipment, partially offset by $0.4 million of proceeds from the sale of property and equipment.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Financing Activities</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by financing activities for the year ended December 31, 2019 was $127.3 million, consisting of $137.8 million in net proceeds from the issuance of common stock in a public offering in May 2019 and $14.6 million in proceeds from the exercise of options to purchase our common stock and purchase of stock under our Employee Stock Purchase Plan, or ESPP, during the year, partially offset by $24.9 million of loan principal repayments and finance lease payments of $0.3 million.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by financing activities for the year ended December 31, 2018 was $59.5 million, consisting of $55.0 million in net proceeds from the issuance of common stock in a public offering in the second quarter of 2018, $4.4 million in proceeds from the exercise of options to purchase our common stock and purchases under our ESPP and $0.4 million in proceeds from a legal settlement, partially offset by capital lease payments of $0.3 million during the period.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in financing activities for the year ended December 31, 2017 was $0.2 million, consisting of a $25.4 million payment of the principal on prior credit agreement, $1.5 million payment for the prepayment premium for terminating the prior credit agreement and $0.3 million of capital lease payments, partially offset by $24.9 million of net proceeds from our new loan and security agreement, $1.9 million in proceeds from the purchase of stock under our ESPP and exercise of options to purchase our common stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes certain contractual obligations as of December&#160;31, 2019 (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments Due by Period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year 2021 to 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year 2023 to 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year 2025 and Beyond</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease obligations (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,332</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,873</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,157</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,161</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,523</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt obligations (2)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,288</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,288</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplies purchase commitments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,693</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,913</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,606</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital lease obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,025</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,074</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,157</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,161</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,417</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) Represents minimum operating lease payments under operating leases for facilities.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2) Debt obligations include principal, estimate of variable rate interest and end-of-term debt obligation.  In January 2019 and May 2019, we paid off $12.5 million and $12.4 million of principal from our Loan and Security Agreement, respectively.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-balance Sheet Arrangements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not entered into any off-balance sheet arrangements.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">. This ASU is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU was effective for interim and annual periods beginning after December 15, 2018.  Additionally, the FASB issued ASU No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements.  We elected this transition method and adopted ASC 842 on January 1, 2019 and as a result, recorded operating lease right-of-use ("ROU") assets of </span><span style="font-family:inherit;font-size:10pt;">$9.8 million</span><span style="font-family:inherit;font-size:10pt;">, including offsetting deferred rent of </span><span style="font-family:inherit;font-size:10pt;">$4.3 million</span><span style="font-family:inherit;font-size:10pt;">, along with the associated operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;">$14.1 million</span><span style="font-family:inherit;font-size:10pt;">.  On January 1, 2019, we had finance lease ROU assets of </span><span style="font-family:inherit;font-size:10pt;">$0.8 million</span><span style="font-family:inherit;font-size:10pt;"> and associated finance lease liabilities of </span><span style="font-family:inherit;font-size:10pt;">$0.3 million</span><span style="font-family:inherit;font-size:10pt;"> for leases classified as finance leases prior to the adoption of ASC 842. The adoption of ASC 842 had an immaterial impact on the our consolidated statement of operations and comprehensive loss, consolidated statement of stockholders' equity and consolidated statement of cash flows for the year ended December 31, 2019.  In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">classification.  Additional information and disclosures required by this new standard are contained in Note 7,&#160;Commitments and Contingencies.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for us beginning January 1, 2020 with early adoption permitted. We are currently evaluating the potential effect of this standard on its financial statements.  We do not expect to have a material impact on our financial statements and related disclosures from the adoption of this guidance.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808). </span><span style="font-family:inherit;font-size:10pt;">Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  We adopted the ASU in 2019 with no cumulative-effect adjustments or retrospective impact. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s2F57DC36EFF9B6A98088428B095524EF"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. We had cash and cash equivalents of $159.3&#160;million as of December&#160;31, 2019 which consisted of bank deposits, money market funds and overnight reverse repurchase agreements. Such interest-bearing instruments carry a degree of risk; however, a hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1837B6F1B0F8DCBCDABB428B095B6AFE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Veracyte,&#160;Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Index to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Page No.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s058D9FC5B91F67B85745428B096787BC"><span style="font-family:inherit;font-size:10pt;">REPORT OF INDEPENDENT REGISTERED ACCOUNTING FIRM</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s058D9FC5B91F67B85745428B096787BC">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s89F03F032141D9A55797428AF792BEE9"><span style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets as of December&#160;31, 2019 and 2018</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s89F03F032141D9A55797428AF792BEE9">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBD564F6206028FD45216428AF94F6F92"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December&#160;31, 2019, 2018 and 2017</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBD564F6206028FD45216428AF94F6F92">79</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s135003682E36B5D0B962428AF7CAC7C6"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders' Equity for the Years Ended December&#160;31, 2019, 2018 and 2017</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s135003682E36B5D0B962428AF7CAC7C6">80</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF64ED807D72185FE1D6E428AF81498B7"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2019, 2018 and 2017</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF64ED807D72185FE1D6E428AF81498B7">81</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2ECC74DF0157011EF5CB428B0AC55419"><span style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2ECC74DF0157011EF5CB428B0AC55419">83</a></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><a id="s058D9FC5B91F67B85745428B096787BC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Stockholders and the Board of Directors of Veracyte, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Veracyte, Inc. (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework), and our report dated February 25, 2020 expressed an unqualified opinion thereon.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Audit Matters</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span><span style="font-family:inherit;font-size:10pt;">financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.01559454191033%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:18%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue from diagnostic services</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Description of the Matter</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2019, the Company&#8217;s revenue from diagnostic services was approximately $107.4 million. As discussed in Note 2, the Company&#8217;s diagnostic services revenue is recognized upon the delivery of test results to the prescribing physician, at which time the Company bills for its services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized. </span></div><div style="text-align:justify;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auditing the measurement of the Company&#8217;s diagnostic services revenue was complex due to the judgments used in estimating the amount to be realized per test. In determining the amount to recognize for a delivered test the Company considers factors such as payment history, amount collected per test, payer coverage, and whether there is a reimbursement contract between the payer and the Company. The Company also considers whether historical collections per test are indicative of future collections or if there are any current or expected developments or changes that could affect reimbursement rates, which is an estimate that requires significant judgment by the Company.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">How We Addressed the Matter in Our Audit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls used by management in making this estimate. For example, we tested controls over management&#8217;s review of changes in collection trends, payer rates, contract terms, and payer behavior and expectations of how those changes are expected to impact future collections and the amount of revenue to be recognized per test.</span></div><div style="text-align:justify;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To test management&#8217;s estimate of the amount of revenue to be recognized per test delivered our audit procedures included, among others, evaluating the methodology used, understanding and testing the significant assumptions discussed above, and testing the underlying data used by the Company (including the completeness and accuracy of historical data). We tested payment history and amount collected per test on a sample basis, including agreeing selections to supporting documentation such as physician requisition, cash collected, write-offs of receivables, and proof of delivery, as applicable. We evaluated and tested management&#8217;s assessment of changes in payer trends, behaviors, and contract terms and how those changes will impact future cash collections as well as management&#8217;s consideration of any contrary factors. We also assessed and tested management&#8217;s review of differences between prior period accrual rates and actual cash collections and how those differences were factored into management&#8217;s estimate of current period accrual rates.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.01559454191033%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:18%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation of intangible assets and contingent consideration</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Description of the Matter</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 3, 2019, the Company entered into an agreement to acquire a license and certain assets for consideration of $60 million, including up to $10 million of contingent consideration upon achievement of certain milestones. As discussed in Note 4 to the consolidated financial statements, the Company accounted for this transaction as a business combination. </span></div><div style="padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auditing the accounting for this business combination was complex due to the significant estimation uncertainty in determining the fair value of identified intangible assets and contingent consideration. The significant estimation uncertainty was primarily due to the sensitivity of the fair value estimates to the significant underlying assumptions about the forecasted results of the acquired business. The significant assumptions used to form the basis of the forecasted results included revenue growth rates, profit margins, timing of cash flows, and the discount rate. These significant assumptions are forward-looking and could be affected by future economic and market conditions.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">How We Addressed the Matter in Our Audit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company&#8217;s controls over the valuation of intangible assets and contingent consideration related to the business combination. This included testing controls over the estimation process supporting the recognition and measurement of identified intangible assets and contingent consideration and management&#8217;s judgment and evaluation of underlying assumptions and estimates with regards to these fair values.</span></div><div style="text-align:justify;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To test these fair values, our audit procedures included, among others, involvement of a specialist to assist us in the evaluation of the Company&#8217;s valuation methodology and testing of the discount rate, evaluating prospective financial information, and testing the completeness and accuracy of underlying data. For example, we compared the significant assumptions to current industry and market trends, historical results and other relevant factors.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</span><span style="font-family:inherit;font-size:10pt;color:#333333;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have served as the Company&#8217;s auditor since 2014.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redwood City, California </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><a id="s89F03F032141D9A55797428AF792BEE9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e920-wk-Fact-85FA5F8054B2E56BBECEC7EB6A1CA24A" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e939-wk-Fact-88BEE610D654577571D4C7EB6A07D9C0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e954-wk-Fact-66CE026418D2AA925E97C7EB69F467AD" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e973-wk-Fact-C42345A8597D0B3EA492C7EB69F33377" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e993-wk-Fact-A371EBBEAC16FB610FE5C7EB69EE827C" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,806</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1012-wk-Fact-448536BD8706BD05E8CEC7EB6A0F8AA2" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1032-wk-Fact-744C9366ED22E385F479C7EB6A1546FD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1051-wk-Fact-D8BE05E4553EAF347411C7EB6A1B1FBA" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1071-wk-Fact-A9535703801013D2F2DCC7EB6A0B0220" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">187,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1090-wk-Fact-CBDAB585D53E6F2EFC5CC7EB6A073C6B" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">96,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1110-wk-Fact-BC904E8E1E34A858FE66C7EB69C3C495" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1129-wk-Fact-F30BF87645E2C558788CC7EB69E8B74F" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets - operating lease</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1149-wk-Fact-544B7D5445B8DDD6D7D3E7BE8267FF17" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1168-wk-Fact-A3B2F00DF7489EBF9A4DE7BE824D4315" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1189-wk-Fact-75E37D38A5E99637ED54C7EB69E7C084" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,019</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1208-wk-Fact-05D77A7F1F0983F16406C7EB6A16033B" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1228-wk-Fact-90CA3E6A3CCF873EE25FC7EB6A1EA47B" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1247-wk-Fact-33F567FC1DBC0B4F7937C7EB69EF0939" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,057</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1267-wk-Fact-058EE48AA43EBE8DA017C7EB6A1C4694" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1286-wk-Fact-D8FC4B0370974C14AE12C7EB6A127112" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1306-wk-Fact-0052F5104DCAEE0900CEC7EB6A1D0495" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1325-wk-Fact-5C3288E6FC44095D2C52C7EB6A124D4D" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1350-wk-Fact-D7455FB99D194B126DBAC7EB6A07CAEB" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">275,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1369-wk-Fact-94E5134A34844AEEDFE3C7EB6A097A48" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and Stockholders' Equity</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1471-wk-Fact-6F28EBD06510E560B1CFC7EB6A169577" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,328</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1490-wk-Fact-8EEF59D401600F82AA0FC7EB6A0F4A2C" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1505-wk-Fact-44F2146EFC93E9182624C7EB6A0D77DE" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1524-wk-Fact-DFD7CCCFD7DF8EABBE28C7EB69F57292" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1544-wk-Fact-247417FB0094EF313842C7EB6A1A4A2F" name="us-gaap:LongTermDebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1563-wk-Fact-1BB75384301A8FD4AA55C7EB6A1ED993" name="us-gaap:LongTermDebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1583-wk-Fact-DA69985FEE89AB339388E7C06DCF75A8" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1602-wk-Fact-31B061E9913139ADCEFCE7C06DD30F81" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1623-wk-Fact-C013170F8581EABA1363C7EB6A0A7D35" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1642-wk-Fact-1AD3549BFF9FB089E149C7EB69F7327E" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1662-wk-Fact-A7E463194A59373330F2C7EB6A18605A" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1681-wk-Fact-846FA26C1D6134B58F0AC7EB69F50048" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred rent, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1701-wk-Fact-4ED8D2DBBB3BF2F90F49C7EB69E9346B" name="us-gaap:DeferredRevenueLeasesNetNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1720-wk-Fact-4AAAD3FDCFFB07EA4677C7EB69EB531D" name="us-gaap:DeferredRevenueLeasesNetNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,899</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition related contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1740-wk-Fact-13E537B0D8AC66010191E7C510ADC85F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1759-wk-Fact-F59804FBD220BA292E26E7C510BC4825" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1779-wk-Fact-22852C72B4C466775DD0E7C1744D50AA" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1798-wk-Fact-CB01E42F6EF7CBA5D646E7C17467561F" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1818-wk-Fact-E045F0B48158EABE958BC7EB6A0F14E5" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1837-wk-Fact-84C49E321E11A565E870C7EB69F5858A" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments and contingencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1857-wk-Fact-8DCD21BC98E211495B45C7EB6A0C0705" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1875-wk-Fact-2AB7B7E06F905A10D01CC7EB69C21BC8" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stockholders' equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December&#160;31, 2019 and 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1935-wk-Fact-4D779C0287A233FFFFA7C7EB69F15C39" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1954-wk-Fact-96D6774B3E95CE6B4DB3C7EB69EFD1D5" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value; 125,000,000 shares authorized, 49,625,341 and 40,863,202 shares issued and outstanding as of December&#160;31, 2019 and 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1974-wk-Fact-0998AEA052B8F245597DC7EB6A1326B5" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e1993-wk-Fact-523ACF13799B865755F6C7EB6A1543D9" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e2013-wk-Fact-A9B383395DCF7CD6B094C7EB6A15C5C8" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e2032-wk-Fact-078BF013D2C6BFCCBF33C7EB69F642C5" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">313,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32775652e2053-wk-Fact-627529976ADD516CB456C7EB6A0C9EF9" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">246,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32775652e2073-wk-Fact-F5B5023A9F3E1F7F421CC7EB69EF0D33" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">234,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders' equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e2094-wk-Fact-B29DA4BB134FDC60DE41C7EB69F0A0D3" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e2113-wk-Fact-B98A1AF43330D54A4B8FC7EB69C3A655" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,755</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders' equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e2138-wk-Fact-653AB1F1283A3427CC2FC7EB6A1441B6" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">275,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32775652e2157-wk-Fact-F37AC69AD822E858ED6DC7EB6A0F03EF" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBD564F6206028FD45216428AF94F6F92"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e946-wk-Fact-AF4C19BD2049D80EFD71E7C7BC8D5E19" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">107,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e965-wk-Fact-29BCA614035BE02D486EE7C7BF04CEFD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e984-wk-Fact-EDB8ADC16E235F5D9389E7C7C1448E6D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1000-wk-Fact-445DC488F14CB213643AE7C7C1F4BF50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">923</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1019-wk-Fact-34A3D877E4312330B162E7C7C34C92DA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1038-wk-Fact-7E8DD6757548D745C32CE7C7C51D9D44" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharmaceutical revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1059-wk-Fact-6C251DBEEDCD98CE946D40300740E147" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1078-wk-Fact-BF00AA83C01A6DDE757440300AD5909C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">950</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1097-wk-Fact-106A9E09BC24677AA72940300E51064C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1118-wk-Fact-7F3B2256A1FB130D8215E7C7C6018B2A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1137-wk-Fact-4529D6C3952CFDF3B3ACE7C7C7D277E4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1156-wk-Fact-348F4A25E6222B7586F2E7C7C99EE7B3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1177-wk-Fact-A78B1DBB0CF9A33A9A86C7EB69FCCBF6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,368</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1196-wk-Fact-DD5C5A320A5DFD181F1EC7EB69D16F02" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1215-wk-Fact-C04B878F5CC45DEF463EC7EB69D00D82" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating Expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1360-wk-Fact-D70AFECDC08A594CA98AC7EB69FD3EB5" name="us-gaap:CostOfRevenue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,077</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1379-wk-Fact-07168ADA3314A0A4815FC7EB69CC83E2" name="us-gaap:CostOfRevenue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1398-wk-Fact-41794193EB4596AA8090C7EB69C4DBC2" name="us-gaap:CostOfRevenue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1420-wk-Fact-593DD84203A225636563E7CC9D30AEBE" name="us-gaap:CostDirectMaterial" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1439-wk-Fact-FB6F94581869E63557B2E7CC9D3BD611" name="us-gaap:CostDirectMaterial" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1458-wk-Fact-263BFDEDA8233DBE5536E7CC9D2A9581" name="us-gaap:CostDirectMaterial" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1479-wk-Fact-94731EBF813114F1576CC7EB69F97F31" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1498-wk-Fact-36E1E5B17A4B85B45E4FC7EB69D208CC" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1517-wk-Fact-33F7F39DD58CA3350CCCC7EB69C27C56" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,881</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1538-wk-Fact-3F4971916302BEC02F4EC7EB69CBB3A1" name="us-gaap:SellingAndMarketingExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1557-wk-Fact-287907084002D20223BDC7EB69C24081" name="us-gaap:SellingAndMarketingExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1576-wk-Fact-FF4EC47ADA3190217AC7C7EB69D1DE2B" name="us-gaap:SellingAndMarketingExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1597-wk-Fact-4E887354184E1B4439E5C7EB69D4E91E" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,029</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1616-wk-Fact-A9955BE33DCB3B9DB301C7EB69FF100F" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1635-wk-Fact-A876E56967AA2CA74E31C7EB6A0217E8" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1656-wk-Fact-9279F7BE19C5EE84109DC7EB69C68C99" name="us-gaap:AdjustmentForAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1675-wk-Fact-58C06E135B28C929DEBCC7EB69D47E1C" name="us-gaap:AdjustmentForAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,067</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1694-wk-Fact-4198294F8F65751F696BC7EB69C95AA3" name="us-gaap:AdjustmentForAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,067</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1715-wk-Fact-76CDB7D96764838BC09AC7EB69CE7650" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">135,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1734-wk-Fact-8CCC17DBC8C287A26887C7EB69C978DF" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">114,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1753-wk-Fact-FB968A05665EE9CF9D6AC7EB69CEB817" name="us-gaap:CostsAndExpenses" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98,491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e1774-wk-Fact-C96633BD36DA5D38205BC7EB6A02E72F" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e1794-wk-Fact-D571C07D6AE28B59EEA6C7EB69FA0FB6" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e1814-wk-Fact-08344C7E7799148F2765C7EB69C05186" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e1836-wk-Fact-AEBE32353278432F2913C7EB69C343BA" name="us-gaap:InterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e1856-wk-Fact-15055D40E4A2580210FCC7EB6A06BE30" name="us-gaap:InterestExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e1876-wk-Fact-C38EF3C9F3EE53A41BBAC7EB69CCEEB5" name="us-gaap:InterestExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1898-wk-Fact-E6D3BF84A591AAE2F309C7EB69CED318" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1917-wk-Fact-D585F050603824FF33F8C7EB6A010200" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e1936-wk-Fact-8A5D2DC0384455D6818DC7EB69CB484E" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss and comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e1962-wk-Fact-59EB930132FF9E8EA314C7EB69D4D3E3" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,599</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e1982-wk-Fact-4675E7BD94D094705776C7EB69D50F75" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e2002-wk-Fact-318A7311D6271D38C27FC7EB69FA1BCA" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per common share, basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e2024-wk-Fact-ACF53696CB103C6A6481C7EB6A04937B" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e2044-wk-Fact-19BB46325B16FD84A989C7EB69C31B03" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32778833e2064-wk-Fact-44F4A9520B2A2D474161C7EB69C02746" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used to compute net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e2082-wk-Fact-E42A52C1C2013D42B649C7EB69D0B907" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">46,138,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e2101-wk-Fact-BF7BF6146A6A409CED20C7EB69FCF58B" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">37,020,246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32778833e2120-wk-Fact-AE405842BEA9939E9E9FC7EB69CA1BE3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">33,925,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><a id="s135003682E36B5D0B962428AF7CAC7C6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Stockholders' Equity</span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except shares)</span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:48%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders'</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1069-wk-Fact-75AAE97F8CB6FA316E3CC7EB6A167A81" name="us-gaap:SharesOutstanding" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">33,762,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1088-wk-Fact-7CA60473CAC7DF008E82C7EB6A061DC1" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1107-wk-Fact-2FD68436BCC350BAB376C7EB6A187762" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239,631</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e1127-wk-Fact-767DDABA0FEC124ADC81C7EB6A11E831" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">180,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1147-wk-Fact-6368A7E9DF1864B0EB4BC7EB6A0BB18C" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock on exercise of stock options and vesting of restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1162-wk-Fact-73D990FC75E835D84F3AC7EB6A173B25" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">295,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1195-wk-Fact-A649F8CB570D7A057234C7EB6A0E5745" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1234-wk-Fact-BC75B29BDE31B221EA55C7EB6A19D4B1" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock under employee stock purchase plan (ESPP)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1254-wk-Fact-4B97F3375E7E7361A2B2C7EB6A030DD0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">153,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1287-wk-Fact-EDA211235A35F3112E55C7EB6A0D2396" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1326-wk-Fact-2D7BA1A61F221C64C010C7EB6A0726E2" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (employee)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1379-wk-Fact-8146B21D6DA9A73D3D6EC7EB6A083F69" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1418-wk-Fact-1B4527348908B4779159C7EB6A13ABB9" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (non-employee)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1471-wk-Fact-AE4D187F2349C43436C5C7EB6A04A166" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1510-wk-Fact-58853720423E11B7E82EC7EB6A0E7CBD" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (ESPP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1563-wk-Fact-E1428C125AFF25BD11DBC7EB6A0FD282" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1602-wk-Fact-45C6AD0F96E736F82144C7EB6A1546C1" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss and comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e1675-wk-Fact-69E4889D0CA424AAE40CC7EB6A15EEFD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e1695-wk-Fact-318A7311D6271D38C27FC7EB69FA1BCA" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1716-wk-Fact-F9459694F4B3DFADE9B2C7EB6A05090B" name="us-gaap:SharesOutstanding" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,210,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1730-wk-Fact-710961BA96271B59CBD1C7EB6A0C9BCF" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1749-wk-Fact-4945D49F9E939C6B048FC7EB6A12547B" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">248,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e1769-wk-Fact-FAEBDB1DD886BE60C871C7EB6A11ECC3" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">211,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1789-wk-Fact-D67F8EF6B0AC53C83C44C7EB6A1396B1" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock on exercise of stock options and vesting of restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1810-wk-Fact-C29D0056AD94953E9CDBC7EB6A13448C" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">756,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1824-wk-Fact-AA8C33587962EACF0EBFC7EB6A172CF6" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1843-wk-Fact-682AC63FF0ED6E2DDB34C7EB6A0838FD" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1882-wk-Fact-F7F442A36CCE8322694CC7EB6A17CCE1" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock under employee stock purchase plan (ESPP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1902-wk-Fact-9F2BE4B9F598F48ECBE4C7EB6A039834" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">146,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1935-wk-Fact-1A889DE16E0DC51D376FC7EB6A0CBFBF" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">790</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1974-wk-Fact-6D6D133BA4E1F52D6D51C7EB6A017265" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">790</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sale of common stock in a public offering, net of issuance costs of $3,890</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e1994-wk-Fact-D9866976E957116AEF76C7EB6A0BBBCD" name="vcyt:StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,750,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2008-wk-Fact-B4AF52567E01BE843C7CC7EB6A069D34" name="vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2027-wk-Fact-EA1F3E8023637605E67FC7EB6A101660" name="vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2066-wk-Fact-9E6C98AD83391166D775C7EB6A1185C3" name="vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (employee)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2119-wk-Fact-A3315801B25D6D667621C7EB6A05CA25" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2158-wk-Fact-E121788E226E450B4C0CC7EB6A060C74" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (non-employee)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2211-wk-Fact-3FB876F2EB2BAC1D6048C7EB6A18D308" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2250-wk-Fact-FF68B40AF1BF9DBF36C4C7EB6A0FD43D" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (ESPP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2303-wk-Fact-06658F99CB4F7543823EC7EB6A02D60F" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2342-wk-Fact-8EC7A46807F31E8E773EC7EB6A0B75C7" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Legal settlement from short-swing profits, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2395-wk-Fact-5D81785E2AA5E0915ECAC7EB6A03B803" name="vcyt:LegalSettlementRegardingShortSwingProfitsNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2434-wk-Fact-0A3C4E87D3080DBC3B0DC7EB6A14CFB7" name="vcyt:LegalSettlementRegardingShortSwingProfitsNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss and comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e2507-wk-Fact-1DFCCD1969BE4E9AF105C7EB6A0D2455" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e2527-wk-Fact-4675E7BD94D094705776C7EB69D50F75" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2548-wk-Fact-2EA943EC8196427F9B55C7EB6A047B1C" name="us-gaap:SharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">40,863,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2562-wk-Fact-77D531659A79042D9C6EC7EB6A08400F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2581-wk-Fact-21A37D78A31A7D431654C7EB6A19C11B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">313,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e2601-wk-Fact-49F9716D7A0B97E50908C7EB6A189CB2" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">234,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2621-wk-Fact-B98A1AF43330D54A4B8FC7EB69C3A655" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,755</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock on exercise of stock options and vesting of restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2641-wk-Fact-25049332183CB2E90A66E7CEF160C10A" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,924,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2655-wk-Fact-8010AB601F5F3D852514E7CEF0C460EF" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2674-wk-Fact-CB51C43AA9FEA966CEF0E7CEF0BBD3A9" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2713-wk-Fact-76E6EE3E65C59939480FE7CEF0B7EDD6" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock under employee stock purchase plan (ESPP)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2733-wk-Fact-CE8178C0B75EA48D1416E7CEF1769DED" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">136,251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2766-wk-Fact-CC541D8520F772CC7780E7CEF0BF1EAD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2805-wk-Fact-D30C42A1D42F2C621F8FE7CEF09F5078" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sale of common stock in a public offering, net of issuance costs of $9,208</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2826-wk-Fact-EB68E76C6994848B85D5E7CEF0B1BA0C" name="vcyt:StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,325,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2840-wk-Fact-4E7854F0C5E798479866E7CEF16DEFB2" name="vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2859-wk-Fact-9F62B7C49CC5693C7B73E7CEF0C8A71D" name="vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">137,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2898-wk-Fact-DB19B13C0AC2292D2D51E7CEF0CD7A8C" name="vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">137,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock for acquisition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2918-wk-Fact-B32EAD9A4CC3B37127CEE7D08AC2C758" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">376,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2932-wk-Fact-8743F69C8F0077BF894DE7D099A57BD3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2951-wk-Fact-722D79E287F6A68D259BE7D103BECCD8" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e2990-wk-Fact-D660AC90218275DDACC1E7D1122B17EC" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (employee)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3043-wk-Fact-1B2DC13F4A9D4D7D0838E7CEF1696B5E" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3082-wk-Fact-21FC48F99F26F2C2FB4FE7CEF0D5E352" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (non-employee)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3135-wk-Fact-172D9E53AC82A41B1AFCE7CEF0D98818" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3174-wk-Fact-999E1EBCFC8AB300716EE7CEF17A9E0E" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation expense (ESPP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3227-wk-Fact-0A919FDA65ADD740EEE6E7CEF0AD3A0D" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3266-wk-Fact-CCE7693D078BFC89FF71E7CEF17273A6" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss and comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e3339-wk-Fact-3E5EA6FAA18792093F41E7CEF17E4469" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,599</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e3359-wk-Fact-59EB930132FF9E8EA314C7EB69D4D3E3" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,599</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3380-wk-Fact-FBD2BE68B80981FD2EE8E7CEF0A8531D" name="us-gaap:SharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">49,625,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3399-wk-Fact-ED6FCEE2BBBF59093AB0E7CEF099A7CD" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3418-wk-Fact-CBF130877ADE5BB74C94E7CEF0A3CBA2" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32787351e3438-wk-Fact-13C08551E4E274B1838CE7CEF1650CC2" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">246,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32787351e3458-wk-Fact-B29DA4BB134FDC60DE41C7EB69F0A0D3" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF64ED807D72185FE1D6E428AF81498B7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands of dollars)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e944-wk-Fact-1DE796C8009C8E6A5D88C7EB6A1D5BEE" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,599</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e964-wk-Fact-453059434A55F94973F2C7EB6A1F0DE7" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e984-wk-Fact-B1563AF1B868AB00D10FC7EB6A1FB62B" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1060-wk-Fact-0F0AC620FF7D5ECD9A3EC7EB69FAF93A" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1079-wk-Fact-A8F68F702BDAFF25E3DFC7EB6A097EF5" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1098-wk-Fact-0FAC63FF54B623DDAB4CC7EB69F71C08" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,841</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Gain) loss on disposal of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1119-wk-Fact-75A42FED1B9E683A840AC7EB69ED1B0A" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1139-wk-Fact-117327C35159635D4B1BC7EB69FB6AF2" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1158-wk-Fact-4E9F2D33F4AC18D4EA6AC7EB6A0B4AB0" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1179-wk-Fact-D025BE25999113815158C7EB69F6B725" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1198-wk-Fact-A8FCBB2C56A61BA520F4C7EB6A00BC7F" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,958</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1217-wk-Fact-909F2F480AA79D72F6D3C7EB69F102CF" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1238-wk-Fact-54AF4D42EF7AF672D43AC7EB6A046631" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1257-wk-Fact-8FF3D915B68989C2D779C7EB69FED8DE" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1277-wk-Fact-445AA3A14BC44563958CC7EB69F20BA2" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortization and write-off of debt discount and issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1298-wk-Fact-2D9D8FD363B87A3B67A6C7EB69F2917F" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1317-wk-Fact-9422E6AA0EC19F6E6064C7EB69F22302" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1336-wk-Fact-5E6DE239CCB3DD22767FC7EB6A00096C" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest on end-of-term debt obligation and prepayment penalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1357-wk-Fact-EAAE3581261EF537F4D5C7EB69F94D03" name="vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1376-wk-Fact-4CF9D9DC2BFABB402699C7EB69FE7BB0" name="vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1395-wk-Fact-2BAEF7AED028548E8C96C7EB6A030F80" name="vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,589</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1476-wk-Fact-B9EEF942205381B7319BC7EB6A09BA64" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1496-wk-Fact-8C7502FF21A418DED320C7EB69F1EA65" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1516-wk-Fact-25E73882BF3BCE99DD58C7EB69FC300A" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Supplies</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1538-wk-Fact-8539F0545CCEF090C7CAC7EB69F6FA7F" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1558-wk-Fact-BE3077F2859090B2CCEAC7EB6A041738" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1577-wk-Fact-2454FFB25F0023A00B71C7EB69F6F1CA" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,849</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1599-wk-Fact-949B33EB3B0306DB0105C7EB69F1F139" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1618-wk-Fact-4226695B66ABB25B9962C7EB69F6CA85" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1638-wk-Fact-A8DB85698AF1350E330DC7EB6A06BA41" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Right-of-use assets - operating lease and operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1660-wk-Fact-F5AF626F2A5116063219E7DDBC7BCAAB" name="vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1680-wk-Fact-480B753C16CA1702355FE7DDBC76FB76" name="vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1699-wk-Fact-ECA2870FC3C083361062E7DDBC64800E" name="vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1720-wk-Fact-D48ECAFE8FA3B1943DF5C7EB69F6F2DB" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1740-wk-Fact-3DD3609607CDC293274DC7EB6A0A7D0F" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1760-wk-Fact-85340D033721ABCDEB3DC7EB6A057823" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1782-wk-Fact-332F36104E5060E6D48AC7EB69EE3C3A" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1802-wk-Fact-AE81B459E34E7C9DE284C7EB6A00B610" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1822-wk-Fact-849D4CF4C6A113FA0478C7EB69FF6793" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued liabilities and deferred rent</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1843-wk-Fact-20D99125E381912E981AC7EB69F45D64" name="vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e1862-wk-Fact-7D752E99B96F0A56D051C7EB69FD888B" name="vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">724</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1881-wk-Fact-8514B001B94222E930B4C7EB69F2F7F2" name="vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1903-wk-Fact-AE09DC98C84D901B0641C7EB69F4120C" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1923-wk-Fact-AD16A12FCECACA7E2A89C7EB69FEDD5B" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e1943-wk-Fact-0DD6D13FF4C6750244F9C7EB69F9B90A" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash paid for acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2024-wk-Fact-09D56CDD39457E911EA6E7E05B64DFD0" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2044-wk-Fact-858A9A85BF67DBE5065DE7E05B54C20B" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2063-wk-Fact-5453BFB1703A73E56B1EE7E05B40AB47" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2085-wk-Fact-1620CBA42EF69333C0B2C7EB69FDEA47" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2105-wk-Fact-8E1C4AA4A52FF9BFD9DAC7EB6A0AA54F" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2125-wk-Fact-E7C861D0619F0D8CCA0FC7EB69F75E06" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,755</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from the sale of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2147-wk-Fact-8B1B987CF0A98A4ACFD5C7EB69FD12B7" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2166-wk-Fact-FE8DD29EBFC46285CC62C7EB69F4441E" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2185-wk-Fact-577E2DB3449E4B1FADCFC7EB69FDF82E" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2206-wk-Fact-720CD374AD9CC8BC4CF4C7EB69FB17E6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">42,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2226-wk-Fact-DFFD2BB907E6F7F449B7C7EB69ED0AB4" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2246-wk-Fact-5953CCCC9317A6B5DA15C7EB69EF860A" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from the issuance of long-term debt, net of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2327-wk-Fact-8E9EBC08849C2F49092FC7EB6A0107B2" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2346-wk-Fact-357A149881D79371373AC7EB6A0A7853" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2365-wk-Fact-0D53D08A2493CD98CA81C7EB69F4A4FA" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from issuance of common stock in a public offering, net of issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2386-wk-Fact-F22188FBE9CBAD986BBEC7EB69F1F4A6" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">137,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2405-wk-Fact-57777FCE2CB650F9C8C0C7EB69F25B4F" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2424-wk-Fact-DD77535188EF298EE6D0C7EB6A075E11" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Payment of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2445-wk-Fact-100E22CC2A4B4D807F27C7EB69F40F4B" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2465-wk-Fact-054A8B86A1357F55407CC7EB69F52D1F" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2484-wk-Fact-1446FABDDFB296169C8FC7EB6A01E495" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Payment of end-of-term debt obligation and prepayment penalty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2506-wk-Fact-CCE78E00BA29576AB067C7EB69EFF890" name="vcyt:PaymentOfEndOfTermObligation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2525-wk-Fact-0030137EDF83ADAEA340C7EB6A085477" name="vcyt:PaymentOfEndOfTermObligation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2544-wk-Fact-F391B5DB3F501FC23CB1C7EB69F1785C" name="vcyt:PaymentOfEndOfTermObligation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from legal settlement regarding short-swing profits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2566-wk-Fact-8088F25FCB2AB6A79B20C7EB6A001A4D" name="us-gaap:ProceedsFromLegalSettlements" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2585-wk-Fact-1FE55CD3F1EAF93BD616C7EB69ED7651" name="us-gaap:ProceedsFromLegalSettlements" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2604-wk-Fact-72397BF3B6DD38E65EFCC7EB69F84471" name="us-gaap:ProceedsFromLegalSettlements" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Payment of financial lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2625-wk-Fact-B1D558E4834BA2684D93C7EB69F40B01" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2645-wk-Fact-9EDBB037DE0C69F327EFC7EB69F9A089" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2665-wk-Fact-370BD7DB17A2CE512998C7EB69EE7801" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from the exercise of common stock options and employee stock purchases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2687-wk-Fact-BA6AAF680D222ADCE20FC7EB69FCAF1E" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,647</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2706-wk-Fact-19FF8F650E6204C2895DC7EB6A0A1D3D" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2725-wk-Fact-FE75BDBDB024BFD81B0FC7EB69F9450D" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net cash provided by (used in) financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2747-wk-Fact-C599BCD299C0105DE4D4C7EB69FC6A22" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2766-wk-Fact-22BEBABA2E9AFF714DA1C7EB69FC7B29" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,499</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2785-wk-Fact-07089E4F9236ABA926D1C7EB69FA9DDB" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2807-wk-Fact-81F16E2BD087CB4F6CF6C7EB69F7A1EF" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2826-wk-Fact-044DD30E79A2828E5EB0C7EB69F58F2A" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d32782655e2845-wk-Fact-F1337111ECEE5024A117C7EB69F39C60" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash, cash equivalents and restricted cash at beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2867-wk-Fact-13B421D1C11B19932B7EC7EB69D2045A" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2886-wk-Fact-036EA14211F702059E51C7EB69D2EFE1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2905-wk-Fact-B0D8750124AF04CCC83DC7EB6A0AF429" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash, cash equivalents and restricted cash at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2931-wk-Fact-8D056D23254B5389F076C7EB69D20D9B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2950-wk-Fact-13B421D1C11B19932B7EC7EB69D2045A" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e2969-wk-Fact-036EA14211F702059E51C7EB69D2EFE1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Supplementary cash flow information of non-cash investing and financing activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;">Operating lease liability arising from obtaining right-of-use assets - operating lease at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3111-wk-Fact-3BDEEC28831A2DB276FEE7E1DB528644" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3130-wk-Fact-61D18D690C41345FEA81E7E1DB3D363E" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3149-wk-Fact-4E38CA28BE27C4BD0C27E7E1DB2E4D9D" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares issued for purchase consideration for a business combination</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3165-wk-Fact-9CEA36BA03ACF966B293F79264C53004" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3184-wk-Fact-ABF163510506778B2C30F7926489E920" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3203-wk-Fact-B12B5AF72EF80C5E68ADF792645BC4B6" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Deferred purchase consideration for a business combination</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3224-wk-Fact-54E9266D8A886B1714C6F795AA4C4163" name="vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3243-wk-Fact-5E6543A86E00F08A8956F795AA540EA6" name="vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3262-wk-Fact-6197E4F6F015E4B34047F795AA5AA981" name="vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Purchases of property and equipment included in accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3283-wk-Fact-E40C12ADA9D815CC31DCC7EB6A0457FF" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3302-wk-Fact-A52A69967110A7373E54C7EB6A06A878" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3321-wk-Fact-8EA47800D8EE15B92626C7EB69FAC70F" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Supplementary cash flow information:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash paid for interest on debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3405-wk-Fact-CE914324B18B49D817FDC7EB6A074134" name="us-gaap:InterestPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3424-wk-Fact-DAD2C32C88DB46D77314C7EB69FE02F0" name="us-gaap:InterestPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,547</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3443-wk-Fact-BCE2A161E57F1E751399C7EB69F92710" name="us-gaap:InterestPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash paid for tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3464-wk-Fact-D55EC1ABAF02D83890C3C7EB69FA4C97" name="us-gaap:IncomeTaxesPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3483-wk-Fact-0EAEA3341EC3535D2108C7EB6A031A52" name="us-gaap:IncomeTaxesPaid" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3502-wk-Fact-63A5F4F2E494C0FE657FC7EB6A0B6E07" name="us-gaap:IncomeTaxesPaid" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3700-wk-Fact-85FA5F8054B2E56BBECEC7EB6A1CA24A" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3719-wk-Fact-88BEE610D654577571D4C7EB6A07D9C0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3738-wk-Fact-499862F5EB32E43687A7407EF28AF936" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,891</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3754-wk-Fact-058EE48AA43EBE8DA017C7EB6A1C4694" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3773-wk-Fact-D8FC4B0370974C14AE12C7EB6A127112" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3792-wk-Fact-CD68A20E95034CEDC4A5407EF28E3CBE" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3818-wk-Fact-8D056D23254B5389F076C7EB69D20D9B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3837-wk-Fact-13B421D1C11B19932B7EC7EB69D2045A" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d32782655e3856-wk-Fact-036EA14211F702059E51C7EB69D2EFE1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2ECC74DF0157011EF5CB428B0AC55419"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sB44CBCE77DF24105BCDD428AF7BBC5FE"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="TextSelection-7E1373FDDEAA52AA6C45C7EB6A29FF25-0-wk-Fact-EF6BB2E240268ED43FACC7EB69E07CE5" continuedAt="TextSelection-7E1373FDDEAA52AA6C45C7EB6A29FF25-1" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7E1373FDDEAA52AA6C45C7EB6A29FF25-1" continuedAt="TextSelection-7E1373FDDEAA52AA6C45C7EB6A29FF25-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Veracyte, Inc. (&#8220;Veracyte&#8221; or the &#8220;Company&#8221;) is a leading genomic diagnostics company that is creating value through innovation. The Company was founded in 2008 with a mission to improve diagnostic accuracy.  Today, the Company's growing menu of tests leverage advances in genomic science and technology to improve care throughout the patient journey, enabling more confident diagnostic, prognostic and treatment decisions in cancer and other challenging diseases. The Company is creating new standards of care by enabling more patients to avoid risks of unnecessary invasive procedures and removing costs from the healthcare system, while speeding the time to diagnosis and treatment decisions. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Veracyte was incorporated in the state of Delaware on August&#160;15, 2006 as Calderome,&#160;Inc. Calderome operated as an incubator until early 2008. On March&#160;4, 2008, the Company changed its name to Veracyte,&#160;Inc.  The Company&#8217;s operations are based in South San Francisco, California and Austin, Texas, and it operates in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787339e731-wk-Fact-D3DD3443486CB372D29AC7EB69E01ACD" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q4YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> segment.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performs its genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in our CLIA-certified laboratory in South San Francisco, California. In December 2019, we announced our acquisition of the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System, as well as the Prosigna breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company offers genomic tests in thyroid cancer; lung cancer; IPF and breast cancer:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Afirma Genomic Sequencing Classifier and Xpression Atlas.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">The Company's Afirma offerings include the Afirma GSC and  Xpression Atlas, to help guide next steps for patients with potentially cancerous thyroid nodules.  The  offerings are intended to provide physicians with clinically actionable results from a single fine needle aspiration, or FNA biopsy. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning, and is used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery. </span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company commercially launched the Afirma Xpression Atlas in 2018 to complement the Afirma GSC. The Xpression Atlas provides physicians with genomic alteration content from the same FNA samples that are used in Afirma GSC testing and may help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. </span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Percepta Genomic Sequencing Classifier.  </span><span style="font-family:inherit;font-size:10pt;">The Percepta classifier improves lung cancer diagnosis by enhancing the performance of diagnostic bronchoscopies, thus identifying more patients with lung nodules who are at low risk of cancer and may avoid further, invasive procedures. This second-generation test was developed on our RNA whole-transcriptome sequencing platform and commercially introduced in June 2019, provides expanded clinical utility by also identifying patients as high risk of cancer so they may obtain faster diagnosis and treatment. The test is built upon foundational "field of injury" science - through which genomic changes associated with lung cancer in current and former smokers can be identified with a simple brushing of a person's airway - without the need to sample the often hard-to-reach nodule directly.&#160;</span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Envisia Genomic Classifier.  </span><span style="font-family:inherit;font-size:10pt;">The Envisia classifier improves diagnosis of IPF by helping physicians better differentiate IPF from other interstitial lung diseases, or ILDs, without the need for surgery. The test identifies the genomic pattern of usual interstitial pneumonia, or UIP, a hallmark of IPF, with high accuracy on patient samples that are obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation. </span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prosigna Breast Cancer Prognostic Gene Signature Assay</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span><span style="font-family:inherit;font-size:10pt;"> The Prosigna test, acquired in December 2019 through our strategic transaction with NanoString, uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test leverages a collection of 50 genes known as the PAM50 gene signature and can provide a breast cancer patient and physician with prognostic score that indicates the probability of cancer recurrence over ten years. Physicians use Prosigna to help guide therapeutic decisions so that patients receive a therapeutic intervention, such as chemotherapy, only if clinically warranted. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-7E1373FDDEAA52AA6C45C7EB6A29FF25-2"><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s approach also provides multiple opportunities for partnerships with biopharmaceutical companies. In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of the Company's testing services are made available through its clinical reference laboratories located in South San Francisco, California and Austin, Texas.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s6F37A4858A4E5AC0B26B428AF7DA2142"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-0-wk-Fact-8F5DD1B610AAA9BE7E50C7EB69E74EA3" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-1" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-1D27DC2CF6B069521499C7EB6A2A3158-0-wk-Fact-08923C11DC7F77F72FC4C7EB69EBF0CF" continuedAt="TextSelection-1D27DC2CF6B069521499C7EB6A2A3158-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-1D27DC2CF6B069521499C7EB6A2A3158-1">The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP").</ix:continuation> The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, which was created in 2019 to process certain administrative functions associated with the business combination in Note 4, Business Combination. All intercompany accounts and transactions have been eliminated in consolidation.  Certain amounts have been reclassified on the consolidated statements of operations for presentation purposes.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:UseOfEstimates" id="TextSelection-386B645574F4184AF154C7EB6A2BF068-0-wk-Fact-FD9338BDC8FF8A6F5D3AC7EB69EB0F9C" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has incurred net losses since its inception and as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e780-wk-Fact-3C7A02E26785DEDDAD46C7EB69E9A8D5" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">246.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.  The Company believes its cash and cash equivalents of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e784-wk-Fact-2981EBB24DE659EE78E9C7EB69E9CE18" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and its revenue from sales in 2020 will be sufficient to meet its anticipated cash requirements through at least February 2021.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 7, 2019, the Company issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e797-wk-Fact-F14E1E0B042CCA31097DE85431FEF51E" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q2May07" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,325,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock in a registered public offering, including&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e801-wk-Fact-0E23D053462F0B1BD33FE854BC8230FF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q2May07_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">825,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e805-wk-Fact-C5495141AE56C4F84FE5E8560BFEC7AB" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2019Q2May07" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">23.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company's net proceeds from the offering were approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e809-wk-Fact-32A66B66A05C2F6E9B02E856AFDE1696" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2019Q2May07" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">137.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e813-wk-Fact-FCB7C8C8939E7C7D70E7E8578B2E4899" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="D2019Q2May07" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, the Company issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e822-wk-Fact-E03D35475575CEB2BA4EC7EB69EE0E68" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q3July" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,750,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock in a registered public offering, including </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e826-wk-Fact-66772D250B09C00E1F31C7EB69E81A37" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">750,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares issued and sold upon the underwriters' exercise in full of their option to purchase additional&#160;shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e830-wk-Fact-C31ACACBF781E231E595C7EB69EC4877" name="us-gaap:SharesIssuedPricePerShare" contextRef="I2018Q3Jul31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">10.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company's net proceeds from the offering were approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e834-wk-Fact-93A7CE4FB86A6B46EB0AC7EB69EAF469" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting commissions and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e838-wk-Fact-32A5C4030FEB0AE81407C7EB69E81F6D" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2017, the Company entered into a Loan and Security Agreement and drew down a term loan advance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e847-wk-Fact-04BAE4952369DB21D4CFC7EB69E8D16F" name="us-gaap:ProceedsFromLongTermLinesOfCredit" contextRef="D2017Q4Nov_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of which the entire amount was used to pay the outstanding balance of the Company's previous long-term debt as discussed in Note 8 - Debt.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-2" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-3"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company is not able to generate cash proceeds from revenue sufficient to satisfy its cash obligations, the Company will need to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations or licensing arrangements. If the Company is not able to secure additional funding when needed, on acceptable terms, it may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives which may have a material adverse effect on the Company's business, results of operations, financial condition and/or its ability to fund its scheduled obligations on a timely basis or at all.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" id="TextSelection-BE5D9B4B7F4919B04BDAC7EB6A2A92C9-0-wk-Fact-6E225E52C34583394436C7EB69EBE138" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company's cash and cash equivalents are deposited with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e875-wk-Fact-512A9EEE40383AECA138C7EB69EABEFF" name="vcyt:NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" contextRef="FI2019Q4" unitRef="financial_institution" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Several of the components of the Company's sample collection kit and test reagents, and its nCounter FLEX DX systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable related to its sales. The Company does not perform evaluations of customers' financial condition and does not require collateral.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, most of the Company's revenue have been derived from the sale of Afirma. To date, Afirma has been delivered primarily to physicians in the United States. <ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_vcyt_SalesRevenueGrossMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="TextSelection-B603E7555292D9C4018EC7EB6A2944AE-0-wk-Fact-0B8C30DE20DA93AF8C95C7EB69EEC75E" continuedAt="TextSelection-B603E7555292D9C4018EC7EB6A2944AE-1" escape="true">The Company's third-party payers and other customers in excess of 10% of revenue and their related revenue as a percentage of total revenue were as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B603E7555292D9C4018EC7EB6A2944AE-1"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1027-wk-Fact-E69CF6249C23B9E7C64DC7EB69C5EA3F" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1042-wk-Fact-76B24DCDDE3128135539E85B515F0BBB" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1057-wk-Fact-7072E89B370735556EFBC7EB69C5ABC7" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UnitedHealthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1073-wk-Fact-606DB8FE73ADEB498591C7EB69C7AD06" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1088-wk-Fact-3522907C6B084CC29FE2E85B5171F9F4" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1103-wk-Fact-37EBB83CC78A11414514C7EB69C9A8F2" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1119-wk-Fact-F28F7570F9D453E35D80C7EB69C46C7C" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1134-wk-Fact-376131A4B14285C5B923E85B5169CCA8" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1149-wk-Fact-456C9B687259E87A1FCBC7EB69C68288" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="TextSelection-4C5B7F100252EA2D46EAC7EB6A2A98AB-0-wk-Fact-4B3B98B926D78863E668C7EB69E31137" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's significant third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1258-wk-Fact-9F14E3AF05B85E109FA8C7EB6A173A68" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1273-wk-Fact-6AEA882E2605F626E8AFE85B3FF99E10" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Johnson and Johnson Services, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1289-wk-Fact-6D239E7E47C851A38AC0E861BB4D687F" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1304-wk-Fact-B4A0CE4B8C6C661B7E52E861C4427460" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UnitedHealthcare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1320-wk-Fact-FE39DC1E092084082603C7EB69D1F95A" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1335-wk-Fact-E676770340BD5F682FDDE85B400969A0" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="TextSelection-F7C5E4D29AFBBD1DD181C7EB6A2BC573-0-wk-Fact-503C73C6A4032DB89F93C7EB69DED3A1" continuedAt="TextSelection-F7C5E4D29AFBBD1DD181C7EB6A2BC573-1" escape="true">Cash Equivalents</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F7C5E4D29AFBBD1DD181C7EB6A2BC573-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist of amounts invested in a money market account primarily consisting of U.S. Treasury reserves, and overnight reverse repurchase agreements which are tri-party repurchase agreements and are collateralized by U.S. Treasury and agency securities of at&#160;least&#160;102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="TextSelection-2F73BF48DAFCFCCD3A40C7EB6A2AA2D4-0-wk-Fact-AD51AC51F0E7B829BB03C7EB69E76923" continuedAt="TextSelection-2F73BF48DAFCFCCD3A40C7EB6A2AA2D4-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-3" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-4"><ix:continuation id="TextSelection-2F73BF48DAFCFCCD3A40C7EB6A2AA2D4-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had deposits of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e1386-wk-Fact-058EE48AA43EBE8DA017C7EB6A1C4694" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">603,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> included in long-term assets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company's South San Francisco facility.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationsPolicy" id="TextSelection-99C6ACEB0DD7D1CC98E2E85E544F97A1-0-wk-Fact-A0BF11593A53A6D8AC6BE8605A901A30" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company first determines whether a set of assets acquired and liabilities assumed constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.&#160; Contingent consideration obligations incurred in connection with a business combination are recorded at  fair value on the acquisition date and remeasured at each subsequent reporting period until the related contingencies are resolved, with the resulting changes in fair value recorded in earnings. </span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="TextSelection-A043F95F8A07FC1E9A877BDAD6419479-0-wk-Fact-D9825DA8005EEE66D4E47BDB42D19817" continuedAt="TextSelection-A043F95F8A07FC1E9A877BDAD6419479-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts for Product Sales </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-A043F95F8A07FC1E9A877BDAD6419479-1">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable regularly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value by analyzing the status of significant past due receivables.</ix:continuation> Product sales commenced in December 2019 and there was no allowance for doubtful accounts at either December 31, 2019 or 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="TextSelection-3F1B1599A6ED34ABE0F8C7EB6A2B17B7-0-wk-Fact-653DADFFDFB1ADAC8D9FC7EB69E27CCD" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32802967e1466-wk-Fact-D3138033E05C071AE2D5C7EB69EB6BA1" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="TextSelection-BB41566385EDE86E65D1C7EB6A29A905-0-wk-Fact-25F7509FD699EA924D72C7EB69EAE031" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finite-lived Intangible Assets </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets consist of intangible assets acquired as part of business combinations. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 5 to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32802967e1498-wk-Fact-64BD69516EB3C7E9FA67C7EB69ECE841" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">15</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. The Company tests these finite-lived intangible assets for impairment when events or circumstances indicate a reduction in the fair value below their carrying amounts. There was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1505-wk-Fact-A26213BC8284455D2474C7EB69F3D3EA" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="FD2019Q4YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> impairment for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="TextSelection-549379A35B73A2DF67EBC7EB6A2A51E5-0-wk-Fact-FBD0165CDF4E251388A6C7EB69D60159" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill, derived from the Company's acquisition of Allegro Diagnostics Corp. in September 2014 and the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System and Prosigna and LymphMark assays in December 2019, is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired. The Company's goodwill evaluation is done annually on October 31 and is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company has determined that it operates in a single segment and has a single reporting unit associated with the development and commercialization of diagnostic products. In the event the Company determines that it is more likely than not the carrying value of the reporting unit is higher than its fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value.  There was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1546-wk-Fact-F27E9582D3F470225EE1C7EB69ED058B" name="us-gaap:GoodwillImpairmentLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> impairment for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-4" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-5"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="TextSelection-0ABAAD7DC1D774E58CF4C7EB6A2AB460-0-wk-Fact-87235E90B6C6BFD32D8EC7EB69E74D6F" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note&#160;6, "Fair Value Measurements" for further information on the fair value of the Company&#8217;s financial instruments.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-CF78421317AFD905A122C7EB6A2ACE03-0-wk-Fact-6F2B109BAB1EF809C5BAC7EB6A19F792" continuedAt="TextSelection-58083E4A4249494E1607C7EB6A2AC1D7-0" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Testing Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company commenced recognizing testing revenue in accordance with the provisions of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">, or ASC 606, starting January 1, 2018.  Prior to January 1, 2018, the Company recognized testing revenue in accordance with the provisions of ASC 954-605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Health Care Entities - Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, or ASC 954. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most of the Company&#8217;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method, which requires a cumulative catch-up adjustment as if the Company had recognized revenue under ASC 606 from January 1, 2016.  Prior to January 1, 2018, the Company recognized revenue in accordance with ASC 954 and recognized revenue for tests delivered on an accrual basis when amounts that will ultimately be realized could be reasonably estimated, and on the cash basis when there was insufficient information to estimate revenue accruals.  There was sufficient payment history for the Company to substantially accrue all revenue upon delivery of test results starting July 1, 2016 and the Company continued to recognize revenue in 2017 upon cash receipt for unaccrued tests that were delivered prior to July 1, 2016.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-FA3D829EAB06E3954ACFC7EB6A2A6FA8-0-wk-Fact-76813A314507882D0A08C7EB69C23EE4" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was as follows (in thousands of dollars):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized on the accrual basis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1920-wk-Fact-FC897C21B57C6F8B501DC7EB69F9AC72" name="vcyt:RevenueRecognizedOnAccrualBasis" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">107,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1934-wk-Fact-E2A3BB2226F37C44FE36C7EB69D932EE" name="vcyt:RevenueRecognizedOnAccrualBasisPercentage" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1954-wk-Fact-546BB1E3C9451D4C107CE85B44BF3781" name="vcyt:RevenueRecognizedOnAccrualBasis" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1969-wk-Fact-98E3EAA3C188E385F975C7EB69DEFE52" name="vcyt:RevenueRecognizedOnAccrualBasisPercentage" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e1989-wk-Fact-3B208852EC8BB71E020BC7EB6A186B9F" name="vcyt:RevenueRecognizedOnAccrualBasis" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69,274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2003-wk-Fact-1D419CAFE32DEB7C44DEC7EB69ECC51F" name="vcyt:RevenueRecognizedOnAccrualBasisPercentage" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized on the cash basis</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2019-wk-Fact-9DA90D3A296F7D04C11AC7EB69D85729" name="vcyt:RevenueRecognizedReceivedInCash" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2038-wk-Fact-E3848748C2772438A3C4C7EB69EC0CBD" name="vcyt:RevenueRecognizedReceivedInCashPercentage" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2053-wk-Fact-EF206CF9E93DBD3EDF84E85B44CC4114" name="vcyt:RevenueRecognizedReceivedInCash" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2073-wk-Fact-08CF4C0570263712ED56C7EB69FFB886" name="vcyt:RevenueRecognizedReceivedInCashPercentage" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2088-wk-Fact-B4C515F873C0BD14C77BC7EB6A1162C6" name="vcyt:RevenueRecognizedReceivedInCash" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2107-wk-Fact-C3E45F5B5BD739409F68C7EB6A198901" name="vcyt:RevenueRecognizedReceivedInCashPercentage" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2128-wk-Fact-AF4C19BD2049D80EFD71E7C7BC8D5E19" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">107,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2142-wk-Fact-0318F0A408F47F716ECFC7EB69DDAC74" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2162-wk-Fact-29BCA614035BE02D486EE7C7BF04CEFD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2177-wk-Fact-A5DEAD2D0EABD69794BEC7EB69F9F143" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2197-wk-Fact-EDB8ADC16E235F5D9389E7C7C1448E6D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2211-wk-Fact-AEC7323551D71EBB6731C7EB69E3CE57" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:continuation id="TextSelection-58083E4A4249494E1607C7EB6A2AC1D7-0" continuedAt="TextSelection-58083E4A4249494E1607C7EB6A2AC1D7-1"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, on July 1, 2016 the Company began recognizing testing revenue from substantially all its tests on the accrual basis of accounting at an amount equal to management&#8217;s best estimate of the cash to ultimately be collected. For tests delivered prior to July 1, 2016, substantially all the related cash had been collected by December 31, 2017. Thus, at January 1, 2018, the cumulative impact of adopting ASC 606 was not material and no adjustment was recorded.  Since the Company commenced recognizing revenue from substantially all of its tests on the accrual basis of accounting commencing on July 1, 2016, and continued to do so after the adoption of ASC 606, the adoption of ASC 606 did not have a material impact on the Company's statement of operations for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.   </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2241-wk-Fact-031DAAB22CC890956B90C7EB69FB8F68" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which resulted in a decrease in the Company's loss from operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2245-wk-Fact-A45519DA30D153CA3993C7EB69ECC880" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and a decrease in loss per share of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2249-wk-Fact-BF20EBE25D179D870579C7EB69EA5059" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.04</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-58083E4A4249494E1607C7EB6A2AC1D7-1" continuedAt="TextSelection-58083E4A4249494E1607C7EB6A2AC1D7-2"><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-5" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-6"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2018, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2017 or prior years and recognized additional revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2263-wk-Fact-FEA6B2749C6FADDA89AF406C9B87D1FD" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which resulted in a decrease in the Company's loss from operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2267-wk-Fact-86EA30E82D9C3C5113CC406CAEE9DCCD" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and a decrease in loss per share of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2271-wk-Fact-2B848D720F02F24B964B406CC1CCDA45" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.04</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities. There was no revenue from instrument sales for the years ended December 31, 2019, 2018 or 2017. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Biopharmaceutical and Collaboration Revenue</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company enters into arrangements for research and development and/or commercialization services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;D services, and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-58083E4A4249494E1607C7EB6A2AC1D7-2" continuedAt="TextSelection-58083E4A4249494E1607C7EB6A2AC1D7-3"><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-6" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-7"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue and collaboration revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Up-front Fees: </span><span style="font-family:inherit;font-size:10pt;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments:</span><span style="font-family:inherit;font-size:10pt;"> At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the collaborative partner&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Services Agreement with Loxo Oncology</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc. ("Loxo") whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees. During the quarter ended June 30, 2018, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2369-wk-Fact-0F70B7F4365CA0A2F72EED68F0787E83" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of revenue upon deliveries of tissue samples and the Company received </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2373-wk-Fact-D8A6FA0EE1B2BE379C5DC7EB69E84124" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2018Q2_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for other services, which was recognized ratably during the quarters ended September 30 and December 31, 2018 as the services were  performed. Thereafter, the Company expects to receive approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2377-wk-Fact-D3203CF48F7F78F8C539C7EB69EB128C" name="vcyt:RevenueRemainingPerformanceObligationAmountPerQuarter" contextRef="FI2019Q4_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per quarter as services are performed and may also recognize revenue related to the deliveries of additional tissue samples as long as the agreement is not terminated.  The agreement has a </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year term with an automatic renewal of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32802967e2385-wk-Fact-8E0057817DB9132AD990C7EB6A1AF700" name="vcyt:AutomaticRenewalPeriodContractAgreement" contextRef="D2018Q2Apr09_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> and  Loxo may terminate the agreement at any time with at least </span><span style="font-family:inherit;font-size:10pt;">90</span><span style="font-family:inherit;font-size:10pt;"> days' notice.   As of December 31, 2019, the agreement had not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded that the performance obligations thereunder are the deliveries of tissue samples and performance of services, both of which are distinct.  For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2398-wk-Fact-08BD707B873BAD473E04C7EB69EEBB4A" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">90,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for  deliveries of tissue samples and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2402-wk-Fact-D2E4F792A2648746D506C7EB6A112CCD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the performance of services and is classified under biopharmaceutical revenue in the Consolidated Statement of Operations and Comprehensive Loss.  There was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2406-wk-Fact-AC9B1DA85ABC69746B66C7EB69D59D0A" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> deferred revenue related to this agreement at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Diagnostic Development Agreement with Johnson &amp; Johnson</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc. ("JJSI") (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-7" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-8"><ix:continuation id="TextSelection-58083E4A4249494E1607C7EB6A2AC1D7-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">bronchial genomic classifier diagnostic for lung cancer diagnosis (&#8220;Percepta v.2") and a nasal genomic classifier diagnostic for lung cancer (&#8220;NasaRISK&#8221;) and (ii) for JJSI to use Veracyte data generated in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2428-wk-Fact-7EDEA9CA98F7A4F719AEED2F2A481B88" name="vcyt:DevelopmentPrograms" contextRef="D2018Q4Dec28" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and NasaRISK programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2438-wk-Fact-9304792FBDF207A81B09ED318B474C7B" name="vcyt:ContractAgreementReceivableForServices" contextRef="I2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2442-wk-Fact-98173E287132E67D3C51ED33819BAA95" name="vcyt:ContractAgreementConditionalAccountsReceivable" contextRef="I2018Q4Dec28" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, conditioned upon the achievement of certain milestones relating to the development and reimbursement of Percepta v.2 and NasaRISK.  For a period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32802967e2446-wk-Fact-6B134E6B2E86BF28ADE8ED3662EF4F14" name="vcyt:TermContractAgreement" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> commencing with the first commercial sale of Percepta v.2 and NasaRISK, respectively, the Company will make payments to JJSI of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2450-wk-Fact-26E1BF6804FB3957672FED3AF77D3446" name="vcyt:ContractAgreementFeePercentageOfCashCollections" contextRef="D2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member" unitRef="number" decimals="INF" scale="-2" format="ixt-sec:numwordsen">one</ix:nonFraction> percent</span></span><span style="font-family:inherit;font-size:10pt;"> of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for NasaRISK, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of data from its RNA whole-transcriptome sequencing platform to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2459-wk-Fact-9304792FBDF207A81B09ED318B474C7B" name="vcyt:ContractAgreementReceivableForServices" contextRef="I2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments which was allocated to the obligation to deliver data.  The </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2463-wk-Fact-98173E287132E67D3C51ED33819BAA95" name="vcyt:ContractAgreementConditionalAccountsReceivable" contextRef="I2018Q4Dec28" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2473-wk-Fact-5991A11AABBA334469DD407032F924E6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_srt_ProductOrServiceAxis_vcyt_ProvisionofDataMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2477-wk-Fact-45D2140844B5340866954070678B33C5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_srt_ProductOrServiceAxis_vcyt_FulfillmentofObligationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and NasaRISK development milestones, respectively.  This revenue is classified under biopharmaceutical revenue and collaboration revenue, respectively, in the consolidated statement of operations and comprehensive loss.  Accounts receivable from JJSI was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2481-wk-Fact-DEC775A25FCDA61916ADED4265C89BAC" name="us-gaap:AccountsReceivableGross" contextRef="FI2019Q4_srt_MajorCustomersAxis_vcyt_Perceptav.2andNassaRiskMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.  The cost of biopharmaceutical revenue recognized under the agreement with JJSI is not significant and recorded in research and development in the statement of operations and comprehensive loss.  There was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802967e2489-wk-Fact-5FBD68C44C74AFC7328BED4844E9AAAD" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_srt_MajorCustomersAxis_vcyt_Perceptav.2andNassaRiskMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> deferred revenue related to this agreement at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Agreement with AstraZeneca Group</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V. ("Acerta"), a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#8217;s development of oncology therapeutics.  Acerta will reimburse the Company for certain development costs and pay milestones to the Company for the achievement of development milestones.   As of December 31, 2019, there was no performance of obligations under the agreement or consideration paid.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Testing Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Revenue </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#8217;s products and labor expenses. Cost of product revenue for instruments and </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-8" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-9"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-DBF1FD17D1FB875EEDFAC7EB6A2BD9EA-0-wk-Fact-62C5DABD98F0E26E574BC7EB69E7231E" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses include expenses incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products. These expenses consist of compensation expenses, direct research and development expenses such as prototype materials, laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses. We expense all research and development costs in the periods in which they are incurred. </span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-B68B3CD6ADF0488D5D78C7EB6A2A1632-0-wk-Fact-FC0B09D2FA47C4DC1BB7C7EB69E25CB1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company's assessment of an uncertain tax position begins with the initial determination of the position's sustainability and is measured at the largest amount of benefit that is more-likely-than-not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="TextSelection-2126EE56DB84FA51D32FC7EB6A2B1238-0-wk-Fact-2C47F864FC615715F3B0C7EB69E0207F" continuedAt="TextSelection-2126EE56DB84FA51D32FC7EB6A2B1238-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense for stock options issued to employees is measured based on the grant-date fair value of the award. The fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model.  Stock-based compensation expense for stock units is measured based on the fair value of the award, which is determined based upon the closing price of the Company&#8217;s common stock on the date of the grant.  The Company grants performance-based stock units to certain employees which vest upon the achievement of certain performance conditions, subject to the employees&#8217; continued service with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes compensation costs on a straight-line basis for all employee stock-based compensation awards that are expected to vest over the requisite service period of the awards, which is generally the awards' vesting period. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><ix:continuation id="TextSelection-2126EE56DB84FA51D32FC7EB6A2B1238-1" continuedAt="TextSelection-2126EE56DB84FA51D32FC7EB6A2B1238-2"><span style="font-family:inherit;font-size:10pt;">Following the adoption of ASU No. 2018-07, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-2126EE56DB84FA51D32FC7EB6A2B1238-2"> by the Company on October 1, 2018, stock-based compensation expense for equity instruments issued to non-employees is also measured based on the grant-date fair value of the awards using the Black-Scholes option-pricing model.  Prior to this, the fair value of such awards was subject to re-measurement as the underlying equity awards vest.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-9" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-10"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-FDF23C189AF593BF7101C7EB6A2B2EBD-0-wk-Fact-242AF6FB4E855CAD7A4CC7EB6A0EACBB" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Common Share</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance.  The Company has a single reporting unit associated with the development and commercialization of diagnostic products.  Substantially all the Company&#8217;s revenue for the years ended December 31, 2019, 2018 and 2017 was derived in the United States.  All of the Company&#8217;s long-lived assets were located in the United States as of December&#160;31, 2019 and 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-F348D50AD7FB38B760FDC7EB6A292DF4-0-wk-Fact-8E4195B785616ACB4847C7EB69E8B3C7" continuedAt="TextSelection-F348D50AD7FB38B760FDC7EB6A292DF4-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">. This ASU is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU was effective for interim and annual periods beginning after December 15, 2018.  Additionally, the FASB issued ASU No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements.  The Company elected this transition method and adopted ASC 842 on January 1, 2019 and as a result, recorded operating lease right-of-use ("ROU") assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2680-wk-Fact-53BC922840CEE1EB148DED5261E58C90" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, including offsetting deferred rent of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2684-wk-Fact-80F448671BE249A09994ED535EB1A299" name="us-gaap:ContractWithCustomerLiability" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, along with the associated operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2688-wk-Fact-85945D3F9C58C9FEA0AEED53F70FE8B5" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.  On January 1, 2019, the Company had finance lease ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2693-wk-Fact-117105DA7488C8FAECA4ED54523D05A8" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and associated finance lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802967e2697-wk-Fact-E176484FD259A4F1E544ED548E452AE0" name="us-gaap:FinanceLeaseLiability" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for leases classified as finance leases prior to the adoption of ASC 842. The adoption of ASC 842 had an immaterial impact on the Company's consolidated statement of operations and comprehensive loss, consolidated statement of stockholders' equity and consolidated statement of cash flows for the year ended December 31, 2019.  In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease classification.  Additional information and disclosures required by this new standard are contained in Note 7,&#160;Commitments and Contingencies.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company does not expect to have a material impact on its financial statements and related disclosures from the adoption of this guidance.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-F348D50AD7FB38B760FDC7EB6A292DF4-1" continuedAt="TextSelection-F348D50AD7FB38B760FDC7EB6A292DF4-2"><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-10" continuedAt="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-11"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808). </span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-F348D50AD7FB38B760FDC7EB6A292DF4-2"><ix:continuation id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-11">Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.</ix:continuation></ix:continuation> </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sAB5199256D544522BC9D428AF8D9BA7D"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-FCF235337A0B53D00CDEC7EB6A2B56F1-0-wk-Fact-35C195ED37E551D7AE68C7EB6A1919D7" continuedAt="TextSelection-FCF235337A0B53D00CDEC7EB6A2B56F1-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-E653008D25B7D2F54C52C7EB6A2BBE4A-0-wk-Fact-008C0C78401D0C5E8222C7EB6A199629" continuedAt="TextSelection-E653008D25B7D2F54C52C7EB6A2BBE4A-1" escape="true"><ix:continuation id="TextSelection-FCF235337A0B53D00CDEC7EB6A2B56F1-1" continuedAt="TextSelection-FCF235337A0B53D00CDEC7EB6A2B56F1-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following outstanding common stock equivalents have been excluded from diluted net loss per common share for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> because their inclusion would be anti-dilutive:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-E653008D25B7D2F54C52C7EB6A2BBE4A-1"><ix:continuation id="TextSelection-FCF235337A0B53D00CDEC7EB6A2B56F1-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock subject to outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e866-wk-Fact-DB9BAE421F3D96B01072C7EB69E0C991" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,394,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e880-wk-Fact-9BA188C3EE8B8A216E40C7EB69D65338" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,998,163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e894-wk-Fact-6A57A55C07499532FF9DC7EB69DBEA1E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,163,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e909-wk-Fact-45D69AA62D5CA5747850C7EB69CD4438" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">26,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e923-wk-Fact-3AF8CBDDA7645B22F3F8C7EB69E233D9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">34,869</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e937-wk-Fact-9F0FE16375D003D04F2BC7EB69E40C0B" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">34,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e952-wk-Fact-6D53610870D2D9109E41C7EB69E46DE6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">712,122</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e966-wk-Fact-7F70FE344A0612FCCBF6C7EB69DFECB0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">384,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e980-wk-Fact-1A67DCE6904AEC2E5B0FC7EB69CDF07A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">63,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e995-wk-Fact-1F41E0FD0BA17F7BF11FC7EB69D31321" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,133,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e1009-wk-Fact-C9ED0F67B6C5B8A9DB39C7EB69D48F6F" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,417,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32787343e1023-wk-Fact-D9DD2F51EF67A94FDE79C7EB69D78EF8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,261,718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sa99be1b2d2e24a688c21c4294f5c860f"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-F88BEB0016AC6265426F7BF510B8FE0C-0-wk-Fact-9E381B3845EF530FCB317BF5AF9FE2BE" continuedAt="TextSelection-F88BEB0016AC6265426F7BF510B8FE0C-1" escape="true">Business Combination</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F88BEB0016AC6265426F7BF510B8FE0C-1" continuedAt="TextSelection-F88BEB0016AC6265426F7BF510B8FE0C-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exclusive License to NanoString Diagnostics Platform</span><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 3, 2019, the Company executed an agreement with NanoString for the exclusive global diagnostics license to the nCounter FLEX Analysis System, the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. The strategic transaction positions the Company to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to physicians and their patients via hospital and clinical laboratories throughout the European Union and other parts of the world.  The Company has accounted for this agreement under Accounting Standards Codification 805, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span><span style="font-family:inherit;font-size:10pt;">.  Pursuant to the terms of the agreement, Veracyte paid NanoString </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32788206e735-wk-Fact-02CB3C410F3805D37FCF4055ACC42195" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32788206e739-wk-Fact-1EE963A314BAD516FF994057F063CF76" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in Veracyte common stock, and may pay up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32788206e743-wk-Fact-6E691EFBBEA2051DB8F3405DF2F7FA82" name="vcyt:BusinessCombinationContingentConsiderationCashtobePaid" contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, contingent upon the commercial launch of Veracyte diagnostic tests for use on the platform.  This contingency was valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32788206e747-wk-Fact-6F132BD33B4F8765BCBC405E075C313F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of the acquisition date, recorded as a liability, and will be remeasured to fair value at each reporting date until the contingent consideration is settled.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets acquired are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and the resulting amount of goodwill. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-9211494B7494C7525385404DF12C2C5D-0-wk-Fact-47B2ADF936FD3A9FEB15404E04FCDDA2" continuedAt="TextSelection-9211494B7494C7525385404DF12C2C5D-1" escape="true">The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9211494B7494C7525385404DF12C2C5D-1"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.95711500974659%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e785-wk-Fact-15A42FBB6CBE50F376B264A81A071629" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e800-wk-Fact-A191995A176557EFCEEB64A81A140CDB" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e820-wk-Fact-96FCC11E12B95C3705F864A81A2FA375" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e840-wk-Fact-7953C0B6C049B741079464A819FE96C4" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">990</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total identifiable intangible assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e860-wk-Fact-0CAEDE5D7795AFDF310B64A81A110A93" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,420</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e880-wk-Fact-E06C4279FAD35F34DAE164A81A1DEF64" name="us-gaap:Goodwill" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e905-wk-Fact-3534F45FD130B1A7A84E64A81A264ACE" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="TextSelection-EF76D86E1DAB635854A8404EBB0461FD-0-wk-Fact-3974A1B67252E44C8387405136EB9429" escape="true"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.33723196881091%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:81%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Useful life (In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32788206e951-wk-Fact-DB1BF82392F5F14C617E64A81206DBB2" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32788206e962-wk-Fact-9B25203D06535E28A5B164A8120BF2DB" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear">5</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32788206e973-wk-Fact-49F22AE98A1185BF601964A811F51FE7" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32788206e984-wk-Fact-34265CB10DFE2902D9D564A812009769" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" format="ixt-sec:duryear">7</ix:nonNumeric></span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. This acquisition includes </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32788206e993-wk-Fact-967B9338D4E3813882A8406929CBDC74" name="us-gaap:Goodwill" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of goodwill which the Company believes consists principally of the organized workforce </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F88BEB0016AC6265426F7BF510B8FE0C-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">that will help the Company execute its strategic plans in relation to the assets acquired. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. As of December 31, 2019, goodwill is not deductible for tax purposes, however, if contingent consideration is paid at a future date, the portions of contingent consideration paid and allocated to the intangible assets for tax purposes will be tax deductible.  The accounting for this acquisition is preliminary and will be finalized upon completion of the analysis of certain contracts acquired and executed as part of this acquisition along with the impact on goodwill, should there be any.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited pro forma financial information in the table below summarizes the combined revenue for the Company and acquired business from NanoString as though the acquisition had been executed as of January 1, 2018. The pro forma amounts have been adjusted in the table below. NanoString&#8217;s historical books and records did not contain the operating expense information to prepare the financial disclosures required in the pro forma table below. Thus, the pro forma financial disclosures are limited to revenue only. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="TextSelection-6C16F09C8F2A8AB674FE5FE52F29BD7F-0-wk-Fact-D62A7CB83941089156945FE73F989AE6" continuedAt="TextSelection-6C16F09C8F2A8AB674FE5FE52F29BD7F-1" escape="true">The unaudited pro forma revenue information is for informational purposes only and is not necessarily indicative of the revenue that would have been achieved if the acquisition had taken place as of January 1, 2018 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6C16F09C8F2A8AB674FE5FE52F29BD7F-1" continuedAt="TextSelection-6C16F09C8F2A8AB674FE5FE52F29BD7F-2"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.99610136452242%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e1119-wk-Fact-B8AE32F5C6E768EBCB0A600646E23E5B" name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32788206e1138-wk-Fact-6F08BEA5F29F779371D7600657BAEB14" name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,482</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><ix:continuation id="TextSelection-6C16F09C8F2A8AB674FE5FE52F29BD7F-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><a id="s37EB5D521881D77A6BF3428AF8C9BAF1"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="TextSelection-F5CD4A82591EAC5A10C0C7EB6A2BB6AD-0-wk-Fact-29DBAA532B71B9F854F9C7EB69CD06D4" continuedAt="TextSelection-F5CD4A82591EAC5A10C0C7EB6A2BB6AD-1" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F5CD4A82591EAC5A10C0C7EB6A2BB6AD-1" continuedAt="TextSelection-F5CD4A82591EAC5A10C0C7EB6A2BB6AD-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-232CB3C1378854A95B6BC7EB6A2C92EA-0-wk-Fact-E3E5956052F18D278371C7EB69E6D707" escape="true"><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e849-wk-Fact-A924C36D62402111D32EC7EB69CF2474" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,926</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e868-wk-Fact-D6FCE57E596A45CBDEF3C7EB6A1044F8" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e883-wk-Fact-644105048D981074C055C7EB69C1ED3C" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsLeasedToOthersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,655</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e902-wk-Fact-7AF32D3AE7BCD5EAE0F2C7EB69C26102" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsLeasedToOthersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e922-wk-Fact-4BE80B457140A6ADAE2CC7EB6A18E554" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e941-wk-Fact-EE81207F6A3C5328613CC7EB6A1E1D40" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,615</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Software, including software developed for internal use</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e961-wk-Fact-324DBFA633035360CBF4C7EB6A1F7250" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e980-wk-Fact-86BB5236729F0EC42FD4C7EB6A14D793" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1000-wk-Fact-6CA4B40D84052679BEECC7EB6A1B7F71" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,482</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1019-wk-Fact-3990347ADAEE94B4F7D8C7EB69CAB961" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,435</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1039-wk-Fact-403BC646B6AB14FEBFEFC7EB69C12A5B" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1058-wk-Fact-7997F0D32386173EED5DC7EB6A1C63C1" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1078-wk-Fact-DACF1FDFE7B92742E104C7EB6A1C8386" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,013</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1097-wk-Fact-C7C08DDB2E8A368FFD01C7EB69CC6AF3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e1117-wk-Fact-7632EF8CACFE876DD880C7EB6A1F4063" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,080</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e1137-wk-Fact-64FEA9A3DBE0878EF55BC7EB6A18DECE" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1163-wk-Fact-BC904E8E1E34A858FE66C7EB69C3C495" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1182-wk-Fact-F30BF87645E2C558788CC7EB69E8B74F" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1199-wk-Fact-D6B0800AA8FC4724D84DC7EB69D805CA" name="vcyt:DepreciationandAmortizationofTangibleAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1203-wk-Fact-4C5F4297CD8844F54451C7EB69C1E9D0" name="vcyt:DepreciationandAmortizationofTangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1207-wk-Fact-BC176AC4D16DF6BDAFEBC7EB69CBB652" name="vcyt:DepreciationandAmortizationofTangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had a capital lease for laboratory equipment that went into service in 2017.  The lease was paid off in 2019 and the cost of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1229-wk-Fact-15DD9807D88CA9DC2B49C7EB69D8F4C9" name="vcyt:FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was included in Property and Equipment as of December 31, 2019.  The laboratory equipment had accumulated depreciation of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1233-wk-Fact-66BD8C5877C0A52EA227C7EB69E26280" name="vcyt:FinanceLeaseRightofUseAssetAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">600,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1237-wk-Fact-6C80566AEA4DF05715D4C7EB69C30845" name="vcyt:FinanceLeaseRightofUseAssetAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">367,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively and depreciation of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1250-wk-Fact-05CE6EC4CB8F6CE7F10CC7EB69DBDA39" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">233,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1254-wk-Fact-08CFE0CD72FE116F030AC7EB69DA3C52" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">232,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e1258-wk-Fact-66EF64D2AF20DD1CB67D6DB479C06A49" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">135,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and 2017, respectively.   </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finite-lived Intangible Assets, Net</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="TextSelection-8B75C50A7CC409A8543DF77A605E7B55-0-wk-Fact-DAF5C80B044A7A02AF83F77BE11A7237" continuedAt="TextSelection-8B75C50A7CC409A8543DF77A605E7B55-1" escape="true"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-live intangible assets consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F5CD4A82591EAC5A10C0C7EB6A2BB6AD-2"><ix:continuation id="TextSelection-8B75C50A7CC409A8543DF77A605E7B55-1"><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Amortization Period (Years)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percepta product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1597-wk-Fact-2418EB5E80F01CCD2E65403A048C43CE" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e1616-wk-Fact-4F9236037B0F8442AB4564ABCC2B86C0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,067</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1636-wk-Fact-3E9BC72E6CB768CEE4F264ABCC566DDB" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1656-wk-Fact-894101FC571F43F6742C64ABCCDBA7B1" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e1675-wk-Fact-8A0126666079DF1E930864ABCC62F6B9" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1696-wk-Fact-C7238380C6C72EE0D60F64ABCCD78919" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32799112e1710-wk-Fact-E42EC2578D1AC8BBECD264ABCC4D40DA" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1721-wk-Fact-3A94AF87FDC7A2423217403A047E92B5" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e1740-wk-Fact-E0AFE6C94D28983CB7A664ABCC6F2746" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1760-wk-Fact-90F7E51C8D3A666C2B6864ABCC94E808" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1780-wk-Fact-8B61A3200B67206D90A564ABCCB58088" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1799-wk-Fact-4486275169E19F3AE84964ABCCA0C0A3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1818-wk-Fact-F9169CEAEFFA533727D864ABCCAC8B8A" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32799112e1838-wk-Fact-80EC11ECE0101991BAF864ABCC87FF5F" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1849-wk-Fact-E5F91ECF77C6CA1AC0CE403A046F5A1E" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e1868-wk-Fact-3ABF611C91E76D0046C464ABCC44EF00" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1888-wk-Fact-E5969A1631DF0F1E6B8964ABCC66EA3C" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1908-wk-Fact-1C5A63F19F21EB0096B564ABCCF2587D" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1927-wk-Fact-2ABECE7235781188670364ABCCE4E3FE" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1946-wk-Fact-8D617DA61AD78B77D0EB64ABCCFE33B3" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32799112e1966-wk-Fact-C94B7F4013CB31F2335464ABCC1CCBD3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear">5</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e1977-wk-Fact-ED1C327A6183804E1952403A04A4FFDD" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e1996-wk-Fact-8AA668EE8D0764702C4564ABCC7BA426" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2016-wk-Fact-B87C6375F7AEE07B698B64ABCC34C54B" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2036-wk-Fact-C6230F439B1DB88F43C164ABCCC23A61" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2055-wk-Fact-FBE3A2E6507551449F3E64ABCCB9F2C6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2074-wk-Fact-97AD06DD9583D4E1214164ABCC90330D" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32799112e2094-wk-Fact-6CBA8FC068D421F11F6064ABCCC5AB39" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2105-wk-Fact-EF52E1F4F1168BBA1C1B403A0454A615" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">990</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e2124-wk-Fact-3EE8F5681C6BA48E602164ABCD068548" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2144-wk-Fact-4A130E805263C6FCE2CC64ABCC594CEB" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2164-wk-Fact-C88D6D3D1FC54FC15D2964ABCC9DD0D8" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2183-wk-Fact-CA9250A15428E1831BFB64ABCCCE1C92" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2202-wk-Fact-27DA91CFAE9AB5AAA41D64ABCC40D3D2" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32799112e2222-wk-Fact-F0A79FFE6CB8C23610AF64ABCC373075" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember" format="ixt-sec:duryear">7</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2238-wk-Fact-6704D3C47FF1EB88B911403A04968F77" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,420</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e2257-wk-Fact-1DF751DEAF16420C890364ABCCE71276" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2277-wk-Fact-75E37D38A5E99637ED54C7EB69E7C084" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,019</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2297-wk-Fact-6740EDEB9313B03F0C5C64ABCCEF968E" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32799112e2316-wk-Fact-B72682E54A6C522734CD64ABCC845DFA" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2337-wk-Fact-05D77A7F1F0983F16406C7EB6A16033B" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32799112e2351-wk-Fact-65B6B4F6EAA02D22AC1A64ABCC73D7B8" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">14.5</ix:nonNumeric></span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of the Percepta product technology, which was acquired from the acquisition of Allegro in September 2014, began in April 2015 when research and development activities were deemed to be completed and is recognized on a straight-line basis.   Amortization of the Prosigna product technology, Prosigna customer relationships, nCounter FLEX Dx license and LymphMark product technology, which were acquired under an agreement with NanoString, see Note 4 - Business Combination, began in December 2019 and is recognized on a straight-line basis. Amortization of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e2360-wk-Fact-AB70F4F25C75682A461EF77DEAED2DCE" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e2364-wk-Fact-C1672A46CB5EF94FD722F77E0AD88CEF" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32799112e2368-wk-Fact-DE4A8E44AC909AA37638F77E1869F104" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recognized for the years ended&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-7FE066979F10FCF68463F779D79E03A9-0-wk-Fact-21270B63A333FC7A5C7EF77A279EB266" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated future aggregate amortization expense as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2442-wk-Fact-7863297EE4731393A1EAF7748DC2A825" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2457-wk-Fact-FA45CE84288732D8C2BEF77498E9C1FB" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2477-wk-Fact-61C6F50A97F5B1B7F10AF774A3DAD098" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2497-wk-Fact-03682E98F6C1145FAA41F774B264B21F" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2517-wk-Fact-9023AB07306E5A9F75A3F774BCA738D4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2537-wk-Fact-4047DCCF907C8552E90AF774CB5F7563" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2562-wk-Fact-75E37D38A5E99637ED54C7EB69E7C084" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,019</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-A7E0CB792A4756BDC0ECC7EB6A2C6FB0-0-wk-Fact-97FFAD0BDFAF22FE86C9C7EB69E155D6" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2699-wk-Fact-9521E79D9BD371C050A1C7EB69EA195B" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2718-wk-Fact-DFBFC53D3AD089D8182AC7EB69E87AE6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2733-wk-Fact-A5F4E3E511DA181CFEEEC7EB69E2193C" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2752-wk-Fact-556F876FCF0B7BC527BDC7EB69DD44EA" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2777-wk-Fact-44F2146EFC93E9182624C7EB6A0D77DE" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32799112e2796-wk-Fact-DFD7CCCFD7DF8EABBE28C7EB69F57292" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD3E1DCD6D5B197EC428E428AF83C7CAC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-CD0F19E7E50567F6FE65C7EB6A2C6CFF-0-wk-Fact-C2B441F56207E2AFEE7EC7EB69F0093C" continuedAt="TextSelection-CD0F19E7E50567F6FE65C7EB6A2C6CFF-1" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="TextSelection-CD0F19E7E50567F6FE65C7EB6A2C6CFF-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The carrying value of the Company's debt approximates its fair value because the interest rate approximates market rates that the Company could obtain for debt with similar terms. The   fair value of the Company&#8217;s debt is estimated using the net present value of the payments, discounted at an interest rate that is consistent with market interest rates, which is a Level II input.&#160;The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;I: Inputs which include quoted prices in active markets for identical assets and liabilities;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;II: Inputs other than Level&#160;I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the Company's financial assets includes money market funds, overnight reverse repurchase agreements&#160;and a deposit for the lease of the Company's South San Francisco facility.  Money market funds, included in cash and cash equivalents in the accompanying consolidated balance sheets, was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32795742e758-wk-Fact-B81AB58D23D3148034D4C7EB69F03E72" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32795742e762-wk-Fact-C98658F42A3B431F614FC7EB69ED75BF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and are Level&#160;I assets as described above.  Overnight reverse repurchase agreements, included in cash and cash equivalents in the accompanying consolidated balance sheets, were&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32795742e774-wk-Fact-66F99D29331B41B99293E86FC8EFF4E9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_vcyt_OvernightRepurchaseAgreementsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32795742e779-wk-Fact-F4674E5832D98EB71A30E871C538F431" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_vcyt_OvernightRepurchaseAgreementsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-5" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;as of&#160;December 31, 2019&#160;and&#160;2018, respectively, and are Level II assets as described above.  There were no unrealized gains or losses from overnight reverse repurchase agreements at December 31, 2019 and 2018.  The deposit for the lease, included in restricted cash in the accompanying consolidated balance sheets, was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32795742e783-wk-Fact-D14F5A5686B395163920C7EB69ED896E" name="us-gaap:SecurityDeposit" contextRef="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">603,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and is a Level I asset as described above. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration in Note 4, Business Combination, associated with the agreement with NanoString on December 3, 2019, is a Level III financial liability.  As of December 31, 2019, the contingent consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32795742e801-wk-Fact-6F132BD33B4F8765BCBC405E075C313F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is dependent on the achievement of certain milestones and is payable in cash of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32795742e805-wk-Fact-6E691EFBBEA2051DB8F3405DF2F7FA82" name="vcyt:BusinessCombinationContingentConsiderationCashtobePaid" contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.  Estimation of the fair value of the contingent consideration is based on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.  Changes to the forecasts for the achievement of milestones can significantly affect the estimated fair value of the contingent consideration.  There has been no change to the estimated fair value of the contingent consideration from the date of the agreement with NanoString to December 31, 2019 and the Company will assess the fair value of the contingent liability on a quarterly basis.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sCFE05A1F37D92459353F428AF7B4C0F3"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-515F612103B8351691C8C7EB6A2C1B27-0-wk-Fact-DC026617FFA4A249E156C7EB6A0953F1" continuedAt="TextSelection-515F612103B8351691C8C7EB6A2C1B27-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-515F612103B8351691C8C7EB6A2C1B27-1" continuedAt="TextSelection-515F612103B8351691C8C7EB6A2C1B27-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases its headquarters and laboratory facilities in South San Francisco, California under a non-cancelable lease agreement for approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e732-wk-Fact-7C7EF9010400CA1C3768C7EB69D8279F" name="vcyt:LesseeLeasingArrangementsOperatingLeasesSpaceLeased" contextRef="FD2019Q4YTD_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">59,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The lease began in June 2015 and ends in March 2026 and contains extension of lease term and expansion options.  In February 2017, the Company relinquished certain expansion rights for a nominal fee.  The Company had deposits of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802884e736-wk-Fact-D14F5A5686B395163920C7EB69ED896E" name="us-gaap:SecurityDeposit" contextRef="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">603,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> included in long-term assets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the South San Francisco facility.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">96</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-515F612103B8351691C8C7EB6A2C1B27-2" continuedAt="TextSelection-515F612103B8351691C8C7EB6A2C1B27-3"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also leases laboratory and office space in Austin, Texas under a lease that expires in January 2029 and includes options for expansion and early termination in 2025.  The Company provided a cash security deposit for this lease of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802884e753-wk-Fact-3BFC689FB1846EE3DF79C7EB6A0CE4FD" name="us-gaap:SecurityDeposit" contextRef="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_LaboratoryFacilitiesAustinTexasMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">139,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">,   included in other assets in the Company's balance sheets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined its operating lease liabilities for the two operating leases mentioned above using a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e770-wk-Fact-71D8DF9D86447B5BAD9AF79B6CDD4BC1" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="FI2019Q4" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">7.53</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> based on the rate that the Company would have to pay to borrow on a collateralized basis for a similar lease an amount equal to the lease payments in a similar economic environment.  Operating lease liabilities along with the associated right-of-use assets as of December&#160;31, 2019 are disclosed in the accompanying consolidated balance sheets.  After the adoption of ASC 842, the Company classified its deferred rent for tenant improvements with its operating lease right-of-use assets on the consolidated balance sheets.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-7E3638F2896EFA2DE448C7EB6A2C16E8-0-wk-Fact-584633AFE23B77BF6E21C7EB6A0556BC" continuedAt="TextSelection-7E3638F2896EFA2DE448C7EB6A2C16E8-1" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating leases as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands of dollars):</span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-7E3638F2896EFA2DE448C7EB6A2C16E8-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e835-wk-Fact-1FFBD50DB21F2F82FA99C7EB69CE1B8C" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e850-wk-Fact-F63F8DD77DF2E9BA8D31C7EB69D586C8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e870-wk-Fact-266A5F0771501669D19DC7EB69D03B20" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e890-wk-Fact-D0ED21E48A8243680CB5C7EB69D04AAD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e910-wk-Fact-1160FE104D90D20D20FDC7EB69D23D56" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e930-wk-Fact-3A15E885FE9936F0506DC7EB69D13BC4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total future minimum lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e950-wk-Fact-392D5F5FD7B9390C86B0C7EB69D3908F" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e970-wk-Fact-3BBDFC7158DBA04AFD6B68B595CDFBCE" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e990-wk-Fact-B6E5E357628D0B943D5968B5D327B6C9" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: short-term lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e1010-wk-Fact-DA69985FEE89AB339388E7C06DCF75A8" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32802884e1036-wk-Fact-22852C72B4C466775DD0E7C1744D50AA" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes rent expense on a straight-line basis over the non-cancelable lease period. Rent expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802884e1054-wk-Fact-207A386A71160C1FCD5EC7EB69FAB5A4" name="us-gaap:OperatingLeaseExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802884e1058-wk-Fact-3B967EF8E1FFA5388428C7EB6A0C218D" name="us-gaap:OperatingLeaseExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802884e1062-wk-Fact-B37F8FD4717E53CE2EF1C7EB69FA6465" name="us-gaap:OperatingLeaseExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Supplies Purchase Commitments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had non-cancelable purchase commitments with suppliers to purchase a minimum quantity of supplies for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32802884e1089-wk-Fact-4650EBDD38B9175733BBC7EB6A0C77D7" name="us-gaap:PurchaseObligation" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-515F612103B8351691C8C7EB6A2C1B27-3">From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no litigation pending that could have, either individually or in the aggregate, a material impact on the Company's financial statements.</ix:continuation>  </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">97</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5B52B971AEA652F90F7A428AF82C737E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-B524A9D7875FC0F1B218C7EB6A29DFBA-0-wk-Fact-2A53E85E332DE36D11FCC7EB69FFFD21" continuedAt="TextSelection-B524A9D7875FC0F1B218C7EB6A29DFBA-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B524A9D7875FC0F1B218C7EB6A29DFBA-1" continuedAt="TextSelection-B524A9D7875FC0F1B218C7EB6A29DFBA-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loan and Security Agreement</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 3, 2017, the Company entered into a loan and security agreement (the &#8220;Loan and Security Agreement&#8221;) with Silicon Valley Bank.  The Loan and Security Agreement allows the Company to borrow up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e731-wk-Fact-C492D2ABC5C5983685EFC7EB69C5261F" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="I2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">35.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, with a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e735-wk-Fact-C28217F1F1205E8B6F10C7EB6A018EAA" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> advance term loan (the &#8220;Term Loan Advance&#8221;) and a revolving line of credit of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e739-wk-Fact-591BD0C91735986850F5C7EB69C0A4A1" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (the &#8220;Revolving Line of Credit&#8221;).  The Term Loan Advance was advanced upon the closing of the Loan and Security Agreement and was used to pay the outstanding balance of the Company&#8217;s existing long-term debt, which was canceled at that date.  The Company had not drawn on the Revolving Line of Credit as of December 31, 2019.  Borrowings under the Loan and Security Agreement mature on October 1, 2022.  Amounts may be borrowed and repaid under the Revolving Line of Credit up until the earliest of full repayment or maturity of the Loan and Security Agreement, termination of the Loan and Security Agreement, or October 1, 2022.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Term Loan Advance bears interest at a variable rate equal to (i) the thirty-day U.S. London Interbank Offer Rate (&#8220;LIBOR&#8221;) plus (ii) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e748-wk-Fact-7C48C13DCAD86B8B9D38C7EB69C3C44A" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4.20</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, with a minimum rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e752-wk-Fact-EF6BE71E1459C13D290BC7EB6A038FBB" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2017Q4Nov3_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.43</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. Principal amounts outstanding under the Revolving Line of Credit bear interest at a variable rate equal to (i) LIBOR plus (ii) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e756-wk-Fact-C7DDCC2550FC3A73E6F2C7EB69C30FC1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, with a minimum rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e760-wk-Fact-F40D5B2E22918E1C782EC7EB69C1E796" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2017Q4Nov3_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4.70</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum.  The average Term Loan Advance interest rate for the year ended&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e769-wk-Fact-7A2EE7322761268F1926C7EB69C1A89A" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">6.70</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may prepay the outstanding principal amount under the Term Loan Advance plus accrued and unpaid interest and, if the Term Loan Advance is repaid in full, a prepayment premium. The prepayment premium will be (i) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e778-wk-Fact-81199799DE2972952098C7EB69FFC985" name="vcyt:DebtInstrumentPrepaymentPremium" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheOneMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">750,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> if prepayment is made prior to November 3, 2018, (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e782-wk-Fact-FA9A8FC9125F381B3FF1C7EB69FF2B76" name="vcyt:DebtInstrumentPrepaymentPremium" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheTwoMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> if the prepayment is made after November 3, 2018 but on or before November 3, 2019, or (iii) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e786-wk-Fact-8DE1947FA739DBE7731CC7EB6A02B974" name="vcyt:DebtInstrumentPrepaymentPremium" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheThreeMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> if the prepayment is made after November 3, 2019.  In January 2019 and May 2019, the Company prepaid&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e790-wk-Fact-AF3AC49B848081608ABDE880249F2130" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="D2018Q1Jan01-Jan31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e794-wk-Fact-8982CB103DEABB81BCE3E88023928B85" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="D2019Q2May2019_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the principal amount of the Term Loan Advance. These prepayments did not trigger any prepayment premium because they were partial, not full, repayments of the principal amount. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, a final payment on the Term Loan Advance in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e803-wk-Fact-08F9F1383706DEAF8042C7EB69C04B5D" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is due upon the earlier of the maturity date of the Term Loan Advance or its payment in full.  The Loan and Security Agreement contains customary representations, warranties, and events of default such as a material adverse change in our business, operations or financial condition, as well as affirmative and negative covenants. The negative covenants include, among other provisions, covenants that limit or restrict the Company's ability to incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of its equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company&#8217;s obligations under the Loan and Security Agreement are secured by substantially all of its assets (excluding intellectual property), subject to certain customary exceptions.  The Loan and Security Agreement also requires the Company to achieve certain revenue levels tested quarterly on a trailing twelve-month basis.  However, failure to maintain the revenue levels will not be considered a default if the Company maintains liquidity of at least </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e807-wk-Fact-0AFDAF5EA1C986BAADA4C7EB6A01339D" name="vcyt:LiquidityRequirementMinimum" contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.  As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with the loan covenants.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDebtTableTextBlock" id="TextSelection-199C35F6A9DBD86B38D7C7EB6A29855B-0-wk-Fact-F4062C063F459F9072BAC7EB6A055CE5" escape="true"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e947-wk-Fact-656030E1C19893B5C0FCC7EB69E30964" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e966-wk-Fact-D66870793B5BFBA7F6FDC7EB69E39288" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End-of-term debt obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e981-wk-Fact-8C0C0A24AEC28188B8DB7C9C9FF3E1A9" name="vcyt:DebtInstrumentEndOfTermPaymentInterestAmount" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">594</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1000-wk-Fact-CB140B71A67A19CB10267C9CA119D14D" name="vcyt:DebtInstrumentEndOfTermPaymentInterestAmount" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1020-wk-Fact-EA6CA2A962559AA63495C7EB69E3166C" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32804889e1039-wk-Fact-0385952551FDD181AEC6C7EB69E32423" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net debt obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1065-wk-Fact-81970322869A90FDCE06C7EB69E29A34" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1084-wk-Fact-617081BA1FA222FBAD15C7EB69E37024" name="us-gaap:LongTermDebt" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future principal and end-of-term debt obligation payments due under the Loan and Security Agreement are </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e1103-wk-Fact-D9F03DB053646D415EABC7EB69F94023" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2022.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The end-of-term debt obligation accretes over the term of the Loan and Security Agreement until maturity and is included in interest expense in the Company's consolidated statement of operations and comprehensive loss.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-B524A9D7875FC0F1B218C7EB6A29DFBA-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit Agreement</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March&#160;2016, the Company entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with Visium Healthcare Partners, LP (&#8220;Visium&#8221;). Under the Credit Agreement, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1130-wk-Fact-AA7D0176D28362880CFDC7EB69C045C2" name="vcyt:NumberOfTermLoans" contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="term_loan" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> term loans were available to the Company with an aggregate principal amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e1134-wk-Fact-8FA06A5DC38D68E8EFE8C7EB69FF1670" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company drew down the initial </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e1138-wk-Fact-9B4B33BD0A94FF7956BAC7EB69C2D1CA" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="D2016Q1Mar30-Mar30_us-gaap_DebtInstrumentAxis_vcyt_InitialTermLoanMember_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> term loan (the &#8220;Initial Term Loan&#8221;) on March&#160;30, 2016, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e1142-wk-Fact-8481C0E88C112A0609BAC7EB69FF5DA8" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="D2016Q1Mar30-Mar30_us-gaap_DebtInstrumentAxis_vcyt_InitialTermLoanMember_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was used to pay the outstanding balance of the Company&#8217;s previous long-term debt, which was canceled at that date. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Term Loans bore interest at a fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1152-wk-Fact-9EE076F910CF6F27238BC7EB69C3E6DC" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">12.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per annum and no principal payments were due through March&#160;31, 2020. The Company was obligated to repay the outstanding principal amounts under the Term Loans in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1156-wk-Fact-E53A9BF1522B5D2241DBC7EB69C44977" name="vcyt:DebtInstrumentNumberOfInstallments" contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="installment" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> equal installments during the final </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32804889e1160-wk-Fact-E462754B554516CC86C3C7EB69C23199" name="vcyt:TermOfDebtWithEqualQuarterlyInstallments" contextRef="FD2019Q4YTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> under the Credit Agreement. Prepayment of the outstanding principal amount under the Term Loans prior to March 31, 2018 was subject to a prepayment premium equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1164-wk-Fact-275B4ECBA8DF08AAA9B8C7EB69C4F630" name="vcyt:DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne" contextRef="FD2019Q4YTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">24.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding principal balance, less the aggregate amount of all interest payments in cash.  For any quarterly interest payment through and including the 16th interest payment date after the Initial Borrowing Date, so long as no event of default had occurred and was then continuing, the Company could have elected to pay interest in cash on the outstanding principal amounts of the Term Loans at a fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1168-wk-Fact-93F50FE39B48D2148A4CC7EB69C33D3A" name="vcyt:DebtInstrumentFixedRatePercentagePaidInCash" contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">9.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, with the remaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1173-wk-Fact-E2BB353C958A51E00FE4C7EB69C24504" name="vcyt:DebtInstrumentInterestPaidInKindPercentage" contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1177-wk-Fact-9EE076F910CF6F27238BC7EB69C3E6DC" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">12.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> interest paid-in-kind by adding such paid-in-kind interest to the outstanding principal amounts of the Term Loans.  The Company elected to pay interest in-kind for the quarters ended June 30, 2016 and September 30, 2016, totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e1181-wk-Fact-2A28690522B11B7E8C53C7EB69FE217D" name="us-gaap:PaidInKindInterest" contextRef="FD2016Q2QTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">385,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, upon entering into the Loan and Security Agreement, the Credit Agreement was paid in full and terminated on November 3, 2017, wherein all commitments were terminated, all liens were released and all outstanding principal, interest and fees accrued thereunder were repaid in the aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e1191-wk-Fact-1E843413AF00182C4165C7EB69C00574" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="D2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, including a prepayment premium of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32804889e1195-wk-Fact-1351F4C4F224131CF9D8C7EB69C1008F" name="vcyt:PaymentOfEndOfTermObligation" contextRef="D2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="TextSelection-227C645AB5C7A4803C97C7EB6A29DDC8-0-wk-Fact-AF79593C3A371893669AC7EB69FE3ADE" escape="true"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was recognized as follows (in thousands of dollars):&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nominal debt interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1391-wk-Fact-DA70F0E93D397E7E3E57C7EB69C6187C" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1410-wk-Fact-E5579B6B54553D50CD5CC7EB69C5C5A8" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1429-wk-Fact-E397AACD0A14A450ACA6C7EB69C7DAD8" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization and write-off of debt discount and issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1445-wk-Fact-B9E80BBF080688E97EECC7EB69C52F74" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1464-wk-Fact-096EFD9A63FCADEBB827C7EB69C72602" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1483-wk-Fact-62A4761FC211620A6E5FC7EB69C94B57" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End-of-term debt obligation interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1504-wk-Fact-2AA68FC65F838D6B10DD7C9142B4346A" name="vcyt:DebtInstrumentEndOfTermInterestObligationAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1523-wk-Fact-F2BE154BD710F1E7FE617C9142A7C457" name="vcyt:DebtInstrumentEndOfTermInterestObligationAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1542-wk-Fact-7BFE1176C0006AD2328E7C9142A15A6F" name="vcyt:DebtInstrumentEndOfTermInterestObligationAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt prepayment penalty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1563-wk-Fact-BA8C5C3804DCE6F2BC77C7EB69C6254C" name="vcyt:PrepaymentPenalty" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1582-wk-Fact-88D42661B8D8CBCC54F7C7EB69C47A0E" name="vcyt:PrepaymentPenalty" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1601-wk-Fact-54CCCB312B9C8632AB40C7EB69C9E769" name="vcyt:PrepaymentPenalty" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest on capital lease</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1622-wk-Fact-C175AF5A578158838BA7C7EB69C4BD0C" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1641-wk-Fact-A8DBD6604FB7DB172752C7EB69C5D267" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1660-wk-Fact-6CEEFA1E61E2F69B333AC7EB69C8F452" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1686-wk-Fact-23F7CD23D2F02C042CE7C7EB69C72155" name="us-gaap:InterestExpenseDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1705-wk-Fact-E4075190162DE36B941AC7EB69C5A5C4" name="us-gaap:InterestExpenseDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32804889e1724-wk-Fact-5E36DD8E5B21D078FAC5C7EB69C8B409" name="us-gaap:InterestExpenseDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99</span></div></div><hr style="page-break-after:always"></hr><div><a id="s139EA2778552E786DBD1428AF85D0C7F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-A1A4D4053FCC4C704852C7EB6A2CCE44-0-wk-Fact-9FDF23EE12BCD0270FB0C7EB69F3CC9F" continuedAt="TextSelection-A1A4D4053FCC4C704852C7EB6A2CCE44-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A1A4D4053FCC4C704852C7EB6A2CCE44-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Restated Certificate of Incorporation authorizes the Company to issue </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e731-wk-Fact-EE464A49BDE3BB98ECC4C7EB69EAA9A7" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">125,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32803588e735-wk-Fact-950FDA869E35200EDC84C7EB69F1AB64" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The holder of each share of common stock shall have </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e739-wk-Fact-454FAD01F36DDD1397A5C7EB69FBA8EA" name="vcyt:VotingRightsForEachShareOfStock" contextRef="FD2019Q4YTD" unitRef="vote" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> vote for each share of stock. The common stockholders are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all series of convertible preferred stock outstanding. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e743-wk-Fact-E06F47DCB56072998119C7EB69F224D7" name="us-gaap:DividendsPayableCurrentAndNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> dividends have been declared as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="TextSelection-10CC5E0D26A3E299614AC7EB6A2C49D6-0-wk-Fact-55CF2BA4EACC03E1F862C7EB69F3D119" continuedAt="TextSelection-10CC5E0D26A3E299614AC7EB6A2C49D6-1" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had reserved shares of common stock for issuance as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-10CC5E0D26A3E299614AC7EB6A2C49D6-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units issued and outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e854-wk-Fact-7147AADB2ED4AC369D95C7EB6A1BC4DF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,562,484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e868-wk-Fact-17D38D8E7EFB61AB8F88C7EB6A1B2078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,235,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units available for grant under stock option plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e883-wk-Fact-EC583663A6FCDC2D03E9C7EB6A0E5E14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,954,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e897-wk-Fact-1F4E405EF5FD4B86779AC7EB6A183371" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,571,658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock available for the Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e912-wk-Fact-CDAA2434153C67383374C7EB6A1A4736" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">173,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e926-wk-Fact-CF0B958D78CBD852D0BBC7EB6A13B5C6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">309,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e941-wk-Fact-632D7DAC613E0C14812FC7EB6A1B0FD0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,690,456</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e955-wk-Fact-AE4E6E5DF1B8709E8A24C7EB6A163292" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,116,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 7, 2019, the Company issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e973-wk-Fact-F14E1E0B042CCA31097DE85431FEF51E" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q2May07" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,325,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock in a registered public offering, including&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e977-wk-Fact-0E23D053462F0B1BD33FE854BC8230FF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q2May07_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">825,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32803588e981-wk-Fact-C5495141AE56C4F84FE5E8560BFEC7AB" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2019Q2May07" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">23.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company's net proceeds from the offering were approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32803588e985-wk-Fact-32A66B66A05C2F6E9B02E856AFDE1696" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2019Q2May07" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">137.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32803588e989-wk-Fact-FCB7C8C8939E7C7D70E7E8578B2E4899" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="D2019Q2May07" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, the Company issued and sold </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e999-wk-Fact-E03D35475575CEB2BA4EC7EB69EE0E68" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q3July" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,750,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in a registered public offering, including </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32803588e1003-wk-Fact-66772D250B09C00E1F31C7EB69E81A37" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">750,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares issued and sold upon the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32803588e1007-wk-Fact-C31ACACBF781E231E595C7EB69EC4877" name="us-gaap:SharesIssuedPricePerShare" contextRef="I2018Q3Jul31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">10.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Company's net proceeds from the offering were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32803588e1011-wk-Fact-93A7CE4FB86A6B46EB0AC7EB69EAF469" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting commissions and offering expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32803588e1015-wk-Fact-32A5C4030FEB0AE81407C7EB69E81F6D" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s6890610B110F06CEBA73428AF835B841"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-0-wk-Fact-56246CEAB561C2D20280C7EB6A095352" continuedAt="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-1" escape="true">Stock Incentive Plans</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-1" continuedAt="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2008, the Company adopted the 2008 Stock Plan (the "2008 Plan"). The 2008 Plan provides for the granting of options to purchase common stock and common stock to employees, directors and consultants of the Company. The Company may grant incentive stock options ("ISOs"), non-statutory stock options ("NSOs") or restricted stock under the 2008 Plan. ISOs may only be granted to Company employees (including directors who are also considered employees). NSOs and restricted stock may be granted to Company employees, directors and consultants. Options may be granted for terms of up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e734-wk-Fact-22C8C326C7EA8CBE36D2C7EB69D4D682" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to a person who owns stock representing more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e738-wk-Fact-3C9DCE72C15835027D4DC7EB6A00FB65" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock" contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the voting power of all classes of stock of the Company, the term shall be for no more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e742-wk-Fact-D9A19009EC11AAEDDE36C7EB69F29AC4" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock" contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant. The exercise price of options granted must be at a price no less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e746-wk-Fact-676430472D86DF363F3FC7EB69D451CD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to an employee who at the time of grant of such option owns stock representing more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e750-wk-Fact-3C9DCE72C15835027D4DC7EB6A00FB65" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock" contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the voting power of all classes of stock of the Company, the exercise price shall not be less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e755-wk-Fact-EE99BCFCFAC8FB5B9721C7EB6A0FFA4B" name="vcyt:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock" contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">110</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the estimated fair value of the shares on the date of grant. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2013, the Company adopted the 2013 Stock Incentive Plan (the "2013 Plan"). The 2013 Plan was subsequently approved by the Company's stockholders and became effective on November&#160;4, 2013, immediately before the closing of the Company's initial public offering ("IPO"). Following the effectiveness of the 2013 Plan, no additional options were granted under the 2008 Plan. An aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e764-wk-Fact-96C0F8D26973FF633F06C7EB69D50D23" name="vcyt:CommonStockCapitalAdditionalSharesReservedForFutureIssuance" contextRef="I2013Q4Oct31_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,700,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were initially reserved for issuance under the 2013 Plan. In addition, to the extent that any awards outstanding or subject to vesting restrictions under the 2008 Plan are subsequently forfeited or terminated for any </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-2" continuedAt="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reason before being exercised or settled, the shares of common stock reserved for issuance pursuant to such awards as of the closing of the IPO will become available for issuance under the 2013 Plan. The remaining shares available for grant under the 2008 Plan became available for issuance under the 2013 Plan upon the closing of the IPO. On the first day of each year from 2014 to 2023, the 2013 Plan authorizes an annual increase of the lesser of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e771-wk-Fact-06FFFAAAC65037E5C9E2C7EB69F6C4C6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of outstanding shares on the last day of the immediately preceding fiscal year or a lesser amount as determined by the Company's Board of Directors. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e779-wk-Fact-8BE506586061BDFE8A2EC7EB69F113A8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q4_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,954,799</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for future issuance under the 2013 Plan.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the 2013 Plan, stock options, restricted shares, stock units, including restricted stock units and stock appreciation rights may be granted to employees, consultants, and outside directors of the Company. Options granted may be either ISOs or NSOs.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options are governed by stock option agreements between the Company and recipients of stock options. ISOs and NSOs may be granted under the 2013 Plan at an exercise price of not less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e794-wk-Fact-14C6CC78D499EF2A8B88C7EB69F5FE85" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the Board of Directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of ISOs may not exceed ten years from the date of grant. Stock option agreements may provide for accelerated exercisability in the event of an optionee's death, disability, or retirement or other events.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock units are governed by stock unit agreements between the Company and recipients of stock units. Stock units may be granted under the 2013 Plan and the number of stock units awarded are determined by the Compensation Committee of the Board of Directors. Stock units vest and expire as determined by the Compensation Committee.  Stock unit agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any outside director who was not previously an employee and who first joins the Company's Board of Directors on or after the effective date of the 2013 Plan will be automatically granted an initial NSO to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e808-wk-Fact-328E8A98ABE7B14AEF2FC7EB6A1B6674" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants" contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">35,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock upon first becoming a member of the Board of Directors.  The shares subject to the initial option will vest and become exercisable one-third (1/3) each of the first, second and third annual anniversaries of the date of grant.  On the first business day after each regularly scheduled annual meeting of stockholders, each outside director who was not elected to the Board of Directors for the first time at such meeting and who will continue serving as a member of the Board of Directors thereafter will be automatically granted an option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e812-wk-Fact-03E1DB18D87EA6D2D345C7EB69F7FD3B" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants" contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, provided that the outside director has served on the Board of Directors for at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e816-wk-Fact-D1699ABE02FF2CA4E381C7EB69DAD366" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" format="ixt-sec:durwordsen">six months</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. Each annual option will vest and become exercisable on the first anniversary of the date of grant, or immediately prior to the next regular annual meeting of the Company's stockholders following the date of grant if the meeting occurs prior to the first anniversary date. The options granted to outside directors will have a per share exercise price equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e820-wk-Fact-2F1C68E8CF724C810A13C7EB6A030700" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of the underlying shares on the date of grant and will become fully vested in the event of a change of control. In addition, such options will terminate on the earlier of (i)&#160;the day before the&#160;</span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;">th anniversary of the date of grant or (ii)&#160;the date </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e829-wk-Fact-361E0CF6D133883BA6A1C7EB69E675FA" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span></span><span style="font-family:inherit;font-size:10pt;"> after the termination of the outside director's service for any reason.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-76278BF2E9044BE52F35C7EB6A2DF2BB-0-wk-Fact-0E68927A64CEFECDB943C7EB69FDAB9F" continuedAt="TextSelection-76278BF2E9044BE52F35C7EB6A2DF2BB-1" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes activity under the Company's stock incentive plans (aggregate intrinsic value in thousands):</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-3" continuedAt="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-4"><ix:continuation id="TextSelection-76278BF2E9044BE52F35C7EB6A2DF2BB-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Available</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">for Grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options<br/>Outstanding and Unvested Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise Price of Stock Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br/>Remaining<br/>Contractual Life of Stock Options<br/>(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value of Stock Options</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance&#8212;December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e964-wk-Fact-1F4E405EF5FD4B86779AC7EB6A183371" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,571,658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e978-wk-Fact-44701CC745B307046BC0C7EB69CDC59C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,235,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e997-wk-Fact-ED8D7240B8484DCDCBDEC7EB69CF423D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e1012-wk-Fact-2B8250DE4910E781F4ADE8AC70A52872" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD" format="ixt-sec:duryear">6.95</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1027-wk-Fact-289489DF41031F44C0D3C7EB6A12C98E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional shares authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1042-wk-Fact-E8EFB43B49BF1681ED85C7EB69CE3402" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,634,528</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted - stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811342e1120-wk-Fact-04F0928E5D2E0A218324C7EB6A0EF231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">969,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1135-wk-Fact-04F0928E5D2E0A218324C7EB6A0EF231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">969,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1149-wk-Fact-7804C69FF87C5ECD033AC7EB6A0E9D9C" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted - restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811342e1199-wk-Fact-B342F1C909C8C4B951EAC7EB6A192477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">505,965</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1214-wk-Fact-B342F1C909C8C4B951EAC7EB6A192477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">505,965</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1280-wk-Fact-5A3046DD37C0534C41FFC7EB69D13BC8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">180,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811342e1294-wk-Fact-5A3046DD37C0534C41FFC7EB69D13BC8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">180,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1309-wk-Fact-DB5904730DA01414669DC7EB69CE30FC" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811342e1373-wk-Fact-A8018B56FEDDC463CC9DC7EB69D4775D" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,846,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1388-wk-Fact-C8407BB35184E482E470C7EB6A0CD487" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811342e1452-wk-Fact-36F8DA0225D0433F13C4C7EB69D45924" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">122,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax portion of restricted stock units vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1519-wk-Fact-B026CBFB9EB59C633CBFC7EB6A0AA8EC" name="vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">44,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1599-wk-Fact-EC583663A6FCDC2D03E9C7EB6A0E5E14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,954,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1613-wk-Fact-47C805DBCB1C5B213202C7EB6A11F061" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,562,484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1632-wk-Fact-459DDF6DFB2BEB8D92DEC7EB6A0FF28A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e1647-wk-Fact-735D4BAFA14534F9E144C7EB6A0C5093" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">6.97</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1662-wk-Fact-D0850444DCBB67AACE85C7EB69D07CDF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options vested and exercisable&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1774-wk-Fact-BDAA0EF939AD82117367C7EB69CED8B3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,651,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1793-wk-Fact-5E013378BF155645ECABC7EB6A0B09A2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e1808-wk-Fact-52125299D851754EFED2C7EB69CDA7D9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">5.90</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1823-wk-Fact-3F53C30C637A4BE55EC4C7EB69D57520" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options vested and expected to vest&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1852-wk-Fact-D8DBD532EBC62F35729AC7EB69D3EE73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,442,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1871-wk-Fact-FCE09982C18EAAC82590C7EB6A094E01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e1886-wk-Fact-5DED8C1337CC32A4B1C3C7EB6A0EA9BC" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">6.91</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e1901-wk-Fact-7D2BDD4D27E0C2298AE4C7EB69D0069F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value was calculated as the difference between the exercise price of the options to purchase common stock and the fair market value of the Company's common stock, which was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1918-wk-Fact-F09A13C9D9DBA6D4E6ABC7EB6A01374B" name="us-gaap:SharePrice" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">27.92</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1922-wk-Fact-686469D00EC7F99D9354E8AC9A0946B7" name="us-gaap:SharePrice" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">12.58</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share as of December&#160;31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average fair value of options to purchase common stock granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1932-wk-Fact-7C05B130092EC234A6A3C7EB6A00F9A6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.07</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1936-wk-Fact-E2593EAEB33D83DA8FDBE8ACC41677EC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.62</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1940-wk-Fact-9A921687EBE546640F15C7EB69FD86E2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.49</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate estimated grant date fair value of employee options to purchase common stock vested during the years ended December&#160;31, 2019, 2018 and 2017 was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1949-wk-Fact-FA1498E11A858616A3BAC7EB69E576AD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1953-wk-Fact-F177C8E46776CF289FD4E8AD0E26918D" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1957-wk-Fact-755BE5EB04C35648FDCFC7EB69DED8E4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intrinsic value of stock options exercised was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1966-wk-Fact-CB0CC348A5017F67A155C7EB69F43492" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1970-wk-Fact-54ECAE9664378495B855E8AD5C0442BA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1974-wk-Fact-E33E19C00875B3C259DDC7EB69F9E4D1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average fair value of restricted stock units granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1983-wk-Fact-21B9B8A2555BB4725E5AC7EB69FCE5F3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.90</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1987-wk-Fact-E0B57C230B63EE8158A3E8ADEFAF91F9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.17</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2019 and 2018, respectively.  The intrinsic value of restricted stock units vested was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1991-wk-Fact-C493DCA0A3A283536814C7EB6A130CB1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">2,720,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e1995-wk-Fact-B9A8F14E7A050FDC4024E8AE1A2177BE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">184,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2015, the Company's stockholders approved the Company's ESPP. The ESPP provides eligible employees with an opportunity to purchase common stock from the Company and to pay for their purchases through payroll deductions. The ESPP will be implemented through a series of offerings of purchase rights to eligible employees. Under the ESPP, the Compensation Committee of the Company's Board of Directors may specify offerings with a duration of not more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e2009-wk-Fact-95AE7CE8F70EE1080106C7EB6A16AD3F" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span></span><span style="font-family:inherit;font-size:10pt;">, and may specify shorter purchase periods within each offering. During each purchase period, payroll deductions will accumulate, without interest. On the last day of the purchase period, accumulated payroll deductions will be used to purchase common stock for employees participating in the offering.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price will be specified pursuant to the offering, but cannot, under the terms of the ESPP, be less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2019-wk-Fact-3AD572979CE952031D65C7EB69E1FC7E" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value per share of the Company's common stock on either the offering date or on the purchase date, whichever is less.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Board of Directors has determined that the purchase periods initially shall have a duration of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e2028-wk-Fact-219C48DE207BF3D9AA92C7EB69FE3275" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durwordsen">six months</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">, that the first purchase period began on August&#160;3, 2015 and that the purchase price will be </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2032-wk-Fact-3AD572979CE952031D65C7EB69E1FC7E" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value per share </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">102</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-4" continuedAt="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-5"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of the Company's common stock on either the offering date or the purchase date, whichever is less. The length of the purchase period applicable to U.S. employees and the purchase price may not be changed without the approval of the independent members of the Compensation Committee of the Company's Board of Directors. The Compensation Committee has determined that if the fair market value of a share of the Company's common stock on any purchase date within a particular offering period is less than the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No employee is permitted to accrue, under the ESPP, a right to purchase stock of the Company having a value in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e2044-wk-Fact-8C68CF97C17940A6E4FCC7EB69FEA394" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of such stock (determined at the time the right is granted) for each calendar year.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-700F551A844844C81E20C7EB6A2D406C-0-wk-Fact-F3908BAA9D33BEF7D9F9C7EB69FCC54E" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense related to stock options, restricted stock units and the ESPP for the years ended December&#160;31, 2019, 2018 and 2017, and are included in the consolidated statements of operations and comprehensive loss as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2224-wk-Fact-8F18F57393D9E440133EC7EB6A0E6F27" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2243-wk-Fact-63C1AB1D876B3D800015C7EB69E4D098" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2262-wk-Fact-ACB88209EF2E69F95EFBC7EB69E724B9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2278-wk-Fact-5467F84B64B2DE42D5F5C7EB6A1AC405" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,856</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2297-wk-Fact-759ECFE23068962AD30BC7EB6A192747" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2316-wk-Fact-F56E6AB66BF49A9DAEFAC7EB69E46E1C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2337-wk-Fact-68914B865D7F61CDA9F7C7EB69E9ABB6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2356-wk-Fact-1AAEF0040260DB43E44DC7EB69E59B80" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2375-wk-Fact-C283BA7970CF08337F9FC7EB69E92185" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,899</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2396-wk-Fact-705635915D5AB5E86E3FC7EB69E639F0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2415-wk-Fact-F2CCBA0501C383BD5421C7EB69E55B31" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2434-wk-Fact-9D7EE486F31EDA88F6B7C7EB6A1E5B4D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2460-wk-Fact-FD2D0108AEAC5312EA2EC7EB6A14A127" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2479-wk-Fact-918B56AB80510B7980B7C7EB69E941CE" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,958</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2498-wk-Fact-AF2B9E94D61AA7CD2752C7EB69E813AD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2019, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811342e2516-wk-Fact-8F236B51758E395DDEEBC7EB69D56098" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested stock options and restricted stock units, which is expected to be recognized over an estimated weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811342e2520-wk-Fact-75B1F3378C94A6C737FCC7EB69F8B846" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" format="ixt-sec:duryear">2.20</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-D893A0FCD76B967939EAC7EB6A2C8C56-0-wk-Fact-1B11C58216B431133248C7EB69F79E83" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated grant-date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:56%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52.90 - 53.40%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 52.70%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 52.40%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.90 - 2.60%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.40 - 3.10%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.80 - 2.33%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-646EBE93DD05DE70F384C7EB6A2CABD2-0-wk-Fact-2BABEF0041A75EC9F47DC7EB69DE1FDA" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of non-employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:56%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.60 - 50.50%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 51.10%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.25 - 6.75</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.80 - 7.75</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.84 - 2.87%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.16 - 2.37%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-D57508DD7AD27039E626C7EB6A2DF4BD-0-wk-Fact-020809F23D4804447258C7EB69D8C306" continuedAt="TextSelection-D57508DD7AD27039E626C7EB6A2DF4BD-1" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">103</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-D57508DD7AD27039E626C7EB6A2DF4BD-1"><ix:continuation id="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-5"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811342e2968-wk-Fact-339F5A903023007CF0B4782CF902A0B9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> non-employee stock options outstanding as of December 31, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated grant date fair value of the ESPP shares was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:56%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53.38 - 71.77%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42.88 - 47.74%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37.00 - 43.86%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.88 - 2.56%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.64 - 2.45%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.65 - 1.22%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3B074D908C6D0F3E55E4428AF80094DE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">11. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LongTermContractsOrProgramsDisclosureTextBlock" id="TextSelection-B3A9E68887F5DC72F8DDC7EB6A2DB92F-0-wk-Fact-415609B700F88587F305C7EB69E6DF87" continuedAt="TextSelection-B3A9E68887F5DC72F8DDC7EB6A2DB92F-1" escape="true">Thyroid Cytopathology Partners</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B3A9E68887F5DC72F8DDC7EB6A2DB92F-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an agreement with a specialized pathology practice, Thyroid Cytopathology Partners, ("TCP"), to provide testing services to the Company (the "TCP Agreement").&#160; The TCP Agreement is effective through October 31, 2022, and thereafter automatically renews every year unless either party provides notice of intent not to renew at least&#160;12 months&#160;prior to the end of the then-current term. Under the TCP Agreement, the Company pays TCP based on a fixed price per test schedule which is reviewed periodically for changes in market pricing, and the TCP Agreement included a clause allowing TCP to sublease a portion of the Company's facility in Austin, Texas. &#160;The Company does not have an ownership interest in or provide any form of financial or other support to TCP. &#160;The Company previously concluded that TCP represented a variable interest entity as a result of the facility arrangement clause, but that the Company was not the primary beneficiary as it did not have the ability to direct the activities that most significantly impacted TCP's economic performance, and therefore did not consolidate TCP.&#160; On February 14, 2019, the TCP Agreement was amended to remove the facility clause.&#160; Accordingly, the Company believes TCP was no longer a variable interest entity as of that date.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TCP's portion of rent and related operating expenses reimbursed to the Company for the shared space at the Austin, Texas facility was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32805237e731-wk-Fact-A4DB47A3963062D31262C7EB6A05A0E0" name="vcyt:OtherIncomeRentReimbursement" contextRef="FD2019Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">11,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32805237e735-wk-Fact-61E2A181C2A05765A28AC7EB6A064D1C" name="vcyt:OtherIncomeRentReimbursement" contextRef="FD2018Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">128,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32805237e739-wk-Fact-43382273C24B6317F86EC7EB6A03F8B9" name="vcyt:OtherIncomeRentReimbursement" contextRef="FD2017Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">114,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and is included other income, net in the Company's consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sC316A275589C9FC5253C428AF7BFE40A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-B1D68602D75C1559FA68C7EB6A2D0884-0-wk-Fact-CA880B9A140B00FF573CC7EB6A11CBB7" continuedAt="TextSelection-B1D68602D75C1559FA68C7EB6A2D0884-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B1D68602D75C1559FA68C7EB6A2D0884-1" continuedAt="TextSelection-B1D68602D75C1559FA68C7EB6A2D0884-2"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generated a pretax loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e726-wk-Fact-C36A7880192747F17755C7EB69D8E858" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e730-wk-Fact-E4CF2CE782D25D0E8239C7EB6A111B01" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">23.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e734-wk-Fact-64D7C8BF0BCA6F802959C7EB69D7C3C1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the United States for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Since inception, the Company has not generated any pretax income or loss outside of the United States. The Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e751-wk-Fact-852167221E0A3FB62D61C7EB6A12F420" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="INF" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> provision for income taxes during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company follows FASB ASC No.&#160;740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes for the Computation and Presentation of its Tax Provision.</span><span style="font-family:inherit;font-size:10pt;"> <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-5BA0C18CA5B7684F5535C7EB6A2EC126-0-wk-Fact-452088269E1B3C5F5277C7EB6A0D4972" continuedAt="TextSelection-5BA0C18CA5B7684F5535C7EB6A2EC126-1" escape="true">The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company's income tax expense for the periods presented (in thousands of dollars):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5BA0C18CA5B7684F5535C7EB6A2EC126-1"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December, 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal taxes at statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e941-wk-Fact-986F042E18B95D40B2A6C7EB6A1D567F" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e961-wk-Fact-3A4A8D4EA567F356B7E9C7EB6A0ED829" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e981-wk-Fact-0CCAF611294DFFD6ABFBC7EB6A11775F" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State tax (net of federal benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e998-wk-Fact-BD4DCF1CB893C059CA9CC7EB6A05B4EE" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1018-wk-Fact-C220B76AB54D5B74F5E6C7EB6A04D7B4" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1037-wk-Fact-65EA4E3A138960268654C7EB6A13C902" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non deductible officers' compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1058-wk-Fact-98CA36835D412A9612F7C7EB69E842DF" name="vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1077-wk-Fact-CAEA31A710A0D225A25CC7EB6A1A27F0" name="vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1096-wk-Fact-AF8D931D5C8C38650A72C7EB6A1DA8C9" name="vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock based compensation - PSU/RSU/NQSQ</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1117-wk-Fact-474567B1C5D87F56AFEE40422C1EDBC9" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1136-wk-Fact-60C81E477A6D803019F2404242E08420" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1155-wk-Fact-8556779A3D175AA34A7040424F9625E2" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1176-wk-Fact-174129832A9C46FEA187C7EB6A105693" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1195-wk-Fact-B22A595E4A9BC1BC7AE3C7EB69FBC159" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1214-wk-Fact-373E59D35E607861D4DCC7EB6A106AEA" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incentive stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e1235-wk-Fact-C31BA6CFE4CD13CC6D47C7EB6A0FBB55" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e1255-wk-Fact-4397EC77E0844D208001C7EB69F7B98C" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1275-wk-Fact-5C1CD0E776718DD1363CC7EB6A1CD30A" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e1296-wk-Fact-B57C22A0657CEBC28E32C7EB6A10C42A" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">996</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e1316-wk-Fact-EED66889ADDBE881E6EAC7EB6A1A9AB5" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">777</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e1336-wk-Fact-BF39F5833C7CD2A527BEC7EB6A1B7E2A" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1358-wk-Fact-A80268BFD3A24D24C6C4C7EB6A129FBD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1377-wk-Fact-92060D846E66F5EB7ACEC7EB69F452C7" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e1396-wk-Fact-08FA150F5AD8F408A1A2C7EB69FD6CE0" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,552</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rate differential impact - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Cuts and Jobs Act</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1420-wk-Fact-F16FB7692F11DF74E847C7EB6A1C3401" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1439-wk-Fact-D669E145C68DADDA61C8C7EB6A1FC0E7" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1458-wk-Fact-59F8A60DD2566D003D68C7EB6A1E90A6" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,474</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1485-wk-Fact-533CE0650954522E5890C7EB6A1CC308" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1504-wk-Fact-B830F66DE3633110BAE2C7EB6A1E5797" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1523-wk-Fact-568F44F692A8F05490AEC7EB6A1FC9FA" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-B1D68602D75C1559FA68C7EB6A2D0884-2" continuedAt="TextSelection-B1D68602D75C1559FA68C7EB6A2D0884-3"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="TextSelection-CD9944AABE826230B200C7EB6A2D9A92-0-wk-Fact-8B10ABE236EE6AD669F0C7EB69D68AE5" continuedAt="TextSelection-CD9944AABE826230B200C7EB6A2D9A92-1" escape="true">Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands of dollars):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CD9944AABE826230B200C7EB6A2D9A92-1" continuedAt="TextSelection-CD9944AABE826230B200C7EB6A2D9A92-2"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-CD9944AABE826230B200C7EB6A2D9A92-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1766-wk-Fact-AB214F76E00700C63A5FC7EB69D7955D" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1785-wk-Fact-2B7E385AF48B16002243C7EB6A1E1358" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,410</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1804-wk-Fact-44C3BE18D7D8F3F66A79C7EB69DDB46F" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1820-wk-Fact-818C6AE3391BFF03DBDCC7EB69D65AFF" name="vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1839-wk-Fact-174C5CE48AB74E664176C7EB69E2E656" name="vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1858-wk-Fact-BE623EC7E620070FE6C6C7EB6A1D9FCF" name="vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,034</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1879-wk-Fact-7B5C5BC0D4D25F01DBA1C7EB69E33C82" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1898-wk-Fact-8244B672FCB09BE872E7C7EB69DB65A1" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1917-wk-Fact-A2B650EAFAC39693A52EC7EB69D82DBE" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,068</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NanoString intangibles and goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1938-wk-Fact-090F034167B8E56E906A4044DBC81304" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1957-wk-Fact-3C6FB1C87FE759B7A1C140450AA881C5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1976-wk-Fact-61294A21DB3E94BE145D404515E32009" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e1997-wk-Fact-3F046C474496C6493AD44045E899925B" name="vcyt:DeferredTaxAssetsOperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,068</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2016-wk-Fact-3B233324A6A6BB80288B4045F613169A" name="vcyt:DeferredTaxAssetsOperatingLeaseLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2035-wk-Fact-B4D6B51640381774C79B4046027438D9" name="vcyt:DeferredTaxAssetsOperatingLeaseLiability" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2056-wk-Fact-165970B9BF63367460E8C7EB69DA91EF" name="vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2075-wk-Fact-53A6A513CF792E97DC16C7EB69DCE6E0" name="vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,918</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2094-wk-Fact-DB603C3F35FDBD0360D1C7EB69D73F51" name="vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2115-wk-Fact-88F7DBEAB8FD9D856EA7C7EB69DAF1F6" name="us-gaap:DeferredTaxAssetsGrossNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2134-wk-Fact-53CEDCBCF4B65662354CC7EB6A1F4FDD" name="us-gaap:DeferredTaxAssetsGrossNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2153-wk-Fact-FBD72B36A712DBCA28B4C7EB69DBA5B4" name="us-gaap:DeferredTaxAssetsGrossNoncurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2174-wk-Fact-08A0FC21DDDFAF4C6C93C7EB69D6385C" name="us-gaap:TaxCreditCarryforwardValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2194-wk-Fact-2F74AC2684305A3A2D76C7EB69DC9907" name="us-gaap:TaxCreditCarryforwardValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2214-wk-Fact-675582AF20F40013A45AC7EB69D81586" name="us-gaap:TaxCreditCarryforwardValuationAllowance" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2237-wk-Fact-18BF41293B2EABEBDDCEC7EB69DE65E2" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2256-wk-Fact-7B338E4FE52CCA398DE2C7EB69D867A9" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2275-wk-Fact-9FCD5BB7A6282B52EF3BC7EB69D8A5EF" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,997</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2355-wk-Fact-0E1019514F3992D3ED86C7EB69D9475A" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2375-wk-Fact-52135B7C2EBB24E9DB00C7EB6A1EF982" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2395-wk-Fact-B5EA34F31EDB749854D0C7EB69D86125" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2417-wk-Fact-494A2B81BDDECF5AA58FC7EB69D94D44" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2437-wk-Fact-FECE491D112FFA820F97C7EB69DA5755" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2457-wk-Fact-F54E89ABAC472713B67CC7EB69D81057" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2479-wk-Fact-AFDBA8F884BDFA5B99794046ED20002C" name="vcyt:DeferredTaxLiabilitiesRightofUseAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,093</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2499-wk-Fact-F8B88DA31F7BBBCDBA184046FF530883" name="vcyt:DeferredTaxLiabilitiesRightofUseAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2518-wk-Fact-251FDE70C26E18E7E84940470C03B068" name="vcyt:DeferredTaxLiabilitiesRightofUseAssets" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2539-wk-Fact-57AA608907573F210319C7EB6A1F9B5F" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2559-wk-Fact-D7B6D3A0C5108B49C375C7EB69DCD445" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2579-wk-Fact-A4D9F3B64330EF3C943BC7EB69DBC4A3" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,997</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2601-wk-Fact-FEFFC0AE0EBE5575BFCAC7EB6A1CF67D" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2621-wk-Fact-47D51DA1CA2306A3BDF5C7EB69D9C774" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e2641-wk-Fact-38649C2EC8F4A8186DDDC7EB69E2525A" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,997</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2668-wk-Fact-301DE6FBD088234187EFC7EB69D7D25E" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2687-wk-Fact-EB10ACD06CCC807E99C2C7EB69DF1666" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2706-wk-Fact-E15BD12195F682F8B19AC7EB69DA33F0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets. The valuation allowance increased </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2726-wk-Fact-16E5B7ACA5DA153CB2DEC7EB6A1D745A" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, increased </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2734-wk-Fact-1535EC4932AA038CC3CEC7EB69D89EFF" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and decreased </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2742-wk-Fact-7B6ABA7D2437D2D1DEE0C7EB6A10552B" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2760-wk-Fact-21E16675A737593672B3C7EB6A1B7D29" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">236.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2764-wk-Fact-9ECBE79F6BA6ABF35E70C7EB6A1EB625" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_srt_StatementGeographicalAxis_stpr_CA_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2768-wk-Fact-FC96F4468EE7DD6A5530C7EB6A148F68" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_srt_StatementGeographicalAxis_vcyt_OtherStatesNotSeparatelyDisclosedMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> available to reduce future taxable income, if any, for federal, California and other state income tax purposes, respectively.  The U.S. federal net operating loss carryforwards will begin to expire in 2026 while for state purposes, the net operating losses began to expire in 2028.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had net research and development credit carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2781-wk-Fact-C72ACF66AB3E88F6FB0FC7EB6A1CC062" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2785-wk-Fact-A4A60DBC359639BD612DC7EB6A0B9B46" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal credit carryforwards begin to expire in </span><span style="font-family:inherit;font-size:10pt;">2028</span><span style="font-family:inherit;font-size:10pt;">. California credits have no expiration date. Other state credit carryforwards begin to expire in </span><span style="font-family:inherit;font-size:10pt;">2023</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Internal Revenue Code of 1986, as amended, imposes restrictions on the utilization of net operating losses and tax credits in the event of an "ownership change" of a corporation. Accordingly, a company's ability to use net operating losses and tax credits may be limited as prescribed under Internal Revenue Code Section 382 and 383 ("IRC Section 382"). Events which may cause limitations in the amount of the net operating losses or tax credits that the Company may use in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. Utilization of the federal and state net operating losses may be subject to substantial annual limitation due to the ownership change limitations provided by the IRC Section 382 rules and similar state provisions. In the event the Company has any changes in ownership, net operating losses and research and development credit carryovers could be limited and may expire unutilized.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Uncertain Tax Positions</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">106</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-B1D68602D75C1559FA68C7EB6A2D0884-3"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had unrecognized tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811328e2817-wk-Fact-746C330B27B56B22FD7A651358C5B8EF" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, none of which would currently affect the Company's effective tax rate if recognized due to the Company's deferred tax assets being fully offset by a valuation allowance. The Company does not anticipate that the amount of unrecognized tax benefits relating to tax positions existing at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> will significantly increase or decrease within the next 12&#160;months.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="TextSelection-D9D88CFB59535BE1E2A7C7EB6A2DEEBF-0-wk-Fact-9DD57C9CE41707A4D676C7EB6A14A79A" escape="true"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e2994-wk-Fact-3ED137AF0196091A3173C7EB69DDD018" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3013-wk-Fact-F29429FF9C4C194EABA0C7EB69D852AE" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3032-wk-Fact-9B77080EE02EA01558F7C7EB69DCE7F8" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross increases&#8212;tax position in prior period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3048-wk-Fact-4EFB2A53EB86263DFD0AC7EB69D91DD8" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3067-wk-Fact-EE5D3CC111215485F059C7EB69D9D211" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3086-wk-Fact-2E3BF5737C9515440BDEC7EB69FB5163" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross decreases&#8212;tax position in prior period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3107-wk-Fact-8CF00C39FB11DAF48274C7EB69D61C7F" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32811328e3126-wk-Fact-69A0F9E6669376D664C9C7EB69DB81AF" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3146-wk-Fact-9A17E092A8D49B58AE4AC7EB6A01D6E5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross increases&#8212;current period tax position</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3167-wk-Fact-AA1C4A1A0228891767D0C7EB69DA0049" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3186-wk-Fact-C130CBBB4C8E161D1133C7EB6A02FC77" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3205-wk-Fact-D9201A61053DDC249AA7C7EB69DC6E31" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statute of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3226-wk-Fact-6ADDFAA0C29C1CEA6E94C7EB69FC5629" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3245-wk-Fact-89378E331EF7D6F96E84C7EB69D8C479" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3264-wk-Fact-197675F877533AE44430C7EB6A02BC9A" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3290-wk-Fact-92B588ECC0BEC4479CE7C7EB69D8A5C4" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3309-wk-Fact-3ED137AF0196091A3173C7EB69DDD018" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3328-wk-Fact-F29429FF9C4C194EABA0C7EB69D852AE" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is the Company's policy to include penalties and interest expense related to income taxes as a component of other income (expense), net, and interest expense, respectively, as necessary. There was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32811328e3346-wk-Fact-8FB6A3C25503A0E5CB51C7EB6A15FAFF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> interest expense or penalties related to unrecognized tax benefits recorded through </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's major tax jurisdictions are the United States and California. All of the Company's tax years will remain open for examination by the Federal and state tax authorities for </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d32811328e3363-wk-Fact-0D0FDBE5DDA62AEF1CC1C7EB6A1B98F6" name="vcyt:IncomeTaxExaminationPeriod" contextRef="FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" format="ixt-sec:durwordsen">four years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from the date of utilization of the net operating loss or research and development credit. The Company does not have any tax audits pending.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s613AF9DADA220E7ACC9F428AF8565FFC"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">13. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-0FC4F47AD4B0B2E31F67C7EB6A2EE5C7-0-wk-Fact-F5B943EDFBFE0F7153E4C7EB6A1A4EF4" continuedAt="TextSelection-0FC4F47AD4B0B2E31F67C7EB6A2EE5C7-1" escape="true">401(k) Plan</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0FC4F47AD4B0B2E31F67C7EB6A2EE5C7-1" continuedAt="TextSelection-0FC4F47AD4B0B2E31F67C7EB6A2EE5C7-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><ix:continuation id="TextSelection-0FC4F47AD4B0B2E31F67C7EB6A2EE5C7-2" continuedAt="TextSelection-0FC4F47AD4B0B2E31F67C7EB6A2EE5C7-3"><span style="font-family:inherit;font-size:10pt;">The Company sponsors a 401(k) defined contribution plan covering all employees. Employer contributions to the plan were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811626e726-wk-Fact-93A3BDAB2B9B442A855BC7EB6A1526AA" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">509,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811626e730-wk-Fact-F62DD958A0BE66A651CDC7EB6A158048" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">448,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d32811626e734-wk-Fact-A5717EDFDE2C503613B7C7EB6A145105" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">324,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-0FC4F47AD4B0B2E31F67C7EB6A2EE5C7-3">, respectively.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s135D288A9BE7D155E766428AF7B96E73"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">14. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="TextSelection-4BD2CB0BB019D1F87767C7EB6A2E402B-0-wk-Fact-9D6BFF1C5B0A593F8D00C7EB6A087035" continuedAt="TextSelection-4BD2CB0BB019D1F87767C7EB6A2E402B-1" escape="true">Selected Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4BD2CB0BB019D1F87767C7EB6A2E402B-1" continuedAt="TextSelection-4BD2CB0BB019D1F87767C7EB6A2E402B-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents selected unaudited financial data for each of the eight quarters in the two-year period ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company believes this information reflects all recurring adjustments necessary to fairly present this information when read in conjunction with the Company's financial statements and the related notes. Net loss per common share, basic and diluted, for the four quarters of each fiscal year may not sum to the total for the fiscal year because of the different number of shares outstanding during each period. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="TextSelection-F5C6E694203491F78B8DC7EB6A2E0C95-0-wk-Fact-739E49F9DD38AFECFD18C7EB6A00846B" continuedAt="TextSelection-F5C6E694203491F78B8DC7EB6A2E0C95-1" escape="true">The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period (in thousands of dollars, except for share and per share data):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F5C6E694203491F78B8DC7EB6A2E0C95-1" continuedAt="TextSelection-F5C6E694203491F78B8DC7EB6A2E0C95-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">107</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VERACYTE,&#160;INC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-F5C6E694203491F78B8DC7EB6A2E0C95-2"><ix:continuation id="TextSelection-4BD2CB0BB019D1F87767C7EB6A2E402B-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Ended</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e937-wk-Fact-47BCFE3AE10A6DCF5A63C7EB69D2538E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e956-wk-Fact-DC5BCD53490B5084659DC7EB69CB7703" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e975-wk-Fact-D68061C79BB0B812A5DEC7EB69C108CC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,973</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e995-wk-Fact-6A7BB882AF35474CF459C7EB69C82027" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1010-wk-Fact-828CF12D48E585FA10A2C7EB69C76A4F" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,917</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1030-wk-Fact-F95C069571B74EE649E4C7EB69CF0408" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1050-wk-Fact-6EBF060564F11A64768CC7EB69C742C9" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1071-wk-Fact-0633E040AFF7F0264514C7EB69C8C777" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1092-wk-Fact-432DB526ED1212239204C7EB69C62D4A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.05</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1112-wk-Fact-31F0C7C65E4AE9879E0AC7EB69D2EA24" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.05</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1132-wk-Fact-BAE1E471E56361563319C7EB69CAD9BF" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.02</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1153-wk-Fact-64E76552049A82760921C7EB69CA0A73" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used to compute net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1174-wk-Fact-834216C3FA64051F3FC2C7EB69CBD8F2" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,168,593</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1193-wk-Fact-731AD0E99E7C727E24FBC7EB69D660F2" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">45,586,081</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1212-wk-Fact-489926AEEE386832BD52C7EB69C6F71C" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q3QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">48,588,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1232-wk-Fact-9F0E2344A8444420CFD5C7EB69D3ADA1" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q4QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">49,095,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1335-wk-Fact-BD63204B41767EFC9A59C7EB69C66608" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1354-wk-Fact-76E94D207DFBEBFACF63C7EB69CA55B5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1373-wk-Fact-3D7F066071A6A548DC51C7EB69CCA5B9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,466</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1393-wk-Fact-2350DB098948676BC150C7EB69C43EC2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1408-wk-Fact-97F75F4B3F4772305783C7EB69D53661" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1428-wk-Fact-0C63839638CC0D183ED2C7EB69C822F6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1448-wk-Fact-74C7D198BB0B1F49AD4CC7EB69C16716" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1469-wk-Fact-3B38A50A93428DFD7682C7EB69CB1BD8" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1490-wk-Fact-312DC66C5DB134B72655C7EB69CF51F6" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1510-wk-Fact-8924A7957435BC285253C7EB69CFA7A7" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1530-wk-Fact-B13B045DE9047B02C1E1C7EB69CA6361" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d32812916e1551-wk-Fact-788093E78B3D774D3DDAC7EB69D4C033" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used to compute net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1572-wk-Fact-90705F57D3A9996AF1CFC7EB69C85EF0" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">34,271,254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1591-wk-Fact-C81658FF0B98CF82EEE0C7EB69C7091E" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">34,314,234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1610-wk-Fact-17E1ED686A3447CDFF32C7EB69D1D67E" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">38,620,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d32812916e1630-wk-Fact-F994C446CEC4C2F95261C7EB69CB867F" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q4QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">40,731,334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s625A924426068315B080428B0E8C728B"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s8CAEE5D98F0AD75DEBB3428B0EBF2FD5"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We maintain "disclosure controls and procedures," as such term is defined in Rule&#160;13a-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on their evaluation as of the end of the period covered by this Annual Report on Form&#160;10-K, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule&#160;13a-15(f) under the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of the effectiveness of internal control to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2019 using the criteria established in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control Integrated Framework</span><span style="font-family:inherit;font-size:10pt;"> ("2013 Framework") issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">108</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on our evaluation using those criteria, our management has concluded that, as of December&#160;31, 2019, our internal control over financial reporting was effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with guidance issued by the Securities and Exchange Commission, companies are permitted to exclude acquisitions from their final assessment of internal control over financial reporting for the first fiscal year in which the acquisition occurred. Our management&#8217;s evaluation of internal control over financial reporting excluded the internal control activities of the diagnostics business which we acquired from NanoString Technologies, Inc. on December 3, 2019, as discussed in Note 4 to our consolidated financial statements. We have included the financial results of the acquired business in the consolidated financial statements from the date of acquisition. Revenue from the acquired business comprised less than 1% of our total revenue for the year ended December 31, 2019 and approximately 5% of our accounts receivable as of December 31, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting (as such term is defined in Rule&#160;13a-15(f) under the Exchange Act) identified in connection with the evaluation identified above that occurred during the quarter ended December&#160;31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">To the Stockholders and the Board of Directors of Veracyte Inc. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">Opinion on Internal Control over Financial Reporting</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">We have audited Veracyte, Inc.&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework)</span><span style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;color:#333333;">(the COSO criteria). In our opinion, Veracyte, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">As indicated in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting,  management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting </span><span style="font-family:inherit;font-size:10pt;">did not include the internal control activities of the diagnostics business acquired from NanoString Technologies, Inc. on December 3, 2019, which is included in the 2019 consolidated financial statements of the Company and constituted less than 1% of the Company&#8217;s total revenue, for the year ended December 31, 2019, and approximately 5% of its accounts receivable as of December 31, 2019.</span><span style="font-family:inherit;font-size:10pt;color:#333333;"> Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of the diagnostic business acquired from NanoString Technologies, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2019 consolidated financial statements of</span><span style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;color:#333333;">the Company</span><span style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;color:#333333;">and our report dated February 25, 2020 expressed an unqualified opinion thereon.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">109</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redwood City, California</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">February 25, 2020</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sE602F25C2B72CFF3E9B6428B0EDF801E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">110</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1191F7D3C499A5756101428B0F137650"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s17735FADC8734C128EBF428B0F33F4C3"></a></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item with respect to directors is incorporated by reference from the information contained in our proxy statement to be filed with the Securities and Exchange Commission no later than 120&#160;days from the end of our fiscal year ended December&#160;31, 2019 in connection with the solicitation of proxies for our 2020 Annual Meeting of Stockholders, or the Proxy Statement. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sDC37643363C871A7D934428B0F64BC47"></a></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s074085FFCCDDCD29AC6C428B0F850D86"></a></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sAF474B99CD13CE3FDE3A428B0FC6C2F2"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s6A444EBE1E84C2362F9D428B0FD9C1A1"></a></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">111</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3273C41ACFE1B54CF3DE428B100976A8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s59B4F7AD48DCE2DF52F4428B102D13A6"></a></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Documents filed as part of this report</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;&#160;Financial Statements:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reference is made to the Index to Financial Statements of Veracyte,&#160;Inc. included in Item&#160;8 of Part&#160;II hereof.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All schedules have been omitted because they are not required, not applicable, or the required information is included in the financial statements or notes thereto.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;Exhibits</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Item&#160;15(b) below. Each management contract or compensating plan or arrangement required to be filed has been identified.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibits (to be updated)</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:9%;"></td><td style="width:43%;"></td><td style="width:10%;"></td><td style="width:11%;"></td><td style="width:8%;"></td><td style="width:10%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incorporated by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit Number</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">File No.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filing Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filed Herewith</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000110465913082910/a13-23874_1ex3d1.htm"><span style="font-family:inherit;font-size:10pt;">Restated Certificate of Incorporation of the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11/8/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000110465913082910/a13-23874_1ex3d2.htm"><span style="font-family:inherit;font-size:10pt;">Restated Bylaws of the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11/8/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000104746913009631/a2216954zex-4_1.htm"><span style="font-family:inherit;font-size:10pt;">Form of Common Stock Certificate</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1/A</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">333-191282</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10/15/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex42.htm"><span style="font-family:inherit;font-size:10pt;">Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000104746913009532/a2216908zex-10_1.htm"><span style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement between the Registrant and its officers and directors</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1/A</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">333-191282</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10/7/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000104746913009208/a2216719zex-10_2.htm"><span style="font-family:inherit;font-size:10pt;">2008 Stock Plan and forms of agreements thereunder</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">333-191282</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/20/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.3#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410118000006/vcyt-12312017xex103.htm"><span style="font-family:inherit;font-size:10pt;">2013 Stock Incentive Plan, as amended, and forms of stock option award agreement, stock option exercise agreement, restricted stock agreement and restricted stock unit agreement</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.3</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/27/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.4#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000110465915059626/a15-12130_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Employee Stock Purchase Plan</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8/13/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.5</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000104746913009208/a2216719zex-10_6.htm"><span style="font-family:inherit;font-size:10pt;">Lease Agreement between Riata Holdings,&#160;L.P., as landlord, and the Registrant, as tenant, dated November&#160;28, 2012</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">333-191282</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.6</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/20/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.6</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410117000068/vcyt-09302017xex101.htm"><span style="font-family:inherit;font-size:10pt;">Second Amendment to Lease Agreement dated as of August 14, 2017 by and between BRI 1868 RIATA, LLC and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11/7/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.7</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000104746914002734/a2219000zex-10_7.htm"><span style="font-family:inherit;font-size:10pt;">First Amendment to Lease Agreement dated as of January&#160;7, 2014 by and between Riata Holdings,&#160;L.P. and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.7</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/20/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">112</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:9%;"></td><td style="width:43%;"></td><td style="width:10%;"></td><td style="width:11%;"></td><td style="width:8%;"></td><td style="width:10%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incorporated by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.8</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000110465915059626/a15-12130_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">Office Building Lease by and between American Fund US Investments&#160;LP and the Registrant dated April&#160;29, 2015</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8/13/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.9</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410118000006/vcty-12312017xex109.htm"><span style="font-family:inherit;font-size:10pt;">First Amendment to Office Building Lease dated May 3, 2016 by and between American Fund US Investments&#160;LP and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.9</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/27/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.10</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410117000008/vcyt-12312016xex1010.htm"><span style="font-family:inherit;font-size:10pt;">Second Amendment to Office Building Lease dated February 8, 2017 by and between CRP 6000 Shoreline, L.L.C. and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.10</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/1/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.11#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000104746913009208/a2216719zex-10_10.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, dated as of February&#160;15, 2008, between Bonnie Anderson and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">333-191282</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.10</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/20/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.12#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000104746913009208/a2216719zex-10_11.htm"><span style="font-family:inherit;font-size:10pt;">Amendment to Bonnie Anderson Employment Agreement, dated as of December&#160;22, 2008, between Bonnie Anderson and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">333-191282</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.11</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/20/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.13#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000104746913009208/a2216719zex-10_12.htm"><span style="font-family:inherit;font-size:10pt;">Amendment No.&#160;2 to Bonnie Anderson Employment Agreement, effective as of March&#160;11, 2009, between Bonnie Anderson and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">333-191282</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.12</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/20/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.14#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000100/vcyt-06302019xex101.htm"><span style="font-family:inherit;font-size:10pt;">Services and Separation Agreement, effective April 22, 2019, between Christopher M. Hall and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.15#</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex1015.htm"><span style="font-family:inherit;font-size:10pt;">Offer Letter dated as of March 5, 2008 with Giulia Kennedy</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.16#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex1016.htm"><span style="font-family:inherit;font-size:10pt;">Offer Letter dated as of August 9, 2011 with John Hanna</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.17&#8224;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000046/vcyt-03312019xex101.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Pathology Services Agreement dated as of February 14, 2019 between Thyroid Cytopathology Partners, P.A. and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.18</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410118000006/vcyt-12312017xex1019.htm"><span style="font-family:inherit;font-size:10pt;">Loan and Security Agreement dated as of November 3, 2017 between Silicon Valley Bank and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.19</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/27/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.19#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410118000006/vcyt-12312017exx1020.htm"><span style="font-family:inherit;font-size:10pt;">Offer Letter dated as of November 17, 2016 with Keith Kennedy</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.20</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/27/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.20</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410118000026/vcyt-03312018xex10.htm"><span style="font-family:inherit;font-size:10pt;">Form of Performance Stock Unit</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5/1/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.21#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000100/vcyt-06302019xex102.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Change in Control and Severance Agreement, effective July 1, 2019 between Bonnie Anderson and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.22#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000100/vcyt-06302019xex103.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Change in Control and Severance Agreement, effective July 1, 2019 between Keith Kennedy and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.3</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.23#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000100/vcyt-06302019xex104.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Change in Control and Severance Agreement, effective July 1, 2019 between Giulia Kennedy and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.4</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.24#</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000100/vcyt-06302019xex105.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Change in Control and Severance Agreement, effective July 1, 2019 between John Hanna and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.5</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.25&#8224;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000010/vcyt-12312018xex1023.htm"><span style="font-family:inherit;font-size:10pt;">Diagnostic Development Agreement, dated December 28, 2018, between Johnson &amp; Johnson Services, Inc. and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.22</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/25/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">113</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:9%;"></td><td style="width:43%;"></td><td style="width:10%;"></td><td style="width:11%;"></td><td style="width:8%;"></td><td style="width:10%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incorporated by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.26&#8224;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000146/vcyt-12320198xkxex21.htm"><span style="font-family:inherit;font-size:10pt;">License and Asset Purchase Agreement, dated December 3, 2019, between NanoString Technologies, Inc. and the Registrant</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/3/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.27</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1384101/000138410119000146/vcyt-12320198xkxex41.htm"><span style="font-family:inherit;font-size:10pt;">Registration Rights Schedule, dated December 3, 2019</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">001-36156</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/3/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex211.htm"><span style="font-family:inherit;font-size:10pt;">List of Subsidiaries</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex231.htm"><span style="font-family:inherit;font-size:10pt;">Consent of Independent Registered Public Accounting Firm</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCEB843679FBE48109975428B10815692"><span style="font-family:inherit;font-size:10pt;">Power of Attorney (see the signature page of this Annual Report on Form&#160;10-K)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex311.htm"><span style="font-family:inherit;font-size:10pt;">Principal Executive Officer&#8217;s Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex312.htm"><span style="font-family:inherit;font-size:10pt;">Principal Financial Officer&#8217;s Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1*</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex321.htm"><span style="font-family:inherit;font-size:10pt;">Certification Pursuant to 18 U.S.C. &#167;&#160;1350 (Section&#160;906 of the Sarbanes-Oxley Act of 2002)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.2*</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-12312019xex322.htm"><span style="font-family:inherit;font-size:10pt;">Certification Pursuant to 18 U.S.C. &#167;&#160;1350 (Section&#160;906 of the Sarbanes-Oxley Act of 2002)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.INS</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Instance Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.SCH</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Schema</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.CAL </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.DEF</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Definition Linkbase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.LAB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Label Linkbase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">_____________________________________________</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:5%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicates management contract or compensatory plan or arrangement.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with Item&#160;601(b)(32)(ii) of Regulation&#160;S-K and SEC Release No.&#160;34-47986, the certifications furnished in Exhibits&#160;32.1 and 32.2 hereto are deemed to accompany this Form&#160;10-K and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the registrant specifically incorporates it by reference.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Registrant is requesting or has previously been granted confidential treatment with respect to certain portions of this Exhibit.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Copies of the above exhibits not contained herein are available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Veracyte,&#160;Inc., 6000 Shoreline Court, Suite&#160;300, South San Francisco, California 94080.</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial Statement Schedules</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reference is made to Item&#160;15(a) 2 above.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">114</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0CF504962AE5827E5F42428B105F93F4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sEFDB29A731B62A077FF4428B070FCFF4"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sCEB843679FBE48109975428B10815692"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:5%;"></td><td style="width:5%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VERACYTE,&#160;INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;BONNIE H. ANDERSON</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bonnie H. Anderson</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chairman and Chief Executive Officer</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: </span><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">POWER OF ATTORNEY</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Bonnie H. Anderson and Keith Kennedy, and each of them, his true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this annual report on Form&#160;10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons, on behalf of the registrant on the dates and the capacities indicated.</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:37%;"></td><td style="width:4%;"></td><td style="width:37%;"></td><td style="width:4%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Signature</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Title</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;BONNIE H. ANDERSON</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer (Principal Executive Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bonnie H. Anderson</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;KEITH KENNEDY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer (Principal Financial  Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Keith Kennedy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;JOHN L. BISHOP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lead Independent Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">John L. Bishop</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;FRED E. COHEN, M.D., D.PHIL.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fred E. Cohen, M.D., D.Phil.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;KARIN EASTHAM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Karin Eastham</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;ROBERT S. EPSTEIN</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Robert S. Epstein</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;KEVIN K. GORDON</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Kevin K. Gordon</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;EVAN JONES</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Evan Jones</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;TINA S. NOVA, PH.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tina S. Nova, Ph.D.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">115</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>vcyt-12312019xex42.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s809bcce5d45343148322425fdc3561c4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 4.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of December 31, 2019, Veracyte, Inc.  (the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;our&#8221;) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;): our common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following description summarizes the most important terms of our capital stock and certain provisions of our restated certificate of incorporation and restated bylaws. Because it is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our restated certificate of incorporation and amended and restated bylaws, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.2 is a part, and to the provisions of applicable Delaware law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Authorized Capital Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our authorized capital stock consists of 125,000,000 shares of common stock, $0.001 par value per share and 5,000,000 shares of undesignated preferred stock, $0.001 par value per share.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Common Stock </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Dividend Rights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available at the times and in the amounts that our board of directors may determine from time to time.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Voting Rights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each holder of common stock is entitled to one vote per share on all matters submitted to a vote of stockholders. We do not provide for cumulative voting in the election of directors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">No Preemptive or Similar Rights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Holders of common stock have no preemptive or conversion rights or other subscription rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Right to Receive Liquidation Distributions</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon our liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding preferred stock.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fully Paid and Nonassessable</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All of our outstanding shares of common stock are fully paid and non-assessable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Preferred Stock </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our board of directors is authorized, subject to limitations prescribed by Delaware law, without further action by our stockholders, to issue from time to time up to 5,000,000&#160;shares of preferred stock in one or more series, to establish the number of shares to be included in each series and fix the powers, preferences and rights of the shares of each wholly unissued series and any of its qualifications, limitations or restrictions. Our board of directors can also increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding, without any further vote or action by the stockholders. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of common stock or </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">adversely affect the rights and powers, including voting rights, of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company, which could depress the market price of our common stock. We have no current plans to issue any shares of preferred stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Anti-Takeover Effects of Delaware Law and Our Restated Certificate of Incorporation and Bylaws</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain provisions of Delaware law, our restated certificate of incorporation and our amended and restated bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of our company. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of our company to first negotiate with our board of directors.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our restated certificate of incorporation and amended and restated bylaws include a number of provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our management team, including the following:</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of undesignated preferred stock.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our amended and restated bylaws further provide that special meetings of our stockholders may be called only by a majority of our board of directors, our chairman of the board, or our chief executive officer.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our amended and restated bylaws provide advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our restated certificate of incorporation and amended and restated bylaws provide that our board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with each class serving staggered terms.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our restated certificate of incorporation provides that our directors may be removed only for cause.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our restated certificate of incorporation and amended and restated bylaws provide that vacancies on our board of directors may, except as otherwise required by law, be filled only by a majority of directors then in office, even if less than a quorum;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our restated certificate of incorporation provides that no stockholder is permitted to cumulate votes at any election of directors.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our restated certificate of incorporation and amended and restated bylaws require a super-majority of votes to amend certain of the above-mentioned provisions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Delaware Law</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, </font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Section 203 defines a business combination to include: </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">subject to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Choice of Forum</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provisions of the Delaware General Corporation Law, our restated certificate of incorporation or our restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. This exclusive forum provision will not apply to claims that are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not preclude the filing of claims brought to enforce any liability or duty created by the Exchange Act or Securities Act or the rules and regulations thereunder in federal court.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Transfer Agent and Registrar</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Listing</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our common stock is traded on The Nasdaq Global Market under the symbol "VCYT".</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>vcyt-12312019xex1015.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9136b446058d46f8b492f511c117fa8f"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:right;padding-left:582px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 10.15</font></div><div style="line-height:120%;padding-top:4px;text-align:right;padding-left:582px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:434px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">VERACYTE,  INC.</font></div><div style="line-height:120%;text-align:left;padding-left:434px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7000 SHORELINE CT., SUITE 250 SOUTH SAN FRANCISCO, CA</font></div><div style="line-height:120%;text-align:left;padding-left:434px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;94080</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 5, 2008</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Giulia Kennedy, Ph.D. 360 Castenada Avenue San Francisco, CA 94116</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dear Giulia,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">We are uniformly impressed with your abilities and experience, and we are excited to extend an offer of employment. We hope you find the opportunity to be compelling and we look forward to having you join us as a member of our founding executive team  We believe we can provide an environment in which you may continue your professional growth while making key contributions to the success of Veracyte. We are, therefore, pleased to offer you the position of Senior Vice President, Research </font><font style="font-family:Arial;font-size:11pt;">&amp; </font><font style="font-family:inherit;font-size:10pt;">Development. Your responsibilities focus primarily on managing the Company's research and development efforts, and ensuring that the Company's goals are met.    </font><font style="font-family:Arial;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">this role, you will report to me. You should note that the Company may modify job titles and reporting relationships from time to time as it deems necessa1y.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms of this offer are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:61px;text-indent:-23px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.   You will receive a salary of $18,750 per month less all applicable taxes and withholdings, which will be paid in accordance with Veracyte's established payroll schedule, presently semi-monthly.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You will be eligible to receive certain benefits routinely provided to Veracyte employees, which benefits may be changed from time to time. Presently, these include medical, dental and vision, and participation in the Company's 401(k) plan as soon as it is in place, all of which will be further detailed in a separate conversation with Human Resources.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You will be eligible for paid time off and company paid holidays in accordance with Veracyte's established policies.  These and other policies are explained fully in the Company's employee handbook.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Board of Directors has agreed to offer significant equity participation to the members of its founding team Consistent with this philosophy, if you decide to join the Company, you will be granted the option to purchase one percent (1%) of the fully diluted outstanding shares of the Common Stock of Veracyte as recommended and approved by the Company's Board of Directors at its next regularly scheduled meeting following your hire date. The price per share will be equal to the fair market value of the Common Stock on the date of grant, as determined by the Company's Board of Directors.  The vesting schedule will be &#188; of the shares vesting on the first anniversa1y of your employment, and then 1/48 of the shares vesting each month for the next 36 months.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:62px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with Federal immigration law, you will be required to provide the Company documentary evidence of your identity and eligibility for employment in the United States.  This</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:center;padding-left:170px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">I</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">documentation must be provided to the Company within three (3) business days of your date of hire, or the Company may terminate its employment relationship with you.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:73px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the law, employment with the Company is at-will, and may be terminated at any time by you or the Company, with or without cause and with or without notice.  However, </font><font style="font-family:Arial;font-size:11pt;">if </font><font style="font-family:inherit;font-size:10pt;">employment is terminated by you, the Company requests that you provide a minimum two weeks' notice, or as much notice as possible.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:73px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Employment with the Company </font><font style="font-family:Arial;font-size:11pt;">is </font><font style="font-family:inherit;font-size:10pt;">contingent upon your signature of, and compliance with, its At-Will Employment, Confidential Information and Invention Assignment   and Arbitration Agreement which requires, among other provisions, the assignment of patent rights to any invention made during your employment with the Company, as well as non-disclosure of Company proprietary information.  This agreement outlines, among other provisions, a 1&#183;equirement for resolution by binding arbitration of any dispute arising out of OUI" employment relationship.  This arbitration requirement is described in detail in the aforementioned</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">agreement, a copy of which is enclosed with this offer.  A signed copy of this agreement must be received by the Company prior to your first day of employment.</font></div><div style="line-height:120%;text-align:left;padding-left:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To accept the Company's offer, please sign and date this letter in the space provided below.   A duplicate original is enclosed for your records.  This offer of employment expires on March 21, 2008.  </font><font style="font-family:Arial;font-size:10pt;">If </font><font style="font-family:inherit;font-size:10pt;">you accept our offer, your start date is anticipated to be no later than April 21, 2008. This letter, together with any agreements 1&#183;elating to proprietary tights as herein described, sets forth the terms of your employment</font></div><div style="line-height:120%;text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">with the Company, and supersedes any prior representations or agreements including, but not limited to, any representations made during your recruitment, interviews or pre-employment negotiations, whether written or oral.  This letter including, but not limited to, its at-will employment provision, may not be modified or amended except by written agreement signed by an Officer of the Company and you.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:20px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We look forward to your acceptance of this offer, and to working with you at Veracyte, Inc.  </font><font style="font-family:Arial;font-size:10pt;">If </font><font style="font-family:inherit;font-size:10pt;">you have any questions about this offer or its terms, please feel free to contact me directly at 760-889-7755, or Michele Benjamin (Human Resources) at 707-266-8907.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:31.8359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sincerely,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Bonnie Anderson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bonnie Anderson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:162px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:30%;"></td><td style="width:70%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Agreed to and accepted:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signature:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Giulia Kennedy</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Printed Name:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Giulia Kennedy</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/10/08</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enclosures:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Duplicate Original letter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>4
<FILENAME>vcyt-12312019xex1016.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8140d0c211bb4ac29a525c4d035ac5d0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.16</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Veracyte</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">August 9, 2011</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">John Hanna</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7118 Bonita Drive, Suite 402 Miami Beach, FL  33141</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dear John:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are uniformly impressed with your abilities and experience, and we are excited to extend an offer of employment. We hope you find the opportunity to be compelling and we look forward to having you join us. We believe we can provide an environment in which you may continue your professional growth while making key contributions to the success of Veracyte. We are, therefore, pleased to offer you the position of Director of Global Health Care Policy &amp; Governmental Affairs. Your responsibilities will broadly cover driving Veracyte's efforts for insurance policies to cover our Afirma product, leading the understanding of changes to insurance policies, and creating plans to respond to them. This role will help the company achieve both short and long term business objectives. In this role, you will report to Chris Hall, Chief Commercial Officer. You should note that the Company may modify job titles and reporting relationships from time to time as it deems necessary.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The terms of this offer are as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">You will receive a base salary of $130,000.00 per year ($5,416</font><font style="font-family:inherit;font-size:9pt;">.</font><font style="font-family:Arial;font-size:9pt;">67 per pay period), less all applicable taxes and withholdings paid in accordance with Veracyte's established payroll schedule, presently semi&#173; monthly.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">You will receive a bonus of 1</font><font style="font-family:inherit;font-size:9pt;">.</font><font style="font-family:Arial;font-size:9pt;">5 cents for every ten new covered lives in the U</font><font style="font-family:inherit;font-size:9pt;">.</font><font style="font-family:Arial;font-size:9pt;">S., paid semi&#173; annually in July and January based on the previous six months. The bonus will be calculated by determining the </font><font style="font-family:Arial;font-size:9pt;font-style:italic;">growth in covered lives, </font><font style="font-family:Arial;font-size:9pt;">which is the</font><font style="font-family:inherit;font-size:9pt;">.</font><font style="font-family:Arial;font-size:9pt;">&#32;difference between the number of commercial</font><font style="font-family:inherit;font-size:9pt;">,</font><font style="font-family:Arial;font-size:9pt;">&#32;Medicaid and Medicare Advantage lives for which a positive coverage determination is achieved at the beginning of the bonus period and the end of the period. Medicare fee-for-service lives will be excluded from the bonus plan unless you have a significant role in supporting the team in achieving a positive coverage determination for the Medicare population.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">You will be eligible for medical, dental and vision benefits, and participation in the Company's 401(k) plan, which will be further detailed in a separate conversation with Human Resources.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">You will be eligible for paid time off and company paid holidays in accordance with Veracyte's established policies. These and other policies are explained fully in the Company's employee handbook.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">The Company's Board of Directors has agreed to offer significant equity participation to the members of its founding team. Consistent with this philosophy, if you decide to join the Company, you will be granted the option to purchase 65,000 shares of the Common Stock of Veracyte as recommended and approved by the Company's Board of Directors at its next regularly scheduled meeting following commencement of your full-time employment with Veracyte.  The price per share will be equal to the fair market value of the Common Stock on the date of grant, as determined by the Company's Board  of Directors. The vesting schedule will be 1/4 of the shares vesting on the first anniversary of your employment, and then 1/48 of the shares vesting each month for the next 36 months.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">In accordance with Federal immigration law, you will be required to provide the Company documentary evidence of your identity and eligibility for employment in the United States. This documentation must be provided to the Company within three (3) business days of your date of hire, or the Company may terminate its employment relationship with you.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">In accordance with the law, employment with the Company is at-will, and may be terminated at any time by you or the Company, with or without cause and with or without notice.  However, if employment is terminated by you, the Company requests that you provide a minimum two weeks' notice, or as much notice as possible.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Employment with the Company is contingent upon your signature of, and compliance with, its At-Will Employment, Confidential Information and Invention Assignment  and Arbitration Agreement which requires, among other provisions, the assignment of patent rights to any invention made during your employment with the Company, as well as non-disclosure of Company proprietary information. This agreement outlines, among other provisions, a requirement for resolution by binding arbitration of any dispute arising out of our employment relationship.  This arbitration requirement is described in detail in the aforementioned agreement, a copy of which is enclosed with this offer. A signed copy of this agreement must be received by the Company prior to your first day of employment.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">To accept the Company's offer, please sign and date this letter in the space provided below; a duplicate original is enclosed for your records.  This offer expires Tuesday, August 16, 2011. Your start date is to be determined, but preferably no later than Tuesday, September 6, 2011</font><font style="font-family:inherit;font-size:9pt;">.</font><font style="font-family:Arial;font-size:9pt;">&#32;This letter, together with any agreements relating to proprietary rights as herein described, sets forth the terms of your employment with the Company, and supersedes any prior representations or agreements including, but not limited to, any representations made during your recruitment, interviews or pre-employment negotiations, whether written or oral. This letter including, but not limited to, its at-will employment provision, may not be modified or amended except by written agreement signed by an Officer of the Company and you.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We look forward to your acceptance of this offer, and to working with you at Veracyte, Inc.  If you have any questions about this offer or its terms, please feel free to contact me directly at 650-243-6302.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:31.8359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sincerely,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Bonnie Anderson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bonnie Anderson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:162px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:30%;"></td><td style="width:70%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Agreed to and accepted:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signature:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John Hanna</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Printed Name:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John Hanna</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/12/11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enclosures:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Duplicate Original letter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company Confidential</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>vcyt-12312019xex211.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5e8ed177f00d40ca93f0dd7530041d18"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 21.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Veracyte, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">List of Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:46%;"></td><td style="width:54%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Entity Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jurisdiction of Incorporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Veracyte International Corp.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Delaware</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>vcyt-12312019xex231.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s323AF5FEF5905AEE94C0428B202066B7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;23.1&#160;</font><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Forms S-8 Nos.&#160;333&#8209;191992, 333-203097, 333-210185, 333-216388, 333-223292, and 333-229848) pertaining to the 2008 Stock Plan and 2013 Stock Incentive Plan of Veracyte, Inc., </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-205206) pertaining to the Employee Stock Purchase Plan of Veracyte, Inc., and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Forms S-3 Nos. 333-204368, 333-205204, 333-224576, 333-231153, and 333-231173) of Veracyte, Inc.&#894; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our reports dated February 25, 2020, with respect to the consolidated financial statements of Veracyte, Inc. and the effectiveness of internal control over financial reporting of Veracyte, Inc. included in this Annual Report (Form 10-K) of Veracyte, Inc. for the year ended December 31, 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>vcyt-12312019xex311.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFBDBF5B634814CD1C9CC428B20C677A8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRINCIPAL EXECUTIVE OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Bonnie H. Anderson, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;I have reviewed this annual report on Form&#160;10-K of Veracyte,&#160;Inc.:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Bonnie H. Anderson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bonnie H. Anderson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chairman and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>vcyt-12312019xex312.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBDF556A3B9C500490E18428B216DF4F5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRINCIPAL FINANCIAL OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Keith Kennedy, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;I have reviewed this annual report on Form&#160;10-K of Veracyte,&#160;Inc.;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-left:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Keith Kennedy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Keith Kennedy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer and Chief Operating Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>vcyt-12312019xex321.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s097AFFC0F97134953B7D428B2214F4E4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1&#160;</font><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION&#160;1350,</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002&#160;</font><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with the annual report of Veracyte,&#160;Inc. (the "Company") on Form&#160;10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowledge:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Bonnie H. Anderson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bonnie H. Anderson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chairman and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>vcyt-12312019xex322.htm
<DESCRIPTION>VCYT - 2019 10-K EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC4AA7B75B6CDA124535D428B22BB97D1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.2</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION&#160;1350,</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002&#160;</font><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with the annual report of Veracyte,&#160;Inc. (the "Company") on Form&#160;10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowledge:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Keith Kennedy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Keith Kennedy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer and Chief Operating Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>vcyt-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.veracyte.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:vcyt="http://www.veracyte.com/20191231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="A401KPlan" roleURI="http://www.veracyte.com/role/A401KPlan">
        <link:definition>2116100 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401KPlanDetails" roleURI="http://www.veracyte.com/role/A401KPlanDetails">
        <link:definition>2416401 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.veracyte.com/role/BalanceSheetComponents">
        <link:definition>2105100 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>2405406 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>2405404 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails">
        <link:definition>2405403 - Disclosure - Balance Sheet Components - Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsFutureAmortizationDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails">
        <link:definition>2405405 - Disclosure - Balance Sheet Components - Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsPropertyAndEquipmentNetDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails">
        <link:definition>2405402 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsTables">
        <link:definition>2305301 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombination" roleURI="http://www.veracyte.com/role/BusinessCombination">
        <link:definition>2104100 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationDetails" roleURI="http://www.veracyte.com/role/BusinessCombinationDetails">
        <link:definition>2404402 - Disclosure - Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationProFormaFinancialInformationDetails" roleURI="http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails">
        <link:definition>2404405 - Disclosure - Business Combination - Pro forma financial information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>2404403 - Disclosure - Business Combination - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" roleURI="http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails">
        <link:definition>2404404 - Disclosure - Business Combination - Schedule of Identifiable Acquisition-Related Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationTables" roleURI="http://www.veracyte.com/role/BusinessCombinationTables">
        <link:definition>2304301 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.veracyte.com/role/CommitmentsAndContingencies">
        <link:definition>2107100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesOperatingLeaseDetails" roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails">
        <link:definition>2407402 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesOperatingLeaseDetailsCalc2" roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetailsCalc2">
        <link:definition>2407402 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2307301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.veracyte.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1003000 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>1003501 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.veracyte.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.veracyte.com/role/Debt">
        <link:definition>2108100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCreditAgreementDetails" roleURI="http://www.veracyte.com/role/DebtCreditAgreementDetails">
        <link:definition>2408404 - Disclosure - Debt - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.veracyte.com/role/DebtInterestExpenseDetails">
        <link:definition>2408405 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLoanAndSecurityAgreementDetails" roleURI="http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails">
        <link:definition>2408402 - Disclosure - Debt - Loan and Security Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleOfLoanAndSecurityAgreementDetails" roleURI="http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails">
        <link:definition>2408403 - Disclosure - Debt - Schedule of Loan and Security Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.veracyte.com/role/DebtTables">
        <link:definition>2308301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.veracyte.com/role/FairValueMeasurements">
        <link:definition>2106100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.veracyte.com/role/FairValueMeasurementsDetails">
        <link:definition>2406401 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.veracyte.com/role/IncomeTaxes">
        <link:definition>2115100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2415402 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2415404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxExaminationDetails" roleURI="http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails">
        <link:definition>2415406 - Disclosure - Income Taxes - Income Tax Examination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.veracyte.com/role/IncomeTaxesTables">
        <link:definition>2315301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxProvisionDetails" roleURI="http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails">
        <link:definition>2415403 - Disclosure - Income Taxes - Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUncertainTaxPositionsDetails" roleURI="http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails">
        <link:definition>2415405 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.veracyte.com/role/NetLossPerShare">
        <link:definition>2103100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://www.veracyte.com/role/NetLossPerShareDetails">
        <link:definition>2403402 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.veracyte.com/role/NetLossPerShareTables">
        <link:definition>2303301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusiness" roleURI="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusinessDetails" roleURI="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails">
        <link:definition>2401401 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2120100 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedDetails" roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails">
        <link:definition>2420402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2320301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlans" roleURI="http://www.veracyte.com/role/StockIncentivePlans">
        <link:definition>2112100 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansActivityUnderStockOptionPlansDetails" roleURI="http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails">
        <link:definition>2412403 - Disclosure - Stock Incentive Plans - Activity Under Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansAdditionalInformationDetails" roleURI="http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails">
        <link:definition>2412404 - Disclosure - Stock Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansStockBasedCompensationDetails" roleURI="http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails">
        <link:definition>2412406 - Disclosure - Stock Incentive Plans - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansStockIncentivePlansEsppDetails" roleURI="http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails">
        <link:definition>2412405 - Disclosure - Stock Incentive Plans Stock Incentive Plans - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansStockOptionPlansDetails" roleURI="http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails">
        <link:definition>2412402 - Disclosure - Stock Incentive Plans - Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansTables" roleURI="http://www.veracyte.com/role/StockIncentivePlansTables">
        <link:definition>2312301 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.veracyte.com/role/StockholdersEquity">
        <link:definition>2111100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.veracyte.com/role/StockholdersEquityDetails">
        <link:definition>2411402 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.veracyte.com/role/StockholdersEquityTables">
        <link:definition>2311301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Credit Risk, Restricted Cash, and Allowance for Doubtful Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Diagnostic Development Agreement with Johnson &amp; Johnson (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets, Bonus Accruals, and Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesLiquidityDetails" roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ThyroidCytopathologyPartners" roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartners">
        <link:definition>2114100 - Disclosure - Thyroid Cytopathology Partners</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ThyroidCytopathologyPartnersDetails" roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails">
        <link:definition>2414401 - Disclosure - Thyroid Cytopathology Partners (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="vcyt_AZCollaborationLicenseMember" name="AZCollaborationLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_AutomaticRenewalPeriodContractAgreement" name="AutomaticRenewalPeriodContractAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_BiopharmaceuticalCompanyMember" name="BiopharmaceuticalCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_BiopharmaceuticalMember" name="BiopharmaceuticalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_BusinessCombinationContingentConsiderationCashtobePaid" name="BusinessCombinationContingentConsiderationCashtobePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_CollaborationMember" name="CollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_CommonStockAbstract" name="CommonStockAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" name="CommonStockCapitalAdditionalSharesReservedForFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract" name="ComponentsOfDeferredTaxAssetsNonCurrentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract" name="ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_ConcentrationRiskAbstract" name="ConcentrationRiskAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" name="ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ContractAgreementConditionalAccountsReceivable" name="ContractAgreementConditionalAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vcyt_ContractAgreementFeePercentageOfCashCollections" name="ContractAgreementFeePercentageOfCashCollections" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ContractAgreementReceivableForServices" name="ContractAgreementReceivableForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DebtInstrumentEndOfTermInterestObligationAmount" name="DebtInstrumentEndOfTermInterestObligationAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_DebtInstrumentEndOfTermPaymentInterestAmount" name="DebtInstrumentEndOfTermPaymentInterestAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DebtInstrumentFixedRatePercentagePaidInCash" name="DebtInstrumentFixedRatePercentagePaidInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DebtInstrumentInterestPaidInKindPercentage" name="DebtInstrumentInterestPaidInKindPercentage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DebtInstrumentNumberOfInstallments" name="DebtInstrumentNumberOfInstallments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne" name="DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_DebtInstrumentPrepaymentPremium" name="DebtInstrumentPrepaymentPremium" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="vcyt_DebtPaymentTrancheDomain" name="DebtPaymentTrancheDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_DebtPrepaymentTrancheAxis" name="DebtPrepaymentTrancheAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_DebtPrepaymentTrancheOneMember" name="DebtPrepaymentTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_DebtPrepaymentTrancheThreeMember" name="DebtPrepaymentTrancheThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_DebtPrepaymentTrancheTwoMember" name="DebtPrepaymentTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty" name="DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther" name="DeferredTaxAssetsAccrualsDeferredRentAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DeferredTaxLiabilitiesRightofUseAssets" name="DeferredTaxLiabilitiesRightofUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="vcyt_DepreciationandAmortizationofTangibleAssets" name="DepreciationandAmortizationofTangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_DevelopedProductTechnologyMember" name="DevelopedProductTechnologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_DevelopmentPrograms" name="DevelopmentPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" name="EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_EmployeeAndNonEmployeeStockOptionMember" name="EmployeeAndNonEmployeeStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_EmployeeStockOptionExcludingBonusCompensationMember" name="EmployeeStockOptionExcludingBonusCompensationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization" name="FinanceLeaseRightofUseAssetAccumulatedAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization" name="FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="vcyt_FulfillmentofObligationsMember" name="FulfillmentofObligationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" name="HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_IncentiveStockOptionsMember" name="IncentiveStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_IncomeTaxExaminationPeriod" name="IncomeTaxExaminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" name="IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities" name="IncreaseDecreaseinOperatingLeaseAssetsandLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_InitialTermLoanMember" name="InitialTermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_JohnsonandJohnsonServicesInc.Member" name="JohnsonandJohnsonServicesInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_LaboratoryFacilitiesAustinTexasMember" name="LaboratoryFacilitiesAustinTexasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax" name="LegalSettlementRegardingShortSwingProfitsNetOfTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" name="LesseeLeasingArrangementsOperatingLeasesSpaceLeased" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_LiquidityLineItems" name="LiquidityLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_LiquidityRequirementMinimum" name="LiquidityRequirementMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="vcyt_MedicareMember" name="MedicareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_NCounterFLEXDxLicenseMember" name="NCounterFLEXDxLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_NanoStringMember" name="NanoStringMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_NonEmployeeStockOptionMember" name="NonEmployeeStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_NonStatutoryStockOptionsMember" name="NonStatutoryStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration" name="NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" name="NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="vcyt_NumberOfTermLoans" name="NumberOfTermLoans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="vcyt_OtherIncomeRentReimbursement" name="OtherIncomeRentReimbursement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_OtherStatesNotSeparatelyDisclosedMember" name="OtherStatesNotSeparatelyDisclosedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_OutsideDirectorMember" name="OutsideDirectorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember" name="OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember" name="OutsideDirectorWhoWasNotPreviouslyEmployeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_OvernightRepurchaseAgreementsMember" name="OvernightRepurchaseAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_PaymentOfEndOfTermObligation" name="PaymentOfEndOfTermObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_PerceptaTechnologyMember" name="PerceptaTechnologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_Perceptav.2andNassaRiskMember" name="Perceptav.2andNassaRiskMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_PrepaymentPenalty" name="PrepaymentPenalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_ProvisionofDataMember" name="ProvisionofDataMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_RevenueRecognizedOnAccrualBasis" name="RevenueRecognizedOnAccrualBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_RevenueRecognizedOnAccrualBasisPercentage" name="RevenueRecognizedOnAccrualBasisPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_RevenueRecognizedReceivedInCash" name="RevenueRecognizedReceivedInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="vcyt_RevenueRecognizedReceivedInCashPercentage" name="RevenueRecognizedReceivedInCashPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter" name="RevenueRemainingPerformanceObligationAmountPerQuarter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="vcyt_SalesRevenueGrossMember" name="SalesRevenueGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_ServicesAgreementAbstract" name="ServicesAgreementAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne" name="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock" name="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_SiliconValleyBankMember" name="SiliconValleyBankMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_StockIncentivePlan2013Member" name="StockIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement" name="StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" name="StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_StockPlan2008Member" name="StockPlan2008Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_TermContractAgreement" name="TermContractAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_TermOfDebtWithEqualQuarterlyInstallments" name="TermOfDebtWithEqualQuarterlyInstallments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_TestingMember" name="TestingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_UnitedHealthcareMember" name="UnitedHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vcyt_VisiumMember" name="VisiumMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vcyt_VotingRightsForEachShareOfStock" name="VotingRightsForEachShareOfStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>vcyt-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.veracyte.com/role/A401KPlan" xlink:href="vcyt-20191231.xsd#A401KPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/A401KPlanDetails" xlink:href="vcyt-20191231.xsd#A401KPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponents" xlink:href="vcyt-20191231.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsTables" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombination" xlink:href="vcyt-20191231.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationTables" xlink:href="vcyt-20191231.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingencies" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetailsCalc2" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingenciesOperatingLeaseDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesTables" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedBalanceSheets" xlink:href="vcyt-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="vcyt-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CoverPage" xlink:href="vcyt-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/Debt" xlink:href="vcyt-20191231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtCreditAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtCreditAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtInterestExpenseDetails" xlink:href="vcyt-20191231.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtTables" xlink:href="vcyt-20191231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurements" xlink:href="vcyt-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:href="vcyt-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxes" xlink:href="vcyt-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesIncomeTaxExaminationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesTables" xlink:href="vcyt-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesTaxProvisionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShare" xlink:href="vcyt-20191231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShareDetails" xlink:href="vcyt-20191231.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShareTables" xlink:href="vcyt-20191231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="vcyt-20191231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails" xlink:href="vcyt-20191231.xsd#OrganizationAndDescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlans" xlink:href="vcyt-20191231.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockIncentivePlansEsppDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockOptionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansTables" xlink:href="vcyt-20191231.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquity" xlink:href="vcyt-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:href="vcyt-20191231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityTables" xlink:href="vcyt-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:href="vcyt-20191231.xsd#ThyroidCytopathologyPartners" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:href="vcyt-20191231.xsd#ThyroidCytopathologyPartnersDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/A401KPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/A401KPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cddb4eb0-3110-27ee-28d5-5d7adef4fa0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cddb4eb0-3110-27ee-28d5-5d7adef4fa0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombination" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05d93b57-3f76-323b-8b13-07dc435183c2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2b45a640-6b3e-a8a9-fe33-8d916bef202d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05d93b57-3f76-323b-8b13-07dc435183c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2b45a640-6b3e-a8a9-fe33-8d916bef202d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05d93b57-3f76-323b-8b13-07dc435183c2" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C4ED003ACDF62736CFC77CA15904F828_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_C4ED003ACDF62736CFC77CA15904F828_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C4ED003ACDF62736CFC77CA15904F828_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_C4ED003ACDF62736CFC77CA15904F828_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_C4ED003ACDF62736CFC77CA15904F828_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C4ED003ACDF62736CFC77CA15904F828_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_C4ED003ACDF62736CFC77CA15904F828_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_4909d223-7980-3e65-3e19-5f45ac16b538" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_LongTermDebtCurrent_4909d223-7980-3e65-3e19-5f45ac16b538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueLeasesNetNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueLeasesNetNoncurrent_eda39f54-c937-d5aa-c36c-a9fc79b555d5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredRevenueLeasesNetNoncurrent_eda39f54-c937-d5aa-c36c-a9fc79b555d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_293ecac9-0396-b0f6-2701-a4671048537d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_293ecac9-0396-b0f6-2701-a4671048537d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_293ecac9-0396-b0f6-2701-a4671048537d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_293ecac9-0396-b0f6-2701-a4671048537d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae064a9e-7563-5fa2-95b8-bfe0f620685d" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae064a9e-7563-5fa2-95b8-bfe0f620685d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1571e7d6-d666-48e2-395f-6e58ea563df3" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1571e7d6-d666-48e2-395f-6e58ea563df3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty" xlink:label="loc_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_3638f621-5b82-d403-3102-c7eb78f1e8f3" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_3638f621-5b82-d403-3102-c7eb78f1e8f3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_596f4189-155d-4012-cbaf-764843162122" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_596f4189-155d-4012-cbaf-764843162122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_6687c399-d659-8227-25d6-c7eb78e1c17f" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_6687c399-d659-8227-25d6-c7eb78e1c17f" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities" xlink:label="loc_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_A84CEA7A98881319DCB949CB12D5FEF0" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_A84CEA7A98881319DCB949CB12D5FEF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_941cba82-eff1-a6cb-562a-fa169e3f9684" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_941cba82-eff1-a6cb-562a-fa169e3f9684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_505a1499-71a2-e5de-2af8-1565f94fa52c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_505a1499-71a2-e5de-2af8-1565f94fa52c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PaymentOfEndOfTermObligation" xlink:label="loc_vcyt_PaymentOfEndOfTermObligation_f8488bba-3198-f016-1217-c7eb78686672" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_vcyt_PaymentOfEndOfTermObligation_f8488bba-3198-f016-1217-c7eb78686672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_9234b981-6f7f-2ced-fbd2-4046d3fb1fb9" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_9234b981-6f7f-2ced-fbd2-4046d3fb1fb9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_b7e0679c-4684-33a3-1aa6-41b7f5823917" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_b7e0679c-4684-33a3-1aa6-41b7f5823917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_b362f93c-0412-ea6c-3d48-01ede1ed7f3f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostOfRevenue_b362f93c-0412-ea6c-3d48-01ede1ed7f3f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_731c29d0-c256-edba-6ba9-ec31b7c2ca7b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_SellingAndMarketingExpense_731c29d0-c256-edba-6ba9-ec31b7c2ca7b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_de285b79-f632-6a58-7309-c47895796efb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_AdjustmentForAmortization_de285b79-f632-6a58-7309-c47895796efb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostDirectMaterial" xlink:label="loc_us-gaap_CostDirectMaterial_2dee7c07-feda-01a7-e28f-174c4dc61c91" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostDirectMaterial_2dee7c07-feda-01a7-e28f-174c4dc61c91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/DebtCreditAgreementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8707b686-ab67-5afd-96da-fedb3cce1b93" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8707b686-ab67-5afd-96da-fedb3cce1b93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_a4567c23-eef7-473f-21b3-15ac8f57524e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_a4567c23-eef7-473f-21b3-15ac8f57524e" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:label="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_CBD8CE2AAB4A0F2C1BE37C91FF572986" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_CBD8CE2AAB4A0F2C1BE37C91FF572986" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PrepaymentPenalty" xlink:label="loc_vcyt_PrepaymentPenalty_756e758b-c0c9-d2a2-81d5-c7eb789d34c3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_vcyt_PrepaymentPenalty_756e758b-c0c9-d2a2-81d5-c7eb789d34c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_a4a8e3bb-2ee6-a2f3-d86b-f05bd98679a7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_a4a8e3bb-2ee6-a2f3-d86b-f05bd98679a7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_440d49bc-ab70-2673-3639-4fbbaa711932" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_440d49bc-ab70-2673-3639-4fbbaa711932" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentEndOfTermPaymentInterestAmount" xlink:label="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_252D435156B229D566BE7C9E2D504E72" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_252D435156B229D566BE7C9E2D504E72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_736d2dab-e6d0-241f-ea81-d597b26683aa" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_736d2dab-e6d0-241f-ea81-d597b26683aa" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:to="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_99c42ff1-c704-7b6b-59a2-e814ed399b28" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_99c42ff1-c704-7b6b-59a2-e814ed399b28" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxLiabilitiesRightofUseAssets" xlink:label="loc_vcyt_DeferredTaxLiabilitiesRightofUseAssets_4082652A5D0596882CB84046E4A22D0F" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_vcyt_DeferredTaxLiabilitiesRightofUseAssets_4082652A5D0596882CB84046E4A22D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_f72e6635-9781-4eeb-a34f-ac9dbd191546" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_f72e6635-9781-4eeb-a34f-ac9dbd191546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_f72e6635-9781-4eeb-a34f-ac9dbd191546" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="loc_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_52df70bc-dda5-2c71-622d-c7eb789aae56" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_f72e6635-9781-4eeb-a34f-ac9dbd191546" xlink:to="loc_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_52df70bc-dda5-2c71-622d-c7eb789aae56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de5e795f-0165-d088-d22e-d01ff8d44317" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_f72e6635-9781-4eeb-a34f-ac9dbd191546" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de5e795f-0165-d088-d22e-d01ff8d44317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1ccc1eb-ffbd-3ad3-bc7a-09819cccad11" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_f72e6635-9781-4eeb-a34f-ac9dbd191546" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1ccc1eb-ffbd-3ad3-bc7a-09819cccad11" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="loc_vcyt_DeferredTaxAssetsOperatingLeaseLiability_2A74F7DC2D4CE68AAA9F4045E1BF90AF" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_f72e6635-9781-4eeb-a34f-ac9dbd191546" xlink:to="loc_vcyt_DeferredTaxAssetsOperatingLeaseLiability_2A74F7DC2D4CE68AAA9F4045E1BF90AF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther" xlink:label="loc_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_179d2f3f-afbe-4069-3616-c7eb7899baf5" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_f72e6635-9781-4eeb-a34f-ac9dbd191546" xlink:to="loc_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_179d2f3f-afbe-4069-3616-c7eb7899baf5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_b75b8d15-ac48-13ee-d8ed-83ab59a98edd" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_b75b8d15-ac48-13ee-d8ed-83ab59a98edd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c7e16b8-0aa9-c1c4-f1b1-272374ca83dc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c7e16b8-0aa9-c1c4-f1b1-272374ca83dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f57a32ed-0dd0-7e89-043f-8fdc81833b87" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f57a32ed-0dd0-7e89-043f-8fdc81833b87" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" xlink:label="loc_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_81cfea37-3a1d-744a-3afd-c7eb7889341b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_81cfea37-3a1d-744a-3afd-c7eb7889341b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_293be6dc-6bee-7ef3-e6e4-ebd60965ac94" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_293be6dc-6bee-7ef3-e6e4-ebd60965ac94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_8aacea24-b78b-d0a4-5334-45b52d9eb0b2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_8aacea24-b78b-d0a4-5334-45b52d9eb0b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2998d3ea-3247-4459-9f66-28bd5dfb1499" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2998d3ea-3247-4459-9f66-28bd5dfb1499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_c4fdeb46-4aee-508e-a0bc-a3b116ae2542" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_c4fdeb46-4aee-508e-a0bc-a3b116ae2542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0223de0-196e-53c5-0690-f9f0d2ab9105" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0223de0-196e-53c5-0690-f9f0d2ab9105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_05cc23a1-95bf-5dfd-ffdf-58b097230187" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_05cc23a1-95bf-5dfd-ffdf-58b097230187" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/NetLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c9d834bf-f438-2496-f972-a3b581d35a37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_922768c9-f90f-e497-0ea9-311e9212e227" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c9d834bf-f438-2496-f972-a3b581d35a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_922768c9-f90f-e497-0ea9-311e9212e227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_21bb64a8-3c45-dc12-3204-b1ada4c8bec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c9d834bf-f438-2496-f972-a3b581d35a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_21bb64a8-3c45-dc12-3204-b1ada4c8bec6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedReceivedInCash" xlink:label="loc_vcyt_RevenueRecognizedReceivedInCash_4f086a30-2feb-15b1-6dfc-c7eb78c2ae2c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:to="loc_vcyt_RevenueRecognizedReceivedInCash_4f086a30-2feb-15b1-6dfc-c7eb78c2ae2c" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedOnAccrualBasis" xlink:label="loc_vcyt_RevenueRecognizedOnAccrualBasis_01f2fe6f-9536-3c8f-2cab-c7eb7873e322" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:to="loc_vcyt_RevenueRecognizedOnAccrualBasis_01f2fe6f-9536-3c8f-2cab-c7eb7873e322" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>vcyt-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.veracyte.com/role/A401KPlan" xlink:href="vcyt-20191231.xsd#A401KPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/A401KPlanDetails" xlink:href="vcyt-20191231.xsd#A401KPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponents" xlink:href="vcyt-20191231.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsTables" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombination" xlink:href="vcyt-20191231.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationTables" xlink:href="vcyt-20191231.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingencies" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesTables" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedBalanceSheets" xlink:href="vcyt-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="vcyt-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CoverPage" xlink:href="vcyt-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/Debt" xlink:href="vcyt-20191231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtCreditAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtCreditAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtInterestExpenseDetails" xlink:href="vcyt-20191231.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtTables" xlink:href="vcyt-20191231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurements" xlink:href="vcyt-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:href="vcyt-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxes" xlink:href="vcyt-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesIncomeTaxExaminationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesTables" xlink:href="vcyt-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesTaxProvisionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShare" xlink:href="vcyt-20191231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShareDetails" xlink:href="vcyt-20191231.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShareTables" xlink:href="vcyt-20191231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="vcyt-20191231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails" xlink:href="vcyt-20191231.xsd#OrganizationAndDescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlans" xlink:href="vcyt-20191231.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockIncentivePlansEsppDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockOptionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansTables" xlink:href="vcyt-20191231.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquity" xlink:href="vcyt-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:href="vcyt-20191231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityTables" xlink:href="vcyt-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:href="vcyt-20191231.xsd#ThyroidCytopathologyPartners" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:href="vcyt-20191231.xsd#ThyroidCytopathologyPartnersDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/A401KPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/A401KPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_545C56F3B00AE7FF944064AA520C2906" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_545C56F3B00AE7FF944064AA520C2906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_545C56F3B00AE7FF944064AA520C2906" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_545C56F3B00AE7FF944064AA520C2906" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PerceptaTechnologyMember" xlink:label="loc_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopedProductTechnologyMember" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NCounterFLEXDxLicenseMember" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AZCollaborationLicenseMember" xlink:label="loc_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsLeasedToOthersMember" xlink:label="loc_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DepreciationandAmortizationofTangibleAssets" xlink:label="loc_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization" xlink:label="loc_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization" xlink:label="loc_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombination" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:to="loc_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:to="loc_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9D1A4EA8D0862820E006406A33989136" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9D1A4EA8D0862820E006406A33989136" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BusinessCombinationContingentConsiderationCashtobePaid" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0CD44592AC6DFC264CE27CA15951B1B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0CD44592AC6DFC264CE27CA15951B1B4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BE841F3AB685D91264157CA1594FD621" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:to="loc_srt_ProductOrServiceAxis_BE841F3AB685D91264157CA1594FD621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7DE76614A4342D47EB457CA1594F3F68_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_BE841F3AB685D91264157CA1594FD621" xlink:to="loc_srt_ProductsAndServicesDomain_7DE76614A4342D47EB457CA1594F3F68_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7DE76614A4342D47EB457CA1594F3F68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_BE841F3AB685D91264157CA1594FD621" xlink:to="loc_srt_ProductsAndServicesDomain_7DE76614A4342D47EB457CA1594F3F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7DE76614A4342D47EB457CA1594F3F68" xlink:to="loc_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5B1D7CCC4067F66C43FC7CA159507881" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5B1D7CCC4067F66C43FC7CA159507881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ACE7027C67299D935EF47CA159506B0B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5B1D7CCC4067F66C43FC7CA159507881" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ACE7027C67299D935EF47CA159506B0B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ACE7027C67299D935EF47CA159506B0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5B1D7CCC4067F66C43FC7CA159507881" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ACE7027C67299D935EF47CA159506B0B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_1F776B4A518710B6A59C7CA15950501F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ACE7027C67299D935EF47CA159506B0B" xlink:to="loc_vcyt_NanoStringMember_1F776B4A518710B6A59C7CA15950501F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0CD44592AC6DFC264CE27CA15951B1B4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_427CB7C730A7D4BED2E1654D90D873D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_427CB7C730A7D4BED2E1654D90D873D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_427CB7C730A7D4BED2E1654D90D873D0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_427CB7C730A7D4BED2E1654D90D873D0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopedProductTechnologyMember" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_C4C92328A619B6D46C45654D90D9E0DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_C4C92328A619B6D46C45654D90D9E0DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_CB04B6D1A3917A0A21A0654D90D958E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:to="loc_us-gaap_CustomerRelationshipsMember_CB04B6D1A3917A0A21A0654D90D958E4" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NCounterFLEXDxLicenseMember" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_C32EF969300094C7BA08654D90DA02C2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:to="loc_vcyt_NCounterFLEXDxLicenseMember_C32EF969300094C7BA08654D90DA02C2" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AZCollaborationLicenseMember" xlink:label="loc_vcyt_AZCollaborationLicenseMember_C2682D44404F8BB44F78654D90DA39E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:to="loc_vcyt_AZCollaborationLicenseMember_C2682D44404F8BB44F78654D90DA39E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0AE3C486E3FD934FD895654D90DA5A6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0AE3C486E3FD934FD895654D90DA5A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B14C40AD4B01B8D91938654D90DB9446_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0AE3C486E3FD934FD895654D90DA5A6B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B14C40AD4B01B8D91938654D90DB9446_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B14C40AD4B01B8D91938654D90DB9446" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0AE3C486E3FD934FD895654D90DA5A6B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B14C40AD4B01B8D91938654D90DB9446" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_FC3CED1B73E98E713EA3654D90E0818F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B14C40AD4B01B8D91938654D90DB9446" xlink:to="loc_vcyt_NanoStringMember_FC3CED1B73E98E713EA3654D90E0818F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_34F9A2DCD0B47D4BD2DA654D90E2F0CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:to="loc_us-gaap_Goodwill_34F9A2DCD0B47D4BD2DA654D90E2F0CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopedProductTechnologyMember" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NCounterFLEXDxLicenseMember" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="loc_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AZCollaborationLicenseMember" xlink:label="loc_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="loc_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_396C45A5695F609D8602598B71113C13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_396C45A5695F609D8602598B71113C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FDFB1562D8C842548BF1598B7111ADA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_396C45A5695F609D8602598B71113C13" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FDFB1562D8C842548BF1598B7111ADA7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FDFB1562D8C842548BF1598B7111ADA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_396C45A5695F609D8602598B71113C13" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FDFB1562D8C842548BF1598B7111ADA7" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FDFB1562D8C842548BF1598B7111ADA7" xlink:to="loc_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BusinessCombinationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_AAFE9F65C0CC3C989D9C7CA1590955EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_AAFE9F65C0CC3C989D9C7CA1590955EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_AAFE9F65C0CC3C989D9C7CA1590955EA" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_AAFE9F65C0CC3C989D9C7CA1590955EA" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_B71613717E81C5C5BA537CA15909DB10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_B71613717E81C5C5BA537CA15909DB10" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:label="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5" xlink:to="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:label="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_E110ACD17B86999900887CA1590AA008" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_SecurityDeposit_E110ACD17B86999900887CA1590AA008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C47349A8D613C19D998C49ADE1F6138C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_StatementTable_C47349A8D613C19D998C49ADE1F6138C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_15173D4179CC14F42DC449C8B5C3EEB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C47349A8D613C19D998C49ADE1F6138C" xlink:to="loc_srt_ProductOrServiceAxis_15173D4179CC14F42DC449C8B5C3EEB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_15173D4179CC14F42DC449C8B5C3EEB4" xlink:to="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_15173D4179CC14F42DC449C8B5C3EEB4" xlink:to="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TestingMember" xlink:label="loc_vcyt_TestingMember_8DF46100B91F438E4E6449C9295E67D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:to="loc_vcyt_TestingMember_8DF46100B91F438E4E6449C9295E67D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_29C7A7E3D9D98C0A3EC549C9295EC5AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:to="loc_us-gaap_ProductMember_29C7A7E3D9D98C0A3EC549C9295EC5AA" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BiopharmaceuticalMember" xlink:label="loc_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:to="loc_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CollaborationMember" xlink:label="loc_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:to="loc_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5D437D982090827C716A49ADE1F82018" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5D437D982090827C716A49ADE1F82018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostDirectMaterial" xlink:label="loc_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9263DE0F5A2C4EA8AA1A49ADE1FA64B3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9263DE0F5A2C4EA8AA1A49ADE1FA64B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8C690288FE4154F6EE2649ADE1FB2475" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8C690288FE4154F6EE2649ADE1FB2475" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:to="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:to="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:to="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:to="loc_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:to="loc_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" xlink:label="loc_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement" xlink:label="loc_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax" xlink:label="loc_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_390C3BC26F15B9DD5331ED4F9E75CCC1" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_390C3BC26F15B9DD5331ED4F9E75CCC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/DebtCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_DB84B50316606E67344CE8A9983F8F91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_DB84B50316606E67344CE8A9983F8F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_84677FF1C8D837CD0598E8A99841E2FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_DB84B50316606E67344CE8A9983F8F91" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_84677FF1C8D837CD0598E8A99841E2FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_84677FF1C8D837CD0598E8A99841E2FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_DB84B50316606E67344CE8A9983F8F91" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_84677FF1C8D837CD0598E8A99841E2FB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_VisiumMember" xlink:label="loc_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_84677FF1C8D837CD0598E8A99841E2FB" xlink:to="loc_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E05262C194FCAA8D133EE8A99846F755" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E05262C194FCAA8D133EE8A99846F755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ADE748A5AEB0E211C01E8A99846B443_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E05262C194FCAA8D133EE8A99846F755" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ADE748A5AEB0E211C01E8A99846B443_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ADE748A5AEB0E211C01E8A99846B443" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E05262C194FCAA8D133EE8A99846F755" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ADE748A5AEB0E211C01E8A99846B443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_830AD92832610A6A3D6EE8A99848F90B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ADE748A5AEB0E211C01E8A99846B443" xlink:to="loc_us-gaap_LineOfCreditMember_830AD92832610A6A3D6EE8A99848F90B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:to="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_InitialTermLoanMember" xlink:label="loc_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:to="loc_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NumberOfTermLoans" xlink:label="loc_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8A5D322063A227CF978AE8A9984F6BFD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8A5D322063A227CF978AE8A9984F6BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_720D7CF81BED363DBD2EE8A9985124A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_720D7CF81BED363DBD2EE8A9985124A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31CE2DA7465962A6112BE8A99851ED73" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31CE2DA7465962A6112BE8A99851ED73" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentNumberOfInstallments" xlink:label="loc_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TermOfDebtWithEqualQuarterlyInstallments" xlink:label="loc_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne" xlink:label="loc_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentFixedRatePercentagePaidInCash" xlink:label="loc_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentInterestPaidInKindPercentage" xlink:label="loc_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PaymentOfEndOfTermObligation" xlink:label="loc_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/DebtInterestExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheAxis" xlink:label="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPaymentTrancheDomain" xlink:label="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:to="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96_default" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPaymentTrancheDomain" xlink:label="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:to="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheOneMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:to="loc_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheTwoMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:to="loc_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheThreeMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:to="loc_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:to="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:to="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:to="loc_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:to="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:to="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:to="loc_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SiliconValleyBankMember" xlink:label="loc_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:to="loc_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:to="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:to="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:to="loc_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentPrepaymentPremium" xlink:label="loc_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LiquidityRequirementMinimum" xlink:label="loc_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_FA22F07AFB704648F67F49ADE0C327F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_us-gaap_DebtInstrumentTable_FA22F07AFB704648F67F49ADE0C327F9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FE34664E1E88CC25B77E49ADE0C3D9D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_FA22F07AFB704648F67F49ADE0C327F9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FE34664E1E88CC25B77E49ADE0C3D9D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1F7042C48EE738C02C4949ADE0C3C40D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FE34664E1E88CC25B77E49ADE0C3D9D3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1F7042C48EE738C02C4949ADE0C3C40D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1F7042C48EE738C02C4949ADE0C3C40D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FE34664E1E88CC25B77E49ADE0C3D9D3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1F7042C48EE738C02C4949ADE0C3C40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_154D6595E90ED56D400649ADE0C4B6C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1F7042C48EE738C02C4949ADE0C3C40D" xlink:to="loc_us-gaap_LineOfCreditMember_154D6595E90ED56D400649ADE0C4B6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentEndOfTermPaymentInterestAmount" xlink:label="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AC5952BA90D29F0818145FFEC6FFD5ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AC5952BA90D29F0818145FFEC6FFD5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F39AC7414EC25FE9A7015FFEC8295AB4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AC5952BA90D29F0818145FFEC6FFD5ED" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F39AC7414EC25FE9A7015FFEC8295AB4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F39AC7414EC25FE9A7015FFEC8295AB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AC5952BA90D29F0818145FFEC6FFD5ED" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F39AC7414EC25FE9A7015FFEC8295AB4" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_90E97D2D5C94EA447BBB5FFEC70DA057" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F39AC7414EC25FE9A7015FFEC8295AB4" xlink:to="loc_vcyt_NanoStringMember_90E97D2D5C94EA447BBB5FFEC70DA057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OvernightRepurchaseAgreementsMember" xlink:label="loc_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:to="loc_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F728C69EB5684353AD955FFEC6E6423F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F728C69EB5684353AD955FFEC6E6423F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BusinessCombinationContingentConsiderationCashtobePaid" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_52B5F655858D8011C7175FFEC6F3D75B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_52B5F655858D8011C7175FFEC6F3D75B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:to="loc_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:to="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:to="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:to="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:to="loc_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OtherStatesNotSeparatelyDisclosedMember" xlink:label="loc_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:to="loc_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:to="loc_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_098E86B5697E9E9DC38CE8A996957EAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_098E86B5697E9E9DC38CE8A996957EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_098E86B5697E9E9DC38CE8A996957EAF" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_098E86B5697E9E9DC38CE8A996957EAF" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_CB0782E7968A3D2B2572E8A99696851A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39" xlink:to="loc_us-gaap_DomesticCountryMember_CB0782E7968A3D2B2572E8A99696851A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_B15BA76EB00B18A29ABDE8A996964044" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_B15BA76EB00B18A29ABDE8A996964044" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncomeTaxExaminationPeriod" xlink:label="loc_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:to="loc_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:to="loc_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockIncentivePlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_89B3CB79EC7242786A4F49ADE056C0B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:to="loc_us-gaap_AwardTypeAxis_89B3CB79EC7242786A4F49ADE056C0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_89B3CB79EC7242786A4F49ADE056C0B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_89B3CB79EC7242786A4F49ADE056C0B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5DE73EF626E6AEBE01AB49ADE057836D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5DE73EF626E6AEBE01AB49ADE057836D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_34624FE4A4657E83612649B3077DE646" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_34624FE4A4657E83612649B3077DE646" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_90C31934EAE727247832782B0BE31FCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:to="loc_us-gaap_AwardTypeAxis_90C31934EAE727247832782B0BE31FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_90C31934EAE727247832782B0BE31FCE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_90C31934EAE727247832782B0BE31FCE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonEmployeeStockOptionMember" xlink:label="loc_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:to="loc_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CE41CCFBD91604BF4F50782B0BE4CB17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_CE41CCFBD91604BF4F50782B0BE4CB17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B4776D110C18FDB02D52782B0BE44682" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B4776D110C18FDB02D52782B0BE44682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DD6888C8D3D3082B9158782B0BE443EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DD6888C8D3D3082B9158782B0BE443EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C38FE5BCD5837EADAC0E782B0BE41FB8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DD6888C8D3D3082B9158782B0BE443EE" xlink:to="loc_us-gaap_EquityComponentDomain_C38FE5BCD5837EADAC0E782B0BE41FB8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C38FE5BCD5837EADAC0E782B0BE41FB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DD6888C8D3D3082B9158782B0BE443EE" xlink:to="loc_us-gaap_EquityComponentDomain_C38FE5BCD5837EADAC0E782B0BE41FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_69F72DCD5FF78057CD69782B0BE495BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C38FE5BCD5837EADAC0E782B0BE41FB8" xlink:to="loc_us-gaap_CommonStockMember_69F72DCD5FF78057CD69782B0BE495BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:to="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:to="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockPlan2008Member" xlink:label="loc_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:to="loc_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B50D200FD5C0A9BEAB9F363F70ECE64F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_srt_RangeAxis_B50D200FD5C0A9BEAB9F363F70ECE64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_B50D200FD5C0A9BEAB9F363F70ECE64F" xlink:to="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_B50D200FD5C0A9BEAB9F363F70ECE64F" xlink:to="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_109F28B8A7044A36E485363F70ED02E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B" xlink:to="loc_srt_MinimumMember_109F28B8A7044A36E485363F70ED02E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B" xlink:to="loc_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonEmployeeStockOptionMember" xlink:label="loc_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="loc_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_19ABB678541B466303AA363F70EE2E57" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="loc_us-gaap_EmployeeStockMember_19ABB678541B466303AA363F70EE2E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="loc_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9AE266596006A0374A08E8A996FE4366" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:to="loc_us-gaap_AwardTypeAxis_9AE266596006A0374A08E8A996FE4366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DCD08B22157501A5599E8A996FFA0ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9AE266596006A0374A08E8A996FE4366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DCD08B22157501A5599E8A996FFA0ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DCD08B22157501A5599E8A996FFA0ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9AE266596006A0374A08E8A996FE4366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DCD08B22157501A5599E8A996FFA0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_FFCD2014C1242AC3046BE8A997002DA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DCD08B22157501A5599E8A996FFA0ED" xlink:to="loc_us-gaap_EmployeeStockMember_FFCD2014C1242AC3046BE8A997002DA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9B3B2C8D504E45DC8754E8A99701A428" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:to="loc_srt_RangeAxis_9B3B2C8D504E45DC8754E8A99701A428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_65EE61335C23C5627A9FE8A9970129CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9B3B2C8D504E45DC8754E8A99701A428" xlink:to="loc_srt_RangeMember_65EE61335C23C5627A9FE8A9970129CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_65EE61335C23C5627A9FE8A9970129CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9B3B2C8D504E45DC8754E8A99701A428" xlink:to="loc_srt_RangeMember_65EE61335C23C5627A9FE8A9970129CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9B8017EE836AD399B6E0E8A99702AA0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65EE61335C23C5627A9FE8A9970129CA" xlink:to="loc_srt_MinimumMember_9B8017EE836AD399B6E0E8A99702AA0C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:to="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:to="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_23181CA161F0A0DEFF30E8A9977AD78D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_us-gaap_PlanNameAxis_23181CA161F0A0DEFF30E8A9977AD78D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_23181CA161F0A0DEFF30E8A9977AD78D" xlink:to="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_23181CA161F0A0DEFF30E8A9977AD78D" xlink:to="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockPlan2008Member" xlink:label="loc_vcyt_StockPlan2008Member_5097F8D135936CDC5E39E8A9977C166B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7" xlink:to="loc_vcyt_StockPlan2008Member_5097F8D135936CDC5E39E8A9977C166B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIncentivePlan2013Member" xlink:label="loc_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7" xlink:to="loc_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2689CD2BCD898778B289E8A9977C3C91" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_us-gaap_AwardTypeAxis_2689CD2BCD898778B289E8A9977C3C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2689CD2BCD898778B289E8A9977C3C91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2689CD2BCD898778B289E8A9977C3C91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncentiveStockOptionsMember" xlink:label="loc_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:to="loc_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonStatutoryStockOptionsMember" xlink:label="loc_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:to="loc_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIncentivePlan2013Member" xlink:label="loc_vcyt_StockIncentivePlan2013Member_0820A309EC07DB31064FE8A9977EE9E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:to="loc_vcyt_StockIncentivePlan2013Member_0820A309EC07DB31064FE8A9977EE9E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AD97E107FAACD60AC61CE8A9977E624F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:to="loc_us-gaap_EmployeeStockOptionMember_AD97E107FAACD60AC61CE8A9977E624F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember" xlink:label="loc_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:to="loc_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember" xlink:label="loc_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:to="loc_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorMember" xlink:label="loc_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:to="loc_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_C729C4A968240E1A41B2E8A9977F722F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_srt_RangeAxis_C729C4A968240E1A41B2E8A9977F722F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_C729C4A968240E1A41B2E8A9977F722F" xlink:to="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_C729C4A968240E1A41B2E8A9977F722F" xlink:to="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_44E61549BA127608E892E8A99780A851" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430" xlink:to="loc_srt_MinimumMember_44E61549BA127608E892E8A99780A851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D4E64E9549097F0ADC8DE8A997807687" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430" xlink:to="loc_srt_MaximumMember_D4E64E9549097F0ADC8DE8A997807687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DE3D679EB09B15DFE1C7E8A997811C34" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DE3D679EB09B15DFE1C7E8A997811C34" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock" xlink:label="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne" xlink:label="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:label="loc_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CDDA97676DC71CFC003DE8A997A1A640" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CDDA97676DC71CFC003DE8A997A1A640" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D0410A6EEAD1933B6E25E8A997A2F2B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CDDA97676DC71CFC003DE8A997A1A640" xlink:to="loc_us-gaap_AwardTypeAxis_D0410A6EEAD1933B6E25E8A997A2F2B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D0410A6EEAD1933B6E25E8A997A2F2B4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D0410A6EEAD1933B6E25E8A997A2F2B4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_33CB48CF5944526B6E14E8A997A32343" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_33CB48CF5944526B6E14E8A997A32343" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_99C6171327C6D0D129B3E8A997A394B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:to="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_99C6171327C6D0D129B3E8A997A394B1" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonEmployeeStockOptionMember" xlink:label="loc_vcyt_NonEmployeeStockOptionMember_D42E6228D55E8DA4D075E8A997A4F758" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:to="loc_vcyt_NonEmployeeStockOptionMember_D42E6228D55E8DA4D075E8A997A4F758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_21BD10B3CD31B3790791E8A997A46C0E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:to="loc_us-gaap_EmployeeStockMember_21BD10B3CD31B3790791E8A997A46C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6C5B09598B0E6D410DD8402FCF0E34CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6C5B09598B0E6D410DD8402FCF0E34CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EDE773B915D647A5FDDA402FCF0EDE63_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6C5B09598B0E6D410DD8402FCF0E34CE" xlink:to="loc_us-gaap_EquityComponentDomain_EDE773B915D647A5FDDA402FCF0EDE63_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EDE773B915D647A5FDDA402FCF0EDE63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6C5B09598B0E6D410DD8402FCF0E34CE" xlink:to="loc_us-gaap_EquityComponentDomain_EDE773B915D647A5FDDA402FCF0EDE63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_16FC6DB6E809F330B12F402FCF0F9B0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EDE773B915D647A5FDDA402FCF0EDE63" xlink:to="loc_us-gaap_CommonStockMember_16FC6DB6E809F330B12F402FCF0F9B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19A5ADAD3116B11A9212402FCF0F3A14" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:to="loc_us-gaap_AwardTypeAxis_19A5ADAD3116B11A9212402FCF0F3A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_19A5ADAD3116B11A9212402FCF0F3A14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_19A5ADAD3116B11A9212402FCF0F3A14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_9734F675ABC6916C0F51402FCF0F26FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_9734F675ABC6916C0F51402FCF0F26FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_E7CB2C7CA090760BE953402FCF101089" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C" xlink:to="loc_us-gaap_EmployeeStockMember_E7CB2C7CA090760BE953402FCF101089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:to="loc_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CommonStockAbstract" xlink:label="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:to="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_VotingRightsForEachShareOfStock" xlink:label="loc_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:to="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_22BD2220B4BFA85647EB49ADE162B96F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_22BD2220B4BFA85647EB49ADE162B96F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_22BD2220B4BFA85647EB49ADE162B96F" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_22BD2220B4BFA85647EB49ADE162B96F" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6" xlink:to="loc_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_3F98B698A4436A1DE06D49ADE16330AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6" xlink:to="loc_us-gaap_AccountsReceivableMember_3F98B698A4436A1DE06D49ADE16330AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_652445DC51EE608B287149ADE163CD13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_652445DC51EE608B287149ADE163CD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_652445DC51EE608B287149ADE163CD13" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_652445DC51EE608B287149ADE163CD13" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_486582BF374D036A2E5A49ADE1638EEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_486582BF374D036A2E5A49ADE1638EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_3057F7A92191D229E3BF49ADE164CFC9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_3057F7A92191D229E3BF49ADE164CFC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_315104023221823FE2FB49ADE164CD1A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:to="loc_srt_MajorCustomersAxis_315104023221823FE2FB49ADE164CD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_315104023221823FE2FB49ADE164CD1A" xlink:to="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_315104023221823FE2FB49ADE164CD1A" xlink:to="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_MedicareMember" xlink:label="loc_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:to="loc_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_JohnsonandJohnsonServicesInc.Member" xlink:label="loc_vcyt_JohnsonandJohnsonServicesInc.Member_15381DC07AB53B7FFEAA49ADE1652FFC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:to="loc_vcyt_JohnsonandJohnsonServicesInc.Member_15381DC07AB53B7FFEAA49ADE1652FFC" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_UnitedHealthcareMember" xlink:label="loc_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:to="loc_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ConcentrationRiskAbstract" xlink:label="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:to="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:label="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:to="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4B64EE189FE6852A6DFD49ADE1666833" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4B64EE189FE6852A6DFD49ADE1666833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:to="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:to="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:to="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ProvisionofDataMember" xlink:label="loc_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:to="loc_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FulfillmentofObligationsMember" xlink:label="loc_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:to="loc_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:to="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:to="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:to="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_JohnsonandJohnsonServicesInc.Member" xlink:label="loc_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:to="loc_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_Perceptav.2andNassaRiskMember" xlink:label="loc_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:to="loc_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopmentPrograms" xlink:label="loc_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementReceivableForServices" xlink:label="loc_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementConditionalAccountsReceivable" xlink:label="loc_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TermContractAgreement" xlink:label="loc_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:label="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="loc_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_DE63ECDC87E077F312F764B32EFBEAF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_srt_MajorCustomersAxis_DE63ECDC87E077F312F764B32EFBEAF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DEC0EE5BE5C033513ABB64B32EFB3277_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_DE63ECDC87E077F312F764B32EFBEAF2" xlink:to="loc_srt_NameOfMajorCustomerDomain_DEC0EE5BE5C033513ABB64B32EFB3277_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DEC0EE5BE5C033513ABB64B32EFB3277" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_DE63ECDC87E077F312F764B32EFBEAF2" xlink:to="loc_srt_NameOfMajorCustomerDomain_DEC0EE5BE5C033513ABB64B32EFB3277" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_JohnsonandJohnsonServicesInc.Member" xlink:label="loc_vcyt_JohnsonandJohnsonServicesInc.Member_2CFD38EA68DCEBCE52CB64B32EFB4E44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_DEC0EE5BE5C033513ABB64B32EFB3277" xlink:to="loc_vcyt_JohnsonandJohnsonServicesInc.Member_2CFD38EA68DCEBCE52CB64B32EFB4E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_57E0419E5C4CE91096A364B32EFC0CA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_57E0419E5C4CE91096A364B32EFC0CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57E0419E5C4CE91096A364B32EFC0CA3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57E0419E5C4CE91096A364B32EFC0CA3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_E419670D4085A39D9E1C64B32EFDAF84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_E419670D4085A39D9E1C64B32EFDAF84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_82E3E5ECAC14EE9D002064B32EFD20E9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_82E3E5ECAC14EE9D002064B32EFD20E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_82E3E5ECAC14EE9D002064B32EFD20E9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_82E3E5ECAC14EE9D002064B32EFD20E9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_19ABB65D7E935EA487DB64B32EFE7728" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588" xlink:to="loc_us-gaap_AccountsReceivableMember_19ABB65D7E935EA487DB64B32EFE7728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_DA9D9A8A6A3EE91FA13464B32EFE9DF0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_srt_ProductOrServiceAxis_DA9D9A8A6A3EE91FA13464B32EFE9DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_DA9D9A8A6A3EE91FA13464B32EFE9DF0" xlink:to="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_DA9D9A8A6A3EE91FA13464B32EFE9DF0" xlink:to="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TestingMember" xlink:label="loc_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:to="loc_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:to="loc_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:to="loc_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2714E03E8FCB568AC7AA64B32EFF9CC5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_srt_RangeAxis_2714E03E8FCB568AC7AA64B32EFF9CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2714E03E8FCB568AC7AA64B32EFF9CC5" xlink:to="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2714E03E8FCB568AC7AA64B32EFF9CC5" xlink:to="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_EDE5B35134037322AC9264B32EFF79D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1" xlink:to="loc_srt_MinimumMember_EDE5B35134037322AC9264B32EFF79D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_143554D900D4FECF253464B32F00CCA1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1" xlink:to="loc_srt_MaximumMember_143554D900D4FECF253464B32F00CCA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BiopharmaceuticalCompanyMember" xlink:label="loc_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:to="loc_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGrossAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DF58BD975B9A0DAB3D2664B32F02355C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DF58BD975B9A0DAB3D2664B32F02355C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAbstract" xlink:label="loc_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedOnAccrualBasis" xlink:label="loc_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedOnAccrualBasisPercentage" xlink:label="loc_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedReceivedInCash" xlink:label="loc_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedReceivedInCashPercentage" xlink:label="loc_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_B83A0044124C0744A37A64B32F042D4F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_ContractWithCustomerLiability_B83A0044124C0744A37A64B32F042D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter" xlink:label="loc_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TermContractAgreement" xlink:label="loc_vcyt_TermContractAgreement_82129AF0AA466B8AFA6D64B32F043291" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_vcyt_TermContractAgreement_82129AF0AA466B8AFA6D64B32F043291" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AutomaticRenewalPeriodContractAgreement" xlink:label="loc_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LiquidityLineItems" xlink:label="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E246FB6A10E7BE965099E8A999B1F2BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E246FB6A10E7BE965099E8A999B1F2BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AF9E6D21230AFC2DB9D7E8A999B1880C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E246FB6A10E7BE965099E8A999B1F2BC" xlink:to="loc_us-gaap_EquityComponentDomain_AF9E6D21230AFC2DB9D7E8A999B1880C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AF9E6D21230AFC2DB9D7E8A999B1880C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E246FB6A10E7BE965099E8A999B1F2BC" xlink:to="loc_us-gaap_EquityComponentDomain_AF9E6D21230AFC2DB9D7E8A999B1880C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9E8D0E7FE93EEA58AD50E8A999B275C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_AF9E6D21230AFC2DB9D7E8A999B1880C" xlink:to="loc_us-gaap_CommonStockMember_9E8D0E7FE93EEA58AD50E8A999B275C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_19BA44365AE195A90CBFE8A999B26404" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_19BA44365AE195A90CBFE8A999B26404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F6EE5AE019D8A564B8EE8A999B2FE51_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_19BA44365AE195A90CBFE8A999B26404" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F6EE5AE019D8A564B8EE8A999B2FE51_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F6EE5AE019D8A564B8EE8A999B2FE51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_19BA44365AE195A90CBFE8A999B26404" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F6EE5AE019D8A564B8EE8A999B2FE51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_E8978F44E95D3EC0ECE1E8A999B2E7AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F6EE5AE019D8A564B8EE8A999B2FE51" xlink:to="loc_us-gaap_OverAllotmentOptionMember_E8978F44E95D3EC0ECE1E8A999B2E7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_F8421877E42874B062C3E8A999B3619C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_CreditFacilityAxis_F8421877E42874B062C3E8A999B3619C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_88FDF8BF963490BA4FC2E8A999B3B933_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_F8421877E42874B062C3E8A999B3619C" xlink:to="loc_us-gaap_CreditFacilityDomain_88FDF8BF963490BA4FC2E8A999B3B933_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_88FDF8BF963490BA4FC2E8A999B3B933" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_F8421877E42874B062C3E8A999B3619C" xlink:to="loc_us-gaap_CreditFacilityDomain_88FDF8BF963490BA4FC2E8A999B3B933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_C86574FF88A8C43CE9CBE8A999B32358" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_88FDF8BF963490BA4FC2E8A999B3B933" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_C86574FF88A8C43CE9CBE8A999B32358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0E9800FE4E0ABB67904FE8A999B33F84" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0E9800FE4E0ABB67904FE8A999B33F84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21360F471269E1846B7DE8A999B4DD9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0E9800FE4E0ABB67904FE8A999B33F84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21360F471269E1846B7DE8A999B4DD9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21360F471269E1846B7DE8A999B4DD9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0E9800FE4E0ABB67904FE8A999B33F84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21360F471269E1846B7DE8A999B4DD9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_4F0A01A89451DCE70DF6E8A999B4F6D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_21360F471269E1846B7DE8A999B4DD9C" xlink:to="loc_us-gaap_LineOfCreditMember_4F0A01A89451DCE70DF6E8A999B4F6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_AFE6C5EC60F799E44F8AE8A999B4B8FB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_AFE6C5EC60F799E44F8AE8A999B4B8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_744EA51D3366780E488BE8A999B452EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_AFE6C5EC60F799E44F8AE8A999B4B8FB" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_744EA51D3366780E488BE8A999B452EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_744EA51D3366780E488BE8A999B452EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_AFE6C5EC60F799E44F8AE8A999B4B8FB" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_744EA51D3366780E488BE8A999B452EF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SiliconValleyBankMember" xlink:label="loc_vcyt_SiliconValleyBankMember_90B260E5A321F27DEBD9E8A999B52F52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_744EA51D3366780E488BE8A999B452EF" xlink:to="loc_vcyt_SiliconValleyBankMember_90B260E5A321F27DEBD9E8A999B52F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB7A162CA393D06401DDE8A999B52652" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB7A162CA393D06401DDE8A999B52652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_F781A973C783E4BDB61EE8A999B65F98" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_F781A973C783E4BDB61EE8A999B65F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_311A42412C53C1637001E8A999B6FFB0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_311A42412C53C1637001E8A999B6FFB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2B309C4D39F6C58C3A27E8A999B6F820" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2B309C4D39F6C58C3A27E8A999B6F820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_C73EF9B9F9EC91B546A2E8A999B6C4AB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_C73EF9B9F9EC91B546A2E8A999B6C4AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_8C3A00CB8325DB5A2DD6E8A999B6C32F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_8C3A00CB8325DB5A2DD6E8A999B6C32F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_BA8B71D126AD5AA647E6E8A999B67123" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_BA8B71D126AD5AA647E6E8A999B67123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2F5BE7FA007B57ED84E9E8A999B7EC5C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2F5BE7FA007B57ED84E9E8A999B7EC5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7E35784805B86596510ED55E78E7057" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7E35784805B86596510ED55E78E7057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_22169E67ABC4FD909F54ED55E78F3921_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7E35784805B86596510ED55E78E7057" xlink:to="loc_us-gaap_TypeOfAdoptionMember_22169E67ABC4FD909F54ED55E78F3921_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_22169E67ABC4FD909F54ED55E78F3921" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7E35784805B86596510ED55E78E7057" xlink:to="loc_us-gaap_TypeOfAdoptionMember_22169E67ABC4FD909F54ED55E78F3921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_22169E67ABC4FD909F54ED55E78F3921" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_D8B731BDBBDCF80F03F5ED5261C6384A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_D8B731BDBBDCF80F03F5ED5261C6384A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_829F4E53B8DECD157545ED535E9D7E27" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_ContractWithCustomerLiability_829F4E53B8DECD157545ED535E9D7E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:to="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SalesRevenueGrossMember" xlink:label="loc_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:to="loc_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:to="loc_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:to="loc_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OtherIncomeRentReimbursement" xlink:label="loc_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:to="loc_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>vcyt-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D_label_en-US" xlink:label="lab_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:label id="lab_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D_documentation_en-US" xlink:label="lab_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ServicesAgreementAbstract" xlink:label="loc_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D" xlink:to="lab_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:type="arc" />
    <link:label id="lab_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F_terseLabel_en-US" xlink:label="lab_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction to rent expense for TCP's portion of costs for shared space</link:label>
    <link:label id="lab_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F_label_en-US" xlink:label="lab_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income Rent Reimbursement</link:label>
    <link:label id="lab_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F_documentation_en-US" xlink:label="lab_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OtherIncomeRentReimbursement" xlink:label="loc_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:to="lab_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_CED2B99AB1F815D6FEF1F75CA47F12D9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_CED2B99AB1F815D6FEF1F75CA47F12D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CED2B99AB1F815D6FEF1F75CA47F12D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CED2B99AB1F815D6FEF1F75CA47F12D9" xlink:to="lab_us-gaap_EarningsPerShareAbstract_CED2B99AB1F815D6FEF1F75CA47F12D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:type="arc" />
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B_terseLabel_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock subject to outstanding options</link:label>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B_label_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B_documentation_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:to="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:to="lab_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock subject to outstanding options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_A1CAE39FBE5274164AA9402FCF3537B1_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_A1CAE39FBE5274164AA9402FCF3537B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A1CAE39FBE5274164AA9402FCF3537B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A1CAE39FBE5274164AA9402FCF3537B1" xlink:to="lab_us-gaap_DebtDisclosureAbstract_A1CAE39FBE5274164AA9402FCF3537B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="lab_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF_terseLabel_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche [Axis]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF_label_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche [Axis]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF_documentation_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche [Axis]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheAxis" xlink:label="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:to="lab_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96_terseLabel_en-US" xlink:label="lab_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Payment Tranche [Domain]</link:label>
    <link:label id="lab_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96_label_en-US" xlink:label="lab_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Payment Tranche [Domain]</link:label>
    <link:label id="lab_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96_documentation_en-US" xlink:label="lab_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt Payment Tranche [Axis]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPaymentTrancheDomain" xlink:label="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:to="lab_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F_terseLabel_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt prepayment tranche one</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F_label_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche One [Member]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F_documentation_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche One [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheOneMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:to="lab_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634_terseLabel_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt prepayment tranche two</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634_label_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche Two [Member]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634_documentation_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche Two [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheTwoMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:to="lab_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868_terseLabel_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt prepayment tranche three</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868_label_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche Three [Member]</link:label>
    <link:label id="lab_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868_documentation_en-US" xlink:label="lab_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Tranche Three [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheThreeMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:to="lab_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_B71516271E573454473F402FCF3607D9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_B71516271E573454473F402FCF3607D9_label_en-US" xlink:label="lab_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:to="lab_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63_terseLabel_en-US" xlink:label="lab_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63_label_en-US" xlink:label="lab_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:to="lab_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2_label_en-US" xlink:label="lab_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:to="lab_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:to="lab_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:to="lab_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:to="lab_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:type="arc" />
    <link:label id="lab_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124_terseLabel_en-US" xlink:label="lab_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank</link:label>
    <link:label id="lab_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124_label_en-US" xlink:label="lab_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
    <link:label id="lab_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124_documentation_en-US" xlink:label="lab_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SiliconValleyBankMember" xlink:label="loc_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:to="lab_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:to="lab_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:to="lab_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:to="lab_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium</link:label>
    <link:label id="lab_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3_label_en-US" xlink:label="lab_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium</link:label>
    <link:label id="lab_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of prepayment premium waived.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentPrepaymentPremium" xlink:label="loc_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:to="lab_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic payment terms, balloon payment to be paid</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:type="arc" />
    <link:label id="lab_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647_terseLabel_en-US" xlink:label="lab_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum requirement liability</link:label>
    <link:label id="lab_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647_label_en-US" xlink:label="lab_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Requirement, Minimum</link:label>
    <link:label id="lab_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647_documentation_en-US" xlink:label="lab_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liquidity Requirement, Minimum</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LiquidityRequirementMinimum" xlink:label="loc_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:to="lab_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Pretax loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation excess tax benefit amount</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:to="lab_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:to="lab_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:to="lab_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:type="arc" />
    <link:label id="lab_stpr_CA_AD4B20F17F3E3421885B64B4468D1652_terseLabel_en-US" xlink:label="lab_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_AD4B20F17F3E3421885B64B4468D1652_label_en-US" xlink:label="lab_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:to="lab_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:type="arc" />
    <link:label id="lab_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222_terseLabel_en-US" xlink:label="lab_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other state income tax purposes</link:label>
    <link:label id="lab_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222_label_en-US" xlink:label="lab_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other States, Not Separately Disclosed [Member]</link:label>
    <link:label id="lab_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222_documentation_en-US" xlink:label="lab_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other States, Not Separately Disclosed [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OtherStatesNotSeparatelyDisclosedMember" xlink:label="loc_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:to="lab_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:to="lab_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of tax expense computed at the statutory federal rate and the Company's tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal taxes at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7" xlink:type="arc" />
    <link:label id="lab_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F_terseLabel_en-US" xlink:label="lab_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non deductible officers' compensation</link:label>
    <link:label id="lab_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F_label_en-US" xlink:label="lab_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer Compensation, Amount</link:label>
    <link:label id="lab_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F_documentation_en-US" xlink:label="lab_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer Compensation, Amount</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" xlink:label="loc_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F" xlink:to="lab_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_970A8A6B52E072C98B8240422EB043FA_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_970A8A6B52E072C98B8240422EB043FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation - PSU/RSU/NQSQ</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_970A8A6B52E072C98B8240422EB043FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_970A8A6B52E072C98B8240422EB043FA" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_970A8A6B52E072C98B8240422EB043FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive stock options</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate differential impact - Tax Cuts and Jobs Act</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_BE8AA83EAC412161D68D402FCE6FA308_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_BE8AA83EAC412161D68D402FCE6FA308" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BE8AA83EAC412161D68D402FCE6FA308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_BE8AA83EAC412161D68D402FCE6FA308" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_BE8AA83EAC412161D68D402FCE6FA308" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_27A3460CB1FE63F9952349ADE1B5B763_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_27A3460CB1FE63F9952349ADE1B5B763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_27A3460CB1FE63F9952349ADE1B5B763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27A3460CB1FE63F9952349ADE1B5B763" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_27A3460CB1FE63F9952349ADE1B5B763" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:to="lab_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross receivables concentration risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:to="lab_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:type="arc" />
    <link:label id="lab_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861_terseLabel_en-US" xlink:label="lab_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861_label_en-US" xlink:label="lab_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue Gross [Member]</link:label>
    <link:label id="lab_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861_documentation_en-US" xlink:label="lab_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods and services rendered, in the normal course of business, before deducting sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SalesRevenueGrossMember" xlink:label="loc_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:to="lab_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:to="lab_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Company's third-party payers as a percentage of total</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:to="lab_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue recognized when cash is received and on an accrual basis</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_AEEB067CFBAA73A5CB9DE8A9968923C3_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_AEEB067CFBAA73A5CB9DE8A9968923C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_AEEB067CFBAA73A5CB9DE8A9968923C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_AEEB067CFBAA73A5CB9DE8A9968923C3" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_AEEB067CFBAA73A5CB9DE8A9968923C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contributions to the plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6" xlink:to="lab_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and write-off of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345_terseLabel_en-US" xlink:label="lab_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on end-of-term debt obligation and prepayment penalty</link:label>
    <link:label id="lab_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345_label_en-US" xlink:label="lab_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instrument, End of Term Payment Interest Amount and Prepayment Penalty</link:label>
    <link:label id="lab_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345_documentation_en-US" xlink:label="lab_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument, End of Term Payment Interest Amount and Prepayment Penalty</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty" xlink:label="loc_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345" xlink:to="lab_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04" xlink:type="arc" />
    <link:label id="lab_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B_negatedTerseLabel_en-US" xlink:label="lab_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets - operating lease and operating lease liability</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B_label_en-US" xlink:label="lab_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Assets and Liabilities</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B_documentation_en-US" xlink:label="lab_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Assets and Liabilities</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities" xlink:label="loc_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B" xlink:to="lab_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562" xlink:type="arc" />
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3_terseLabel_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and deferred rent</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3_label_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Deferred Rent</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3_documentation_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3" xlink:to="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of long-term debt, net of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in a public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_DC8DCA99B72724450B7E64AA44577BDC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_DC8DCA99B72724450B7E64AA44577BDC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_DC8DCA99B72724450B7E64AA44577BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_DC8DCA99B72724450B7E64AA44577BDC" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_DC8DCA99B72724450B7E64AA44577BDC" xlink:type="arc" />
    <link:label id="lab_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A_negatedLabel_en-US" xlink:label="lab_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of end-of-term debt obligation and prepayment penalty</link:label>
    <link:label id="lab_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A_label_en-US" xlink:label="lab_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of End of Term Obligation</link:label>
    <link:label id="lab_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A_documentation_en-US" xlink:label="lab_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow for the payment of the end-of-term obligation and prepayment penalty.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PaymentOfEndOfTermObligation" xlink:label="loc_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A" xlink:to="lab_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from legal settlement regarding short-swing profits</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335" xlink:to="lab_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of financial lease liability</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of common stock options and employee stock purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260DC3DA86A36853A64A64AA44584559_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260DC3DA86A36853A64A64AA44584559" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260DC3DA86A36853A64A64AA44584559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260DC3DA86A36853A64A64AA44584559" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260DC3DA86A36853A64A64AA44584559" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary cash flow information of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability arising from obtaining right-of-use assets - operating lease at beginning of period</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for purchase consideration for a business combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B" xlink:type="arc" />
    <link:label id="lab_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C_terseLabel_en-US" xlink:label="lab_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred purchase consideration for a business combination</link:label>
    <link:label id="lab_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C_label_en-US" xlink:label="lab_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Deferred Purchase Consideration</link:label>
    <link:label id="lab_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C_documentation_en-US" xlink:label="lab_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Deferred Purchase Consideration</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration" xlink:label="loc_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C" xlink:to="lab_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest on debt</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D" xlink:to="lab_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9" xlink:to="lab_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042_netLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4225B3B76D977F7568D264AA445AD6BC_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4225B3B76D977F7568D264AA445AD6BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4225B3B76D977F7568D264AA445AD6BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4225B3B76D977F7568D264AA445AD6BC" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4225B3B76D977F7568D264AA445AD6BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_7DD6109E1C6145B2C8F9402FCF87F409_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_7DD6109E1C6145B2C8F9402FCF87F409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7DD6109E1C6145B2C8F9402FCF87F409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7DD6109E1C6145B2C8F9402FCF87F409" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_7DD6109E1C6145B2C8F9402FCF87F409" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:to="lab_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:type="arc" />
    <link:label id="lab_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5_terseLabel_en-US" xlink:label="lab_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NanoString</link:label>
    <link:label id="lab_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5_label_en-US" xlink:label="lab_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NanoString [Member]</link:label>
    <link:label id="lab_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5_documentation_en-US" xlink:label="lab_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NanoString [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:to="lab_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:type="arc" />
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B_terseLabel_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional cash to be paid</link:label>
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B_label_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Cash to be Paid</link:label>
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B_documentation_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Cash to be Paid</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BusinessCombinationContingentConsiderationCashtobePaid" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:to="lab_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0_label_en-US" xlink:label="lab_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:to="lab_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fair value of assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of identifiable acquisition-related intangibles</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma financial information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nominal debt interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and write-off of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">End-of-term debt obligation interest</link:label>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9_label_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument End Of Term, Interest Obligation Amount</link:label>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument End Of Term, Interest Obligation Amount</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:label="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9" xlink:to="lab_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9" xlink:type="arc" />
    <link:label id="lab_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34_terseLabel_en-US" xlink:label="lab_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt prepayment penalty</link:label>
    <link:label id="lab_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34_label_en-US" xlink:label="lab_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment Penalty</link:label>
    <link:label id="lab_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34_documentation_en-US" xlink:label="lab_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayment penalty.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PrepaymentPenalty" xlink:label="loc_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34" xlink:to="lab_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on capital lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC" xlink:to="lab_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of future amortization</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_6268A8B5BAF85C1ED949E8A997E2C36F_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_6268A8B5BAF85C1ED949E8A997E2C36F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6268A8B5BAF85C1ED949E8A997E2C36F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_6268A8B5BAF85C1ED949E8A997E2C36F" xlink:to="lab_us-gaap_EquityAbstract_6268A8B5BAF85C1ED949E8A997E2C36F" xlink:type="arc" />
    <link:label id="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0_terseLabel_en-US" xlink:label="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of reserved shares of common stock for issuance</link:label>
    <link:label id="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0_label_en-US" xlink:label="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Capital Shares Reserved for Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0_documentation_en-US" xlink:label="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of number of common shares reserved for future issuance.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="loc_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0" xlink:to="lab_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of net debt obligation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of interest expense on debt</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:type="arc" />
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80_verboseLabel_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prosigna product technology</link:label>
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80_label_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Product Technology [Member]</link:label>
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80_documentation_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Product Technology [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopedProductTechnologyMember" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:to="lab_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prosigna customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:to="lab_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:type="arc" />
    <link:label id="lab_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D_verboseLabel_en-US" xlink:label="lab_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">nCounter FLEX Dx license</link:label>
    <link:label id="lab_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D_label_en-US" xlink:label="lab_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nCounter FLEX Dx License [Member]</link:label>
    <link:label id="lab_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D_documentation_en-US" xlink:label="lab_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">nCounter FLEX Dx License [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NCounterFLEXDxLicenseMember" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:to="lab_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:type="arc" />
    <link:label id="lab_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF_verboseLabel_en-US" xlink:label="lab_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LymphMark product technology</link:label>
    <link:label id="lab_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF_label_en-US" xlink:label="lab_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AZ Collaboration License [Member]</link:label>
    <link:label id="lab_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF_documentation_en-US" xlink:label="lab_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AZ Collaboration License [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AZCollaborationLicenseMember" xlink:label="loc_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:to="lab_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:type="arc" />
    <link:label id="lab_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5_verboseLabel_en-US" xlink:label="lab_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">NanoString</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5" xlink:to="lab_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful life (In Years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thyroid Cytopathology Partners</link:label>
    <link:label id="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5_label_en-US" xlink:label="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Contracts or Programs Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:label="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5" xlink:to="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_482DB262824776C53D98363F70EBB449_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_482DB262824776C53D98363F70EBB449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_482DB262824776C53D98363F70EBB449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_482DB262824776C53D98363F70EBB449" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_482DB262824776C53D98363F70EBB449" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:to="lab_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:to="lab_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:type="arc" />
    <link:label id="lab_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF_terseLabel_en-US" xlink:label="lab_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2008 Plan</link:label>
    <link:label id="lab_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF_label_en-US" xlink:label="lab_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Plan2008 [Member]</link:label>
    <link:label id="lab_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF_documentation_en-US" xlink:label="lab_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the 2008 Stock Plan (the 2008 Plan).</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockPlan2008Member" xlink:label="loc_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:to="lab_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B_label_en-US" xlink:label="lab_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:to="lab_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:to="lab_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:type="arc" />
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE_terseLabel_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE_label_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee And Non Employee Stock Option Excluding Bonus Compensation [Member]</link:label>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE_documentation_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus related compensation.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:to="lab_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:type="arc" />
    <link:label id="lab_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82_terseLabel_en-US" xlink:label="lab_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation, employees</link:label>
    <link:label id="lab_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82_label_en-US" xlink:label="lab_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option Excluding Bonus Compensation [Member]</link:label>
    <link:label id="lab_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82_documentation_en-US" xlink:label="lab_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus compensation.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:to="lab_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:type="arc" />
    <link:label id="lab_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202_terseLabel_en-US" xlink:label="lab_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation, non-employees</link:label>
    <link:label id="lab_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202_label_en-US" xlink:label="lab_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202_documentation_en-US" xlink:label="lab_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonEmployeeStockOptionMember" xlink:label="loc_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:to="lab_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of testing revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:to="lab_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense (in dollars)</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense (in dollars)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period over which unrecognized compensation expense expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average volatility, low end of range (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average volatility, high end of range (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, low end of range (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, high end of range (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:to="lab_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:to="lab_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:type="arc" />
    <link:label id="lab_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097_terseLabel_en-US" xlink:label="lab_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision of Data</link:label>
    <link:label id="lab_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097_label_en-US" xlink:label="lab_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision of Data [Member]</link:label>
    <link:label id="lab_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097_documentation_en-US" xlink:label="lab_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision of Data [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ProvisionofDataMember" xlink:label="loc_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:to="lab_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:type="arc" />
    <link:label id="lab_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E_terseLabel_en-US" xlink:label="lab_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fulfillment of Obligations</link:label>
    <link:label id="lab_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E_label_en-US" xlink:label="lab_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fulfillment of Obligations [Member]</link:label>
    <link:label id="lab_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E_documentation_en-US" xlink:label="lab_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fulfillment of Obligations [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FulfillmentofObligationsMember" xlink:label="loc_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:to="lab_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:to="lab_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:to="lab_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:type="arc" />
    <link:label id="lab_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB_terseLabel_en-US" xlink:label="lab_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Johnson and Johnson Services, Inc.</link:label>
    <link:label id="lab_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB_label_en-US" xlink:label="lab_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Johnson and Johnson Services, Inc. [Member]</link:label>
    <link:label id="lab_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB_documentation_en-US" xlink:label="lab_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Johnson and Johnson Services, Inc. [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_JohnsonandJohnsonServicesInc.Member" xlink:label="loc_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:to="lab_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:type="arc" />
    <link:label id="lab_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C_terseLabel_en-US" xlink:label="lab_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percepta v.2 and Nassa Risk</link:label>
    <link:label id="lab_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C_label_en-US" xlink:label="lab_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percepta v.2 and Nassa Risk [Member]</link:label>
    <link:label id="lab_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C_documentation_en-US" xlink:label="lab_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percepta v.2 and Nassa Risk [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_Perceptav.2andNassaRiskMember" xlink:label="loc_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:to="lab_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:type="arc" />
    <link:label id="lab_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1_terseLabel_en-US" xlink:label="lab_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development programs</link:label>
    <link:label id="lab_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1_label_en-US" xlink:label="lab_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Programs</link:label>
    <link:label id="lab_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1_documentation_en-US" xlink:label="lab_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Programs</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopmentPrograms" xlink:label="loc_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:to="lab_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:type="arc" />
    <link:label id="lab_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C_terseLabel_en-US" xlink:label="lab_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract agreement receivable for services</link:label>
    <link:label id="lab_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C_label_en-US" xlink:label="lab_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Agreement Receivable For Services</link:label>
    <link:label id="lab_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C_documentation_en-US" xlink:label="lab_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Agreement Receivable For Services</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementReceivableForServices" xlink:label="loc_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:to="lab_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:type="arc" />
    <link:label id="lab_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230_terseLabel_en-US" xlink:label="lab_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, current</link:label>
    <link:label id="lab_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230_label_en-US" xlink:label="lab_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Agreement, Conditional, Accounts Receivable</link:label>
    <link:label id="lab_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230_documentation_en-US" xlink:label="lab_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Agreement, Conditional, Accounts Receivable</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementConditionalAccountsReceivable" xlink:label="loc_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:to="lab_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:type="arc" />
    <link:label id="lab_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5_terseLabel_en-US" xlink:label="lab_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract agreement term</link:label>
    <link:label id="lab_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5_label_en-US" xlink:label="lab_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term, Contract Agreement</link:label>
    <link:label id="lab_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5_documentation_en-US" xlink:label="lab_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term, Contract Agreement</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TermContractAgreement" xlink:label="loc_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:to="lab_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:type="arc" />
    <link:label id="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F_terseLabel_en-US" xlink:label="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of collections</link:label>
    <link:label id="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F_label_en-US" xlink:label="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Agreement Fee Percentage Of Cash Collections</link:label>
    <link:label id="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F_documentation_en-US" xlink:label="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Agreement Fee Percentage Of Cash Collections</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:label="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:to="lab_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="loc_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:to="lab_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:to="lab_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:to="lab_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax examination</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:type="arc" />
    <link:label id="lab_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60_terseLabel_en-US" xlink:label="lab_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax examination period</link:label>
    <link:label id="lab_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60_label_en-US" xlink:label="lab_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination Period</link:label>
    <link:label id="lab_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60_documentation_en-US" xlink:label="lab_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period which will remain open for examination by tax authorities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncomeTaxExaminationPeriod" xlink:label="loc_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:to="lab_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E" xlink:to="lab_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E" xlink:type="arc" />
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196_terseLabel_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196_label_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196_documentation_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196" xlink:to="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts for Product Sales</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_B25244485B2811DCF598E8A99A0561C9_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_B25244485B2811DCF598E8A99A0561C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_B25244485B2811DCF598E8A99A0561C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_B25244485B2811DCF598E8A99A0561C9" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_B25244485B2811DCF598E8A99A0561C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:to="lab_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock incentive plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Available for Grant</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional options authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:type="arc" />
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC_terseLabel_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax portion of restricted stock units vested (in shares)</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC_label_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares, Tax Portion</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC_documentation_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares, Tax Portion</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:to="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_64ABEB5DA4FBCF7B273C49ADE05843FD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_64ABEB5DA4FBCF7B273C49ADE05843FD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_64ABEB5DA4FBCF7B273C49ADE05843FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_64ABEB5DA4FBCF7B273C49ADE05843FD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_64ABEB5DA4FBCF7B273C49ADE05843FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8734BB0A57ED12568A7149ADE05954CC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8734BB0A57ED12568A7149ADE05954CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8734BB0A57ED12568A7149ADE05954CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8734BB0A57ED12568A7149ADE05954CC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8734BB0A57ED12568A7149ADE05954CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BDDD96524C2316B620549ADE059DA8F_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BDDD96524C2316B620549ADE059DA8F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BDDD96524C2316B620549ADE059DA8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BDDD96524C2316B620549ADE059DA8F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BDDD96524C2316B620549ADE059DA8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CF72B92DDAA82B87220949ADE05A4044_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CF72B92DDAA82B87220949ADE05A4044" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CF72B92DDAA82B87220949ADE05A4044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CF72B92DDAA82B87220949ADE05A4044" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CF72B92DDAA82B87220949ADE05A4044" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_188C5909056F2345920C49ADE05B6F0A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_188C5909056F2345920C49ADE05B6F0A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_188C5909056F2345920C49ADE05B6F0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_188C5909056F2345920C49ADE05B6F0A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_188C5909056F2345920C49ADE05B6F0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract]</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D_label_en-US" xlink:label="lab_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:to="lab_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:to="lab_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4" xlink:to="lab_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:to="lab_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:to="lab_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Rollforward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:to="lab_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:to="lab_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:type="arc" />
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674_terseLabel_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on exercise of stock options and vesting of restricted stock units</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674_label_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674_documentation_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:to="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:type="arc" />
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3_terseLabel_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3_label_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3_documentation_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:to="lab_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (ESPP)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on employee stock purchase plan (ESPP) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:type="arc" />
    <link:label id="lab_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5_terseLabel_en-US" xlink:label="lab_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock in a private placement, net of issuance costs</link:label>
    <link:label id="lab_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5_label_en-US" xlink:label="lab_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued And Sold During Period Value In Private Placement</link:label>
    <link:label id="lab_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5_documentation_en-US" xlink:label="lab_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of shares issued and sold during the period in a private placement.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" xlink:label="loc_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:to="lab_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:type="arc" />
    <link:label id="lab_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED_terseLabel_en-US" xlink:label="lab_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock in a private placement, net of issuance costs (in shares)</link:label>
    <link:label id="lab_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED_label_en-US" xlink:label="lab_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued And Sold During Period, Shares, In Private Placement</link:label>
    <link:label id="lab_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED_documentation_en-US" xlink:label="lab_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued and sold during the period in a private placement.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement" xlink:label="loc_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:to="lab_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:type="arc" />
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense (employee)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital Share Based Compensation Employee</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:type="arc" />
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense (non-employee)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital Share Based Compensation Non Employee</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:type="arc" />
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense (ESPP)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Share Based Compensation ESPP</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:type="arc" />
    <link:label id="lab_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705_terseLabel_en-US" xlink:label="lab_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal settlement from short-swing profits, net of tax</link:label>
    <link:label id="lab_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705_label_en-US" xlink:label="lab_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Settlement Regarding Short-Swing Profits, Net Of Tax</link:label>
    <link:label id="lab_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705_documentation_en-US" xlink:label="lab_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal Settlement Regarding Short-Swing Profits, Net Of Tax</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax" xlink:label="loc_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:to="lab_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_902CBBA60184C70CF56CED4F9E769AAA_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_902CBBA60184C70CF56CED4F9E769AAA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_902CBBA60184C70CF56CED4F9E769AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_902CBBA60184C70CF56CED4F9E769AAA" xlink:to="lab_us-gaap_StockholdersEquity_902CBBA60184C70CF56CED4F9E769AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_DC6CDCDDD6F5FDFEEE60ED4F9E760D02_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_DC6CDCDDD6F5FDFEEE60ED4F9E760D02" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_DC6CDCDDD6F5FDFEEE60ED4F9E760D02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_DC6CDCDDD6F5FDFEEE60ED4F9E760D02" xlink:to="lab_us-gaap_SharesOutstanding_DC6CDCDDD6F5FDFEEE60ED4F9E760D02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of reconciliation of tax expense computed at the statutory federal rate and the Company's tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of significant components of the Company's deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of reconciliation of the beginning and ending amount of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:type="arc" />
    <link:label id="lab_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2_terseLabel_en-US" xlink:label="lab_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percepta technology</link:label>
    <link:label id="lab_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2_label_en-US" xlink:label="lab_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percepta Technology [Member]</link:label>
    <link:label id="lab_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2_documentation_en-US" xlink:label="lab_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percepta Technology [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PerceptaTechnologyMember" xlink:label="loc_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:to="lab_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:type="arc" />
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9_terseLabel_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prosigna product technology</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopedProductTechnologyMember" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9" xlink:to="lab_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prosigna customer relationships</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879" xlink:to="lab_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879" xlink:type="arc" />
    <link:label id="lab_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3_terseLabel_en-US" xlink:label="lab_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">nCounter FLEX Dx license</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NCounterFLEXDxLicenseMember" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3" xlink:to="lab_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3" xlink:type="arc" />
    <link:label id="lab_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5_terseLabel_en-US" xlink:label="lab_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LymphMark product technology</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AZCollaborationLicenseMember" xlink:label="loc_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5" xlink:to="lab_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58D5ED672494EDD4921DE8A998EB5169_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58D5ED672494EDD4921DE8A998EB5169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58D5ED672494EDD4921DE8A998EB5169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58D5ED672494EDD4921DE8A998EB5169" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58D5ED672494EDD4921DE8A998EB5169" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity under the Company's stock option plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of assumptions used to calculate estimated grant date fair value of stock options using the Black-Scholes option-pricing valuation model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_A2DCD1049EDB8865FAEF5FFB7CA8C615_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_A2DCD1049EDB8865FAEF5FFB7CA8C615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A2DCD1049EDB8865FAEF5FFB7CA8C615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A2DCD1049EDB8865FAEF5FFB7CA8C615" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_A2DCD1049EDB8865FAEF5FFB7CA8C615" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:type="arc" />
    <link:label id="lab_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A_terseLabel_en-US" xlink:label="lab_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight Repurchase Agreements</link:label>
    <link:label id="lab_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A_label_en-US" xlink:label="lab_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overnight Repurchase Agreements [Member]</link:label>
    <link:label id="lab_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A_documentation_en-US" xlink:label="lab_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overnight Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OvernightRepurchaseAgreementsMember" xlink:label="loc_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:to="lab_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:to="lab_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:to="lab_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:type="arc" />
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56_terseLabel_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Headquarters and laboratory facilities, South San Francisco, Lease signed in April 2015</link:label>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56_label_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Headquarters And Laboratory Facilities South San Francisco Lease Two [Member]</link:label>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56_documentation_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the lease for headquarters and laboratory space in South San Francisco, California that expires March 2026.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:to="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:to="lab_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:to="lab_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:to="lab_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:type="arc" />
    <link:label id="lab_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB_terseLabel_en-US" xlink:label="lab_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB_label_en-US" xlink:label="lab_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:label id="lab_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB_documentation_en-US" xlink:label="lab_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CommonStockAbstract" xlink:label="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="lab_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value of shares of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:type="arc" />
    <link:label id="lab_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2_terseLabel_en-US" xlink:label="lab_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes for each share of stock (in votes)</link:label>
    <link:label id="lab_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2_label_en-US" xlink:label="lab_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voting Rights for Each Share of Stock</link:label>
    <link:label id="lab_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2_documentation_en-US" xlink:label="lab_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of votes for each share of stock.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_VotingRightsForEachShareOfStock" xlink:label="loc_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:to="lab_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options issued and outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total number of shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:to="lab_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:type="arc" />
    <link:label id="lab_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F_terseLabel_en-US" xlink:label="lab_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Testing revenue</link:label>
    <link:label id="lab_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F_label_en-US" xlink:label="lab_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Testing [Member]</link:label>
    <link:label id="lab_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F_documentation_en-US" xlink:label="lab_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Testing [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TestingMember" xlink:label="loc_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:to="lab_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3_label_en-US" xlink:label="lab_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:to="lab_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8_label_en-US" xlink:label="lab_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:to="lab_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:to="lab_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:to="lab_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:type="arc" />
    <link:label id="lab_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F_terseLabel_en-US" xlink:label="lab_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharmaceutical Company</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F_label_en-US" xlink:label="lab_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceutical Company [Member]</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F_documentation_en-US" xlink:label="lab_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharmaceutical Company [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BiopharmaceuticalCompanyMember" xlink:label="loc_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:to="lab_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGrossAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAbstract" xlink:label="loc_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:to="lab_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="lab_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:type="arc" />
    <link:label id="lab_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919_terseLabel_en-US" xlink:label="lab_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized on an accrual basis</link:label>
    <link:label id="lab_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919_label_en-US" xlink:label="lab_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognized On Accrual Basis</link:label>
    <link:label id="lab_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919_documentation_en-US" xlink:label="lab_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognized during the period on an accrual basis.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedOnAccrualBasis" xlink:label="loc_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:to="lab_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:type="arc" />
    <link:label id="lab_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB_terseLabel_en-US" xlink:label="lab_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized on accrual basis, percentage</link:label>
    <link:label id="lab_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB_label_en-US" xlink:label="lab_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognized On Accrual Basis, Percentage</link:label>
    <link:label id="lab_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB_documentation_en-US" xlink:label="lab_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognized On Accrual Basis, Percentage</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedOnAccrualBasisPercentage" xlink:label="loc_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:to="lab_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:type="arc" />
    <link:label id="lab_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC_terseLabel_en-US" xlink:label="lab_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized on a cash basis</link:label>
    <link:label id="lab_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC_label_en-US" xlink:label="lab_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognized Received In Cash</link:label>
    <link:label id="lab_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC_documentation_en-US" xlink:label="lab_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognized during the period based on cash receipts.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedReceivedInCash" xlink:label="loc_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:to="lab_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:type="arc" />
    <link:label id="lab_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7_terseLabel_en-US" xlink:label="lab_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized received in cash, percentage</link:label>
    <link:label id="lab_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7_label_en-US" xlink:label="lab_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognized Received In Cash, Percentage</link:label>
    <link:label id="lab_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7_documentation_en-US" xlink:label="lab_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognized Received In Cash, Percentage</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedReceivedInCashPercentage" xlink:label="loc_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:to="lab_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7_totalLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:to="lab_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, amount of remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:type="arc" />
    <link:label id="lab_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34_terseLabel_en-US" xlink:label="lab_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, quarterly amount of remaining performance obligation</link:label>
    <link:label id="lab_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34_label_en-US" xlink:label="lab_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount, Per Quarter</link:label>
    <link:label id="lab_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34_documentation_en-US" xlink:label="lab_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount, Per Quarter</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter" xlink:label="loc_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:to="lab_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:type="arc" />
    <link:label id="lab_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199_terseLabel_en-US" xlink:label="lab_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Automatic renewal period of contract agreement</link:label>
    <link:label id="lab_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199_label_en-US" xlink:label="lab_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Automatic Renewal Period, Contract Agreement</link:label>
    <link:label id="lab_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199_documentation_en-US" xlink:label="lab_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Automatic Renewal Period, Contract Agreement</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AutomaticRenewalPeriodContractAgreement" xlink:label="loc_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:to="lab_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7AC89A7E66A253777770E8A996764C80_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7AC89A7E66A253777770E8A996764C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7AC89A7E66A253777770E8A996764C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7AC89A7E66A253777770E8A996764C80" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7AC89A7E66A253777770E8A996764C80" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF" xlink:to="lab_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8BA951A2AADF2897A755E8A99A2B65D1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_8BA951A2AADF2897A755E8A99A2B65D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8BA951A2AADF2897A755E8A99A2B65D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_8BA951A2AADF2897A755E8A99A2B65D1" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_8BA951A2AADF2897A755E8A99A2B65D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F" xlink:to="lab_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total identifiable intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:type="arc" />
    <link:label id="lab_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E_verboseLabel_en-US" xlink:label="lab_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non Employee Stock Option</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonEmployeeStockOptionMember" xlink:label="loc_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E" xlink:to="lab_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC_label_en-US" xlink:label="lab_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:to="lab_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options to purchase common stock granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total estimated grant date fair value of options to purchase common stock vested (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of stock options exercised (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of stock options outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0_label_en-US" xlink:label="lab_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="lab_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C628D235859FA70EC3C6363F734E5786_terseLabel_en-US" xlink:label="lab_dei_DocumentType_C628D235859FA70EC3C6363F734E5786" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C628D235859FA70EC3C6363F734E5786_label_en-US" xlink:label="lab_dei_DocumentType_C628D235859FA70EC3C6363F734E5786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C628D235859FA70EC3C6363F734E5786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_C628D235859FA70EC3C6363F734E5786" xlink:to="lab_dei_DocumentType_C628D235859FA70EC3C6363F734E5786" xlink:type="arc" />
    <link:label id="lab_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA_label_en-US" xlink:label="lab_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA" xlink:to="lab_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6" xlink:to="lab_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384" xlink:to="lab_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693_label_en-US" xlink:label="lab_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693" xlink:to="lab_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E_label_en-US" xlink:label="lab_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E" xlink:to="lab_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024" xlink:to="lab_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C" xlink:to="lab_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0" xlink:to="lab_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD" xlink:to="lab_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E" xlink:to="lab_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3" xlink:to="lab_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E" xlink:to="lab_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925_label_en-US" xlink:label="lab_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925" xlink:to="lab_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E" xlink:to="lab_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072_label_en-US" xlink:label="lab_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072" xlink:to="lab_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19_label_en-US" xlink:label="lab_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19" xlink:to="lab_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778_label_en-US" xlink:label="lab_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778" xlink:to="lab_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64" xlink:to="lab_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452" xlink:to="lab_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56" xlink:to="lab_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE_label_en-US" xlink:label="lab_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE" xlink:to="lab_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349" xlink:to="lab_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72" xlink:to="lab_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6_label_en-US" xlink:label="lab_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6" xlink:to="lab_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661_label_en-US" xlink:label="lab_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661" xlink:to="lab_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2" xlink:to="lab_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3_label_en-US" xlink:label="lab_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3" xlink:to="lab_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5" xlink:to="lab_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91" xlink:to="lab_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723" xlink:to="lab_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A4ADF1CFC4CFE15374EA402FCFEECA9E_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A4ADF1CFC4CFE15374EA402FCFEECA9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A4ADF1CFC4CFE15374EA402FCFEECA9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A4ADF1CFC4CFE15374EA402FCFEECA9E" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A4ADF1CFC4CFE15374EA402FCFEECA9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments (in segments)</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F" xlink:to="lab_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="lab_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:to="lab_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395_label_en-US" xlink:label="lab_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395" xlink:to="lab_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD" xlink:to="lab_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets - operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C949AAECEB6A52B9A5A9E8A99A3DA92D_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C949AAECEB6A52B9A5A9E8A99A3DA92D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C949AAECEB6A52B9A5A9E8A99A3DA92D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C949AAECEB6A52B9A5A9E8A99A3DA92D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C949AAECEB6A52B9A5A9E8A99A3DA92D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F8EE0562EF8CF6F5A5A3E8A99A3DA473_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F8EE0562EF8CF6F5A5A3E8A99A3DA473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F8EE0562EF8CF6F5A5A3E8A99A3DA473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F8EE0562EF8CF6F5A5A3E8A99A3DA473" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F8EE0562EF8CF6F5A5A3E8A99A3DA473" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270_label_en-US" xlink:label="lab_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270" xlink:to="lab_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A" xlink:to="lab_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371" xlink:to="lab_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732" xlink:to="lab_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Lease Income, after Accumulated Amortization, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueLeasesNetNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F" xlink:to="lab_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0E197E003F3562CDD87EE8A99A41C073_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0E197E003F3562CDD87EE8A99A41C073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0E197E003F3562CDD87EE8A99A41C073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0E197E003F3562CDD87EE8A99A41C073" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0E197E003F3562CDD87EE8A99A41C073" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68_label_en-US" xlink:label="lab_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68" xlink:to="lab_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:to="lab_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D" xlink:to="lab_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized, 49,625,341 and 40,863,202 shares issued and outstanding as of December 31, 2019 and 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114" xlink:to="lab_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_6E400A5070B4E3E215FBE8A99A449C39_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6E400A5070B4E3E215FBE8A99A449C39" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6E400A5070B4E3E215FBE8A99A449C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_6E400A5070B4E3E215FBE8A99A449C39" xlink:to="lab_us-gaap_StockholdersEquity_6E400A5070B4E3E215FBE8A99A449C39" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum offering period</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Offering Period, Maximum</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum purchase price as a percentage of fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The purchase period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum fair market value of shares an employee can purchase per calendar year</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Value of Shares Per Employee</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum fair market value of shares an employee can purchase under the plan per calendar year.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12AC4107A362E57D7605E8A9966EFCFE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12AC4107A362E57D7605E8A9966EFCFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12AC4107A362E57D7605E8A9966EFCFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12AC4107A362E57D7605E8A9966EFCFE" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12AC4107A362E57D7605E8A9966EFCFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_BF801196A0753DF46D16E8A9966FB853_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_BF801196A0753DF46D16E8A9966FB853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share, basic and diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF801196A0753DF46D16E8A9966FB853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF801196A0753DF46D16E8A9966FB853" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_BF801196A0753DF46D16E8A9966FB853" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares use to compute net loss per common share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46" xlink:type="arc" />
    <link:label id="lab_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3_terseLabel_en-US" xlink:label="lab_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3_label_en-US" xlink:label="lab_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity [Line Items]</link:label>
    <link:label id="lab_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3_documentation_en-US" xlink:label="lab_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LiquidityLineItems" xlink:label="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="lab_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of selected quarterly financial data (unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:to="lab_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets - finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:to="lab_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:to="lab_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:type="arc" />
    <link:label id="lab_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87_terseLabel_en-US" xlink:label="lab_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Visium</link:label>
    <link:label id="lab_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87_label_en-US" xlink:label="lab_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Visium [Member]</link:label>
    <link:label id="lab_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87_documentation_en-US" xlink:label="lab_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Visium Healthcare Partners, LP</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_VisiumMember" xlink:label="loc_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:to="lab_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:to="lab_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:type="arc" />
    <link:label id="lab_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561_terseLabel_en-US" xlink:label="lab_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Term Loan</link:label>
    <link:label id="lab_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561_label_en-US" xlink:label="lab_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Term Loan [Member]</link:label>
    <link:label id="lab_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561_documentation_en-US" xlink:label="lab_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the initial term loan.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_InitialTermLoanMember" xlink:label="loc_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:to="lab_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="lab_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:type="arc" />
    <link:label id="lab_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465_terseLabel_en-US" xlink:label="lab_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of term loans (in term loans)</link:label>
    <link:label id="lab_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465_label_en-US" xlink:label="lab_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Term Loans</link:label>
    <link:label id="lab_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465_documentation_en-US" xlink:label="lab_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of term loans available to the Company.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NumberOfTermLoans" xlink:label="loc_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:to="lab_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of installments (in installments)</link:label>
    <link:label id="lab_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD_label_en-US" xlink:label="lab_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Number of Installments</link:label>
    <link:label id="lab_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of installments for payment of the debt.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentNumberOfInstallments" xlink:label="loc_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:to="lab_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:type="arc" />
    <link:label id="lab_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561_terseLabel_en-US" xlink:label="lab_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of debt with equal quarterly installments</link:label>
    <link:label id="lab_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561_label_en-US" xlink:label="lab_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Debt With Equal Quarterly Installments</link:label>
    <link:label id="lab_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561_documentation_en-US" xlink:label="lab_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the term of debt with equal quarterly installments.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TermOfDebtWithEqualQuarterlyInstallments" xlink:label="loc_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:to="lab_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium</link:label>
    <link:label id="lab_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561_label_en-US" xlink:label="lab_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Penalty Percentage On Prepayment Period One</link:label>
    <link:label id="lab_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of prepayment premium for prepayment made on or prior to March 31, 2018.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne" xlink:label="loc_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:to="lab_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed rate percentage paid in cash</link:label>
    <link:label id="lab_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B_label_en-US" xlink:label="lab_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Fixed Rate Percentage Paid In Cash</link:label>
    <link:label id="lab_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rate for which Company may elect to pay interest in cash.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentFixedRatePercentagePaidInCash" xlink:label="loc_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:to="lab_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid-in-kind percentage</link:label>
    <link:label id="lab_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05_label_en-US" xlink:label="lab_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Paid-In-Kind Percentage</link:label>
    <link:label id="lab_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of interest rate for which interest is paid-in-kind by adding paid-in-kind interest to the outstanding principal amounts of the Term Loans.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentInterestPaidInKindPercentage" xlink:label="loc_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:to="lab_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of accrued interest to long-term debt</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:to="lab_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:type="arc" />
    <link:label id="lab_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911_terseLabel_en-US" xlink:label="lab_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PaymentOfEndOfTermObligation" xlink:label="loc_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911" xlink:to="lab_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_09DA5ADED5179F880D0EE8A9990A7274_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_09DA5ADED5179F880D0EE8A9990A7274" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_09DA5ADED5179F880D0EE8A9990A7274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_09DA5ADED5179F880D0EE8A9990A7274" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_09DA5ADED5179F880D0EE8A9990A7274" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the beginning and ending amount of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_432E72D316087CE5DDC9E8A9969C988F_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_432E72D316087CE5DDC9E8A9969C988F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_432E72D316087CE5DDC9E8A9969C988F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_432E72D316087CE5DDC9E8A9969C988F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_432E72D316087CE5DDC9E8A9969C988F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increases&#8212;tax position in prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross decreases&#8212;tax position in prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increases&#8212;current period tax position</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_FB168605D4B487C09434E8A9969EED17_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_FB168605D4B487C09434E8A9969EED17" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_FB168605D4B487C09434E8A9969EED17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_FB168605D4B487C09434E8A9969EED17" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_FB168605D4B487C09434E8A9969EED17" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense or penalties related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_B88C8DDECDA09E42FC5549ADE1F69593_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_B88C8DDECDA09E42FC5549ADE1F69593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B88C8DDECDA09E42FC5549ADE1F69593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_B88C8DDECDA09E42FC5549ADE1F69593" xlink:to="lab_us-gaap_IncomeStatementAbstract_B88C8DDECDA09E42FC5549ADE1F69593" xlink:type="arc" />
    <link:label id="lab_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE_terseLabel_en-US" xlink:label="lab_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharmaceutical revenue</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE_label_en-US" xlink:label="lab_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceutical [Member]</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE_documentation_en-US" xlink:label="lab_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharmaceutical [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BiopharmaceuticalMember" xlink:label="loc_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE" xlink:to="lab_vcyt_BiopharmaceuticalMember_B14CD2FF0F43C2D0E52049C9295FDEBE" xlink:type="arc" />
    <link:label id="lab_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE_terseLabel_en-US" xlink:label="lab_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE_label_en-US" xlink:label="lab_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE_documentation_en-US" xlink:label="lab_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CollaborationMember" xlink:label="loc_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE" xlink:to="lab_vcyt_CollaborationMember_C7A704B77F09BA95FEAB49C9295F20AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="lab_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of testing revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:to="lab_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035_terseLabel_en-US" xlink:label="lab_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:label id="lab_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035_label_en-US" xlink:label="lab_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostDirectMaterial" xlink:label="loc_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:to="lab_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:to="lab_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:to="lab_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:to="lab_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB" xlink:to="lab_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346_label_en-US" xlink:label="lab_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:to="lab_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E_label_en-US" xlink:label="lab_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:to="lab_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851_label_en-US" xlink:label="lab_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:to="lab_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation award, tranche one</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation award, tranche two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation award, tranche three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:type="arc" />
    <link:label id="lab_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711_terseLabel_en-US" xlink:label="lab_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711_label_en-US" xlink:label="lab_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan2013 [Member]</link:label>
    <link:label id="lab_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711_documentation_en-US" xlink:label="lab_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the 2013 Stock Incentive Plan (the 2013 Plan).</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIncentivePlan2013Member" xlink:label="loc_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:to="lab_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:type="arc" />
    <link:label id="lab_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4_terseLabel_en-US" xlink:label="lab_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ISO</link:label>
    <link:label id="lab_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4_label_en-US" xlink:label="lab_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4_documentation_en-US" xlink:label="lab_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to incentive stock options (ISOs).</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncentiveStockOptionsMember" xlink:label="loc_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:to="lab_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:type="arc" />
    <link:label id="lab_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668_terseLabel_en-US" xlink:label="lab_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NSO</link:label>
    <link:label id="lab_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668_label_en-US" xlink:label="lab_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Statutory Stock Options [Member]</link:label>
    <link:label id="lab_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668_documentation_en-US" xlink:label="lab_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to non statutory stock options (NSOs).</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonStatutoryStockOptionsMember" xlink:label="loc_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:to="lab_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:to="lab_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:type="arc" />
    <link:label id="lab_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553_terseLabel_en-US" xlink:label="lab_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside director who was not previously an employee</link:label>
    <link:label id="lab_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553_label_en-US" xlink:label="lab_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside Director Who Was Not Previously Employee [Member]</link:label>
    <link:label id="lab_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553_documentation_en-US" xlink:label="lab_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to outside director, who was not previously an employee.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember" xlink:label="loc_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:to="lab_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:type="arc" />
    <link:label id="lab_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8_terseLabel_en-US" xlink:label="lab_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside director serving as a member of Board of Directors for at least six months</link:label>
    <link:label id="lab_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8_label_en-US" xlink:label="lab_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside Director Serving As Member Of Board Of Directors For At Least Six Months [Member]</link:label>
    <link:label id="lab_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8_documentation_en-US" xlink:label="lab_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to outside director serving as a member of Board of Directors for at least six months.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember" xlink:label="loc_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:to="lab_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:type="arc" />
    <link:label id="lab_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231_terseLabel_en-US" xlink:label="lab_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside director</link:label>
    <link:label id="lab_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231_label_en-US" xlink:label="lab_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside Director [Member]</link:label>
    <link:label id="lab_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231_documentation_en-US" xlink:label="lab_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nonemployee serving on the board of directors (who collectively have responsibility for governing the entity).</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorMember" xlink:label="loc_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:to="lab_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of options granted</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting power of person owning stock</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Percentage of Voting Power of All Classes of Stock</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Voting power of all classes of stock, as a percent, of person owning stock as threshold for option terms under the entity's stock option plan.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of options granted to a person owning stock representing more than 10% of voting power of all classes of stock</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Term of Options Granted to Employees Who Owned Specified Percentage of Class of Stock</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the term of options granted to persons owning stock representing specified percentage of voting power of all classes of stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:type="arc" />
    <link:label id="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480_terseLabel_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option price as a percentage of estimated fair value of shares on date of grant to a person owning stock representing more than 10% of voting power of all classes of stock</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480_label_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Purchase Price of Stock Percentage for Grants to Persons Who Owned Specified Percentage of Class of Stock</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480_documentation_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option price as a percentage of estimated fair value of shares on date of grant to a person owning stock representing specified percentage of voting power of all classes of stock.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock" xlink:label="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:to="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:type="arc" />
    <link:label id="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C_terseLabel_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of award vesting after one year</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C_label_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Award Vesting Rights Percentage Year One</link:label>
    <link:label id="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C_documentation_en-US" xlink:label="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of vesting of share-based compensation awards after one year from date of grant.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne" xlink:label="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:to="lab_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:type="arc" />
    <link:label id="lab_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300_terseLabel_en-US" xlink:label="lab_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300_label_en-US" xlink:label="lab_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Additional Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300_documentation_en-US" xlink:label="lab_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate number of additional common shares reserved for future issuance under the plan.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:label="loc_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:to="lab_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum annual increase in outstanding shares on the last day of the immediately preceding fiscal year (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares granted as initial grant (in shares)</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Initial Grants</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross number of share options (or share units) granted to each individual as an initial grant.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares granted as annual grant (in shares)</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Annual Grants</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross number of share options (or share units) granted to each individual as an annual grant.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for which director has to serve as board of director to receive grant to purchase shares</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share based Payment Award Period for Which Director Has to Serve as Board of Director to Receive Grant to Purchase Shares</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the period for which director has to serve as board of director to receive grant to purchase shares.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:type="arc" />
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period after termination of service</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Award Expiration Period After Termination</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration period of award after termination of service, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of future minimum lease payments under non-cancelable operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90" xlink:to="lab_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0_label_en-US" xlink:label="lab_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Leased to Others [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsLeasedToOthersMember" xlink:label="loc_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:to="lab_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:to="lab_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software, including software developed for internal use</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:to="lab_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C" xlink:type="arc" />
    <link:label id="lab_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A_verboseLabel_en-US" xlink:label="lab_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A_label_en-US" xlink:label="lab_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization of Tangible Assets</link:label>
    <link:label id="lab_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A_documentation_en-US" xlink:label="lab_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization of Tangible Assets</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DepreciationandAmortizationofTangibleAssets" xlink:label="loc_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:to="lab_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:type="arc" />
    <link:label id="lab_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87_terseLabel_en-US" xlink:label="lab_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leased assets</link:label>
    <link:label id="lab_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87_label_en-US" xlink:label="lab_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:label id="lab_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87_documentation_en-US" xlink:label="lab_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization" xlink:label="loc_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:to="lab_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:type="arc" />
    <link:label id="lab_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B_terseLabel_en-US" xlink:label="lab_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B_label_en-US" xlink:label="lab_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:label id="lab_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B_documentation_en-US" xlink:label="lab_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization" xlink:label="loc_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:to="lab_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, depreciation expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:type="arc" />
    <link:label id="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B_terseLabel_en-US" xlink:label="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory facilities, Austin, Texas</link:label>
    <link:label id="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B_label_en-US" xlink:label="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Facilities Austin Texas [Member]</link:label>
    <link:label id="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B_documentation_en-US" xlink:label="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the lease for laboratory facilities in Austin, Texas that expires July 2018.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:label="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:to="lab_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:type="arc" />
    <link:label id="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705_terseLabel_en-US" xlink:label="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of space leased (in square feet)</link:label>
    <link:label id="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705_label_en-US" xlink:label="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Space Leased</link:label>
    <link:label id="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705_documentation_en-US" xlink:label="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of space leased under the terms of the agreement.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:label="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:to="lab_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:to="lab_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:to="lab_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum lease payments under non-cancelable operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: amount representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Present value of future lease payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A" xlink:to="lab_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: short-term lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:type="arc" />
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">End-of-term debt obligation</link:label>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634_label_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, End Of Term Payment, Interest Amount</link:label>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, End Of Term Payment, Interest Amount</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentEndOfTermPaymentInterestAmount" xlink:label="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:to="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net debt obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:to="lab_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:to="lab_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:type="arc" />
    <link:label id="lab_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6_terseLabel_en-US" xlink:label="lab_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6_label_en-US" xlink:label="lab_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6_documentation_en-US" xlink:label="lab_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Medicare, a significant third-party payer.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_MedicareMember" xlink:label="loc_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:to="lab_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:type="arc" />
    <link:label id="lab_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E_verboseLabel_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">United Healthcare</link:label>
    <link:label id="lab_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E_label_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E_documentation_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to United Healthcare, a significant third-party payer.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_UnitedHealthcareMember" xlink:label="loc_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:to="lab_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:type="arc" />
    <link:label id="lab_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5_terseLabel_en-US" xlink:label="lab_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5_label_en-US" xlink:label="lab_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5_documentation_en-US" xlink:label="lab_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ConcentrationRiskAbstract" xlink:label="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:to="lab_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:type="arc" />
    <link:label id="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF_terseLabel_en-US" xlink:label="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of major financial institutions with which the company's cash and cash equivalents are deposited (in financial institutions)</link:label>
    <link:label id="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF_label_en-US" xlink:label="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited</link:label>
    <link:label id="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF_documentation_en-US" xlink:label="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:label="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:to="lab_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long term deposit consisting of letter of credit serving as security for lease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF" xlink:type="arc" />
    <link:label id="lab_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334_terseLabel_en-US" xlink:label="lab_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334_label_en-US" xlink:label="lab_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets Non Current [Abstract]</link:label>
    <link:label id="lab_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334_documentation_en-US" xlink:label="lab_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract" xlink:label="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="lab_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235" xlink:type="arc" />
    <link:label id="lab_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2_terseLabel_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2_label_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Tax Credit Carryforwards Research and Development</link:label>
    <link:label id="lab_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2_documentation_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible research and development tax credit carryforwards.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="loc_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2" xlink:to="lab_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NanoString intangibles and goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B" xlink:type="arc" />
    <link:label id="lab_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41_terseLabel_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41_label_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41_documentation_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="loc_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41" xlink:to="lab_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41" xlink:type="arc" />
    <link:label id="lab_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5_terseLabel_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and other</link:label>
    <link:label id="lab_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5_label_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Accruals, Deferred Rent and Other</link:label>
    <link:label id="lab_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5_documentation_en-US" xlink:label="lab_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-current accruals, deferred rent and other reserves and accruals not separately disclosed.</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther" xlink:label="loc_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5" xlink:to="lab_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578_negatedLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578" xlink:to="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB" xlink:type="arc" />
    <link:label id="lab_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF_terseLabel_en-US" xlink:label="lab_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF_label_en-US" xlink:label="lab_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities Non Current [Abstract]</link:label>
    <link:label id="lab_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF_documentation_en-US" xlink:label="lab_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract" xlink:label="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:to="lab_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0" xlink:type="arc" />
    <link:label id="lab_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF_negatedTerseLabel_en-US" xlink:label="lab_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF_label_en-US" xlink:label="lab_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right of Use Assets</link:label>
    <link:label id="lab_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF_documentation_en-US" xlink:label="lab_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right of Use Assets</link:label>
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxLiabilitiesRightofUseAssets" xlink:label="loc_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF" xlink:to="lab_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729" xlink:to="lab_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>vcyt-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.veracyte.com/role/A401KPlan" xlink:href="vcyt-20191231.xsd#A401KPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/A401KPlanDetails" xlink:href="vcyt-20191231.xsd#A401KPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponents" xlink:href="vcyt-20191231.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsTables" xlink:href="vcyt-20191231.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombination" xlink:href="vcyt-20191231.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:href="vcyt-20191231.xsd#BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/BusinessCombinationTables" xlink:href="vcyt-20191231.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingencies" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsAndContingenciesTables" xlink:href="vcyt-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedBalanceSheets" xlink:href="vcyt-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="vcyt-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="vcyt-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/CoverPage" xlink:href="vcyt-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/Debt" xlink:href="vcyt-20191231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtCreditAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtCreditAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtInterestExpenseDetails" xlink:href="vcyt-20191231.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:href="vcyt-20191231.xsd#DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/DebtTables" xlink:href="vcyt-20191231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurements" xlink:href="vcyt-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:href="vcyt-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxes" xlink:href="vcyt-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesIncomeTaxExaminationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesTables" xlink:href="vcyt-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesTaxProvisionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="vcyt-20191231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShare" xlink:href="vcyt-20191231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShareDetails" xlink:href="vcyt-20191231.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerShareTables" xlink:href="vcyt-20191231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="vcyt-20191231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails" xlink:href="vcyt-20191231.xsd#OrganizationAndDescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="vcyt-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlans" xlink:href="vcyt-20191231.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockIncentivePlansEsppDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails" xlink:href="vcyt-20191231.xsd#StockIncentivePlansStockOptionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockIncentivePlansTables" xlink:href="vcyt-20191231.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquity" xlink:href="vcyt-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:href="vcyt-20191231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityTables" xlink:href="vcyt-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="vcyt-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:href="vcyt-20191231.xsd#ThyroidCytopathologyPartners" xlink:type="simple" />
  <link:roleRef roleURI="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:href="vcyt-20191231.xsd#ThyroidCytopathologyPartnersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.veracyte.com/role/A401KPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_719129B87C4B5446550FE8A9968F7979" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_719129B87C4B5446550FE8A9968F7979" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_542AD09F1EB8DE577E64E8A9968F979D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/A401KPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_AEEB067CFBAA73A5CB9DE8A9968923C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_AEEB067CFBAA73A5CB9DE8A9968923C3" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_804F1D084B066A16E682E8A9968A3B5B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_845B1CBBE5143EC1B553E8A9992C0655" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_845B1CBBE5143EC1B553E8A9992C0655" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_949E77208B38216FEC2BE8A9992C560B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_EE111831EA02DEFC4CD9E8A999099596" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_EE111831EA02DEFC4CD9E8A999099596" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_FB2F97DA00E5A934BA96E8A99909C555" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_25CDE80A63B79B11EC28E8A9990A0AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_09DA5ADED5179F880D0EE8A9990A7274" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_489D6937AEAF7A587EC2E8A9990979C2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_09DA5ADED5179F880D0EE8A9990A7274" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_809CA29C20AB00E876F9F77DA16086A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_809CA29C20AB00E876F9F77DA16086A4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_B0BF5A9513026DF5EE12F77DEAD7CE13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_84008CB32DBCB2DB8B4964AA520CFE82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_84008CB32DBCB2DB8B4964AA520CFE82" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_545C56F3B00AE7FF944064AA520C2906" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_545C56F3B00AE7FF944064AA520C2906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_545C56F3B00AE7FF944064AA520C2906" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PerceptaTechnologyMember" xlink:label="loc_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_vcyt_PerceptaTechnologyMember_F2C470F53EB9B794DB1964AA520D67B2" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopedProductTechnologyMember" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_2B59F8D12A60B4797FB864AA520DC5A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6E4AE64387601C04335C64AA520E9879" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NCounterFLEXDxLicenseMember" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_vcyt_NCounterFLEXDxLicenseMember_5B4F26F7AC14D077137F64AA520ED5D3" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AZCollaborationLicenseMember" xlink:label="loc_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B52C75C93C624C0F1E5E64AA520D0A48" xlink:to="loc_vcyt_AZCollaborationLicenseMember_A0BFB9A07E8031FC912B64AA520E88F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_37CBA40756C792494D5264AA520CC429" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_55BF7C927B33676D6C4A64AA520E1DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_BADEC6B7D175976D436464AA520F1C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_62C2FEDC8AB4F74FA73A64AA520F727D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B34E0FF1874EA534C4A164AA520E3345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_609AA27D89418515703464AA520FA1E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_503FFC30D3134F5A0245F773DFA5C2F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_503FFC30D3134F5A0245F773DFA5C2F1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_17D9C37F5E0B2153229FF7751A0F290B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_503FFC30D3134F5A0245F773DFA5C2F1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_D269C76AFA93866C29C3F7751A194976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_503FFC30D3134F5A0245F773DFA5C2F1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29FC8F0A0F53D2834B58F7751A21C343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_503FFC30D3134F5A0245F773DFA5C2F1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D673F297AB75E70ABF47F7751A2666D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_503FFC30D3134F5A0245F773DFA5C2F1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81B720F605DB9DEBACADF7751A261C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_503FFC30D3134F5A0245F773DFA5C2F1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F89B9E33FDF2D9F2A536F7751A36C82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_F94166E636011E0B5843F7751A452C35" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_503FFC30D3134F5A0245F773DFA5C2F1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_F94166E636011E0B5843F7751A452C35" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_911A665B9F29208214EF7A1C559B370C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_911A665B9F29208214EF7A1C559B370C" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0312B3FDF475FC99EC9B7A1C559C7E35" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_69FB359B2D3E401A6F267A1C559C70C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsLeasedToOthersMember" xlink:label="loc_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_AssetsLeasedToOthersMember_D1512C71BA70649262867A1C559C05C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_ComputerEquipmentMember_7A88322432D7C8BA51357A1C559DA106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_BA81B232D3C9DA2829AD7A1C559D97E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6EB0C57B1642DFBBBCC77A1C559DEAA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2840A73547EBFC4F0E77A1C559CE9B6" xlink:to="loc_us-gaap_ConstructionInProgressMember_5DCF5ACDBC5F372809AD7A1C559DB6A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A56554663D4EF50A91E07A1C559BD65E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_DD8C5D75B5E22993F4AC7A1C559D9068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A56FF5D75B6412C7AD9A7A1C559EBA3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_04B9069617F7230B093F7A1C559ED82C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DepreciationandAmortizationofTangibleAssets" xlink:label="loc_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_vcyt_DepreciationandAmortizationofTangibleAssets_E450970B49A53774721B7A1C559E543A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization" xlink:label="loc_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization_2514408A403E98ECD2717A1C559E5F87" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization" xlink:label="loc_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization_5605506132DE6664BFF17A1C559E0B8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05E187ACC78C86F837AE7A1C559D6FB1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_810D9B4531CECE97475D7A1C559E253E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_AEA3229E508953FEA5B3F731FF4C1DF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7D17C0A1F95E17F46432F77BE1078401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B86C9A3F1F55240D5C04F77A278B9D3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_37D0673A6D238494FA7CF731FF4CA484" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C5FA3DD56E00769ACCB1F731FF4C21BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombination" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_40FB0F0F2E432A3AE4F4E8A9996052D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_40FB0F0F2E432A3AE4F4E8A9996052D6" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47F040D715130C4C94BFE8A999604042" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7DD6109E1C6145B2C8F9402FCF87F409" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7DD6109E1C6145B2C8F9402FCF87F409" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_DFC5CE4EA63D069F75FE405816BCB6DD" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_A9F6653FDB9457ADB2DD4058E4D40DE6" xlink:to="loc_us-gaap_CommonStockMember_45AF99A15737DB52387A40590C837723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A806B7E27F0CA8ACC331402FCF88FBF8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A48D0780089301F804F402FCF88A181" xlink:to="loc_vcyt_NanoStringMember_A2B00CE7978553547250405FF0F2C3C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D48C27209F9478C4D6BE402FCF87B85A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_EAF24DBF7F3F2C6FAD54406A338F0AEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9D1A4EA8D0862820E006406A33989136" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9D1A4EA8D0862820E006406A33989136" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BusinessCombinationContingentConsiderationCashtobePaid" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_C4CE99F3952436C5FD90406A339F542B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_68126B9C16FF58A969E6406A33A70BD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17E33DAE68E03FE87FA0402FCF8B8A60" xlink:to="loc_us-gaap_Goodwill_85DD91E3FE4734F19C86406A5709FBB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_D1A3802CB5AAFD11D54D7CA1594D8506" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_D1A3802CB5AAFD11D54D7CA1594D8506" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BE841F3AB685D91264157CA1594FD621" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:to="loc_srt_ProductOrServiceAxis_BE841F3AB685D91264157CA1594FD621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7DE76614A4342D47EB457CA1594F3F68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_BE841F3AB685D91264157CA1594FD621" xlink:to="loc_srt_ProductsAndServicesDomain_7DE76614A4342D47EB457CA1594F3F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7DE76614A4342D47EB457CA1594F3F68" xlink:to="loc_us-gaap_ProductMember_E23DFCF773BFA0DB109F7CA1594F5B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5B1D7CCC4067F66C43FC7CA159507881" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5B1D7CCC4067F66C43FC7CA159507881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ACE7027C67299D935EF47CA159506B0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5B1D7CCC4067F66C43FC7CA159507881" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ACE7027C67299D935EF47CA159506B0B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_1F776B4A518710B6A59C7CA15950501F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ACE7027C67299D935EF47CA159506B0B" xlink:to="loc_vcyt_NanoStringMember_1F776B4A518710B6A59C7CA15950501F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0CD44592AC6DFC264CE27CA15951B1B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2B66A834976A084B849B7CA1594D2345" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0CD44592AC6DFC264CE27CA15951B1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0CD44592AC6DFC264CE27CA15951B1B4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_2E2A42918738442344707CA2466C51D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3C2045B43EF0D6B01C06654D90D7A038" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3C2045B43EF0D6B01C06654D90D7A038" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_427CB7C730A7D4BED2E1654D90D873D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_427CB7C730A7D4BED2E1654D90D873D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_427CB7C730A7D4BED2E1654D90D873D0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopedProductTechnologyMember" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_C4C92328A619B6D46C45654D90D9E0DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_C4C92328A619B6D46C45654D90D9E0DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_CB04B6D1A3917A0A21A0654D90D958E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:to="loc_us-gaap_CustomerRelationshipsMember_CB04B6D1A3917A0A21A0654D90D958E4" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NCounterFLEXDxLicenseMember" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_C32EF969300094C7BA08654D90DA02C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:to="loc_vcyt_NCounterFLEXDxLicenseMember_C32EF969300094C7BA08654D90DA02C2" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AZCollaborationLicenseMember" xlink:label="loc_vcyt_AZCollaborationLicenseMember_C2682D44404F8BB44F78654D90DA39E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0A16A264434F9D18E7A4654D90D9304D" xlink:to="loc_vcyt_AZCollaborationLicenseMember_C2682D44404F8BB44F78654D90DA39E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0AE3C486E3FD934FD895654D90DA5A6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0AE3C486E3FD934FD895654D90DA5A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B14C40AD4B01B8D91938654D90DB9446" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0AE3C486E3FD934FD895654D90DA5A6B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B14C40AD4B01B8D91938654D90DB9446" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_FC3CED1B73E98E713EA3654D90E0818F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B14C40AD4B01B8D91938654D90DB9446" xlink:to="loc_vcyt_NanoStringMember_FC3CED1B73E98E713EA3654D90E0818F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13D6EF2B28743BC06F77654D90D85DCF" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9902EBAD9D0262BEC5E4654D90E10D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_34F9A2DCD0B47D4BD2DA654D90E2F0CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:to="loc_us-gaap_Goodwill_34F9A2DCD0B47D4BD2DA654D90E2F0CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D88FC97C97929FDECB8D654D90E0584F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08B80805C71957A377B9654D90E2F38E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_AC6A4467A38B9D05D6F5598B710F0FC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_AC6A4467A38B9D05D6F5598B710F0FC0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0886C28CF1CC5495BAAD598B7110C88A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopedProductTechnologyMember" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_0BB6676A06B46F57502E598B7110BC80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0049884E36954F042054598B711011E6" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NCounterFLEXDxLicenseMember" xlink:label="loc_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="loc_vcyt_NCounterFLEXDxLicenseMember_F07104C633BB5126E418598B7111D67D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AZCollaborationLicenseMember" xlink:label="loc_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E3C4490BBC13CD65F913598B7110F3DB" xlink:to="loc_vcyt_AZCollaborationLicenseMember_08574A3F659F53EA9D48598B7111BAAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_396C45A5695F609D8602598B71113C13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_396C45A5695F609D8602598B71113C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FDFB1562D8C842548BF1598B7111ADA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_396C45A5695F609D8602598B71113C13" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FDFB1562D8C842548BF1598B7111ADA7" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FDFB1562D8C842548BF1598B7111ADA7" xlink:to="loc_vcyt_NanoStringMember_D7B8A5A5E4C0BCBE1F49598B7111FCE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_CD63855432310C4BF353598B710F6AF4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33AA399719FE11E325AE598B7112A630" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_B99D067B9BF110CB1FC0598B7112797A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BusinessCombinationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4CD32A7C01EF4E07C8445FE4DF2DA55E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4CD32A7C01EF4E07C8445FE4DF2DA55E" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_562D4A27791E78BC52925FE4DF2E5E3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4CD32A7C01EF4E07C8445FE4DF2DA55E" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_C0C081586E81C1332C155FE4DF2FAE07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4CD32A7C01EF4E07C8445FE4DF2DA55E" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_939955926B4940DCBBE95FE73F8BFD7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58D5ED672494EDD4921DE8A998EB5169" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58D5ED672494EDD4921DE8A998EB5169" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_960850BD07818AD377C4E8A998EBA782" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7B4E80080F60C4CA5D6D7CA1590861B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7B4E80080F60C4CA5D6D7CA1590861B1" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_AAFE9F65C0CC3C989D9C7CA1590955EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_AAFE9F65C0CC3C989D9C7CA1590955EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_AAFE9F65C0CC3C989D9C7CA1590955EA" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_B71613717E81C5C5BA537CA15909DB10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_B71613717E81C5C5BA537CA15909DB10" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LaboratoryFacilitiesAustinTexasMember" xlink:label="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FDB568FE8ABCA732B5347CA15909F8D5" xlink:to="loc_vcyt_LaboratoryFacilitiesAustinTexasMember_93B001695192F71938217CA1590A686B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_96CAB6118528869852B17CA15908EFF4" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased" xlink:label="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased_6A86459934B6F01D76A97CA1590A4705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_E110ACD17B86999900887CA1590AA008" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_SecurityDeposit_E110ACD17B86999900887CA1590AA008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_E73D484401B2BA773CEF7CA1590A5B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_OperatingLeaseExpense_E6241A212FEC7369B60B7CA1590AB59A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_PurchaseObligation_E4CB1D44BA7F0D4FDD9E7CA1590BDC90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_62446852BC108E34513E7CA1590A9338" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85E9262AAC863635F4D17CA1590B333E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BFDAE5F5651AEB736BC47CA1590B527A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_52B8457F05EC55CF4DF67CA1590C36AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39CFA5FCA2471C3A75BE7CA1590C458E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2191A431F8895DC662307CA1590CB309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7CD745F5B073E070C2997CA1590C31D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B54B396D157FA487CCC17CA1590CE948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_279E04E0BA811B40DA867CA1590CB71D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_OperatingLeaseLiability_768B27449233C0A68A667CA1590DA57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_E8BD23C9C27626B672A47CA1590DEFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_383A1A442A1625493CE87CA1590B5C9D" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_809EFA007006AD35B42F7CA1590DE030" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_82BA6192EEAEDA64600BE8A998E8F42C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_82BA6192EEAEDA64600BE8A998E8F42C" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1708E8941BC1ED046D12E8A998E8B3ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F23D46C671D639BF2F1FE8A99A3AE55E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F23D46C671D639BF2F1FE8A99A3AE55E" xlink:to="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9738B782602568E8786CE8A99A3B34EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9738B782602568E8786CE8A99A3B34EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_48F821A3C8840FC27B3DE8A99A3C352F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:to="loc_us-gaap_InventoryNet_778F55C0EF5F0C466445E8A99A3C2395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30A6C9915321C1BE2E5CE8A99A3CFDC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6BD75A7F299065F2BCFCE8A99A3B4108" xlink:to="loc_us-gaap_AssetsCurrent_8EBBD07C7506ED0AAB58E8A99A3CFBAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8048005EEB8DD4ED05D5E8A99A3CF634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2EB90506D01A3DCFB847E8A99A3CBF99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C949AAECEB6A52B9A5A9E8A99A3DA92D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C949AAECEB6A52B9A5A9E8A99A3DA92D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_65A0C68F99584387B82CE8A99A3DCA99" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="loc_us-gaap_Goodwill_65A0C68F99584387B82CE8A99A3DCA99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F8EE0562EF8CF6F5A5A3E8A99A3DA473" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F8EE0562EF8CF6F5A5A3E8A99A3DA473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_F4A6C4B9BFB95B5F4978E8A99A3DAAB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_523E376CE39141DE4C25E8A99A3B7179" xlink:to="loc_us-gaap_Assets_A729CCFA7381C0FFF1D8E8A99A3DC270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F23D46C671D639BF2F1FE8A99A3AE55E" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:to="loc_us-gaap_AccountsPayableCurrent_AAD01C526C6B037E6092E8A99A3E4B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3546F150BCAFC5467A4BE8A99A3FECA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:to="loc_us-gaap_LongTermDebtCurrent_8ABD2F2BE67DAD0A77A5E8A99A3F4371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_803385F479ED2CB95C86E8A99A3F29E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_646D7C4595C24593EB72E8A99A3EDDF6" xlink:to="loc_us-gaap_LiabilitiesCurrent_193C1B013E500DA5E9B8E8A99A3FC732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4AF237D342C934DF204AE8A99A4004F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueLeasesNetNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_DeferredRevenueLeasesNetNoncurrent_07DFAC5905F54E2B1BFAE8A99A40C44F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0E197E003F3562CDD87EE8A99A41C073" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0E197E003F3562CDD87EE8A99A41C073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2701BD7384EC66C25B06E8A99A42E1D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_Liabilities_3D711063EBD22248836CE8A99A424F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0FBAAFE5BBEB6C0A9AD2E8A99A4241A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:to="loc_us-gaap_PreferredStockValue_F69A5277EC0E67F2C8B7E8A99A43B48D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:to="loc_us-gaap_CommonStockValue_65A024C2797C1AB243B1E8A99A44D114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_A431C4B2DD4B381D3CDEE8A99A44DF07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B5F1D25E856F291F382DE8A99A445E8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6E400A5070B4E3E215FBE8A99A449C39" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2CB487D732E3D150EE1DE8A99A42927D" xlink:to="loc_us-gaap_StockholdersEquity_6E400A5070B4E3E215FBE8A99A449C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_025EAD584B9C0A0AD525E8A99A3EEBFC" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_34615905AD81583757C7E8A99A44E795" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2370C8D76461D7B6DFCFE8A99A2AE25F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6952D2D8F96E82D6B7CFE8A99A2ADCA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="loc_us-gaap_PreferredStockSharesIssued_B335A4AF07B082088E05E8A99A2A90CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_C25EAC782898EDDAB9FDE8A99A2AAAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8BA951A2AADF2897A755E8A99A2B65D1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8BA951A2AADF2897A755E8A99A2B65D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20D49678ABD2A9F5679AE8A99A2B190F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20D49678ABD2A9F5679AE8A99A2B190F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="loc_us-gaap_CommonStockSharesIssued_4F9C60B68277D68B69F6E8A99A2B2F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6FA92E665D67D6B06048E8A99A2A7C56" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F0B04284BF1D27C88C9AE8A99A2B9AC8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_312CEDA05520089E729F64AA444E244B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1EAA95020747D9535BB764AA444EA29F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_850895D5CE8C4347E1BF64AA444E90F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:to="loc_us-gaap_ShareBasedCompensation_3DCBF2D17C5D51EF2F8864AA444F26B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_BC30017CF586D0108E8D64AA444FED71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_811CF34245A1A825F4D364AA444F6192" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty" xlink:label="loc_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A754C6D8D1921665035864AA444E737E" xlink:to="loc_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty_E3038F6CC07030F43D8F64AA444F2345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_51D274E7851D9B7DC9F064AA444FD854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1FD39841AFC649480D6864AA44501826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5D754E688EDDFC1F67B764AA44500B04" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities" xlink:label="loc_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:to="loc_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities_1FEF633EDE66B83BBEC664AA4450DA3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9E44A7A856A54F162FBE64AA4450817C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5E418EFECC1A3E502D1164AA4450D562" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15F8F9A2CD2BB4DFBB8A64AA444F418A" xlink:to="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent_8C98D64785527F31E70D64AA4455A5E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_CF42D3BB677BA0C315BC64AA444D3490" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B9CFF25AE8A8E0B56ACE64AA4455DCF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9C324389358563743B7264AA4455844A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5AF3CC98CC98A6EB4C3F64AA445593D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_D43DB4BE2EF25EB9F1FA64AA4456E078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_79FBEE9DFEA4C12098C864AA4455AA39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8D97388B0FC415F6BAE564AA4456874A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56A39EC6BF4318FDF43C64AA44567866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4342DF15F9CF6D81D66464AA44566D54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_DC8DCA99B72724450B7E64AA44577BDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_DC8DCA99B72724450B7E64AA44577BDC" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PaymentOfEndOfTermObligation" xlink:label="loc_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="loc_vcyt_PaymentOfEndOfTermObligation_D0B7149E75EC43421D6C64AA44572F1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_4B0984DBFBBFE43C3E0164AA44575335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_11003AA480CC7163C56E64AA44576235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5F9260C0AEC0881E971864AA4457E709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_112FB1874EA33885D91564AA44562E12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2662299CBF951AD0778F64AA445759ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C0A8C7569FF47EC0E15664AA4458D866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7CC025697BD5A49A8F1B64AA44580D70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260DC3DA86A36853A64A64AA44584559" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260DC3DA86A36853A64A64AA44584559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9AF7A11C67487189368A64AA4458FDC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_175D2071922479D2A86864AA4459B23B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration" xlink:label="loc_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:to="loc_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration_857FD9788F5347949EA964AA4459667C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956B5A18C8B5DC93D31664AA44586BBC" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_EDD30213BAC475802B5564AA445948C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:to="loc_us-gaap_InterestPaidNet_6956A03647BA9F106BEC64AA4459816D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_B31971D16BA70544F0A664AA4459BBBC" xlink:to="loc_us-gaap_IncomeTaxesPaid_D44B1448AB8ABB8BC56E64AA445A28B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E959849F86E68B5D1E764AA445A6C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_CB18A0085E488DEA0F5D64AA445A2042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4225B3B76D977F7568D264AA445AD6BC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55937A635D7C6616D74664AA444D871C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4225B3B76D977F7568D264AA445AD6BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B88C8DDECDA09E42FC5549ADE1F69593" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C47349A8D613C19D998C49ADE1F6138C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B88C8DDECDA09E42FC5549ADE1F69593" xlink:to="loc_us-gaap_StatementTable_C47349A8D613C19D998C49ADE1F6138C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_15173D4179CC14F42DC449C8B5C3EEB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C47349A8D613C19D998C49ADE1F6138C" xlink:to="loc_srt_ProductOrServiceAxis_15173D4179CC14F42DC449C8B5C3EEB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_15173D4179CC14F42DC449C8B5C3EEB4" xlink:to="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TestingMember" xlink:label="loc_vcyt_TestingMember_84C15BE198D7D3178B6149ADE1F7AF46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:to="loc_vcyt_TestingMember_84C15BE198D7D3178B6149ADE1F7AF46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_E0751FBBD331AA70A6A949ADE1F79EEE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:to="loc_us-gaap_ProductMember_E0751FBBD331AA70A6A949ADE1F79EEE" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BiopharmaceuticalMember" xlink:label="loc_vcyt_BiopharmaceuticalMember_37DA8CA5EFB2FA988D0749ADE1F8C0FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:to="loc_vcyt_BiopharmaceuticalMember_37DA8CA5EFB2FA988D0749ADE1F8C0FF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CollaborationMember" xlink:label="loc_vcyt_CollaborationMember_83A774CDED0720D7FA8B49ADE1F810FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D97BD656A9A7A92E036749C92958406C" xlink:to="loc_vcyt_CollaborationMember_83A774CDED0720D7FA8B49ADE1F810FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C47349A8D613C19D998C49ADE1F6138C" xlink:to="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5D437D982090827C716A49ADE1F82018" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5D437D982090827C716A49ADE1F82018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_CostOfRevenue_53E32EEA96E48E58B15949ADE1F8F232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostDirectMaterial" xlink:label="loc_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_CostDirectMaterial_6189FC80DC98CD1D68A249ADE1F9F035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_57F8A14D7F927EF9DD9F49ADE1F95899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_SellingAndMarketingExpense_F2666963E369188D982649ADE1F926BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_BCF5DDA7BC9AEAF63B1249ADE1F90245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_AdjustmentForAmortization_846E7AE00D2B23EF0E9D49ADE1F90FAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D84FA359CFB800C1942549ADE1F8B809" xlink:to="loc_us-gaap_CostsAndExpenses_6845F698DB293B77552A49ADE1F98300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_OperatingIncomeLoss_51E39F233D0B17A1C51749ADE1FAA6EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_InterestExpense_5A0529158B43302D578049ADE1FA1346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9FDC4A14308281ADE5FB49ADE1FA4D18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AB15E8CC4370EFE5D09149ADE1FAB55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1D79B154F68EA31DBF1649ADE1FA61C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9263DE0F5A2C4EA8AA1A49ADE1FA64B3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9263DE0F5A2C4EA8AA1A49ADE1FA64B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8C690288FE4154F6EE2649ADE1FB2475" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_34AAE5B8AFCF560F2ABA49ADE1F809B0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8C690288FE4154F6EE2649ADE1FB2475" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_A020364D37A973FD201FED4F9E6B9CAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_A020364D37A973FD201FED4F9E6B9CAE" xlink:to="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EF0B2CD6FCB02371E328ED4F9E6C59AE" xlink:to="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:to="loc_us-gaap_CommonStockMember_6D61035D8D021CE9C890ED4F9E6FD7F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_C425C66568119F0F9E5BED4F9E70D32A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3B75644AD0890856B3A7ED4F9E6C14BC" xlink:to="loc_us-gaap_RetainedEarningsMember_37FDA7DC60713128CE4EED4F9E708E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D08961729B6619265C70ED4F9E6BD81D" xlink:to="loc_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_817F3CECD48DA89AA5F7ED4F9E717EEF" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockholdersEquity_21A4C31C854BD4CCCD5DED4F9E71BA8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_SharesOutstanding_A7F14CCFAC317C7688FEED4F9E7256F1" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod_D996B8DC07EB3D7C0DCBED4F9E725674" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod_FAB66C47467BE8DAFB6AED4F9E73CEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_231F65D9E19D2A6F923EED4F9E73966B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_BA9EB59305B14B78D686ED4F9E739910" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement" xlink:label="loc_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement_3EB86804403BEFE2A6D1ED4F9E73A5F5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement" xlink:label="loc_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement_379E8CEAD284FEC5716EED4F9E74CAED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2CFB46C540FCDFCD5809ED4F9E749362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_AC6301F4571E2DF656BEED4F9E7462E0" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_D821B18C9871574894C8ED4F9E748182" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_5E44427D9327375B3598ED4F9E75E3B5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_78A28A59B2E862C124DBED4F9E75D4F9" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax" xlink:label="loc_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax_2781501F55EEB74F1E39ED4F9E753705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_390C3BC26F15B9DD5331ED4F9E75CCC1" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_390C3BC26F15B9DD5331ED4F9E75CCC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_A0DF4BC510AB4964AA05ED4F9E761FE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_902CBBA60184C70CF56CED4F9E769AAA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_StockholdersEquity_902CBBA60184C70CF56CED4F9E769AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_DC6CDCDDD6F5FDFEEE60ED4F9E760D02" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_BA3BE23213A05AD14286ED4F9E711416" xlink:to="loc_us-gaap_SharesOutstanding_DC6CDCDDD6F5FDFEEE60ED4F9E760D02" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_B25244485B2811DCF598E8A99A0561C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_B25244485B2811DCF598E8A99A0561C9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2A2E228154EFE5CB19DBE8A99A055BD4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C628D235859FA70EC3C6363F734E5786" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_DocumentType_C628D235859FA70EC3C6363F734E5786" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_DocumentAnnualReport_96FDB9DB897B1EC191E8363F734EC4FA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_DocumentPeriodEndDate_B912964E154735CA0888363F734ED0D6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_DocumentTransitionReport_FDB4F2881A25B70AA61A363F734E3384" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityFileNumber_ED52842333326D26FC16363F734E6693" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityRegistrantName_180ABC74A76BD47B1E3A363F734E962E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_B08A7513D14910950337363F734E3024" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityTaxIdentificationNumber_09F8B1AD7E19F3B3FB05363F734E320C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityAddressAddressLine1_FFFA499C9B828BF7731E363F734EEAE0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityAddressAddressLine2_3F2B07C95664ECAA716E363F734E02DD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityAddressCityOrTown_99191D31A7064302A2A1363F734E179E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityAddressStateOrProvince_454F5F7B8D078D3A5622363F734E75B3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityAddressPostalZipCode_400F58792F756CE808B7363F734E152E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_CityAreaCode_6E787466108DAEAE94D6363F734E1925" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_LocalPhoneNumber_30D1AB8D667B6C8B5F5E363F734E4D4E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_Security12bTitle_F7F56AF7FCFE5DCA629E363F734E1072" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_TradingSymbol_9B8FFB495D147251A373363F734E2B19" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_SecurityExchangeName_E722627F97AF7F0BA26D363F734E2778" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_D5952F0236F1AA2CF3EF363F734E7315" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityVoluntaryFilers_48B8AA21B6BA009C62A0363F734E1F64" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityCurrentReportingStatus_7F24DA52B5CA7F85BC1E363F734E1452" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityInteractiveDataCurrent_72BE7F8C399E8E65BFBE363F734E8B56" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityFilerCategory_846C73A1B84544405773363F734EA7EE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntitySmallBusiness_1197FD8D2AC5A45BE1EA363F734EB349" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityEmergingGrowthCompany_7BBCBD03C6D8BB13816E363F734E5C72" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityShellCompany_123F13D1B8640D21F3CF363F734EE7B6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityPublicFloat_999622F7C4DE76FC67C3363F734EE661" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_D5A4D6B5D2657C51780E363F734E08E3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_101A66F1A54E8E6B9599363F734EC205" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_EntityCentralIndexKey_F9663DFD797B344EC43B363F734E0ED2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_AmendmentFlag_6AE0DC4E84C9841FCD3D363F734E9DF3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_CurrentFiscalYearEndDate_31817F0C4AA6F4F21E7C363F734EEFE5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_DocumentFiscalYearFocus_34D69DB405554F3537F5363F734ECC91" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41B82AF46163953BE166363F734EBCA0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_E6C477F93F8280E2A4B3363F734E5723" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6100A3E00FAA34C04666E8A998BE625D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6100A3E00FAA34C04666E8A998BE625D" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_DDBF312B9CAAD7EAF5DCE8A998BE54B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/DebtCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8194580241027892BE00E8A9983D1AEE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8194580241027892BE00E8A9983D1AEE" xlink:to="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_DB84B50316606E67344CE8A9983F8F91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_DB84B50316606E67344CE8A9983F8F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_84677FF1C8D837CD0598E8A99841E2FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_DB84B50316606E67344CE8A9983F8F91" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_84677FF1C8D837CD0598E8A99841E2FB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_VisiumMember" xlink:label="loc_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_84677FF1C8D837CD0598E8A99841E2FB" xlink:to="loc_vcyt_VisiumMember_BDD69FA374A5C5FFB751E8A998421F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E05262C194FCAA8D133EE8A99846F755" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E05262C194FCAA8D133EE8A99846F755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ADE748A5AEB0E211C01E8A99846B443" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E05262C194FCAA8D133EE8A99846F755" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ADE748A5AEB0E211C01E8A99846B443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_830AD92832610A6A3D6EE8A99848F90B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ADE748A5AEB0E211C01E8A99846B443" xlink:to="loc_us-gaap_LineOfCreditMember_830AD92832610A6A3D6EE8A99848F90B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:to="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_AD25F9490F44F439BAA2E8A99849C776" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_InitialTermLoanMember" xlink:label="loc_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8A1673218CCE83F7CAA2E8A998494E4A" xlink:to="loc_vcyt_InitialTermLoanMember_BB1FC55A21DA6E76898FE8A9984A4561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7E4A410A7455975D8EE7E8A9983EB815" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NumberOfTermLoans" xlink:label="loc_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_NumberOfTermLoans_08496F483C8306D38AD8E8A9984B2465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8A5D322063A227CF978AE8A9984F6BFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8A5D322063A227CF978AE8A9984F6BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_F5D0BCDC567E9B2F82BBE8A998505793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_720D7CF81BED363DBD2EE8A9985124A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_720D7CF81BED363DBD2EE8A9985124A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31CE2DA7465962A6112BE8A99851ED73" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31CE2DA7465962A6112BE8A99851ED73" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentNumberOfInstallments" xlink:label="loc_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_DebtInstrumentNumberOfInstallments_C65D5B4F336105B9C442E8A99852A1CD" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TermOfDebtWithEqualQuarterlyInstallments" xlink:label="loc_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_TermOfDebtWithEqualQuarterlyInstallments_5E76B8AE56057982CAC4E8A998537561" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne" xlink:label="loc_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne_60DD378C8C68ACD8E05BE8A998559561" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentFixedRatePercentagePaidInCash" xlink:label="loc_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_DebtInstrumentFixedRatePercentagePaidInCash_09640B617F4BECF17736E8A99855A95B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentInterestPaidInKindPercentage" xlink:label="loc_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_DebtInstrumentInterestPaidInKindPercentage_2E601B30A8D692AB0C83E8A99856BA05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_us-gaap_PaidInKindInterest_BF3379386BEDE8F9A1CDE8A998567412" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PaymentOfEndOfTermObligation" xlink:label="loc_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7624D9A59D07EB2E9FAFE8A9984B4CC9" xlink:to="loc_vcyt_PaymentOfEndOfTermObligation_E3F2F84948D9316F9D5DE8A998560911" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_56DEC3C550A4B7077B785DDACB6F2F7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56DEC3C550A4B7077B785DDACB6F2F7E" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_F48CD0A6D2F5652215865DDACB7174D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56DEC3C550A4B7077B785DDACB6F2F7E" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_3F553AB351A41A64DAE05DDACB71C54F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentEndOfTermInterestObligationAmount" xlink:label="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56DEC3C550A4B7077B785DDACB6F2F7E" xlink:to="loc_vcyt_DebtInstrumentEndOfTermInterestObligationAmount_5828464E1FF7C1F8BC505DDACB7138B9" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_PrepaymentPenalty" xlink:label="loc_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56DEC3C550A4B7077B785DDACB6F2F7E" xlink:to="loc_vcyt_PrepaymentPenalty_44AF46EBE556BDA4A6385DDACB71AE34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56DEC3C550A4B7077B785DDACB6F2F7E" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_4EFB488A1B709264C5015DDACB72581E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56DEC3C550A4B7077B785DDACB6F2F7E" xlink:to="loc_us-gaap_InterestExpenseDebt_DB2BC34CE38E52CB52905DDACB721DBC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A1CAE39FBE5274164AA9402FCF3537B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A1CAE39FBE5274164AA9402FCF3537B1" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheAxis" xlink:label="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPaymentTrancheDomain" xlink:label="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_DebtPrepaymentTrancheAxis_3C201686CBF0F6DB4F34402FCF358ECF" xlink:to="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheOneMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:to="loc_vcyt_DebtPrepaymentTrancheOneMember_7923C5189C22BCB2E54F402FCF36BD1F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheTwoMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:to="loc_vcyt_DebtPrepaymentTrancheTwoMember_646A9DA5F97D2DF98DFD402FCF369634" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtPrepaymentTrancheThreeMember" xlink:label="loc_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_DebtPaymentTrancheDomain_AE0871D9960D84850996402FCF36FB96" xlink:to="loc_vcyt_DebtPrepaymentTrancheThreeMember_41B5D4675C99F277B6EA402FCF368868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_B71516271E573454473F402FCF3607D9" xlink:to="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_466CC1DA23A804CC1440402FCF37AE63" xlink:to="loc_srt_MinimumMember_79CCC16D314AE1356E82402FCF371EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_371131C0D3316BBE7808402FCF3707A4" xlink:to="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_59F860A0847EE0C180B2402FCF377A5B" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6FFF530E63EFB1911A2D402FCF383C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DA62F8E568679E5935DE402FCF384F95" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E0E9C3B45E30EE2A2B9F402FCF38D23C" xlink:to="loc_us-gaap_LineOfCreditMember_2EA488DF2508AD76A6D0402FCF385B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_F3263EFFB0F4FE5884D1402FCF3937A1" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SiliconValleyBankMember" xlink:label="loc_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_F5A1C8260F1529EE3B09402FCF39EB55" xlink:to="loc_vcyt_SiliconValleyBankMember_8BC474E3AFEF29260F73402FCF39E124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_D4ACDB11B8183950CEEF402FCF39C652" xlink:to="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:to="loc_us-gaap_SecuredDebtMember_9A1A89BA8AC2BA90B899402FCF3AECBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_F08750E12544824E314B402FCF39EEA5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_C65F9F67E2E31711AEA3402FCF3A47B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_754F459BDB0F60B03241402FCF35D203" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EBC48A51A66FE4F3E9B402FCF3AEA8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_C21B7A2C34FCBE5E9C77402FCF3BA132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_28C080BEDC141FD55F87402FCF3B6D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0EF08314DA0E06C5A376402FCF3BB15B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentPrepaymentPremium" xlink:label="loc_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_vcyt_DebtInstrumentPrepaymentPremium_A6720F7B853A36B64A6B402FCF3BF9B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_FBBD75F342521E968F1F402FCF3BB0A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_ABEED3A6227277DB27B3402FCF3B224A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LiquidityRequirementMinimum" xlink:label="loc_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_vcyt_LiquidityRequirementMinimum_DEFD2E6C6EDA608995A1402FCF3BE647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_30C1250477A8F30EF456402FCF3A3F43" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C01B9F19BF89A1B75EEC402FCF3C51C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_FB0EEFED62AE6EEBAF0949ADE0C3E669" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_FA22F07AFB704648F67F49ADE0C327F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_FB0EEFED62AE6EEBAF0949ADE0C3E669" xlink:to="loc_us-gaap_DebtInstrumentTable_FA22F07AFB704648F67F49ADE0C327F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FE34664E1E88CC25B77E49ADE0C3D9D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FA22F07AFB704648F67F49ADE0C327F9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FE34664E1E88CC25B77E49ADE0C3D9D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1F7042C48EE738C02C4949ADE0C3C40D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FE34664E1E88CC25B77E49ADE0C3D9D3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1F7042C48EE738C02C4949ADE0C3C40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_154D6595E90ED56D400649ADE0C4B6C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1F7042C48EE738C02C4949ADE0C3C40D" xlink:to="loc_us-gaap_LineOfCreditMember_154D6595E90ED56D400649ADE0C4B6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FA22F07AFB704648F67F49ADE0C327F9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1B42BA97AD1FDD6FAF8349ADE0C47176" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DebtInstrumentEndOfTermPaymentInterestAmount" xlink:label="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount_60E0137ADFA577C6949049ADE0C42634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_24631712603F906E889D49ADE0C54990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E4E74DACC76141A0229149ADE0C4E244" xlink:to="loc_us-gaap_LongTermDebt_230B41D37971851DDE3D49ADE0C53158" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F5759A15DCF4B14C0FCF5DDA891F7553" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F5759A15DCF4B14C0FCF5DDA891F7553" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_8ADD214CA0683730F3815DDA892041CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F5759A15DCF4B14C0FCF5DDA891F7553" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_317923237CEF5CF717145DDA8920775B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A682A63540FA6BA8A207E8A9990239CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A682A63540FA6BA8A207E8A9990239CB" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8A881E2626BD22285FB1E8A999025398" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A2DCD1049EDB8865FAEF5FFB7CA8C615" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A2DCD1049EDB8865FAEF5FFB7CA8C615" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AC5952BA90D29F0818145FFEC6FFD5ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AC5952BA90D29F0818145FFEC6FFD5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F39AC7414EC25FE9A7015FFEC8295AB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AC5952BA90D29F0818145FFEC6FFD5ED" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F39AC7414EC25FE9A7015FFEC8295AB4" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NanoStringMember" xlink:label="loc_vcyt_NanoStringMember_90E97D2D5C94EA447BBB5FFEC70DA057" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F39AC7414EC25FE9A7015FFEC8295AB4" xlink:to="loc_vcyt_NanoStringMember_90E97D2D5C94EA447BBB5FFEC70DA057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1209C19C7601754849A15FFB7CAB9CF7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2052E217A5FDD3C2F4025FFB7CAC891D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_25366D5E1D351BEAFE815FFB7CAC731A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_C598EA5A9F6B21E6A3A15FFB7CACED3C" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OvernightRepurchaseAgreementsMember" xlink:label="loc_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_D02A528D66AD49DF05F75FFB7CAD9C56" xlink:to="loc_vcyt_OvernightRepurchaseAgreementsMember_A69A5F076BEDBF7106B85FFB7CAD866A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B5E2BD0435C0FBB9DE6F5FFB7CADA1FC" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DAEA2291AFE8C04343545FFB7CADBAA4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7E9A85BC17354A4956CD5FFB7CAEF502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_E3837B22AC44C414632A5FFB7CAED360" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_B307CAB3FB3D40A3B6EC5FFB7CAE7AB7" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember_FA7ECFA455E2C3C46FAE5FFB7CAE3D56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01F4CC7654BA7660981A5FFB7CAA697C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_311D67BFC110DCB8E5D35FFB7CAFC9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_us-gaap_SecurityDeposit_EA52BB12DB57DB207F145FFB7CAF9895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F728C69EB5684353AD955FFEC6E6423F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F728C69EB5684353AD955FFEC6E6423F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BusinessCombinationContingentConsiderationCashtobePaid" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_52B5F655858D8011C7175FFEC6F3D75B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40E04C85DC94D3E03E785FFB7CAFB7E7" xlink:to="loc_vcyt_BusinessCombinationContingentConsiderationCashtobePaid_52B5F655858D8011C7175FFEC6F3D75B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0B2B9E68FCF876201A1AE8A996CB1073" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0B2B9E68FCF876201A1AE8A996CB1073" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9B515DBB14CBBB0380E4E8A996CB4FAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E021A05732F5EEE7C4E664B4468B79D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_FCE7AC3E0D7C5E7B359364B4468BE218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D9BFB76C182145F7A5F964B4468BD845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_E585A823182405EFC32764B4468B0549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B26FA9EC4E5945446D9564B4468BE9BD" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_B6472027CEC430396B7C64B4468C0018" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:to="loc_us-gaap_DomesticCountryMember_15FB30256FACB62645E564B4468C0C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_C6E4BC1B83F9D263028564B4468CD40D" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_FED556EC8D883811494664B4468D60BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:to="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_CC97F2DE844A080F8A5564B4468DB834" xlink:to="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:to="loc_stpr_CA_AD4B20F17F3E3421885B64B4468D1652" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OtherStatesNotSeparatelyDisclosedMember" xlink:label="loc_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9396592AEE395D613E5864B4468DC6EF" xlink:to="loc_vcyt_OtherStatesNotSeparatelyDisclosedMember_B8268127391E22D3ECA964B4468D9222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B738C56EB15009102BB864B4468B67A9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:to="loc_us-gaap_OperatingLossCarryforwards_5779E5B050828C41D1A964B4468E84BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_157C2E9405072B0D642564B4468ED75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C88E9EA5004B1FDC1BBE64B4468E7CB2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_74388CD34D26885497F56514634BFBE9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2276AF549A5BA21B2354598E4F4EC071" xlink:type="locator" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract" xlink:label="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2276AF549A5BA21B2354598E4F4EC071" xlink:to="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1D61487C1D1175D98BE8598E4F506235" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="loc_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ACC3ED10639DBF465065598E4F506CA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_528ABAFC68671D0F5A25598E4F50604E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4D369709EFA59986CCCF598E4F504F9B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="loc_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_vcyt_DeferredTaxAssetsOperatingLeaseLiability_43D68388B571ABD38B11598E4F504C41" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther" xlink:label="loc_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther_FDF8F2E30678FD8B2AE1598E4F502DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_83D6F8DB0DB64BC8F18C598E4F50DE54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_E8EBB1306EE4A1607463598E4F510578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract_B30EF8A3BE7B006AB304598E4F4F1334" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_C495F847C8384C1FB52F598E4F51C3DB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract" xlink:label="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2276AF549A5BA21B2354598E4F4EC071" xlink:to="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_F1BCF43764E5109702A0598E4F511267" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_44EA67156166A718862A598E4F52A6F0" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DeferredTaxLiabilitiesRightofUseAssets" xlink:label="loc_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:to="loc_vcyt_DeferredTaxLiabilitiesRightofUseAssets_711C7734664815E346C0598E4F5268DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_356DB187872D8E4D6DF4598E4F520FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract_88FADD3DA44371688ECD598E4F51B3DF" xlink:to="loc_us-gaap_DeferredTaxLiabilities_48166C8492512A142D89598E4F527729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2276AF549A5BA21B2354598E4F4EC071" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_B1D5A429EF536416EB3D598E4F52A2ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2F23BF3E0BBB23BF5249E8A996942615" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2F23BF3E0BBB23BF5249E8A996942615" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_098E86B5697E9E9DC38CE8A996957EAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_098E86B5697E9E9DC38CE8A996957EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_098E86B5697E9E9DC38CE8A996957EAF" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_CB0782E7968A3D2B2572E8A99696851A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39" xlink:to="loc_us-gaap_DomesticCountryMember_CB0782E7968A3D2B2572E8A99696851A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_B15BA76EB00B18A29ABDE8A996964044" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_771F0BCF8AE2A58BEFF5E8A99696CE39" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_B15BA76EB00B18A29ABDE8A996964044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_9B75F06DE164D5E41E3BE8A9969541AA" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncomeTaxExaminationPeriod" xlink:label="loc_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8781F125FD31DF6448C0E8A9969634A0" xlink:to="loc_vcyt_IncomeTaxExaminationPeriod_A74945FEEC781C4CF243E8A996963E60" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_455FC05DA0C12F54DF2BE8A996C897CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_455FC05DA0C12F54DF2BE8A996C897CF" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_13054FB1A68CD051C894E8A996C893F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_455FC05DA0C12F54DF2BE8A996C897CF" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_89C693DE5B183485AFE1E8A996C86F99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_455FC05DA0C12F54DF2BE8A996C897CF" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F556441BC27FE13C5AA9E8A996C8E967" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8D280941D7C6EFBDFE76402FCE6D47BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8D280941D7C6EFBDFE76402FCE6D47BA" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3B6D1059D6E88B79E73C402FCE6E02FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E873E395867087472758402FCE6E2BF7" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" xlink:label="loc_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_84953176AF1D3EBF80CA402FCE6E090F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_970A8A6B52E072C98B8240422EB043FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_970A8A6B52E072C98B8240422EB043FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_CB1D8306674998FFB0A3402FCE6ED5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B5CC1BCFA888AE5A7AFD402FCE6F9110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5D843A9E1909A4A63028402FCE6FDF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72661BAAC346D333B061402FCE6F63F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73E06BFCE7E07CDFD964402FCE6FB696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BE8AA83EAC412161D68D402FCE6FA308" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3278B054581B15C1FFBC402FCE6DE487" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_BE8AA83EAC412161D68D402FCE6FA308" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E399601759359DC661B8E8A9969CFF93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E399601759359DC661B8E8A9969CFF93" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_432E72D316087CE5DDC9E8A9969C988F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_432E72D316087CE5DDC9E8A9969C988F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8921657D49E48E83361CE8A9969D01A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E6FC4D57AEE780F966D6E8A9969DFCCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7B472FAE841EEE30B5D8E8A9969EBD3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_D5A585EFE09212716729E8A9969E18E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_FB168605D4B487C09434E8A9969EED17" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_240104B49435F7DA2DD8E8A9969CB325" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_FB168605D4B487C09434E8A9969EED17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E399601759359DC661B8E8A9969CFF93" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_05A47EF27583A94D56E4E8A9969E5C5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_EC2A5D42A40BCA3DF53EE8A99971DE9A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_EC2A5D42A40BCA3DF53EE8A99971DE9A" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_E65631AB94629A2CCE45E8A99971AEB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CED2B99AB1F815D6FEF1F75CA47F12D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CED2B99AB1F815D6FEF1F75CA47F12D9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8C304CB2E609996423EAF75CA4801795" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_86768A36CCD26F17A9D8F75CA480E76B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:to="loc_us-gaap_EmployeeStockMember_3CFE04EACED55A0279D7F75CA48019DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C90B76C0DD58B4A4E64FF75CA4801E3A" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_176F88232037FC93EE29F75CA48167F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD949C49C4774371B772F75CA47FFFFA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_45AAC7AF0D61FB51DD81F75CA481F817" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_625B4D1B5B9102D5A618F75CA4819C37" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_49BE95544FEB392EE630E8A9996DF387" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_49BE95544FEB392EE630E8A9996DF387" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D17F13C3DA8841D56F48E8A9996D984D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E8A587C2694FBA7ACAEE8A999E0CE1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E8A587C2694FBA7ACAEE8A999E0CE1C" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_BEA7DE64248B37874E21E8A999E08A46" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A4ADF1CFC4CFE15374EA402FCFEECA9E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A4ADF1CFC4CFE15374EA402FCFEECA9E" xlink:to="loc_us-gaap_NumberOfOperatingSegments_55701C13C4E4A099D134402FCFEE379F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7AC89A7E66A253777770E8A996764C80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7AC89A7E66A253777770E8A996764C80" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C898E25800DD856C981BE8A996774570" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_49D84B1D1A5342E18C9AE8A9966E0D45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_49D84B1D1A5342E18C9AE8A9966E0D45" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12AC4107A362E57D7605E8A9966EFCFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12AC4107A362E57D7605E8A9966EFCFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_408E3A5CAC2B7196BBF9E8A9966EE929" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_408E3A5CAC2B7196BBF9E8A9966EE929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF801196A0753DF46D16E8A9966FB853" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF801196A0753DF46D16E8A9966FB853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B9F91EF8692CF634EC18E8A9966EE6D6" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3272DF2E10DCFFFA513DE8A9966FAE31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_FDC6218A26F0D027908CE8A996726F65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_FDC6218A26F0D027908CE8A996726F65" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C1299FCCFAD5730C83B2E8A996734B0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ED46E5FC143B2B2819AE8A997B0DF35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ED46E5FC143B2B2819AE8A997B0DF35" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BC502E07EDA456252D15E8A997B01B4D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C831B92C7A062413D49B49ADE056F83B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C831B92C7A062413D49B49ADE056F83B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_89B3CB79EC7242786A4F49ADE056C0B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:to="loc_us-gaap_AwardTypeAxis_89B3CB79EC7242786A4F49ADE056C0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_89B3CB79EC7242786A4F49ADE056C0B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4460A9C6974D004CB10449ADE0564FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5DE73EF626E6AEBE01AB49ADE057836D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5DE73EF626E6AEBE01AB49ADE057836D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_34624FE4A4657E83612649B3077DE646" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913374C4E482AEFCD56849ADE056AACC" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_34624FE4A4657E83612649B3077DE646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F9DEB29E0F36E1725D749ADE05690DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07A3C13B93DF6E6BE55849ADE0578DDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_666CAF4CB9A9BAB7D6F349ADE0586CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17315BA1E6979EEBC9C949ADE0589AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E8F497BBD24B0D4B2D8C49ADE05851E4" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion" xlink:label="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion_F12EA9BCE3A02D8AA93149ADE058F9CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_64ABEB5DA4FBCF7B273C49ADE05843FD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward_83CB9ED98335313D326849ADE05779D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_64ABEB5DA4FBCF7B273C49ADE05843FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_94F1F0E0898A3D3F4AD949ADE059B81A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8734BB0A57ED12568A7149ADE05954CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8734BB0A57ED12568A7149ADE05954CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BDDD96524C2316B620549ADE059DA8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BDDD96524C2316B620549ADE059DA8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3FD96F3912D64572B45949ADE0590657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D9FFA5D4D6CEAEA2F9C049ADE059D995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CF72B92DDAA82B87220949ADE05A4044" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC6F1D1D2B1F75EEC4D49ADE0586B08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CF72B92DDAA82B87220949ADE05A4044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C5316E280CC888C574EB49ADE05AFF00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4CBBBDD61A0D2C1B2E1149ADE05A5FB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7F4C9089BC25716E8D5049ADE05A1801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1F2E94C4D4BF28E7206A49ADE05AD1EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9A615515123FDB002EF249ADE05BF615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A0C387E7B97D218E23F949ADE05BF805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_188C5909056F2345920C49ADE05B6F0A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_AA80A08FCE5EC53FD78049ADE05AC69C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_188C5909056F2345920C49ADE05B6F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CC6BC12D5C380BC6866749ADE05BC2FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_91260C2CF94CB129B0BE49ADE05B3EDC" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_806C048C903AECF637EA49ADE05CB769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A181F168507779ED39C249ADE05C7965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_AC4C6EDE9CA7DEEAAE1F49ADE05B9E2E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6B5B19C9E7E797D7C89049ADE05C5870" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D47C962CF7AFD694441E49ADE057E806" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2B096C8E97753681995B49ADE05CA67B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3A8CEF733196F38B89C849ADE05DC31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4067E110C6243725D62949ADE05CE49B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_37CBCE392D00902C8B5749ADE05DE300" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1FE1F46EA2DAF54FF33E782B0BE18086" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1FE1F46EA2DAF54FF33E782B0BE18086" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_90C31934EAE727247832782B0BE31FCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:to="loc_us-gaap_AwardTypeAxis_90C31934EAE727247832782B0BE31FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_90C31934EAE727247832782B0BE31FCE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonEmployeeStockOptionMember" xlink:label="loc_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:to="loc_vcyt_NonEmployeeStockOptionMember_C4A32C5DB09B0EE23B19782D30D4108E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CE41CCFBD91604BF4F50782B0BE4CB17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_CE41CCFBD91604BF4F50782B0BE4CB17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B4776D110C18FDB02D52782B0BE44682" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4989175A7D67C6906748782B0BE3715F" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B4776D110C18FDB02D52782B0BE44682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DD6888C8D3D3082B9158782B0BE443EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DD6888C8D3D3082B9158782B0BE443EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C38FE5BCD5837EADAC0E782B0BE41FB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DD6888C8D3D3082B9158782B0BE443EE" xlink:to="loc_us-gaap_EquityComponentDomain_C38FE5BCD5837EADAC0E782B0BE41FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_69F72DCD5FF78057CD69782B0BE495BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C38FE5BCD5837EADAC0E782B0BE41FB8" xlink:to="loc_us-gaap_CommonStockMember_69F72DCD5FF78057CD69782B0BE495BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65E5E82C039D3E75BDF1782B0BE3648D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_SharePrice_1444B42019D9519ABF27782B0BE55BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2190AC5FD3A2BA1473FB782B0BE5B9A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42408A397661DA102DC9782B0BE572A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_433F96F921EB9CB73971782B0BE5794F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1B0F2FC8FE8492010AD6782B0BEB2774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3F7195CE94D064361EAC782B0BEB553E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C44C8CF97D009B394F33782B0BE5B734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6E92B39F9FD774E1D99B782CF71D1C48" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_482DB262824776C53D98363F70EBB449" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_482DB262824776C53D98363F70EBB449" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2FEB1CCCFC058E8A44F5363F70EBADE1" xlink:to="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockPlan2008Member" xlink:label="loc_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ECBCEDE2358528ECCA21363F70EC6304" xlink:to="loc_vcyt_StockPlan2008Member_FE6D92D710C84D3DAEE6363F70ECC2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B50D200FD5C0A9BEAB9F363F70ECE64F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_srt_RangeAxis_B50D200FD5C0A9BEAB9F363F70ECE64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_B50D200FD5C0A9BEAB9F363F70ECE64F" xlink:to="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_109F28B8A7044A36E485363F70ED02E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B" xlink:to="loc_srt_MinimumMember_109F28B8A7044A36E485363F70ED02E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9A12D6F246BB6CEC721F363F70EC449B" xlink:to="loc_srt_MaximumMember_D66F86F26F7851B14C97363F70EDA93B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A6576DC220C801C32019363F70ED63FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_95519D4793D231163677363F70ED15AE" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_80AC0BB221D01889FB5E363F70EE0C82" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonEmployeeStockOptionMember" xlink:label="loc_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="loc_vcyt_NonEmployeeStockOptionMember_E9BA2FC39A99EE3D2E77363F70EE5202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_19ABB678541B466303AA363F70EE2E57" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65BC7E3E9A7C952E8720363F70EDC92C" xlink:to="loc_us-gaap_EmployeeStockMember_19ABB678541B466303AA363F70EE2E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_865305253165B33601AA363F70EEFCD4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="loc_us-gaap_CostOfSalesMember_4A8E23BBF1AF849E7CA6363F70EF245A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A1A97B18CE03A599449363F70EF2B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_D8094780EDAB4F50FF93363F70EF3190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5AD0EE85C3ECD82EBC01363F70EE335C" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5C10CDA86802357FC52B363F70EFD20C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CBEC0F0126D141454455363F70EB1A92" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D64C278517B7A8C12591363F70F05750" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_166029B88A26841F4835363F70F05E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DFAEBD3CF7F86B10AA04363F70F0D408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_81136EBAD4D573314C2E363F70EF9C15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2311C1FC23627B6A5DC4363F70F656EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_A7F48EF650C153D281C6363F70F67613" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B357BD19DCCD3AFD312363F70F6A205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_33F9033BF7DF6A26292A363F70F6355B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_A4F97AEC3E2C03EBD93A363F70F5F0BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11C44B8DB49B24DC3458363F70F60B43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6F2A5FADEE7465CD7485E8A996FD8270" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6F2A5FADEE7465CD7485E8A996FD8270" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9AE266596006A0374A08E8A996FE4366" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:to="loc_us-gaap_AwardTypeAxis_9AE266596006A0374A08E8A996FE4366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DCD08B22157501A5599E8A996FFA0ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9AE266596006A0374A08E8A996FE4366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DCD08B22157501A5599E8A996FFA0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_FFCD2014C1242AC3046BE8A997002DA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DCD08B22157501A5599E8A996FFA0ED" xlink:to="loc_us-gaap_EmployeeStockMember_FFCD2014C1242AC3046BE8A997002DA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9B3B2C8D504E45DC8754E8A99701A428" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:to="loc_srt_RangeAxis_9B3B2C8D504E45DC8754E8A99701A428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_65EE61335C23C5627A9FE8A9970129CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9B3B2C8D504E45DC8754E8A99701A428" xlink:to="loc_srt_RangeMember_65EE61335C23C5627A9FE8A9970129CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9B8017EE836AD399B6E0E8A99702AA0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65EE61335C23C5627A9FE8A9970129CA" xlink:to="loc_srt_MinimumMember_9B8017EE836AD399B6E0E8A99702AA0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FD03E40053B396BB8E8A996FE45BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum_F86E7FF0B62808B3648BE8A99703C23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6BDA19C260ED62744508E8A99703D304" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_1D1B8BFB2F3E0A9669E7E8A99703F32A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4D5C35830B512F07306FE8A99703FB3A" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee_A9882DE47208819760ADE8A997031AC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45FC87EDF5C56294563EE8A9977688B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45FC87EDF5C56294563EE8A9977688B2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_2E4C7A64700F6783F05CE8A997782D8E" xlink:to="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5B256E5F8A6707931002E8A997793DF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2D4B72DE5C31B20E7412E8A9977941EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_005A32D72FD677C97F47E8A99779C851" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_AA077794B2292FA3239AE8A9977AD475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_23181CA161F0A0DEFF30E8A9977AD78D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_us-gaap_PlanNameAxis_23181CA161F0A0DEFF30E8A9977AD78D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_23181CA161F0A0DEFF30E8A9977AD78D" xlink:to="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockPlan2008Member" xlink:label="loc_vcyt_StockPlan2008Member_5097F8D135936CDC5E39E8A9977C166B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7" xlink:to="loc_vcyt_StockPlan2008Member_5097F8D135936CDC5E39E8A9977C166B" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_StockIncentivePlan2013Member" xlink:label="loc_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_B86BD3326AC00013728FE8A9977B53D7" xlink:to="loc_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2689CD2BCD898778B289E8A9977C3C91" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_us-gaap_AwardTypeAxis_2689CD2BCD898778B289E8A9977C3C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2689CD2BCD898778B289E8A9977C3C91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_IncentiveStockOptionsMember" xlink:label="loc_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:to="loc_vcyt_IncentiveStockOptionsMember_AE17838D5858E30B0CA0E8A9977DEFC4" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonStatutoryStockOptionsMember" xlink:label="loc_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:to="loc_vcyt_NonStatutoryStockOptionsMember_59066D81E54A1E94541EE8A9977DB668" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:to="loc_vcyt_StockIncentivePlan2013Member_7777CE63DAC9296D117CE8A9977CE711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AD97E107FAACD60AC61CE8A9977E624F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B49866D7011C39AFC63BE8A9977D7C12" xlink:to="loc_us-gaap_EmployeeStockOptionMember_AD97E107FAACD60AC61CE8A9977E624F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_D19CEC5B6044A26D2C01E8A9977E5889" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember" xlink:label="loc_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:to="loc_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_30051CB26966DF0C7A64E8A9977EC553" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember" xlink:label="loc_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:to="loc_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_ED376646F3E0D4C11A62E8A9977F51C8" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OutsideDirectorMember" xlink:label="loc_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_626C66AA791A0D02EBA2E8A9977ED46E" xlink:to="loc_vcyt_OutsideDirectorMember_207B5F50365658A2E78EE8A9977F7231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_C729C4A968240E1A41B2E8A9977F722F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_srt_RangeAxis_C729C4A968240E1A41B2E8A9977F722F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_C729C4A968240E1A41B2E8A9977F722F" xlink:to="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_44E61549BA127608E892E8A99780A851" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430" xlink:to="loc_srt_MinimumMember_44E61549BA127608E892E8A99780A851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D4E64E9549097F0ADC8DE8A997807687" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7B1E52F07641C2EE4237E8A9977F4430" xlink:to="loc_srt_MaximumMember_D4E64E9549097F0ADC8DE8A997807687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B64F03E71A6F05EBDBBE8A9977879C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0D7650D1CC47B3AEC6C0E8A99780E0EF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock_33D1A3327E518180C3C6E8A997814CA8" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock_0DE8FCAEB98738A1E124E8A997811C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DE3D679EB09B15DFE1C7E8A997811C34" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DE3D679EB09B15DFE1C7E8A997811C34" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock" xlink:label="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock_EB1715CE40FD0E8EC3B3E8A997823480" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne" xlink:label="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne_8F02FE85EFBE28B2ED1DE8A99782126C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_446705BD7B12D9EF6F09E8A997822EDB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:label="loc_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_0FD5DDE3564D9527B642E8A99782C300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_40B4BE53CA9F9871FD73E8A9978855D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_293D3529C256395B8DC4E8A9978800AF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants_CEE91A863348ADF7D73CE8A9978B4F36" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants_AF3E93A90F13039D18E9E8A9978BF8FE" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares_599C4A7D64896F06EA77E8A9978C6754" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3145E7B72C0A80F1CA5CE8A997800BE5" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination_A15A158D3AC91DEB1BC3E8A9978CFB33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F04AD2D92749F3B7DC1E8A997A18A1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CDDA97676DC71CFC003DE8A997A1A640" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F04AD2D92749F3B7DC1E8A997A18A1A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CDDA97676DC71CFC003DE8A997A1A640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D0410A6EEAD1933B6E25E8A997A2F2B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CDDA97676DC71CFC003DE8A997A1A640" xlink:to="loc_us-gaap_AwardTypeAxis_D0410A6EEAD1933B6E25E8A997A2F2B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D0410A6EEAD1933B6E25E8A997A2F2B4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_33CB48CF5944526B6E14E8A997A32343" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember_33CB48CF5944526B6E14E8A997A32343" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeStockOptionExcludingBonusCompensationMember" xlink:label="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_99C6171327C6D0D129B3E8A997A394B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:to="loc_vcyt_EmployeeStockOptionExcludingBonusCompensationMember_99C6171327C6D0D129B3E8A997A394B1" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NonEmployeeStockOptionMember" xlink:label="loc_vcyt_NonEmployeeStockOptionMember_D42E6228D55E8DA4D075E8A997A4F758" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:to="loc_vcyt_NonEmployeeStockOptionMember_D42E6228D55E8DA4D075E8A997A4F758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_21BD10B3CD31B3790791E8A997A46C0E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1E9BB857BEB846CCC19E8A997A26720" xlink:to="loc_us-gaap_EmployeeStockMember_21BD10B3CD31B3790791E8A997A46C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CDDA97676DC71CFC003DE8A997A1A640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1A209497B3A8C5D94A05E8A997A6E27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAF0537D8A8D16762818E8A997A950F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96A28130453DFCD4EEACE8A997A42E0C" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8DF4BC45D766FB33B8D4E8A997A9DF8C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0A5685DDCC44583E6ED6E8A997E656D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0A5685DDCC44583E6ED6E8A997E656D8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C22EA3E895BFA6ACDD7E8A997E6425F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0BE8CEEFCA7B66BA6EAE402FCF0D30DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0BE8CEEFCA7B66BA6EAE402FCF0D30DA" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6C5B09598B0E6D410DD8402FCF0E34CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6C5B09598B0E6D410DD8402FCF0E34CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EDE773B915D647A5FDDA402FCF0EDE63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6C5B09598B0E6D410DD8402FCF0E34CE" xlink:to="loc_us-gaap_EquityComponentDomain_EDE773B915D647A5FDDA402FCF0EDE63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_16FC6DB6E809F330B12F402FCF0F9B0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EDE773B915D647A5FDDA402FCF0EDE63" xlink:to="loc_us-gaap_CommonStockMember_16FC6DB6E809F330B12F402FCF0F9B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19A5ADAD3116B11A9212402FCF0F3A14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:to="loc_us-gaap_AwardTypeAxis_19A5ADAD3116B11A9212402FCF0F3A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_19A5ADAD3116B11A9212402FCF0F3A14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_9734F675ABC6916C0F51402FCF0F26FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_9734F675ABC6916C0F51402FCF0F26FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_E7CB2C7CA090760BE953402FCF101089" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71E054FE064CCD35F3A1402FCF0F144C" xlink:to="loc_us-gaap_EmployeeStockMember_E7CB2C7CA090760BE953402FCF101089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EF5C745AEB19BBAD662D402FCF10B8AE" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805C5752D906103F3A16402FCF10324B" xlink:to="loc_us-gaap_OverAllotmentOptionMember_4C2AAE9B56B46D068847402FCF10B296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53AECB533EAAE666B16D402FCF0D1B38" xlink:to="loc_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_CommonStockAbstract" xlink:label="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B3CCEC7FF36BA81DE441402FCF101A64" xlink:to="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9A7430A58BBCCCF1ACBA402FCF119FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_60978349F52C5964768C402FCF119E7C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_VotingRightsForEachShareOfStock" xlink:label="loc_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_vcyt_VotingRightsForEachShareOfStock_6C531437C05BEAFBE2BE402FCF11E6D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_0E8B9B5173AB64280D8E402FCF11484E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F43A207117648FA2CAC2402FCF110560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4BC1054D0FFB99701B1F402FCF1294C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4EC442FC624F328D61C1402FCF12173D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DD24BDDBCC8334D908AF402FCF12901C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_CE6CBE0F5A198DEEE496402FCF128049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A5619EE77F3D87B23341402FCF123257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_71D95DBF8139A88B2C48402FCF1261A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79EB3FB6F63859172D26402FCF131704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_40B848B563A22541D4D4402FCF13522A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_CommonStockAbstract_7F1B268D239F71397CF4402FCF112FFB" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02BBC241EEDA05F9DC6D402FCF13EAA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6268A8B5BAF85C1ED949E8A997E2C36F" xlink:type="locator" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="loc_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6268A8B5BAF85C1ED949E8A997E2C36F" xlink:to="loc_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_B88444D325A8C88569CAE8A997E2A7C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6B4F8E9ACD5AF2445851E8A999D6A597" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6B4F8E9ACD5AF2445851E8A999D6A597" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6E9E83F76A3C10C59F47E8A999D634DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9462CB951191DBBD05E249ADE1623BB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9462CB951191DBBD05E249ADE1623BB2" xlink:to="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_22BD2220B4BFA85647EB49ADE162B96F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_22BD2220B4BFA85647EB49ADE162B96F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_22BD2220B4BFA85647EB49ADE162B96F" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6" xlink:to="loc_us-gaap_SalesRevenueNetMember_7A4FE46E8738453652AF49ADE1637E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_3F98B698A4436A1DE06D49ADE16330AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EAC9812E6262E538115149ADE162C3B6" xlink:to="loc_us-gaap_AccountsReceivableMember_3F98B698A4436A1DE06D49ADE16330AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_652445DC51EE608B287149ADE163CD13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_652445DC51EE608B287149ADE163CD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_652445DC51EE608B287149ADE163CD13" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_486582BF374D036A2E5A49ADE1638EEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_486582BF374D036A2E5A49ADE1638EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_3057F7A92191D229E3BF49ADE164CFC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B7B8B039AD526BC1F1A949ADE16323E0" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_3057F7A92191D229E3BF49ADE164CFC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_315104023221823FE2FB49ADE164CD1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:to="loc_srt_MajorCustomersAxis_315104023221823FE2FB49ADE164CD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_315104023221823FE2FB49ADE164CD1A" xlink:to="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_MedicareMember" xlink:label="loc_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:to="loc_vcyt_MedicareMember_4EB3F58F763D21F3A67749ADE164BEF6" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_JohnsonandJohnsonServicesInc.Member" xlink:label="loc_vcyt_JohnsonandJohnsonServicesInc.Member_15381DC07AB53B7FFEAA49ADE1652FFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:to="loc_vcyt_JohnsonandJohnsonServicesInc.Member_15381DC07AB53B7FFEAA49ADE1652FFC" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_UnitedHealthcareMember" xlink:label="loc_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8C63384E41CD0B047BEB49ADE1649378" xlink:to="loc_vcyt_UnitedHealthcareMember_C6B8BB1ECE06F82E075F49ADE165BC9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_E66154460DC813051A7F49ADE1623D0F" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ConcentrationRiskAbstract" xlink:label="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:to="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited" xlink:label="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:to="loc_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited_3D1107B21FAA65CE096E49ADE165A9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4B64EE189FE6852A6DFD49ADE1666833" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ConcentrationRiskAbstract_F06148D478CFBE38CF4F49ADE16520D5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4B64EE189FE6852A6DFD49ADE1666833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_91AD6FD8E2FDF020C06149ADE1655C1A" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_0C6D57D80CB68FE8845849ADE166D2D9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_F02766F2E492BBA4058049ADE166F1DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_00EF9027FA5EC0F250A249BB0B01ADFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00EF9027FA5EC0F250A249BB0B01ADFD" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:to="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_CC09CAA23872CC69564A49BB0B0162FE" xlink:to="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ProvisionofDataMember" xlink:label="loc_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:to="loc_vcyt_ProvisionofDataMember_7A152FE9FD51EE6751DE49BB0B022097" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_FulfillmentofObligationsMember" xlink:label="loc_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_906C3CE3613AC6D056D849BB0B026382" xlink:to="loc_vcyt_FulfillmentofObligationsMember_E34D363DD9FB8E4319C349BB0B03AB3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:to="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3BC45E9B0273C6C0555849BB0B03DCF1" xlink:to="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_JohnsonandJohnsonServicesInc.Member" xlink:label="loc_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:to="loc_vcyt_JohnsonandJohnsonServicesInc.Member_183102F73BEEBBD3CCEF49BB0B030AEB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_Perceptav.2andNassaRiskMember" xlink:label="loc_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05B2095836D019C277AD49BB0B032F93" xlink:to="loc_vcyt_Perceptav.2andNassaRiskMember_90D6A9957D7BD9F9E0BB49BB0B03243C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_522D3F8C7C74BCE3EDA749BB0B018FE8" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_DevelopmentPrograms" xlink:label="loc_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_DevelopmentPrograms_27E0D2E9A4A3B4E40DCF49BB0B049DF1" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementReceivableForServices" xlink:label="loc_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_ContractAgreementReceivableForServices_924E6FE01D1F820DFA2749BB0B04872C" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementConditionalAccountsReceivable" xlink:label="loc_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_ContractAgreementConditionalAccountsReceivable_453D56CCF4B7B9F4DC3749BB0B042230" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TermContractAgreement" xlink:label="loc_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_TermContractAgreement_3F6AC36F64AB72464D6349BB0B051BC5" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ContractAgreementFeePercentageOfCashCollections" xlink:label="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_vcyt_ContractAgreementFeePercentageOfCashCollections_4235D6AD5D5FCE727ABD49BB0B054D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A88E4F615203093E10C749BB0B053849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="loc_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_us-gaap_AccountsReceivableGross_50DCE4A53BBABC316D7C49BB0B051151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6B56061B5E17154CD12849BB0B047D06" xlink:to="loc_us-gaap_ContractWithCustomerLiability_C845E5576341EF26CB9D49BB0B05179D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_83D884DF9C5E39FC779C64B32EF8B622" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83D884DF9C5E39FC779C64B32EF8B622" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_DE63ECDC87E077F312F764B32EFBEAF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_srt_MajorCustomersAxis_DE63ECDC87E077F312F764B32EFBEAF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DEC0EE5BE5C033513ABB64B32EFB3277" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_DE63ECDC87E077F312F764B32EFBEAF2" xlink:to="loc_srt_NameOfMajorCustomerDomain_DEC0EE5BE5C033513ABB64B32EFB3277" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_JohnsonandJohnsonServicesInc.Member" xlink:label="loc_vcyt_JohnsonandJohnsonServicesInc.Member_2CFD38EA68DCEBCE52CB64B32EFB4E44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DEC0EE5BE5C033513ABB64B32EFB3277" xlink:to="loc_vcyt_JohnsonandJohnsonServicesInc.Member_2CFD38EA68DCEBCE52CB64B32EFB4E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_57E0419E5C4CE91096A364B32EFC0CA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_57E0419E5C4CE91096A364B32EFC0CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57E0419E5C4CE91096A364B32EFC0CA3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_FDB601C6F71948E5A87464B32EFCB83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_E419670D4085A39D9E1C64B32EFDAF84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2B3F77D277759C85A86764B32EFC4343" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_E419670D4085A39D9E1C64B32EFDAF84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_82E3E5ECAC14EE9D002064B32EFD20E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_82E3E5ECAC14EE9D002064B32EFD20E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_82E3E5ECAC14EE9D002064B32EFD20E9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_FF10A53B715AB5215C0564B32EFD9624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_19ABB65D7E935EA487DB64B32EFE7728" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EE93DDEE7BECCFABF1B864B32EFD1588" xlink:to="loc_us-gaap_AccountsReceivableMember_19ABB65D7E935EA487DB64B32EFE7728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_DA9D9A8A6A3EE91FA13464B32EFE9DF0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_srt_ProductOrServiceAxis_DA9D9A8A6A3EE91FA13464B32EFE9DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_DA9D9A8A6A3EE91FA13464B32EFE9DF0" xlink:to="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TestingMember" xlink:label="loc_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:to="loc_vcyt_TestingMember_0DF37BFFD739F105C47964B32EFEAA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:to="loc_us-gaap_ProductMember_140460DCAB4BE60CA3F064B32EFF42E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67952B544544642624D664B32EFE3669" xlink:to="loc_us-gaap_ServiceMember_4D2862D91C48A541F10264B32EFFE7C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2714E03E8FCB568AC7AA64B32EFF9CC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_srt_RangeAxis_2714E03E8FCB568AC7AA64B32EFF9CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2714E03E8FCB568AC7AA64B32EFF9CC5" xlink:to="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_EDE5B35134037322AC9264B32EFF79D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1" xlink:to="loc_srt_MinimumMember_EDE5B35134037322AC9264B32EFF79D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_143554D900D4FECF253464B32F00CCA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9D4ABAAE7E3E9AE5C39C64B32EFF99F1" xlink:to="loc_srt_MaximumMember_143554D900D4FECF253464B32F00CCA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0658A0895BE98CC53BDF64B32F001FDF" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B1BFBD011B77C48BA3E064B32F005502" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_8B6814F3FF67FF314D8B64B32F00B189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_C8E73C693F9573874DBD64B32F009079" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_BiopharmaceuticalCompanyMember" xlink:label="loc_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8FB6890D503B92B0E61B64B32F014C7F" xlink:to="loc_vcyt_BiopharmaceuticalCompanyMember_357BF2A1B90AFD00BBCA64B32F012B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17FE8884CE9F52F774DB64B32EFAF965" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_C92EB5FDC237B9204E0964B32F01AA13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_400FD9DD8AB742B6AE8564B32F026385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGrossAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DF58BD975B9A0DAB3D2664B32F02355C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DF58BD975B9A0DAB3D2664B32F02355C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract_1AA65A5CA053F968241764B32F022C1C" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_E4F5D944B128C0BCAE5864B32F0298A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAbstract" xlink:label="loc_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillImpairedAbstract_087D6ABCD04B7DECC50064B32F02597A" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9521901A60F37638B39A64B32F033B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedOnAccrualBasis" xlink:label="loc_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_vcyt_RevenueRecognizedOnAccrualBasis_945BDF63181F9592CA8E64B32F037919" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedOnAccrualBasisPercentage" xlink:label="loc_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_vcyt_RevenueRecognizedOnAccrualBasisPercentage_F3CC1825683BF02C83F464B3A38DEECB" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedReceivedInCash" xlink:label="loc_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_vcyt_RevenueRecognizedReceivedInCash_2552877FF55E8444DA2E64B32F035FEC" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRecognizedReceivedInCashPercentage" xlink:label="loc_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_vcyt_RevenueRecognizedReceivedInCashPercentage_68C438DA88064F54825C64B332B00EE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_D048D523E5E36EB4A2A364B32F03F954" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DD7B90871A4268C86A464B32F0302B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_B83A0044124C0744A37A64B32F042D4F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_ContractWithCustomerLiability_B83A0044124C0744A37A64B32F042D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7F99BFEAA0840C55624B64B32F04B878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_OperatingIncomeLoss_769BE38F003415509D6464B32F04B498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6A684314D5C47F03BF7064B32F04082B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6EA1F6BB40F48829ED1464B32F04B31D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter" xlink:label="loc_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter_BC5DF38A495B8400467864B32F04DC34" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_TermContractAgreement" xlink:label="loc_vcyt_TermContractAgreement_82129AF0AA466B8AFA6D64B32F043291" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_vcyt_TermContractAgreement_82129AF0AA466B8AFA6D64B32F043291" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_AutomaticRenewalPeriodContractAgreement" xlink:label="loc_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79FA37A8228228CAD0B064B32F01A640" xlink:to="loc_vcyt_AutomaticRenewalPeriodContractAgreement_297E1104D020027D667464B32F051199" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C86248B174BB44E9F382E8A999B074FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C86248B174BB44E9F382E8A999B074FF" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E246FB6A10E7BE965099E8A999B1F2BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E246FB6A10E7BE965099E8A999B1F2BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AF9E6D21230AFC2DB9D7E8A999B1880C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E246FB6A10E7BE965099E8A999B1F2BC" xlink:to="loc_us-gaap_EquityComponentDomain_AF9E6D21230AFC2DB9D7E8A999B1880C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9E8D0E7FE93EEA58AD50E8A999B275C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_AF9E6D21230AFC2DB9D7E8A999B1880C" xlink:to="loc_us-gaap_CommonStockMember_9E8D0E7FE93EEA58AD50E8A999B275C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_19BA44365AE195A90CBFE8A999B26404" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_19BA44365AE195A90CBFE8A999B26404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F6EE5AE019D8A564B8EE8A999B2FE51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_19BA44365AE195A90CBFE8A999B26404" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F6EE5AE019D8A564B8EE8A999B2FE51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_E8978F44E95D3EC0ECE1E8A999B2E7AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F6EE5AE019D8A564B8EE8A999B2FE51" xlink:to="loc_us-gaap_OverAllotmentOptionMember_E8978F44E95D3EC0ECE1E8A999B2E7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_F8421877E42874B062C3E8A999B3619C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_CreditFacilityAxis_F8421877E42874B062C3E8A999B3619C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_88FDF8BF963490BA4FC2E8A999B3B933" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_F8421877E42874B062C3E8A999B3619C" xlink:to="loc_us-gaap_CreditFacilityDomain_88FDF8BF963490BA4FC2E8A999B3B933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_C86574FF88A8C43CE9CBE8A999B32358" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_88FDF8BF963490BA4FC2E8A999B3B933" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_C86574FF88A8C43CE9CBE8A999B32358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0E9800FE4E0ABB67904FE8A999B33F84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0E9800FE4E0ABB67904FE8A999B33F84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21360F471269E1846B7DE8A999B4DD9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0E9800FE4E0ABB67904FE8A999B33F84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21360F471269E1846B7DE8A999B4DD9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_4F0A01A89451DCE70DF6E8A999B4F6D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_21360F471269E1846B7DE8A999B4DD9C" xlink:to="loc_us-gaap_LineOfCreditMember_4F0A01A89451DCE70DF6E8A999B4F6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_AFE6C5EC60F799E44F8AE8A999B4B8FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_AFE6C5EC60F799E44F8AE8A999B4B8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_744EA51D3366780E488BE8A999B452EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_AFE6C5EC60F799E44F8AE8A999B4B8FB" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_744EA51D3366780E488BE8A999B452EF" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SiliconValleyBankMember" xlink:label="loc_vcyt_SiliconValleyBankMember_90B260E5A321F27DEBD9E8A999B52F52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_744EA51D3366780E488BE8A999B452EF" xlink:to="loc_vcyt_SiliconValleyBankMember_90B260E5A321F27DEBD9E8A999B52F52" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_LiquidityLineItems" xlink:label="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E57A4903873CFC545BF0E8A999B08886" xlink:to="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E6AAFE66C430B365B1FE8A999B59265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB7A162CA393D06401DDE8A999B52652" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB7A162CA393D06401DDE8A999B52652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_F781A973C783E4BDB61EE8A999B65F98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_F781A973C783E4BDB61EE8A999B65F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_311A42412C53C1637001E8A999B6FFB0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_311A42412C53C1637001E8A999B6FFB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2B309C4D39F6C58C3A27E8A999B6F820" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2B309C4D39F6C58C3A27E8A999B6F820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_C73EF9B9F9EC91B546A2E8A999B6C4AB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_C73EF9B9F9EC91B546A2E8A999B6C4AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_8C3A00CB8325DB5A2DD6E8A999B6C32F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_8C3A00CB8325DB5A2DD6E8A999B6C32F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_BA8B71D126AD5AA647E6E8A999B67123" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_BA8B71D126AD5AA647E6E8A999B67123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2F5BE7FA007B57ED84E9E8A999B7EC5C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2F5BE7FA007B57ED84E9E8A999B7EC5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_LiquidityLineItems_5AE983AD8D7708F2BDACE8A999B5F1B3" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ABC421050684FE85E12FE8A999B79E7E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3A1E881F292FC2A067FDE8A999CA4347" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_UseOfEstimates_C1F2327C1E91CFDEF4EAE8A999CB864E" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_8B5F2575459AE2890EC8E8A999CB8196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_7CC9BDED219DEE001103E8A999CC9FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_C2908A0D930BD7B9CD31E8A999CDB9B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_95208BB99FFA79821921E8A999CEFEEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_08C5A0728674DC7EBCA6E8A999CEAEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0169D58D92AE68654153E8A999CE0177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_D75540A17E7B21DDDD1AE8A999CEFFAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33CE596E690FB1D991ACE8A999CF9995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2E2A8F953EF46964639AE8A999CF5AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_78A54E285BF48C186697E8A999CF554A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D98C81995C7C74E4A166E8A999D05346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3F6FD3E1BF147C5AACDFE8A999D07903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_06E12798EF8BBBFF1670E8A999D04334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_90B13B73FFD102B05F02E8A999D0C50C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F671A821951065B69C48E8A999CA37B9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C9016FA929821F80BE89E8A999D0B93D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C4E199A248D561195255ED5114EAF60D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C4E199A248D561195255ED5114EAF60D" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7E35784805B86596510ED55E78E7057" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7E35784805B86596510ED55E78E7057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_22169E67ABC4FD909F54ED55E78F3921" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7E35784805B86596510ED55E78E7057" xlink:to="loc_us-gaap_TypeOfAdoptionMember_22169E67ABC4FD909F54ED55E78F3921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_22169E67ABC4FD909F54ED55E78F3921" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_E6C9E268D2517A724D98ED561BFCF0F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9F684B82BFEAB6569404ED55AB304875" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_D8B731BDBBDCF80F03F5ED5261C6384A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_D8B731BDBBDCF80F03F5ED5261C6384A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_829F4E53B8DECD157545ED535E9D7E27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_ContractWithCustomerLiability_829F4E53B8DECD157545ED535E9D7E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_OperatingLeaseLiability_09AD324E1F3A34C0324FED53F6E44396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_FD3B3C8352368BAA0D98ED54D38DE7CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_CDD274955842A525518AED55AB316F28" xlink:to="loc_us-gaap_FinanceLeaseLiability_29DB2CF46866DC982A12ED54522D0753" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_27A3460CB1FE63F9952349ADE1B5B763" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27A3460CB1FE63F9952349ADE1B5B763" xlink:to="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_AEB51D25AE18541F6D5349ADE1B5802E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1072ED0F3AE42901D4D649ADE1B60AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9C75CC2F721F4A33BCE749ADE1B6D0E5" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_6EF17EFBFCB0FB5922E449ADE1B66228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_68441DCD38798DC9C0DB49ADE1B697CB" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_SalesRevenueGrossMember" xlink:label="loc_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:to="loc_vcyt_SalesRevenueGrossMember_ABF54C3EAA33F465F7E649ADE1B76861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64E936DFC5BDB4B9C6C649ADE1B7E97D" xlink:to="loc_us-gaap_AccountsReceivableMember_E123F1AB659E2A6C3A6049ADE1B75983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_F945F5065642BD04775549ADE1B59AE9" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_BF05B622A72497BC93A449ADE1B75068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5D57E1E664F50D0330A549ADE1B74CDA" xlink:to="loc_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2CA393F3C29E43EBE5BC49ADE1B81745" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_04ED8C4DFC797384170449E24E8C640E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartners" xlink:type="extended">
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ServicesAgreementAbstract" xlink:label="loc_vcyt_ServicesAgreementAbstract_CE20E184EC7A6639A910E8A996D76F23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:label="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ServicesAgreementAbstract_CE20E184EC7A6639A910E8A996D76F23" xlink:to="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_59876F79745E7753847CE8A996D7F7B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails" xlink:type="extended">
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_ServicesAgreementAbstract" xlink:label="loc_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vcyt_ServicesAgreementAbstract_7B13B758D689509EF4B0E8A996D1040D" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_86D4BBBE773B830A78BBE8A996D16EA4" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FAB26F82F11CBDC30427E8A996D20707" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_A4478FBB3AC76695FCD6E8A996D24EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_382C854AA8C2AD157F73E8A996D11ED2" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:type="arc" />
    <link:loc xlink:href="vcyt-20191231.xsd#vcyt_OtherIncomeRentReimbursement" xlink:label="loc_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_314EEF975E3FA8EF3867E8A996D214D3" xlink:to="loc_vcyt_OtherIncomeRentReimbursement_DC21978E840FEA79B4BBE8A996D4C93F" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>businessone.jpg
<DESCRIPTION>VCYT CHART 1
<TEXT>
begin 644 businessone.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .T!: # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ:Y^T)\.]<\3:[;6EG+%KDUE;VUFI"10+! ZJ222S9D;+=\]!TKW>@ HHHH
M**** "BBB@ HHHH **\\^/7QDLO@/\--0\7WNGSZJEL\<,=I;N$,DCMM4%C]
MU<]3@GV-<7^QW\=-<_:$^'>N>)M=MK2SEBUR:RM[:S4A(H%@@=5)))9LR-EN
M^>@Z4 >[T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7PS_P51_Y$OP%_P!A"Y_]%K7W-7PS_P %4?\ D2_ 7_80N?\ T6M
M'CWP'_X*!3_!#X4Z)X*3P-'K"Z9Y^+UM4,)D\R>27[GDMC'F8ZGIFO8?AS_P
M4LN/'WQ"\,^&6^'L5DNLZG;:<;H:P7,7FRK'OV^0-V-V<9&<=:Z+]C.\^%$7
M[-OA%?$TW@U-;!O/M"ZL]H+G_C\FV[_,^;[NW&>V.U>X6>N?!+3KJ&ZM-0\
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M#R6U^+.DS6>L6DP6TOKB2(RW<!&1YBHQ(=2""2%R"O4@D_!OCO\ 8=\4^!?
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M?V>)B/E\R.>5G /KB6//U%6=._9BFNO@;;^/;K]HF_M?"#Z:LL\:VL\B0J5
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M:*X[_@F+K%C;_ W6K.6]MXKM_$TVR!Y5#MNM;;;A2<G.UL?[I]* /LJBBB@
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M 92JD^O/TK[4^%/PK\/_  9\$V/A?PU;-!IUKEF>1MTL\A^]+(V.6;Z #
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MR&# YQC!%>UT4 ?!?B;_ ()=_9];>\\'?$&;3+;=F*"_M"\T0/4>=&Z[N/\
M9%>A? '_ ()]>'?A'XNM/%6OZ[-XNUNRE$]FAMA;V\$@Z2%2SL[@\@D@ \XR
M 1]944 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /X=1_\ 54O_ "WO_NJC_AU'_P!52_\ +>_^ZJ /T HK\_\ _AU'_P!52_\
M+>_^ZJ/^'4?_ %5+_P M[_[JH _0"BOS_P#^'4?_ %5+_P M[_[JH_X=1_\
M54O_ "WO_NJ@#] **_/_ /X=1_\ 54O_ "WO_NJC_AU'_P!52_\ +>_^ZJ /
MT HK\_\ _AU'_P!52_\ +>_^ZJ/^'4?_ %5+_P M[_[JH _0"BOS_P#^'4?_
M %5+_P M[_[JH_X=1_\ 54O_ "WO_NJ@#] **_/_ /X=1_\ 54O_ "WO_NJC
M_AU'_P!52_\ +>_^ZJ /T HK\_\ _AU'_P!52_\ +>_^ZJ/^'4?_ %5+_P M
M[_[JH _0"BOS_P#^'4?_ %5+_P M[_[JH_X=1_\ 54O_ "WO_NJ@#] **_/_
M /X=1_\ 54O_ "WO_NJC_AU'_P!52_\ +>_^ZJ /T HK\_\ _AU'_P!52_\
M+>_^ZJ/^'4?_ %5+_P M[_[JH _0"BOS_P#^'4?_ %5+_P M[_[JH_X=1_\
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M\.H_^JI?^6]_]U4 ?H!17Y__ /#J/_JJ7_EO?_=5'_#J/_JJ7_EO?_=5 'Z
M45^?_P#PZC_ZJE_Y;W_W51_PZC_ZJE_Y;W_W50!^@%%?G_\ \.H_^JI?^6]_
M]U4?\.H_^JI?^6]_]U4 ?H!17Y__ /#J/_JJ7_EO?_=5'_#J/_JJ7_EO?_=5
M 'Z 45^?_P#PZC_ZJE_Y;W_W51_PZC_ZJE_Y;W_W50!^@%%?G_\ \.H_^JI?
M^6]_]U4?\.H_^JI?^6]_]U4 ?H!17Y__ /#J/_JJ7_EO?_=5'_#J/_JJ7_EO
M?_=5 'Z 45^?_P#PZC_ZJE_Y;W_W51_PZC_ZJE_Y;W_W50!^@%%?G_\ \.H_
M^JI?^6]_]U4?\.H_^JI?^6]_]U4 ?H!17Y__ /#J/_JJ7_EO?_=5'_#J/_JJ
M7_EO?_=5 'Z 45^?_P#PZC_ZJE_Y;W_W51_PZC_ZJE_Y;W_W50!^@%%?G_\
M\.H_^JI?^6]_]U4?\.H_^JI?^6]_]U4 ?H!17Y__ /#J/_JJ7_EO?_=5'_#J
M/_JJ7_EO?_=5 'Z 45^?_P#PZC_ZJE_Y;W_W51_PZC_ZJE_Y;W_W50!^@%%?
MG_\ \.H_^JI?^6]_]U4?\.H_^JI?^6]_]U4 ?H!17Y__ /#J/_JJ7_EO?_=5
M'_#J/_JJ7_EO?_=5 'Z 45^?_P#PZC_ZJE_Y;W_W51_PZC_ZJE_Y;W_W50!^
M@%%?G_\ \.H_^JI?^6]_]U4?\.H_^JI?^6]_]U4 ?H!17Y__ /#J/_JJ7_EO
M?_=5'_#J/_JJ7_EO?_=5 'Z 45^?_P#PZC_ZJE_Y;W_W51_PZC_ZJE_Y;W_W
M50!^@%%?G_\ \.H_^JI?^6]_]U4?\.H_^JI?^6]_]U4 ?H!17Y__ /#J/_JJ
M7_EO?_=5'_#J/_JJ7_EO?_=5 'Z 45^?_P#PZC_ZJE_Y;W_W51_PZC_ZJE_Y
M;W_W50!^@%%?G_\ \.H_^JI?^6]_]U4?\.H_^JI?^6]_]U4 ?H!17Y__ /#J
M/_JJ7_EO?_=5'_#J/_JJ7_EO?_=5 'Z 45^?_P#PZC_ZJE_Y;W_W51_PZC_Z
MJE_Y;W_W50!^@%%?G_\ \.H_^JI?^6]_]U4?\.H_^JI?^6]_]U4 ?H!17Y__
M /#J/_JJ7_EO?_=5'_#J/_JJ7_EO?_=5 'Z 45^?_P#PZC_ZJE_Y;W_W51_P
MZC_ZJE_Y;W_W50!^@%%?G_\ \.H_^JI?^6]_]U4?\.H_^JI?^6]_]U4 ?H!1
M7Y__ /#J/_JJ7_EO?_=5?87P+^%7_"E/A?H_@_\ MFXU[^SQ(/MMPFPMN=FP
MJ;FV*-V N3C'6@#OJ*** "BBB@ HHHH **** "BBB@ HKX+UK_@EG_:VL7M[
M_P +3N#]HF>7-UHOG2_,2?G?[2-S>IP,^E4_^'4?_54O_+>_^ZJ /T HK\__
M /AU'_U5+_RWO_NJC_AU'_U5+_RWO_NJ@#] **_/_P#X=1_]52_\M[_[JH_X
M=1_]52_\M[_[JH _0"BOS_\ ^'4?_54O_+>_^ZJ/^'4?_54O_+>_^ZJ /T H
MK\__ /AU'_U5+_RWO_NJC_AU'_U5+_RWO_NJ@#] **_/_P#X=1_]52_\M[_[
MJH_X=1_]52_\M[_[JH _0"BOS_\ ^'4?_54O_+>_^ZJ/^'4?_54O_+>_^ZJ
M/T HK\__ /AU'_U5+_RWO_NJC_AU'_U5+_RWO_NJ@#] **_/_P#X=1_]52_\
MM[_[JH_X=1_]52_\M[_[JH _0"BOS_\ ^'4?_54O_+>_^ZJ/^'4?_54O_+>_
M^ZJ /T HK\__ /AU'_U5+_RWO_NJC_AU'_U5+_RWO_NJ@#] **_/_P#X=1_]
M52_\M[_[JH_X=1_]52_\M[_[JH _0"BOS_\ ^'4?_54O_+>_^ZJ/^'4?_54O
M_+>_^ZJ /T HK\__ /AU'_U5+_RWO_NJC_AU'_U5+_RWO_NJ@#] **_/_P#X
M=1_]52_\M[_[JH_X=1_]52_\M[_[JH _0"BOS_\ ^'4?_54O_+>_^ZJ/^'4?
M_54O_+>_^ZJ /T HK\__ /AU'_U5+_RWO_NJC_AU'_U5+_RWO_NJ@#] **_/
M_P#X=1_]52_\M[_[JH_X=1_]52_\M[_[JH _0"BOS_\ ^'4?_54O_+>_^ZJ/
M^'4?_54O_+>_^ZJ /T HKQ']EO\ 9I_X9I\.ZSI?_"47'B7^T;A)\O;?9HH=
MJD82/>^"<\G/.%XXKVZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBD)P,G@4 +17S[\7/VX/AG\*YIK&/4'\4:S'E6L]&VR
M(C>CS$[!SU +,/2OE/QY_P %*/'^O-)%X9TG2_"]L?NR.IO+A?\ @3@)_P"0
MZ]?#Y5B\0KQC9=WI_P $[J6#K5=4K+S/TNHK\7?$7[1WQ1\4W#3:AX^U]BW6
M.WOGMXO^_<95?TKC-4\4:UKBE=1U>_U -U%U<O)G_OHFO8CP[4?QU$OE?_([
MHY7+K,_=6BOP@L]2O-/YM;J>V.<_N9"G\C75Z#\;/B!X79#I7C;Q!8JO2.+4
MI@GXINVG\152X<G]FK^'_!8WE<ND_P #]M**_+#P1_P4)^+'A5HTU.ZT_P 4
MVR\%=2M0DFWV>+8<^[!J^FOA;_P4:\">+I8;/Q58W7@Z]? \]S]IM"?=U 9?
MQ3 [FO)KY-BZ&O+S+RU_#<XJF!KT];7]#ZUHJCHNN:=XCTV#4=*O[;4]/G7=
M%=6DJRQ./4,I(-7J\5IIV9YX4444@"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-R[=%BN&/4GH)#UZ-SS7W=7PN+PE7!U/9U%\^Y\Y6HSH2Y9A1117$8!1110
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ME^C)RR^4YA+*T[T:BYZ?E_-']5_FSW&BBBOE3[@**** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU>0CT50S'V4U^S_@WPCI7PQ\%:5X<T: 0:=IL"V\"=VQU9O5F.6)[DFOA_\
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M^HE?A%I&JW6A:M9:E8RM!>V<Z7$$J]4D1@RL/H0#7[>_#_Q=;^/O V@>)+4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &!\0/$R^#/ GB/7VQC2].N+WYNA\N-GQ^E?AS--)
M<322RNTDLC%F=CDL2<DFOV _;&U1M)_9G\>SJ=I>R2W_  EFCC/Z/7X^5]WP
M["U*I/N[?<O^"?1Y7'W)2\S]>?V,_!Z>"?V;?"$939/?V[:I,V.6,S%T/_?L
MQC\*]09BS%CU)S1X9TM?#O@;1],0;4LM/@M57T"1JN/TI*^+KU'5JSJ/JVSP
M*DN>;EW9P_QJ^)UI\'_AGKGBF['F-9PXMH.\UPWRQ1@>[$?ADUYA^Q]\4/$?
MB30=9\&^/A-#X[\.S+)<I=?ZR6VG'FQ/[XW%?8!:\W_:'^,WA+Q!^TEX8\)>
M)M3:W\&^#W_M74A%;R7"W6H8!AA98U;A <G/JPZUC_%?]I3X?Z5\;/!/Q,\(
M:O<75S&3H_B&U^PSPB;3W.1(2Z*"T;<CG)^7TKWZ. G+#JE[-N4US7L]+?"K
M^:O]Z/HJ. G+#JE[-N4US7L]+?"K^:O]Z/I;]I'XGV/PM^$?B&_GU>/2-3N+
M&X@TMV)W/=&)BBI@?>R./I7C/['^D?"ZWT*VO_"-[%J'C2?2H'UZX-Q+).9'
MVO)O#':/WF1P.U>T?M%O:ZE^SWXYN$\JZADT*ZEADP&4@P,0RGZ<@UD_ >"*
M/X,^!9$BC1WT.RW,B!2?W"=<5Y\9QA@9)73<K/7RZZ;>7<\^,XPP,DKIN5GK
MY==-O+N.^#5IX8\$^"O$;>$-6_MJT_MV\NKZ:=@PAN&8>='E0N I ]?J:;_P
MTYX0W:&B^(])D?6V"Z<D;,[7&7V @#) WY7)P,@UY[^S)(8_A?\ $CT;Q+K:
MG\2*E_8'^&.BZ3\ M(U^2QBFU?6I)IYKJ1<R;$E:..,'LH"9 Z98GO6M:A3B
MZM6K)MII=-;I[Z>1K6H4XNK4JMMQ:736Z>^GD>LWWQDTW2]:?2+S4=.M-22T
M:_>WG<H5MP2#*23@*"""2:Q?!7[4WP^\:>(AHEEXKTN?4I,K!;IYB&=\_=1G
M 5S[*3FO*/B=\,]'\>?MR>$]*U2V\[1X?"QO;BRR1'<E+B4HD@_B3?M8J>#L
M&:Z[]LCPGHLOP%\130:;:V]UH<"7MA<PQ!)+:5)$P8V'*\<<5,<-A[TJ<F^:
M:7:RN[=M?P]28X;#ITJ<F^::7:RN[=M?P]3J/'_Q^\ _#O5A9>)O%%GI^HN
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M5T7]I;Q[;HNT/?"YQ[RQ)*3^;U]3_P#!+S5&F\+>/=.)^6WO;6X ]Y$D4_\
MHH5^@9M^_P N55_W7]__  Y]+C?WF%4_1GV_1117YZ?,!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?,7[67QF^+/P3\
M0:-KOAC0K35? 45N#J+M TC";>P82,IS$NW9M8#&XG.>!71AZ$L145.#5WWT
M-:=-U9<D=SZ=HKQ;X#?M8>"?CS;QVUC<_P!C^(]N9=$OG EX')B;I*O7IR!R
M5%>TU-6C4H3<*BLR9PE3?+-684445B0%%%% !1110 4444 %%%% !1110 44
M44 %%%% 'EG[4GB!_#'[//CZ^C;9(=*EME8=09L0@CW_ 'E?C57ZX?MS;O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M -5._P#*!_\ =-?>E%']LX[_ )^?@O\ (/K^)_F_!?Y'P7_PZS_ZJ=_Y0/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCKP.316G8V?EXDD'S=AZ4 5]0U*Q\)Z#>ZKJES'96-G"UQ<W$IPL<:@DD_0
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M !35UTZ+U_JQ[^&P"I?O*W3[C.T#0=1\4ZU9:1I-G+J&I7DJPV]M NYY')P
M!_G%?K-^RE^S58_L^^"S]I\J[\6ZDJOJ5ZO(3N((S_<7U_B//H!G_LM_LD:-
M\ --&IW[1:QXTN8]L^H!?W=LIZQ09Y ]6/+>PXKZ#KRLVS3ZU^YHOW/S_P"
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MIUT4Q^[;E&]15*O,/@[^TYI?B2SB\-^/7&DZ[;GR?MMR/+BG8<?.3_JY/7.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ>_' &3@"NXHKY3&9E7QNDW:/9;?\$\:OBJF(TD].P4445Y9QA1110 4444
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MBO'K8>MAWRUH.+\U8^@P^+P^+CS8>HIKR:?Y$E%%%<YUA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445!<7UO:_ZZ9(SZ,>?RII
M-Z(3DHJ[9/16=_PD&G[L?:1G_=/^%6K>^M[K_4S)(?13S^54Z<XZM&<:M.3M
M&2?S)Z***@U"BBB@ HHK+N]<BMY  \<:I-Y<IG)0XQDE?[U &I16!:Z[;S/$
MO]L0DK(2X:/9O4]%R>F/45HPW4\1BCNHPSOO8RP@^6@'3)/J* +U%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;5:DWA\J7ES-7;_PK_/7R1VGCSX\^-OB(\BZGK,T%D__ "X6),, 'H5!RW_
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M6*ARW[^]'^OD?,XK@O,\ _;8&ISM=O=E\O\ AS-^&O[;,<S167C;3A 3\O\
M:FGJ2OU>+J/<J3_NU].Z#XBTSQ3I<.HZ1?0:C8RCY)[=PRGU''0CN#R*_,_Q
MQ\.?$7PYU+[%X@TN:PD8GRY&&Z*4#NCCY6_ Y'?%3_#OXH>(OA?K O\ 0KYH
M0Q'G6LF6@G [.G?ZC!&>"*SQW#6%QD/;X"2BW\XO_+\O(VRWC'&X"I]6S2+D
MEHW:TUZ]_GKYGZ=45YA\&/CYH7Q@L/+A(T[784W7&FRMDX[O&?XU_4=QT)]/
MK\RQ&'JX6HZ5:-I(_9<+BJ&-HJOAY<T7U7]?@%%%%<YUA1110 4444 %%%%
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M?Y1_X#/R^?$&?YY-PP2<5V@MO67_  4<)K'QH\=Z],TEYXMU=BW5(;MX8_\
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M6;6DK;IH!\I/4I_];_"O,Q%!17/ Y*M-+WD=-1117G'*%%%% !1110 4444
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MYY[9>I*G^-!_WT!Z\D?7NC>($O\ $,V(Y^WHW_UZV:QP.8XK*:O[MZ=5T?\
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M^=^MZU?>(]6N]3U*YDO+^ZD,LT\ARS,?\].@'%?:\/Y)]>E]9Q"_=K9?S/\
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MHK\V/V **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR_X&Q^Q\.YY#.,%&M+22TDNS_P GNONZ'G]%;TW@G58V(6*.4>J2#^N*EM?
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M&:JPE-TU)<RW75?(EHHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!"W_RK#_(^LZ*^3/\ A@S_ *GG_P I'_V^C_A@S_J>?_*1_P#;Z/J.5_\
M0;_Y3E_F']IYW_T+?_*L/\CZSHKY,_X8,_ZGG_RD?_;Z/^&#/^IY_P#*1_\
M;Z/J.5_]!O\ Y3E_F']IYW_T+?\ RK#_ "/K.BODS_A@S_J>?_*1_P#;Z/\
MA@S_ *GG_P I'_V^CZCE?_0;_P"4Y?YA_:>=_P#0M_\ *L/\CZSHKY,_X8,_
MZGG_ ,I'_P!OH_X8,_ZGG_RD?_;Z/J.5_P#0;_Y3E_F']IYW_P!"W_RK#_(^
MLZ*^3/\ A@S_ *GG_P I'_V^C_A@S_J>?_*1_P#;Z/J.5_\ 0;_Y3E_F']IY
MW_T+?_*L/\CZSHKY,_X8,_ZGG_RD?_;Z/^&#/^IY_P#*1_\ ;Z/J.5_]!O\
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M8?V#9F:'QM$3\JM9,/J1.#_(5X=^T-JR:U\:O%MPAW*MX;?/O$JQ']4KW_\
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M&/\ QV3\Z\(_9_\ %:^#?B_X;OY'V6\EQ]EF)/&R4&/)]@6#?\!K]>PZ^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN9V/2X?UIXB4?A=6;7IH%%%%>D?4A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y]\>O!)\??"G7M,BC\R\6'
M[5:@#),L?S@#W8 K_P "K\VPQ4@@X(Z&OUEK\[?VDOAJWPW^)M_'#%LTK4B;
MVR('RA6/S(/]ULC'IM]:_1^$<:DYX.3W]Y?K^GXGY!Q[ESDJ>806WNR_-/\
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MU6<ZJUMIWOT/,R.6(>-ITZ+TOKVMU_KN?35%%%?EY^SA1110 4JJ68*!DDX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5\!?M:>"3X3^+EY>1Q[;/6
M4%]&0.-Y^64?7<"W_ Q7W[7BO[5_PU;QY\-9+ZSB\S5-$+7<0499XL?O4'X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHI"0H)/ H 6J]Q?6]KQ+,B'T)Y_*N?U;Q#),S16S;(AP7'5O\!6(2
M3R>37/*M;1'EU<<HNU-7.T&N6+-C[0OY'_"K<-Q%<+NBD60?[)S7 4^*9X)
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M *=7Y=C\;4S#$2Q%3KLNRZ(_;,KRVEE6$AA:73=]WU?]=- HHHKSCU@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I" P((R*6B@#\
M_OVF?@R_PO\ &#7UA 1X<U1VDMBH^6"3JT)],=5_V?7!K"^!?QBO/@_XN6\
M>XT>ZVQ7]HI^^F>'7_;7)(]<D<9S7W_XY\$Z7\0O#%[H6KP^;:7*XW+]^)Q]
MUU/9@>?T/!(K\Y_BC\,=6^%/BF?1]43<GW[:[5<1W$>>'7^H['\Z_6\ES&EF
M^%>"Q>LDK?XEW]5_P3\'XBRFOD&-698'2#=U;[+[>CZ>6GK^DVDZMI_BK1;7
M4=/N([W3[N,2PSQG(8'O['VZ@@@U5N+9[=L'E>S>M?"WP!_:$OOA#J!L;U9+
M_P ,W+[IK93EX&/62//?U7H<=CS7W;X9\4:/XWT6'4]&O8=2T^8?+)$<X/=6
M'56'<'!%?!9ME%;*ZMFKP>S_ $?F?J&19]A\ZHIQ=JB^*/ZKNORZE:BK]QIA
MY,1S_LFJ+(T;88%3[UX)]0)1110 4444 %%%6X-.DDP7^1?UH K1QM*P51DU
MKVMJMLGJYZM0?(TZWDD=TAAC4L\DC   #)))Z"ODG]HK]J>/5;:Z\+^"[@FV
MD!BO-7C./,7H8X3_ '3T+]^W')]3+\NKYE55.BM.KZ+^NQXN:YOALHH.MB'K
MT75OR_5]#)_:L^/J^++J3P?X?N-^CVTG^G74;?+=2J>$4]T4]^Y'H 3XA\/?
M FI?$CQ98Z#I:9GN&^>4C*PQC[TC>P'YG ZD5CZ3I-YKVIVVG:?;27E[<R"*
M&"(99V/0"OT&^ 'P2M?@_P"&?W_EW'B&]4->W2\A>XB0_P!U?7N>?0#]/QF(
MP_#F!5&A\;V\WUD_Z\C\6P&$Q?%V9/$XG2FMWT2Z17]=V_/N_!_A2P\#^&=.
MT+3(_+LK*(1IGJQZLQ]V))/N36S117X_.4JDG.3NV?T!3A&E!4X*R6B7D%%%
M%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8GB:_,,*VZ'#2<M_N_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %17-M#>6\D%Q
M$D\$BE7CD4,K ]00>HJ6BC86^C/#?'G[(7@GQ<\ESIBS>&;UN<V(#0$^IB/
M^BE:\+\4_L6^-M'+OI%Q8:_"/NK')Y$Q^JO\H_[Z-?<U%?1X7B#,,*E%3YEV
MEK^._P")\CCN%,JQS<G3Y)/K'3\-OP/S+UCX-^.=!9A>^$]7C5>LD=H\B?\
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M5JK:[;+[EH?3X+),NR]J6&HI/ON_O=V%%%%>4>X%%%% !1110 4444 %%%%
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MLXDAF#4I04(M2=^=.RC;=67?7L>[T5XGX3_:Z\">+-?@TE?[1TR6XD$4,]_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEN)DX<?UKC*OZ)=FTU"(Y^1SL;\?_KUK3ERL[,+6=*:71G:4445W'T@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN.O0CWJ:J-2[IMQM?RB>&Z?6OCS]LSX:)X>\5VGBJRBV6>L9CN0HX6Y4=?\
M@:\_56/>OK=6*L&'4'(KF/CYX/7Q]\(]=LTCWW4,'VVVXR1)&-P ]R R_P#
MJX<;1]O0E'JM4?/Y]@5F& J4[>\M5ZK_ #V^9\:?LU^/CX!^*^E2RR;-/U%O
ML%T">-LA 5C_ +K[3GTSZU^B-?DZK%6!!P1R"*_3?X4^*SXX^'/A[6V;?-=6
MB&9O^FJ_+)_X^K5Y>45KJ5)]-3Y+@O&.4*N#D]O>7Y/]/O.KHHHKZ(_30HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\]/VG/'C>.
M?BQJ@CDWV&EG^S[8 \?(3O;\7W<^@%?=_CCQ /"O@W7-9XS864UPH/=E0E1^
M) 'XU^74DCS2/)(Q=V)9F8Y))ZDU\]F]6T8TEUU/S7C3%N-*EA8OXM7\MOZ\
MCZ#_ &/?A?'XJ\77'B;4(A)IVBE?(5Q\KW)Y4_\  !\WU*5]5ZUJ9U"Y.T_N
M4.$'K[UR7P+\.+X'^!.AQ!=EUJ4?VV9NA+3?,,^XCV+^%;M=&'I^QH1@MWJS
MOR[#+ 8"G17Q27-+U?3Y(KZAJ%MI-C/>WDR6]K ADEED.%50,DFOE?QA^U)X
MANM>D;P]Y-CI,3XB6: .\RCN^>F>N!C'K6I^U)\2I+K4$\(V,I6W@VRWQ4_?
MD/*1GV PQ]R/2OGNO(QF*ES<E-VL?&9SF]3VOU?#RLH[M=^WR/N'P]XN?QU\
M-M&UR6%8)KHGS(T^Z'4NC8]B5)'L:T?'/BY_ OPWO-<BA6>6UMH_+C?[I=BJ
M+GV!8$^PKC/@_P#\D+\-_P#76?\ ]'S5H_'C_DA>K_\ 7*U_]'Q5W*<O9N?7
MEO\ @>[&M4^K2K7][V:=_/EN>/\ @_\ :E\0VNO1MXA\F]TF5\2K# $>%3W3
M'7'7#9SZU]4:?J%MJUC!>V<R7%K.@DBEC.592,@BOSGKZ$_9;^)4EKJ#^$;Z
M7-O/NEL2Q^Y(.7C'L1EA[@^M<.#Q4N;DJ.]SPLFS>I[7ZOB)74MF^C[?,^K-
M%U,Z?<C<?W+G#CT]Z\N_:^^&:^(?!\?B[3T*:OHF&DDCX:2V)YY'="=P/8;J
M]!KJ;*&#Q!X<GL;Q!-;S1/:S(?XD9<$?]\FO?<%6IRI2ZGZ,Z,<?AJF#J=5I
MY/I^.I\>?!?QEKFK^ OB'<WVJ7%W/I>G>;9R3-O:)_*G.[)Y/*+USTJAX<^+
M7B"/X7Z_83ZC</XCFO+5+&9G_>;;@!@%/^ZC?3?1\&]&GT[7OB7X ,D<>H75
ME<643S$JADC,D63@'C]YG@'@&NSTW]GN_M_%7@_5)[FQ,&EVD27J([EI)HMQ
M1DRG(_U?7!X->'#V\X1LWI=/[_T/S^C]>KT*2A*3MS1>KTNVOO2:9@^'/'/B
M"Y\-_#&:76+R26_UUX+IVE),T8E4;6]1@D8KT/Q)XDO]/^/&@:>+V:/2GTF:
MXFM58^6S+YIW$=S\H_*L"'X%ZY;_  YT#38=2LK?Q'HFH-?VTREG@8E]P!)4
M$?PG[IZ8[YK=\)_#WQ1>>/D\6>,;W39;BWLVL[:UTU6V!3G)8L!_>;USGMC%
M;PC55HM/[/X;G=1IXJ*A3DG=\COT5DN:^OEMU.5\+V/C;XN>'[WQ7;>+KK1;
MB2>0:=IMN=MNJJ<!9,=<GC)!Z9YSBK7Q<\4>*=#MO!FE27]W;ZG<)*^I7&@P
MF9GV*H!12%SGYCCC&*DC^$_COPOIVI>'?"^NZ;%X;O979)+H2+=6RO\ >52H
M(Z=\]>?ES74:KX0\:Z/I_A]?#/B*.ZFT^$Q74.M%FCNR1]\L,MD$G SV'/'(
MHSY&FG?K]_34(T:SHRBXS4K+F=[W=];*_P"5M-#ROQ+XZGM_!GA.XL_'&JSV
MEUJDL5]J.PQ7$* )N1D!.2H)8#G.:Z#X0^-KO4OB<^F:9XKO/$V@_83-))J:
MB.190> @/S''';')] :5_@+XCT_1=#?3M1TR77+35WUBXDNC(L!E.S"J%4DJ
M-@ZXZFNH\+_#'Q9K'Q.TGQ-XJO\ 2?-L8VAA@T='&_<&7YRP!P Q/?I]:B$*
MW.FT^G];F5&CC/;P;BUK'OM;77F^]6=^Y]*T445]2?KX4444 %%%% !1110
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ME_\ T$0_\"C_ )GK-%>3?\-5?"W_ *&C_P I]U_\:H_X:J^%O_0T?^4^Z_\
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MTL0KTW\NITY?FF%S.'-AY:]5U7JOUV+M%%%=1ZP4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVBM*&&I8=6IKY]3IR_*\+ED.7#QUZOJ_5_IL%%%%=1ZP4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\"/V&KGQE<+XZ^-%W>:KJVH$7(T6:9MYSR#<OG=G&/W:D;< $]5'U[:S>'?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\_^.GPV7XI?#K4-)C5?[1C_P!)L6;C$Z X&>P8$K_P+->@
M45$X*I%PELS#$4(8FE*C45XR5F?E!/!+:7$D,R-%-&Q1T<896!P01V(-??7[
M,OQC3XF^#4L;^?=XBTI%BN0Q^:>/HDP]<]&_VA[BO(OVO/@FVG7TGCG1K?-I
M<,!JD,8_U4AX$V/1N W^US_$<?/G@;QMJGP]\36>N:1-Y5W;-RK?<E0_>1AW
M4C_$<@5\C3G/+<0XRV_-=S\7PM:OPOF4J=76#W\X]&O-?YH_3"^M/);S$'R'
MK[54K.^%_P 3=(^+'A6+5M,<*W^KNK-SE[>3'*-ZCT/<?B!N75@T.63YD_45
M]?&49Q4HNZ9^U4:T*]-5:3O%ZIF8VGV[G)B&?;(J2*WC@^X@6I**HU"BBB@
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MP4,NPL,-#IOYOJPHHHKH/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"70K/Q%IMQK,;O$]A'<J9@Z$AUVYSD8.1[&L#Q=^SAIGQ(O+B?29DT76W4R
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MJ+Z/D2.!<K++A( %Y*CTZ'\:WE8.H93E2,@CO0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !4$E]!')$C2KND8HF.<L.HJCK&H?94D+M-;0P[9/.0*1)S_
M *L9[G_/OQLWC"Z5F%G%#9Q%RX"H&.3U))_PH [Z#4K6Y5&CF4AV*+G@L1U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJKAE_P" T5X<KYEU+XRRA8/$+&T5:%3?RE_P=_6YUM%%%<I^<!1110 4444
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M?HS^SG^WSX0^,4MKHGB-(_"'BN7")%-)FSNW/&(I#]UB?X'YY !8UX/\=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV-4*G\..LOT7S_*YXKXH\3:IXT\1:AKFM7DFH:KJ$S3W-S,<L[D\_0=@!P
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M)%8_@;X<^,_C#\=++XG>.(=+TA?#]MY6E^'K*\$[>8-^UI'&0!N<MN'4A1C
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M$P[#).,OVZG '<CHO$'C?QYH>CZ2H\.V$^JW$4EQ>7#2-'962J,A&<GECZY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3C@+;@S\^Q,8'XUZ-'W:=S]WX77U'(98B6E^>7W*W_MI^TE%%%><?A 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_4]7HHHKSC\+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNS$EB>Y)-=#7'4G[25S\LSS-IYQC)5WI%:179?YO=A11161\^%%%% !1110
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M/H2#WS@JT>:)^RYOE>'XGP4,9@Y+G2T??O%_UH_4_:::W>W;:P^A[&HZ\W^
MG[57@7]H;38X],NUT[Q $W7&@WS@7"$#DQGI*O\ M+R!C(7I7K$VE]XF_P"
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MJG'EB?IO$&9T,AP*R[!:3:LO[JZM^;Z>>IVM%%%><?A84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU-4\:E&7:>EO27_!3\CZ3\-?\%0/AKJ5O'_;.A>(-&NC]]8X8KF(?1PZL?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6VDM/#D;:/9'C[2V&N''\D_#)]Z\8NKJ:]N))[B:2>>0[GDE8LS'U)/6NO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTV;RYMIZ-Q^-9RBI)QDKIEQDXM2B[-'Q1\2/!,_P_P#%UYI$I9X5/F6\K?\
M+2)ONM]>H/N#7K/[+/CIH;V[\+74F8Y@;FSW'HX'SH/J/F_X"WK74_M0^#QJ
MWA.WUV%,W.F2;9"!R87(!_)MOYM7S5X7UZ;POXBT[5K?/FV<ZR[0?O 'E?H1
MD?C7X/B(/AG/%*'P7O\ ]N/=?+5?*Y^[X>:XFR-QG\=K?]OK9_/1_.Q]_P!%
M0V=Y%J%G!=0-YD$\:RQL.ZL,@_D:FK]X34E='X.TXNS"BBBF(**** "BBB@
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MQ2HT,T3%61@0RL#@@CL0:^[Z^??VD? BVEU!XILX]L=TX@O54<"7'RO_ ,"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO=J^[R&N\1EE"H]^5+[M/T/A,^H+#YG7IK;F;^_7]0HHHKWCP0HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#*;_\ ;:^BJ*/]5,F_Y\?^33_^2#_6O.?^?_\ Y+#_ .1/G7_AD7_J;/\
MRF__ &VC_AD7_J;/_*;_ /;:^BJ*/]5,F_Y\?^33_P#D@_UKSG_G_P#^2P_^
M1/G7_AD7_J;/_*;_ /;:/^&1?^IL_P#*;_\ ;:^BJ*/]5,F_Y\?^33_^2#_6
MO.?^?_\ Y+#_ .1/G7_AD7_J;/\ RF__ &VC_AD7_J;/_*;_ /;:^BJ*/]5,
MF_Y\?^33_P#D@_UKSG_G_P#^2P_^1/G7_AD7_J;/_*;_ /;:/^&1?^IL_P#*
M;_\ ;:^BJ*/]5,F_Y\?^33_^2#_6O.?^?_\ Y+#_ .1/G7_AD7_J;/\ RF__
M &VC_AD7_J;/_*;_ /;:^BJ*/]5,F_Y\?^33_P#D@_UKSG_G_P#^2P_^1/G7
M_AD7_J;/_*;_ /;:/^&1?^IL_P#*;_\ ;:^BJ*/]5,F_Y\?^33_^2#_6O.?^
M?_\ Y+#_ .1/G7_AD7_J;/\ RF__ &VC_AD7_J;/_*;_ /;:^BJ*/]5,F_Y\
M?^33_P#D@_UKSG_G_P#^2P_^1/B?XF?#S2OA[J']F1>(9-7U==IDMH['RUC!
M (W/YAY((( !Z]JZWX7?L]:]K%Q::OJ=Q-X=MHW66+:"+IL$'*C_ )9^S'D>
MAKZ2D\&Z'-X@&N2:7:OJP  NVC!?@8!^H'&>N.*V:\G#\'X6.*E7J_ G[L4W
MMTNVV[^EE^1ZV(XPQ4L+&A1^-KWI-+?K9))6];O\QL:>7&B;F?: -S')/N?>
MG445^AGYX%%%% !1110 4444 %%%% !1110 55NK1I)//B=EN%C9$W,=F3W(
M[U:HH I&:]C##[,DQ6$,&5]H>3NH!Z#WI)+>ZO5>.5_L\+HI'DL1(K9R1GIB
MKU% "*H7I7SQ^UTQV>%5_A)NB?\ R#7T17@G[6EB9-"\/WF/EBN9(B?]]0?_
M &2OE>*(N63UTO+_ -*1]5PO)1SB@WY_^DL\J_9]4-\7M !Z9G/_ ) DKZXU
M#_C[?\/Y5\<?!G4%TSXH^')F. UT(<_]= 4_]FK[*U1=LX;^\*\/@:2^H5(]
M5-_^DQ_R/<XYB_K].71P7_I4O\S@?B5 6M+*;'".R'\0#_[+4OQ&NFG^&.MS
MPG/F6#-Q_=*\_H36WXDTS^UM'N(%&9,;H_\ >'(_/I^-<UX:FC\1>&[_ $"Y
M;:SP20\]?+8$'\L_RK]!Q5.5?"SIQW::^]'P.%J*CB*=26R:?W,^1**MZMI=
MQHFIW5A=QF*YMY&CD4^H/\JJ5_*<HN$G&2LT?U3&2G%2B[IG2_#WP>OCKQ-#
MI+7JV D1G\QEW$[1G"C(R?QZ U[!X9_9IM[#5EN-8U)=0LXVRMM%&4\STWG/
M ]A^=<1\!_!5]KGBZUU=5:'3M.D\QY^@=\<(OJ>>?0?45]2U^L\*Y'A,7A%B
M<71O)2T;;LUITV:O?U/R?BK/,7A,6\-A*UHN.J25T]>NZ=K>@R&%+>)(HD6.
M- %5%& H'0 >E/HK+\1ZTFB:;),2/.;Y8E]6_P !UK]82Z(_)F^K.9T]OMWQ
M%GE3E8BV3]$V?SKNJY/P#I+V]I+?S ^;<GY=W7;Z_B?Y"NOMU\R9%]2*TGO;
ML)'S5\2M=7PS^T#JUT3BW8PQS8_NM!'D_@<'\*]#5A(H92&5AD$<@BO#_C-J
M"ZG\4?$<RG(6Z,.?^N8"?^RUZ3\&8=3USP1<W+ SPV%Q]G7NVW:&_$#/Y$>E
M?AN"Q3J9EB</%73G.2^]W_ _;<=A%3RW#8B3LXPA%_<K?B=11117T)\V%%%%
M !72>!=)-]JPN67]S;?-GU;L/Z_A6/I>EW&KW2P6Z;F/5NRCU->JZ3I<.CV,
M=M".%Y9N[-W)KV<MPCK5%4DO=7XL\?,<4J--TXOWG^1=HHHK[0^/"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIMKH]C#9V5O':VL*[4BC&% JU7#?\+'FC^633</_ -=2/TVTUO%>NZI^[LK
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3[.7Q5?Q;9KI3%9*PY6//S2?\"(P/8'L:]\ID,,=M#'#$BQ11J$1$& J@8
M["GU^PY9E]/+,+##4^F[[OJ_ZZ'X]F>85,SQ4\34Z[+LNB_KJ%%%%>J>4%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:]JHHK]IR_ 4<MP\<-06B^]OJV?BV88^MF6(EB:[U?W)=$@HHHKT3S@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:QH]EX
M@TRXT_4;=+JSN%V212#@C^A]".15VBIE&,XN,E=,J,I0DI1=FCY(^*7[/VJ>
M#I)K_1UDU71>6.T9F@'^T!]X#^\/Q KR>WN9K.XCGMY7@FC.Y)(V*LI]01T-
M?H?7FGC[X!^&_&S27,4?]CZFW)N;11M<^KIT/U&#[U^5YMP;S2=?+79_RO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>businessthree.jpg
<DESCRIPTION>VCYT CHART 3
<TEXT>
begin 644 businessthree.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1@!]@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGP-_:?\ %OPXTSP;H&OZ1ICI:V2^5<?;IIY;1'BR5EVL/.D7*J@+*"H()W4
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MXM<\0PK(X@BL[A(Y50?.T<K1A'4>H;GMD8- 'M]%,FFCMH9)I7$<4:EW9N
M!DDU^,'B/XB?%K_@J1^T=JG@WP=XCG\-?#;3C)<0Q,7BMX+)6$8N)T3!FFDR
M"J,>-Q *@,U '[/Q31S*6C=9%R1E3D9'!%/K\6OC+^P/\:OV';C0/&_PF\::
MMXLDDNUMG;P[ITL%Y#,P)4-;*\HFB;:5.<C) *X-?J]^SOXV\4_$+X*^%=>\
M<>';KPIXMN;3&IZ7>0- \<Z,49]C<JK[=X4\@. >10!Z/17S5XX_X*.?L[_#
M_P 33:#JGQ%MI=0@D,4YTVRN;V&%@2"#+#&R$@@@A22.XKUKPG\<O ?CSX<W
M?COPYXEM-<\*V=O+<W%]8!YC$L2%Y T2J9 X49V%=W3 Y% '=T5Y;\$OVGOA
MC^T9_:X^'?BJ'Q&VD^5]M5;6>W:'S-VPXFC0D'8W(STYJEXZ_:W^$WPU^)VG
M_#SQ%XNCL?&=^UO';:3'8W5Q([3MMA7=%$R@L2, D'D$\$4 >OT5Y7\;OVHO
MA?\ LYV]I)\0?%UIH,UX"UM9^7)<7,RC^)88E9]N>-Q 7/&:K_!#]K+X3_M&
M27,'@#QC::U?6T8EFT^2*6VND7IN\J559E!X+*"!D<\B@#URBO(?B5^UM\)/
M@_\ $'3O!'C+QG;:!XEU".&6WM+FVG*%)7:.-FF6,QH"RL"68 8R<#FJ7P;_
M &S/@]\?O$VJ:!X%\7IK.JZ; ]W<0M97-NH@5E5I0\L:J4#.HR#W'8@T >UT
M5\M>)?\ @IQ^S?X7UJ;3)_B&E[/"YCDET[3;NZ@4CTE2(HX]T+"O>/A?\6/"
M'QI\(V_B?P1KUKXBT.=F1;JU)&UQU1T8!D89'RL <$''(H ZVBOG[XI?M[?
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M@\97&L6NJ^*-#TRXE,SZ+I]U!Y$>3G9&SPLZI[$L>>".* /D;_@F;:6>G_\
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M&7:F,]20:_0_]D?]CSXJ^$_V(?'GPSUS4-0^%/CO5-?FU'2]2TS5$:2)?(M
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M9BV]G(?YCC)Y'Z._'KX36/QR^#?B[P'J&Q(=;T^2VCE<9$,P^:&7'^Q(J/\
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MXPBN)K<V\MM]JTJ0S202A#,R-&6,9;<-R#=N!5B: -;_ ())^*=4T?Q!\;_
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M"G@(<]LT ?/?_!5CQM/XK_;4\,^%-:M]2U7POH5M81C1]/XFN!<.)+CR./\
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MC\%?V[_"OPCNO@78:!YG@JX2:S\^.\T]A]DD8^9$MPTFY8FW,=IP^&(&!\M
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M:W_";^-]!AU[1M26]&K>*;/5;5DDEN8C*TPB9UF;]_A3^['4D#% 'GVFV?\
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M[1M+?RG%T[D;9I49OE(/ (K]': .7^*=E>ZE\,?%]IIK%-1N-'O(K9@,D2M
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MMYJ%U+?W>D2S1120S2KBY5EF=4FBE+.V P8%C@9"M5[X'_!O]K[XQ_M$V'Q
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M"ZDA="C1L\:L5*GD$$XP:UZCMX1;V\<09W$:A0TC%F.!C))Y)]S4E !1110
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MP[?'3];FO!;0V<IMG\JX:?I&J,5?S/X0,]J .ZHKY&_X)SV7CZR\!^+5\?\
MQ1TKXI7K:E&;:]TKQ*-:6UC\H9C:0$["3SM_&O?_ ![\=OAQ\+;R*S\8>//#
MGAB]E :.UU75(;>9E/\ $$9@V/?&* .ZHK(\*^,-!\=:/'JWAO6].\0:7(Q5
M+[2KN.Y@8CJ Z$J2,^M9DOQ7\$P^,6\)2>,= C\5KUT)M4@%\/W?F_ZC?O\
M]7\_3[O/3F@#JJ*\_P##O[0GPO\ %WB;_A'-#^(OA76->SM&FV.LV\UPQ )(
M5%<EB #D#..]>@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?G;\:O^"46M?'#XR:YXFUGXQWJ>
M&=1U2?48='>QDG>S660NT,1>?8HYP&"XX'R\8K]$J* .9^&OP[T3X2^ ="\'
M>&[;[)HFBVJ6EK&QRVU1RS'NS'+,>Y8GO73444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XC^V!^
MS.G[6'PA/@5_$3>&!_:$%_\ ;ELOM?\ JPXV[/,3KOZ[N,=*Z+]FOX++^SO\
M$?"_P\35SKRZ)'-&-1:V^SF;S)Y)<^7O;;CS,?>/3->F44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!^;WCC_ ()$:G\4/BMJ&O\
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M"9'Q%T_P/\0KKXD^&;?PCKJVFIWD?ERVX-E*3;&/ :,(22$?D!AVVU\/^/\
MQQ\3_BA\,9_ _C7]DRZUWXGM$UO_ ,)VOAVYM]29MQQ,RQ6X,CCCYB^PXR5.
M37UA^S%^ROXZ^!__  3Q^,N@>(=-N&\7^*]'UB[M_#UF/M$\1?3S###MCW;I
MG*YVKD_,B_>!% 'D'_!,[XD7'P?_ &+?V@_&EE&LU]HLC7=JD@RIF6T_=[AZ
M;RN?;-<1_P $_P#]C'1OVVQX[^)'Q7U[6=5*ZC]C"VUT$GN;ID$DLTLC*QP
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M45F_VJW_ #S'YT?VJW_/,?G0!I45F_VJW_/,?G1_:K?\\Q^= &E16;_:K?\
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M:K?\\Q^= &E16;_:K?\ /,?G1_:K?\\Q^= &E16;_:K?\\Q^=']JM_SS'YT
M:5%9O]JM_P \Q^=']JM_SS'YT :5%9O]JM_SS'YT?VJW_/,?G0!I45F_VJW_
M #S'YT?VJW_/,?G0!I45F_VJW_/,?G1_:K?\\Q^= &E16;_:K?\ /,?G1_:K
M?\\Q^= &E16;_:K?\\Q^=']JM_SS'YT :5%9O]JM_P \Q^=']JM_SS'YT :5
M%9O]JM_SS'YT?VJW_/,?G0!I45F_VJW_ #S'YT?VJW_/,?G0!I45F_VJW_/,
M?G1_:K?\\Q^= &E16;_:K?\ /,?G1_:K?\\Q^= &E16;_:K?\\Q^=']JM_SS
M'YT :5%9O]JM_P \Q^=']JM_SS'YT 9_Q%\.W'C#X?>)]!M)(XKK5-+NK&&2
M8D(KRQ,BEL G +#. :^6/^"<W[&/C']C_3?'=OXNU;0]5?7Y;*2V.BS32!!"
MLP;?YD4>,^:N,9Z&OK?^U6_YYC\Z/[5;_GF/SH TJ*S?[5;_ )YC\Z/[5;_G
MF/SH TJ*S?[5;_GF/SH_M5O^>8_.@#2HK-_M5O\ GF/SH_M5O^>8_.@#2HK-
M_M5O^>8_.C^U6_YYC\Z -*BLW^U6_P">8_.C^U6_YYC\Z -*BLW^U6_YYC\Z
M/[5;_GF/SH TJ*S?[5;_ )YC\Z/[5;_GF/SH TJ*S?[5;_GF/SH_M5O^>8_.
M@#2HK-_M5O\ GF/SH_M5O^>8_.@#2HK-_M5O^>8_.C^U6_YYC\Z -*BLW^U6
M_P">8_.C^U6_YYC\Z -*BLW^U6_YYC\ZT(VWQJW3(S0 ZBBB@ HHHH ****
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M244 1^0GI1Y">E244 1^0GI1Y">E244 1^0GI1Y">E244 1^0GI1Y">E244
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$%S_  TZW_U9^M-N?X:=;_ZL_6@"6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** (+G[RT^#_5BF7/WEI\'^K% $E%%% !1110 4444 %%%% !1110 4444
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M,%M]Y+%".3, ?O#!^7('&2?7C;CX-_M2ZM8OJLOQ(MK/4I!YHTR&4*B$_P
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M??XK_,/J&)_E_%?YGW717PI_P\__ .J:?^5[_P"YJ/\ AY__ -4T_P#*]_\
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M *II_P"5[_[FH_L;'?\ /O\ %?YA]0Q/\OXK_,^ZZ*^%/^'G_P#U33_RO?\
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M?_\ 5-/_ "O?_<U']C8[_GW^*_S#ZAB?Y?Q7^9]UT5\*?\//_P#JFG_E>_\
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MR_BO\S[LHKX4_P"'G_\ U33_ ,KW_P!S4?\ #S__ *II_P"5[_[FH_L;'?\
M/O\ %?YA]0Q/\OXK_,^ZZ*^%/^'G_P#U33_RO?\ W-1_P\__ .J:?^5[_P"Y
MJ/[&QW_/O\5_F'U#$_R_BO\ ,^ZZ*^%/^'G_ /U33_RO?_<U'_#S_P#ZII_Y
M7O\ [FH_L;'?\^_Q7^8?4,3_ "_BO\S[KHKX4_X>?_\ 5-/_ "O?_<U'_#S_
M /ZII_Y7O_N:C^QL=_S[_%?YA]0Q/\OXK_,^ZZ*^%/\ AY__ -4T_P#*]_\
M<U'_  \__P"J:?\ E>_^YJ/[&QW_ #[_ !7^8?4,3_+^*_S/NNBOA3_AY_\
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M!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK\.]9NB=!UIT@BN)!@-NR;:4^A.2A]S[<?3/[:W_ ";7XO\ ^N</_HU*X_\
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M[QO# \O.J!1Y/%DJ'G/][BL,!*,75YG]B1GAVESW_E9]AUYG^TS_ ,F_^/\
M_L#W'_H!KTRN ^/VAW_B7X*^--*TNUDOM1N]+FA@MHAEI'*G"CW-<-!VJP;[
MK\S"GI.+\SR7_@GDH7]G6W(')U2[)_[Z KZ9KP/]B3P3KWP_^!MOI/B/2[C1
M]274+F4VUR '"LV5/T->^5T8Z2EB:C3NKFF(:=637<^%OVZ/^3B?A#_O1?\
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M_P###OQL_P"A*_\ *K8__'J/^&'?C9_T)7_E5L?_ (]7ZP44?ZPXK^6/W/\
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M?]"5_P"56Q_^/5^L%%'^L.*_EC]S_P P_M.MV7X_YGY/_P###OQL_P"A*_\
M*K8__'J/^&'?C9_T)7_E5L?_ (]7ZP44?ZPXK^6/W/\ S#^TZW9?C_F?D_\
M\,._&S_H2O\ RJV/_P >H_X8=^-G_0E?^56Q_P#CU?K!11_K#BOY8_<_\P_M
M.MV7X_YGY/\ _##OQL_Z$K_RJV/_ ,>H_P"&'?C9_P!"5_Y5;'_X]7ZP44?Z
MPXK^6/W/_,/[3K=E^/\ F?D__P ,._&S_H2O_*K8_P#QZC_AAWXV?]"5_P"5
M6Q_^/5^L%%'^L.*_EC]S_P P_M.MV7X_YGY/_P###OQL_P"A*_\ *K8__'J/
M^&'?C9_T)7_E5L?_ (]7ZP44?ZPXK^6/W/\ S#^TZW9?C_F?D_\ \,._&S_H
M2O\ RJV/_P >H_X8=^-G_0E?^56Q_P#CU?K!11_K#BOY8_<_\P_M.MV7X_YG
MY/\ _##OQL_Z$K_RJV/_ ,>H_P"&'?C9_P!"5_Y5;'_X]7ZP44?ZPXK^6/W/
M_,/[3K=E^/\ F?DZW[$/QK3&?!>/^XK9?_'J5?V(/C6PR/!>?^XK9?\ QZOU
M:N?X:=;_ .K/UH_UAQ7\L?N?^8?VG6[+\?\ ,_*3_AAWXV?]"5_Y5;'_ ./4
M?\,._&S_ *$K_P JMC_\>K]8**/]8<5_+'[G_F']IUNR_'_,_)__ (8=^-G_
M $)7_E5L?_CU'_##OQL_Z$K_ ,JMC_\ 'J_6"BC_ %AQ7\L?N?\ F']IUNR_
M'_,_)_\ X8=^-G_0E?\ E5L?_CU'_##OQL_Z$K_RJV/_ ,>K]8**/]8<5_+'
M[G_F']IUNR_'_,_)_P#X8=^-G_0E?^56Q_\ CU'_  P[\;/^A*_\JMC_ /'J
M_6"BC_6'%?RQ^Y_YA_:=;LOQ_P S\G_^&'?C9_T)7_E5L?\ X]1_PP[\;/\
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M )5;'_X]1_PP[\;/^A*_\JMC_P#'J_6"BC_6'%?RQ^Y_YA_:=;LOQ_S/R?\
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MC9_T)7_E5L?_ (]7ZP44?ZPXK^6/W/\ S#^TZW9?C_F?D_\ \,._&S_H2O\
MRJV/_P >H_X8=^-G_0E?^56Q_P#CU?K!11_K#BOY8_<_\P_M.MV7X_YGY/\
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M$K_RJV/_ ,>H_P"&'?C9_P!"5_Y5;'_X]7ZP44?ZPXK^6/W/_,/[3K=E^/\
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MZ$K_ ,JMC_\ 'J_6"BC_ %AQ7\L?N?\ F']IUNR_'_,_)_\ X8=^-G_0E?\
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MF(4444 %%%% !1110!6G_P!8:GC_ -6OTJ"?_6&IX_\ 5K]* '4444 %%%%
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M445\Z>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0
MW'W1]:+;[K47'W1]:+;[K4 34444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M!<_PTZW_ -6?K3;G^&G6_P#JS]: ):*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH @N?O+3X/]6*9<_>6GP?ZL4 24444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!7N/]8/I4L/^K6HKC_6#Z5+#_JUH ?1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 9/BSPGI'CGP_>Z'KUA#J>E7B;)K:
M895AG(/'(((!!&"" 1S7G'P[_91^&/POUS^V=$\.*=34YAN+Z9[DP?\ 7,.2
M%/\ M8W>]>NT5M&M5IQ<(2:3W5S2-2<4XIZ,****Q,PHHHH **** "BBB@ H
MHHH **** *T_^L-3Q_ZM?I4$_P#K#4\?^K7Z4 .HHHH **** "BBB@ HHHH
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MS:/^TK\,?C5\1];^'_@2&'1->U>>8VQ6*2VN0LCB.X >;>KNI+-@@$N?E
M]E^ GQ _:/\ $'Q(L[/XD>#;#1O"K0RM-=V\*JZN$)09$S=6P.E?*?Q<\=_%
MWQ_=?%?Q[8^/M5T7P]X3UU=+.CZ;J,]N8HFF:&-A'&0O&%RQY8D^E>J_ #PK
MXN^'7[7OA[0O&_Q&U#Q>EYH$VJ:+*]Y-<PW22(PP1*^8R%21N V=HYYX]NM3
MO2;FH\UNSOHEU^:/0G&\&Y6O;SOL??5%%%?,GDA1110 4444 %%%% !1110
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M1110!7N/]8/I4L/^K6HKC_6#Z5+#_JUH ?1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %:?_6&IX_\ 5K]*@G_UAJ>/_5K]* '4444 %%%% !1110 4444
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M)))"R+'C)R-^/6NVG5E5A5A&;VOTV7?SL;QFYQFE)_\  /OVBBBO&.$****
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M_P"A=_\ )VV_^.4?\,W_ !%_Z%W_ ,G;;_XY1]3R7O'_ ,#_ /M@]A@.Z_\
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M1]3R7O'_ ,#_ /M@]A@.Z_\  O\ @GI?_#9?_4H?^5/_ .TT?\-E_P#4H?\
ME3_^TUYI_P ,W_$7_H7?_)VV_P#CE'_#-_Q%_P"A=_\ )VV_^.4?4\E[Q_\
M _\ [8/88#NO_ O^">E_\-E_]2A_Y4__ +31_P -E_\ 4H?^5/\ ^TUYI_PS
M?\1?^A=_\G;;_P".4?\ #-_Q%_Z%W_R=MO\ XY1]3R7O'_P/_P"V#V& [K_P
M+_@GI?\ PV7_ -2A_P"5/_[31_PV7_U*'_E3_P#M->:?\,W_ !%_Z%W_ ,G;
M;_XY1_PS?\1?^A=_\G;;_P".4?4\E[Q_\#_^V#V& [K_ ,"_X)Z7_P -E_\
M4H?^5/\ ^TT?\-E_]2A_Y4__ +37FG_#-_Q%_P"A=_\ )VV_^.4?\,W_ !%_
MZ%W_ ,G;;_XY1]3R7O'_ ,#_ /M@]A@.Z_\  O\ @GI?_#9?_4H?^5/_ .TT
M?\-E_P#4H?\ E3_^TUYI_P ,W_$7_H7?_)VV_P#CE'_#-_Q%_P"A=_\ )VV_
M^.4?4\E[Q_\  _\ [8/88#NO_ O^">E_\-E_]2A_Y4__ +31_P -E_\ 4H?^
M5/\ ^TUYI_PS?\1?^A=_\G;;_P".4?\ #-_Q%_Z%W_R=MO\ XY1]3R7O'_P/
M_P"V#V& [K_P+_@GI?\ PV7_ -2A_P"5/_[31_PV7_U*'_E3_P#M->:?\,W_
M !%_Z%W_ ,G;;_XY1_PS?\1?^A=_\G;;_P".4?4\E[Q_\#_^V#V& [K_ ,"_
MX)Z/)^V-YF/^*1QC_J)__::6/]LCRUQ_PB&>?^@G_P#::\U;]G/XAIC/A['_
M &^V_P#\<I5_9R^(C#(\/9_[?;?_ ..4?4\E[Q_\#_\ M@]A@.Z_\"_X)Z9_
MPV7_ -2A_P"5/_[31_PV7_U*'_E3_P#M->:?\,W_ !%_Z%W_ ,G;;_XY1_PS
M?\1?^A=_\G;;_P".4?4\E[Q_\#_^V#V& [K_ ,"_X)Z7_P -E_\ 4H?^5/\
M^TT?\-E_]2A_Y4__ +37FG_#-_Q%_P"A=_\ )VV_^.4?\,W_ !%_Z%W_ ,G;
M;_XY1]3R7O'_ ,#_ /M@]A@.Z_\  O\ @GI?_#9?_4H?^5/_ .TT?\-E_P#4
MH?\ E3_^TUYI_P ,W_$7_H7?_)VV_P#CE'_#-_Q%_P"A=_\ )VV_^.4?4\E[
MQ_\  _\ [8/88#NO_ O^">E_\-E_]2A_Y4__ +31_P -E_\ 4H?^5/\ ^TUY
MI_PS?\1?^A=_\G;;_P".4?\ #-_Q%_Z%W_R=MO\ XY1]3R7O'_P/_P"V#V&
M[K_P+_@GI?\ PV7_ -2A_P"5/_[31_PV7_U*'_E3_P#M->:?\,W_ !%_Z%W_
M ,G;;_XY1_PS?\1?^A=_\G;;_P".4?4\E[Q_\#_^V#V& [K_ ,"_X)Z7_P -
ME_\ 4H?^5/\ ^TT?\-E_]2A_Y4__ +37FG_#-_Q%_P"A=_\ )VV_^.4?\,W_
M !%_Z%W_ ,G;;_XY1]3R7O'_ ,#_ /M@]A@.Z_\  O\ @GI?_#9?_4H?^5/_
M .TT?\-E_P#4H?\ E3_^TUYI_P ,W_$7_H7?_)VV_P#CE'_#-_Q%_P"A=_\
M)VV_^.4?4\E[Q_\  _\ [8/88#NO_ O^">E_\-E_]2A_Y4__ +31_P -E_\
M4H?^5/\ ^TUYI_PS?\1?^A=_\G;;_P".4?\ #-_Q%_Z%W_R=MO\ XY1]3R7O
M'_P/_P"V#V& [K_P+_@GI?\ PV7_ -2A_P"5/_[31_PV7_U*'_E3_P#M->:?
M\,W_ !%_Z%W_ ,G;;_XY1_PS?\1?^A=_\G;;_P".4?4\E[Q_\#_^V#V& [K_
M ,"_X)Z7_P -E_\ 4H?^5/\ ^TT?\-E_]2A_Y4__ +37FG_#-_Q%_P"A=_\
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M\-E_]2A_Y4__ +31_P -E_\ 4H?^5/\ ^TUYI_PS?\1?^A=_\G;;_P".4?\
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M -L'L,!W7_@7_!/3/^&R_P#J4/\ RI__ &FC_ALO_J4/_*G_ /::\T_X9O\
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M (9O^(O_ $+O_D[;?_'*/J>2]X_^!_\ VP>PP'=?^!?\$]+_ .&R_P#J4/\
MRI__ &FC_ALO_J4/_*G_ /::\T_X9O\ B+_T+O\ Y.VW_P <H_X9O^(O_0N_
M^3MM_P#'*/J>2]X_^!__ &P>PP'=?^!?\$]+_P"&R_\ J4/_ "I__::/^&R_
M^I0_\J?_ -IKS3_AF_XB_P#0N_\ D[;?_'*/^&;_ (B_]"[_ .3MM_\ '*/J
M>2]X_P#@?_VP>PP'=?\ @7_!/2_^&R_^I0_\J?\ ]IH_X;+_ .I0_P#*G_\
M::\T_P"&;_B+_P!"[_Y.VW_QRC_AF_XB_P#0N_\ D[;?_'*/J>2]X_\ @?\
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M.M!CUZ'Q+9-XHO)GMM3T]$=+B:+S6<HP#;S <$IA@"6Q7:?#/P3\!]#\<_\
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M?='UHMONM1<?='UHMONM0!-1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%
MS_#3K?\ U9^M-N?X:=;_ .K/UH EHHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"M/_K#4\?^K7Z5!/\ ZPU/'_JU^E #J***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYB?WA1YB?WA6;]LC]_RH^V1^_P"5 &EYB?WA1YB?WA6;]LC]_P J/MD?O^5
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M[9'[_E0!I>8G]X4>8G]X5F_;(_?\J/MD?O\ E0!I>8G]X4>8G]X5F_;(_?\
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M+S$_O"CS$_O"LW[9'[_E1]LC]_RH TO,3^\*/,3^\*S?MD?O^5'VR/W_ "H
MTO,3^\*/,3^\*S?MD?O^5'VR/W_*@"S(<R$CI6W%_JD^@K C<2*&'0UOP\0Q
M_P"Z/Y4 /HHHH **** "BBB@ KE]:_Y"4W_ ?_01745R^M?\A*;_ (#_ .@B
M@"C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 6+'_6G_ ':=??>3Z4VQ_P!:?]VG7WWD^E %6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** +5C]Y_I3;S_7?A3K'[S_ $IMY_KO
MPH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!<L?NO45Y_KC]*EL?NO45
MY_KC]* (**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH NV/^K;ZU7N?]>]6+
M'_5M]:KW/^O>@"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]G_J?QJI-
M_KG^M6[/_4_C52;_ %S_ %H CHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#0M?^/=?Q_G71Q?ZM/H*YRU_X]U_'^=='%_JT^@H ?1110 4444 %%%% !7+
MZU_R$IO^ _\ H(KJ*Y?6O^0E-_P'_P!!% %&BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** %I-P]:X[XS.\?PE\7/&[1NNGR$,IP1R.A[5X?
M\)?@#9_$#P%IVO7OB;6K2XNC)F*WD!10KLHZG/:O9PV!HU<.\37J\B3Y=K]+
MGS>.S3$4,9'!X:C[23CS?$EI>W4^HMIVDX./7%)7@.I?LY>(/"L+:AX)\;ZH
M-3A!9+>\D*K-C^$$''/3# @YKM/@9\5I?B;H-Y'J4 M=?TN00WL:KM5\YPX'
M\/*L".Q%*O@(1HO$8:ISQ6^C35_)]"L+FTY8A83&472G+X=4T[;V:Z^1Z512
MTXPN #M/S=.*\<^ANEN,HHI0"W &30,2BE"EN@S001P1@T )13E5F^Z"?H*#
M&RYRI^4X/M0*ZV&T444#"BGI#)(,JC$>N*1D:,X92I]Q0*ZV&T44O/7M0,2B
MG+&S_=4GM0R-&<,"#[T"NMAM!(7&65<]-Q S]**\&_:L;RKKX=%P<#56;ITP
M8NG^>U=V!POURO&A>U[_ (*YY>:8[^SL++$J-[6T]6D>]4E/FC:.1@1T.,TR
MN$]1.ZN%%.VMMSM./7%-H&%%%% !1110 4444 %%%% %BQ_UI_W:=??>3Z4V
MQ_UI_P!VG7WWD^E %6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +5C]Y_I
M3;S_ %WX4ZQ^\_TIMY_KOPH KT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!<L?NO45Y_KC]*EL?NO45Y_KC]* (**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH NV/^K;ZU7N?]>]6+'_5M]:KW/\ KWH BHHHH ***\_^.7Q N_AOX#FU
M.PC5[Z:9+6!W7<L;,"=Y'? 4X]\5T8>A/$U8T:>\G9'+BL33P=">(J_#%79Z
M!17Q3X5_::\::%JHN-0O1KEFQ_>VMRBIGW5E4%3^8]J^H?AU\7O#OQ+M0=-N
MO)OU7,NGW&%F3U('\0]QGWQTKV,PR/&9<N>HN:/=:I>O8^>RKB;+\VE[.E+E
MG_++1OTU:?WW.UHHHKY\^K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7^ON9_\ /NG]TO\ Y(^Y/^&DOAS_ -#%_P"2-S_\;H_X:2^'/_0Q?^2-S_\
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M/^&DOAS_ -#%_P"2-S_\;H_X:2^'/_0Q?^2-S_\ &Z^&Z*/]4<#_ #S^]?\
MR(?Z^YG_ ,^Z?W2_^2/N3_AI+X<_]#%_Y(W/_P ;H_X:2^'/_0Q?^2-S_P#&
MZ^&Z*/\ 5' _SS^]?_(A_K[F?_/NG]TO_DC[D_X:2^'/_0Q?^2-S_P#&Z/\
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M !NOA:BC_5' _P \_O7_ ,B'^ON9_P#/NG]TO_DC[D_X:2^'/_0Q?^2-S_\
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M **** "BBB@ HHHH **** "BBB@ HHHH OV?^I_&JDW^N?ZU;L_]3^-5)O\
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MO>@"*BBB@ KCOBQ\0X_AEX-N-8:$7-P76"VA8X5Y6!(R?0 $GZ8KL:YKXB>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH N6/W7J*\_UQ^E2V/W7J*\_P!<?I0!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+ _Z</\ R-_]C6/_ ,(EJW_/I_Y$3_&C_A$M6_Y]/_(B?XT?5LK[Q_\  O\
M@A]=SSM+_P  _P#M38_X6!_TX?\ D;_[&C_A8'_3A_Y&_P#L:Q_^$2U;_GT_
M\B)_C1_PB6K?\^G_ )$3_&CZME?>/_@7_!#Z[GG:7_@'_P!J;'_"P/\ IP_\
MC?\ V-'_  L#_IP_\C?_ &-8_P#PB6K?\^G_ )$3_&C_ (1+5O\ GT_\B)_C
M1]6ROO'_ ,"_X(?7<\[2_P# /_M38_X6!_TX?^1O_L:/^%@?].'_ )&_^QK'
M_P"$2U;_ )]/_(B?XT?\(EJW_/I_Y$3_ !H^K97WC_X%_P $/KN>=I?^ ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% %VQ_P!6WUJO<_Z]ZL6/^K;ZU7N?]>]
M$5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 7[/_4_C52;_ %S_ %JW9_ZG
M\:J3?ZY_K0!'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &A:_\>Z_C_.NC
MB_U:?05SEK_Q[K^/\ZZ.+_5I]!0 ^BBB@ HHHH **** "N7UK_D)3?\  ?\
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M7W270^RPL(0I)P2][5N.S;W?S/G7X*^//&7Q.^.GC*_FOUC\(Z*TNG)IN\J
M3(1&X4#YF_=,2S'C<0..*H_#WQIXV\%_M,:AX$\3:J-8TW6OM%_9KYAD%L#Y
MDJ!"PRH"HRE.@XQ[TOB?^S?K&E^.M3\2>!?'D'A&?5W:>YM+J]DM,NQRQ5TR
M64L6.TC@]/;<^ /P+B\'^,KGQ3XB\8VOBSQ9-&T<?DW1FV @!G+L=SMM&.0
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M)Y,G]QORH\F3^XWY4 1T5)Y,G]QORH\F3^XWY4 1T5)Y,G]QORH\F3^XWY4
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M-;2"*0ENF,59^V1^_P"54** +_VR/W_*C[9'[_E5"B@"_P#;(_?\J/MD?O\
ME5"B@"_]LC]_RH^V1^_Y50HH O\ VR/W_*C[9'[_ )50HH O_;(_?\J/MD?O
M^54** +_ -LC]_RH^V1^_P"54** +_VR/W_*C[9'[_E5"B@"_P#;(_?\J/MD
M?O\ E5"B@"_]LC]_RH^V1^_Y50HH O\ VR/W_*C[9'[_ )50HH O_;(_?\J/
MMD?O^54** +_ -LC]_RH^V1^_P"54** +_VR/W_*C[9'[_E5"B@"_P#;(_?\
MJ/MD?O\ E5"B@"_]LC]_RH^V1^_Y50HH O\ VR/W_*C[9'[_ )50HH O_;(_
M?\J/MD?O^54** +_ -LC]_RH^V1^_P"54** +_VR/W_*C[9'[_E5"B@"_P#;
M(_?\J/MD?O\ E5"B@#1CN%E;"YSC-+).L. V>:JV/^M/^[3K[[R?2@"7[9'[
M_E1]LC]_RJA10!?^V1^_Y4?;(_?\JH44 7_MD?O^5'VR/W_*J%% %_[9'[_E
M1]LC]_RJA10!?^V1^_Y4?;(_?\JH44 7_MD?O^5'VR/W_*J%% %_[9'[_E1]
MLC]_RJA10!?^V1^_Y4?;(_?\JH44 7_MD?O^5'VR/W_*J%% %_[9'[_E1]LC
M]_RJA10!?^V1^_Y4?;(_?\JH44 7_MD?O^5'VR/W_*J%% %_[9'[_E1]LC]_
MRJA10!?^V1^_Y4?;(_?\JH44 7_MD?O^5'VR/W_*J%% %_[9'[_E1]LC]_RJ
MA10!?^V1^_Y4?;(_?\JH44 7_MD?O^5'VR/W_*J%% &E'.LV0N>*22X2)L-G
M-06/WG^E-O/]=^% $_VR/W_*C[9'[_E5"B@"_P#;(_?\J/MD?O\ E5"B@"_]
MLC]_RH^V1^_Y50HH O\ VR/W_*C[9'[_ )50HH O_;(_?\J/MD?O^54** +_
M -LC]_RH^V1^_P"54** +_VR/W_*C[9'[_E5"B@"_P#;(_?\J/MD?O\ E5"B
M@"_]LC]_RH^V1^_Y50HH O\ VR/W_*C[9'[_ )50HH O_;(_?\J/MD?O^54*
M* +_ -LC]_RH^V1^_P"54** +_VR/W_*C[9'[_E5"B@"_P#;(_?\J/MD?O\
ME5"B@"_]LC]_RH^V1^_Y50HH O\ VR/W_*C[9'[_ )50HH O_;(_?\J/MD?O
M^54** +_ -LC]_RH^V1^_P"54** -*.99L[<\4DEPD;;3G-16/W7J*\_UQ^E
M %C[9'[_ )4?;(_?\JH44 7_ +9'[_E1]LC]_P JH44 7_MD?O\ E1]LC]_R
MJA10!?\ MD?O^5'VR/W_ "JA10!?^V1^_P"5'VR/W_*J%% %_P"V1^_Y4?;(
M_?\ *J%% %_[9'[_ )4?;(_?\JH44 7_ +9'[_E1]LC]_P JH44 7_MD?O\
ME1]LC]_RJA10!?\ MD?O^5'VR/W_ "JA10!?^V1^_P"5'VR/W_*J%% %_P"V
M1^_Y4?;(_?\ *J%% %_[9'[_ )4?;(_?\JH44 7_ +9'[_E1]LC]_P JH44
M7_MD?O\ E1]LC]_RJA10!?\ MD?O^5'VR/W_ "JA10!?^V1^_P"5'VR/W_*J
M%% %_P"V1^_Y4?;(_?\ *J%% &G'*LH)7I3'NDC8J<Y'M3+'_5M]:KW/^O>@
M"U]LC]_RH^V1^_Y50HH O_;(_?\ *C[9'[_E5"B@"_\ ;(_?\J/MD?O^54**
M +_VR/W_ "H^V1^_Y50HH O_ &R/W_*C[9'[_E5"B@"_]LC]_P J/MD?O^54
M** +_P!LC]_RH^V1^_Y50HH O_;(_?\ *C[9'[_E5"B@"_\ ;(_?\J/MD?O^
M54** +_VR/W_ "H^V1^_Y50HH O_ &R/W_*C[9'[_E5"B@"_]LC]_P J/MD?
MO^54** +_P!LC]_RH^V1^_Y50HH O_;(_?\ *C[9'[_E5"B@"_\ ;(_?\J/M
MD?O^54** +_VR/W_ "H^V1^_Y50HH O_ &R/W_*C[9'[_E5"B@"_]LC]_P J
M/MD?O^54** -..02+E>E,:Z16(.<CVI+/_4_C52;_7/]: +?VR/W_*C[9'[_
M )50HH O_;(_?\J/MD?O^54** +_ -LC]_RH^V1^_P"54** +_VR/W_*C[9'
M[_E5"B@"_P#;(_?\J/MD?O\ E5"B@"_]LC]_RH^V1^_Y50HH O\ VR/W_*C[
M9'[_ )50HH O_;(_?\J/MD?O^54** +_ -LC]_RH^V1^_P"54** +_VR/W_*
MC[9'[_E5"B@"_P#;(_?\J/MD?O\ E5"B@"_]LC]_RH^V1^_Y50HH O\ VR/W
M_*C[9'[_ )50HH O_;(_?\J/MD?O^54** +_ -LC]_RH^V1^_P"54** +_VR
M/W_*C[9'[_E5"B@"_P#;(_?\J/MD?O\ E5"B@"_]LC]_RH^V1^_Y50HH U(W
M$BAAT-;\/$,?^Z/Y5SEK_P >Z_C_ #KHXO\ 5I]!0 ^BBB@ HHHH **** "N
M7UK_ )"4W_ ?_01745R^M?\ (2F_X#_Z"* *-%%% $-U96]]&([F"*X0'<%E
M0,,^N#7GGQPE'@OX3^)=:T2&WTW5;.VWP74,"!XVWJ,CCT)KQ2^UW]J%;VX%
MOI41@\QO+_=V7W<\=6]*PO%EI^TOXV\.WVAZKHJS:?>IY<T:"R0LN0<9#Y'2
MOH:&7N%2,I5H<J:NN;H?)8K-E4I3A##U>9II/DZVTU/I#X >(M1\6?!_PSJV
MK737NHW4#M-<. "Y$C@$X '0"O0:X#X!^&M2\'_"'PUH^L6IL]2M8&6:!F5B
MA,CD#*D@\$=#63^T/\<(_@EX3M[N"UCO]9OY3#96\I(C^4 N[8Y*KE> 026'
MN:\VI1>(Q<J5!7O)VMMO^1[%+$+"X"%;$NW+%7OO>R^=[_B?(NM^!X=2F^,V
MGWVCW+^,-+NVU>WO"#C[,+C$HZ_Q)*) <'('48Y[?X"^)/#>N?M*:)=>"/#[
MZ5IUQHTB:G!+$I6&<(Q=XN6V*6$2Y!&=QXYY^E? .O:OKWPKM?%6K>'A'XLE
MTZ4R69MO*EE*ERD8#<A7PI )_B%>4?LO_%JSU3Q7JGA/6/!VF>$?%RHSR2:?
M8+:&YV8W)(F,AQG=UP1DX&.?HY8NI6H5TX7Y5;XM-DF[=4K71\?# 4L/B<-)
M5+<[YE>.KLW)*_1M2L^]CZ:HHHKXT_10HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"Q8_ZT_[M.OOO)]*;8_ZT_P"[3K[[R?2@"K11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %JQ^\_TIMY_KOPIUC]Y_I3;S_7?
MA0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"Y8_=>HKS_7'Z5+8_=>HK
MS_7'Z4 04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!=L?]6WUJO<_Z]ZL6
M/^K;ZU7N?]>] $5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7[/_4_C52;
M_7/]:MV?^I_&JDW^N?ZT 1T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!H6
MO_'NOX_SKHXO]6GT%<Y:_P#'NOX_SKHXO]6GT% #Z*** "BBB@ HHHH *Y?6
MO^0E-_P'_P!!%=17+ZU_R$IO^ _^@B@"C1110 4444 %?,O[;7AV_.F^$/%U
MK:?;K7P_>.UW"W*A7:(J6']TM'M)_P!H5]-4V6))XGCD19(W!5D89# ]01W%
M=>$Q#PM:-9*]O^&9P8_"+'8:>';M?KV:=U^*/"-+_;5^&MYI<=S=7=]I]T5R
M]G)9N[JW<!E!4_7(_"O.O@_K,WQR_:HN_'VF:=-8Z#I=J8S)* &<F$PH'QQN
M;<S8!. HYXKW2\_9L^&5_>_:I?!VGB7);$6^-,G_ &%8+^E=UH/A_3/"^F1:
M=I%A;Z;8Q?<M[6,1H/4X'<^O>O2>*P=&$_JL)<TE;5JR3WM8\=8',,35IO&U
M(\D&I>ZG=M;7OM\C0HHHKPCZ<**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH L6/^M/^[3K[[R?2FV/^M/\ NTZ^^\GTH JT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!:L?O/]*;>?Z[\*=8_>?Z4V\_UWX4 5Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH N6/W7J*\_UQ^E2V/W7J*\_UQ^E
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=)%R1D'US@\X^E?@K\5H?B;\-M(U^\:"ROIM\%Q%O"KYR':VW)Z'AL=MP%>
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MZMIE#QS0N'1U/0@C@BIJ\[8]5.^J"BBB@84444 %%%% !1110 4444 %%%%
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M/_J'_P#)O_M3]@J*_'VBC_5K_I]_Y+_P0_US_P"H?_R;_P"U/V"HK\?:*/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH OV?\ J?QJI-_KG^M6[/\
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M7_@3_P P_LS ?\^(?^ K_(\?_P"&1?A-_P!"I_Y4;O\ ^.T?\,B_";_H5/\
MRHW?_P =KV"BCZ]B_P#G[+_P)_YA_9F _P"?$/\ P%?Y'C__  R+\)O^A4_\
MJ-W_ /':/^&1?A-_T*G_ )4;O_X[7L%%'U[%_P#/V7_@3_S#^S,!_P ^(?\
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M2N__ ([3;K]D'X21R87PG@8_Z"5W_P#':]EL?O/]*;>?Z[\*/KV+_P"?LO\
MP)_YA_9F _Y\0_\  5_D>+_\,B_";_H5/_*C=_\ QVC_ (9%^$W_ $*G_E1N
M_P#X[7L%%'U[%_\ /V7_ ($_\P_LS ?\^(?^ K_(\?\ ^&1?A-_T*G_E1N__
M ([1_P ,B_";_H5/_*C=_P#QVO8**/KV+_Y^R_\  G_F']F8#_GQ#_P%?Y'C
M_P#PR+\)O^A4_P#*C=__ !VC_AD7X3?]"I_Y4;O_ ..U[!11]>Q?_/V7_@3_
M ,P_LS ?\^(?^ K_ "/'_P#AD7X3?]"I_P"5&[_^.T?\,B_";_H5/_*C=_\
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MPR+\)O\ H5/_ "HW?_QVO8**/KV+_P"?LO\ P)_YA_9F _Y\0_\  5_D>/\
M_#(OPF_Z%3_RHW?_ ,=H_P"&1?A-_P!"I_Y4;O\ ^.U[!11]>Q?_ #]E_P"!
M/_,/[,P'_/B'_@*_R/'_ /AD7X3?]"I_Y4;O_P".T?\ #(OPF_Z%3_RHW?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM>ZD8?H:U]@IU(SE&,DXRUCLVEU71HP^LRIT9TX3G&2G#W97O%-]'?5,Y/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH N6/W7J*\_UQ^E2V/W7J*\_P!<?I0!!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME/K6)8?LX_%?X0ZQJ!^&GBVS_L>[?=]GOL!_;<CQLA8# W@@G'0=*^LJ*O\
MM3$.3E.SNDFFKIV\NYE_8>$C",*=X\K;33::OND^Q\X_#?\ 9K\3-\2H/'GQ
M)\10:[K%J0]O;VF2@<#Y2254*%SD*JXSSGL8OB;^S3XG3XDS>//AKX@AT75[
MEC)<6]R2J[S]]E(5@P;@E&7&<G/0#Z3HJ?[2Q'M/:76UK65K=K&G]C83V/LK
M/?FO=\W-WOO<^4=0_9S^*WQ>U'3O^%E^+[/^Q[23?]EL -_OA5C1 Q'&XDD9
MZ=J[7XA?L^ZMXC^,W@/Q/H\^FV>@^'8;2![6:203;(9F?" (0?E( RPY%>\T
M4/,J[::LDDTDE9:[Z"CDV%46I7DVTVVVV^7;4\/_ &A_@;KOQ;\1^#=0TB[T
M^VAT:61[A;V2168,\3#9M1LG"'KCM6Q^TI\)]7^,G@&TT31;FRM;N'4([LO?
MNZ1E%CD4@%58YRX[=C7K%%80QM6'L[?\N[V^9U5,NH5/;<R?[VW-KV5E8\V\
M0?!>Q\;_  ;TKP1KL@6:SL;:%;RU^8PSQ1A?,3<!D<,.0,JQ'%>+:/\ !7X^
M_#_36T#PUXUTU]#RRPF1_FB4^F^)FC^B,0">/6OK*BM*.85J47"RE%N]FKJ_
M<RKY5AZ\HU+N,DK7BVG;L^YXE^SW^SB/A%<7VN:SJ*ZUXIOU*2W";C'$K$,P
M4MR[,P!+D \#@<YC_9@^!NN_!2U\1QZW>:==MJ4D+P_V?)(X4('SNWHN/OCI
MFO<:*FICJ]55%-WY[7^6UNQ5'*\+0=)TXV]G>W_;V]^X4445YYZP4444 %%%
M% !1110 4444 %%%% !1110 4444 6+'_6G_ ':=??>3Z4VQ_P!:?]VG7WWD
M^E %6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** +5C]Y_I3;S_7?A3K'[S_
M $IMY_KOPH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<L?NO45Y_KC]
M*EL?NO45Y_KC]* (**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH NV/^K;ZU
M7N?]>]6+'_5M]:KW/^O>@"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]
MG_J?QJI-_KG^M6[/_4_C52;_ %S_ %H CHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#0M?^/=?Q_G71Q?ZM/H*YRU_X]U_'^=='%_JT^@H ?1110 4444
M%%%% !7+ZU_R$IO^ _\ H(KJ*Y?6O^0E-_P'_P!!% %&BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH L6/^M/^[3K[[R?2FV/^M/^[3K[[R?2@"K1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML[^U &3]GD_N&C[/)_<-:WV=_:C[._M0!D_9Y/[AH^SR?W#6M]G?VH^SO[4
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M %AJ>/\ U:_2H)_]8:GC_P!6OTH =1110 4444 %%%% !1110 4444 %%%%
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M7?\ AI[X:_\ 0QK_ . TO_Q-;7@_XV>#/'FL#2]#UA;V^\MI1#Y,B94=3EE
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,<1!/#X2K7BY45'WDN]E9M=4=CX0_9ZUWX9>.K*[\+^)I1X=D;-[9W?S,1Z
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M .,T?\-D_![_ *&__P IEY_\9K\Q:*/[1J]E^/\ F'^LN,_EC]S_ ,S].O\
MALGX/?\ 0W_^4R\_^,T?\-D_![_H;_\ RF7G_P 9K\Q:*/[1J]E^/^8?ZRXS
M^6/W/_,_3K_ALGX/?]#?_P"4R\_^,T?\-D_![_H;_P#RF7G_ ,9K\Q:*/[1J
M]E^/^8?ZRXS^6/W/_,_3K_ALGX/?]#?_ .4R\_\ C-'_  V3\'O^AO\ _*9>
M?_&:_,6BC^T:O9?C_F'^LN,_EC]S_P S].O^&R?@]_T-_P#Y3+S_ .,T?\-D
M_![_ *&__P IEY_\9K\Q:*/[1J]E^/\ F'^LN,_EC]S_ ,S].O\ ALGX/?\
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MD_![_H;_ /RF7G_QFOS%HH_M&KV7X_YA_K+C/Y8_<_\ ,_3K_ALGX/?]#?\
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M&KV7X_YA_K+C/Y8_<_\ ,_3K_ALGX/?]#?\ ^4R\_P#C-'_#9/P>_P"AO_\
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M<9_+'[G_ )GZ:3?MB_"!V!'B[(Q_T#;S_P",U)%^V1\'UC /B_G_ +!EY_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% $%S_#3K?_5GZTVY_AIUO_JS]: ):*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH @N?O+3X/]6*9<_>6GP?ZL4 24444 %%%% !1110
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M** "BBB@""Y^\M/@_P!6*9<_>6GP?ZL4 24444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!7N/]8/I4L/^K6HKC_6#Z5+#_JUH ?1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %:?_6&IX_]6OTJ"?\ UAJ>/_5K]* '4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %:?_6&IX_\ 5K]*@G_UAJ>/_5K]* '4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=;_POO\ Z@7_ ).?_:Z/^%]_]0+_ ,G/_M=<E_PJCQ5_T"__ "8B_P#BZ/\
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MJ/%7_0+_ /)B+_XNC_A5'BK_ *!?_DQ%_P#%T>WQ_9_^ _\  #^T.(?Y9_\
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M_5GZT 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!<_>6GP?ZL4RY^\M/
M@_U8H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O<?ZP?2I8?]6M17'^
ML'TJ6'_5K0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *T_\ K#4\?^K7
MZ5!/_K#4\?\ JU^E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J2_P"L
M:MN+_5I]!6)+_K&K;B_U:?04 /HHHH **** "BBB@ JC<_ZYO\]JO51N?]<W
M^>U $5%%% 'S]^VEX!UWXA?#?2K'P[H3:WJ,>II(?+X>&/RY 6'S <G:#G/7
MIG!'F>D_$3]J33+&&V?PC'?&) GG7-G'O; QD[9%&?PKU+]LKXFZY\.?AK9)
MX?NFTZ_U:_6S-^IVF"/8S,5;^%C@#/8;L8.#7SG'X+\4>#6^+^C+XWDDU30]
M.T_4VU8W,B>=A5N-D;ELAB6"J<_,0.F>/(KOEJMQ;OUMZ,^,S"2AC).FYIV5
M^5I+9M+;71,^WOA?J7B+5_ >CWGBRR33O$4L3&\M8UVJC;V  &3CY0#U[UY]
M^TG^SW=_'F/PZ+378]#?27G?<]N92YD\O&,,,8\O]:Z;]GOQKJ'Q#^#/A?7]
M5;?J-U;LD\FT#S&CD>,O@<9;9NXXYKT2O0Y8UJ24M4TCZ14J6,PL83O*,DM]
MWL];=3XU_P"&%/%O_149O^_$W_QVNQ^"O[(NJ?"WXG6?B[4/%Z:XT$4L31-;
M.KOOC*#YRYZ9_2NCU[]M#X;>'-<U'2;RXU(7=A<R6LP2R++O1BK8.>1D&JL/
M[<OPKED56OM2A4]7>P<@?ED_I7'&&$C)-/5>9XD*.3T:BDIKFB_YGNOF?0%%
M9WAWQ%IOBS1;35]'O(M0TV[3S(+F$Y5USC\""""#R""#6C7I;ZH^I34E=;!1
M113&%%%% !1110 4444 <KXH^%OACQIXH\.^(M9TS[9K'AZ1IM,N?M$J?9V8
MJ6.U6"MG8OW@>E=5110!R_Q ^&?AKXI:79:=XHTW^T[.RO(]0@C\^6+9.@8*
M^8V4G =N"<<]*Z&_L+;5+&>SO;>*[M+A&BFMYT#QR(1@JRG@@CC!J>B@#PRT
M_8D^#%EX@35X_!L1F1_-6WDNYWMPV<Y\IG*D?[)&WVJ7]J>^\0Z7X.TO^S/
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M6B@#@/A;\!_ OP7CN?\ A$= ATR>Z 6>Z:1YIY0.<&21F;&>=H(&>U=_110
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M1^@4J-.A!4Z4;)=$%%%%4:A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $%S_#3K?\ U9^M-N?X:=;_ .K/UH EHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@""Y^\M/@_U8IES]Y:?!_JQ0!)1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% %>X_U@^E2P_ZM:BN/]8/I4L/^K6@!]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 5I_]8:GC_P!6OTJ"?_6&IX_]6OTH =1110 4444
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MH$CC4= %' %6J]FG#V<%#L?;86C]7H0HMWY4D%%%%:'4%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!#<?='UHMONM1<?='UHMONM0!-1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% $%S_#3K?_ %9^M-N?X:=;_P"K/UH
MEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@""Y^\M/@_P!6*9<_>6GP?ZL4
M 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!7N/]8/I4L/^K6HKC_6#Z5+
M#_JUH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:?_6&IX_]6OTJ"?\
MUAJ>/_5K]* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4A*,HN<VU='S6)H5:52E.M6<DYJRLEKT^X^GJ***]$^E"BBB@ HHHH ****
M"BBB@#RG]I+X%V7QZ^'<^DEEM==LR;K2-0Z&WN . 2.0C8VM^!ZJ*^3O#/CG
MQW^V!>>'_@[K9?1K7P_ND\9WR3+YM]Y$NQ4 '<D+GJ-YW8PH!]__ &L/CAJ?
MA.UTWX>>!@UW\1_%1^SVD<)^:RA8E6G)_A/#!2>F&;/R<^.^/OV9=4_9:\*^
M$_B9\/9Y;_Q'X7CSXCC+,4U*%B3*^WLHR5([)M;JF2 >[?M'_%A_V6?A/X=O
MO#.B64UC%J5MI*Z?(&5([?RI6PFTC# 1  G(Y.0:XGQ#^T%\:?AAI>F^-?'7
M@;0;?P'<31+>6NESROJ>FQR, K2[FV$\@8 ZX!*YKF/VP?BUHGQ%_9E\!>.-
M&/VK3I/$]E</;L1OC=(;@O"X[,""#^8X(-;W[4/[0_@;X@_ "\T+PGK=KXE\
M0>*A;VFGZ18.);H.TJ-^\B'S1D 'A@#NP!0!T/Q^_:;\2_#OQMX&T'P3X?LO
M%3>*[)Y;-96='>5L"$@[@ GS!FSC@'E>H/$'[1/C[X5_#/3YO'?A&P?XD:UJ
MK:7HN@:/<;H[OA-LK'>^!N;!4'/*CC)QQFO>&Y?"_P"TK^S'H5Z?-N=,\/S6
MDK,=Q,D5HRDY[_,N:?\ \% /#8DU/X6>*=2DU.#PKI.IRV^K7FDOLN+-)FA*
MRH0"5;$3\XZA1U(H W]8_: ^+OP9N-(U7XL>$O#J>#=0N4M9[_PY/*TNF,_W
M3,'9@P&#G;QQP<X!Z#XM?'KQA;_&#3/AC\-M*T6\\07&G?VG/?\ B"9UM4C)
M.%14(9FP,\9ZCC@D?._Q9\._!"QT/2K.Q^(/C?XGWNKW,4-OH.E^)([IV+'A
MG4QD*0< *PW9(XZD>A?M 6/PF\2?%/0/ _Q&M-2\':E9Z-$VF^-?MR0AU&,0
MLY4J<-YGS,,!@<8W4 >L_"/XQ>/+_P 2^)O#7Q+\&+H=_HUK]N76-(CFDTVZ
MCPI*H[9&_#9 W$G## *FO-/#?[1GQP^)WA'4?'O@GP=X5N/"-M+.L.FW5Q-)
MJDR1]<;'"[\#[N,G/ .03A_L_>-?$/A'X[>(O ^@^.+SXP>"++0Y+_SVE$Y@
MF4#9"DVY@220F VT[^@*FO/]+T3X,^*/#NK^./!GQ!U'X'^*H#.\^@G4U38Z
MEL*D65=@W'RHQ SMV\8H ^@OCI\;&'[*UKXYU'P'9SSW4UN)O#?BZR:2.%S*
M4.Z-PI.""5; R"#WK7^+?[0FOZ!XU\/?#KX=^'+7Q!XXU.S6^D%[(8[.PM\<
M-)@@GHW&X8 7J6 KP#XG>.O%'Q&_X)XVFM^+2TVJ2ZE#&EVZ!&N84G*I(0 .
M3@C/?;GO7<ZQXBL/@C^VE:^*?%<O]G>&_%?AB/3[75I_]1#.GDY5F_A'[D9[
M#S 3@9- ';>$_P!H+QWX0^*NB> OB]X=TG3+CQ "ND:WH$LC6D\H_P"63*Y+
M DE1U&"R\8;(Q[S]I'XG^)/C)XW^'7@?PAHNHWVBSIY6I:A-)';P0;?F:?#9
M9BS(%"8X#<'&1A?'#QMH_P =OV@/@YX:\!W\'B270=776M4U#2Y!-!:P))$Q
M_>KE<D(W?J4'4XKHOV<5'_#57[0K8&X75@ ?8K+_ ("@#I_V?_CWXG\;>//%
M?P^\?Z!9:'XS\/QQW#G3)&:VGA;;\RABQ'WXR/F.0_0$&O>698U+,0JJ,EB<
M "OF#P%_RD"^)?\ V+%K_*UKKOVSOB:WPS^ NN/:R%=7UK&CV*I]\O,"'(QS
MD1B0@COMH ^5_$7@N_\ VD=%^-7QELFE%QI-_"/#$L>0P@LOFD9?K%M88_CS
M7V+X%^*&L_%;]G_3/%WA"'3KGQ)>V*E;;4'9+9;I6"3(Y7Y@ ROC_@/K7C_P
M_P#V(=6T'P+I>F_\+9\:Z#YEJKW>E:7?>5:QS.H,JJ@XQN+#W[U1_8]EN/@K
M\7/B%\#M3NGGAMIO[6T::; ,T3*N[VR4:)L#@%9* .#_ &7[CQ8W[''Q,AN+
M72U\&#0M::VN4D?[:UUY!W*R_=V;=W(YSBO5?AO\6KGX/?L8_#_5=.T&Y\2Z
MO=Q+8V.G6P;#S/))AG8 [4&.3W) XSFO-OV9?&&BR?L4_$SPH-1@'B2STC7+
MF?3"V)TB^SD>9MZ[<L!GU.*-:^*?B3X;_L<_!FVT#5&\-P:Y.+&_\0)%YC6,
M.]R2OH2-QR.<(<$'F@#T+QY\>OCM\$=.LO%/CSPEX1NO"3W$<-W#H=Q-]KM=
M_ RSN5)[< @G R,YKM/C5\?_ !)X?^(GA'X??#[2M+U#Q/XAM&OTNM=E>.TA
M@&_'"D,S'RWX!R,#@YX^1OVIM$^'>@_#V'^S?BOKWQ1\774T;@W.MB_M[:(<
MO(RID)G*J S$_-QTKW/]H:^^%?BSQ%\/?"WQ(TV]T>&]T=+K3?&]K=+!'!\N
M3$6(((RJGY@0I=3QN)H ]2^$OQ6^)EW\1KWP3\2?!=OI]REG]LMM?T%)GTZ8
M9QL+/G:Q^8C+ _*1CD9]QKXE^!?B+5O O[3FE_#_ ,)_$NY^*7@2ZTV6YO'F
MG%TFFE5D*!9067.Y8Q\I _>X*Y -?;5 !1110 4444 %%%% !1110 4444 0
MW'W1]:X#7?&E_;ZC/;V;K!'$Q0G8&+$<'J#WKO[C[H^M<QJG@6#6+I[F.X:V
M=SEQLW GUZBN;$1J2C^[/)S*GB:E)+"NSOKK9_><M_PF^M_\_O\ Y"3_ .)H
M_P"$WUO_ )_?_(2?_$UN_P#"L?\ J)?^0/\ [*C_ (5C_P!1+_R!_P#95Y_L
M\3Y_?_P3YGZKF_>7_@7_  3"_P"$WUO_ )_?_(2?_$T?\)MK1X-[D?\ 7)/_
M (FMW_A6/_42_P#('_V55K_P%;:7;F:ZUA8HQW,')/H!NY-)T\2E=M_?_P $
MF6&S6*<I2DE_C7^9R4TS7$K2/MW,<G:H4?D!BHZDF6-96$3M)'GAF7:3^&3_
M #IBJ68 #)/  KB/GW>^NYI:/XBOM$;_ $:7]WG)B?E#^';\*](\/^)K;Q!&
M?+5HIT&7C;G'T/<5R.A^ +B]59;YFM8CSY8'[P_X?YXKOK&PM]-MUAMHEAC7
MLO\ ,GN:];"QJQ^+8^UR>CC*:O4=H=G^G;^M"Q1117HGU(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07/\
M#3K?_5GZTVY_AIUO_JS]: ):*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @
MN?O+3X/]6*9<_>6GP?ZL4 24444 %%%% !1110 4444 %%%% !1110 4444
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MCCP=ID=['<-=6-AJ%O'=2V*Y_=DE@0LVT*6V]#QVKLYH([A0LL:RJK*X#J"
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M110 4444 %%%% !1110!!<_PTZW_ -6?K3;G^&G6_P#JS]: ):*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH @N?O+3X/]6*9<_>6GP?ZL4 24444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!7N/]8/I4L/^K6HKC_6#Z5+#_JUH ?1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% %:?_6&IX_\ 5K]*@G_UAJ>/_5K]* '4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!4E_UC5MQ?ZM/H*Q)?]8U;<7^K
M3Z"@!]%%% !1110 4444 %4;G_7-_GM5ZJ-S_KF_SVH BHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** (;C[H^M%M]UJ+C[H^M%M]UJ )J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH @N?X:=;_ .K/UIMS_#3K?_5GZT 2T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!!<_>6GP?ZL4RY^\M/@_U8H DHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"O<?ZP?2I8?\ 5K45Q_K!]*EA_P!6M #Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH K3_ZPU/'_ *M?I4$_^L-3Q_ZM?I0 ZBBB@ HHHH ****
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M_:1_=H^TC^[6%_:TO]U/R/\ C1_:TO\ =3\C_C0!N_:1_=H^TC^[6%_:TO\
M=3\C_C1_:TO]U/R/^- &[]I']VC[2/[M87]K2_W4_(_XT?VM+_=3\C_C0!N_
M:1_=H^TC^[6%_:TO]U/R/^-']K2_W4_(_P"- &[]I']VC[2/[M87]K2_W4_(
M_P"-']K2_P!U/R/^- &[]I']VC[2/[M87]K2_P!U/R/^-']K2_W4_(_XT ;O
MVD?W:/M(_NUA?VM+_=3\C_C1_:TO]U/R/^- &[]I']VC[2/[M87]K2_W4_(_
MXT?VM+_=3\C_ (T ;OVD?W:/M(_NUA?VM+_=3\C_ (T?VM+_ '4_(_XT ;OV
MD?W:/M(_NUA?VM+_ '4_(_XT?VM+_=3\C_C0!N_:1_=H^TC^[6%_:TO]U/R/
M^-']K2_W4_(_XT ;OVD?W:/M(_NUA?VM+_=3\C_C1_:TO]U/R/\ C0!N_:1_
M=H^TC^[6%_:TO]U/R/\ C1_:TO\ =3\C_C0!N_:1_=H^TC^[6%_:TO\ =3\C
M_C1_:TO]U/R/^- &[]I']VC[2/[M87]K2_W4_(_XT?VM+_=3\C_C0!M22^8
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MW:/M(_NUA?VM+_=3\C_C1_:TO]U/R/\ C0!N_:1_=H^TC^[6%_:TO]U/R/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:.=[*;[\+,H)0_0FO*OB5^T)=_"'XJV.D^)?#:+X%U-(H[77[5G,D,Q \PR
MG:=K'E1@[>1FM?QQ\%;'XK>-_#/CK1_&=YI%]HNVW6;2V$\%Q&LA;:'#84DL
MRGJ"#TJ/XL:C_P +6\"^)1I,VN^'M6\)ZF+J2*XT<W,5YC/ B/%Q$02>.1@'
M&>MT84N=-ZI[K5<O;4\?%2Q,82BO=E%Z/1\UEK=:6ZZ:>3/4=R-S&XDC/*L.
MA'8T5@ZYXD;P[X)EUJ2*.]GBMED2U1Q;&ZE*;A%$'Y#M@[4QGC&*R/A+\6M$
M^,?A./6M&,D+*WDW=C/CS;:8 $JV.HYR&[CT.0./V4^1U+:+0]'V]/VBI-^\
MU>QVM%%%9&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!=
MTG_CX;_<_J*?J_\ K(_H:9I/_'PW^Y_44_5_]9']#0!GT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!H:1_K)/H*9JW_'PO^Y_4T_2/]9)]!3-6_P"/A?\
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MZE_Q]M]!_*@"K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &KI/^H?_ 'OZ
M"J6H?\?DGX?RJ[I/^H?_ 'OZ"J6H?\?DGX?RH KT444 %%%% !1110 4444
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MBB@ HHHH **** "BBB@"[I/_ !\-_N?U%/U?_61_0TS2?^/AO]S^HK@?BO\
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MM+X-?]#C_P"4N]_^,T?\-I?!K_H<?_*7>_\ QFCZO6_D?W,/['S+_H&G_P"
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M!K_H<?\ REWO_P 9H_X;2^#7_0X_^4N]_P#C-'U>M_(_N8?V/F7_ $#3_P#
M)?Y'MM%>)?\ #:7P:_Z''_REWO\ \9H_X;2^#7_0X_\ E+O?_C-'U>M_(_N8
M?V/F7_0-/_P"7^1[;17B7_#:7P:_Z''_ ,I=[_\ &:/^&TO@U_T./_E+O?\
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MN8?V/F7_ $#3_P# )?Y'MM%>)?\ #:7P:_Z''_REWO\ \9H_X;2^#7_0X_\
ME+O?_C-'U>M_(_N8?V/F7_0-/_P"7^1[;17B7_#:7P:_Z''_ ,I=[_\ &:/^
M&TO@U_T./_E+O?\ XS1]7K?R/[F']CYE_P! T_\ P"7^1[;17B7_  VE\&O^
MAQ_\I=[_ /&:/^&TO@U_T./_ )2[W_XS1]7K?R/[F']CYE_T#3_\ E_D>VT5
MXE_PVE\&O^AQ_P#*7>__ !FC_AM+X-?]#C_Y2[W_ .,T?5ZW\C^YA_8^9?\
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M!K_H<?\ REWO_P 9H_X;2^#7_0X_^4N]_P#C-'U>M_(_N8?V/F7_ $#3_P#
M)?Y'MM%>)?\ #:7P:_Z''_REWO\ \9H_X;2^#7_0X_\ E+O?_C-'U>M_(_N8
M?V/F7_0-/_P"7^1[;17B7_#:7P:_Z''_ ,I=[_\ &:/^&TO@U_T./_E+O?\
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MN8?V/F7_ $#3_P# )?Y'MM%>)?\ #:7P:_Z''_REWO\ \9H_X;2^#7_0X_\
ME+O?_C-'U>M_(_N8?V/F7_0-/_P"7^1[;17B7_#:7P:_Z''_ ,I=[_\ &:/^
M&TO@U_T./_E+O?\ XS1]7K?R/[F']CYE_P! T_\ P"7^1[;17B7_  VE\&O^
MAQ_\I=[_ /&:/^&TO@U_T./_ )2[W_XS1]7K?R/[F']CYE_T#3_\ E_D>VT5
MXE_PVE\&O^AQ_P#*7>__ !FC_AM+X-?]#C_Y2[W_ .,T?5ZW\C^YA_8^9?\
M0-/_ , E_D>VT5XE_P -I?!K_H<?_*7>_P#QFC_AM+X-?]#C_P"4N]_^,T?5
MZW\C^YA_8^9?] T__ )?Y'MM%>)?\-I?!K_H<?\ REWO_P 9H_X;2^#7_0X_
M^4N]_P#C-'U>M_(_N8?V/F7_ $#3_P# )?Y'MM%>)?\ #:7P:_Z''_REWO\
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M?!K_ *''_P I=[_\9H_X;2^#7_0X_P#E+O?_ (S1]7K?R/[F']CYE_T#3_\
M )?Y'MM%>)?\-I?!K_H<?_*7>_\ QFC_ (;2^#7_ $./_E+O?_C-'U>M_(_N
M8?V/F7_0-/\ \ E_D>VT5XE_PVE\&O\ H<?_ "EWO_QFC_AM+X-?]#C_ .4N
M]_\ C-'U>M_(_N8?V/F7_0-/_P  E_D>VT5XE_PVE\&O^AQ_\I=[_P#&:/\
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M%']J_P!S\?\ @!_K]_U"_P#D_P#]J?B517[:T4?VK_<_'_@!_K]_U"_^3_\
MVI^)5%?MK11_:O\ <_'_ ( ?Z_?]0O\ Y/\ _:GXE45^VM%']J_W/Q_X ?Z_
M?]0O_D__ -J?B517[:T4?VK_ '/Q_P" '^OW_4+_ .3_ /VI^)5%?MK11_:O
M]S\?^ '^OW_4+_Y/_P#:GXE45^VM%']J_P!S\?\ @!_K]_U"_P#D_P#]J?B5
M17[:T4?VK_<_'_@!_K]_U"_^3_\ VI^)5%?MK11_:O\ <_'_ ( ?Z_?]0O\
MY/\ _:GXE45^VM%']J_W/Q_X ?Z_?]0O_D__ -J?B517[:T4?VK_ '/Q_P"
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MT4?VK_<_'_@!_K]_U"_^3_\ VI^)5%?MK11_:O\ <_'_ ( ?Z_?]0O\ Y/\
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MUHH_M7^Y^/\ P _U^_ZA?_)__M3\2J*_;6BC^U?[GX_\ /\ 7[_J%_\ )_\
M[4_$JBOVUHH_M7^Y^/\ P _U^_ZA?_)__M3\2J*_;6BC^U?[GX_\ /\ 7[_J
M%_\ )_\ [4_$JBOVUHH_M7^Y^/\ P _U^_ZA?_)__M3\2J*_;6BC^U?[GX_\
M /\ 7[_J%_\ )_\ [4_$JBOVUHH_M7^Y^/\ P _U^_ZA?_)__M3\2J*_;6BC
M^U?[GX_\ /\ 7[_J%_\ )_\ [4_$JBOVUHH_M7^Y^/\ P _U^_ZA?_)__M3\
M2J*_;6BC^U?[GX_\ /\ 7[_J%_\ )_\ [4_$JBOVUHH_M7^Y^/\ P _U^_ZA
M?_)__M3\2J*_;6BC^U?[GX_\ /\ 7[_J%_\ )_\ [4_$JBOVUHH_M7^Y^/\
MP _U^_ZA?_)__M3\2J*_;6BC^U?[GX_\ /\ 7[_J%_\ )_\ [4_$JBOVUHH_
MM7^Y^/\ P _U^_ZA?_)__M3\2J*_<S2_^/7_ ($:S;K_ (^9?]XT?VK_ '/Q
M_P" '^OW_4+_ .3_ /VI^(M%?MK11_:O]S\?^ '^OW_4+_Y/_P#:GXE45^VM
M%']J_P!S\?\ @!_K]_U"_P#D_P#]J?B517[:T4?VK_<_'_@!_K]_U"_^3_\
MVI^)5%?MK11_:O\ <_'_ ( ?Z_?]0O\ Y/\ _:GXE45^VM%']J_W/Q_X ?Z_
M?]0O_D__ -J?B517[:T4?VK_ '/Q_P" '^OW_4+_ .3_ /VI^)5%?MK11_:O
M]S\?^ '^OW_4+_Y/_P#:GXE45^VM%']J_P!S\?\ @!_K]_U"_P#D_P#]J?B5
M17[:T4?VK_<_'_@!_K]_U"_^3_\ VI^)5%?MK11_:O\ <_'_ ( ?Z_?]0O\
MY/\ _:GXE45^VM%']J_W/Q_X ?Z_?]0O_D__ -J?B517[:T4?VK_ '/Q_P"
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MZE_Q]M]!_*K&C_=E_#^M5]2_X^V^@_E0!5HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"[I/_ !\-_N?U%/U?_61_0TS2?^/AO]S^HI^K_P"LC^AH SZ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH T-(_UDGT%,U;_CX7_<_J:?I'^LD^@IFK?\
M?"_[G]30!2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#2T?[LOX?UJOJ7_
M !]M]!_*K&C_ '9?P_K5?4O^/MOH/Y4 5:*** "BBB@ HHHH **** "BBB@
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M^>8H^PP?\\Q6Y10!A_88/^>8H^PP?\\Q6Y10!A_88/\ GF*/L,'_ #S%;E%
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M$H R/L,'_/,4?88/^>8K<HH P_L,'_/,4?88/^>8K<HH P_L,'_/,4?88/\
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M^>8H^PP?\\Q6Y10!A_88/^>8H^PP?\\Q6Y10!A_88/\ GF*/L,'_ #S%;E%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *M]]U/K3K'_5'_ 'J;??=3ZTZQ_P!4?]Z@"Q1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %2^^\E2V?\ J1]:BOOO)4MG_J1]: )J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_9]MIK6.2#QQ"8W 8&& %3GT/F\U^5YM1J8K-ZL%0E648QT]I[/EO?;75/\
M!GV^!J0HX"$G45-MR^QSWVW[6/:O!VCW?A_PU8Z??7AO[N!2KW#$DOEB1R>>
MA _"MFL3P7H/_",^%[#3/MG]H?9U*_:=NW?EB<XR?7'7M6W7Z5A(N&'IQ<>6
MT5I>]M-K];=^I\?7ES59N]]7K:U]=[=/0****ZC **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *]]_JA_O4VQ^Z_UIU]_JA_O
M4VQ^Z_UH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5OONI]:=8_ZH_[
MU-OONI]:=8_ZH_[U %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *E]]Y*
MEL_]2/K45]]Y*EL_]2/K0!-1110 4444 %%%% !1110 4444 %%%% !1110
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M'^]3;'[K_6@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6^^ZGUIUC_J
MC_O4V^^ZGUIUC_JC_O4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J7W
MWDJ6S_U(^M17WWDJ6S_U(^M $U%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 4K[_6+]*L6W^H2J]]_K%^E6+;_4)0!+1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %&\_UWX5;A_U*?2JEY_KOPJW#_J4^E #Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH S[K_CX;\/Y5L1?ZM/H*Q[K_CX;\/Y5L1?ZM/H* 'T444
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MW_Y*3_\ Q%']M99_T%4__ X_YA_9^-_Y\R_\!?\ D=[17!?\+T\#_P#0;_\
M)2?_ .(H_P"%Z>!_^@W_ .2D_P#\11_;66?]!5/_ ,#C_F']GXW_ )\R_P#
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M8?V?C?\ GS+_ ,!?^1WM%<%_PO3P/_T&_P#R4G_^(H_X7IX'_P"@W_Y*3_\
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M10!GW7_'PWX?RK8B_P!6GT%8]U_Q\-^'\JV(O]6GT% #Z*** "BBB@ HHHH
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M/W7I?K;]3:&&KX;*L0JVE^6RZ[[V\_T*?@W3X;_]H36&F02?9Y[F9 PR-P;
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M !#S_J*_\D_^W#_6S_IQ_P"3?_:GP917WG11_P 0\_ZBO_)/_MP_UL_Z<?\
MDW_VI\&45]YT4?\ $//^HK_R3_[</];/^G'_ )-_]J?!E%?>=%'_ !#S_J*_
M\D_^W#_6S_IQ_P"3?_:GP917WG11_P 0\_ZBO_)/_MP_UL_Z<?\ DW_VI\&4
M5]YT4?\ $//^HK_R3_[</];/^G'_ )-_]J?!E%?>=%'_ !#S_J*_\D_^W#_6
MS_IQ_P"3?_:GP917WG11_P 0\_ZBO_)/_MP_UL_Z<?\ DW_VI\&45]YT4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW-;4?,[<M]"K?Z59:JB)>V=O>(ARJW$2N ?49%<1\<HUB^%VI(BA$5H JJ,
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M]U_K0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'UJ*^^\E2V?^I'UH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!7OO]4/]ZFV/W7^M.OO]4/]ZFV/W7^M %JBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** *M]]U/K3K'_5'_ 'J;??=3ZTZQ_P!4?]Z@"Q1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %2^^\E2V?\ J1]:BOOO)4MG_J1]: )J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH I7W^L7Z58MO\ 4)5>^_UB_2K%M_J$
MH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C>?Z[\*MP_P"I3Z54O/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"K??=3ZTZQ_U1_P!ZFWWW4^M.L?\
M5'_>H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4OOO)4MG_ *D?6HK[
M[R5+9_ZD?6@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3^ZU %BBJ_VY/[K4?;D_NM0!8HJO]N3^ZU'VY/[K4 6**K_;D_NM1]N3^ZU
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M5_MR?W6H^W)_=:@"O=?\?#?A_*MB+_5I]!6+-())"PZ&MJ'F%#_LB@!]%%%
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M% %'^RT_OM1_9:?WVJ]10!1_LM/[[4?V6G]]JO44 4?[+3^^U']EI_?:KU%
M% Z4O:0_E2C2E[R-^57J* */]EI_?:C^RT_OM5ZB@"C_ &6G]]J/[+3^^U7J
M* */]EI_?:C^RT_OM5ZB@"C_ &6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB
M@"C_ &6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_ &6G]]J/[+3^^U7J
M* */]EI_?:C^RT_OM5ZB@"C_ &6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB
M@"C_ &6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_ &6G]]J/[+3^^U7J
M* */]EI_?:C^RT_OM5ZB@"C_ &6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB
M@"C_ &6G]]J/[+3^^U7J* *!TI>TA_*E_LI>\C?E5ZB@"C_9:?WVH_LM/[[5
M>HH H_V6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>H
MH H_V6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH
MH_V6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_
MV6G]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_V6
MG]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_V6G]
M]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"@=*7M(?RI?[*3O(WY5>HH H_P!E
MI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_P!EI_?:C^RT_OM5ZB@"C_9:
M?WVH_LM/[[5>HH H_P!EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_P!E
MI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_P!EI_?:C^RT_OM5ZB@"C_9:
M?WVH_LM/[[5>HH H_P!EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_P!E
MI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_P!EI_?:C^RT_OM5ZB@"C_9:
M?WVH_LM/[[5>HH H_P!EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H'2E[
M2'\J7^RD_OM^57J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_V6
MG]]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_V6G]
M]J/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_V6G]]J
M/[+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_V6G]]J/[
M+3^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_V6G]]J/[+3
M^^U7J* */]EI_?:C^RT_OM5ZB@"C_9:?WVH_LM/[[5>HH H_V6G]]J/[+3^^
MU7J* *']E+VD/Y5=1=B*O7 Q3J* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>chart-86950a12b9c0e735da0.jpg
<DESCRIPTION>VCYT CHART A
<TEXT>
begin 644 chart-86950a12b9c0e735da0.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &% JP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]H?\ @DE_
MP24_X)F?%[_@F5^PE\3?B=^PI^R]X[^(7CG]E[X2>)_&7C/Q1\(?"NK>(_$_
MB+5_#5O>:IK>MZK<69NM1U._N96FNKRY>2>9SEGP%5?T1_X<F?\ !)'_ *1T
M?L@_^&1\'_\ R%2?\$2_^42'_!.C_LT+X)_^HC9U^H] 'Y<_\.3/^"2/_2.C
M]D'_ ,,CX/\ _D*C_AR9_P $D?\ I'1^R#_X9'P?_P#(5?J-10!^7/\ PY,_
MX)(_](Z/V0?_  R/@_\ ^0J/^')G_!)'_I'1^R#_ .&1\'__ "%7ZC44 ?ES
M_P .3/\ @DC_ -(Z/V0?_#(^#_\ Y"H_X<F?\$D?^D='[(/_ (9'P?\ _(5?
MJ-10!^7/_#DS_@DC_P!(Z/V0?_#(^#__ )"H_P"')G_!)'_I'1^R#_X9'P?_
M /(5?J-10!^7/_#DS_@DC_TCH_9!_P##(^#_ /Y"H_X<F?\ !)'_ *1T?L@_
M^&1\'_\ R%7ZC44 ?ES_ ,.3/^"2/_2.C]D'_P ,CX/_ /D*C_AR9_P21_Z1
MT?L@_P#AD?!__P A5^HU% 'Y<_\ #DS_ ()(_P#2.C]D'_PR/@__ .0J/^')
MG_!)'_I'1^R#_P"&1\'_ /R%7ZC44 ?ES_PY,_X)(_\ 2.C]D'_PR/@__P"0
MJ/\ AR9_P21_Z1T?L@_^&1\'_P#R%7ZC44 ?ES_PY,_X)(_](Z/V0?\ PR/@
M_P#^0J/^')G_  21_P"D='[(/_AD?!__ ,A5^HU% 'Y<_P##DS_@DC_TCH_9
M!_\ #(^#_P#Y"H_X<F?\$D?^D='[(/\ X9'P?_\ (5?J-10!^7/_  Y,_P""
M2/\ TCH_9!_\,CX/_P#D*C_AR9_P21_Z1T?L@_\ AD?!_P#\A5^HU% 'Y<_\
M.3/^"2/_ $CH_9!_\,CX/_\ D*C_ (<F?\$D?^D='[(/_AD?!_\ \A5^HU%
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M'_PR/@__ .0J/^')G_!)'_I'1^R#_P"&1\'_ /R%7ZC44 ?ES_PY,_X)(_\
M2.C]D'_PR/@__P"0J/\ AR9_P21_Z1T?L@_^&1\'_P#R%7ZC44 ?ES_PY,_X
M)(_](Z/V0?\ PR/@_P#^0J/^')G_  21_P"D='[(/_AD?!__ ,A5^HU% 'Y<
M_P##DS_@DC_TCH_9!_\ #(^#_P#Y"H_X<F?\$D?^D='[(/\ X9'P?_\ (5?J
M-10!^7/_  Y,_P""2/\ TCH_9!_\,CX/_P#D*C_AR9_P21_Z1T?L@_\ AD?!
M_P#\A5^HU% 'Y<_\.3/^"2/_ $CH_9!_\,CX/_\ D*C_ (<F?\$D?^D='[(/
M_AD?!_\ \A5^HU% 'Y<_\.3/^"2/_2.C]D'_ ,,CX/\ _D*C_AR9_P $D?\
MI'1^R#_X9'P?_P#(5?J-10!^7/\ PY,_X)(_](Z/V0?_  R/@_\ ^0J/^')G
M_!)'_I'1^R#_ .&1\'__ "%7ZC44 ?ES_P .3/\ @DC_ -(Z/V0?_#(^#_\
MY"H_X<F?\$D?^D='[(/_ (9'P?\ _(5?J-10!^7/_#DS_@DC_P!(Z/V0?_#(
M^#__ )"H_P"')G_!)'_I'1^R#_X9'P?_ /(5?J-10!^7/_#DS_@DC_TCH_9!
M_P##(^#_ /Y"H_X<F?\ !)'_ *1T?L@_^&1\'_\ R%7ZC44 ?ES_ ,.3/^"2
M/_2.C]D'_P ,CX/_ /D*C_AR9_P21_Z1T?L@_P#AD?!__P A5^HU% 'Y<_\
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M (<F?\$D?^D='[(/_AD?!_\ \A5^HU% 'Y<_\.3/^"2/_2.C]D'_ ,,CX/\
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MO[JRNM T;PN :WQM_P""HO[-'P$_:M\'?L3>,M.^-FJ_M*_$CP?/X_\ AO\
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MNO\ B6T\4:A<W4LVJR3^-8&O+&VT^&S\<2^(;2TT!7T.V@CTZ1X6_+S]EO\
MX)C>*_B_^V3_ ,%O[/\ :W^$OQZ^'G[.?[:_QJ^&^K^ M8T#XC3> ]"^/GP?
M\,6?C;0_'/A'Q&? 'C"\\1Z7H7B"XO=&E%GK.G>$?%6H^&-2O;;2]6T^VO\
MQ!IK_P!1M(%4$D*H)ZD  GZD=: /@#QS_P $Q?V.O'?Q2_9:^+]Q\.=7\*>+
M/V.O &L?"?X&P_#CQ_XZ^''A[0_A7K>A1>'+OX;:UX>\&Z]I&G>)_!#:-&^F
MR^'=82:QU#3KJ^TO6$U/2KZZL9?"H/\ @B#^P%;?LAQ_L+0>"?B;%^S+!\:K
MCX]V7P[C^.?Q21=)\>->W6I:>NAZXOB$:YH7AG1M2NY-5T_PIH]]8Z+-K0&N
MZQ;ZKK;SZC-^NM% 'QK^V'^PC^S_ /MX?!#1_P!GK]IC3?&'C;X9:3XC\+^+
MI=-TSQ[XD\&:MK/B3P=;W,7A[5=;\1^$;K1];OI;&YNIM4-NEY;V5UJOE7UU
M:S26]N(N3^*'_!.+]G+XSZWK&H?$]OBGXS\.^,/&7P@^(/Q)^&FN?%KQI>?"
MGXG^,?@-8>#K3X6:WXT^'LE^?#TTN@7?@'PEK&K6N@6_A[3_ !WJFBV+_$.T
M\5V5K;6$/WM10!^<_P ;_P#@E?\ L>?'[Q]\7_'WC;P;XKT^;]I'2_AWHG[4
M/A?P1\1?%_@;P1^TMI'PEN_MGPYLOC-X9\-ZC96WB&3PWDZ:^J:3/X>UKQ'X
M;QX0\7:GX@\**NBCO_B%_P $_/V;/B3^TE^SA^U=K?AWQ'IOQ?\ V2_#.K^#
M_@#>>%/&6N^%/"/@#PUXATN^T+Q!H]I\/M%FMO!FI6.LZ%?'1;RWUC1[^)-+
ML]-LK-+2'3K41_;-% 'QY^QI^PO^S_\ L&>#?'W@']G72?%N@^%OB7\3M?\
MC'XMT_Q3X^\5>/GO?B1XKM-.L_%/B6VO?%M_J5[ITWB!-)TV74K&RGATQ[JU
M6YM[*WFEN&FX+]H?_@F?^RM^TOX\\??$?QWX>\::#XH^,OPF@^ ?QZN_AE\1
M_%_PVA^/7P2MKR2\M_AK\5[;PMJ%FFOZ5;^?<Z=;>(-.;1/'EMX=O+[PG!XN
MC\+7ESHTGZ 44 ?!WQ1_X)O?LK_%;QC^R-XUU?PCK_AN]_84EM9_V5]$^'OC
M+7O 7@[X42VEIH>EQC3?!WAV>U\/ZQ:_V%X;T7P]_9OB.QU?2TT*R.FPV4<-
MU?&Y^Y[RQLM1LKK3K^TMKW3[VVFLKRQNX(KFSN[.YB>"XM;JVG22"XMKB!WA
MG@FC>*:%WBD1D9E-JB@#\\_A5_P3-_9T_9^EU_2_V<]5^-?[/GPS\5>(M6\6
M:]\$/@_\;?'GA+X-+XBU]Q)KFH^$/!8U"^/PH759!YUYIOP>U3X?:0UUB]BL
M(;U8[A-_]HW_ ()P?LI_M.>!O@/X#\=>#/$/ABS_ &8OB!H7Q.^ ?B#X1^/_
M !E\(_&WPM\9:"K1QZMX5\9^!M7TO7[2748G<ZP\]Y<7&HWQCUN6X7Q#;6NK
MP?=M% 'YA^&_^"0?[$?@WX=_MB_"?PGX*\=:#\/OV\=2EU?]I?P[:_%[XC72
M^-M1O9;XZU=V.K:MKNI:]X7N?$EIJ=_IWB6Z\/ZK97>NV-U(FHW$]P$N5U-!
M_P""47[(?AOQQ^QA\1-+T3XD1^*O^"?W@6Z^&O[*]]/\7/'-W!\//!=_I]QH
MFIZ)>6%QJ,EEXSBU/PY+!X9OKGQG#KEY-H.G:98B=/L4<I_2BB@#\R/!W_!(
M;]A[P;\ ?VK?V9+;X>^*M<^#?[:?C/7?B1^T)X8\5_$[QYXCF\7?$3Q)/97N
MM>-]/UN_UDZUX5\17FJ:5HNKBY\-WNG6UMJNB:5>VMI#):D26/@?_P $FOV0
M?V?/CI\._P!ICX?:9\69?CQ\-_@@O[/&E_$WQK\<OB?\0_$&M?"J&*:&Q\.>
M+$\;:_K>F>((](0Z?'H3SZ?#%H-OH6@V>CV]E9:5!;']+Z* /R!;_@AO_P $
M^V_9W\<?LO?\(-\2U^%'C[]HO2?VLM7M4^.'Q/C\3V'[0>F+'#+\2O#GC-->
M7Q)X>U?5;6-;;4K73;^+2B/]+L+'3]26.^3W'P1_P2W_ &-_ /Q._:P^*FB^
M O%-WK7[;GPZT_X8?M,:+XB^*?Q*\3>#_BCX<LO#=SX3N;S7O#6M^)KRTN/%
MFLZ%>7UKK'C.:6?Q1<3:GKE];:I97WB+Q!<:I^AM% 'Y)W__  12_89U?]E3
MX;_L7Z[HOQFU_P" 'PE^)&E_%/P!X6UO]H3XM:CJ7AOQ-X;76$\&VFE>)KCQ
M&VN:=X3\%#Q!K,OACP5IMW8^%;*^U&\U:YTF^UBYGU"3[V^*?[-OP?\ C9JG
MP+UWXJ>$K3QIKG[.7Q4TCXU?"?5]6;-_X=^)>B>%O$?A&P\3>;;);I=SIIOB
MG4[E[2:/^SWUB/2]8^RK?:/IDMM[M10!\%?MB_\ !-G]E;]N+Q+\'?B!\:/#
M7C/2_BO\ =7OM7^#WQF^#_Q1\?\ P3^,'@-M6:!M9L-#^(OPUUW0/$<6F:G]
MFC:2UENI&L)VGO=%GTN_NKJZF^P_A[X \*_"WP7X>\ >"M/FTSPQX8L%T_2[
M:[U35]=U!U,LMS=W^KZ_X@OM4\0>(M<U6_N+K5-=\1>(-4U/7M?UB\OM8UK4
M;[4[VZNI>RHH _/_ /:2_P"":7[,'[5W[07P(_:?^,>F?$#5?C%^S%JL6N_
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M$M]"_96U35?C/\1-7NO UO'!H]E=SZPVJZQ>IXYN-1TGP_HFA7,?C!-7L(-
MTRST32['3=,@2V'TS^TA^RM\%OVL/#/@CPE\;/#^LZ]I'PX^)WACXR>")/#O
MC;QK\/=;\-?$SP39:Y:>#O%^C^*?A]K_ (8\4:=JWAF77[W4=(EL=8ME@U..
MSNY4G%JL3?1-% 'RC\-/V._A9\/?BK'\=-3U7XB_%?XRZ=X0U3X>>%OB1\9/
M'>J>/M?\"> -;U:RUO7/"7@.WN8[#0/"=EXAU/2])N/%>KZ5HL/BOQDNC:';
M>+O$.N6FB:7!:^"_"G_@DI^PW\'OAS^TQ\%_#'PNUK4?@A^UAK/C#6_BK\$_
M%WQ)^(?BSX3V]SX^DM;KQ@OP_P#!&K^(YM(^&SZWJ%AIFI2:EX.CTS7K&]T7
MP\^EZQ8P^&O#\&F?I110!\+_  *_X)V?LS_ ;QWKWQ3TK0/%'Q%^*&O?!WPW
M^SHWQ!^-?C36_BQXGTG]GOP>UQ)X=^"FAW/BJ2>STSP%!-=37>N6T=B^M^.=
M0,6J?$'7/%>IV\%W'R?[*7_!+G]E3]BB?Q9;_LX6?Q<\!>#O$.K>)O$&@_"E
M_CQ\6O$7P=^&&O\ C""[@\1:]\*/A;XD\4ZIX,\$:WJ"WUSY>K6FE7=_IL<T
MMKI5Q964TUM)^BE% 'X^#_@A;_P3N'[-/A']DP?#?Q\OP=^'WQ[D_:9\ 6L?
MQH^)</C?P/\ &:>PGLKKQ=X3^*$.NQ_$30GNYKA]5N--L/$D6F2:R(]3%LMQ
M%&5][UW_ ()F?LR>)/V@?B!^U'K,/Q0O/CE\4/V;M0_9-\;>-V^+7C*.36/@
M=JFC6FDWWA@:+%>)H%AJ$T]FGB >*-.TRU\2P^*);G7H=4CO;B0G]"** /S5
M\-_\$F?V+_!_[-?P1_98\+>"?%NB?#G]F3XF#XQ_LW:S;?$GQE/\3/@9\2H_
M$6J^*K?Q/\/OB5?:E=>*;0QZUKVM2W&AZU=ZYX9U?3]3NM"UW1=5T$Q:9%!X
MJ_X)'_L3^-OV8_BY^R9XH\">*]6^%W[0WQ5F^-_[0U_)\2O&D'Q'^.GQ5NO$
MEAXOOO&/Q,^)MKJ</C#6;RZ\1Z1H]^FGV6H:5H>FVVCZ7H>BZ5IGAZSCTH_I
MC10!^?7C+_@F9^RWXT^)'[.?QEN=+^(OAWXO_LQ?#JW^#7P_^)_@7XK^.? O
MC76?@S%:QVEQ\*/B/K'A?5-,;XB>"KZ.(2SVGB.*?5(;R:_O].U>QO=4U.>[
MX'0/^"-G_!/+P[^QU\1/V#;7X%RZA^S)\4?%U]\0?%G@/Q!\1?B5XCN!X_OK
MVQU%O&?AGQ)K7BJ\U_P-K]O>Z9IT]I<>"[[0K:'[)Y36DL%U?PW?ZAT4 ?FS
M=?\ !*;]DW5_V1_&O[%7BN#XS^/?@S\2H/"FG?$2Z^(7[07Q>\<_$SQAH'@7
M4+'4O!WA&_\ BKXG\4ZGXVTOP3X7GTRRC\/^"O"^I^'_  MHUJEU:Z9I-K%J
MNLC4?NOX7_#O0/A)\.? WPM\*R:M)X7^'?A/0/!/AHZYJEQKFKQ>'O#&F6VC
M:);:AK-[F^U:YL]+L[2T?4=0>>_O! L]]<7-T\UQ)W=% 'P+\0_^";?[-/Q/
M_;.^&O[?GBRT^(UQ^T_\'?#S^#_ACXWL?BEXNTS1_!_@^YMO%-GJ/ABP\!V=
MW'X(N])U>W\;>*X]675M"U&\OSK4\DUX9;>P>TK1_P#!,;]D33_VT/$7[??A
MGP1XC\%?M*>.?#]OX5^)7B3P9\0O&7ASPG\5/#D6FVNDW.C_ !-^&=CJH\ >
M.+;4[+3='_M1]=\/W5S>WFAZ-JLDZZKI\5]7Z!T4 ?F[^R7_ ,$HOV-/V(O&
M_B'Q?^SGX1^(7@S2]8\1Z[XNT3X5WOQL^+7BCX&?#SQ3XIB>V\2>)/AI\%?$
M?B[4?ASX-\1:M922:4WB&QT&77=,T"6;PYH>I:5X?GFTR1OPE_X)-_L2_!;X
M<?M/_!CP7\._%'_"EOVN+SQ_=?%CX.Z[\5/B3K_PRME^*5LMOX_MOAYX/U'Q
M+)I?PU7Q,T5K/>WOA"/3M9B?3-#AL]4MK+P_H=II_P"DE% 'Y8?!?_@CG^Q5
M\!_B?^S3\:O ^B_%VZ^*W[)GP_U7X3?!CQQXS^/?Q7\=:IH7PMU6QU?2/^%<
M7MIXI\2:GHNI>!])T+7-2T/PWX8.E6VC^&].N"NB6EC=C[8?H?\ 9I_84^ 7
M[)WQ&_:+^*GP?T_QC8>,/VK?'\GQ4^.5UXD\>^(_%]CXN^(4MWJUR_B>VTK7
MKFZL/#-VR:U?V36?AF'2=*;3S:VCZ>T=A8FW^R** /RQ\3?\$<OV)/%^A?MG
M^&O$/ACXE:AHG_!0+Q=X7\<?M66!^,OQ"MX_B3XA\&^*+KQ9X?N+=[75H9O!
M=K9ZC=&U?3O!$GA^QNM&@M-&NH)=/MHH5_1/X7_#OP]\(OAOX"^%?A$ZG_PB
MGPW\'^&_ GA=-9U2ZUO58?#GA/2+30M"MM0UF^+W^K75KI5C:6LNI:A+/?WI
MA%Q>W%Q=22S2=W10 4444 %%%% !1110 4444 %%%% !1110 4444 %?Y7G_
M  >.?\I;_#__ &:%\%__ %+OBQ7^J'7^5Y_P>.?\I;_#_P#V:%\%_P#U+OBQ
M0!_?Y_P1+_Y1(?\ !.C_ +-"^"?_ *B-G7ZCU^7'_!$O_E$A_P $Z/\ LT+X
M)_\ J(V=?J/0 445\R?%S]J3P=\*_B#X?^%%OX;\8?$/XCZSX6O/B#=^#? E
MIH]SK6B_#NPU5O#\_B^XB\0:UX?MM3BF\0[-$TSP_H-UJ?B?5[\R)8Z4Z1!Y
M #Z;HKXY^(O[:WP\^%WQ ^&_A'Q7X ^-UOX0^)/B?X;> [;XWV_PSO7^#7A3
MXA?&&XL+#X7^"?&NOW&HVOB;1=3\9:QK/A_P_;ZS;>#M3\%Z!XE\1:%X<\8^
M*?#FMZI;V-=!HW[5OAGQ!\7O'GPVTGX?_$&[\$_#&U\1)X^_:/COOA0WP"\*
M>*?"&GV6I>*OA_KFL+\46^(NF^,O#MO?(-8M;SX9P:+8O;WXEUT+873Q@'U-
M17S3\%?VK/A=\<]7L-"\+_\ "0Z/JWB#X6>$OCIX+T_Q;I=MHMYXZ^"OCG4=
M1TKPM\3?#5I%J5_=#0M1OM.\F[TG7(=$\8^'1J?A^3Q1X8T6/Q)H;7_TM0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7^5Y_P>.?\I;_#_P#V:%\%_P#U+OBQ7^J'7^5Y
M_P 'CG_*6_P__P!FA?!?_P!2[XL4 ?W^?\$2_P#E$A_P3H_[-"^"?_J(V=?J
M/7Y<?\$2_P#E$A_P3H_[-"^"?_J(V=?J/0 5^8G_  4)^ ?B#XW7?PUU'P;\
M*_B3'\6_AA=W?B7X!?M,?!'Q?X#\*?$_X.?$'5=-\1V6HZ+?7WC#5+&$?"_Q
M3-8^"9?B%H'B#0_B!\-?'6@VM_HOC+P9=7VG^'&N?T[KDO%7CSP3X&&C-XS\
M6^&_"B^(=7@T'0G\1ZWIFB)K&MW,<LMMI.F/J=U:K>ZC/'#*\5G;F2=U1BJ'
MC(!\ >,_%'[0^N?$3X+?#;XE?L<?%KXNZ'X!U'X+>*?$7QG^'/C/]G'PY\"-
M<^-%K8:;-K/CN\\.>//CCX>^--O\.O@WXINKKQ=HVD6OPPU?7M3\1Z5IVIZ-
MI6JR^&-&CUGA?BC^Q58?M#_$SXH>+?#/P?U/]DO6_'GP;_:D_9X^,WQ)LA\-
M+/6?VC/"_P 7?#5[X-\$:UJEG\*/&6MS^+['PIK,H^+/A3Q7\4$T7X@^#[B6
MY\+Z186#>,/&\5M^GUWXV\&6'BO2? M]XK\,V?C;7M-O=9T3PA=:]I-OXIUC
M2-,8)J.JZ5X>FO$UG4=-T]B%O;^RLI[2T8XN)HC2:7XX\&:WXB\1>$=&\6>&
MM6\5>$18-XJ\-:9KVDW_ (@\-#583<:8?$&BVEY-J>BC4;=6FL#JEK:B\A4R
M6QE0;J /SC_93_9Q^,>A?&3X%_%+XG^'+;P+!^SY^P#X8_8].CKJ^BZZWC7X
M@WOC'P!XA^(?C'0+O0]1OMGP[TZV^#WA&'P3=Z[!H7B;67\5:X=6\+:$=(C6
M\_4-N%;']T_R-<'X8^*WPP\:^)?%W@SP=\1O GBOQ?X NX[#QUX6\-^,/#FO
M>)/!=]--<6\5GXLT+2M3N]5\-W<L]I=0QVVM6EC,\MM<1JA>&55[Q_N-_NM_
M(T ?C1_P2?\ B/\ $3XS>+O^"KL?Q4\?>-O'L7PJ_P""MW[37PC^&T/B;Q7K
MVIP>!?ACX7\"?!>_\/> O"L$NH"'1?"FC7NMZO=:=HMBD5E:SZC>2QQAYW-?
MKW_PC>E?W+S_ ,&VL?\ RPK\4?\ @BE_R./_  6<_P"TV7[7/_JN?@%7[F4
M8/\ PC>E?W+S_P &VL?_ "PH_P"$;TK^Y>?^#;6/_EA6]10!@_\ "-Z5_<O/
M_!MK'_RPH_X1O2O[EY_X-M8_^6%;U% &#_PC>E?W+S_P;:Q_\L*/^$;TK^Y>
M?^#;6/\ Y85O44 8/_"-Z5_<O/\ P;:Q_P#+"C_A&]*_N7G_ (-M8_\ EA6]
M10!@_P#"-Z5_<O/_  ;:Q_\ +"C_ (1O2O[EY_X-M8_^6%;U% &#_P (WI7]
MR\_\&VL?_+"C_A&]*_N7G_@VUC_Y85O44 8/_"-Z5_<O/_!MK'_RPH_X1O2O
M[EY_X-M8_P#EA6]10!@_\(WI7]R\_P#!MK'_ ,L*/^$;TK^Y>?\ @VUC_P"6
M%;U% &#_ ,(WI7]R\_\ !MK'_P L*/\ A&]*_N7G_@VUC_Y85O44 8/_  C>
ME?W+S_P;:Q_\L*/^$;TK^Y>?^#;6/_EA6]10!@_\(WI7]R\_\&VL?_+"C_A&
M]*_N7G_@VUC_ .6%;U% &#_PC>E?W+S_ ,&VL?\ RPH_X1O2O[EY_P"#;6/_
M )85O44 8/\ PC>E?W+S_P &VL?_ "PH_P"$;TK^Y>?^#;6/_EA6]10!@_\
M"-Z5_<O/_!MK'_RPH_X1O2O[EY_X-M8_^6%;U% &#_PC>E?W+S_P;:Q_\L*/
M^$;TK^Y>?^#;6/\ Y85O44 8/_"-Z5_<O/\ P;:Q_P#+"C_A&]*_N7G_ (-M
M8_\ EA6]10!@_P#"-Z5_<O/_  ;:Q_\ +"C_ (1O2O[EY_X-M8_^6%;U% &#
M_P (WI7]R\_\&VL?_+"C_A&]*_N7G_@VUC_Y85O44 8/_"-Z5_<O/_!MK'_R
MPH_X1O2O[EY_X-M8_P#EA6]10!@_\(WI7]R\_P#!MK'_ ,L*/^$;TK^Y>?\
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M#@)^X/V;Q%_T%M(_\$-W_P#-!7XG?\$4O^1Q_P""SG_:;+]KG_U7/P"K]S*
M,3[-XB_Z"VD?^"&[_P#F@H^S>(O^@MI'_@AN_P#YH*VZ* ,3[-XB_P"@MI'_
M ((;O_YH*/LWB+_H+:1_X(;O_P":"MNB@#$^S>(O^@MI'_@AN_\ YH*/LWB+
M_H+:1_X(;O\ ^:"MNB@#$^S>(O\ H+:1_P""&[_^:"C[-XB_Z"VD?^"&[_\
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M"&[_ /F@K;HH Q/LWB+_ *"VD?\ @AN__F@H^S>(O^@MI'_@AN__ )H*VZ*
M,3[-XB_Z"VD?^"&[_P#F@H^S>(O^@MI'_@AN_P#YH*VZ* ,3[-XB_P"@MI'_
M ((;O_YH*/LWB+_H+:1_X(;O_P":"MNB@#$^S>(O^@MI'_@AN_\ YH*/LWB+
M_H+:1_X(;O\ ^:"MNB@#$^S>(O\ H+:1_P""&[_^:"C[-XB_Z"VD?^"&[_\
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M,[L0J*J@LS,0  23BDVDFVTDDVVW9)+5MMZ));L$FW9*[>B2W;[&/]F\1?\
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M_MR3_H"Z[_X 1?\ R76_10!@?VY)_P! 77?_   B_P#DNC^W)/\ H"Z[_P"
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MH_MR3_H"Z[_X 1?_ "76_10!@?VY)_T!==_\ (O_ )+H_MR3_H"Z[_X 1?\
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M "76_10!@?VY)_T!==_\ (O_ )+H_MR3_H"Z[_X 1?\ R76_10!@?VY)_P!
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M4 6_MUE_S^6O_@1%_P#%T?;K+_G\M?\ P(B_^+JI_86B_P#0)TS_ ,%]G_\
M&*/["T7_ *!.F?\ @OL__C% %O[=9?\ /Y:_^!$7_P 71]NLO^?RU_\  B+_
M .+JI_86B_\ 0)TS_P %]G_\8H_L+1?^@3IG_@OL_P#XQ0!;^W67_/Y:_P#@
M1%_\71]NLO\ G\M?_ B+_P"+JI_86B_] G3/_!?9_P#QBC^PM%_Z!.F?^"^S
M_P#C% %O[=9?\_EK_P"!$7_Q='VZR_Y_+7_P(B_^+JI_86B_] G3/_!?9_\
MQBC^PM%_Z!.F?^"^S_\ C% %O[=9?\_EK_X$1?\ Q='VZR_Y_+7_ ,"(O_BZ
MJ?V%HO\ T"=,_P#!?9__ !BC^PM%_P"@3IG_ (+[/_XQ0!;^W67_ #^6O_@1
M%_\ %T?;K+_G\M?_  (B_P#BZJ?V%HO_ $"=,_\ !?9__&*/["T7_H$Z9_X+
M[/\ ^,4 6_MUE_S^6O\ X$1?_%T?;K+_ )_+7_P(B_\ BZJ?V%HO_0)TS_P7
MV?\ \8H_L+1?^@3IG_@OL_\ XQ0!;^W67_/Y:_\ @1%_\71]NLO^?RU_\"(O
M_BZJ?V%HO_0)TS_P7V?_ ,8H_L+1?^@3IG_@OL__ (Q0!;^W67_/Y:_^!$7_
M ,71]NLO^?RU_P# B+_XNJG]A:+_ - G3/\ P7V?_P 8H_L+1?\ H$Z9_P""
M^S_^,4 6_MUE_P _EK_X$1?_ !='VZR_Y_+7_P "(O\ XNJ?]AZ+_P! G3/I
M_9]F3^0@S7-^(=6^''A*$7'BC4/!WAZ%@2CZU/HFF^;@9VPI=F*29ST"1([L
M>%4DBN3&X_ Y;AJN-S'&X3 8.A'FK8O&XBCA<-1CI[U6O7G3I4XZKWIS2\S;
M#X?$8NK##X6A6Q->H[4Z.'I3K59OM"G3C*<GY1BV=A]NLO\ G\M?_ B+_P"+
MH^W67_/Y:_\ @1%_\77B(^)G@S4]H\&?#_Q7X\$F1'=:!X$_L_17?.U0OB/Q
M;'X:T&6,Y#&:UO[E F7!/ *BT^*NN[?L?@7X8^ ;1F(>?Q)/+XVUM%/1CHOA
MRUT+1HY .@'BN[0,.=Z]?D?^(A\.8FRR)YIQ7*=E0J<+Y1C\XRVO-N*]FN(J
M-&/#&'FN=.7UW.\+&*4N:2::/;?#&:4=<Q6$R9+6I'.,;AL#BZ<?YGE=2H\W
MJ1[>PR^JW=-)K4]M^W61( O+4D\ ?:(LD^@&_FOG3]I#]H6V^!.@Z)-9Z/'X
MB\1>)KJ\@TFRFO#::=;V^G1027^H:A/"DURT<;75K!;VL$:O=33-FX@CAD<]
M"GP9O=34CQA\0O$>JQ.Y,FE^%=/T+X>:+)&V=T1/AZR?Q0\9'!$_BN4[<@DY
MS7+>./V2/@UXP\.C1+30/^$4O8;PW]MXDT-S)K_GLC)*FHW^KG49M8M)U;,U
MMJ,DV) L]O+;W \P_#>)>,\:\^X#XDPWA=D& X3XKKX",<ES'BG/LIEFN%Q,
M,1AZF)CA<JR[ \3<.U:^)P4<7A<#B,PXAP]'#8NM0Q&(H>SIR/H>$Z' .7<1
MY56XOS+$YUDU/$N6/PN3Y=C5@ZU)TJD:+K8W%8G*,TA3HXB5&MB*6&RRI.K0
MIU*5.HIR1S_P(_:V\)?$_2=6'C:X\.?#OQ!HLUJLD&I^([*UTG5[2\68Q7>D
M7.KR64[26\D$D.H63B5K4M:S+/+'= 1_1<'Q%^']T8EM?''@^Y,^P0"#Q/H<
MQG\S!3R1'?L9-X(*; =P(QFO-/@_^SG\/?@_HU]IVFVLGB*_U:XAN=4UOQ)!
M87MY<?9D>.UMK>!+6.SL;*V$LS1PV\7F22S22W,\[E/+]4F\#>"[A)([CPCX
M7GCF!$J3>'](E24$Y(D5[-E<$\D,#D\GFEX78'QYP' '#6'\1<VX/S3C2EA*
MRSNI+"8F%5S>+Q$\'#$X[*:U++,1C(9?+"T<96P.5T<,L5"K*F\8E]8KOB_$
M>'&)XES6KPO@L\P>03KT_J$%7I2@HJA1CB)4L/C:<\73H2Q*KU*%/$XRI6=&
M4(S5!VIT]*W\0:%>,R6FLZ5=.B[W2WU*RG94R%W,L4[%5W$#<0!D@9R:T$NK
M9QN2X@9<XRLT;#CW5B/UKB)?A3\+Y\"?X<>!)@I)42>$/#S;20 2,Z=P2  ?
M:LJX^!_P=N96EE^&'@0NX4-L\+Z3$I"J%'R0VT: X !(4$]22>:_0UB>/H)7
MR7A'%/JUQ/G& 5G9I\O^J.8VMJFN9\UW)2A91?S#I<-RVQ^=T=M'E.!Q':ZO
M_;6&Z7=^56>EFK,]/\Z+_GK'_P!]K_C2&X@7&Z>%<],R(,_3+5XU_P ,Z_!4
M8,?P]T.V<$%)K,ZA97$9'>*XM+Z&>+(RI\N1-R%D;*,RF5/@#\+(23;:%J=E
MN #_ &#QAXTL1)C.WS1;>(HQ(4R=A<$H&8+@,12CC^/[KGX7X04;ZN''><RD
MM.B?AW%.[_O*RU>UF?5N&[:9QG;?9\.8&*Z=?]:96Z]'L>N&]LP<&[M@1U!G
MB!'X%Z;]OL?^?VT_\"8?_BZ\F/P-\&H"EM?^.;.(;O*AM_B#XP\N#=DXB6?5
MISA7)<+(T@+$A@R?+0/@S81D/;^./B/!(,_O#XBLKP%2"&4P:GHM]:G.00_V
M?S$(!C=.<U_:W&%-_ON$,)56E_[.XFHXAZ6YN7^T,JRA/?\ =\SASZ^T]BUR
ML6"R2?\ #SNM!_\ 45E,Z2N[6O\ 5L9CFETG9/E?PJI9V]:^WV)Z7EH?^WB'
M_P"+H^W67_/Y:_\ @1%_\77E ^$<R9\KXD^/D!QE9K?X=W_(SRLFH_#^ZEC!
M!P4C=8S@-MW$DUG^%7B!0PM_B=K?&?)^V^"?A7=@X.4%RT7@JSEN!C"R&.6V
MDD&2KQ,<@?$>>0BG/@'B:K*SNL+F'!DXW5MGBN*\%)IWT;A%WNFK+F:65Y?-
M^[Q'E,%I_'PV?1>MMU1R:NM'?1-Z*]V]#V#[=9?\_EK_ .!$7_Q='VZR_P"?
MRU_\"(O_ (NO&1\,_&\9#0_$72)2<AEU#X6^$IXL'!#(MA/I4JR C&YYY(]I
M8&+=M=9X_ 7Q#B4HOC'X>3C)(DN_A #,,@94FR\=V<!0$97]R'Y(9VX(B/%&
M=2?O>'?&,%WEC> 6NG\G'$WK=I::M>93RC+TKKBC(Y;:+#\27UM_-P_%:7[]
M/6WK_P!NLO\ G\M?_ B+_P"+H^W67_/Y:_\ @1%_\77CY\+_ !2C7*7'P8N6
M3&$?X?>(K+SL'!W3IXPO1 2/FRMK. WR!2#O#!HWQ8B.3H7P5OE/86OB;2VC
MP>3DV&KB?<">,0&,KG,N_"$N,*E)I8GA'C##II-R66X''))Z)M97FF/F_>T<
M8Q<E\;BJ?O@LCC-7I9UD=1[)/%XC#MO3KC,)ADM&G=M1>R;E[I[*+NU92ZW-
MN5&<L)HRHQURP; QWR>*3[;9E787=L5C4O(1/%A$ )+.=^%4 $EF(  ))Q7X
M.?&CQ+\4[7XT^(O[?N-1T7Q9I/B&2WT'2M#-W;V=E:1W&-#C\+V4<$!OM.O;
M?[/):7'V*2;5_/9[Q99YIHA^KOA/X):=XET/PUKOQ@;4O&?B2;2M)U+4/#NN
M)I^G^$M"UB:S@GO;*U\'Z!8Z3HER;.X>2W>;6[?6+IG1RT^&VK^">%?TG,1X
MQ<3^('"7"?AIG>!S'@7,W@JV.XGS:AE.52HK%XS!7SF5'+L=FF2YK4JX*LZ&
M2T,JSB<HPJ?6<;@U2J2C^C\8>$M/@;*.&LZSKBS+\1AN(L)]8IX?*,%4QN,4
M_88?$6P*J8K#8/'X.,,1!5,?5QF BG*'L</7YXI]9?\ QQ\%&^GT;P@VH_$G
M7K9_*N-+\!06^LV]E*1]S5O$DUU9>$]%*,1YJ:GKMO/&N6$#$;3G _%WQ?AM
M0U_PM\)]'D*DV/A^6S\;>-WB/RR1S:[JT%OX3T:=EY*V6A>)5B;_ %6H,1N/
MK-OX:\/6EM%96FA:-;6=NJK!:6^E6$-M"J@*JQ01VZQ1JJ@*H1%     %3?V
M%HO_ $"=,_\ !?9__&*_</\ 57/LWM+BKBW'U*,M99+PC&OPEEG25-5LSPV,
MQ?%N(KT)-PG6PG$.58#&Q2=;)J:;IGY\LXR[ Z9/DN&C43TQ^=NGG6+[2]GA
M*M"ADM*G46JIULKQF)H-_N\?)I3/._#WPM^'.@ZA%KLT2^)_%,>&'BWQIJS^
M*O$:2 YWV=]J\L\>CJ> +?0K;2[1  L=NB@"O3_MMC_S^6O_ ($19_/?FJG]
MA:+_ - G3/\ P7V?_P 8H_L+1?\ H$Z9_P""^S_^,5]-DV09'P]AI83(LIR_
M*</4J.M6IX#"4<,L1B))*>)Q,J4(RQ.*JV3K8JO*IB*TKSJU)R;;\G'9EF&9
MU57S'&XG&U8P5.$\36J5G2I1^&E24Y.-*C#:%&DH4X*T81BDD6_MUE_S^6O_
M ($1?_%T?;K+_G\M?_ B+_XNJ?\ 8FB=M)TP\XXTZS;GWQ <?C7CGC?XT_L[
M?#FX>P\9^/?AKHFKK@+X>DO]%OO%$Y) 5;3PMI:WWB*\D8D*D5KIDTCL0JJ6
M(%>N<1[?]NLO^?RU_P# B+_XNC[=9?\ /Y:_^!$7_P 77RJ_QUM?$'FQ_"S]
MG+XN_$,% UGK6H> ]*^$GA.?.<2'6?C#=>"]4FM1C)N=)\.:MN /DQS,0I^2
M?BG^T9^T[K/CJX^!?P%^&?[/%Y\<S%I,FO>%H+OQ/\4]'^"VD:NLLD?BSX]?
M$2RT7P!X+^':M:0R7F@^!K*W\:_$+QFIC/AWPU-ICS:W:>CEF58[-Z\L/@:/
MM)4Z<J^(K5*E/#X7!X:$HQJ8K&XRO.GAL'A:<IPC4Q&)JTJ,93A%SYIPC+SL
MSS7 Y1AUB<?6=.-2HJ&'I4Z=7$8K&8F493AA<%@\/"KBL9BJD83E##8:E5K2
MC"<U#EA*2_0?XS?'SX5_ /P?_P )I\2O%%MI=A=ZA;Z%X=TC3X9]=\6^-_%5
M\0FE>#/ 7A'1X[SQ#XT\8:Q,R1:;X=\/V%]J$^7N)(X+*"YNH?AOQ7I>M?'V
M.'Q9^W'XL\.?LY_LY2R1WWAO]DS6/B#X>T/6_'MK$5DL-3_:F\8VNJV]OK,%
MPW^E)\ O ^HW'@JVD$-M\0/$/C^XCDTBPZGP7_P3MT"^\9VGQE_:%^,/Q/\
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MRE_B?\0Y8T+.PRP3X9Q3,JA(N%A5VD:<&,0K;3^Z?V3=_P#0Q:W_ -\:'_\
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M)[A0NWS4TG7K?XF^%Y[C(W-$WB;1X&+;4:)17T+_ &3=_P#0Q:W_ -\:'_\
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MH[XZKX@TW]I3X(O9Z[X<TSQCX[\&^'?#/B_2I_!WB37?#VMW&AV=W?\ P?\
M$!\=P7GA+Q@ ?KC@9'7VP3C\0./SI 5W$<Y]2#^(!/!''(4X!Z@&OS@U_P <
M)X@_:K_X)UZYX"^('C/7/AQ\0?@3^TMK,9?Q#XFM/#WC_0I? ?P'\2>"O%?B
MOPK<2:?IVJ^(HK;49=0TG6==T6/7]'_MW7+2W:Q74]0M6TM%_9VU;PS^VMHW
MQ=^%_C_XN6.@R>!/BK:_M(Q>,_B7X_\ &7P[^*_B_P 87OA&Y^#GA_2O 'B?
MQ+>^"/#&O?#!=+\7:S'JGPP\/>#I/#'A/4-.\"W8O['Q08-) /T,4J20H/&
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M>W'_ ,HJ/M7B+_H#Z7_X/;C_ .45 &Y16']J\1?] ?2__![<?_**C[5XB_Z
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M";/2?"NDHL<\]OJFL-=ZS=_3%8?VKQ%_T!]+_P#![<?_ "BH^U>(O^@/I?\
MX/;C_P"45?.YAF.-S7%5,;F&(GB<344(N<^6,84J4%3HT*%*G&%'#8;#THQH
MX;"X>G2P^&HPA1H4J=*$8+Z/+\NP6586&"R_#PPV'IN4N2+E*52K4DYUJ]>K
M4E.MB,3B*CE5Q.*KU*F(Q-:<ZU>I4JSE-[E%8?VKQ%_T!]+_ /![<?\ RBH^
MU>(O^@/I?_@]N/\ Y15Q':;E%8?VKQ%_T!]+_P#![<?_ "BH^U>(O^@/I?\
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M\3?^"_4__D*C_A)]&_Y^)O\ P7ZG_P#(5,1T%%<__P )/HW_ #\3?^"_4_\
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M_/\ @B7_ ,HD/^"='_9H7P3_ /41LZ_4>ORX_P"")?\ RB0_X)T?]FA?!/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+&@:YX\\V2WC^&GPX@U;XL?$^6Y1786Z_#GX8Z?XM\8Q,[(T?FW>CVUM&_\
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M,<GQ;^Q5X^N+>,KYUU\,/C'\#/&Z89D&^WM/%_BWX4ZK<*%D 8+IZ2"2.?\
M=^0D5S,_]6<;*\J&.X?Q%-)6G'B3(L/*;=E:&'QN887%N5VO=>'3=TK7T!<4
M8&/*J^ XAP]1[PEPSG^(C!*UW/$8'+L5A%%7UDL1*-DW>Q]0?\(SI'_/"?\
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M9@EW!X"T&3XF?&*\B"A)!9ZWX*\&33;O+-S;$%Q8C_9M_:7^(:*?C#^U7?\
M@/2YXO\ 2/!?[)_@^+X9;"0 UK=_%CXB:G\3_B5?H<$/>^'3X GD!WPP6F%5
M/O0 #H ,G)QW/K]:*7^LD<-ID^1Y)E=M/;SP7]LXV:3O";Q&>SS*EAL1#1^W
MRO#9:^9<T8QV0N&9XG7.<]SW-;Z_5X8W^Q<#!M+GIK#Y##+:N*PT[-.AFN)S
M)<DG&4YN[?R/X1_86_99\)ZW;^+9_A3IGC[QW;,DJ?$7XQZMXC^-7Q"6Z7DW
M<'C+XIZQXLUS3YB^9 -*NM/@B<Y@AA  'TT?#6DLL:-%<LD2JD*-J6JE(44
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MG2/^>$__ (,=3_\ DVC_ (1G2/\ GA/_ .#'4_\ Y-K?HH P/^$9TC_GA/\
M^#'4_P#Y-H_X1G2/^>$__@QU/_Y-K?HH P/^$9TC_GA/_P"#'4__ )-K9MX(
MK6".WA!6*)0B*SR2$*.@+RO)(WU=V/O4U% !1110 5_E>?\ !XY_REO\/_\
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MR>)K?Q5I=Y##XA\/:-KWA33_ !'#"+C1K>+]A'^XW^ZW\C5>UMK.U$R6<%O
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MUNT5D:F%]D\0_P#09TS_ ,$=S_\ +VE^R^(1_P QG2_QT*X/\]=K<HHN^_\
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M@:&"[EGC#R1(C>S*-HQ[L?\ OIBWZ9Q0!^-'_#</_!6/_I![XZ_\6&?L6_\
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MCX VOCG1-9U2P\"_&'0M5^,'[)?BQ?&7BKQ*/'_BCXA> ='NO!7@GXD>'H?
M.E>-+O7O$&EZC\.O#,5K83Z@ ?I_\6_C;X%^"=CX(U7Q[/K%EI/CWXF^"/A+
MI6L:=X?U?6='TKQ7\1=3_L'PA+XNU/3;6>S\(^'-6\13:9X;B\4:_+9:(/$6
MO>'M$-X=1US3K>?Y>^)8_:F\.?&SP/\ $S7_ (RZ#X?^!L/QY\$_#SP]\#/
M/@32_,\6>#?'^FW7@D>)/C5\2O%?]O\ B74M=B\=:[I^K^%_#7POL_AEH?AY
M-/TR+Q5?^/VN+M;7YE^#GA'X=?'WQ#^TO\#/A_X@NO'7["/[7/[-_@WX\?#P
M:-J;3)\ ?B+\0]:\9^!?BAX/\'VM^EQJGPV&H:AH/@_XO^$? ABTE_AE\9=%
M^*XL-&T2Z,FGV/WS\)?!OQ3^(/[.OPH\/?M265CI?Q@T%_AKKGCJY\&Z[9:E
M9:KXZ^$OC+0/%&E^*[2[CT>"SL+?QGK/A#3O$>L>'+>WN5T2WUS4?"]OK-Z;
M6/6) #Z<0[D5CU*@G\0#3J** "BBB@ HHHH **** "BBB@ HJE<:EI]I=6-E
M=7UG;7FJ23Q:;:3W4$-S?RVMN]Y<QV5O)(LUV]O:127,ZVZ2-#;QO/(%B5G'
MS%\8_%W[2'B&XU/P+^S'!\(O#/C/1=<6/7?'WQQTKQ1XX\$Z/HDW@NP\0:'Y
M/P_\ ^,/A]XIUO4_%7B+4CX;CE?QEHNG^&]-T+7_ !+<C6[G^Q?#FI@'U0SJ
MI 8X)S@<DG')P!R<#DXZ#DX%?+OC']HM]0L/VI/!OP3\+ZUXZ^/G[.7AG3+]
M_AIK&C:AX6?Q5JOC'P3=>+/A_<>$[_Q$=#TOQ9X=\3S:?K?AW2M?T_6+'PUJ
M/C/PMXG\'2^)M*OM$U:]T[\Q?&?B?Q5\?_%WP]TO]I2WF_9_M/VP/V+O 1_9
MX^,GAKQ+/;V_[,_[=/P>\3^/_%OC#1?A_P#$ ?V?/I6O>,=)\7>#OB/\-[G6
M6TI?B[X)^#'C+P;XCT[6-.@O_"EW].?"W1OCY\3!^P%^V9;^#]%TGXN^,/@S
MHOPT_:_\)7&IQ^&]$O?AQXX\'P^/)_$FARRP:I)J&H_#'XXZ+9ZU\,=(6T,U
MYX)^)OQ!TY]0TW^U&N5 .B_8N_;5\+?'3QY\4?A5K7CSQ"WC?2M1/B?X?>!/
MB]\$?'O[.WQGF^'NEZ)X4T7Q_<:CX-\;^$?">C^+]/\ !'Q<NO$/AB7Q-\/W
MUO3]/M)M&T_7KR>Y-CKWB'](*^;OAE^S%X,^&.KZ=J%GXC\;>*=.\*Z[\2-<
M^&GA[QGJ.B:OI_PN;XK:U>:YXOTWPGJ5KX=TWQ3?:=+/J.H:?HP\:>(?%E[X
M<\/WDOAS1;VTT=(;:/Z1H **** "BBB@ HHHH **** "BBN+\4^-;#P_X-\5
M>,;$6^O6OA2QUV[OH+#4;0#S?#9N%UJRDNPTT%M=Z<]I=PWL,^);6XMI;:XC
MBF1T4 [2O+OC-\7O"/P)^%7CSXQ^.4\13>#/AQX=U#Q5XH;PIX8UOQCKMOH>
MDIYVJW]IX=\.V=]J]_#I5HL^HZI):VSQZ9I=G?ZG?O;V-C=SQ?&7C_Q9^W1-
M\39_!,R_ [PI\*?CM:_M!_##X77OAV#QM#\:O@GXJ\-_#OQ;KOPF^+WC/Q?<
M^)M5\#>./#_BYO#%]>ZMX1\.>!?">J?#G4=:\'6T'B?QXJZ[-;_(W['?B_4=
M4^(W[*_BGPAH<_AD_&OX2?$+]G7_ (*#?LPZOJ"RQ_"3]I[]GSP-I6I+\1-5
M\$W,ETND:Q<ZGI7C/X8>+/%T4$5K\;/ ?Q&^!7C*_FUFPMO">HW !]3_ +4?
M[4OCCPY\2;7X3_"GXC_#;X;>,?$W[/MQ\</V;-<^)FBIK_PM_:A\?Z!XBU*V
M\0? RR\1V^JZ9+]HA\.-X%U62U^'^J2_$:XT?XEVOCGPSI^O:)X(U_1=2^RO
MV<_C)I_[1'P ^"7Q[TK1-0\,:?\ &CX3_#WXI6OAG5I1/JOAJ/QYX4TKQ,?#
MNJ3+!;)-J6A2:D^DWTT=O%%-<V<LL2+&ZJ/!_P!F7X(_$OX>_ _Q9^SKXSE7
M2?!_PU\7>-/A[^SKXYM->B\0>,F_9YDDE/PR:]@GM%C\,^,/AOX1UN?X4Z'>
MS76K3WVE>#-"\8:A;)<:Q>Z'%]=>#O"/AWP!X1\+>!/"&EV^A^$_!?AS0_"7
MAC1;0R&TT?P]X<TRUT;1=+M?-=Y!;Z?IME:VD.]V?RXE+LS%F(!TE%%% !7^
M5Y_P>.?\I;_#_P#V:%\%_P#U+OBQ7^J'7^5Y_P 'CG_*6_P__P!FA?!?_P!2
M[XL4 ?W^?\$2_P#E$A_P3H_[-"^"?_J(V=?J,2!U('!/)QP.I^@[^E?ES_P1
M+_Y1(?\ !.C_ +-"^"?_ *B-G7N'[8WCGX@?!!?A)^T=HOB_5K3X0_"7QS%9
M?M*^ 8[72Y]#UOX*_$8VO@[6OBC=W#:)>^(;+5/V?=;NM ^)\CZ9JUCI,WP]
MT_XF6^K:7JNH3:#>:, >IZ%^U?\ LW>)_CEKO[-/A[XU_#K6/CSX:TV_U;6?
MA78^);&?Q?:6>D'3!KNW3E<+>7?AQ=;T67Q-IEA-=:GX;AUG29M>L].BU.R>
M?XT^.WQQ_:-^%T'PB_:TD\6>)=3_ &?-.D\+V/Q;_9O^#G[,VL?&[Q5J'A+5
M?">O2_$OXD:GXD\/7-]\1]%O/AMXGAM-5T:W\*6,VC?\(GH&H:;JWA[QOXG\
M5Z=%X>[W]I7QI\//@U\1_P!G'3/#'P6\?_%7XD^'/$'QH^+_ ,-_AE\%_ASJ
M/B+Q'JGB3Q+H&N> _$^H:IXUO5TCX9_"K1/$FK_&G6=4\1^-OBUX\\&>'=1N
MDEDAO=4U...VC^D]&^%WB:]^'7A_PE=^+?$'P]^R^+/%.K:[9>$7\)ZC<ZWX
M2UO7?%MY;>!K[6-;\+ZK_95D^FZ]IL>H:OX1BT3Q-:W.EB+1O$EK%)-=7(!\
MJ:/<^&_@U^UYX2^(?P^MH]1^!'_!1/PQ:SZ[<^$-%U#4=&A_:0\#>#4\1^"_
MBK?0:7'+]DT_XY_ .&^\+^+?&.HV5O9#6?A!\*[34KQ-2\3QM/ZEXQ^ _P ;
M/B+\,?@%X*\-?&O4_P!GH> K5(/B'K/A;P7X1\:?$W4[;3O"%UX+TNU\ >)/
M&Q\1^"O NL""]OK^?Q?J_@?XAWD,$J0Z3I>G:K(FN:?]C:3HVEZ%IFEZ-H]A
M;:=I>BZ?::5I-A:1"&VT_3;"VAL[.QM8TP(K6VM;>""*$?*L<,8P=BD:5 '"
M^$OAWX;\(Z;X2M8(+C7-7\'>#]*\$:?XT\53CQ'X^OM%TJTM[8G7/&>HQ2:]
MJ][J<MN-1UJZNKLG5=6FN-1NHVN9W<]U110 4444 %%%% !1110 444ASC@X
M/8XS^8[CUY!QT(/- '%_$3XC>!/A)X)\1?$?XF>+= \#>!?"=C_:/B+Q5XFU
M*WTG1=)M#/#:1-=7MRZ();J]N;:PL;6/S+O4-0NK73[&"YO;JWMY?&-)_:)\
M+_&;X<?#_P"(7[,GCOX<_$?PS\5=3\9^%?"/CR"\N]?\(6GBK1/"'C^[M(M6
M@TB[T_4MVB>-O!K>'?&/AV:73-?TVXAU+1[F/2M7@9K;R?X/ZSKR_'CXW_LP
M_'S7)?B9JOA;Q9H?[4O[.WBKQ;8>'HM1U7X0^-/$%T+/1%M?#^EZ3I$VM_LX
M?%_3=<\&6EU%I\=]8^ ];^#&KZP]WX@U2XUB]\R_9]\7Z5\4/&OC>R^#/PD^
M)5MX-?\ :0\6?'/Q1\;O$G@B\^%OPJUKQ1'XLLOAOJGACX?P^.8-+\:?$W6M
M8\':7K/B76/'/@SP=/\ "VYOK:YM[;XB:AK&LQQ2 '.^!KZX^)6N_M!_\$X/
MVY/$?C#X\7/C[1/$>L^ _B/XL_9KD^"W@/XK?">[\*^!V\;^&O!OBC0K:\^&
MOB+X@?!3QSXDFO-*N=&ETSQ=IFC-X3\0VB>)=8\(Z_XS/KO[+7BGXD?$/P1\
M--!^)"ZOK/QE_9?^+GCCX#?''Q5/8:EI=CXUNO!_@7Q7X8T_XM:5=ZC%:6.O
M:;\5-'O/AM\1;J/19=2CT/7?%.K>&[N.TU7PUJ<%G]=:;\-_*\=ZEX\\0>*=
M<\6W:S7?_"%:-K%CX5M=&^&]AJ>F:7I^LV'A@Z'X=TG5[^;66TWS[[6/%VK>
M)-8BCNKG3-+N]-TB66QE]*5%0$*H4%F; X&YB2Q Z#<26.,98LQY8D@'R/X"
M_9V^)>F_&SQ9\8/B1^T1XQ\6:-=>+/&FK> O@KX0T'0OA[\*?#NC^)=+L_#F
MFW'CP6R:UXX^,/CK1O#&G6>EVNO>)?%NF>"M,*BZ\.?#31M4@35I/J71-"T7
MPWIMOH_A[2-,T+2;4RFUTS1]/L]+TZV,TKS3?9[&PAM[6#S9I))9/*A3S)7>
M1]SNS'5HH **** "BBB@ HHHH **** #('4X[?CZ5\^>,_VKOV;_ (>?&'P/
M^S_XW^-?PY\+?&?XD-:1>"/ASKGB:PL/$OB&ZU--2?0["TM)G$<6I>(_[%UE
M/"^F7L]KJ/BF32-5A\.VNJ2Z=>)#C_M=6/QM/P4USQ3^SUKFKV7Q3^&6I:'\
M5=#\':9;:3<VWQFL_A]J,7B+7_@5K9U/2-4N;33/BWX>M-5\'6NIZ#/H>MZ5
MXBU'0-3CUE-.L]2TW4_GWX\_%?\ 9UUW]GOX8_&33O#?B/QQX6_:2^*'[.GQ
M1\*0?#/X7>-/B3\1?B'K7A*;PC\8? ]QI_A+P)HNN:^GB.R\-_";2M*BU?5E
MTO0O!$]HDOB+6M"M+2ZG(!9_:A\6_M577@;Q1\1?@-XX/@Z?X#^*O$EWK7PT
M\*? ^+XZ^,OCY=>'O$N@7&A?#B'2;O5-/U'0M$\4^![Z:WO[_P 'SZ;XL@\1
MZS8ZW;^)=!\.^&-0T_Q'YKXY^)/@6[U_]FS_ (*7_!K2?$9\*>*[FR_9K_:,
MTZZ^'?B;PW\2=0^$?CWQ]-X*\-#QG\/]5T:V\>1>/OV7OVE;>RMM4\-WN@RZ
MUX.\)^*?CQ!% D4L[2?8WP]TCXC>._ /C+7M2T[QC^S?XD^+&K:!XVLM*EE^
M&7BKXB_#9W\,^#='U/1=:MS9_$;X82>()E\*S?V@D%QXVTFT_MR<6>I3W=G%
M)![IX7\*:1X1T.TT#2HI3:VUSJ&H2SW4IN+V_P!8UC4KS6M<UN_N=J>?JVMZ
MUJ.HZOJETJ1"XO[ZYE6**-UB0 ^;_&_PH^+?C'X6>/\ X?> O'>F?"37-<^,
M-UXETCQUKG@FR^)HM?!=_P",],^(&K_V3X/U37M*TF76-3GFU/1-,/B9[O1M
M'NF?4=5\+Z_86_\ 8>H^H?#+X+Z1\/\ PAX8\.^(?$_B[XR^(?#.L:]XDC^)
M?QBN=!\3_$"^\2>)-3OM3U365OM*\/>'M \.$-?R:?I6C^"/#OA;P[X?T.&S
MT'0M(L-*LX;<>R44 %%%% !1110 4444 %%%% !5'4M3T[1M/O\ 5M7O[+2]
M*TJSNM1U/4M1NH+'3].T^RMY+J]OKZ]NI(K:SL[2UBEN;JZN)8X+>WCDFFD2
M-&87J^#?$FL^)?"_[7.I_![XN:W=>//V?/VP_AIJ-K\+_#OB/3]+DT7P+\5?
MA1H5PWQ-^#ML^EZ)97&IZ#\8/A1=2?%+1K/Q+J&L:F-5^''Q>A_M(Z)>:)HF
MF 'HW@C]L7X#?&WP%XD\??L[_%3P!\9-)\$>/?!_@GQK-X1UV/4QX:GU[Q%X
M6@ODU6VC:WO;"XE\(>(E\5>&Y[J!-.U_3)=.U?3)]1T:[CN9?FK3OBU\7O@M
M^T_'\'OVKO'>K?%;X8?M1:78:9\-[W1OV8-2T?X(_"'XG:CK/BRSB^!NM?&#
M16U?3]4TKXB^#X;"T\/)\6Q+JVM>+M)O+-_$.FCQ]X7\!VTWB'QGI?C+]I7]
MHWX:_"KX0_$7QEXV\9^&_A_\*?B-\4]+\$7GA+X/_#3_ (5=X-\8?$#PKJ'B
M_P"*_C.UT?P[X[\0-K_Q6M?#EEX1^$L7Q*\5Z$LD,_BK3_#VD6,L]I]X:W\.
MCXE\9Z5XEUSQ3KM[X:T6'1;W3/AH]GX77PE#XPT34[[4[#QO=7Z>'_\ A,M0
MUJRDN;1;#3KCQ4?"MA<:78ZO!H!UJ)-00 ^!/V>]!UOX86/Q=_8@TK1M4N;'
M]FWXA?"OXC_LZ2QV&H1:'-^R]XO^(.G>/?A_X%M?$,\K:+;ZC\%=0\.?$/X,
M6OA>;48M3A^'/@[X=ZI/926GB.V:;Z.\5?L\?$SQQ^T#%\3M8_:&\6^%_A-H
M9^'EUH?P5^&7AW0/"5QXHU/P+J&H:ZT?Q;^*=^OB'QCXG\%W^NZI+<K\/? Z
M?#72[VVMS9>--5\:Z5?SZ-;_ %LJ(I8JH4MC=CC=M 521T)"@+D\[0JYPH =
M0!D:7H&AZ)+J<^CZ/I>ESZUJ$NK:Q-IVG65A+JNJ3A5FU+4I+2"%[_4)E55E
MO;LS74BJH>5@ *UZ** "BBB@ HHHH **** "CIUHKB?B3X8USQK\/_&OA#PU
MXZ\0?#'Q!XG\+:[H.B_$7PI:Z#>^)O VJ:MIMQ96'BS0;3Q1I>M>'KG5M N9
MHM3L8-8TJ_L)9[94GMG5@5 /./CY^U-^SM^RWI&@:]^T-\9/A_\ ![1_$^I3
M:7H6H>//$-IH5OJ$]FEO)J=S&TY9HM)T2&[M+GQ#KURD.A>';6ZMKK7=2TZV
MN(99.8^,\WQB^(4/BKX<_!?XIZ1\%M23P]X$\6)\6[7P'IOQ5\1:;X7UV7XA
MQ:L_A#PAKTTWA'5=>DU'PEH%O8W&N:9KNF1:-JVJSPZ-JFJG21!\Z^%OC7X7
M\9?L<_$7XP_'WP_H=G\9/A1\./BG^S=^T;:V/A?5_&,MA\0_"-W_ ,(CX_\
M#>C>&?#NEZ]XEUOPA\2?$D7A[Q[X/\/:)I6KZKXK\&>+O!D]K9ZK/=64;>J?
MLN#7/$VC:!K>D_"WXG?!KP#X4^%MC\$O!4?Q=T?2_"?Q \4:%X"A\.Q>$?B$
M/AQ<W.L^)/!NCZ@;WQ3;Z5X?^)B>'O'$*Z3'=^(O!&E1:O:JX!\=7GC_ ,0_
MM2?LJZ!\;-.\->(-._;P_P""?FOZ-XXUG0O'OPG\1_ OQ9=_$OPCX'L=5^+'
M@G2/"WBH7>I:-\+?VM?@OK'B3P[H%[I?B#6?"<T'BW0+JZUF?7/ $UOH_P"@
M/AB]U;XJZ)XN^)WPFOKKPYIWQJ^ _P /]8^&?BKQCX;UJW_L;Q+J&E^/WTK4
M/$O@+4KKPYXFAN-&L=>\(:CK.@7+>'[^Y:";2&U.SNHGN+3U?X>?#J#P+IMV
MNH>(-7\=>*];&GOXM\>>)[/PU9^(?%=UIEA%IEC+J%GX1T'PSX8T^ULK*(6]
MAI6A:#IFFVB23RBWDO+N]O+KT8#  ] !R23QZDY)^I))ZF@#Y8^!'[-6H?#7
MP=K&A_%OXM^+OVD-;\3P>$8M<G^(&A^#]'^'NBV_@S3EL=$T#X9_"+PYH\'A
M3P)X3L) ;Z"VO9_%WB_4+X6]]XJ\<^)M1LK.]@^IU54544!550JJ!@*JC
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M@/\ $/XF_$+P3\$M=\'>%O!GPG\ 7D7A[P9\/?C+XZ\"Z;>ZEXX^*FO#P_\
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M8USMC2)=D84$G!5>-WWB.I-3T4 %%%% !1110 4444 %%%% !7^5Y_P>.?\
M*6_P_P#]FA?!?_U+OBQ7^J'7^5Y_P>.?\I;_  __ -FA?!?_ -2[XL4 ?W^?
M\$2_^42'_!.C_LT+X)_^HC9U^H]?EQ_P1+_Y1(?\$Z/^S0O@G_ZB-G7ZCT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5_E>?\'CG_ "EO\/\ _9H7
MP7_]2[XL5_JAU_E>?\'CG_*6_P /_P#9H7P7_P#4N^+% ']_G_!$O_E$A_P3
MH_[-"^"?_J(V=?J/7Y<?\$2_^42'_!.C_LT+X)_^HC9U^H] !1110 4444 %
M%%% !1110 4444 %%%9VKZ@^E:5J>J1Z=J.KOIVGWM^FE:1%#/JNIO9VTMRN
MGZ9!<7%K!-J%ZT0MK**:YMX9+F6))9X49I%J,7.481MS2DHJ[25Y.RNVTDKO
M=M);MI$RDH1E.5^6,7)V3;M%7=DDVW9;)-O9)LT:*_/5?V]?%+*C?\._/^"@
MB[E5MK?"KX3!EW*&VN/^%YG#+G:P!(# @$]:S]9_X*!>+-+TC5=33_@GS^W]
M,^G:9J.H)#-\,?A7;Q3-8V5Q=K#)/!\:;Z>))FA$32065Y.BN6AM;F4)!)];
M_J)Q.W98/!7_ .QYD/\ \\_,^0_U]X8_Z#,;_P"&//;=.O\ 9OFOQ/T9R,XR
M,CJ,\_E2U_GL_"7_ (.%/^"CM_\ M1^$O&OB'Q/IGCCX:^+/B'H6FW_[-NA?
M#_PE%H%SX8\2>(+73(O!_@75H=)@\=1^*[>WOX[3POKFH^*KZ[U/Q#%9#7H;
MZPN[JP']CW_#>?BH%A_P[^_X* MM9ER/A9\)2#M8KG*_'/;DXYVDKG(4D8)]
MW/?";BW(:F%IUH97BGBJ'ME*AFN#H*E--1J4)K,JF G.I3<E>5"-:BTU:JW=
M+P\B\6N$<^IXJI0GFF&6%Q#P[C7RG&5W55DX5H/+J>.C"G43O&->5&MH[TDE
M=_H117Y_6O[=OBBYNK6V;]@3]ONU6YNK:V:ZNOA;\*4M;5;B>. W-T\?QOED
M2VMA(9[ETCD=((Y&2.1@$;] >OMU_P _X5\5FN1YGDKH+,:-&D\2JCH^QQN!
MQG,J7)S\SP6)Q"IV]I"RJ<CE=\O-RRM]KE.>Y9G:KO+:U>JL,Z2K>VP..P3C
M[93=/E6-PV'=1/V<[NGSJ+5I\O-&Z!E)(# D=0",CZCM^- ((R""#T(.0?Q%
M?E?>_&OQ_P#LX?MJ_M(> /B[XY\9^.OAE\:/V?++]HK]DS0=4FTFSL_#_B'X
M37T7P]_:%^ 7@RZTW3-/U6_UF_\ $7CGX+?$+PK)K-YKVM_8OB#K>F:;-9Z#
MX,V1[.E_M@I\!CX6^ VLZ/\ &W]I?XA?#W7? WPJ^-WCCPWX?O/%&N:1\3/'
M7@"R^)/]N:S/H_A#1?!H\ Z%;>(_#<7C+Q+)K.@)\-]"\3>&]5UG2;S1;'Q+
MK6D^0>P?IQ17Y>>*_P#@I9!X(_9L\-?M3>*OV>?B+H/PS\4_!34OVC].GU/Q
MA\-(KL?";1_AG\.OB7<:;++!K]QIC_&?7;#QQK%GX'^$=K?7%SXG7X>>,]7G
M\4:)I5I:3W/T79_M3R^*?'^L^%/A?\*/&7Q.\->%OBGXL^!GC+QYX<U/PU:Z
M7X-^*?A/X;_\+"O;7Q%I.KW]GJT/@F*]FTSX:ZCXTL4OY-*^)6MZ7IL_AR;P
MS_:/BW3P#ZXHK\N/&W_!2&:#]D+Q%^TO\-O@GK^N^(- _9R^*?QOUWX:^,/%
M/A_PQJ/PZ\2?#'QE_P *\U?X6?$R]M#JL%AXOT[QCI/C_1=6MM ;5;.#5?A=
MXRT>+4C*-+OKOUC4_P!N;1=)^*?AWX2#X4_$KQ/XGB^)7PT^#_Q6@\ Z!K7C
M<?"3QO\ %+PGHWB_2[SQ!>Z%X?G\-:AX%\'Z7XG\)W'Q0\7VOB>U'@6Q\4:9
MK5QI&I:'::[J.D 'W>2 ,D@ =2> /QI 01D$$'H0<@_B*\G^.][J>G_!+XN:
MEHFKZEX?UG3OACX]U+1]<T>>*WU71M6T[PIJU_INJ:?+-#=6PO-/OK:"Z@6Z
MM;RRD>(1W=I=6KRP2?F!\+O^"A7B#X7?LE? #7/'G@#XI_';X@P_\$R_AC^W
MC\6?'%IK7P[TE_$/AZ#1/!L_QFGM4U35-!CD\:Z=_;VI>,-)\,VFB:)X;U2R
M%MX<T34M-F0Q6(!^S%%?*7A[]J2W\;_$R;PA\._AMXQ\?>"-#^+NO? KQY\3
M_#MUH!TGX??$/P]\/8?B#JD_B/P]J.H6.O/X'T][O3O &I>*M+2^O;'XCZOI
MFC'PU/H#WOBJP^K <@'U /YT +1110 4444 %%%% !1110 4444 %%%% !16
M#XGUR7PYHE[K,.@Z[XFDL_(VZ+X:M;6\UJ\\^YAMS]CM[V]T^VD\A93<S^9>
M1;;:&9UWNJQMY)_PN_4_^B$_'7_PF?#'_P V=?)Y[QMPYPWBZ>!S?%8RAB:N
M'ABH0P^2YWF,'0G4JTHR=?+<NQ=",G.C43I2J*K%14I049TW+V<NR#-,UHRQ
M&!HT*E*%5T92JX_+\+)5(QIS:5/%XJA4:Y:D&IJ#@VVE)N,DO>:*^2_B;^T?
MXB\+^ O$^O:7\&_BEH^HZ?IK/9:KXN\/Z);^&].N9IH;6*]UB73_ !3>W@M+
M9I_-,<-L_GRK'!*\$,DD\?R1\!/VM?C%??$.UT3Q:NL_$S2]<BU+.AZ%H&B)
MXDL[BVM)KU+O0X[;^PK:2" 0,M_::A=>1'9%YX)$N(52?\/XM^EKX3\'<<\(
M\!9@^*<3F7%TL+'#X[!\-8Z&7Y9]?QT\MR]YA3S#ZCFU98O&TZE&"RG*\SE#
MEYJJIIQYOT')?!;C3/.'LZXCPJR>EA<E59U<-7S;#2Q6+^KX>&+Q"PTL,\3@
MH>QP\XSE]=Q>#4KI0<G>WZUT5X-_PN_4_P#HA/QU_P#"9\,?_-G6UX=^+%_K
M^M:?H\OPB^+GAZ.^EDC?6?$.@Z!::-8".WFG\V_N+3Q1?7$44AB$$9BM)V-Q
M-"A549G3]>PGB=P;C<5AL'AL?F,\1C,10PN'C/AKB>C"5;$5(4:49UJ^3TZ-
M*,JDXJ56M4ITJ:O.I.,$Y'Q-;A+/:%&K7JX;"JE0I5*U1QS7**DE3I0=2;C3
MIXZ52;45=0A&4Y/W8QE)I'K])N7&[<-O][(Q^?2HYHQ-#)$7EC$L;QEXI&AF
M02(4W1RH0\<B[LHZ$,CA64@@5^)FE_M _''X4:?\5_V>OV@/B;XMGLOB_<?M
M ZS^PO\ M2:>OA[1/%%]J7P_\4^.KK6/V6_'U_'I$GAV3XX_#?0/"TGBGX4>
M(;K0%B^/?PCMM=AGT67QY\+_ !G+X@^^/FS]N*0D#&2!DX&2!D^@SU-?D]_P
M4:_;+US]E"U^'>K>#_'OAW1[#X*:KX,^.W[1?A;Q"UA?^*_B/^S)!XG;X;^-
M_"_@]=2N8;R;Q?9:#JWC#XVP7VF)=ZG=_P#"CV\.M"EOXNFN[;<_;E^.GQ0^
M#'BKX0_%.3P[\;_%_P"Q0_@/Q\_QC\??LDVB>-OBE\)/&%Y>^#+[X;_&CQ)X
M T*QUWQI\2?@7H_A!?&]UKR?#71_&,F@:@UAK_C'P#XR\*NDFA 'ZB%E!P64
M$] 2,G\,TZOQ4\#?$[QQ\8?VW/@%\-O"/[6WCSQK\#O%O_!+C3OVA[#QO\.-
M3\#V&B?%CQ_!\8/ 7@71_C5#)'X/U+3HE\6>$=?O-4E\.Z=;VG@MKV^CG?PP
MDUJJ1^@?LZ?MG^/K?X$?MB0_'+Q7X8\0^/OV0/VN/'_[(6E_%R?3])\):'\7
M+V2P^&.N?"3QCXATC2S:>&]$\1V]A\9O"_AGXMVWAJ/3_#T/BOPAXQUG2-'\
M-:5<)H.C@'ZUT@93G!!QP<$'!]#CI7X/6G_!0_XMZ-_P3;UOQ5!XR\&>//VK
MOA9^T[\,/^">WQ%^*VFZ)9WOP]'Q3\>?M%_#7X!Z+^TY_8%G=QZ5_P (EXN^
M&7Q0\&?M&>'?#YF;09;[Q1I/@V[D?3UO&KZP^*_C[XC?LK_M._L*^#]'\>>-
MOBA\.?VL/BI\1?V>OB-X9\?W]IXJ\0:3XJT7X"?$GXY>#_C-X2O[6PTF[\/K
M93?"#6_"WQ"\,Z?'%\/WT7QE9:SI'AWP]J?A^W.J 'Z8DA1DD >I( _,T9''
M(Y.!R.3C.!ZG'/TK\XM?^+OC'XQ?\%!/&/[(=GXK\2?#GX:_!']E3X8_'_QC
M+X4NU\.>,?BGXK^._P 2?BEX"\)Z3:>*#!/J^C> ?AMI'P?U_5-;?PE+I&K^
M)/&?BW0+&^UZTT7PMJ6B>)/#=<_:&UB^?X2:7\-/C=\9/$EKX5_X*OZ/^SA\
M0)_&_AK3_!^K0:9#X,\8S>+?@;J-];:)IZ_$CP5X9U.;2[W2_'$,<USKJ)HT
M5YXI\27>CZMJ&H '['D@ DD #DDG  ]23TI:_&/]I[_@HWI6H_LI_$?Q)\.K
M7Q]X&L_CO^RE^V?XS_9#^/NB7>DRQ:[XT_9\^#?C_P =Q7CV$(GU3P3JFM>'
M_"6J_$[X77FI6FL:?XB\+>&=5;7'\+^(/[.\.:E[?X"_;JU/3]-U'P!XZ^#?
MQ#M/BCX3^&'[,?Q"TY[[Q!X(OO#WCOX;_'_5IOA[:_%_4_%]AK=Y;^"?#O@#
MQMX<\5W'QJA\0V,VL^#_  _8VOB70K'QI;:WIMM( ?I;D9 R,G.!W..N![9&
M?K29&<9&<9QGG'KCKBORE\'_ +6^H_M!?&C_ ()[^._A[J7C'P;\.OB_I/[=
M.A^-_AY?ZAI4VGZQXD^!]YH?@GS]6?2GO[+6X?#?C7PMXHG\%ZW87UK;W^AZ
MO_:5QI\4U]':Z<W]I'X\_%W]GW]O#X,^+)O&^H3_ +(_B+PI\-_@U\>/ -]9
M:7<:/X%\?_M$_$WQ?X#^ ?Q]TW59+6+6M'M+'XG^#_"OP5\;V3ZROAAM-^,6
ME^*;K38K_P /27LH!^KF1G;D9QG&1G'KCKCWI:_%CPW^V!\8(_VZ_P!K?4]6
MD\>^/OV?_A]^Q7\$/C!\#O@?X!T?0/[4U27Q#\?OVC/A'XB^(;75^=$EU6Y\
M?-\)K;Q%I]WXBUZU\-^$OAU#I^LBUBGDU6\F]]T7_@HOIOB^U\+:3X"^#'BW
MQQX[\4?M#?'_ /9@MM+T+QI\/X_!J?$WX!?#/Q?\5K_4;?Q[K&K:5'J7P_\
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MSX>U.ZM(IK[0[G4])DGTK4+G2;EY;"XO=,GN-.N9H));*XGMFBF?:H ****
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MK:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_RO/\
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M\+/VC?AM\-_A[XV^%'BV&V\4RZG<>)-'O?A1X(\:^&/B9I!M(;;4]*N-"N/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^5Y_P
M>.?\I;_#_P#V:%\%_P#U+OBQ7^J'7^5Y_P 'CG_*6_P__P!FA?!?_P!2[XL4
M ?W^?\$2_P#E$A_P3H_[-"^"?_J(V=?J/7Y<?\$2_P#E$A_P3H_[-"^"?_J(
MV=?J/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH /^(X;XK_\ 2/'X??\ B1OBG_YU%'_$<-\5_P#I'C\/O_$C?%/_ ,ZBBB@
M_P"(X;XK_P#2/'X??^)&^*?_ )U%'_$<-\5_^D>/P^_\2-\4_P#SJ*** #_B
M.&^*_P#TCQ^'W_B1OBG_ .=11_Q'#?%?_I'C\/O_ !(WQ3_\ZBBB@ _XCAOB
MO_TCQ^'W_B1OBG_YU%'_ !'#?%?_ *1X_#[_ ,2-\4__ #J*** #_B.&^*__
M $CQ^'W_ (D;XI_^=11_Q'#?%?\ Z1X_#[_Q(WQ3_P#.HHHH /\ B.&^*_\
MTCQ^'W_B1OBG_P"=11_Q'#?%?_I'C\/O_$C?%/\ \ZBBB@ _XCAOBO\ ](\?
MA]_XD;XI_P#G44?\1PWQ7_Z1X_#[_P 2-\4__.HHHH /^(X;XK_](\?A]_XD
M;XI_^=11_P 1PWQ7_P"D>/P^_P#$C?%/_P ZBBB@ _XCAOBO_P!(\?A]_P")
M&^*?_G44?\1PWQ7_ .D>/P^_\2-\4_\ SJ*** #_ (CAOBO_ -(\?A]_XD;X
MI_\ G44?\1PWQ7_Z1X_#[_Q(WQ3_ /.HHHH /^(X;XK_ /2/'X??^)&^*?\
MYU%'_$<-\5_^D>/P^_\ $C?%/_SJ*** #_B.&^*__2/'X??^)&^*?_G44?\
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M_P ZBBB@ _XCAOBO_P!(\?A]_P")&^*?_G44?\1PWQ7_ .D>/P^_\2-\4_\
MSJ*** #_ (CAOBO_ -(\?A]_XD;XI_\ G44?\1PWQ7_Z1X_#[_Q(WQ3_ /.H
MHHH /^(X;XK_ /2/'X??^)&^*?\ YU%'_$<-\5_^D>/P^_\ $C?%/_SJ***
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M_G44?\1PWQ7_ .D>/P^_\2-\4_\ SJ*** #_ (CAOBO_ -(\?A]_XD;XI_\
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9Z2W\GB:6)K'^SF2V2TC;[5<-*Y4HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vcyt-12312019x10k.htm": {
   "axisCustom": 1,
   "axisStandard": 31,
   "contextCount": 257,
   "dts": {
    "calculationLink": {
     "local": [
      "vcyt-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vcyt-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "vcyt-12312019x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vcyt-20191231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vcyt-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vcyt-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 611,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 85,
    "http://www.veracyte.com/20191231": 3,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 93
   },
   "keyCustom": 64,
   "keyStandard": 372,
   "memberCustom": 37,
   "memberStandard": 43,
   "nsprefix": "vcyt",
   "nsuri": "http://www.veracyte.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.veracyte.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Net Loss Per Share",
     "role": "http://www.veracyte.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Business Combination",
     "role": "http://www.veracyte.com/role/BusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Balance Sheet Components",
     "role": "http://www.veracyte.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Fair Value Measurements",
     "role": "http://www.veracyte.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.veracyte.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Debt",
     "role": "http://www.veracyte.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Stockholders' Equity",
     "role": "http://www.veracyte.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Stock Incentive Plans",
     "role": "http://www.veracyte.com/role/StockIncentivePlans",
     "shortName": "Stock Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermContractsOrProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Thyroid Cytopathology Partners",
     "role": "http://www.veracyte.com/role/ThyroidCytopathologyPartners",
     "shortName": "Thyroid Cytopathology Partners",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermContractsOrProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - Income Taxes",
     "role": "http://www.veracyte.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Balance Sheets",
     "role": "http://www.veracyte.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - 401(k) Plan",
     "role": "http://www.veracyte.com/role/A401KPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120100 - Disclosure - Selected Quarterly Financial Data (Unaudited)",
     "role": "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited",
     "shortName": "Selected Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.veracyte.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Business Combination (Tables)",
     "role": "http://www.veracyte.com/role/BusinessCombinationTables",
     "shortName": "Business Combination (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.veracyte.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Debt (Tables)",
     "role": "http://www.veracyte.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.veracyte.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Stock Incentive Plans (Tables)",
     "role": "http://www.veracyte.com/role/StockIncentivePlansTables",
     "shortName": "Stock Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.veracyte.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - Organization and Description of Business (Details)",
     "role": "http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)",
     "role": "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails",
     "shortName": "Summary of Significant Accounting Policies - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "D2017Q4Nov_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromLongTermLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vcyt:NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited",
      "reportCount": 1,
      "unique": true,
      "unitRef": "financial_institution",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Summary of Significant Accounting Policies - Credit Risk, Restricted Cash, and Allowance for Doubtful Accounts (Details)",
     "role": "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
     "shortName": "Summary of Significant Accounting Policies - Credit Risk, Restricted Cash, and Allowance for Doubtful Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vcyt:NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited",
      "reportCount": 1,
      "unique": true,
      "unitRef": "financial_institution",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets, Bonus Accruals, and Revenue Recognition (Details)",
     "role": "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies - Intangible Assets, Bonus Accruals, and Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "D2018Q4Dec28",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vcyt:DevelopmentPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Summary of Significant Accounting Policies - Diagnostic Development Agreement with Johnson & Johnson (Details)",
     "role": "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
     "shortName": "Summary of Significant Accounting Policies - Diagnostic Development Agreement with Johnson & Johnson (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "D2018Q4Dec28",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vcyt:DevelopmentPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)",
     "role": "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Net Loss Per Share (Details)",
     "role": "http://www.veracyte.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Business Combination (Details)",
     "role": "http://www.veracyte.com/role/BusinessCombinationDetails",
     "shortName": "Business Combination (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Business Combination - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "Business Combination - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Business Combination - Schedule of Identifiable Acquisition-Related Intangibles (Details)",
     "role": "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails",
     "shortName": "Business Combination - Schedule of Identifiable Acquisition-Related Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - Business Combination - Pro forma financial information (Details)",
     "role": "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
     "shortName": "Business Combination - Pro forma financial information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Balance Sheet Components - Finite-lived Intangible Assets (Details)",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
     "shortName": "Balance Sheet Components - Finite-lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405405 - Disclosure - Balance Sheet Components - Future Amortization (Details)",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails",
     "shortName": "Balance Sheet Components - Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405406 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.veracyte.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2016Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2016Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Commitments and Contingencies - Operating Lease (Details)",
     "role": "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails",
     "shortName": "Commitments and Contingencies - Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Debt - Loan and Security Agreement (Details)",
     "role": "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
     "shortName": "Debt - Loan and Security Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Debt - Schedule of Loan and Security Agreement (Details)",
     "role": "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails",
     "shortName": "Debt - Schedule of Loan and Security Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Debt - Credit Agreement (Details)",
     "role": "http://www.veracyte.com/role/DebtCreditAgreementDetails",
     "shortName": "Debt - Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember",
      "decimals": "INF",
      "lang": null,
      "name": "vcyt:NumberOfTermLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "term_loan",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.veracyte.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.veracyte.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "lang": null,
      "name": "vcyt:VotingRightsForEachShareOfStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Stock Incentive Plans - Stock Option Plans (Details)",
     "role": "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
     "shortName": "Stock Incentive Plans - Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Stock Incentive Plans - Activity Under Stock Option Plans (Details)",
     "role": "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
     "shortName": "Stock Incentive Plans - Activity Under Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Stock Incentive Plans - Additional Information (Details)",
     "role": "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
     "shortName": "Stock Incentive Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Stock Incentive Plans Stock Incentive Plans - ESPP (Details)",
     "role": "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
     "shortName": "Stock Incentive Plans Stock Incentive Plans - ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003501 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Stock Incentive Plans - Stock-based Compensation (Details)",
     "role": "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
     "shortName": "Stock Incentive Plans - Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vcyt:OtherIncomeRentReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414401 - Disclosure - Thyroid Cytopathology Partners (Details)",
     "role": "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails",
     "shortName": "Thyroid Cytopathology Partners (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vcyt:OtherIncomeRentReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415402 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415403 - Disclosure - Income Taxes - Tax Provision (Details)",
     "role": "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails",
     "shortName": "Income Taxes - Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415405 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)",
     "role": "http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails",
     "shortName": "Income Taxes - Uncertain Tax Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:IncomeTaxExaminationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Income Taxes - Income Tax Examination (Details)",
     "role": "http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails",
     "shortName": "Income Taxes - Income Tax Examination (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vcyt:IncomeTaxExaminationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416401 - Disclosure - 401(k) Plan (Details)",
     "role": "http://www.veracyte.com/role/A401KPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Organization and Description of Business",
     "role": "http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r52",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r132",
      "r199",
      "r204",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r130",
      "r199",
      "r202",
      "r358",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r131",
      "r199",
      "r203",
      "r360",
      "r363",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r133",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASU 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGross": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r22",
      "r134",
      "r135",
      "r200"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r33",
      "r170"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated Useful life (In Years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r82",
      "r165"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Intangible asset amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r185",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r213",
      "r236",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense (in dollars)"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r65",
      "r82",
      "r315"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization and write-off of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r82",
      "r317"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r159",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Shares of common stock subject to outstanding options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r129",
      "r338",
      "r350"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r51"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsLeasedToOthersMember": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable property, plant or equipment held for lease to others under contractual agreements meeting the criteria for operating lease classification.",
        "label": "Assets Leased to Others [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "AssetsLeasedToOthersMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r214",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansTables",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Pro forma financial information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r290",
      "r291",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Cash paid in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Shares issued for purchase consideration for a business combination"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r289",
      "r292",
      "r296"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Acquisition related contingent consideration",
        "verboseLabel": "Acquisition related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Total identifiable intangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r91",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r100",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r30",
      "r84"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r85",
      "r91",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r85",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r84",
      "r90"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r313"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassificationOfVariableInterestEntityDomain": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categorization of Variable Interest Entities (VIE) for consolidation and (or) disclosure purposes, whether individually or in aggregate, by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.",
        "label": "Variable Interest Entity, Classification [Domain]",
        "terseLabel": "Variable Interest Entity, Classification [Domain]"
       }
      }
     },
     "localname": "ClassificationOfVariableInterestEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r174",
      "r344",
      "r356"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.veracyte.com/role/StockholdersEquityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Total number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Par value of shares of common stock (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized, 49,625,341 and 40,863,202 shares issued and outstanding as of December 31, 2019 and 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss and comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r310",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r310",
      "r311",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r310",
      "r311",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties",
        "verboseLabel": "Concentration Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r119",
      "r120",
      "r310",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r116",
      "r119",
      "r120",
      "r121",
      "r310",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r310",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r195",
      "r196",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Contract with customer, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostDirectMaterial": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of material used for good produced and service rendered.",
        "label": "Cost, Direct Material",
        "terseLabel": "Cost, Direct Material"
       }
      }
     },
     "localname": "CostDirectMaterial",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of testing revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of testing revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Gross receivables concentration risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Revenue concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Prosigna customer relationships",
        "verboseLabel": "Prosigna customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r339",
      "r342",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r41",
      "r179",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Periodic payment terms, balloon payment to be paid"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r97",
      "r186",
      "r189",
      "r190",
      "r191",
      "r315",
      "r316",
      "r318",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r315",
      "r318"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r18",
      "r19",
      "r267",
      "r340",
      "r348"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueLeasesNetNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of deferred lease income, classified as noncurrent. Includes, but is not limited to, amount paid in advance by lessee.",
        "label": "Deferred Lease Income, after Accumulated Amortization, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueLeasesNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r247",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "NanoString intangibles and goodwill"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossNoncurrent": {
     "auth_ref": [
      "r253",
      "r254",
      "r268"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsDeferredIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences and carryforwards, classified as noncurrent.",
        "label": "Deferred Tax Assets, Gross, Noncurrent",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r245",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r245",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r254",
      "r270"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r246",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "negatedLabel": "In-process research and development"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r247",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer contributions to the plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/A401KPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r127"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue recognized when cash is received and on an accrual basis"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r15",
      "r17",
      "r341",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share, basic and diluted (in dollars per share)",
        "verboseLabel": "Net income (loss) per common share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r242",
      "r255"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "negatedLabel": "Share-based compensation excess tax benefit amount",
        "terseLabel": "Stock based compensation - PSU/RSU/NQSQ"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which unrecognized compensation expense expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense (in dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansTables",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r304",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r304",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r91",
      "r308",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r322",
      "r325",
      "r328"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtInterestExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on capital lease"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r321",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease, liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - finance lease"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r322",
      "r325",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "verboseLabel": "Capital leases, depreciation expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted Average Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r160",
      "r162",
      "r164",
      "r167",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r164",
      "r335"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross [Abstract]",
        "terseLabel": "Finite-lived Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r160",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount",
        "verboseLabel": "Finite-lived intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
      "http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails",
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "(Gain) loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r153",
      "r155"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r91",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill, Impaired [Abstract]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r82",
      "r154",
      "r156",
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r82",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Finite-lived intangible assets, impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r102",
      "r336",
      "r345",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedLabel": "Pretax loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income tax examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r259",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r128",
      "r277"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation of tax expense computed at the statutory federal rate and the Company's tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r91",
      "r251",
      "r252",
      "r265",
      "r266",
      "r271",
      "r278",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r250",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r249",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Rate differential impact - Tax Cuts and Jobs Act"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r93",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal taxes at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Incentive stock options"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r93",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax (net of federal benefit)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r79",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for tax"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Supplies"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Rollforward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r91",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Finite-lived Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r58",
      "r126",
      "r314",
      "r317",
      "r346"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r65",
      "r180"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Nominal debt interest"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of interest expense on debt"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r75",
      "r78",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest on debt"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r49",
      "r152"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments under non-cancelable operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r343",
      "r354"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r36",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r36",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermContractsOrProgramsDisclosureTextBlock": {
     "auth_ref": [
      "r53",
      "r194",
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term contracts or programs.",
        "label": "Long-term Contracts or Programs Disclosure [Text Block]",
        "terseLabel": "Thyroid Cytopathology Partners"
       }
      }
     },
     "localname": "LongTermContractsOrProgramsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartners"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r178",
      "r342",
      "r352"
     ],
     "calculation": {
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net debt obligation"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r99",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r102",
      "r104"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplementary cash flow information of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments (in segments)"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (loss) from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Facilities rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "totalLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability",
        "verboseLabel": "Less: short-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating lease"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future minimum lease payments under non-cancelable operating leases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r39"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Conversion of accrued interest to long-term debt"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r69",
      "r294"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/A401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r214",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from issuance of common stock in a public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from the issuance of long-term debt, net of debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received for the settlement of litigation during the current period.",
        "label": "Proceeds from Legal Settlements",
        "terseLabel": "Proceeds from legal settlement regarding short-swing profits"
       }
      }
     },
     "localname": "ProceedsFromLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r72",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Proceeds from long-term lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r239"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options and employee stock purchases"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue",
        "verboseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r33",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r32",
      "r169"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r171",
      "r355"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails",
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r91",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of the beginning and ending amount of unrecognized tax benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedTerseLabel": "Payment of financial lease liability"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Payment of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.veracyte.com/role/DebtCreditAgreementDetails",
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r244",
      "r367"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r91",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r13",
      "r84",
      "r90",
      "r364"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "netLabel": "Restricted cash",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Long term deposit consisting of letter of credit serving as security for lease"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restricted Cash and Investments [Abstract]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareDetails",
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r192",
      "r353"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenue",
        "terseLabel": "Total revenue",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition and Cost of Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition [Abstract]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, amount of remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues [Abstract]"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r326",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liability arising from obtaining right-of-use assets - operating lease at beginning of period"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of net debt obligation"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of significant components of the Company's deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of tax expense computed at the statutory federal rate and the Company's tax expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r213",
      "r235",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r213",
      "r235",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of identifiable acquisition-related intangibles"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r160",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r33",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of selected quarterly financial data (unaudited)"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of fair value of assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r214",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r220",
      "r227",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of activity under the Company's stock option plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of assumptions used to calculate estimated grant date fair value of stock options using the Black-Scholes option-pricing valuation model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r45",
      "r96",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r264",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the beginning and ending amount of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future amortization"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r116",
      "r119",
      "r120",
      "r121",
      "r310",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of the Company's third-party payers as a percentage of total"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelectedQuarterlyFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Selected Quarterly Financial Information [Abstract]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Weighted-average volatility, high end of range (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Weighted-average volatility, low end of range (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, high end of range (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, low end of range (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock incentive plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional options authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.veracyte.com/role/StockholdersEquityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "terseLabel": "Shares available for issuance (in shares)",
        "verboseLabel": "Number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options vested and exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)",
        "terseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "negatedLabel": "Granted (in shares)",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options to purchase common stock granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Balance (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r222",
      "r238"
     ],
     "calculation": {
      "http://www.veracyte.com/role/StockholdersEquityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at beginning of the period (in shares)",
        "terseLabel": "Options issued and outstanding (in shares)",
        "verboseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest at the end of the period (in dollars)",
        "verboseLabel": "Intrinsic value of stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum annual increase in outstanding shares on the last day of the immediately preceding fiscal year (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r212",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockIncentivePlansTables",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based compensation award, tranche one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Share-based compensation award, tranche three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based compensation award, tranche two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r91",
      "r214",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Term of options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r233",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Weighted-average expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options vested and exercisable at the end of the period (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options vested and exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "verboseLabel": "Total estimated grant date fair value of options to purchase common stock vested (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Minimum purchase price as a percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software, including software developed for internal use"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r20",
      "r21",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r20",
      "r21",
      "r185",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock on employee stock purchase plan (ESPP) (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r185",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued during the period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r185",
      "r192",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r47",
      "r185",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r20",
      "r21",
      "r185",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (ESPP)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r141"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets",
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsDeferredIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Tax Credit Carryforward, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts for Product Sales"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r248",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits, end of period",
        "periodStartLabel": "Unrecognized tax benefits, beginning of period",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Gross decreases\u2014tax position in prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest expense or penalties related to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases\u2014current period tax position"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases\u2014tax position in prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis": {
     "auth_ref": [
      "r298",
      "r299",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of Variable Interest Entity (VIE).",
        "label": "Variable Interest Entities [Axis]",
        "terseLabel": "Variable Interest Entities [Axis]"
       }
      }
     },
     "localname": "VariableInterestEntitiesByClassificationOfEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "verboseLabel": "Thyroid Cytopathology Partners"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Thyroid Cytopathology Partners"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares use to compute net loss per common share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_AZCollaborationLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AZ Collaboration License [Member]",
        "label": "AZ Collaboration License [Member]",
        "terseLabel": "LymphMark product technology",
        "verboseLabel": "LymphMark product technology"
       }
      }
     },
     "localname": "AZCollaborationLicenseMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation ESPP",
        "terseLabel": "Stock-based compensation expense (ESPP)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.",
        "label": "Adjustments to Additional Paid in Capital Share Based Compensation Employee",
        "terseLabel": "Stock-based compensation expense (employee)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.",
        "label": "Adjustments to Additional Paid in Capital Share Based Compensation Non Employee",
        "terseLabel": "Stock-based compensation expense (non-employee)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_AutomaticRenewalPeriodContractAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Automatic Renewal Period, Contract Agreement",
        "label": "Automatic Renewal Period, Contract Agreement",
        "terseLabel": "Automatic renewal period of contract agreement"
       }
      }
     },
     "localname": "AutomaticRenewalPeriodContractAgreement",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_BiopharmaceuticalCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharmaceutical Company [Member]",
        "label": "Biopharmaceutical Company [Member]",
        "terseLabel": "Biopharmaceutical Company"
       }
      }
     },
     "localname": "BiopharmaceuticalCompanyMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_BiopharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharmaceutical [Member]",
        "label": "Biopharmaceutical [Member]",
        "terseLabel": "Biopharmaceutical revenue"
       }
      }
     },
     "localname": "BiopharmaceuticalMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_BusinessCombinationContingentConsiderationCashtobePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Cash to be Paid",
        "label": "Business Combination, Contingent Consideration, Cash to be Paid",
        "terseLabel": "Additional cash to be paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationCashtobePaid",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_CommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Common Stock [Abstract]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockAbstract",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of additional common shares reserved for future issuance under the plan.",
        "label": "Common Stock Capital Additional Shares Reserved for Future Issuance",
        "terseLabel": "Number of additional shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalAdditionalSharesReservedForFutureIssuance",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Components of Deferred Tax Assets Non Current [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsNonCurrentAbstract",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Components of Deferred Tax Liabilities Non Current [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_ConcentrationRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Concentrations of Credit Risk and Other Risks and Uncertainties",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskAbstract",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.",
        "label": "Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vcyt_ContractAgreementConditionalAccountsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Agreement, Conditional, Accounts Receivable",
        "label": "Contract Agreement, Conditional, Accounts Receivable",
        "terseLabel": "Accounts receivable, current"
       }
      }
     },
     "localname": "ContractAgreementConditionalAccountsReceivable",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_ContractAgreementFeePercentageOfCashCollections": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Agreement Fee Percentage Of Cash Collections",
        "label": "Contract Agreement Fee Percentage Of Cash Collections",
        "terseLabel": "Percent of collections"
       }
      }
     },
     "localname": "ContractAgreementFeePercentageOfCashCollections",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vcyt_ContractAgreementReceivableForServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Agreement Receivable For Services",
        "label": "Contract Agreement Receivable For Services",
        "terseLabel": "Contract agreement receivable for services"
       }
      }
     },
     "localname": "ContractAgreementReceivableForServices",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DebtInstrumentEndOfTermInterestObligationAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/DebtInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument End Of Term, Interest Obligation Amount",
        "label": "Debt Instrument End Of Term, Interest Obligation Amount",
        "terseLabel": "End-of-term debt obligation interest"
       }
      }
     },
     "localname": "DebtInstrumentEndOfTermInterestObligationAmount",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DebtInstrumentEndOfTermPaymentInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, End Of Term Payment, Interest Amount",
        "label": "Debt Instrument, End Of Term Payment, Interest Amount",
        "terseLabel": "End-of-term debt obligation"
       }
      }
     },
     "localname": "DebtInstrumentEndOfTermPaymentInterestAmount",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DebtInstrumentFixedRatePercentagePaidInCash": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate for which Company may elect to pay interest in cash.",
        "label": "Debt Instrument Fixed Rate Percentage Paid In Cash",
        "terseLabel": "Fixed rate percentage paid in cash"
       }
      }
     },
     "localname": "DebtInstrumentFixedRatePercentagePaidInCash",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "vcyt_DebtInstrumentInterestPaidInKindPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of interest rate for which interest is paid-in-kind by adding paid-in-kind interest to the outstanding principal amounts of the Term Loans.",
        "label": "Debt Instrument Interest Paid-In-Kind Percentage",
        "terseLabel": "Interest paid-in-kind percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaidInKindPercentage",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "vcyt_DebtInstrumentNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of installments for payment of the debt.",
        "label": "Debt Instrument Number of Installments",
        "terseLabel": "Number of installments (in installments)"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfInstallments",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of prepayment premium for prepayment made on or prior to March 31, 2018.",
        "label": "Debt Instrument Penalty Percentage On Prepayment Period One",
        "terseLabel": "Prepayment premium"
       }
      }
     },
     "localname": "DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "vcyt_DebtInstrumentPrepaymentPremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of prepayment premium waived.",
        "label": "Debt Instrument, Prepayment Premium",
        "terseLabel": "Prepayment premium"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremium",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DebtPaymentTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Debt Payment Tranche [Axis]",
        "label": "Debt Payment Tranche [Domain]",
        "terseLabel": "Debt Payment Tranche [Domain]"
       }
      }
     },
     "localname": "DebtPaymentTrancheDomain",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DebtPrepaymentTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Prepayment Tranche [Axis]",
        "label": "Debt Prepayment Tranche [Axis]",
        "terseLabel": "Debt Prepayment Tranche [Axis]"
       }
      }
     },
     "localname": "DebtPrepaymentTrancheAxis",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_DebtPrepaymentTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Prepayment Tranche One [Member]",
        "label": "Debt Prepayment Tranche One [Member]",
        "terseLabel": "Debt prepayment tranche one"
       }
      }
     },
     "localname": "DebtPrepaymentTrancheOneMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DebtPrepaymentTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Prepayment Tranche Three [Member]",
        "label": "Debt Prepayment Tranche Three [Member]",
        "terseLabel": "Debt prepayment tranche three"
       }
      }
     },
     "localname": "DebtPrepaymentTrancheThreeMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DebtPrepaymentTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Prepayment Tranche Two [Member]",
        "label": "Debt Prepayment Tranche Two [Member]",
        "terseLabel": "Debt prepayment tranche two"
       }
      }
     },
     "localname": "DebtPrepaymentTrancheTwoMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument, End of Term Payment Interest Amount and Prepayment Penalty",
        "label": "Debt instrument, End of Term Payment Interest Amount and Prepayment Penalty",
        "terseLabel": "Interest on end-of-term debt obligation and prepayment penalty"
       }
      }
     },
     "localname": "DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-current accruals, deferred rent and other reserves and accruals not separately disclosed.",
        "label": "Deferred Tax Assets Accruals, Deferred Rent and Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccrualsDeferredRentAndOther",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible research and development tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DeferredTaxLiabilitiesRightofUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right of Use Assets",
        "label": "Deferred Tax Liabilities, Right of Use Assets",
        "negatedTerseLabel": "ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightofUseAssets",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DepreciationandAmortizationofTangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Depreciation and Amortization of Tangible Assets",
        "label": "Depreciation and Amortization of Tangible Assets",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationandAmortizationofTangibleAssets",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DevelopedProductTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developed Product Technology [Member]",
        "label": "Developed Product Technology [Member]",
        "terseLabel": "Prosigna product technology",
        "verboseLabel": "Prosigna product technology"
       }
      }
     },
     "localname": "DevelopedProductTechnologyMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DevelopmentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Programs",
        "label": "Development Programs",
        "terseLabel": "Development programs"
       }
      }
     },
     "localname": "DevelopmentPrograms",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer Compensation, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer Compensation, Amount",
        "terseLabel": "Non deductible officers' compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus related compensation.",
        "label": "Employee And Non Employee Stock Option Excluding Bonus Compensation [Member]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_EmployeeAndNonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Non Employee Stock Option [Member]",
        "terseLabel": "Shares of common stock subject to outstanding options"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeStockOptionMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerShareDetails",
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_EmployeeStockOptionExcludingBonusCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus compensation.",
        "label": "Employee Stock Option Excluding Bonus Compensation [Member]",
        "terseLabel": "Stock-based Compensation, employees"
       }
      }
     },
     "localname": "EmployeeStockOptionExcludingBonusCompensationMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "FinanceLeaseRightofUseAssetAccumulatedAmortization",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Capital leased assets"
       }
      }
     },
     "localname": "FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_FulfillmentofObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fulfillment of Obligations [Member]",
        "label": "Fulfillment of Obligations [Member]",
        "terseLabel": "Fulfillment of Obligations"
       }
      }
     },
     "localname": "FulfillmentofObligationsMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the lease for headquarters and laboratory space in South San Francisco, California that expires March 2026.",
        "label": "Headquarters And Laboratory Facilities South San Francisco Lease Two [Member]",
        "terseLabel": "Headquarters and laboratory facilities, South San Francisco, Lease signed in April 2015"
       }
      }
     },
     "localname": "HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to incentive stock options (ISOs).",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "ISO"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_IncomeTaxExaminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which will remain open for examination by tax authorities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Income Tax Examination Period",
        "terseLabel": "Income tax examination period"
       }
      }
     },
     "localname": "IncomeTaxExaminationPeriod",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent.",
        "label": "Increase (Decrease) in Accrued Liabilities and Deferred Rent",
        "terseLabel": "Accrued liabilities and deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Assets and Liabilities",
        "label": "Increase (Decrease) in Operating Lease Assets and Liabilities",
        "negatedTerseLabel": "Right-of-use assets - operating lease and operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseinOperatingLeaseAssetsandLiabilities",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_InitialTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the initial term loan.",
        "label": "Initial Term Loan [Member]",
        "terseLabel": "Initial Term Loan"
       }
      }
     },
     "localname": "InitialTermLoanMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_JohnsonandJohnsonServicesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Johnson and Johnson Services, Inc. [Member]",
        "label": "Johnson and Johnson Services, Inc. [Member]",
        "terseLabel": "Johnson and Johnson Services, Inc."
       }
      }
     },
     "localname": "JohnsonandJohnsonServicesInc.Member",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_LaboratoryFacilitiesAustinTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the lease for laboratory facilities in Austin, Texas that expires July 2018.",
        "label": "Laboratory Facilities Austin Texas [Member]",
        "terseLabel": "Laboratory facilities, Austin, Texas"
       }
      }
     },
     "localname": "LaboratoryFacilitiesAustinTexasMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Legal Settlement Regarding Short-Swing Profits, Net Of Tax",
        "label": "Legal Settlement Regarding Short-Swing Profits, Net Of Tax",
        "terseLabel": "Legal settlement from short-swing profits, net of tax"
       }
      }
     },
     "localname": "LegalSettlementRegardingShortSwingProfitsNetOfTax",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of space leased under the terms of the agreement.",
        "label": "Lessee Leasing Arrangements, Operating Leases, Space Leased",
        "terseLabel": "Amount of space leased (in square feet)"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesSpaceLeased",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "vcyt_LiquidityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liquidity [Line Items]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityLineItems",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_LiquidityRequirementMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liquidity Requirement, Minimum",
        "label": "Liquidity Requirement, Minimum",
        "terseLabel": "Minimum requirement liability"
       }
      }
     },
     "localname": "LiquidityRequirementMinimum",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Medicare, a significant third-party payer.",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NCounterFLEXDxLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "nCounter FLEX Dx License [Member]",
        "label": "nCounter FLEX Dx License [Member]",
        "terseLabel": "nCounter FLEX Dx license",
        "verboseLabel": "nCounter FLEX Dx license"
       }
      }
     },
     "localname": "NCounterFLEXDxLicenseMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NanoStringMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NanoString [Member]",
        "label": "NanoString [Member]",
        "terseLabel": "NanoString",
        "verboseLabel": "NanoString"
       }
      }
     },
     "localname": "NanoStringMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BusinessCombinationDetails",
      "http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Stock-based Compensation, non-employees",
        "verboseLabel": "Non Employee Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NonStatutoryStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to non statutory stock options (NSOs).",
        "label": "Non Statutory Stock Options [Member]",
        "terseLabel": "NSO"
       }
      }
     },
     "localname": "NonStatutoryStockOptionsMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash or Part Noncash Acquisition, Deferred Purchase Consideration",
        "label": "Noncash or Part Noncash Acquisition, Deferred Purchase Consideration",
        "terseLabel": "Deferred purchase consideration for a business combination"
       }
      }
     },
     "localname": "NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity.",
        "label": "Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited",
        "terseLabel": "Number of major financial institutions with which the company's cash and cash equivalents are deposited (in financial institutions)"
       }
      }
     },
     "localname": "NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vcyt_NumberOfTermLoans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of term loans available to the Company.",
        "label": "Number Of Term Loans",
        "terseLabel": "Number of term loans (in term loans)"
       }
      }
     },
     "localname": "NumberOfTermLoans",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vcyt_OtherIncomeRentReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement.",
        "label": "Other Income Rent Reimbursement",
        "terseLabel": "Reduction to rent expense for TCP's portion of costs for shared space"
       }
      }
     },
     "localname": "OtherIncomeRentReimbursement",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_OtherStatesNotSeparatelyDisclosedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other States, Not Separately Disclosed [Member]",
        "label": "Other States, Not Separately Disclosed [Member]",
        "terseLabel": "Other state income tax purposes"
       }
      }
     },
     "localname": "OtherStatesNotSeparatelyDisclosedMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_OutsideDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonemployee serving on the board of directors (who collectively have responsibility for governing the entity).",
        "label": "Outside Director [Member]",
        "terseLabel": "Outside director"
       }
      }
     },
     "localname": "OutsideDirectorMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to outside director serving as a member of Board of Directors for at least six months.",
        "label": "Outside Director Serving As Member Of Board Of Directors For At Least Six Months [Member]",
        "terseLabel": "Outside director serving as a member of Board of Directors for at least six months"
       }
      }
     },
     "localname": "OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to outside director, who was not previously an employee.",
        "label": "Outside Director Who Was Not Previously Employee [Member]",
        "terseLabel": "Outside director who was not previously an employee"
       }
      }
     },
     "localname": "OutsideDirectorWhoWasNotPreviouslyEmployeeMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_OvernightRepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Overnight Repurchase Agreements [Member]",
        "label": "Overnight Repurchase Agreements [Member]",
        "terseLabel": "Overnight Repurchase Agreements"
       }
      }
     },
     "localname": "OvernightRepurchaseAgreementsMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_PaymentOfEndOfTermObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the payment of the end-of-term obligation and prepayment penalty.",
        "label": "Payment of End of Term Obligation",
        "negatedLabel": "Payment of end-of-term debt obligation and prepayment penalty",
        "terseLabel": "Prepayment premium"
       }
      }
     },
     "localname": "PaymentOfEndOfTermObligation",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_PerceptaTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percepta Technology [Member]",
        "label": "Percepta Technology [Member]",
        "terseLabel": "Percepta technology"
       }
      }
     },
     "localname": "PerceptaTechnologyMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_Perceptav.2andNassaRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percepta v.2 and Nassa Risk [Member]",
        "label": "Percepta v.2 and Nassa Risk [Member]",
        "terseLabel": "Percepta v.2 and Nassa Risk"
       }
      }
     },
     "localname": "Perceptav.2andNassaRiskMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_PrepaymentPenalty": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/DebtInterestExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepayment penalty.",
        "label": "Prepayment Penalty",
        "terseLabel": "Debt prepayment penalty"
       }
      }
     },
     "localname": "PrepaymentPenalty",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_ProvisionofDataMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provision of Data [Member]",
        "label": "Provision of Data [Member]",
        "terseLabel": "Provision of Data"
       }
      }
     },
     "localname": "ProvisionofDataMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_RevenueRecognizedOnAccrualBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognized during the period on an accrual basis.",
        "label": "Revenue Recognized On Accrual Basis",
        "terseLabel": "Revenue recognized on an accrual basis"
       }
      }
     },
     "localname": "RevenueRecognizedOnAccrualBasis",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_RevenueRecognizedOnAccrualBasisPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognized On Accrual Basis, Percentage",
        "label": "Revenue Recognized On Accrual Basis, Percentage",
        "terseLabel": "Revenue recognized on accrual basis, percentage"
       }
      }
     },
     "localname": "RevenueRecognizedOnAccrualBasisPercentage",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vcyt_RevenueRecognizedReceivedInCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognized during the period based on cash receipts.",
        "label": "Revenue Recognized Received In Cash",
        "terseLabel": "Revenue recognized on a cash basis"
       }
      }
     },
     "localname": "RevenueRecognizedReceivedInCash",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_RevenueRecognizedReceivedInCashPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognized Received In Cash, Percentage",
        "label": "Revenue Recognized Received In Cash, Percentage",
        "terseLabel": "Revenue recognized received in cash, percentage"
       }
      }
     },
     "localname": "RevenueRecognizedReceivedInCashPercentage",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Amount, Per Quarter",
        "label": "Revenue, Remaining Performance Obligation, Amount, Per Quarter",
        "terseLabel": "Revenue, quarterly amount of remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationAmountPerQuarter",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_SalesRevenueGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, before deducting sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Sales Revenue Gross [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueGrossMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of number of common shares reserved for future issuance.",
        "label": "Schedule of Common Stock Capital Shares Reserved for Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of reserved shares of common stock for issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vcyt_ServicesAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Thyroid Cytopathology Partners"
       }
      }
     },
     "localname": "ServicesAgreementAbstract",
     "nsuri": "http://www.veracyte.com/20191231",
     "xbrltype": "stringItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration period of award after termination of service, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Award Expiration Period After Termination",
        "terseLabel": "Expiration period after termination of service"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum fair market value of shares an employee can purchase under the plan per calendar year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Value of Shares Per Employee",
        "terseLabel": "Maximum fair market value of shares an employee can purchase per calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Offering Period, Maximum",
        "terseLabel": "Maximum offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted to each individual as an annual grant.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Annual Grants",
        "terseLabel": "Shares granted as annual grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted to each individual as an initial grant.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Initial Grants",
        "terseLabel": "Shares granted as initial grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Voting power of all classes of stock, as a percent, of person owning stock as threshold for option terms under the entity's stock option plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Percentage of Voting Power of All Classes of Stock",
        "terseLabel": "Voting power of person owning stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the period for which director has to serve as board of director to receive grant to purchase shares.",
        "label": "Share Based Compensation Arrangement by Share based Payment Award Period for Which Director Has to Serve as Board of Director to Receive Grant to Purchase Shares",
        "terseLabel": "Period for which director has to serve as board of director to receive grant to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The purchase period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the term of options granted to persons owning stock representing specified percentage of voting power of all classes of stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Term of Options Granted to Employees Who Owned Specified Percentage of Class of Stock",
        "terseLabel": "Term of options granted to a person owning stock representing more than 10% of voting power of all classes of stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of share-based compensation awards after one year from date of grant.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Award Vesting Rights Percentage Year One",
        "terseLabel": "Percentage of award vesting after one year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Option price as a percentage of estimated fair value of shares on date of grant to a person owning stock representing specified percentage of voting power of all classes of stock.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Purchase Price of Stock Percentage for Grants to Persons Who Owned Specified Percentage of Class of Stock",
        "terseLabel": "Option price as a percentage of estimated fair value of shares on date of grant to a person owning stock representing more than 10% of voting power of all classes of stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares, Tax Portion",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares, Tax Portion",
        "terseLabel": "Tax portion of restricted stock units vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period",
        "terseLabel": "Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period",
        "terseLabel": "Issuance of common stock on exercise of stock options and vesting of restricted stock units"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Silicon Valley Bank [Member]",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2013 Stock Incentive Plan (the 2013 Plan).",
        "label": "Stock Incentive Plan2013 [Member]",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued and sold during the period in a private placement.",
        "label": "Stock Issued And Sold During Period, Shares, In Private Placement",
        "terseLabel": "Sale of common stock in a private placement, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares issued and sold during the period in a private placement.",
        "label": "Stock Issued And Sold During Period Value In Private Placement",
        "terseLabel": "Sale of common stock in a private placement, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedAndSoldDuringPeriodValueInPrivatePlacement",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_StockPlan2008Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2008 Stock Plan (the 2008 Plan).",
        "label": "Stock Plan2008 [Member]",
        "terseLabel": "2008 Plan"
       }
      }
     },
     "localname": "StockPlan2008Member",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails",
      "http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_TermContractAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term, Contract Agreement",
        "label": "Term, Contract Agreement",
        "terseLabel": "Contract agreement term"
       }
      }
     },
     "localname": "TermContractAgreement",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_TermOfDebtWithEqualQuarterlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the term of debt with equal quarterly installments.",
        "label": "Term Of Debt With Equal Quarterly Installments",
        "terseLabel": "Term of debt with equal quarterly installments"
       }
      }
     },
     "localname": "TermOfDebtWithEqualQuarterlyInstallments",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vcyt_TestingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Testing [Member]",
        "label": "Testing [Member]",
        "terseLabel": "Testing revenue"
       }
      }
     },
     "localname": "TestingMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to United Healthcare, a significant third-party payer.",
        "label": "United Healthcare [Member]",
        "verboseLabel": "United Healthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_VisiumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Visium Healthcare Partners, LP",
        "label": "Visium [Member]",
        "terseLabel": "Visium"
       }
      }
     },
     "localname": "VisiumMember",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_VotingRightsForEachShareOfStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of votes for each share of stock.",
        "label": "Voting Rights for Each Share of Stock",
        "terseLabel": "Number of votes for each share of stock (in votes)"
       }
      }
     },
     "localname": "VotingRightsForEachShareOfStock",
     "nsuri": "http://www.veracyte.com/20191231",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "integerItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "35",
   "Topic": "605",
   "URI": "http://asc.fasb.org/subtopic&trid=2197326"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919398-209981"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "912",
   "URI": "http://asc.fasb.org/topic&trid=2145070"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r368": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r371": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r372": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r373": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r374": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>257</ContextCount>
  <ElementCount>436</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003501 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Thyroid Cytopathology Partners</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ThyroidCytopathologyPartners</Role>
      <ShortName>Thyroid Cytopathology Partners</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/A401KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/NetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/BusinessCombination</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/BalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/Debt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/StockIncentivePlans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationAndDescriptionOfBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Credit Risk, Restricted Cash, and Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesCreditRiskRestrictedCashAndAllowanceForDoubtfulAccountsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Credit Risk, Restricted Cash, and Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets, Bonus Accruals, and Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsBonusAccrualsAndRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Intangible Assets, Bonus Accruals, and Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Diagnostic Development Agreement with Johnson &amp; Johnson (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesDiagnosticDevelopmentAgreementWithJohnsonJohnsonDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Diagnostic Development Agreement with Johnson &amp; Johnson (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/NetLossPerShareTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombinationDetails</Role>
      <ShortName>Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/BusinessCombinationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Business Combination - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombinationScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combination - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Business Combination - Schedule of Identifiable Acquisition-Related Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombinationScheduleOfIdentifiableAcquisitionRelatedIntangiblesDetails</Role>
      <ShortName>Business Combination - Schedule of Identifiable Acquisition-Related Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Business Combination - Pro forma financial information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BusinessCombinationProFormaFinancialInformationDetails</Role>
      <ShortName>Business Combination - Pro forma financial information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Balance Sheet Components - Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - Balance Sheet Components - Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsFutureAmortizationDetails</Role>
      <ShortName>Balance Sheet Components - Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2405406 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/FairValueMeasurements</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsAndContingenciesOperatingLeaseDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Debt - Loan and Security Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/DebtLoanAndSecurityAgreementDetails</Role>
      <ShortName>Debt - Loan and Security Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Debt - Schedule of Loan and Security Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/DebtScheduleOfLoanAndSecurityAgreementDetails</Role>
      <ShortName>Debt - Schedule of Loan and Security Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Debt - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/DebtCreditAgreementDetails</Role>
      <ShortName>Debt - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/StockholdersEquityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Stock Incentive Plans - Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockIncentivePlansStockOptionPlansDetails</Role>
      <ShortName>Stock Incentive Plans - Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Stock Incentive Plans - Activity Under Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockIncentivePlansActivityUnderStockOptionPlansDetails</Role>
      <ShortName>Stock Incentive Plans - Activity Under Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Stock Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Stock Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Stock Incentive Plans Stock Incentive Plans - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockIncentivePlansStockIncentivePlansEsppDetails</Role>
      <ShortName>Stock Incentive Plans Stock Incentive Plans - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Stock Incentive Plans - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockIncentivePlansStockBasedCompensationDetails</Role>
      <ShortName>Stock Incentive Plans - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Thyroid Cytopathology Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ThyroidCytopathologyPartnersDetails</Role>
      <ShortName>Thyroid Cytopathology Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/ThyroidCytopathologyPartners</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Income Taxes - Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxesTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2415405 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxesUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Income Taxes - Income Tax Examination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxesIncomeTaxExaminationDetails</Role>
      <ShortName>Income Taxes - Income Tax Examination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/A401KPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/A401KPlan</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="vcyt-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="vcyt-12312019x10k.htm">vcyt-12312019x10k.htm</File>
    <File>vcyt-12312019xex1015.htm</File>
    <File>vcyt-12312019xex1016.htm</File>
    <File>vcyt-12312019xex211.htm</File>
    <File>vcyt-12312019xex231.htm</File>
    <File>vcyt-12312019xex311.htm</File>
    <File>vcyt-12312019xex312.htm</File>
    <File>vcyt-12312019xex321.htm</File>
    <File>vcyt-12312019xex322.htm</File>
    <File>vcyt-12312019xex42.htm</File>
    <File>vcyt-20191231.xsd</File>
    <File>vcyt-20191231_cal.xml</File>
    <File>vcyt-20191231_def.xml</File>
    <File>vcyt-20191231_lab.xml</File>
    <File>vcyt-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>businessone.jpg</File>
    <File>businessthree.jpg</File>
    <File>chart-86950a12b9c0e735da0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983314624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Veracyte, Inc. (&#8220;Veracyte&#8221; or the &#8220;Company&#8221;) is a leading genomic diagnostics company that is creating value through innovation. The Company was founded in 2008 with a mission to improve diagnostic accuracy.  Today, the Company's growing menu of tests leverage advances in genomic science and technology to improve care throughout the patient journey, enabling more confident diagnostic, prognostic and treatment decisions in cancer and other challenging diseases. The Company is creating new standards of care by enabling more patients to avoid risks of unnecessary invasive procedures and removing costs from the healthcare system, while speeding the time to diagnosis and treatment decisions. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Veracyte was incorporated in the state of Delaware on August&#160;15, 2006 as Calderome,&#160;Inc. Calderome operated as an incubator until early 2008. On March&#160;4, 2008, the Company changed its name to Veracyte,&#160;Inc.  The Company&#8217;s operations are based in South San Francisco, California and Austin, Texas, and it operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performs its genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in our CLIA-certified laboratory in South San Francisco, California. In December 2019, we announced our acquisition of the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System, as well as the Prosigna breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company offers genomic tests in thyroid cancer; lung cancer; IPF and breast cancer:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Afirma Genomic Sequencing Classifier and Xpression Atlas.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">The Company's Afirma offerings include the Afirma GSC and  Xpression Atlas, to help guide next steps for patients with potentially cancerous thyroid nodules.  The  offerings are intended to provide physicians with clinically actionable results from a single fine needle aspiration, or FNA biopsy. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning, and is used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery. </span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company commercially launched the Afirma Xpression Atlas in 2018 to complement the Afirma GSC. The Xpression Atlas provides physicians with genomic alteration content from the same FNA samples that are used in Afirma GSC testing and may help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. </span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Percepta Genomic Sequencing Classifier.  </span><span style="font-family:inherit;font-size:10pt;">The Percepta classifier improves lung cancer diagnosis by enhancing the performance of diagnostic bronchoscopies, thus identifying more patients with lung nodules who are at low risk of cancer and may avoid further, invasive procedures. This second-generation test was developed on our RNA whole-transcriptome sequencing platform and commercially introduced in June 2019, provides expanded clinical utility by also identifying patients as high risk of cancer so they may obtain faster diagnosis and treatment. The test is built upon foundational "field of injury" science - through which genomic changes associated with lung cancer in current and former smokers can be identified with a simple brushing of a person's airway - without the need to sample the often hard-to-reach nodule directly.&#160;</span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Envisia Genomic Classifier.  </span><span style="font-family:inherit;font-size:10pt;">The Envisia classifier improves diagnosis of IPF by helping physicians better differentiate IPF from other interstitial lung diseases, or ILDs, without the need for surgery. The test identifies the genomic pattern of usual interstitial pneumonia, or UIP, a hallmark of IPF, with high accuracy on patient samples that are obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation. </span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prosigna Breast Cancer Prognostic Gene Signature Assay</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span><span style="font-family:inherit;font-size:10pt;"> The Prosigna test, acquired in December 2019 through our strategic transaction with NanoString, uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test leverages a collection of 50 genes known as the PAM50 gene signature and can provide a breast cancer patient and physician with prognostic score that indicates the probability of cancer recurrence over ten years. Physicians use Prosigna to help guide therapeutic decisions so that patients receive a therapeutic intervention, such as chemotherapy, only if clinically warranted. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s approach also provides multiple opportunities for partnerships with biopharmaceutical companies. In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of the Company's testing services are made available through its clinical reference laboratories located in South San Francisco, California and Austin, Texas.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983330896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,825</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,615</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Software, including software developed for internal use</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,435</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>726</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,013</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,080</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,006</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,940</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had a capital lease for laboratory equipment that went into service in 2017.  The lease was paid off in 2019 and the cost of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> was included in Property and Equipment as of December 31, 2019.  The laboratory equipment had accumulated depreciation of </span><span style="font-family:inherit;font-size:10pt;"><span>$600,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$367,000</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively and depreciation of </span><span style="font-family:inherit;font-size:10pt;"><span>$233,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$232,000</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$135,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and 2017, respectively.   </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finite-lived Intangible Assets, Net</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-live intangible assets consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Amortization Period (Years)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percepta product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,067</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(263</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,617</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>978</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,420</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,019</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.5</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of the Percepta product technology, which was acquired from the acquisition of Allegro in September 2014, began in April 2015 when research and development activities were deemed to be completed and is recognized on a straight-line basis.   Amortization of the Prosigna product technology, Prosigna customer relationships, nCounter FLEX Dx license and LymphMark product technology, which were acquired under an agreement with NanoString, see Note 4 - Business Combination, began in December 2019 and is recognized on a straight-line basis. Amortization of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recognized for the years ended&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated future aggregate amortization expense as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,094</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,094</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,094</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,588</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,019</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811297344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 120,368<span></span>
</td>
<td class="nump">$ 92,008<span></span>
</td>
<td class="nump">$ 71,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of testing revenue</a></td>
<td class="nump">36,077<span></span>
</td>
<td class="nump">33,078<span></span>
</td>
<td class="nump">28,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Cost, Direct Material</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">14,851<span></span>
</td>
<td class="nump">14,820<span></span>
</td>
<td class="nump">13,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">53,691<span></span>
</td>
<td class="nump">41,313<span></span>
</td>
<td class="nump">32,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,029<span></span>
</td>
<td class="nump">23,963<span></span>
</td>
<td class="nump">23,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Intangible asset amortization</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">135,495<span></span>
</td>
<td class="nump">114,241<span></span>
</td>
<td class="nump">98,491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,127)<span></span>
</td>
<td class="num">(22,233)<span></span>
</td>
<td class="num">(26,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(677)<span></span>
</td>
<td class="num">(1,963)<span></span>
</td>
<td class="num">(4,941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(12,599)<span></span>
</td>
<td class="num">(22,999)<span></span>
</td>
<td class="num">(31,003)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (12,599)<span></span>
</td>
<td class="num">$ (22,999)<span></span>
</td>
<td class="num">$ (31,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares use to compute net loss per common share, basic and diluted (in shares)</a></td>
<td class="nump">46,138,177<span></span>
</td>
<td class="nump">37,020,246<span></span>
</td>
<td class="nump">33,925,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_TestingMember', window );">Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 107,355<span></span>
</td>
<td class="nump">$ 91,058<span></span>
</td>
<td class="nump">$ 71,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember', window );">Biopharmaceutical revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,090<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_TestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_TestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807122640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Restated Certificate of Incorporation authorizes the Company to issue </span><span style="font-family:inherit;font-size:10pt;"><span>125,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The holder of each share of common stock shall have </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> vote for each share of stock. The common stockholders are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all series of convertible preferred stock outstanding. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> dividends have been declared as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had reserved shares of common stock for issuance as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units issued and outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,562,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,235,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units available for grant under stock option plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,954,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,571,658</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock available for the Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,690,456</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,116,335</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 7, 2019, the Company issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>6,325,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock in a registered public offering, including&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>825,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$23.25</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company's net proceeds from the offering were approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$137.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$9.2 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, the Company issued and sold </span><span style="font-family:inherit;font-size:10pt;"><span>5,750,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in a registered public offering, including </span><span style="font-family:inherit;font-size:10pt;"><span>750,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares issued and sold upon the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.25</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Company's net proceeds from the offering were </span><span style="font-family:inherit;font-size:10pt;"><span>$55.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting commissions and offering expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6959028448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock subject to outstanding options (in shares)</a></td>
<td class="nump">6,133,190<span></span>
</td>
<td class="nump">6,417,723<span></span>
</td>
<td class="nump">6,261,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember', window );">Shares of common stock subject to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock subject to outstanding options (in shares)</a></td>
<td class="nump">5,394,944<span></span>
</td>
<td class="nump">5,998,163<span></span>
</td>
<td class="nump">6,163,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock subject to outstanding options (in shares)</a></td>
<td class="nump">26,124<span></span>
</td>
<td class="nump">34,869<span></span>
</td>
<td class="nump">34,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock subject to outstanding options (in shares)</a></td>
<td class="nump">712,122<span></span>
</td>
<td class="nump">384,691<span></span>
</td>
<td class="nump">63,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985538224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Credit Risk, Restricted Cash, and Allowance for Doubtful Accounts (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>financial_institution</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationRiskAbstract', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited', window );">Number of major financial institutions with which the company's cash and cash equivalents are deposited (in financial institutions) | financial_institution</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long term deposit consisting of letter of credit serving as security for lease | $</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Revenue concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationRiskAbstract', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Revenue concentration risk | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationRiskAbstract', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Revenue concentration risk | United Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationRiskAbstract', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Gross receivables concentration risk | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationRiskAbstract', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Gross receivables concentration risk | Johnson and Johnson Services, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationRiskAbstract', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Gross receivables concentration risk | United Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationRiskAbstract', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ConcentrationRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ConcentrationRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983322832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of tax expense computed at the statutory federal rate and the Company's tax expense</a></td>
<td class="text">The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company's income tax expense for the periods presented (in thousands of dollars):<div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December, 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal taxes at statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,632</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,825</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State tax (net of federal benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(828</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non deductible officers' compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>409</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock based compensation - PSU/RSU/NQSQ</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incentive stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,994</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(256</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>994</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(996</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(777</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(588</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,164</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,552</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rate differential impact - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Cuts and Jobs Act</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the Company's deferred tax assets and liabilities</a></td>
<td class="text">Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands of dollars):<div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,068</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NanoString intangibles and goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,068</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,918</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55,366</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,997</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(471</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(695</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(983</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,014</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,997</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,161</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,578</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,997</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of reconciliation of the beginning and ending amount of unrecognized tax benefits</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross increases&#8212;tax position in prior period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross decreases&#8212;tax position in prior period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross increases&#8212;current period tax position</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>479</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statute of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985096928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">7.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Facilities rent expense</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum lease payments under non-cancelable operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">2,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">2,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">2,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">2,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">16,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="nump">3,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">12,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: short-term lease liabilities</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 11,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember', window );">Headquarters and laboratory facilities, South San Francisco, Lease signed in April 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased', window );">Amount of space leased (in square feet) | ft&#178;</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=vcyt_LaboratoryFacilitiesAustinTexasMember', window );">Laboratory facilities, Austin, Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of space leased under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_LesseeLeasingArrangementsOperatingLeasesSpaceLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=vcyt_LaboratoryFacilitiesAustinTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=vcyt_LaboratoryFacilitiesAustinTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985073936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Nominal debt interest</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">$ 1,568<span></span>
</td>
<td class="nump">$ 2,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization and write-off of debt discount and issuance costs</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentEndOfTermInterestObligationAmount', window );">End-of-term debt obligation interest</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_PrepaymentPenalty', window );">Debt prepayment penalty</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on capital lease</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">$ 677<span></span>
</td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="nump">$ 4,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentEndOfTermInterestObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument End Of Term, Interest Obligation Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentEndOfTermInterestObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_PrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment penalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_PrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804876304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options to purchase common stock granted (in dollars per share)</a></td>
<td class="nump">$ 11.07<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="nump">$ 4.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised (in dollars)</a></td>
<td class="nump">$ 31,300<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 21.90<span></span>
</td>
<td class="nump">$ 6.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic value of stock options outstanding</a></td>
<td class="nump">$ 77,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">5,562,484<span></span>
</td>
<td class="nump">6,235,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 27.92<span></span>
</td>
<td class="nump">$ 12.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember', window );">Non Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total estimated grant date fair value of options to purchase common stock vested (in dollars)</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic value of stock options outstanding</a></td>
<td class="nump">$ 2,720<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6962054816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 03, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,088<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember', window );">Headquarters and laboratory facilities, South San Francisco, Lease signed in April 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,600<span></span>
</td>
<td class="nump">76,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 | Overnight Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition related contingent consideration</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_BusinessCombinationContingentConsiderationCashtobePaid', window );">Additional cash to be paid</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_BusinessCombinationContingentConsiderationCashtobePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Cash to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_BusinessCombinationContingentConsiderationCashtobePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=vcyt_OvernightRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=vcyt_OvernightRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985142160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 70,420<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,401)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 65,019<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">14 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_PerceptaTechnologyMember', window );">Percepta technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,067)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 10,933<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember', window );">Prosigna product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 4,120<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 4,103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Prosigna customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 2,430<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2,388<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember', window );">nCounter FLEX Dx license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 46,880<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(263)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 46,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember', window );">LymphMark product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 990<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 978<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_PerceptaTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_PerceptaTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6984795328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 03, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 2,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember', window );">Prosigna product technology | NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Prosigna customer relationships | NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember', window );">nCounter FLEX Dx license | NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember', window );">LymphMark product technology | NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6671299936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pretax loss</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="nump">$ 31,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance against deferred tax assets</a></td>
<td class="nump">9,900,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="num">(14,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based compensation excess tax benefit amount</a></td>
<td class="num">(628,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">3,278,000<span></span>
</td>
<td class="nump">$ 2,799,000<span></span>
</td>
<td class="nump">$ 2,523,000<span></span>
</td>
<td class="nump">$ 2,222,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">236,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">58,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Other state income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 45,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117330312&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vcyt_OtherStatesNotSeparatelyDisclosedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vcyt_OtherStatesNotSeparatelyDisclosedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985689376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Examination (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income tax examination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_IncomeTaxExaminationPeriod', window );">Income tax examination period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income tax examination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_IncomeTaxExaminationPeriod', window );">Income tax examination period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_IncomeTaxExaminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which will remain open for examination by tax authorities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_IncomeTaxExaminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807128592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) Plan<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company sponsors a 401(k) defined contribution plan covering all employees. Employer contributions to the plan were </span><span style="font-family:inherit;font-size:10pt;"><span>$509,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$448,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$324,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span>, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807166112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following outstanding common stock equivalents have been excluded from diluted net loss per common share for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> because their inclusion would be anti-dilutive:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock subject to outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,394,944</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,998,163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,163,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,869</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>712,122</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>384,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,133,190</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,417,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,261,718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6717030928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of net debt obligation</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End-of-term debt obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net debt obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of interest expense on debt</a></td>
<td class="text"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was recognized as follows (in thousands of dollars):&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nominal debt interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization and write-off of debt discount and issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End-of-term debt obligation interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt prepayment penalty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest on capital lease</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>677</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,963</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985128592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">$ 23,013<span></span>
</td>
<td class="nump">$ 20,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(14,080)<span></span>
</td>
<td class="num">(12,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">8,933<span></span>
</td>
<td class="nump">8,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DepreciationandAmortizationofTangibleAssets', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization', window );">Capital leased assets</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization', window );">Accumulated depreciation</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Capital leases, depreciation expense</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">5,926<span></span>
</td>
<td class="nump">5,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsLeasedToOthersMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">9,655<span></span>
</td>
<td class="nump">8,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software, including software developed for internal use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">3,226<span></span>
</td>
<td class="nump">2,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DepreciationandAmortizationofTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation and Amortization of Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DepreciationandAmortizationofTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Right-of-Use Asset, Accumulated Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_FinanceLeaseRightofUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Right-of-Use Asset, before Accumulated Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsLeasedToOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsLeasedToOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6975713792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 03, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Shares issued for purchase consideration for a business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,088<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,725<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember', window );">NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Cash paid in acquisition</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_BusinessCombinationContingentConsiderationCashtobePaid', window );">Additional cash to be paid</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition related contingent consideration</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock | NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Shares issued for purchase consideration for a business combination</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_BusinessCombinationContingentConsiderationCashtobePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Cash to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_BusinessCombinationContingentConsiderationCashtobePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819981648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expense</a></td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="nump">$ 6,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">3,634<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 13,734<span></span>
</td>
<td class="nump">$ 9,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6974699088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax Provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation of tax expense computed at the statutory federal rate and the Company's tax expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal taxes at statutory rate</a></td>
<td class="num">$ (2,632,000)<span></span>
</td>
<td class="num">$ (4,825,000)<span></span>
</td>
<td class="num">$ (10,541,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax (net of federal benefit)</a></td>
<td class="num">(828,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount', window );">Non deductible officers' compensation</a></td>
<td class="nump">439,000<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock based compensation - PSU/RSU/NQSQ</a></td>
<td class="nump">628,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">221,000<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Incentive stock options</a></td>
<td class="num">(4,994,000)<span></span>
</td>
<td class="num">(256,000)<span></span>
</td>
<td class="nump">994,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(996,000)<span></span>
</td>
<td class="num">(777,000)<span></span>
</td>
<td class="num">(588,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">8,162,000<span></span>
</td>
<td class="nump">5,164,000<span></span>
</td>
<td class="num">(14,552,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate differential impact - Tax Cuts and Jobs Act</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,474,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117330312&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983299360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contributions to the plan</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="nump">$ 448<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6595003888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of reserved shares of common stock for issuance</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had reserved shares of common stock for issuance as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units issued and outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,562,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,235,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units available for grant under stock option plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,954,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,571,658</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock available for the Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,690,456</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,116,335</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983289280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text">Selected Quarterly Financial Data (Unaudited)<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents selected unaudited financial data for each of the eight quarters in the two-year period ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company believes this information reflects all recurring adjustments necessary to fairly present this information when read in conjunction with the Company's financial statements and the related notes. Net loss per common share, basic and diluted, for the four quarters of each fiscal year may not sum to the total for the fiscal year because of the different number of shares outstanding during each period. The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period (in thousands of dollars, except for share and per share data):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Ended</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,529</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,494</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used to compute net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,168,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,586,081</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,588,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,095,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,041</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,177</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,248</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,469</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used to compute net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,271,254</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,314,234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,620,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,731,334</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983381536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of fair value of assets acquired and liabilities assumed</a></td>
<td class="text">The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.95711500974659%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total identifiable intangible assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,668</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of identifiable acquisition-related intangibles</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.33723196881091%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:81%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Useful life (In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro forma financial information</a></td>
<td class="text">The unaudited pro forma revenue information is for informational purposes only and is not necessarily indicative of the revenue that would have been achieved if the acquisition had taken place as of January 1, 2018 (in thousands):<div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.99610136452242%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,040</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983306560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The carrying value of the Company's debt approximates its fair value because the interest rate approximates market rates that the Company could obtain for debt with similar terms. The   fair value of the Company&#8217;s debt is estimated using the net present value of the payments, discounted at an interest rate that is consistent with market interest rates, which is a Level II input.&#160;The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;I: Inputs which include quoted prices in active markets for identical assets and liabilities;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;II: Inputs other than Level&#160;I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the Company's financial assets includes money market funds, overnight reverse repurchase agreements&#160;and a deposit for the lease of the Company's South San Francisco facility.  Money market funds, included in cash and cash equivalents in the accompanying consolidated balance sheets, was </span><span style="font-family:inherit;font-size:10pt;"><span>$57.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$76.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and are Level&#160;I assets as described above.  Overnight reverse repurchase agreements, included in cash and cash equivalents in the accompanying consolidated balance sheets, were&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;">&#160;as of&#160;December 31, 2019&#160;and&#160;2018, respectively, and are Level II assets as described above.  There were no unrealized gains or losses from overnight reverse repurchase agreements at December 31, 2019 and 2018.  The deposit for the lease, included in restricted cash in the accompanying consolidated balance sheets, was </span><span style="font-family:inherit;font-size:10pt;"><span>$603,000</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and is a Level I asset as described above. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration in Note 4, Business Combination, associated with the agreement with NanoString on December 3, 2019, is a Level III financial liability.  As of December 31, 2019, the contingent consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> is dependent on the achievement of certain milestones and is payable in cash of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.  Estimation of the fair value of the contingent consideration is based on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.  Changes to the forecasts for the achievement of milestones can significantly affect the estimated fair value of the contingent consideration.  There has been no change to the estimated fair value of the contingent consideration from the date of the agreement with NanoString to December 31, 2019 and the Company will assess the fair value of the contingent liability on a quarterly basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819938640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 20, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VERACYTE,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5455398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6000 Shoreline Court,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-6300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VCYT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,738,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Portions of the registrant's proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for the registrant's 2020 Annual Meeting of Stockholders to be held on or about June 5, 2020 are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2019.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001384101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820649456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 59,581<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 239,631<span></span>
</td>
<td class="num">$ (180,084)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,762,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan (ESPP)</a></td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock on employee stock purchase plan (ESPP) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee', window );">Stock-based compensation expense (employee)</a></td>
<td class="nump">6,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee', window );">Stock-based compensation expense (non-employee)</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP', window );">Stock-based compensation expense (ESPP)</a></td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(31,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(31,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">37,225<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">248,278<span></span>
</td>
<td class="num">(211,087)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,210,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">3,433<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan (ESPP)</a></td>
<td class="nump">790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock on employee stock purchase plan (ESPP) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement', window );">Sale of common stock in a private placement, net of issuance costs</a></td>
<td class="nump">55,038<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">55,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement', window );">Sale of common stock in a private placement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee', window );">Stock-based compensation expense (employee)</a></td>
<td class="nump">5,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee', window );">Stock-based compensation expense (non-employee)</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP', window );">Stock-based compensation expense (ESPP)</a></td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax', window );">Legal settlement from short-swing profits, net of tax</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(22,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(22,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">79,755<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">313,800<span></span>
</td>
<td class="num">(234,086)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,863,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">13,378<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">13,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan (ESPP)</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock on employee stock purchase plan (ESPP) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement', window );">Sale of common stock in a private placement, net of issuance costs</a></td>
<td class="nump">137,848<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">137,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement', window );">Sale of common stock in a private placement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for acquisition</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">376,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee', window );">Stock-based compensation expense (employee)</a></td>
<td class="nump">8,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee', window );">Stock-based compensation expense (non-employee)</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP', window );">Stock-based compensation expense (ESPP)</a></td>
<td class="nump">743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(12,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(12,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 239,455<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 486,090<span></span>
</td>
<td class="num">$ (246,685)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,625,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal Settlement Regarding Short-Swing Profits, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_LegalSettlementRegardingShortSwingProfitsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Exercises in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Value, Options and Non-Option Equity Instruments, Exercises in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued and sold during the period in a private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued and sold during the period in a private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_StockIssuedAndSoldDuringPeriodValueInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983317216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans</a></td>
<td class="text">Stock Incentive Plans<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2008, the Company adopted the 2008 Stock Plan (the "2008 Plan"). The 2008 Plan provides for the granting of options to purchase common stock and common stock to employees, directors and consultants of the Company. The Company may grant incentive stock options ("ISOs"), non-statutory stock options ("NSOs") or restricted stock under the 2008 Plan. ISOs may only be granted to Company employees (including directors who are also considered employees). NSOs and restricted stock may be granted to Company employees, directors and consultants. Options may be granted for terms of up to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to a person who owns stock representing more than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the voting power of all classes of stock of the Company, the term shall be for no more than </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant. The exercise price of options granted must be at a price no less than </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to an employee who at the time of grant of such option owns stock representing more than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the voting power of all classes of stock of the Company, the exercise price shall not be less than </span><span style="font-family:inherit;font-size:10pt;"><span>110%</span></span><span style="font-family:inherit;font-size:10pt;"> of the estimated fair value of the shares on the date of grant. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2013, the Company adopted the 2013 Stock Incentive Plan (the "2013 Plan"). The 2013 Plan was subsequently approved by the Company's stockholders and became effective on November&#160;4, 2013, immediately before the closing of the Company's initial public offering ("IPO"). Following the effectiveness of the 2013 Plan, no additional options were granted under the 2008 Plan. An aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>1,700,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares were initially reserved for issuance under the 2013 Plan. In addition, to the extent that any awards outstanding or subject to vesting restrictions under the 2008 Plan are subsequently forfeited or terminated for any </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reason before being exercised or settled, the shares of common stock reserved for issuance pursuant to such awards as of the closing of the IPO will become available for issuance under the 2013 Plan. The remaining shares available for grant under the 2008 Plan became available for issuance under the 2013 Plan upon the closing of the IPO. On the first day of each year from 2014 to 2023, the 2013 Plan authorizes an annual increase of the lesser of </span><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span><span style="font-family:inherit;font-size:10pt;"> of outstanding shares on the last day of the immediately preceding fiscal year or a lesser amount as determined by the Company's Board of Directors. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1,954,799</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for future issuance under the 2013 Plan.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the 2013 Plan, stock options, restricted shares, stock units, including restricted stock units and stock appreciation rights may be granted to employees, consultants, and outside directors of the Company. Options granted may be either ISOs or NSOs.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options are governed by stock option agreements between the Company and recipients of stock options. ISOs and NSOs may be granted under the 2013 Plan at an exercise price of not less than </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the Board of Directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of ISOs may not exceed ten years from the date of grant. Stock option agreements may provide for accelerated exercisability in the event of an optionee's death, disability, or retirement or other events.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock units are governed by stock unit agreements between the Company and recipients of stock units. Stock units may be granted under the 2013 Plan and the number of stock units awarded are determined by the Compensation Committee of the Board of Directors. Stock units vest and expire as determined by the Compensation Committee.  Stock unit agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any outside director who was not previously an employee and who first joins the Company's Board of Directors on or after the effective date of the 2013 Plan will be automatically granted an initial NSO to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>35,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock upon first becoming a member of the Board of Directors.  The shares subject to the initial option will vest and become exercisable one-third (1/3) each of the first, second and third annual anniversaries of the date of grant.  On the first business day after each regularly scheduled annual meeting of stockholders, each outside director who was not elected to the Board of Directors for the first time at such meeting and who will continue serving as a member of the Board of Directors thereafter will be automatically granted an option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>10,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, provided that the outside director has served on the Board of Directors for at least </span><span style="font-family:inherit;font-size:10pt;"><span>six months</span></span><span style="font-family:inherit;font-size:10pt;">. Each annual option will vest and become exercisable on the first anniversary of the date of grant, or immediately prior to the next regular annual meeting of the Company's stockholders following the date of grant if the meeting occurs prior to the first anniversary date. The options granted to outside directors will have a per share exercise price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of the underlying shares on the date of grant and will become fully vested in the event of a change of control. In addition, such options will terminate on the earlier of (i)&#160;the day before the&#160;</span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;">th anniversary of the date of grant or (ii)&#160;the date </span><span style="font-family:inherit;font-size:10pt;"><span>12 months</span></span><span style="font-family:inherit;font-size:10pt;"> after the termination of the outside director's service for any reason.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes activity under the Company's stock incentive plans (aggregate intrinsic value in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Available</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">for Grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options<br/>Outstanding and Unvested Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise Price of Stock Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br/>Remaining<br/>Contractual Life of Stock Options<br/>(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value of Stock Options</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance&#8212;December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,571,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,235,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional shares authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,634,528</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted - stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(969,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>969,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted - restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(505,965</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>505,965</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(180,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,846,222</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(122,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax portion of restricted stock units vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,954,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,562,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options vested and exercisable&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,651,858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options vested and expected to vest&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,442,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.91</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value was calculated as the difference between the exercise price of the options to purchase common stock and the fair market value of the Company's common stock, which was </span><span style="font-family:inherit;font-size:10pt;"><span>$27.92</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$12.58</span></span><span style="font-family:inherit;font-size:10pt;"> per share as of December&#160;31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average fair value of options to purchase common stock granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$11.07</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.62</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.49</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate estimated grant date fair value of employee options to purchase common stock vested during the years ended December&#160;31, 2019, 2018 and 2017 was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intrinsic value of stock options exercised was </span><span style="font-family:inherit;font-size:10pt;"><span>$31.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average fair value of restricted stock units granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$21.90</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.17</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2019 and 2018, respectively.  The intrinsic value of restricted stock units vested was </span><span style="font-family:inherit;font-size:10pt;"><span>$2,720,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$184,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2015, the Company's stockholders approved the Company's ESPP. The ESPP provides eligible employees with an opportunity to purchase common stock from the Company and to pay for their purchases through payroll deductions. The ESPP will be implemented through a series of offerings of purchase rights to eligible employees. Under the ESPP, the Compensation Committee of the Company's Board of Directors may specify offerings with a duration of not more than </span><span style="font-family:inherit;font-size:10pt;"><span>12 months</span></span><span style="font-family:inherit;font-size:10pt;">, and may specify shorter purchase periods within each offering. During each purchase period, payroll deductions will accumulate, without interest. On the last day of the purchase period, accumulated payroll deductions will be used to purchase common stock for employees participating in the offering.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price will be specified pursuant to the offering, but cannot, under the terms of the ESPP, be less than </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value per share of the Company's common stock on either the offering date or on the purchase date, whichever is less.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Board of Directors has determined that the purchase periods initially shall have a duration of </span><span style="font-family:inherit;font-size:10pt;"><span>six months</span></span><span style="font-family:inherit;font-size:10pt;">, that the first purchase period began on August&#160;3, 2015 and that the purchase price will be </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value per share </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of the Company's common stock on either the offering date or the purchase date, whichever is less. The length of the purchase period applicable to U.S. employees and the purchase price may not be changed without the approval of the independent members of the Compensation Committee of the Company's Board of Directors. The Compensation Committee has determined that if the fair market value of a share of the Company's common stock on any purchase date within a particular offering period is less than the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No employee is permitted to accrue, under the ESPP, a right to purchase stock of the Company having a value in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>$25,000</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of such stock (determined at the time the right is granted) for each calendar year.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense related to stock options, restricted stock units and the ESPP for the years ended December&#160;31, 2019, 2018 and 2017, and are included in the consolidated statements of operations and comprehensive loss as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,856</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,866</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,899</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,736</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,090</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,807</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,958</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,617</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2019, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$18.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested stock options and restricted stock units, which is expected to be recognized over an estimated weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.20 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated grant-date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52.90 - 53.40%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 52.70%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 52.40%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.90 - 2.60%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.40 - 3.10%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.80 - 2.33%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of non-employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.60 - 50.50%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 51.10%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.25 - 6.75</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.80 - 7.75</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.84 - 2.87%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.16 - 2.37%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> non-employee stock options outstanding as of December 31, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated grant date fair value of the ESPP shares was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53.38 - 71.77%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42.88 - 47.74%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37.00 - 43.86%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.88 - 2.56%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.64 - 2.45%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.65 - 1.22%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807215104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, which was created in 2019 to process certain administrative functions associated with the business combination in Note 4, Business Combination. All intercompany accounts and transactions have been eliminated in consolidation.  Certain amounts have been reclassified on the consolidated statements of operations for presentation purposes.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has incurred net losses since its inception and as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$246.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.  The Company believes its cash and cash equivalents of </span><span style="font-family:inherit;font-size:10pt;"><span>$159.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and its revenue from sales in 2020 will be sufficient to meet its anticipated cash requirements through at least February 2021.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 7, 2019, the Company issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>6,325,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock in a registered public offering, including&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>825,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares issued and sold upon the underwriters&#8217; exercise in full of their option to purchase additional shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$23.25</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company's net proceeds from the offering were approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$137.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$9.2 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, the Company issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>5,750,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock in a registered public offering, including </span><span style="font-family:inherit;font-size:10pt;"><span>750,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares issued and sold upon the underwriters' exercise in full of their option to purchase additional&#160;shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$10.25</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company's net proceeds from the offering were approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$55.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting commissions and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2017, the Company entered into a Loan and Security Agreement and drew down a term loan advance of </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which the entire amount was used to pay the outstanding balance of the Company's previous long-term debt as discussed in Note 8 - Debt.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company is not able to generate cash proceeds from revenue sufficient to satisfy its cash obligations, the Company will need to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations or licensing arrangements. If the Company is not able to secure additional funding when needed, on acceptable terms, it may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives which may have a material adverse effect on the Company's business, results of operations, financial condition and/or its ability to fund its scheduled obligations on a timely basis or at all.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company's cash and cash equivalents are deposited with </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Several of the components of the Company's sample collection kit and test reagents, and its nCounter FLEX DX systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable related to its sales. The Company does not perform evaluations of customers' financial condition and does not require collateral.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, most of the Company's revenue have been derived from the sale of Afirma. To date, Afirma has been delivered primarily to physicians in the United States. The Company's third-party payers and other customers in excess of 10% of revenue and their related revenue as a percentage of total revenue were as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UnitedHealthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's significant third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Johnson and Johnson Services, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UnitedHealthcare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Cash Equivalents</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist of amounts invested in a money market account primarily consisting of U.S. Treasury reserves, and overnight reverse repurchase agreements which are tri-party repurchase agreements and are collateralized by U.S. Treasury and agency securities of at&#160;least&#160;102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had deposits of </span><span style="font-family:inherit;font-size:10pt;"><span>$603,000</span></span><span style="font-family:inherit;font-size:10pt;"> included in long-term assets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company's South San Francisco facility.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company first determines whether a set of assets acquired and liabilities assumed constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.&#160; Contingent consideration obligations incurred in connection with a business combination are recorded at  fair value on the acquisition date and remeasured at each subsequent reporting period until the related contingencies are resolved, with the resulting changes in fair value recorded in earnings. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts for Product Sales </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable regularly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value by analyzing the status of significant past due receivables. Product sales commenced in December 2019 and there was no allowance for doubtful accounts at either December 31, 2019 or 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finite-lived Intangible Assets </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets consist of intangible assets acquired as part of business combinations. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 5 to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. The Company tests these finite-lived intangible assets for impairment when events or circumstances indicate a reduction in the fair value below their carrying amounts. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill, derived from the Company's acquisition of Allegro Diagnostics Corp. in September 2014 and the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System and Prosigna and LymphMark assays in December 2019, is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired. The Company's goodwill evaluation is done annually on October 31 and is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company has determined that it operates in a single segment and has a single reporting unit associated with the development and commercialization of diagnostic products. In the event the Company determines that it is more likely than not the carrying value of the reporting unit is higher than its fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value.  There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note&#160;6, "Fair Value Measurements" for further information on the fair value of the Company&#8217;s financial instruments.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Testing Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company commenced recognizing testing revenue in accordance with the provisions of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">, or ASC 606, starting January 1, 2018.  Prior to January 1, 2018, the Company recognized testing revenue in accordance with the provisions of ASC 954-605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Health Care Entities - Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, or ASC 954. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most of the Company&#8217;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method, which requires a cumulative catch-up adjustment as if the Company had recognized revenue under ASC 606 from January 1, 2016.  Prior to January 1, 2018, the Company recognized revenue in accordance with ASC 954 and recognized revenue for tests delivered on an accrual basis when amounts that will ultimately be realized could be reasonably estimated, and on the cash basis when there was insufficient information to estimate revenue accruals.  There was sufficient payment history for the Company to substantially accrue all revenue upon delivery of test results starting July 1, 2016 and the Company continued to recognize revenue in 2017 upon cash receipt for unaccrued tests that were delivered prior to July 1, 2016.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was as follows (in thousands of dollars):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized on the accrual basis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,058</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized on the cash basis</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, on July 1, 2016 the Company began recognizing testing revenue from substantially all its tests on the accrual basis of accounting at an amount equal to management&#8217;s best estimate of the cash to ultimately be collected. For tests delivered prior to July 1, 2016, substantially all the related cash had been collected by December 31, 2017. Thus, at January 1, 2018, the cumulative impact of adopting ASC 606 was not material and no adjustment was recorded.  Since the Company commenced recognizing revenue from substantially all of its tests on the accrual basis of accounting commencing on July 1, 2016, and continued to do so after the adoption of ASC 606, the adoption of ASC 606 did not have a material impact on the Company's statement of operations for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.   </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which resulted in a decrease in the Company's loss from operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a decrease in loss per share of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.04</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2018, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2017 or prior years and recognized additional revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which resulted in a decrease in the Company's loss from operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a decrease in loss per share of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.04</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities. There was no revenue from instrument sales for the years ended December 31, 2019, 2018 or 2017. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Biopharmaceutical and Collaboration Revenue</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company enters into arrangements for research and development and/or commercialization services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;D services, and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue and collaboration revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Up-front Fees: </span><span style="font-family:inherit;font-size:10pt;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments:</span><span style="font-family:inherit;font-size:10pt;"> At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the collaborative partner&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Services Agreement with Loxo Oncology</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc. ("Loxo") whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees. During the quarter ended June 30, 2018, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$450,000</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue upon deliveries of tissue samples and the Company received </span><span style="font-family:inherit;font-size:10pt;"><span>$500,000</span></span><span style="font-family:inherit;font-size:10pt;"> for other services, which was recognized ratably during the quarters ended September 30 and December 31, 2018 as the services were  performed. Thereafter, the Company expects to receive approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> per quarter as services are performed and may also recognize revenue related to the deliveries of additional tissue samples as long as the agreement is not terminated.  The agreement has a </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year term with an automatic renewal of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> and  Loxo may terminate the agreement at any time with at least </span><span style="font-family:inherit;font-size:10pt;">90</span><span style="font-family:inherit;font-size:10pt;"> days' notice.   As of December 31, 2019, the agreement had not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded that the performance obligations thereunder are the deliveries of tissue samples and performance of services, both of which are distinct.  For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$90,000</span></span><span style="font-family:inherit;font-size:10pt;"> for  deliveries of tissue samples and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the performance of services and is classified under biopharmaceutical revenue in the Consolidated Statement of Operations and Comprehensive Loss.  There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> deferred revenue related to this agreement at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Diagnostic Development Agreement with Johnson &amp; Johnson</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc. ("JJSI") (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">bronchial genomic classifier diagnostic for lung cancer diagnosis (&#8220;Percepta v.2") and a nasal genomic classifier diagnostic for lung cancer (&#8220;NasaRISK&#8221;) and (ii) for JJSI to use Veracyte data generated in </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and NasaRISK programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, conditioned upon the achievement of certain milestones relating to the development and reimbursement of Percepta v.2 and NasaRISK.  For a period of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> commencing with the first commercial sale of Percepta v.2 and NasaRISK, respectively, the Company will make payments to JJSI of </span><span style="font-family:inherit;font-size:10pt;"><span>one percent</span></span><span style="font-family:inherit;font-size:10pt;"> of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for NasaRISK, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of data from its RNA whole-transcriptome sequencing platform to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments which was allocated to the obligation to deliver data.  The </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and NasaRISK development milestones, respectively.  This revenue is classified under biopharmaceutical revenue and collaboration revenue, respectively, in the consolidated statement of operations and comprehensive loss.  Accounts receivable from JJSI was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.  The cost of biopharmaceutical revenue recognized under the agreement with JJSI is not significant and recorded in research and development in the statement of operations and comprehensive loss.  There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> deferred revenue related to this agreement at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Agreement with AstraZeneca Group</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V. ("Acerta"), a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#8217;s development of oncology therapeutics.  Acerta will reimburse the Company for certain development costs and pay milestones to the Company for the achievement of development milestones.   As of December 31, 2019, there was no performance of obligations under the agreement or consideration paid.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Testing Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Revenue </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#8217;s products and labor expenses. Cost of product revenue for instruments and </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses include expenses incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products. These expenses consist of compensation expenses, direct research and development expenses such as prototype materials, laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses. We expense all research and development costs in the periods in which they are incurred. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company's assessment of an uncertain tax position begins with the initial determination of the position's sustainability and is measured at the largest amount of benefit that is more-likely-than-not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense for stock options issued to employees is measured based on the grant-date fair value of the award. The fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model.  Stock-based compensation expense for stock units is measured based on the fair value of the award, which is determined based upon the closing price of the Company&#8217;s common stock on the date of the grant.  The Company grants performance-based stock units to certain employees which vest upon the achievement of certain performance conditions, subject to the employees&#8217; continued service with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes compensation costs on a straight-line basis for all employee stock-based compensation awards that are expected to vest over the requisite service period of the awards, which is generally the awards' vesting period. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the adoption of ASU No. 2018-07, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;"> by the Company on October 1, 2018, stock-based compensation expense for equity instruments issued to non-employees is also measured based on the grant-date fair value of the awards using the Black-Scholes option-pricing model.  Prior to this, the fair value of such awards was subject to re-measurement as the underlying equity awards vest. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Common Share</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance.  The Company has a single reporting unit associated with the development and commercialization of diagnostic products.  Substantially all the Company&#8217;s revenue for the years ended December 31, 2019, 2018 and 2017 was derived in the United States.  All of the Company&#8217;s long-lived assets were located in the United States as of December&#160;31, 2019 and 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">. This ASU is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU was effective for interim and annual periods beginning after December 15, 2018.  Additionally, the FASB issued ASU No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements.  The Company elected this transition method and adopted ASC 842 on January 1, 2019 and as a result, recorded operating lease right-of-use ("ROU") assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, including offsetting deferred rent of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, along with the associated operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.1 million</span></span><span style="font-family:inherit;font-size:10pt;">.  On January 1, 2019, the Company had finance lease ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and associated finance lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for leases classified as finance leases prior to the adoption of ASC 842. The adoption of ASC 842 had an immaterial impact on the Company's consolidated statement of operations and comprehensive loss, consolidated statement of stockholders' equity and consolidated statement of cash flows for the year ended December 31, 2019.  In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease classification.  Additional information and disclosures required by this new standard are contained in Note 7,&#160;Commitments and Contingencies.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company does not expect to have a material impact on its financial statements and related disclosures from the adoption of this guidance.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808). </span>Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810908656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Liquidity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 07, 2019</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LiquidityLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,685<span></span>
</td>
<td class="nump">$ 234,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,317<span></span>
</td>
<td class="nump">$ 77,995<span></span>
</td>
<td class="nump">$ 33,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period (in shares)</a></td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in usd per share)</a></td>
<td class="nump">$ 23.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 137,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Line of credit | Silicon Valley Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LiquidityLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from long-term lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LiquidityLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period (in shares)</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LiquidityLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_LiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_LiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=vcyt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=vcyt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6979653920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of activity under the Company's stock option plans</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes activity under the Company's stock incentive plans (aggregate intrinsic value in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Available</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">for Grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options<br/>Outstanding and Unvested Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise Price of Stock Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br/>Remaining<br/>Contractual Life of Stock Options<br/>(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value of Stock Options</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance&#8212;December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,571,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,235,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional shares authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,634,528</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted - stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(969,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>969,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted - restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(505,965</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>505,965</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(180,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,846,222</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(122,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax portion of restricted stock units vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,954,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,562,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options vested and exercisable&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,651,858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options vested and expected to vest&#8212;December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,442,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.91</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember', window );">Stock-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of share-based compensation expense</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense related to stock options, restricted stock units and the ESPP for the years ended December&#160;31, 2019, 2018 and 2017, and are included in the consolidated statements of operations and comprehensive loss as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of testing revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,856</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,866</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,899</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,736</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,090</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,807</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,958</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,617</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_EmployeeStockOptionExcludingBonusCompensationMember', window );">Stock-based Compensation, employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate estimated grant date fair value of stock options using the Black-Scholes option-pricing valuation model</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated grant-date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52.90 - 53.40%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 52.70%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 52.40%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 - 6.08</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.90 - 2.60%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.40 - 3.10%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.80 - 2.33%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember', window );">Stock-based Compensation, non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate estimated grant date fair value of stock options using the Black-Scholes option-pricing valuation model</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of non-employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.60 - 50.50%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.40 - 51.10%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.25 - 6.75</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.80 - 7.75</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.84 - 2.87%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.16 - 2.37%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate estimated grant date fair value of stock options using the Black-Scholes option-pricing valuation model</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> non-employee stock options outstanding as of December 31, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated grant date fair value of the ESPP shares was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53.38 - 71.77%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42.88 - 47.74%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37.00 - 43.86%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average expected term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50 - 1.00</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.88 - 2.56%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.64 - 2.45%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.65 - 1.22%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_EmployeeStockOptionExcludingBonusCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>vcyt-12312019x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:vcyt="http://www.veracyte.com/20191231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vcyt-20191231.xsd" xlink:type="simple"/>
    <context id="FD2019Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_vcyt_SalesRevenueGrossMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">vcyt:SalesRevenueGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2020Q1Feb20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="I2019Q2May07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q3July">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_MajorCustomersAxis_vcyt_Perceptav.2andNassaRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:Perceptav.2andNassaRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2019Q2May07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_srt_ProductOrServiceAxis_vcyt_ProvisionofDataMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:ProvisionofDataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Nov_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="D2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-28</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_srt_ProductOrServiceAxis_vcyt_FulfillmentofObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:JohnsonandJohnsonServicesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:FulfillmentofObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q3Jul31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="D2018Q2Apr09_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-09</startDate>
            <endDate>2018-04-09</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="D2019Q2May07_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Dec28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="D2018Q4Dec28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2018-12-28</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vcyt:BiopharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q2_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanoStringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:AZCollaborationLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterFLEXDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsLeasedToOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsLeasedToOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsLeasedToOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsLeasedToOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_vcyt_OvernightRepurchaseAgreementsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_vcyt_OvernightRepurchaseAgreementsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vcyt:OvernightRepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_LaboratoryFacilitiesAustinTexasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:LaboratoryFacilitiesAustinTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_LaboratoryFacilitiesAustinTexasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vcyt:LaboratoryFacilitiesAustinTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-03</startDate>
            <endDate>2017-11-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q1Jan01-Jan31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="D2019Q2May2019_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="I2017Q4Nov3_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-03</instant>
        </period>
    </context>
    <context id="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-03</instant>
        </period>
    </context>
    <context id="D2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-03</startDate>
            <endDate>2017-11-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-03</instant>
        </period>
    </context>
    <context id="I2017Q4Nov3_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-03</instant>
        </period>
    </context>
    <context id="I2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-03</instant>
        </period>
    </context>
    <context id="D2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-03</startDate>
            <endDate>2017-11-03</endDate>
        </period>
    </context>
    <context id="D2016Q1Mar30-Mar30_us-gaap_DebtInstrumentAxis_vcyt_InitialTermLoanMember_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vcyt:InitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-30</startDate>
            <endDate>2016-03-30</endDate>
        </period>
    </context>
    <context id="FD2016Q2QTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vcyt:DebtPrepaymentTrancheAxis">vcyt:DebtPrepaymentTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">vcyt:VisiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorWhoWasNotPreviouslyEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonStatutoryStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockPlan2008Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-02-01</startDate>
            <endDate>2008-02-29</endDate>
        </period>
    </context>
    <context id="I2013Q4Oct31_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockPlan2008Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-02-01</startDate>
            <endDate>2008-02-29</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockPlan2008Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-02-01</startDate>
            <endDate>2008-02-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vcyt:OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockPlan2008Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-02-01</startDate>
            <endDate>2008-02-29</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeStockOptionExcludingBonusCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonStatutoryStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vcyt:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_stpr_CA_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_vcyt_OtherStatesNotSeparatelyDisclosedMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vcyt:OtherStatesNotSeparatelyDisclosedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="term_loan">
        <measure>vcyt:term_loan</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="financial_institution">
        <measure>vcyt:financial_institution</measure>
    </unit>
    <unit id="segment">
        <measure>vcyt:segment</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="installment">
        <measure>vcyt:installment</measure>
    </unit>
    <unit id="program">
        <measure>vcyt:program</measure>
    </unit>
    <unit id="vote">
        <measure>vcyt:vote</measure>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q4YTD"
      id="Fact-C7EA9DFA9C8BE8590193C7EB69C80BAB-wk-Fact-C7EA9DFA9C8BE8590193C7EB69C80BAB">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q4YTD"
      id="Fact-380BBE08AF5DD2F1D519C7EB69D986BB-wk-Fact-380BBE08AF5DD2F1D519C7EB69D986BB">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q4YTD"
      id="Fact-EDFA1D3C675E6D54DB37C7EB69E2C3A7-wk-Fact-EDFA1D3C675E6D54DB37C7EB69E2C3A7">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q4YTD"
      id="Fact-83D83527B2B33180D8E5C7EB69E6045D-wk-Fact-83D83527B2B33180D8E5C7EB69E6045D">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q4YTD"
      id="Fact-514BC3B61EB72EA0C76EC7EB69CF072B-wk-Fact-514BC3B61EB72EA0C76EC7EB69CF072B">0001384101</dei:EntityCentralIndexKey>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="Fact-BB4577F093D304D63008E7D6651DAD6A-wk-Fact-BB4577F093D304D63008E7D6651DAD6A"
      unitRef="usd">3890000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="Fact-C97A52A613BE38A64032C7EB69DC5FC2-wk-Fact-C97A52A613BE38A64032C7EB69DC5FC2"
      unitRef="usd">9208000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-1F3F9FDD8ED170D3A3D6C7EB69EC5991-wk-Fact-1F3F9FDD8ED170D3A3D6C7EB69EC5991"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-72B62572941C0B0AE68DC7EB69E72C8B-wk-Fact-72B62572941C0B0AE68DC7EB69E72C8B"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-C5239A8A8FC0DA2B15107BCC65802ED0-wk-Fact-C5239A8A8FC0DA2B15107BCC65802ED0"
      unitRef="shares">40863202</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-722F3348297ADD6EE30E7BCC657024CD-wk-Fact-722F3348297ADD6EE30E7BCC657024CD"
      unitRef="shares">49625341</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-4902A9021E862852F2747BCC658D02D6-wk-Fact-4902A9021E862852F2747BCC658D02D6"
      unitRef="shares">40863202</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-7FE8575D8AD272FA79E57BCC6587B8DA-wk-Fact-7FE8575D8AD272FA79E57BCC6587B8DA"
      unitRef="shares">49625341</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-62BF053D1FD67F1D53FC5397047267C4-wk-Fact-62BF053D1FD67F1D53FC5397047267C4">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="Fact-DDE0194F530D9E849A5AC7EB69CD07D6-wk-Fact-DDE0194F530D9E849A5AC7EB69CD07D6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="Fact-90948CB52A7F288E93BAC7EB69C60A5D-wk-Fact-90948CB52A7F288E93BAC7EB69C60A5D"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="Fact-228AC9F46CDCD8B88DEAC7EB69D0D4DB-wk-Fact-228AC9F46CDCD8B88DEAC7EB69D0D4DB"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="Fact-806EC5A991D9C6F510A8C7EB69C19174-wk-Fact-806EC5A991D9C6F510A8C7EB69C19174"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="Fact-E712606F0D6A842AD3B1C7EB69D9A019-wk-Fact-E712606F0D6A842AD3B1C7EB69D9A019"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="Fact-478657FB290362098FB7C7EB69D83CF9-wk-Fact-478657FB290362098FB7C7EB69D83CF9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:PaidInKindInterest
      contextRef="FD2016Q3QTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="Fact-5ABC214C47CA6D157180C7EB6A16DE91-wk-Fact-5ABC214C47CA6D157180C7EB6A16DE91"
      unitRef="usd">385000</us-gaap:PaidInKindInterest>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-7942ED17154389051FBAC7EB69F0EA1A-wk-Fact-7942ED17154389051FBAC7EB69F0EA1A"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-1A77A9339CC21D1A8AB9C7EB69F39E28-wk-Fact-1A77A9339CC21D1A8AB9C7EB69F39E28"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-CF6EDC76A3930D2C8B20C7EB69EEC456-wk-Fact-CF6EDC76A3930D2C8B20C7EB69EEC456"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-6DA7D367331ECDD6A7CDC7EB69EB7424-wk-Fact-6DA7D367331ECDD6A7CDC7EB69EB7424"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-2DE4E8A7F6F6F713FACFC7EB69EDB582-wk-Fact-2DE4E8A7F6F6F713FACFC7EB69EDB582"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-EBB545C5209BB9582E04C7EB69F0F0D2-wk-Fact-EBB545C5209BB9582E04C7EB69F0F0D2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-E56FA1E4000E91FFEF99C7EB69EA6CD1-wk-Fact-E56FA1E4000E91FFEF99C7EB69EA6CD1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-9188E838628B9591FD21C7EB69E93329-wk-Fact-9188E838628B9591FD21C7EB69E93329"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-A20863AEBA0936AEBC60C802D4007815-wk-Fact-A20863AEBA0936AEBC60C802D4007815">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SecurityDeposit
      contextRef="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"
      decimals="-3"
      id="Fact-5123A7D92BA0BB51327CC7EB69D08693-wk-Fact-5123A7D92BA0BB51327CC7EB69D08693"
      unitRef="usd">603000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_LaboratoryFacilitiesAustinTexasMember"
      decimals="-3"
      id="Fact-8FC288A6C3FCD991044EC7EB69D4E961-wk-Fact-8FC288A6C3FCD991044EC7EB69D4E961"
      unitRef="usd">139000</us-gaap:SecurityDeposit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-E72EE3BE20076D6D5068C7EB69C91AD7-wk-Fact-E72EE3BE20076D6D5068C7EB69C91AD7"
      unitRef="number">0.4386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-37BD2986117B8A7E0B40C7EB69DFBDF3-wk-Fact-37BD2986117B8A7E0B40C7EB69DFBDF3"
      unitRef="number">0.5240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-7B2A83E32CAE36EA7232C7EB69F3A8EC-wk-Fact-7B2A83E32CAE36EA7232C7EB69F3A8EC"
      unitRef="number">0.5110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-54D4A630D5E82B822D57C7EB69CEC98C-wk-Fact-54D4A630D5E82B822D57C7EB69CEC98C"
      unitRef="number">0.4774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-D012DEB4490BE2619736C7EB69DF410E-wk-Fact-D012DEB4490BE2619736C7EB69DF410E"
      unitRef="number">0.5270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-21E63619C61E27C8DC71C7EB69E5E81E-wk-Fact-21E63619C61E27C8DC71C7EB69E5E81E"
      unitRef="number">0.5050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-03E19714845A995BED77C7EB69D10A68-wk-Fact-03E19714845A995BED77C7EB69D10A68"
      unitRef="number">0.7177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-5D2050442196E735D5DBC7EB69DF5342-wk-Fact-5D2050442196E735D5DBC7EB69DF5342"
      unitRef="number">0.5340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-B79456F34F80AC0288EAC7EB69E090F0-wk-Fact-B79456F34F80AC0288EAC7EB69E090F0"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-42B327FD81544C355C46C7EB69C77BEF-wk-Fact-42B327FD81544C355C46C7EB69C77BEF"
      unitRef="number">0.3700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-2595332A975F3CFEE5F3C7EB69E02806-wk-Fact-2595332A975F3CFEE5F3C7EB69E02806"
      unitRef="number">0.5040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-3B071F91C7D2AD6D06AFC7EB69ED055C-wk-Fact-3B071F91C7D2AD6D06AFC7EB69ED055C"
      unitRef="number">0.5040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-39738B14B4D76E4DF22EC7EB69D3C43E-wk-Fact-39738B14B4D76E4DF22EC7EB69D3C43E"
      unitRef="number">0.4288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-95D70EB55CDCC51A618CC7EB69DD5F18-wk-Fact-95D70EB55CDCC51A618CC7EB69DD5F18"
      unitRef="number">0.5040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-9808A69AD09E59281B91C7EB69E228F9-wk-Fact-9808A69AD09E59281B91C7EB69E228F9"
      unitRef="number">0.4360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-F72F98B0F6F747B6FEE5C7EB69CC15CC-wk-Fact-F72F98B0F6F747B6FEE5C7EB69CC15CC"
      unitRef="number">0.5338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-C9857DA5A7867ED7EB23C7EB69DE899D-wk-Fact-C9857DA5A7867ED7EB23C7EB69DE899D"
      unitRef="number">0.5290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-0119050365A363787CA2C7EB69E6213C-wk-Fact-0119050365A363787CA2C7EB69E6213C"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-0DE3C0F2BF7062A1387BC7EB69D0A070-wk-Fact-0DE3C0F2BF7062A1387BC7EB69D0A070"
      unitRef="number">0.0122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-B0D42CDE0C3B6D52E001C7EB69DDFC36-wk-Fact-B0D42CDE0C3B6D52E001C7EB69DDFC36"
      unitRef="number">0.0233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-F4F0F104CBF0922B1982C7EB69E577B0-wk-Fact-F4F0F104CBF0922B1982C7EB69E577B0"
      unitRef="number">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-2D80B360E1876AB5E601C7EB69CAF349-wk-Fact-2D80B360E1876AB5E601C7EB69CAF349"
      unitRef="number">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-72AE6C6BC89952195926C7EB69DD8C4B-wk-Fact-72AE6C6BC89952195926C7EB69DD8C4B"
      unitRef="number">0.0310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-FAC98266426F800F35DDC7EB69EC3AFE-wk-Fact-FAC98266426F800F35DDC7EB69EC3AFE"
      unitRef="number">0.0287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-E345FC6D1897A2342CEBC7EB69CED2AB-wk-Fact-E345FC6D1897A2342CEBC7EB69CED2AB"
      unitRef="number">0.0256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-35FFE1675CC9C9414BD8C7EB69DD9D92-wk-Fact-35FFE1675CC9C9414BD8C7EB69DD9D92"
      unitRef="number">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-FE3F4421651C416BDBB5C7EB69ED9E61-wk-Fact-FE3F4421651C416BDBB5C7EB69ED9E61"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-1833961D76C5434DD449C7EB69CA6C25-wk-Fact-1833961D76C5434DD449C7EB69CA6C25"
      unitRef="number">0.0065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-1BB9EAC36F08484908C8C7EB69DF88E9-wk-Fact-1BB9EAC36F08484908C8C7EB69DF88E9"
      unitRef="number">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-3A44D78F3875DC03402AC7EB69EA8B29-wk-Fact-3A44D78F3875DC03402AC7EB69EA8B29"
      unitRef="number">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-4AA548C01CA48B727EF8C7EB69C99B9A-wk-Fact-4AA548C01CA48B727EF8C7EB69C99B9A"
      unitRef="number">0.0164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-CA607BB5AF5B897D2A8EC7EB69DC4614-wk-Fact-CA607BB5AF5B897D2A8EC7EB69DC4614"
      unitRef="number">0.0240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-E3E5DC2EF42B4B17088CC7EB69EA14F9-wk-Fact-E3E5DC2EF42B4B17088CC7EB69EA14F9"
      unitRef="number">0.0184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="Fact-8481D96329510AC93043C7EB69C90ED8-wk-Fact-8481D96329510AC93043C7EB69C90ED8"
      unitRef="number">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      decimals="4"
      id="Fact-058E4679E5F3BE02BBF3C7EB69E0B042-wk-Fact-058E4679E5F3BE02BBF3C7EB69E0B042"
      unitRef="number">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="4"
      id="Fact-3F6D304D1E4B6FFB5A4CC7EB69E15600-wk-Fact-3F6D304D1E4B6FFB5A4CC7EB69E15600"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact-28CCB9A9E9DC1E513C28C7EB69DFFAE2-wk-Fact-28CCB9A9E9DC1E513C28C7EB69DFFAE2"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="INF"
      id="Fact-5664806DF8EC3A69CE4DC7EB69E1746C-wk-Fact-5664806DF8EC3A69CE4DC7EB69E1746C"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact-F79C2EE0FCDF6C522413C7EB69DFC730-wk-Fact-F79C2EE0FCDF6C522413C7EB69DFC730"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-7C1AB79275FB505CBC22C7EB69CFBF2E-wk-Fact-7C1AB79275FB505CBC22C7EB69CFBF2E">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      id="Fact-5FB4686527A5FEA19D88C7EB69E138FF-wk-Fact-5FB4686527A5FEA19D88C7EB69E138FF">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      id="Fact-A25842AB400DF5F15E5DC7EB69EFAAB2-wk-Fact-A25842AB400DF5F15E5DC7EB69EFAAB2">P7Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-5DF1CB35A5228C3ABFE0C7EB69CBB886-wk-Fact-5DF1CB35A5228C3ABFE0C7EB69CBB886">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      id="Fact-951D35523C019B6123B6C7EB69DD02CC-wk-Fact-951D35523C019B6123B6C7EB69DD02CC">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      id="Fact-C7CC70CDEBEC81946E4DC7EB69EBD230-wk-Fact-C7CC70CDEBEC81946E4DC7EB69EBD230">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-22234B2CC7C92795CFFEC7EB69CD8BD7-wk-Fact-22234B2CC7C92795CFFEC7EB69CD8BD7">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      id="Fact-A115A1D1361912B43287C7EB69E0254E-wk-Fact-A115A1D1361912B43287C7EB69E0254E">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      id="Fact-D4C0CC99C38484E58BB0C7EB69E0792A-wk-Fact-D4C0CC99C38484E58BB0C7EB69E0792A">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-5E0867889770575BCF05C7EB69C91C6C-wk-Fact-5E0867889770575BCF05C7EB69C91C6C">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      id="Fact-F8373E9A0E584BA22CD8C7EB69DFE9F8-wk-Fact-F8373E9A0E584BA22CD8C7EB69DFE9F8">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      id="Fact-6358043445D40868313AC7EB69E5F55A-wk-Fact-6358043445D40868313AC7EB69E5F55A">P3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-63F83846DEA9D693DF1EC7EB69CDA0E9-wk-Fact-63F83846DEA9D693DF1EC7EB69CDA0E9">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      id="Fact-9F4DA860C72A2EF27BC9C7EB69DC8AE1-wk-Fact-9F4DA860C72A2EF27BC9C7EB69DC8AE1">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      id="Fact-FFC946AA97E2E941C295C7EB69E70A14-wk-Fact-FFC946AA97E2E941C295C7EB69E70A14">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-DBFA6CDAB2FEE0C53F9CC7EB69CC94D7-wk-Fact-DBFA6CDAB2FEE0C53F9CC7EB69CC94D7">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      id="Fact-7EDA898231FB57D8D2B7C7EB69DCA758-wk-Fact-7EDA898231FB57D8D2B7C7EB69DCA758">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      id="Fact-11FB1F608F962657D0F0C7EB69EC7AE8-wk-Fact-11FB1F608F962657D0F0C7EB69EC7AE8">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="INF"
      id="Fact-4B88507127CB42F9473FC7EB69E13E42-wk-Fact-4B88507127CB42F9473FC7EB69E13E42"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vcyt:IncomeTaxExaminationPeriod
      contextRef="FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      id="Fact-2EF8D3875E6527A08C57C808C5DCE0DC-wk-Fact-2EF8D3875E6527A08C57C808C5DCE0DC">P3Y</vcyt:IncomeTaxExaminationPeriod>
    <vcyt:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne
      contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="2"
      id="Fact-3F32EE6829DD01E7ABD9C7EB69E1F42B-wk-Fact-3F32EE6829DD01E7ABD9C7EB69E1F42B"
      unitRef="number">0.25</vcyt:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne>
    <vcyt:TermContractAgreement
      contextRef="D2018Q2Apr09_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      id="Fact-0809570B5CBA5DC81C01C80CAA02A78B-wk-Fact-0809570B5CBA5DC81C01C80CAA02A78B">P1Y</vcyt:TermContractAgreement>
    <dei:DocumentType
      contextRef="FD2019Q4YTD"
      id="d32763161e726-wk-Fact-E619E94F65725AB5DA87C8143D3546CB">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="FD2019Q4YTD"
      id="d32763161e748-wk-Fact-18FA9A33AB647F334279C814EBADDB31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q4YTD"
      id="d32763161e760-wk-Fact-142D2631C617238DFE5BC89C58F6F353">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q4YTD"
      id="d32763161e777-wk-Fact-5C34545CB0D36C518CC8C8170C9FEF57">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q4YTD"
      id="d32763161e796-wk-Fact-1BF3FEFDB2AB73D67BC8C8182D67B293">001-36156</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q4YTD"
      id="d32763161e804-wk-Fact-909AAA00504913C9C1D0C8189C73CCFF">VERACYTE,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q4YTD"
      id="d32763161e833-wk-Fact-61B39289A743983F7C01C82137D539AD">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q4YTD"
      id="d32763161e843-wk-Fact-D70F937AC9AA7F971F6FC8215F19FA62">20-5455398</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q4YTD"
      id="d32763161e885-wk-Fact-FD4F7CA128ADE150852AC821C44981EB">6000 Shoreline Court,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="FD2019Q4YTD"
      id="d32763161e890-wk-Fact-E8FA9EDE4E7BD9E7BB32C822159D6D54">Suite&#160;300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q4YTD"
      id="d32763161e896-wk-Fact-15A7EBB5394894D0C476C8226A746CDC">South San Francisco,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q4YTD"
      id="d32763161e901-wk-Fact-F2DBBE8A4ABC9B3CDF7AC8229D3CB902">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q4YTD"
      id="d32763161e906-wk-Fact-F04F79C08EFCFCF42810C822EC2C8CE6">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q4YTD"
      id="d32763161e920-wk-Fact-3C78E465746CD6FAF38EC8234BD41A91">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q4YTD"
      id="d32763161e925-wk-Fact-A92FD40BD36F3CBD29FEC8238F0C14AA">243-6300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD"
      id="d32763161e982-wk-Fact-758044072AF54820B50FC8243506D695">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD"
      id="d32763161e992-wk-Fact-4D57BF2179693589BB0DC8246173BE53">VCYT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD"
      id="d32763161e1002-wk-Fact-3F31642CA396FFEE51E8C824835AEB8C">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="FD2019Q4YTD"
      id="d32763161e1016-wk-Fact-A95D3A237053ABF080F8C82E3782EB3A">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="FD2019Q4YTD"
      id="d32763161e1037-wk-Fact-1D805A960BA4A992313BC8320E8B45CD">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q4YTD"
      id="d32763161e1049-wk-Fact-5F19ADBAA4D5296AE4C5C833930E0496">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q4YTD"
      id="d32763161e1065-wk-Fact-F6600292B03DD7A51214C834CC76629D">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q4YTD"
      id="d32763161e1097-wk-Fact-F56B5E7EAF700409F7B8C837FD32F5D8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q4YTD"
      id="d32763161e1153-wk-Fact-8B0575252897F2621396C83BA52598CB">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q4YTD"
      id="d32763161e1184-wk-Fact-3E3177F1656528BE796BC83BCFF357CF">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q4YTD"
      id="d32763161e1199-wk-Fact-169CCC5237C389837BE6C83CB04667AE">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="FI2019Q2"
      decimals="-8"
      id="d32763161e1216-wk-Fact-67348B753E31A73577BDC7EB69D6F7E2"
      unitRef="usd">1300000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q1Feb20"
      decimals="INF"
      id="d32763161e1229-wk-Fact-26FDF92B768DB3E7249FC7EB69E7C3CB"
      unitRef="shares">49738822</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C8A953BBB8E4B67A855DC83FD76C3AE9-0-wk-Fact-8F6F501386931F13507BC83FE8A3911C">&lt;div style="line-height:120%;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Portions of the registrant's proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for the registrant's 2020 Annual Meeting of Stockholders to be held on or about June 5, 2020 are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e920-wk-Fact-85FA5F8054B2E56BBECEC7EB6A1CA24A"
      unitRef="usd">159317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e939-wk-Fact-88BEE610D654577571D4C7EB6A07D9C0"
      unitRef="usd">77995000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e954-wk-Fact-66CE026418D2AA925E97C7EB69F467AD"
      unitRef="usd">19329000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e973-wk-Fact-C42345A8597D0B3EA492C7EB69F33377"
      unitRef="usd">13168000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e993-wk-Fact-A371EBBEAC16FB610FE5C7EB69EE827C"
      unitRef="usd">6806000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1012-wk-Fact-448536BD8706BD05E8CEC7EB6A0F8AA2"
      unitRef="usd">3402000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1032-wk-Fact-744C9366ED22E385F479C7EB6A1546FD"
      unitRef="usd">2235000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1051-wk-Fact-D8BE05E4553EAF347411C7EB6A1B1FBA"
      unitRef="usd">2387000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1071-wk-Fact-A9535703801013D2F2DCC7EB6A0B0220"
      unitRef="usd">187687000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1090-wk-Fact-CBDAB585D53E6F2EFC5CC7EB6A073C6B"
      unitRef="usd">96952000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1110-wk-Fact-BC904E8E1E34A858FE66C7EB69C3C495"
      unitRef="usd">8933000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1129-wk-Fact-F30BF87645E2C558788CC7EB69E8B74F"
      unitRef="usd">8940000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1149-wk-Fact-544B7D5445B8DDD6D7D3E7BE8267FF17"
      unitRef="usd">8808000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1168-wk-Fact-A3B2F00DF7489EBF9A4DE7BE824D4315"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1189-wk-Fact-75E37D38A5E99637ED54C7EB69E7C084"
      unitRef="usd">65019000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1208-wk-Fact-05D77A7F1F0983F16406C7EB6A16033B"
      unitRef="usd">12000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1228-wk-Fact-90CA3E6A3CCF873EE25FC7EB6A1EA47B"
      unitRef="usd">2725000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1247-wk-Fact-33F567FC1DBC0B4F7937C7EB69EF0939"
      unitRef="usd">1057000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1267-wk-Fact-058EE48AA43EBE8DA017C7EB6A1C4694"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1286-wk-Fact-D8FC4B0370974C14AE12C7EB6A127112"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1306-wk-Fact-0052F5104DCAEE0900CEC7EB6A1D0495"
      unitRef="usd">1437000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1325-wk-Fact-5C3288E6FC44095D2C52C7EB6A124D4D"
      unitRef="usd">1086000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1350-wk-Fact-D7455FB99D194B126DBAC7EB6A07CAEB"
      unitRef="usd">275212000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1369-wk-Fact-94E5134A34844AEEDFE3C7EB6A097A48"
      unitRef="usd">120638000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1471-wk-Fact-6F28EBD06510E560B1CFC7EB6A169577"
      unitRef="usd">2328000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1490-wk-Fact-8EEF59D401600F82AA0FC7EB6A0F4A2C"
      unitRef="usd">2516000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1505-wk-Fact-44F2146EFC93E9182624C7EB6A0D77DE"
      unitRef="usd">13734000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1524-wk-Fact-DFD7CCCFD7DF8EABBE28C7EB69F57292"
      unitRef="usd">9186000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1544-wk-Fact-247417FB0094EF313842C7EB6A1A4A2F"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1563-wk-Fact-1BB75384301A8FD4AA55C7EB6A1ED993"
      unitRef="usd">1357000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1583-wk-Fact-DA69985FEE89AB339388E7C06DCF75A8"
      unitRef="usd">1407000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1602-wk-Fact-31B061E9913139ADCEFCE7C06DD30F81"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1623-wk-Fact-C013170F8581EABA1363C7EB6A0A7D35"
      unitRef="usd">17469000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1642-wk-Fact-1AD3549BFF9FB089E149C7EB69F7327E"
      unitRef="usd">13059000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1662-wk-Fact-A7E463194A59373330F2C7EB6A18605A"
      unitRef="usd">694000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1681-wk-Fact-846FA26C1D6134B58F0AC7EB69F50048"
      unitRef="usd">23925000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredRevenueLeasesNetNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1701-wk-Fact-4ED8D2DBBB3BF2F90F49C7EB69E9346B"
      unitRef="usd">0</us-gaap:DeferredRevenueLeasesNetNoncurrent>
    <us-gaap:DeferredRevenueLeasesNetNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1720-wk-Fact-4AAAD3FDCFFB07EA4677C7EB69EB531D"
      unitRef="usd">3899000</us-gaap:DeferredRevenueLeasesNetNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1740-wk-Fact-13E537B0D8AC66010191E7C510ADC85F"
      unitRef="usd">6088000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1759-wk-Fact-F59804FBD220BA292E26E7C510BC4825"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1779-wk-Fact-22852C72B4C466775DD0E7C1744D50AA"
      unitRef="usd">11506000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1798-wk-Fact-CB01E42F6EF7CBA5D646E7C17467561F"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1818-wk-Fact-E045F0B48158EABE958BC7EB6A0F14E5"
      unitRef="usd">35757000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1837-wk-Fact-84C49E321E11A565E870C7EB69F5858A"
      unitRef="usd">40883000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d32775652e1857-wk-Fact-8DCD21BC98E211495B45C7EB6A0C0705"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d32775652e1875-wk-Fact-2AB7B7E06F905A10D01CC7EB69C21BC8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1935-wk-Fact-4D779C0287A233FFFFA7C7EB69F15C39"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1954-wk-Fact-96D6774B3E95CE6B4DB3C7EB69EFD1D5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e1974-wk-Fact-0998AEA052B8F245597DC7EB6A1326B5"
      unitRef="usd">50000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e1993-wk-Fact-523ACF13799B865755F6C7EB6A1543D9"
      unitRef="usd">41000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e2013-wk-Fact-A9B383395DCF7CD6B094C7EB6A15C5C8"
      unitRef="usd">486090000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e2032-wk-Fact-078BF013D2C6BFCCBF33C7EB69F642C5"
      unitRef="usd">313800000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e2053-wk-Fact-627529976ADD516CB456C7EB6A0C9EF9"
      unitRef="usd">-246685000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e2073-wk-Fact-F5B5023A9F3E1F7F421CC7EB69EF0D33"
      unitRef="usd">-234086000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e2094-wk-Fact-B29DA4BB134FDC60DE41C7EB69F0A0D3"
      unitRef="usd">239455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e2113-wk-Fact-B98A1AF43330D54A4B8FC7EB69C3A655"
      unitRef="usd">79755000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32775652e2138-wk-Fact-653AB1F1283A3427CC2FC7EB6A1441B6"
      unitRef="usd">275212000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32775652e2157-wk-Fact-F37AC69AD822E858ED6DC7EB6A0F03EF"
      unitRef="usd">120638000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32778833e946-wk-Fact-AF4C19BD2049D80EFD71E7C7BC8D5E19"
      unitRef="usd">107355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32778833e965-wk-Fact-29BCA614035BE02D486EE7C7BF04CEFD"
      unitRef="usd">91058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32778833e984-wk-Fact-EDB8ADC16E235F5D9389E7C7C1448E6D"
      unitRef="usd">71953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d32778833e1000-wk-Fact-445DC488F14CB213643AE7C7C1F4BF50"
      unitRef="usd">923000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d32778833e1019-wk-Fact-34A3D877E4312330B162E7C7C34C92DA"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d32778833e1038-wk-Fact-7E8DD6757548D745C32CE7C7C51D9D44"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember"
      decimals="-3"
      id="d32778833e1059-wk-Fact-6C251DBEEDCD98CE946D40300740E147"
      unitRef="usd">8090000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember"
      decimals="-3"
      id="d32778833e1078-wk-Fact-BF00AA83C01A6DDE757440300AD5909C"
      unitRef="usd">950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_BiopharmaceuticalMember"
      decimals="-3"
      id="d32778833e1097-wk-Fact-106A9E09BC24677AA72940300E51064C"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember"
      decimals="-3"
      id="d32778833e1118-wk-Fact-7F3B2256A1FB130D8215E7C7C6018B2A"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember"
      decimals="-3"
      id="d32778833e1137-wk-Fact-4529D6C3952CFDF3B3ACE7C7C7D277E4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_CollaborationMember"
      decimals="-3"
      id="d32778833e1156-wk-Fact-348F4A25E6222B7586F2E7C7C99EE7B3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1177-wk-Fact-A78B1DBB0CF9A33A9A86C7EB69FCCBF6"
      unitRef="usd">120368000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1196-wk-Fact-DD5C5A320A5DFD181F1EC7EB69D16F02"
      unitRef="usd">92008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1215-wk-Fact-C04B878F5CC45DEF463EC7EB69D00D82"
      unitRef="usd">71953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1360-wk-Fact-D70AFECDC08A594CA98AC7EB69FD3EB5"
      unitRef="usd">36077000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1379-wk-Fact-07168ADA3314A0A4815FC7EB69CC83E2"
      unitRef="usd">33078000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1398-wk-Fact-41794193EB4596AA8090C7EB69C4DBC2"
      unitRef="usd">28195000</us-gaap:CostOfRevenue>
    <us-gaap:CostDirectMaterial
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1420-wk-Fact-593DD84203A225636563E7CC9D30AEBE"
      unitRef="usd">446000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1439-wk-Fact-FB6F94581869E63557B2E7CC9D3BD611"
      unitRef="usd">0</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1458-wk-Fact-263BFDEDA8233DBE5536E7CC9D2A9581"
      unitRef="usd">0</us-gaap:CostDirectMaterial>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1479-wk-Fact-94731EBF813114F1576CC7EB69F97F31"
      unitRef="usd">14851000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1498-wk-Fact-36E1E5B17A4B85B45E4FC7EB69D208CC"
      unitRef="usd">14820000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1517-wk-Fact-33F7F39DD58CA3350CCCC7EB69C27C56"
      unitRef="usd">13881000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1538-wk-Fact-3F4971916302BEC02F4EC7EB69CBB3A1"
      unitRef="usd">53691000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1557-wk-Fact-287907084002D20223BDC7EB69C24081"
      unitRef="usd">41313000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1576-wk-Fact-FF4EC47ADA3190217AC7C7EB69D1DE2B"
      unitRef="usd">32260000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1597-wk-Fact-4E887354184E1B4439E5C7EB69D4E91E"
      unitRef="usd">29029000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1616-wk-Fact-A9955BE33DCB3B9DB301C7EB69FF100F"
      unitRef="usd">23963000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1635-wk-Fact-A876E56967AA2CA74E31C7EB6A0217E8"
      unitRef="usd">23088000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1656-wk-Fact-9279F7BE19C5EE84109DC7EB69C68C99"
      unitRef="usd">1401000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1675-wk-Fact-58C06E135B28C929DEBCC7EB69D47E1C"
      unitRef="usd">1067000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1694-wk-Fact-4198294F8F65751F696BC7EB69C95AA3"
      unitRef="usd">1067000</us-gaap:AdjustmentForAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1715-wk-Fact-76CDB7D96764838BC09AC7EB69CE7650"
      unitRef="usd">135495000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1734-wk-Fact-8CCC17DBC8C287A26887C7EB69C978DF"
      unitRef="usd">114241000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1753-wk-Fact-FB968A05665EE9CF9D6AC7EB69CEB817"
      unitRef="usd">98491000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1774-wk-Fact-C96633BD36DA5D38205BC7EB6A02E72F"
      unitRef="usd">-15127000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1794-wk-Fact-D571C07D6AE28B59EEA6C7EB69FA0FB6"
      unitRef="usd">-22233000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1814-wk-Fact-08344C7E7799148F2765C7EB69C05186"
      unitRef="usd">-26538000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1836-wk-Fact-AEBE32353278432F2913C7EB69C343BA"
      unitRef="usd">677000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1856-wk-Fact-15055D40E4A2580210FCC7EB6A06BE30"
      unitRef="usd">1963000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1876-wk-Fact-C38EF3C9F3EE53A41BBAC7EB69CCEEB5"
      unitRef="usd">4941000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1898-wk-Fact-E6D3BF84A591AAE2F309C7EB69CED318"
      unitRef="usd">3205000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1917-wk-Fact-D585F050603824FF33F8C7EB6A010200"
      unitRef="usd">1197000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e1936-wk-Fact-8A5D2DC0384455D6818DC7EB69CB484E"
      unitRef="usd">476000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32778833e1962-wk-Fact-59EB930132FF9E8EA314C7EB69D4D3E3"
      unitRef="usd">-12599000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32778833e1982-wk-Fact-4675E7BD94D094705776C7EB69D50F75"
      unitRef="usd">-22999000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32778833e2002-wk-Fact-318A7311D6271D38C27FC7EB69FA1BCA"
      unitRef="usd">-31003000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d32778833e2024-wk-Fact-ACF53696CB103C6A6481C7EB6A04937B"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d32778833e2044-wk-Fact-19BB46325B16FD84A989C7EB69C31B03"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d32778833e2064-wk-Fact-44F4A9520B2A2D474161C7EB69C02746"
      unitRef="usdPerShare">-0.91</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="0"
      id="d32778833e2082-wk-Fact-E42A52C1C2013D42B649C7EB69D0B907"
      unitRef="shares">46138177</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="0"
      id="d32778833e2101-wk-Fact-BF7BF6146A6A409CED20C7EB69FCF58B"
      unitRef="shares">37020246</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="0"
      id="d32778833e2120-wk-Fact-AE405842BEA9939E9E9FC7EB69CA1BE3"
      unitRef="shares">33925617</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e1069-wk-Fact-75AAE97F8CB6FA316E3CC7EB6A167A81"
      unitRef="shares">33762278</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e1088-wk-Fact-7CA60473CAC7DF008E82C7EB6A061DC1"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1107-wk-Fact-2FD68436BCC350BAB376C7EB6A187762"
      unitRef="usd">239631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d32787351e1127-wk-Fact-767DDABA0FEC124ADC81C7EB6A11E831"
      unitRef="usd">-180084000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4"
      decimals="-3"
      id="d32787351e1147-wk-Fact-6368A7E9DF1864B0EB4BC7EB6A0BB18C"
      unitRef="usd">59581000</us-gaap:StockholdersEquity>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e1162-wk-Fact-73D990FC75E835D84F3AC7EB6A173B25"
      unitRef="shares">295059</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1195-wk-Fact-A649F8CB570D7A057234C7EB6A0E5745"
      unitRef="usd">1374000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32787351e1234-wk-Fact-BC75B29BDE31B221EA55C7EB6A19D4B1"
      unitRef="usd">1374000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e1254-wk-Fact-4B97F3375E7E7361A2B2C7EB6A030DD0"
      unitRef="shares">153051</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1287-wk-Fact-EDA211235A35F3112E55C7EB6A0D2396"
      unitRef="usd">656000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32787351e1326-wk-Fact-2D7BA1A61F221C64C010C7EB6A0726E2"
      unitRef="usd">656000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1379-wk-Fact-8146B21D6DA9A73D3D6EC7EB6A083F69"
      unitRef="usd">6352000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32787351e1418-wk-Fact-1B4527348908B4779159C7EB6A13ABB9"
      unitRef="usd">6352000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1471-wk-Fact-AE4D187F2349C43436C5C7EB6A04A166"
      unitRef="usd">19000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32787351e1510-wk-Fact-58853720423E11B7E82EC7EB6A0E7CBD"
      unitRef="usd">19000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1563-wk-Fact-E1428C125AFF25BD11DBC7EB6A0FD282"
      unitRef="usd">246000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32787351e1602-wk-Fact-45C6AD0F96E736F82144C7EB6A1546C1"
      unitRef="usd">246000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d32787351e1675-wk-Fact-69E4889D0CA424AAE40CC7EB6A15EEFD"
      unitRef="usd">-31003000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32787351e1695-wk-Fact-318A7311D6271D38C27FC7EB69FA1BCA"
      unitRef="usd">-31003000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e1716-wk-Fact-F9459694F4B3DFADE9B2C7EB6A05090B"
      unitRef="shares">34210388</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e1730-wk-Fact-710961BA96271B59CBD1C7EB6A0C9BCF"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1749-wk-Fact-4945D49F9E939C6B048FC7EB6A12547B"
      unitRef="usd">248278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d32787351e1769-wk-Fact-FAEBDB1DD886BE60C871C7EB6A11ECC3"
      unitRef="usd">-211087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32787351e1789-wk-Fact-D67F8EF6B0AC53C83C44C7EB6A1396B1"
      unitRef="usd">37225000</us-gaap:StockholdersEquity>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e1810-wk-Fact-C29D0056AD94953E9CDBC7EB6A13448C"
      unitRef="shares">756231</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e1824-wk-Fact-AA8C33587962EACF0EBFC7EB6A172CF6"
      unitRef="usd">1000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1843-wk-Fact-682AC63FF0ED6E2DDB34C7EB6A0838FD"
      unitRef="usd">3432000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32787351e1882-wk-Fact-F7F442A36CCE8322694CC7EB6A17CCE1"
      unitRef="usd">3433000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e1902-wk-Fact-9F2BE4B9F598F48ECBE4C7EB6A039834"
      unitRef="shares">146583</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e1935-wk-Fact-1A889DE16E0DC51D376FC7EB6A0CBFBF"
      unitRef="usd">790000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32787351e1974-wk-Fact-6D6D133BA4E1F52D6D51C7EB6A017265"
      unitRef="usd">790000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <vcyt:StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e1994-wk-Fact-D9866976E957116AEF76C7EB6A0BBBCD"
      unitRef="shares">5750000</vcyt:StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement>
    <vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e2008-wk-Fact-B4AF52567E01BE843C7CC7EB6A069D34"
      unitRef="usd">6000</vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement>
    <vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2027-wk-Fact-EA1F3E8023637605E67FC7EB6A101660"
      unitRef="usd">55032000</vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement>
    <vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32787351e2066-wk-Fact-9E6C98AD83391166D775C7EB6A1185C3"
      unitRef="usd">55038000</vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2119-wk-Fact-A3315801B25D6D667621C7EB6A05CA25"
      unitRef="usd">5602000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32787351e2158-wk-Fact-E121788E226E450B4C0CC7EB6A060C74"
      unitRef="usd">5602000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2211-wk-Fact-3FB876F2EB2BAC1D6048C7EB6A18D308"
      unitRef="usd">24000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32787351e2250-wk-Fact-FF68B40AF1BF9DBF36C4C7EB6A0FD43D"
      unitRef="usd">24000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2303-wk-Fact-06658F99CB4F7543823EC7EB6A02D60F"
      unitRef="usd">332000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32787351e2342-wk-Fact-8EC7A46807F31E8E773EC7EB6A0B75C7"
      unitRef="usd">332000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <vcyt:LegalSettlementRegardingShortSwingProfitsNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2395-wk-Fact-5D81785E2AA5E0915ECAC7EB6A03B803"
      unitRef="usd">310000</vcyt:LegalSettlementRegardingShortSwingProfitsNetOfTax>
    <vcyt:LegalSettlementRegardingShortSwingProfitsNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32787351e2434-wk-Fact-0A3C4E87D3080DBC3B0DC7EB6A14CFB7"
      unitRef="usd">310000</vcyt:LegalSettlementRegardingShortSwingProfitsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d32787351e2507-wk-Fact-1DFCCD1969BE4E9AF105C7EB6A0D2455"
      unitRef="usd">-22999000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32787351e2527-wk-Fact-4675E7BD94D094705776C7EB69D50F75"
      unitRef="usd">-22999000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e2548-wk-Fact-2EA943EC8196427F9B55C7EB6A047B1C"
      unitRef="shares">40863202</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e2562-wk-Fact-77D531659A79042D9C6EC7EB6A08400F"
      unitRef="usd">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2581-wk-Fact-21A37D78A31A7D431654C7EB6A19C11B"
      unitRef="usd">313800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d32787351e2601-wk-Fact-49F9716D7A0B97E50908C7EB6A189CB2"
      unitRef="usd">-234086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32787351e2621-wk-Fact-B98A1AF43330D54A4B8FC7EB69C3A655"
      unitRef="usd">79755000</us-gaap:StockholdersEquity>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e2641-wk-Fact-25049332183CB2E90A66E7CEF160C10A"
      unitRef="shares">1924156</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e2655-wk-Fact-8010AB601F5F3D852514E7CEF0C460EF"
      unitRef="usd">2000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2674-wk-Fact-CB51C43AA9FEA966CEF0E7CEF0BBD3A9"
      unitRef="usd">13376000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32787351e2713-wk-Fact-76E6EE3E65C59939480FE7CEF0B7EDD6"
      unitRef="usd">13378000</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e2733-wk-Fact-CE8178C0B75EA48D1416E7CEF1769DED"
      unitRef="shares">136251</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2766-wk-Fact-CC541D8520F772CC7780E7CEF0BF1EAD"
      unitRef="usd">1266000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32787351e2805-wk-Fact-D30C42A1D42F2C621F8FE7CEF09F5078"
      unitRef="usd">1266000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <vcyt:StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e2826-wk-Fact-EB68E76C6994848B85D5E7CEF0B1BA0C"
      unitRef="shares">6325000</vcyt:StockIssuedAndSoldDuringPeriodSharesInPrivatePlacement>
    <vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e2840-wk-Fact-4E7854F0C5E798479866E7CEF16DEFB2"
      unitRef="usd">6000</vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement>
    <vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2859-wk-Fact-9F62B7C49CC5693C7B73E7CEF0C8A71D"
      unitRef="usd">137842000</vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement>
    <vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32787351e2898-wk-Fact-DB19B13C0AC2292D2D51E7CEF0CD7A8C"
      unitRef="usd">137848000</vcyt:StockIssuedAndSoldDuringPeriodValueInPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e2918-wk-Fact-B32EAD9A4CC3B37127CEE7D08AC2C758"
      unitRef="shares">376732</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e2932-wk-Fact-8743F69C8F0077BF894DE7D099A57BD3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e2951-wk-Fact-722D79E287F6A68D259BE7D103BECCD8"
      unitRef="usd">9999000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32787351e2990-wk-Fact-D660AC90218275DDACC1E7D1122B17EC"
      unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e3043-wk-Fact-1B2DC13F4A9D4D7D0838E7CEF1696B5E"
      unitRef="usd">8883000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32787351e3082-wk-Fact-21FC48F99F26F2C2FB4FE7CEF0D5E352"
      unitRef="usd">8883000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e3135-wk-Fact-172D9E53AC82A41B1AFCE7CEF0D98818"
      unitRef="usd">181000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32787351e3174-wk-Fact-999E1EBCFC8AB300716EE7CEF17A9E0E"
      unitRef="usd">181000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e3227-wk-Fact-0A919FDA65ADD740EEE6E7CEF0AD3A0D"
      unitRef="usd">743000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32787351e3266-wk-Fact-CCE7693D078BFC89FF71E7CEF17273A6"
      unitRef="usd">743000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d32787351e3339-wk-Fact-3E5EA6FAA18792093F41E7CEF17E4469"
      unitRef="usd">-12599000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32787351e3359-wk-Fact-59EB930132FF9E8EA314C7EB69D4D3E3"
      unitRef="usd">-12599000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32787351e3380-wk-Fact-FBD2BE68B80981FD2EE8E7CEF0A8531D"
      unitRef="shares">49625341</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d32787351e3399-wk-Fact-ED6FCEE2BBBF59093AB0E7CEF099A7CD"
      unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d32787351e3418-wk-Fact-CBF130877ADE5BB74C94E7CEF0A3CBA2"
      unitRef="usd">486090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d32787351e3438-wk-Fact-13C08551E4E274B1838CE7CEF1650CC2"
      unitRef="usd">-246685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32787351e3458-wk-Fact-B29DA4BB134FDC60DE41C7EB69F0A0D3"
      unitRef="usd">239455000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e944-wk-Fact-1DE796C8009C8E6A5D88C7EB6A1D5BEE"
      unitRef="usd">-12599000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e964-wk-Fact-453059434A55F94973F2C7EB6A1F0DE7"
      unitRef="usd">-22999000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e984-wk-Fact-B1563AF1B868AB00D10FC7EB6A1FB62B"
      unitRef="usd">-31003000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1060-wk-Fact-0F0AC620FF7D5ECD9A3EC7EB69FAF93A"
      unitRef="usd">4117000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1079-wk-Fact-A8F68F702BDAFF25E3DFC7EB6A097EF5"
      unitRef="usd">3920000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1098-wk-Fact-0FAC63FF54B623DDAB4CC7EB69F71C08"
      unitRef="usd">3841000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1119-wk-Fact-75A42FED1B9E683A840AC7EB69ED1B0A"
      unitRef="usd">23000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1139-wk-Fact-117327C35159635D4B1BC7EB69FB6AF2"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1158-wk-Fact-4E9F2D33F4AC18D4EA6AC7EB6A0B4AB0"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1179-wk-Fact-D025BE25999113815158C7EB69F6B725"
      unitRef="usd">9807000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1198-wk-Fact-A8FCBB2C56A61BA520F4C7EB6A00BC7F"
      unitRef="usd">5958000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1217-wk-Fact-909F2F480AA79D72F6D3C7EB69F102CF"
      unitRef="usd">6617000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1238-wk-Fact-54AF4D42EF7AF672D43AC7EB6A046631"
      unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1257-wk-Fact-8FF3D915B68989C2D779C7EB69FED8DE"
      unitRef="usd">-93000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1277-wk-Fact-445AA3A14BC44563958CC7EB69F20BA2"
      unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1298-wk-Fact-2D9D8FD363B87A3B67A6C7EB69F2917F"
      unitRef="usd">83000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1317-wk-Fact-9422E6AA0EC19F6E6064C7EB69F22302"
      unitRef="usd">32000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1336-wk-Fact-5E6DE239CCB3DD22767FC7EB6A00096C"
      unitRef="usd">472000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1357-wk-Fact-EAAE3581261EF537F4D5C7EB69F94D03"
      unitRef="usd">229000</vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty>
    <vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1376-wk-Fact-4CF9D9DC2BFABB402699C7EB69FE7BB0"
      unitRef="usd">312000</vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty>
    <vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1395-wk-Fact-2BAEF7AED028548E8C96C7EB6A030F80"
      unitRef="usd">1589000</vcyt:DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1476-wk-Fact-B9EEF942205381B7319BC7EB6A09BA64"
      unitRef="usd">6161000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1496-wk-Fact-8C7502FF21A418DED320C7EB69F1EA65"
      unitRef="usd">452000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1516-wk-Fact-25E73882BF3BCE99DD58C7EB69FC300A"
      unitRef="usd">3960000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1538-wk-Fact-8539F0545CCEF090C7CAC7EB69F6FA7F"
      unitRef="usd">3404000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1558-wk-Fact-BE3077F2859090B2CCEAC7EB6A041738"
      unitRef="usd">-1922000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1577-wk-Fact-2454FFB25F0023A00B71C7EB69F6F1CA"
      unitRef="usd">1849000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1599-wk-Fact-949B33EB3B0306DB0105C7EB69F1F139"
      unitRef="usd">-154000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1618-wk-Fact-4226695B66ABB25B9962C7EB69F6CA85"
      unitRef="usd">517000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1638-wk-Fact-A8DB85698AF1350E330DC7EB6A06BA41"
      unitRef="usd">7000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1660-wk-Fact-F5AF626F2A5116063219E7DDBC7BCAAB"
      unitRef="usd">171000</vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities>
    <vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1680-wk-Fact-480B753C16CA1702355FE7DDBC76FB76"
      unitRef="usd">0</vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities>
    <vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1699-wk-Fact-ECA2870FC3C083361062E7DDBC64800E"
      unitRef="usd">0</vcyt:IncreaseDecreaseinOperatingLeaseAssetsandLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1720-wk-Fact-D48ECAFE8FA3B1943DF5C7EB69F6F2DB"
      unitRef="usd">351000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1740-wk-Fact-3DD3609607CDC293274DC7EB6A0A7D0F"
      unitRef="usd">760000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1760-wk-Fact-85340D033721ABCDEB3DC7EB6A057823"
      unitRef="usd">192000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1782-wk-Fact-332F36104E5060E6D48AC7EB69EE3C3A"
      unitRef="usd">-141000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1802-wk-Fact-AE81B459E34E7C9DE284C7EB6A00B610"
      unitRef="usd">-1568000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1822-wk-Fact-849D4CF4C6A113FA0478C7EB69FF6793"
      unitRef="usd">1728000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1843-wk-Fact-20D99125E381912E981AC7EB69F45D64"
      unitRef="usd">5228000</vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent>
    <vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1862-wk-Fact-7D752E99B96F0A56D051C7EB69FD888B"
      unitRef="usd">724000</vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent>
    <vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1881-wk-Fact-8514B001B94222E930B4C7EB69F2F7F2"
      unitRef="usd">-1163000</vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e1903-wk-Fact-AE09DC98C84D901B0641C7EB69F4120C"
      unitRef="usd">-3232000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e1923-wk-Fact-AD16A12FCECACA7E2A89C7EB69FEDD5B"
      unitRef="usd">-13521000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e1943-wk-Fact-0DD6D13FF4C6750244F9C7EB69F9B90A"
      unitRef="usd">-23915000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2024-wk-Fact-09D56CDD39457E911EA6E7E05B64DFD0"
      unitRef="usd">40000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2044-wk-Fact-858A9A85BF67DBE5065DE7E05B54C20B"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2063-wk-Fact-5453BFB1703A73E56B1EE7E05B40AB47"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2085-wk-Fact-1620CBA42EF69333C0B2C7EB69FDEA47"
      unitRef="usd">2756000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2105-wk-Fact-8E1C4AA4A52FF9BFD9DAC7EB6A0AA54F"
      unitRef="usd">1874000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2125-wk-Fact-E7C861D0619F0D8CCA0FC7EB69F75E06"
      unitRef="usd">1755000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2147-wk-Fact-8B1B987CF0A98A4ACFD5C7EB69FD12B7"
      unitRef="usd">23000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2166-wk-Fact-FE8DD29EBFC46285CC62C7EB69F4441E"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2185-wk-Fact-577E2DB3449E4B1FADCFC7EB69FDF82E"
      unitRef="usd">440000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2206-wk-Fact-720CD374AD9CC8BC4CF4C7EB69FB17E6"
      unitRef="usd">-42733000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2226-wk-Fact-DFFD2BB907E6F7F449B7C7EB69ED0AB4"
      unitRef="usd">-1874000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2246-wk-Fact-5953CCCC9317A6B5DA15C7EB69EF860A"
      unitRef="usd">-1315000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2327-wk-Fact-8E9EBC08849C2F49092FC7EB6A0107B2"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2346-wk-Fact-357A149881D79371373AC7EB6A0A7853"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2365-wk-Fact-0D53D08A2493CD98CA81C7EB69F4A4FA"
      unitRef="usd">24880000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2386-wk-Fact-F22188FBE9CBAD986BBEC7EB69F1F4A6"
      unitRef="usd">137848000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2405-wk-Fact-57777FCE2CB650F9C8C0C7EB69F25B4F"
      unitRef="usd">55038000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2424-wk-Fact-DD77535188EF298EE6D0C7EB6A075E11"
      unitRef="usd">200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2445-wk-Fact-100E22CC2A4B4D807F27C7EB69F40F4B"
      unitRef="usd">24900000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2465-wk-Fact-054A8B86A1357F55407CC7EB69F52D1F"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2484-wk-Fact-1446FABDDFB296169C8FC7EB6A01E495"
      unitRef="usd">25385000</us-gaap:RepaymentsOfLongTermDebt>
    <vcyt:PaymentOfEndOfTermObligation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2506-wk-Fact-CCE78E00BA29576AB067C7EB69EFF890"
      unitRef="usd">0</vcyt:PaymentOfEndOfTermObligation>
    <vcyt:PaymentOfEndOfTermObligation
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2525-wk-Fact-0030137EDF83ADAEA340C7EB6A085477"
      unitRef="usd">0</vcyt:PaymentOfEndOfTermObligation>
    <vcyt:PaymentOfEndOfTermObligation
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2544-wk-Fact-F391B5DB3F501FC23CB1C7EB69F1785C"
      unitRef="usd">1536000</vcyt:PaymentOfEndOfTermObligation>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2566-wk-Fact-8088F25FCB2AB6A79B20C7EB6A001A4D"
      unitRef="usd">0</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2585-wk-Fact-1FE55CD3F1EAF93BD616C7EB69ED7651"
      unitRef="usd">403000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2604-wk-Fact-72397BF3B6DD38E65EFCC7EB69F84471"
      unitRef="usd">0</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2625-wk-Fact-B1D558E4834BA2684D93C7EB69F40B01"
      unitRef="usd">308000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2645-wk-Fact-9EDBB037DE0C69F327EFC7EB69F9A089"
      unitRef="usd">292000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2665-wk-Fact-370BD7DB17A2CE512998C7EB69EE7801"
      unitRef="usd">274000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2687-wk-Fact-BA6AAF680D222ADCE20FC7EB69FCAF1E"
      unitRef="usd">14647000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2706-wk-Fact-19FF8F650E6204C2895DC7EB6A0A1D3D"
      unitRef="usd">4350000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2725-wk-Fact-FE75BDBDB024BFD81B0FC7EB69F9450D"
      unitRef="usd">1897000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2747-wk-Fact-C599BCD299C0105DE4D4C7EB69FC6A22"
      unitRef="usd">127287000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2766-wk-Fact-22BEBABA2E9AFF714DA1C7EB69FC7B29"
      unitRef="usd">59499000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2785-wk-Fact-07089E4F9236ABA926D1C7EB69FA9DDB"
      unitRef="usd">-218000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e2807-wk-Fact-81F16E2BD087CB4F6CF6C7EB69F7A1EF"
      unitRef="usd">81322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e2826-wk-Fact-044DD30E79A2828E5EB0C7EB69F58F2A"
      unitRef="usd">44104000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e2845-wk-Fact-F1337111ECEE5024A117C7EB69F39C60"
      unitRef="usd">-25448000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32782655e2867-wk-Fact-13B421D1C11B19932B7EC7EB69D2045A"
      unitRef="usd">78598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32782655e2886-wk-Fact-036EA14211F702059E51C7EB69D2EFE1"
      unitRef="usd">34494000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2016Q4"
      decimals="-3"
      id="d32782655e2905-wk-Fact-B0D8750124AF04CCC83DC7EB6A0AF429"
      unitRef="usd">59942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32782655e2931-wk-Fact-8D056D23254B5389F076C7EB69D20D9B"
      unitRef="usd">159920000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32782655e2950-wk-Fact-13B421D1C11B19932B7EC7EB69D2045A"
      unitRef="usd">78598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32782655e2969-wk-Fact-036EA14211F702059E51C7EB69D2EFE1"
      unitRef="usd">34494000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e3111-wk-Fact-3BDEEC28831A2DB276FEE7E1DB528644"
      unitRef="usd">14118000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e3130-wk-Fact-61D18D690C41345FEA81E7E1DB3D363E"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e3149-wk-Fact-4E38CA28BE27C4BD0C27E7E1DB2E4D9D"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e3165-wk-Fact-9CEA36BA03ACF966B293F79264C53004"
      unitRef="usd">10000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e3184-wk-Fact-ABF163510506778B2C30F7926489E920"
      unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e3203-wk-Fact-B12B5AF72EF80C5E68ADF792645BC4B6"
      unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e3224-wk-Fact-54E9266D8A886B1714C6F795AA4C4163"
      unitRef="usd">6088000</vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration>
    <vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e3243-wk-Fact-5E6543A86E00F08A8956F795AA540EA6"
      unitRef="usd">0</vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration>
    <vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e3262-wk-Fact-6197E4F6F015E4B34047F795AA5AA981"
      unitRef="usd">0</vcyt:NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e3283-wk-Fact-E40C12ADA9D815CC31DCC7EB6A0457FF"
      unitRef="usd">226000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e3302-wk-Fact-A52A69967110A7373E54C7EB6A06A878"
      unitRef="usd">273000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e3321-wk-Fact-8EA47800D8EE15B92626C7EB69FAC70F"
      unitRef="usd">42000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e3405-wk-Fact-CE914324B18B49D817FDC7EB6A074134"
      unitRef="usd">332000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e3424-wk-Fact-DAD2C32C88DB46D77314C7EB69FE02F0"
      unitRef="usd">1547000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e3443-wk-Fact-BCE2A161E57F1E751399C7EB69F92710"
      unitRef="usd">2718000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32782655e3464-wk-Fact-D55EC1ABAF02D83890C3C7EB69FA4C97"
      unitRef="usd">35000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32782655e3483-wk-Fact-0EAEA3341EC3535D2108C7EB6A031A52"
      unitRef="usd">79000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32782655e3502-wk-Fact-63A5F4F2E494C0FE657FC7EB6A0B6E07"
      unitRef="usd">21000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32782655e3700-wk-Fact-85FA5F8054B2E56BBECEC7EB6A1CA24A"
      unitRef="usd">159317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32782655e3719-wk-Fact-88BEE610D654577571D4C7EB6A07D9C0"
      unitRef="usd">77995000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32782655e3738-wk-Fact-499862F5EB32E43687A7407EF28AF936"
      unitRef="usd">33891000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32782655e3754-wk-Fact-058EE48AA43EBE8DA017C7EB6A1C4694"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32782655e3773-wk-Fact-D8FC4B0370974C14AE12C7EB6A127112"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32782655e3792-wk-Fact-CD68A20E95034CEDC4A5407EF28E3CBE"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32782655e3818-wk-Fact-8D056D23254B5389F076C7EB69D20D9B"
      unitRef="usd">159920000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32782655e3837-wk-Fact-13B421D1C11B19932B7EC7EB69D2045A"
      unitRef="usd">78598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32782655e3856-wk-Fact-036EA14211F702059E51C7EB69D2EFE1"
      unitRef="usd">34494000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7E1373FDDEAA52AA6C45C7EB6A29FF25-0-wk-Fact-EF6BB2E240268ED43FACC7EB69E07CE5">Organization and Description of Business&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Veracyte, Inc. (&#x201c;Veracyte&#x201d; or the &#x201c;Company&#x201d;) is a leading genomic diagnostics company that is creating value through innovation. The Company was founded in 2008 with a mission to improve diagnostic accuracy.  Today, the Company's growing menu of tests leverage advances in genomic science and technology to improve care throughout the patient journey, enabling more confident diagnostic, prognostic and treatment decisions in cancer and other challenging diseases. The Company is creating new standards of care by enabling more patients to avoid risks of unnecessary invasive procedures and removing costs from the healthcare system, while speeding the time to diagnosis and treatment decisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Veracyte was incorporated in the state of Delaware on August&#160;15, 2006 as Calderome,&#160;Inc. Calderome operated as an incubator until early 2008. On March&#160;4, 2008, the Company changed its name to Veracyte,&#160;Inc.  The Company&#x2019;s operations are based in South San Francisco, California and Austin, Texas, and it operates in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company performs its genomic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis, or IPF, in our CLIA-certified laboratory in South San Francisco, California. In December 2019, we announced our acquisition of the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System, as well as the Prosigna breast cancer prognostic gene signature assay, which is commercially available, and the LymphMark lymphoma subtyping assay, which is in development. Both tests are designed for use on the nCounter system. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company offers genomic tests in thyroid cancer; lung cancer; IPF and breast cancer:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Afirma Genomic Sequencing Classifier and Xpression Atlas.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's Afirma offerings include the Afirma GSC and  Xpression Atlas, to help guide next steps for patients with potentially cancerous thyroid nodules.  The  offerings are intended to provide physicians with clinically actionable results from a single fine needle aspiration, or FNA biopsy. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning, and is used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company commercially launched the Afirma Xpression Atlas in 2018 to complement the Afirma GSC. The Xpression Atlas provides physicians with genomic alteration content from the same FNA samples that are used in Afirma GSC testing and may help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Percepta Genomic Sequencing Classifier.  &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Percepta classifier improves lung cancer diagnosis by enhancing the performance of diagnostic bronchoscopies, thus identifying more patients with lung nodules who are at low risk of cancer and may avoid further, invasive procedures. This second-generation test was developed on our RNA whole-transcriptome sequencing platform and commercially introduced in June 2019, provides expanded clinical utility by also identifying patients as high risk of cancer so they may obtain faster diagnosis and treatment. The test is built upon foundational "field of injury" science - through which genomic changes associated with lung cancer in current and former smokers can be identified with a simple brushing of a person's airway - without the need to sample the often hard-to-reach nodule directly.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Envisia Genomic Classifier.  &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Envisia classifier improves diagnosis of IPF by helping physicians better differentiate IPF from other interstitial lung diseases, or ILDs, without the need for surgery. The test identifies the genomic pattern of usual interstitial pneumonia, or UIP, a hallmark of IPF, with high accuracy on patient samples that are obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Prosigna Breast Cancer Prognostic Gene Signature Assay&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; The Prosigna test, acquired in December 2019 through our strategic transaction with NanoString, uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test leverages a collection of 50 genes known as the PAM50 gene signature and can provide a breast cancer patient and physician with prognostic score that indicates the probability of cancer recurrence over ten years. Physicians use Prosigna to help guide therapeutic decisions so that patients receive a therapeutic intervention, such as chemotherapy, only if clinically warranted. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s approach also provides multiple opportunities for partnerships with biopharmaceutical companies. In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;All of the Company's testing services are made available through its clinical reference laboratories located in South San Francisco, California and Austin, Texas.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32787339e731-wk-Fact-D3DD3443486CB372D29AC7EB69E01ACD"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F9FFBD6EF84F402A821BC7EB6A2904C9-0-wk-Fact-8F5DD1B610AAA9BE7E50C7EB69E74EA3">Summary of Significant Accounting Policies&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, which was created in 2019 to process certain administrative functions associated with the business combination in Note 4, Business Combination. All intercompany accounts and transactions have been eliminated in consolidation.  Certain amounts have been reclassified on the consolidated statements of operations for presentation purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has incurred net losses since its inception and as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$246.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  The Company believes its cash and cash equivalents of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$159.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and its revenue from sales in 2020 will be sufficient to meet its anticipated cash requirements through at least February 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On May 7, 2019, the Company issued and sold&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,325,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock in a registered public offering, including&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;825,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares issued and sold upon the underwriters&#x2019; exercise in full of their option to purchase additional shares, at a price to the public of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share. The Company's net proceeds from the offering were approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$137.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2018, the Company issued and sold&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,750,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock in a registered public offering, including &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares issued and sold upon the underwriters' exercise in full of their option to purchase additional&#160;shares, at a price to the public of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share. The Company's net proceeds from the offering were approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$55.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting commissions and offering expenses of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2017, the Company entered into a Loan and Security Agreement and drew down a term loan advance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of which the entire amount was used to pay the outstanding balance of the Company's previous long-term debt as discussed in Note 8 - Debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If the Company is not able to generate cash proceeds from revenue sufficient to satisfy its cash obligations, the Company will need to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations or licensing arrangements. If the Company is not able to secure additional funding when needed, on acceptable terms, it may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives which may have a material adverse effect on the Company's business, results of operations, financial condition and/or its ability to fund its scheduled obligations on a timely basis or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The majority of the Company's cash and cash equivalents are deposited with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Several of the components of the Company's sample collection kit and test reagents, and its nCounter FLEX DX systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is also subject to credit risk from its accounts receivable related to its sales. The Company does not perform evaluations of customers' financial condition and does not require collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, most of the Company's revenue have been derived from the sale of Afirma. To date, Afirma has been delivered primarily to physicians in the United States. The Company's third-party payers and other customers in excess of 10% of revenue and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;UnitedHealthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's significant third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Johnson and Johnson Services, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;UnitedHealthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist of amounts invested in a money market account primarily consisting of U.S. Treasury reserves, and overnight reverse repurchase agreements which are tri-party repurchase agreements and are collateralized by U.S. Treasury and agency securities of at&#160;least&#160;102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had deposits of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$603,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; included in long-term assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company's South San Francisco facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company first determines whether a set of assets acquired and liabilities assumed constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.&#160; Contingent consideration obligations incurred in connection with a business combination are recorded at  fair value on the acquisition date and remeasured at each subsequent reporting period until the related contingencies are resolved, with the resulting changes in fair value recorded in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable and Allowance for Doubtful Accounts for Product Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable regularly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value by analyzing the status of significant past due receivables. Product sales commenced in December 2019 and there was no allowance for doubtful accounts at either December 31, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Finite-lived Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finite-lived intangible assets consist of intangible assets acquired as part of business combinations. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 5 to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. The Company tests these finite-lived intangible assets for impairment when events or circumstances indicate a reduction in the fair value below their carrying amounts. There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; impairment for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill, derived from the Company's acquisition of Allegro Diagnostics Corp. in September 2014 and the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System and Prosigna and LymphMark assays in December 2019, is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired. The Company's goodwill evaluation is done annually on October 31 and is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company has determined that it operates in a single segment and has a single reporting unit associated with the development and commercialization of diagnostic products. In the event the Company determines that it is more likely than not the carrying value of the reporting unit is higher than its fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value.  There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; impairment for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See Note&#160;6, "Fair Value Measurements" for further information on the fair value of the Company&#x2019;s financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company commenced recognizing testing revenue in accordance with the provisions of ASC 606, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or ASC 606, starting January 1, 2018.  Prior to January 1, 2018, the Company recognized testing revenue in accordance with the provisions of ASC 954-605, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Health Care Entities - Revenue Recognition&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or ASC 954. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Most of the Company&#x2019;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method, which requires a cumulative catch-up adjustment as if the Company had recognized revenue under ASC 606 from January 1, 2016.  Prior to January 1, 2018, the Company recognized revenue in accordance with ASC 954 and recognized revenue for tests delivered on an accrual basis when amounts that will ultimately be realized could be reasonably estimated, and on the cash basis when there was insufficient information to estimate revenue accruals.  There was sufficient payment history for the Company to substantially accrue all revenue upon delivery of test results starting July 1, 2016 and the Company continued to recognize revenue in 2017 upon cash receipt for unaccrued tests that were delivered prior to July 1, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Testing revenue recognized for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Testing revenue recognized on the accrual basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;107,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69,274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Testing revenue recognized on the cash basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;107,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As noted above, on July 1, 2016 the Company began recognizing testing revenue from substantially all its tests on the accrual basis of accounting at an amount equal to management&#x2019;s best estimate of the cash to ultimately be collected. For tests delivered prior to July 1, 2016, substantially all the related cash had been collected by December 31, 2017. Thus, at January 1, 2018, the cumulative impact of adopting ASC 606 was not material and no adjustment was recorded.  Since the Company commenced recognizing revenue from substantially all of its tests on the accrual basis of accounting commencing on July 1, 2016, and continued to do so after the adoption of ASC 606, the adoption of ASC 606 did not have a material impact on the Company's statement of operations for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which resulted in a decrease in the Company's loss from operations of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and a decrease in loss per share of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.04&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During 2018, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2017 or prior years and recognized additional revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which resulted in a decrease in the Company's loss from operations of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and a decrease in loss per share of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.04&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the year ended December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities. There was no revenue from instrument sales for the years ended December 31, 2019, 2018 or 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Biopharmaceutical and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company enters into arrangements for research and development and/or commercialization services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;amp;D services, and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC 808&#x201d;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The terms of the Company&#x2019;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net sales of data or other services to our customers are classified under biopharmaceutical revenue and collaboration revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Up-front Fees: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or the collaborative partner&#x2019;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#x2019;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Services Agreement with Loxo Oncology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc. ("Loxo") whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees. During the quarter ended June 30, 2018, the Company recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$450,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of revenue upon deliveries of tissue samples and the Company received &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for other services, which was recognized ratably during the quarters ended September 30 and December 31, 2018 as the services were  performed. Thereafter, the Company expects to receive approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per quarter as services are performed and may also recognize revenue related to the deliveries of additional tissue samples as long as the agreement is not terminated.  The agreement has a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year term with an automatic renewal of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and  Loxo may terminate the agreement at any time with at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;90&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days' notice.   As of December 31, 2019, the agreement had not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded that the performance obligations thereunder are the deliveries of tissue samples and performance of services, both of which are distinct.  For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$90,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for  deliveries of tissue samples and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the performance of services and is classified under biopharmaceutical revenue in the Consolidated Statement of Operations and Comprehensive Loss.  There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; deferred revenue related to this agreement at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Diagnostic Development Agreement with Johnson &amp;amp; Johnson&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc. ("JJSI") (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;bronchial genomic classifier diagnostic for lung cancer diagnosis (&#x201c;Percepta v.2") and a nasal genomic classifier diagnostic for lung cancer (&#x201c;NasaRISK&#x201d;) and (ii) for JJSI to use Veracyte data generated in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and NasaRISK programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, conditioned upon the achievement of certain milestones relating to the development and reimbursement of Percepta v.2 and NasaRISK.  For a period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; commencing with the first commercial sale of Percepta v.2 and NasaRISK, respectively, the Company will make payments to JJSI of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one percent&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for NasaRISK, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of data from its RNA whole-transcriptome sequencing platform to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments which was allocated to the obligation to deliver data.  The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognized revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and NasaRISK development milestones, respectively.  This revenue is classified under biopharmaceutical revenue and collaboration revenue, respectively, in the consolidated statement of operations and comprehensive loss.  Accounts receivable from JJSI was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  The cost of biopharmaceutical revenue recognized under the agreement with JJSI is not significant and recorded in research and development in the statement of operations and comprehensive loss.  There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; deferred revenue related to this agreement at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Collaboration Agreement with AstraZeneca Group&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V. ("Acerta"), a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#x2019;s development of oncology therapeutics.  Acerta will reimburse the Company for certain development costs and pay milestones to the Company for the achievement of development milestones.   As of December 31, 2019, there was no performance of obligations under the agreement or consideration paid.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cost of Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cost of Product Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of product revenue consists primarily of costs of purchasing instruments and consumables from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#x2019;s products and labor expenses. Cost of product revenue for instruments and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;consumables is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses include expenses incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products. These expenses consist of compensation expenses, direct research and development expenses such as prototype materials, laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses. We expense all research and development costs in the periods in which they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for income taxes under the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company's assessment of an uncertain tax position begins with the initial determination of the position's sustainability and is measured at the largest amount of benefit that is more-likely-than-not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense for stock options issued to employees is measured based on the grant-date fair value of the award. The fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model.  Stock-based compensation expense for stock units is measured based on the fair value of the award, which is determined based upon the closing price of the Company&#x2019;s common stock on the date of the grant.  The Company grants performance-based stock units to certain employees which vest upon the achievement of certain performance conditions, subject to the employees&#x2019; continued service with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes compensation costs on a straight-line basis for all employee stock-based compensation awards that are expected to vest over the requisite service period of the awards, which is generally the awards' vesting period. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following the adoption of ASU No. 2018-07, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; by the Company on October 1, 2018, stock-based compensation expense for equity instruments issued to non-employees is also measured based on the grant-date fair value of the awards using the Black-Scholes option-pricing model.  Prior to this, the fair value of such awards was subject to re-measurement as the underlying equity awards vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance.  The Company has a single reporting unit associated with the development and commercialization of diagnostic products.  Substantially all the Company&#x2019;s revenue for the years ended December 31, 2019, 2018 and 2017 was derived in the United States.  All of the Company&#x2019;s long-lived assets were located in the United States as of December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-2, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. This ASU is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU was effective for interim and annual periods beginning after December 15, 2018.  Additionally, the FASB issued ASU No. 2018-11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements.  The Company elected this transition method and adopted ASC 842 on January 1, 2019 and as a result, recorded operating lease right-of-use ("ROU") assets of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, including offsetting deferred rent of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, along with the associated operating lease liabilities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  On January 1, 2019, the Company had finance lease ROU assets of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and associated finance lease liabilities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for leases classified as finance leases prior to the adoption of ASC 842. The adoption of ASC 842 had an immaterial impact on the Company's consolidated statement of operations and comprehensive loss, consolidated statement of stockholders' equity and consolidated statement of cash flows for the year ended December 31, 2019.  In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease classification.  Additional information and disclosures required by this new standard are contained in Note 7,&#160;Commitments and Contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company does not expect to have a material impact on its financial statements and related disclosures from the adoption of this guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808). &lt;/span&gt;Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1D27DC2CF6B069521499C7EB6A2A3158-0-wk-Fact-08923C11DC7F77F72FC4C7EB69EBF0CF">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP").</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q4YTD"
      id="TextSelection-386B645574F4184AF154C7EB6A2BF068-0-wk-Fact-FD9338BDC8FF8A6F5D3AC7EB69EB0F9C">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-5"
      id="d32802967e780-wk-Fact-3C7A02E26785DEDDAD46C7EB69E9A8D5"
      unitRef="usd">-246700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d32802967e784-wk-Fact-2981EBB24DE659EE78E9C7EB69E9CE18"
      unitRef="usd">159300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q2May07"
      decimals="INF"
      id="d32802967e797-wk-Fact-F14E1E0B042CCA31097DE85431FEF51E"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q2May07_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d32802967e801-wk-Fact-0E23D053462F0B1BD33FE854BC8230FF"
      unitRef="shares">825000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I2019Q2May07"
      decimals="2"
      id="d32802967e805-wk-Fact-C5495141AE56C4F84FE5E8560BFEC7AB"
      unitRef="usdPerShare">23.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2019Q2May07"
      decimals="-5"
      id="d32802967e809-wk-Fact-32A66B66A05C2F6E9B02E856AFDE1696"
      unitRef="usd">137800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D2019Q2May07"
      decimals="-5"
      id="d32802967e813-wk-Fact-FCB7C8C8939E7C7D70E7E8578B2E4899"
      unitRef="usd">9200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2018Q3July"
      decimals="INF"
      id="d32802967e822-wk-Fact-E03D35475575CEB2BA4EC7EB69EE0E68"
      unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d32802967e826-wk-Fact-66772D250B09C00E1F31C7EB69E81A37"
      unitRef="shares">750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="I2018Q3Jul31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d32802967e830-wk-Fact-C31ACACBF781E231E595C7EB69EC4877"
      unitRef="usdPerShare">10.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="d32802967e834-wk-Fact-93A7CE4FB86A6B46EB0AC7EB69EAF469"
      unitRef="usd">55000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="d32802967e838-wk-Fact-32A5C4030FEB0AE81407C7EB69E81F6D"
      unitRef="usd">3900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="D2017Q4Nov_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d32802967e847-wk-Fact-04BAE4952369DB21D4CFC7EB69E8D16F"
      unitRef="usd">25000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BE5D9B4B7F4919B04BDAC7EB6A2A92C9-0-wk-Fact-6E225E52C34583394436C7EB69EBE138">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The majority of the Company's cash and cash equivalents are deposited with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Several of the components of the Company's sample collection kit and test reagents, and its nCounter FLEX DX systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is also subject to credit risk from its accounts receivable related to its sales. The Company does not perform evaluations of customers' financial condition and does not require collateral.&lt;/span&gt;&lt;/div&gt;</vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <vcyt:NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited
      contextRef="FI2019Q4"
      decimals="INF"
      id="d32802967e875-wk-Fact-512A9EEE40383AECA138C7EB69EABEFF"
      unitRef="financial_institution">1</vcyt:NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_vcyt_SalesRevenueGrossMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      id="TextSelection-B603E7555292D9C4018EC7EB6A2944AE-0-wk-Fact-0B8C30DE20DA93AF8C95C7EB69EEC75E">The Company's third-party payers and other customers in excess of 10% of revenue and their related revenue as a percentage of total revenue were as follows:&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;UnitedHealthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1027-wk-Fact-E69CF6249C23B9E7C64DC7EB69C5EA3F"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1042-wk-Fact-76B24DCDDE3128135539E85B515F0BBB"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1057-wk-Fact-7072E89B370735556EFBC7EB69C5ABC7"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1073-wk-Fact-606DB8FE73ADEB498591C7EB69C7AD06"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1088-wk-Fact-3522907C6B084CC29FE2E85B5171F9F4"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1103-wk-Fact-37EBB83CC78A11414514C7EB69C9A8F2"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1119-wk-Fact-F28F7570F9D453E35D80C7EB69C46C7C"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1134-wk-Fact-376131A4B14285C5B923E85B5169CCA8"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d32802967e1149-wk-Fact-456C9B687259E87A1FCBC7EB69C68288"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      id="TextSelection-4C5B7F100252EA2D46EAC7EB6A2A98AB-0-wk-Fact-4B3B98B926D78863E668C7EB69E31137">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's significant third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Johnson and Johnson Services, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;UnitedHealthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      decimals="2"
      id="d32802967e1258-wk-Fact-9F14E3AF05B85E109FA8C7EB6A173A68"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_MedicareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      decimals="2"
      id="d32802967e1273-wk-Fact-6AEA882E2605F626E8AFE85B3FF99E10"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      decimals="2"
      id="d32802967e1289-wk-Fact-6D239E7E47C851A38AC0E861BB4D687F"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      decimals="2"
      id="d32802967e1304-wk-Fact-B4A0CE4B8C6C661B7E52E861C4427460"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      decimals="2"
      id="d32802967e1320-wk-Fact-FE39DC1E092084082603C7EB69D1F95A"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_vcyt_UnitedHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      decimals="2"
      id="d32802967e1335-wk-Fact-E676770340BD5F682FDDE85B400969A0"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-F7C5E4D29AFBBD1DD181C7EB6A2BC573-0-wk-Fact-503C73C6A4032DB89F93C7EB69DED3A1">Cash Equivalents&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist of amounts invested in a money market account primarily consisting of U.S. Treasury reserves, and overnight reverse repurchase agreements which are tri-party repurchase agreements and are collateralized by U.S. Treasury and agency securities of at&#160;least&#160;102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-2F73BF48DAFCFCCD3A40C7EB6A2AA2D4-0-wk-Fact-AD51AC51F0E7B829BB03C7EB69E76923">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had deposits of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$603,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; included in long-term assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company's South San Francisco facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802967e1386-wk-Fact-058EE48AA43EBE8DA017C7EB6A1C4694"
      unitRef="usd">603000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-99C6ACEB0DD7D1CC98E2E85E544F97A1-0-wk-Fact-A0BF11593A53A6D8AC6BE8605A901A30">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company first determines whether a set of assets acquired and liabilities assumed constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.&#160; Contingent consideration obligations incurred in connection with a business combination are recorded at  fair value on the acquisition date and remeasured at each subsequent reporting period until the related contingencies are resolved, with the resulting changes in fair value recorded in earnings. &lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-A043F95F8A07FC1E9A877BDAD6419479-0-wk-Fact-D9825DA8005EEE66D4E47BDB42D19817">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable and Allowance for Doubtful Accounts for Product Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable regularly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value by analyzing the status of significant past due receivables.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3F1B1599A6ED34ABE0F8C7EB6A2B17B7-0-wk-Fact-653DADFFDFB1ADAC8D9FC7EB69E27CCD">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d32802967e1466-wk-Fact-D3138033E05C071AE2D5C7EB69EB6BA1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-BB41566385EDE86E65D1C7EB6A29A905-0-wk-Fact-25F7509FD699EA924D72C7EB69EAE031">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Finite-lived Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finite-lived intangible assets consist of intangible assets acquired as part of business combinations. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 5 to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. The Company tests these finite-lived intangible assets for impairment when events or circumstances indicate a reduction in the fair value below their carrying amounts. There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; impairment for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d32802967e1498-wk-Fact-64BD69516EB3C7E9FA67C7EB69ECE841">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32802967e1505-wk-Fact-A26213BC8284455D2474C7EB69F3D3EA"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-549379A35B73A2DF67EBC7EB6A2A51E5-0-wk-Fact-FBD0165CDF4E251388A6C7EB69D60159">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill, derived from the Company's acquisition of Allegro Diagnostics Corp. in September 2014 and the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System and Prosigna and LymphMark assays in December 2019, is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired. The Company's goodwill evaluation is done annually on October 31 and is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company has determined that it operates in a single segment and has a single reporting unit associated with the development and commercialization of diagnostic products. In the event the Company determines that it is more likely than not the carrying value of the reporting unit is higher than its fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value.  There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; impairment for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32802967e1546-wk-Fact-F27E9582D3F470225EE1C7EB69ED058B"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-0ABAAD7DC1D774E58CF4C7EB6A2AB460-0-wk-Fact-87235E90B6C6BFD32D8EC7EB69E74D6F">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CF78421317AFD905A122C7EB6A2ACE03-0-wk-Fact-6F2B109BAB1EF809C5BAC7EB6A19F792">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company commenced recognizing testing revenue in accordance with the provisions of ASC 606, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or ASC 606, starting January 1, 2018.  Prior to January 1, 2018, the Company recognized testing revenue in accordance with the provisions of ASC 954-605, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Health Care Entities - Revenue Recognition&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or ASC 954. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Most of the Company&#x2019;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method, which requires a cumulative catch-up adjustment as if the Company had recognized revenue under ASC 606 from January 1, 2016.  Prior to January 1, 2018, the Company recognized revenue in accordance with ASC 954 and recognized revenue for tests delivered on an accrual basis when amounts that will ultimately be realized could be reasonably estimated, and on the cash basis when there was insufficient information to estimate revenue accruals.  There was sufficient payment history for the Company to substantially accrue all revenue upon delivery of test results starting July 1, 2016 and the Company continued to recognize revenue in 2017 upon cash receipt for unaccrued tests that were delivered prior to July 1, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As noted above, on July 1, 2016 the Company began recognizing testing revenue from substantially all its tests on the accrual basis of accounting at an amount equal to management&#x2019;s best estimate of the cash to ultimately be collected. For tests delivered prior to July 1, 2016, substantially all the related cash had been collected by December 31, 2017. Thus, at January 1, 2018, the cumulative impact of adopting ASC 606 was not material and no adjustment was recorded.  Since the Company commenced recognizing revenue from substantially all of its tests on the accrual basis of accounting commencing on July 1, 2016, and continued to do so after the adoption of ASC 606, the adoption of ASC 606 did not have a material impact on the Company's statement of operations for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which resulted in a decrease in the Company's loss from operations of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and a decrease in loss per share of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.04&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During 2018, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2017 or prior years and recognized additional revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which resulted in a decrease in the Company's loss from operations of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and a decrease in loss per share of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.04&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the year ended December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities. There was no revenue from instrument sales for the years ended December 31, 2019, 2018 or 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Biopharmaceutical and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company enters into arrangements for research and development and/or commercialization services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;amp;D services, and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC 808&#x201d;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The terms of the Company&#x2019;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net sales of data or other services to our customers are classified under biopharmaceutical revenue and collaboration revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Up-front Fees: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or the collaborative partner&#x2019;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#x2019;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Services Agreement with Loxo Oncology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc. ("Loxo") whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees. During the quarter ended June 30, 2018, the Company recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$450,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of revenue upon deliveries of tissue samples and the Company received &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for other services, which was recognized ratably during the quarters ended September 30 and December 31, 2018 as the services were  performed. Thereafter, the Company expects to receive approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per quarter as services are performed and may also recognize revenue related to the deliveries of additional tissue samples as long as the agreement is not terminated.  The agreement has a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year term with an automatic renewal of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and  Loxo may terminate the agreement at any time with at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;90&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days' notice.   As of December 31, 2019, the agreement had not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded that the performance obligations thereunder are the deliveries of tissue samples and performance of services, both of which are distinct.  For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$90,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for  deliveries of tissue samples and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the performance of services and is classified under biopharmaceutical revenue in the Consolidated Statement of Operations and Comprehensive Loss.  There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; deferred revenue related to this agreement at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Diagnostic Development Agreement with Johnson &amp;amp; Johnson&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc. ("JJSI") (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;bronchial genomic classifier diagnostic for lung cancer diagnosis (&#x201c;Percepta v.2") and a nasal genomic classifier diagnostic for lung cancer (&#x201c;NasaRISK&#x201d;) and (ii) for JJSI to use Veracyte data generated in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and NasaRISK programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, conditioned upon the achievement of certain milestones relating to the development and reimbursement of Percepta v.2 and NasaRISK.  For a period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; commencing with the first commercial sale of Percepta v.2 and NasaRISK, respectively, the Company will make payments to JJSI of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one percent&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for NasaRISK, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of data from its RNA whole-transcriptome sequencing platform to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments which was allocated to the obligation to deliver data.  The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognized revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and NasaRISK development milestones, respectively.  This revenue is classified under biopharmaceutical revenue and collaboration revenue, respectively, in the consolidated statement of operations and comprehensive loss.  Accounts receivable from JJSI was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  The cost of biopharmaceutical revenue recognized under the agreement with JJSI is not significant and recorded in research and development in the statement of operations and comprehensive loss.  There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; deferred revenue related to this agreement at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Collaboration Agreement with AstraZeneca Group&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V. ("Acerta"), a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#x2019;s development of oncology therapeutics.  Acerta will reimburse the Company for certain development costs and pay milestones to the Company for the achievement of development milestones.   As of December 31, 2019, there was no performance of obligations under the agreement or consideration paid.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cost of Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-FA3D829EAB06E3954ACFC7EB6A2A6FA8-0-wk-Fact-76813A314507882D0A08C7EB69C23EE4">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Testing revenue recognized for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Testing revenue recognized on the accrual basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;107,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69,274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Testing revenue recognized on the cash basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;107,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <vcyt:RevenueRecognizedOnAccrualBasis
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e1920-wk-Fact-FC897C21B57C6F8B501DC7EB69F9AC72"
      unitRef="usd">107355000</vcyt:RevenueRecognizedOnAccrualBasis>
    <vcyt:RevenueRecognizedOnAccrualBasisPercentage
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e1934-wk-Fact-E2A3BB2226F37C44FE36C7EB69D932EE"
      unitRef="number">1</vcyt:RevenueRecognizedOnAccrualBasisPercentage>
    <vcyt:RevenueRecognizedOnAccrualBasis
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e1954-wk-Fact-546BB1E3C9451D4C107CE85B44BF3781"
      unitRef="usd">91058000</vcyt:RevenueRecognizedOnAccrualBasis>
    <vcyt:RevenueRecognizedOnAccrualBasisPercentage
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e1969-wk-Fact-98E3EAA3C188E385F975C7EB69DEFE52"
      unitRef="number">1</vcyt:RevenueRecognizedOnAccrualBasisPercentage>
    <vcyt:RevenueRecognizedOnAccrualBasis
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e1989-wk-Fact-3B208852EC8BB71E020BC7EB6A186B9F"
      unitRef="usd">69274000</vcyt:RevenueRecognizedOnAccrualBasis>
    <vcyt:RevenueRecognizedOnAccrualBasisPercentage
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e2003-wk-Fact-1D419CAFE32DEB7C44DEC7EB69ECC51F"
      unitRef="number">0.96</vcyt:RevenueRecognizedOnAccrualBasisPercentage>
    <vcyt:RevenueRecognizedReceivedInCash
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e2019-wk-Fact-9DA90D3A296F7D04C11AC7EB69D85729"
      unitRef="usd">0</vcyt:RevenueRecognizedReceivedInCash>
    <vcyt:RevenueRecognizedReceivedInCashPercentage
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e2038-wk-Fact-E3848748C2772438A3C4C7EB69EC0CBD"
      unitRef="number">0</vcyt:RevenueRecognizedReceivedInCashPercentage>
    <vcyt:RevenueRecognizedReceivedInCash
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e2053-wk-Fact-EF206CF9E93DBD3EDF84E85B44CC4114"
      unitRef="usd">0</vcyt:RevenueRecognizedReceivedInCash>
    <vcyt:RevenueRecognizedReceivedInCashPercentage
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e2073-wk-Fact-08CF4C0570263712ED56C7EB69FFB886"
      unitRef="number">0</vcyt:RevenueRecognizedReceivedInCashPercentage>
    <vcyt:RevenueRecognizedReceivedInCash
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e2088-wk-Fact-B4C515F873C0BD14C77BC7EB6A1162C6"
      unitRef="usd">2679000</vcyt:RevenueRecognizedReceivedInCash>
    <vcyt:RevenueRecognizedReceivedInCashPercentage
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e2107-wk-Fact-C3E45F5B5BD739409F68C7EB6A198901"
      unitRef="number">0.04</vcyt:RevenueRecognizedReceivedInCashPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e2128-wk-Fact-AF4C19BD2049D80EFD71E7C7BC8D5E19"
      unitRef="usd">107355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e2142-wk-Fact-0318F0A408F47F716ECFC7EB69DDAC74"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e2162-wk-Fact-29BCA614035BE02D486EE7C7BF04CEFD"
      unitRef="usd">91058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e2177-wk-Fact-A5DEAD2D0EABD69794BEC7EB69F9F143"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember"
      decimals="-3"
      id="d32802967e2197-wk-Fact-EDB8ADC16E235F5D9389E7C7C1448E6D"
      unitRef="usd">71953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vcyt_TestingMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d32802967e2211-wk-Fact-AEC7323551D71EBB6731C7EB69E3CE57"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-5"
      id="d32802967e2241-wk-Fact-031DAAB22CC890956B90C7EB69FB8F68"
      unitRef="usd">1600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-5"
      id="d32802967e2245-wk-Fact-A45519DA30D153CA3993C7EB69ECC880"
      unitRef="usd">1600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="2"
      id="d32802967e2249-wk-Fact-BF20EBE25D179D870579C7EB69EA5059"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-5"
      id="d32802967e2263-wk-Fact-FEA6B2749C6FADDA89AF406C9B87D1FD"
      unitRef="usd">1400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-5"
      id="d32802967e2267-wk-Fact-86EA30E82D9C3C5113CC406CAEE9DCCD"
      unitRef="usd">1400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="2"
      id="d32802967e2271-wk-Fact-2B848D720F02F24B964B406CC1CCDA45"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d32802967e2369-wk-Fact-0F70B7F4365CA0A2F72EED68F0787E83"
      unitRef="usd">450000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2018Q2_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d32802967e2373-wk-Fact-D8A6FA0EE1B2BE379C5DC7EB69E84124"
      unitRef="usd">500000</us-gaap:RevenueRemainingPerformanceObligation>
    <vcyt:RevenueRemainingPerformanceObligationAmountPerQuarter
      contextRef="FI2019Q4_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d32802967e2377-wk-Fact-D3203CF48F7F78F8C539C7EB69EB128C"
      unitRef="usd">250000</vcyt:RevenueRemainingPerformanceObligationAmountPerQuarter>
    <vcyt:AutomaticRenewalPeriodContractAgreement
      contextRef="D2018Q2Apr09_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      id="d32802967e2385-wk-Fact-8E0057817DB9132AD990C7EB6A1AF700">P1Y</vcyt:AutomaticRenewalPeriodContractAgreement>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d32802967e2398-wk-Fact-08BD707B873BAD473E04C7EB69EEBB4A"
      unitRef="usd">90000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d32802967e2402-wk-Fact-D2E4F792A2648746D506C7EB6A112CCD"
      unitRef="usd">1000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_srt_CounterpartyNameAxis_vcyt_BiopharmaceuticalCompanyMember"
      decimals="INF"
      id="d32802967e2406-wk-Fact-AC9B1DA85ABC69746B66C7EB69D59D0A"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <vcyt:DevelopmentPrograms
      contextRef="D2018Q4Dec28"
      decimals="INF"
      id="d32802967e2428-wk-Fact-7EDEA9CA98F7A4F719AEED2F2A481B88"
      unitRef="program">2</vcyt:DevelopmentPrograms>
    <vcyt:ContractAgreementReceivableForServices
      contextRef="I2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member"
      decimals="-5"
      id="d32802967e2438-wk-Fact-9304792FBDF207A81B09ED318B474C7B"
      unitRef="usd">7000000.0</vcyt:ContractAgreementReceivableForServices>
    <vcyt:ContractAgreementConditionalAccountsReceivable
      contextRef="I2018Q4Dec28"
      decimals="-5"
      id="d32802967e2442-wk-Fact-98173E287132E67D3C51ED33819BAA95"
      unitRef="usd">13000000.0</vcyt:ContractAgreementConditionalAccountsReceivable>
    <vcyt:TermContractAgreement
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member"
      id="d32802967e2446-wk-Fact-6B134E6B2E86BF28ADE8ED3662EF4F14">P10Y</vcyt:TermContractAgreement>
    <vcyt:ContractAgreementFeePercentageOfCashCollections
      contextRef="D2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member"
      decimals="INF"
      id="d32802967e2450-wk-Fact-26E1BF6804FB3957672FED3AF77D3446"
      unitRef="number">0.01</vcyt:ContractAgreementFeePercentageOfCashCollections>
    <vcyt:ContractAgreementReceivableForServices
      contextRef="I2018Q4Dec28_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member"
      decimals="-5"
      id="d32802967e2459-wk-Fact-9304792FBDF207A81B09ED318B474C7B"
      unitRef="usd">7000000.0</vcyt:ContractAgreementReceivableForServices>
    <vcyt:ContractAgreementConditionalAccountsReceivable
      contextRef="I2018Q4Dec28"
      decimals="-5"
      id="d32802967e2463-wk-Fact-98173E287132E67D3C51ED33819BAA95"
      unitRef="usd">13000000.0</vcyt:ContractAgreementConditionalAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_srt_ProductOrServiceAxis_vcyt_ProvisionofDataMember"
      decimals="-5"
      id="d32802967e2473-wk-Fact-5991A11AABBA334469DD407032F924E6"
      unitRef="usd">7000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_vcyt_JohnsonandJohnsonServicesInc.Member_srt_ProductOrServiceAxis_vcyt_FulfillmentofObligationsMember"
      decimals="-5"
      id="d32802967e2477-wk-Fact-45D2140844B5340866954070678B33C5"
      unitRef="usd">4000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableGross
      contextRef="FI2019Q4_srt_MajorCustomersAxis_vcyt_Perceptav.2andNassaRiskMember"
      decimals="-5"
      id="d32802967e2481-wk-Fact-DEC775A25FCDA61916ADED4265C89BAC"
      unitRef="usd">2000000.0</us-gaap:AccountsReceivableGross>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_srt_MajorCustomersAxis_vcyt_Perceptav.2andNassaRiskMember"
      decimals="INF"
      id="d32802967e2489-wk-Fact-5FBD68C44C74AFC7328BED4844E9AAAD"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-DBF1FD17D1FB875EEDFAC7EB6A2BD9EA-0-wk-Fact-62C5DABD98F0E26E574BC7EB69E7231E">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses include expenses incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products. These expenses consist of compensation expenses, direct research and development expenses such as prototype materials, laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses. We expense all research and development costs in the periods in which they are incurred. &lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B68B3CD6ADF0488D5D78C7EB6A2A1632-0-wk-Fact-FC0B09D2FA47C4DC1BB7C7EB69E25CB1">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for income taxes under the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company's assessment of an uncertain tax position begins with the initial determination of the position's sustainability and is measured at the largest amount of benefit that is more-likely-than-not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-2126EE56DB84FA51D32FC7EB6A2B1238-0-wk-Fact-2C47F864FC615715F3B0C7EB69E0207F">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense for stock options issued to employees is measured based on the grant-date fair value of the award. The fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model.  Stock-based compensation expense for stock units is measured based on the fair value of the award, which is determined based upon the closing price of the Company&#x2019;s common stock on the date of the grant.  The Company grants performance-based stock units to certain employees which vest upon the achievement of certain performance conditions, subject to the employees&#x2019; continued service with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes compensation costs on a straight-line basis for all employee stock-based compensation awards that are expected to vest over the requisite service period of the awards, which is generally the awards' vesting period. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following the adoption of ASU No. 2018-07, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting&lt;/span&gt; by the Company on October 1, 2018, stock-based compensation expense for equity instruments issued to non-employees is also measured based on the grant-date fair value of the awards using the Black-Scholes option-pricing model.  Prior to this, the fair value of such awards was subject to re-measurement as the underlying equity awards vest.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-FDF23C189AF593BF7101C7EB6A2B2EBD-0-wk-Fact-242AF6FB4E855CAD7A4CC7EB6A0EACBB">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F348D50AD7FB38B760FDC7EB6A292DF4-0-wk-Fact-8E4195B785616ACB4847C7EB69E8B3C7">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-2, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. This ASU is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU was effective for interim and annual periods beginning after December 15, 2018.  Additionally, the FASB issued ASU No. 2018-11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements.  The Company elected this transition method and adopted ASC 842 on January 1, 2019 and as a result, recorded operating lease right-of-use ("ROU") assets of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, including offsetting deferred rent of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, along with the associated operating lease liabilities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  On January 1, 2019, the Company had finance lease ROU assets of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and associated finance lease liabilities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for leases classified as finance leases prior to the adoption of ASC 842. The adoption of ASC 842 had an immaterial impact on the Company's consolidated statement of operations and comprehensive loss, consolidated statement of stockholders' equity and consolidated statement of cash flows for the year ended December 31, 2019.  In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease classification.  Additional information and disclosures required by this new standard are contained in Note 7,&#160;Commitments and Contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company does not expect to have a material impact on its financial statements and related disclosures from the adoption of this guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808). &lt;/span&gt;Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d32802967e2680-wk-Fact-53BC922840CEE1EB148DED5261E58C90"
      unitRef="usd">9800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ContractWithCustomerLiability
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d32802967e2684-wk-Fact-80F448671BE249A09994ED535EB1A299"
      unitRef="usd">4300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d32802967e2688-wk-Fact-85945D3F9C58C9FEA0AEED53F70FE8B5"
      unitRef="usd">14100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d32802967e2693-wk-Fact-117105DA7488C8FAECA4ED54523D05A8"
      unitRef="usd">800000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d32802967e2697-wk-Fact-E176484FD259A4F1E544ED548E452AE0"
      unitRef="usd">300000</us-gaap:FinanceLeaseLiability>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-FCF235337A0B53D00CDEC7EB6A2B56F1-0-wk-Fact-35C195ED37E551D7AE68C7EB6A1919D7">Net Loss Per Share&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following outstanding common stock equivalents have been excluded from diluted net loss per common share for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares of common stock subject to outstanding options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,394,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,998,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,163,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,869&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;712,122&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;384,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total common stock equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,133,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,417,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,261,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E653008D25B7D2F54C52C7EB6A2BBE4A-0-wk-Fact-008C0C78401D0C5E8222C7EB6A199629">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following outstanding common stock equivalents have been excluded from diluted net loss per common share for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares of common stock subject to outstanding options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,394,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,998,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,163,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,869&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;712,122&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;384,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total common stock equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,133,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,417,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,261,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="0"
      id="d32787343e866-wk-Fact-DB9BAE421F3D96B01072C7EB69E0C991"
      unitRef="shares">5394944</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="0"
      id="d32787343e880-wk-Fact-9BA188C3EE8B8A216E40C7EB69D65338"
      unitRef="shares">5998163</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="0"
      id="d32787343e894-wk-Fact-6A57A55C07499532FF9DC7EB69DBEA1E"
      unitRef="shares">6163734</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember"
      decimals="0"
      id="d32787343e909-wk-Fact-45D69AA62D5CA5747850C7EB69CD4438"
      unitRef="shares">26124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember"
      decimals="0"
      id="d32787343e923-wk-Fact-3AF8CBDDA7645B22F3F8C7EB69E233D9"
      unitRef="shares">34869</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember"
      decimals="0"
      id="d32787343e937-wk-Fact-9F0FE16375D003D04F2BC7EB69E40C0B"
      unitRef="shares">34559</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="d32787343e952-wk-Fact-6D53610870D2D9109E41C7EB69E46DE6"
      unitRef="shares">712122</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="d32787343e966-wk-Fact-7F70FE344A0612FCCBF6C7EB69DFECB0"
      unitRef="shares">384691</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="d32787343e980-wk-Fact-1A67DCE6904AEC2E5B0FC7EB69CDF07A"
      unitRef="shares">63425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD"
      decimals="0"
      id="d32787343e995-wk-Fact-1F41E0FD0BA17F7BF11FC7EB69D31321"
      unitRef="shares">6133190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD"
      decimals="0"
      id="d32787343e1009-wk-Fact-C9ED0F67B6C5B8A9DB39C7EB69D48F6F"
      unitRef="shares">6417723</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD"
      decimals="0"
      id="d32787343e1023-wk-Fact-D9DD2F51EF67A94FDE79C7EB69D78EF8"
      unitRef="shares">6261718</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F88BEB0016AC6265426F7BF510B8FE0C-0-wk-Fact-9E381B3845EF530FCB317BF5AF9FE2BE">Business Combination&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Exclusive License to NanoString Diagnostics Platform&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 3, 2019, the Company executed an agreement with NanoString for the exclusive global diagnostics license to the nCounter FLEX Analysis System, the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. The strategic transaction positions the Company to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to physicians and their patients via hospital and clinical laboratories throughout the European Union and other parts of the world.  The Company has accounted for this agreement under Accounting Standards Codification 805, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Business Combinations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  Pursuant to the terms of the agreement, Veracyte paid NanoString &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in Veracyte common stock, and may pay up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash, contingent upon the commercial launch of Veracyte diagnostic tests for use on the platform.  This contingency was valued at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of the acquisition date, recorded as a liability, and will be remeasured to fair value at each reporting date until the contingent consideration is settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets acquired are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.95711500974659%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;LymphMark product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;990&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54,420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.33723196881091%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Useful life (In Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;LymphMark product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. This acquisition includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of goodwill which the Company believes consists principally of the organized workforce &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;that will help the Company execute its strategic plans in relation to the assets acquired. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. As of December 31, 2019, goodwill is not deductible for tax purposes, however, if contingent consideration is paid at a future date, the portions of contingent consideration paid and allocated to the intangible assets for tax purposes will be tax deductible.  The accounting for this acquisition is preliminary and will be finalized upon completion of the analysis of certain contracts acquired and executed as part of this acquisition along with the impact on goodwill, should there be any.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The unaudited pro forma financial information in the table below summarizes the combined revenue for the Company and acquired business from NanoString as though the acquisition had been executed as of January 1, 2018. The pro forma amounts have been adjusted in the table below. NanoString&#x2019;s historical books and records did not contain the operating expense information to prepare the financial disclosures required in the pro forma table below. Thus, the pro forma financial disclosures are limited to revenue only. The unaudited pro forma revenue information is for informational purposes only and is not necessarily indicative of the revenue that would have been achieved if the acquisition had taken place as of January 1, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.99610136452242%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,482&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-5"
      id="d32788206e735-wk-Fact-02CB3C410F3805D37FCF4055ACC42195"
      unitRef="usd">40000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d32788206e739-wk-Fact-1EE963A314BAD516FF994057F063CF76"
      unitRef="usd">10000000.0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <vcyt:BusinessCombinationContingentConsiderationCashtobePaid
      contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-5"
      id="d32788206e743-wk-Fact-6E691EFBBEA2051DB8F3405DF2F7FA82"
      unitRef="usd">10000000.0</vcyt:BusinessCombinationContingentConsiderationCashtobePaid>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-5"
      id="d32788206e747-wk-Fact-6F132BD33B4F8765BCBC405E075C313F"
      unitRef="usd">6100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9211494B7494C7525385404DF12C2C5D-0-wk-Fact-47B2ADF936FD3A9FEB15404E04FCDDA2">The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.95711500974659%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;LymphMark product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;990&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54,420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      decimals="-3"
      id="d32788206e785-wk-Fact-15A42FBB6CBE50F376B264A81A071629"
      unitRef="usd">4120000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="d32788206e800-wk-Fact-A191995A176557EFCEEB64A81A140CDB"
      unitRef="usd">2430000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      decimals="-3"
      id="d32788206e820-wk-Fact-96FCC11E12B95C3705F864A81A2FA375"
      unitRef="usd">46880000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      decimals="-3"
      id="d32788206e840-wk-Fact-7953C0B6C049B741079464A819FE96C4"
      unitRef="usd">990000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-3"
      id="d32788206e860-wk-Fact-0CAEDE5D7795AFDF310B64A81A110A93"
      unitRef="usd">54420000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-3"
      id="d32788206e880-wk-Fact-E06C4279FAD35F34DAE164A81A1DEF64"
      unitRef="usd">1668000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-3"
      id="d32788206e905-wk-Fact-3534F45FD130B1A7A84E64A81A264ACE"
      unitRef="usd">56088000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EF76D86E1DAB635854A8404EBB0461FD-0-wk-Fact-3974A1B67252E44C8387405136EB9429">&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.33723196881091%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Useful life (In Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;LymphMark product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      id="d32788206e951-wk-Fact-DB1BF82392F5F14C617E64A81206DBB2">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      id="d32788206e962-wk-Fact-9B25203D06535E28A5B164A8120BF2DB">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      id="d32788206e973-wk-Fact-49F22AE98A1185BF601964A811F51FE7">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      id="d32788206e984-wk-Fact-34265CB10DFE2902D9D564A812009769">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-5"
      id="d32788206e993-wk-Fact-967B9338D4E3813882A8406929CBDC74"
      unitRef="usd">1700000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6C16F09C8F2A8AB674FE5FE52F29BD7F-0-wk-Fact-D62A7CB83941089156945FE73F989AE6">The unaudited pro forma revenue information is for informational purposes only and is not necessarily indicative of the revenue that would have been achieved if the acquisition had taken place as of January 1, 2018 (in thousands):&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.99610136452242%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,482&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-3"
      id="d32788206e1119-wk-Fact-B8AE32F5C6E768EBCB0A600646E23E5B"
      unitRef="usd">11040000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-3"
      id="d32788206e1138-wk-Fact-6F08BEA5F29F779371D7600657BAEB14"
      unitRef="usd">11482000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F5CD4A82591EAC5A10C0C7EB6A2BB6AD-0-wk-Fact-29DBAA532B71B9F854F9C7EB69CD06D4">Balance Sheet Components&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,926&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,615&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Software, including software developed for internal use&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,482&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,080&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization expense was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had a capital lease for laboratory equipment that went into service in 2017.  The lease was paid off in 2019 and the cost of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was included in Property and Equipment as of December 31, 2019.  The laboratory equipment had accumulated depreciation of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$600,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$367,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively and depreciation of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$233,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$232,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$135,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and 2017, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Finite-lived Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finite-live intangible assets consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Amortization Period (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Percepta product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,067&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,388&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;LymphMark product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;990&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of the Percepta product technology, which was acquired from the acquisition of Allegro in September 2014, began in April 2015 when research and development activities were deemed to be completed and is recognized on a straight-line basis.   Amortization of the Prosigna product technology, Prosigna customer relationships, nCounter FLEX Dx license and LymphMark product technology, which were acquired under an agreement with NanoString, see Note 4 - Business Combination, began in December 2019 and is recognized on a straight-line basis. Amortization of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was recognized for the years ended&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated future aggregate amortization expense as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,094&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,094&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,094&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,412&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-232CB3C1378854A95B6BC7EB6A2C92EA-0-wk-Fact-E3E5956052F18D278371C7EB69E6D707">&lt;div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,926&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,615&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Software, including software developed for internal use&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,482&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,080&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d32799112e849-wk-Fact-A924C36D62402111D32EC7EB69CF2474"
      unitRef="usd">5926000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d32799112e868-wk-Fact-D6FCE57E596A45CBDEF3C7EB6A1044F8"
      unitRef="usd">5825000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsLeasedToOthersMember"
      decimals="-3"
      id="d32799112e883-wk-Fact-644105048D981074C055C7EB69C1ED3C"
      unitRef="usd">9655000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsLeasedToOthersMember"
      decimals="-3"
      id="d32799112e902-wk-Fact-7AF32D3AE7BCD5EAE0F2C7EB69C26102"
      unitRef="usd">8895000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="d32799112e922-wk-Fact-4BE80B457140A6ADAE2CC7EB6A18E554"
      unitRef="usd">1709000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="d32799112e941-wk-Fact-EE81207F6A3C5328613CC7EB6A1E1D40"
      unitRef="usd">1615000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="d32799112e961-wk-Fact-324DBFA633035360CBF4C7EB6A1F7250"
      unitRef="usd">3226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="d32799112e980-wk-Fact-86BB5236729F0EC42FD4C7EB6A14D793"
      unitRef="usd">2450000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d32799112e1000-wk-Fact-6CA4B40D84052679BEECC7EB6A1B7F71"
      unitRef="usd">1482000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d32799112e1019-wk-Fact-3990347ADAEE94B4F7D8C7EB69CAB961"
      unitRef="usd">1435000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d32799112e1039-wk-Fact-403BC646B6AB14FEBFEFC7EB69C12A5B"
      unitRef="usd">1015000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d32799112e1058-wk-Fact-7997F0D32386173EED5DC7EB6A1C63C1"
      unitRef="usd">726000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e1078-wk-Fact-DACF1FDFE7B92742E104C7EB6A1C8386"
      unitRef="usd">23013000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e1097-wk-Fact-C7C08DDB2E8A368FFD01C7EB69CC6AF3"
      unitRef="usd">20946000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e1117-wk-Fact-7632EF8CACFE876DD880C7EB6A1F4063"
      unitRef="usd">14080000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e1137-wk-Fact-64FEA9A3DBE0878EF55BC7EB6A18DECE"
      unitRef="usd">12006000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e1163-wk-Fact-BC904E8E1E34A858FE66C7EB69C3C495"
      unitRef="usd">8933000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e1182-wk-Fact-F30BF87645E2C558788CC7EB69E8B74F"
      unitRef="usd">8940000</us-gaap:PropertyPlantAndEquipmentNet>
    <vcyt:DepreciationandAmortizationofTangibleAssets
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d32799112e1199-wk-Fact-D6B0800AA8FC4724D84DC7EB69D805CA"
      unitRef="usd">2700000</vcyt:DepreciationandAmortizationofTangibleAssets>
    <vcyt:DepreciationandAmortizationofTangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d32799112e1203-wk-Fact-4C5F4297CD8844F54451C7EB69C1E9D0"
      unitRef="usd">2900000</vcyt:DepreciationandAmortizationofTangibleAssets>
    <vcyt:DepreciationandAmortizationofTangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d32799112e1207-wk-Fact-BC176AC4D16DF6BDAFEBC7EB69CBB652"
      unitRef="usd">2800000</vcyt:DepreciationandAmortizationofTangibleAssets>
    <vcyt:FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-5"
      id="d32799112e1229-wk-Fact-15DD9807D88CA9DC2B49C7EB69D8F4C9"
      unitRef="usd">1200000</vcyt:FinanceLeaseRightofUseAssetbeforeAccumulatedAmortization>
    <vcyt:FinanceLeaseRightofUseAssetAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e1233-wk-Fact-66BD8C5877C0A52EA227C7EB69E26280"
      unitRef="usd">600000</vcyt:FinanceLeaseRightofUseAssetAccumulatedAmortization>
    <vcyt:FinanceLeaseRightofUseAssetAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e1237-wk-Fact-6C80566AEA4DF05715D4C7EB69C30845"
      unitRef="usd">367000</vcyt:FinanceLeaseRightofUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32799112e1250-wk-Fact-05CE6EC4CB8F6CE7F10CC7EB69DBDA39"
      unitRef="usd">233000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32799112e1254-wk-Fact-08CFE0CD72FE116F030AC7EB69DA3C52"
      unitRef="usd">232000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32799112e1258-wk-Fact-66EF64D2AF20DD1CB67D6DB479C06A49"
      unitRef="usd">135000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8B75C50A7CC409A8543DF77A605E7B55-0-wk-Fact-DAF5C80B044A7A02AF83F77BE11A7237">&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finite-live intangible assets consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Amortization Period (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Percepta product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,067&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,388&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nCounter FLEX Dx license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;LymphMark product technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;990&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember"
      decimals="-3"
      id="d32799112e1597-wk-Fact-2418EB5E80F01CCD2E65403A048C43CE"
      unitRef="usd">16000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember"
      decimals="-3"
      id="d32799112e1616-wk-Fact-4F9236037B0F8442AB4564ABCC2B86C0"
      unitRef="usd">5067000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember"
      decimals="-3"
      id="d32799112e1636-wk-Fact-3E9BC72E6CB768CEE4F264ABCC566DDB"
      unitRef="usd">10933000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember"
      decimals="-3"
      id="d32799112e1656-wk-Fact-894101FC571F43F6742C64ABCCDBA7B1"
      unitRef="usd">16000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember"
      decimals="-3"
      id="d32799112e1675-wk-Fact-8A0126666079DF1E930864ABCC62F6B9"
      unitRef="usd">4000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember"
      decimals="-3"
      id="d32799112e1696-wk-Fact-C7238380C6C72EE0D60F64ABCCD78919"
      unitRef="usd">12000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_PerceptaTechnologyMember"
      id="d32799112e1710-wk-Fact-E42EC2578D1AC8BBECD264ABCC4D40DA">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      decimals="-3"
      id="d32799112e1721-wk-Fact-3A94AF87FDC7A2423217403A047E92B5"
      unitRef="usd">4120000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      decimals="-3"
      id="d32799112e1740-wk-Fact-E0AFE6C94D28983CB7A664ABCC6F2746"
      unitRef="usd">17000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      decimals="-3"
      id="d32799112e1760-wk-Fact-90F7E51C8D3A666C2B6864ABCC94E808"
      unitRef="usd">4103000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      decimals="-3"
      id="d32799112e1780-wk-Fact-8B61A3200B67206D90A564ABCCB58088"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      decimals="-3"
      id="d32799112e1799-wk-Fact-4486275169E19F3AE84964ABCCA0C0A3"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      decimals="-3"
      id="d32799112e1818-wk-Fact-F9169CEAEFFA533727D864ABCCAC8B8A"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_DevelopedProductTechnologyMember"
      id="d32799112e1838-wk-Fact-80EC11ECE0101991BAF864ABCC87FF5F">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="d32799112e1849-wk-Fact-E5F91ECF77C6CA1AC0CE403A046F5A1E"
      unitRef="usd">2430000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="d32799112e1868-wk-Fact-3ABF611C91E76D0046C464ABCC44EF00"
      unitRef="usd">42000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="d32799112e1888-wk-Fact-E5969A1631DF0F1E6B8964ABCC66EA3C"
      unitRef="usd">2388000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="d32799112e1908-wk-Fact-1C5A63F19F21EB0096B564ABCCF2587D"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="d32799112e1927-wk-Fact-2ABECE7235781188670364ABCCE4E3FE"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="d32799112e1946-wk-Fact-8D617DA61AD78B77D0EB64ABCCFE33B3"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      id="d32799112e1966-wk-Fact-C94B7F4013CB31F2335464ABCC1CCBD3">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      decimals="-3"
      id="d32799112e1977-wk-Fact-ED1C327A6183804E1952403A04A4FFDD"
      unitRef="usd">46880000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      decimals="-3"
      id="d32799112e1996-wk-Fact-8AA668EE8D0764702C4564ABCC7BA426"
      unitRef="usd">263000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      decimals="-3"
      id="d32799112e2016-wk-Fact-B87C6375F7AEE07B698B64ABCC34C54B"
      unitRef="usd">46617000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      decimals="-3"
      id="d32799112e2036-wk-Fact-C6230F439B1DB88F43C164ABCCC23A61"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      decimals="-3"
      id="d32799112e2055-wk-Fact-FBE3A2E6507551449F3E64ABCCB9F2C6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      decimals="-3"
      id="d32799112e2074-wk-Fact-97AD06DD9583D4E1214164ABCC90330D"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_NCounterFLEXDxLicenseMember"
      id="d32799112e2094-wk-Fact-6CBA8FC068D421F11F6064ABCCC5AB39">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      decimals="-3"
      id="d32799112e2105-wk-Fact-EF52E1F4F1168BBA1C1B403A0454A615"
      unitRef="usd">990000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      decimals="-3"
      id="d32799112e2124-wk-Fact-3EE8F5681C6BA48E602164ABCD068548"
      unitRef="usd">12000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      decimals="-3"
      id="d32799112e2144-wk-Fact-4A130E805263C6FCE2CC64ABCC594CEB"
      unitRef="usd">978000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      decimals="-3"
      id="d32799112e2164-wk-Fact-C88D6D3D1FC54FC15D2964ABCC9DD0D8"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      decimals="-3"
      id="d32799112e2183-wk-Fact-CA9250A15428E1831BFB64ABCCCE1C92"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      decimals="-3"
      id="d32799112e2202-wk-Fact-27DA91CFAE9AB5AAA41D64ABCC40D3D2"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_vcyt_AZCollaborationLicenseMember"
      id="d32799112e2222-wk-Fact-F0A79FFE6CB8C23610AF64ABCC373075">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2238-wk-Fact-6704D3C47FF1EB88B911403A04968F77"
      unitRef="usd">70420000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2257-wk-Fact-1DF751DEAF16420C890364ABCCE71276"
      unitRef="usd">5401000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2277-wk-Fact-75E37D38A5E99637ED54C7EB69E7C084"
      unitRef="usd">65019000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e2297-wk-Fact-6740EDEB9313B03F0C5C64ABCCEF968E"
      unitRef="usd">16000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e2316-wk-Fact-B72682E54A6C522734CD64ABCC845DFA"
      unitRef="usd">4000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e2337-wk-Fact-05D77A7F1F0983F16406C7EB6A16033B"
      unitRef="usd">12000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD"
      id="d32799112e2351-wk-Fact-65B6B4F6EAA02D22AC1A64ABCC73D7B8">P14Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d32799112e2360-wk-Fact-AB70F4F25C75682A461EF77DEAED2DCE"
      unitRef="usd">1400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d32799112e2364-wk-Fact-C1672A46CB5EF94FD722F77E0AD88CEF"
      unitRef="usd">1100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d32799112e2368-wk-Fact-DE4A8E44AC909AA37638F77E1869F104"
      unitRef="usd">1100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7FE066979F10FCF68463F779D79E03A9-0-wk-Fact-21270B63A333FC7A5C7EF77A279EB266">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated future aggregate amortization expense as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,094&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,094&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,094&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2442-wk-Fact-7863297EE4731393A1EAF7748DC2A825"
      unitRef="usd">5095000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2457-wk-Fact-FA45CE84288732D8C2BEF77498E9C1FB"
      unitRef="usd">5094000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2477-wk-Fact-61C6F50A97F5B1B7F10AF774A3DAD098"
      unitRef="usd">5094000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2497-wk-Fact-03682E98F6C1145FAA41F774B264B21F"
      unitRef="usd">5094000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2517-wk-Fact-9023AB07306E5A9F75A3F774BCA738D4"
      unitRef="usd">5054000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2537-wk-Fact-4047DCCF907C8552E90AF774CB5F7563"
      unitRef="usd">39588000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2562-wk-Fact-75E37D38A5E99637ED54C7EB69E7C084"
      unitRef="usd">65019000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A7E0CB792A4756BDC0ECC7EB6A2C6FB0-0-wk-Fact-97FFAD0BDFAF22FE86C9C7EB69E155D6">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,412&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2699-wk-Fact-9521E79D9BD371C050A1C7EB69EA195B"
      unitRef="usd">10100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e2718-wk-Fact-DFBFC53D3AD089D8182AC7EB69E87AE6"
      unitRef="usd">6412000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2733-wk-Fact-A5F4E3E511DA181CFEEEC7EB69E2193C"
      unitRef="usd">3634000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e2752-wk-Fact-556F876FCF0B7BC527BDC7EB69DD44EA"
      unitRef="usd">2774000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32799112e2777-wk-Fact-44F2146EFC93E9182624C7EB6A0D77DE"
      unitRef="usd">13734000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32799112e2796-wk-Fact-DFD7CCCFD7DF8EABBE28C7EB69F57292"
      unitRef="usd">9186000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CD0F19E7E50567F6FE65C7EB6A2C6CFF-0-wk-Fact-C2B441F56207E2AFEE7EC7EB69F0093C">Fair Value Measurements &lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company records its financial assets and liabilities at fair value. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The carrying value of the Company's debt approximates its fair value because the interest rate approximates market rates that the Company could obtain for debt with similar terms. The   fair value of the Company&#x2019;s debt is estimated using the net present value of the payments, discounted at an interest rate that is consistent with market interest rates, which is a Level II input.&#160;The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;I: Inputs which include quoted prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;II: Inputs other than Level&#160;I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of the Company's financial assets includes money market funds, overnight reverse repurchase agreements&#160;and a deposit for the lease of the Company's South San Francisco facility.  Money market funds, included in cash and cash equivalents in the accompanying consolidated balance sheets, was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$57.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$76.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and are Level&#160;I assets as described above.  Overnight reverse repurchase agreements, included in cash and cash equivalents in the accompanying consolidated balance sheets, were&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;as of&#160;December 31, 2019&#160;and&#160;2018, respectively, and are Level II assets as described above.  There were no unrealized gains or losses from overnight reverse repurchase agreements at December 31, 2019 and 2018.  The deposit for the lease, included in restricted cash in the accompanying consolidated balance sheets, was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$603,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and is a Level I asset as described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The contingent consideration in Note 4, Business Combination, associated with the agreement with NanoString on December 3, 2019, is a Level III financial liability.  As of December 31, 2019, the contingent consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is dependent on the achievement of certain milestones and is payable in cash of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  Estimation of the fair value of the contingent consideration is based on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.  Changes to the forecasts for the achievement of milestones can significantly affect the estimated fair value of the contingent consideration.  There has been no change to the estimated fair value of the contingent consideration from the date of the agreement with NanoString to December 31, 2019 and the Company will assess the fair value of the contingent liability on a quarterly basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d32795742e758-wk-Fact-B81AB58D23D3148034D4C7EB69F03E72"
      unitRef="usd">57600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d32795742e762-wk-Fact-C98658F42A3B431F614FC7EB69ED75BF"
      unitRef="usd">76600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_vcyt_OvernightRepurchaseAgreementsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-5"
      id="d32795742e774-wk-Fact-66F99D29331B41B99293E86FC8EFF4E9"
      unitRef="usd">100000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_vcyt_OvernightRepurchaseAgreementsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-5"
      id="d32795742e779-wk-Fact-F4674E5832D98EB71A30E871C538F431"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:SecurityDeposit
      contextRef="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"
      decimals="-3"
      id="d32795742e783-wk-Fact-D14F5A5686B395163920C7EB69ED896E"
      unitRef="usd">603000</us-gaap:SecurityDeposit>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-5"
      id="d32795742e801-wk-Fact-6F132BD33B4F8765BCBC405E075C313F"
      unitRef="usd">6100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <vcyt:BusinessCombinationContingentConsiderationCashtobePaid
      contextRef="D2019Q4Dec3_us-gaap_BusinessAcquisitionAxis_vcyt_NanoStringMember"
      decimals="-5"
      id="d32795742e805-wk-Fact-6E691EFBBEA2051DB8F3405DF2F7FA82"
      unitRef="usd">10000000.0</vcyt:BusinessCombinationContingentConsiderationCashtobePaid>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-515F612103B8351691C8C7EB6A2C1B27-0-wk-Fact-DC026617FFA4A249E156C7EB6A0953F1">Commitments and Contingencies&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company leases its headquarters and laboratory facilities in South San Francisco, California under a non-cancelable lease agreement for approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet. The lease began in June 2015 and ends in March 2026 and contains extension of lease term and expansion options.  In February 2017, the Company relinquished certain expansion rights for a nominal fee.  The Company had deposits of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$603,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; included in long-term assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the South San Francisco facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company also leases laboratory and office space in Austin, Texas under a lease that expires in January 2029 and includes options for expansion and early termination in 2025.  The Company provided a cash security deposit for this lease of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$139,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,   included in other assets in the Company's balance sheets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determined its operating lease liabilities for the two operating leases mentioned above using a discount rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.53%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the rate that the Company would have to pay to borrow on a collateralized basis for a similar lease an amount equal to the lease payments in a similar economic environment.  Operating lease liabilities along with the associated right-of-use assets as of December&#160;31, 2019 are disclosed in the accompanying consolidated balance sheets.  After the adoption of ASC 842, the Company classified its deferred rent for tenant improvements with its operating lease right-of-use assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under non-cancelable operating leases as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Present value of future lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: short-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes rent expense on a straight-line basis over the non-cancelable lease period. Rent expense was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Supplies Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had non-cancelable purchase commitments with suppliers to purchase a minimum quantity of supplies for approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no litigation pending that could have, either individually or in the aggregate, a material impact on the Company's financial statements.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vcyt:LesseeLeasingArrangementsOperatingLeasesSpaceLeased
      contextRef="FD2019Q4YTD_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"
      decimals="-3"
      id="d32802884e732-wk-Fact-7C7EF9010400CA1C3768C7EB69D8279F"
      unitRef="sqft">59000</vcyt:LesseeLeasingArrangementsOperatingLeasesSpaceLeased>
    <us-gaap:SecurityDeposit
      contextRef="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoLeaseTwoMember"
      decimals="-3"
      id="d32802884e736-wk-Fact-D14F5A5686B395163920C7EB69ED896E"
      unitRef="usd">603000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="FI2019Q4_us-gaap_LeaseArrangementTypeAxis_vcyt_LaboratoryFacilitiesAustinTexasMember"
      decimals="-3"
      id="d32802884e753-wk-Fact-3BFC689FB1846EE3DF79C7EB6A0CE4FD"
      unitRef="usd">139000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="FI2019Q4"
      decimals="4"
      id="d32802884e770-wk-Fact-71D8DF9D86447B5BAD9AF79B6CDD4BC1"
      unitRef="number">0.0753</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7E3638F2896EFA2DE448C7EB6A2C16E8-0-wk-Fact-584633AFE23B77BF6E21C7EB6A0556BC">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under non-cancelable operating leases as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Present value of future lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: short-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e835-wk-Fact-1FFBD50DB21F2F82FA99C7EB69CE1B8C"
      unitRef="usd">2332000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e850-wk-Fact-F63F8DD77DF2E9BA8D31C7EB69D586C8"
      unitRef="usd">2401000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e870-wk-Fact-266A5F0771501669D19DC7EB69D03B20"
      unitRef="usd">2472000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e890-wk-Fact-D0ED21E48A8243680CB5C7EB69D04AAD"
      unitRef="usd">2543000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e910-wk-Fact-1160FE104D90D20D20FDC7EB69D23D56"
      unitRef="usd">2614000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e930-wk-Fact-3A15E885FE9936F0506DC7EB69D13BC4"
      unitRef="usd">4226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e950-wk-Fact-392D5F5FD7B9390C86B0C7EB69D3908F"
      unitRef="usd">16588000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e970-wk-Fact-3BBDFC7158DBA04AFD6B68B595CDFBCE"
      unitRef="usd">3675000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e990-wk-Fact-B6E5E357628D0B943D5968B5D327B6C9"
      unitRef="usd">12913000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e1010-wk-Fact-DA69985FEE89AB339388E7C06DCF75A8"
      unitRef="usd">1407000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32802884e1036-wk-Fact-22852C72B4C466775DD0E7C1744D50AA"
      unitRef="usd">11506000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d32802884e1054-wk-Fact-207A386A71160C1FCD5EC7EB69FAB5A4"
      unitRef="usd">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d32802884e1058-wk-Fact-3B967EF8E1FFA5388428C7EB6A0C218D"
      unitRef="usd">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d32802884e1062-wk-Fact-B37F8FD4717E53CE2EF1C7EB69FA6465"
      unitRef="usd">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:PurchaseObligation
      contextRef="FI2019Q4"
      decimals="-5"
      id="d32802884e1089-wk-Fact-4650EBDD38B9175733BBC7EB6A0C77D7"
      unitRef="usd">7600000</us-gaap:PurchaseObligation>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B524A9D7875FC0F1B218C7EB6A29DFBA-0-wk-Fact-2A53E85E332DE36D11FCC7EB69FFFD21">Debt&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On November 3, 2017, the Company entered into a loan and security agreement (the &#x201c;Loan and Security Agreement&#x201d;) with Silicon Valley Bank.  The Loan and Security Agreement allows the Company to borrow up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, with a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; advance term loan (the &#x201c;Term Loan Advance&#x201d;) and a revolving line of credit of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the &#x201c;Revolving Line of Credit&#x201d;).  The Term Loan Advance was advanced upon the closing of the Loan and Security Agreement and was used to pay the outstanding balance of the Company&#x2019;s existing long-term debt, which was canceled at that date.  The Company had not drawn on the Revolving Line of Credit as of December 31, 2019.  Borrowings under the Loan and Security Agreement mature on October 1, 2022.  Amounts may be borrowed and repaid under the Revolving Line of Credit up until the earliest of full repayment or maturity of the Loan and Security Agreement, termination of the Loan and Security Agreement, or October 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Term Loan Advance bears interest at a variable rate equal to (i) the thirty-day U.S. London Interbank Offer Rate (&#x201c;LIBOR&#x201d;) plus (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, with a minimum rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.43%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum. Principal amounts outstanding under the Revolving Line of Credit bear interest at a variable rate equal to (i) LIBOR plus (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, with a minimum rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.70%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum.  The average Term Loan Advance interest rate for the year ended&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.70%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company may prepay the outstanding principal amount under the Term Loan Advance plus accrued and unpaid interest and, if the Term Loan Advance is repaid in full, a prepayment premium. The prepayment premium will be (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$750,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if prepayment is made prior to November 3, 2018, (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if the prepayment is made after November 3, 2018 but on or before November 3, 2019, or (iii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if the prepayment is made after November 3, 2019.  In January 2019 and May 2019, the Company prepaid&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the principal amount of the Term Loan Advance. These prepayments did not trigger any prepayment premium because they were partial, not full, repayments of the principal amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition, a final payment on the Term Loan Advance in the amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is due upon the earlier of the maturity date of the Term Loan Advance or its payment in full.  The Loan and Security Agreement contains customary representations, warranties, and events of default such as a material adverse change in our business, operations or financial condition, as well as affirmative and negative covenants. The negative covenants include, among other provisions, covenants that limit or restrict the Company's ability to incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of its equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company&#x2019;s obligations under the Loan and Security Agreement are secured by substantially all of its assets (excluding intellectual property), subject to certain customary exceptions.  The Loan and Security Agreement also requires the Company to achieve certain revenue levels tested quarterly on a trailing twelve-month basis.  However, failure to maintain the revenue levels will not be considered a default if the Company maintains liquidity of at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company was in compliance with the loan covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;End-of-term debt obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net debt obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future principal and end-of-term debt obligation payments due under the Loan and Security Agreement are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The end-of-term debt obligation accretes over the term of the Loan and Security Agreement until maturity and is included in interest expense in the Company's consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March&#160;2016, the Company entered into a credit agreement (the &#x201c;Credit Agreement&#x201d;) with Visium Healthcare Partners, LP (&#x201c;Visium&#x201d;). Under the Credit Agreement, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; term loans were available to the Company with an aggregate principal amount of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company drew down the initial &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; term loan (the &#x201c;Initial Term Loan&#x201d;) on March&#160;30, 2016, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was used to pay the outstanding balance of the Company&#x2019;s previous long-term debt, which was canceled at that date. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Term Loans bore interest at a fixed rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per annum and no principal payments were due through March&#160;31, 2020. The Company was obligated to repay the outstanding principal amounts under the Term Loans in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;eight&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equal installments during the final &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under the Credit Agreement. Prepayment of the outstanding principal amount under the Term Loans prior to March 31, 2018 was subject to a prepayment premium equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the outstanding principal balance, less the aggregate amount of all interest payments in cash.  For any quarterly interest payment through and including the 16th interest payment date after the Initial Borrowing Date, so long as no event of default had occurred and was then continuing, the Company could have elected to pay interest in cash on the outstanding principal amounts of the Term Loans at a fixed rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, with the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; interest paid-in-kind by adding such paid-in-kind interest to the outstanding principal amounts of the Term Loans.  The Company elected to pay interest in-kind for the quarters ended June 30, 2016 and September 30, 2016, totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$385,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As noted above, upon entering into the Loan and Security Agreement, the Credit Agreement was paid in full and terminated on November 3, 2017, wherein all commitments were terminated, all liens were released and all outstanding principal, interest and fees accrued thereunder were repaid in the aggregate amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, including a prepayment premium of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest expense was recognized as follows (in thousands of dollars):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nominal debt interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization and write-off of debt discount and issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;End-of-term debt obligation interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt prepayment penalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,536&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest on capital lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;677&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,963&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="I2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e731-wk-Fact-C492D2ABC5C5983685EFC7EB69C5261F"
      unitRef="usd">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e735-wk-Fact-C28217F1F1205E8B6F10C7EB6A018EAA"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e739-wk-Fact-591BD0C91735986850F5C7EB69C0A4A1"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="INF"
      id="d32804889e748-wk-Fact-7C48C13DCAD86B8B9D38C7EB69C3C44A"
      unitRef="number">0.0420</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2017Q4Nov3_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="INF"
      id="d32804889e752-wk-Fact-EF6BE71E1459C13D290BC7EB6A038FBB"
      unitRef="number">0.0543</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="INF"
      id="d32804889e756-wk-Fact-C7DDCC2550FC3A73E6F2C7EB69C30FC1"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2017Q4Nov3_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="INF"
      id="d32804889e760-wk-Fact-F40D5B2E22918E1C782EC7EB69C1E796"
      unitRef="number">0.0470</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="4"
      id="d32804889e769-wk-Fact-7A2EE7322761268F1926C7EB69C1A89A"
      unitRef="number">0.0670</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <vcyt:DebtInstrumentPrepaymentPremium
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheOneMember"
      decimals="INF"
      id="d32804889e778-wk-Fact-81199799DE2972952098C7EB69FFC985"
      unitRef="usd">750000</vcyt:DebtInstrumentPrepaymentPremium>
    <vcyt:DebtInstrumentPrepaymentPremium
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheTwoMember"
      decimals="INF"
      id="d32804889e782-wk-Fact-FA9A8FC9125F381B3FF1C7EB69FF2B76"
      unitRef="usd">500000</vcyt:DebtInstrumentPrepaymentPremium>
    <vcyt:DebtInstrumentPrepaymentPremium
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_vcyt_DebtPrepaymentTrancheAxis_vcyt_DebtPrepaymentTrancheThreeMember"
      decimals="INF"
      id="d32804889e786-wk-Fact-8DE1947FA739DBE7731CC7EB6A02B974"
      unitRef="usd">250000</vcyt:DebtInstrumentPrepaymentPremium>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="D2018Q1Jan01-Jan31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d32804889e790-wk-Fact-AF3AC49B848081608ABDE880249F2130"
      unitRef="usd">12500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="D2019Q2May2019_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d32804889e794-wk-Fact-8982CB103DEABB81BCE3E88023928B85"
      unitRef="usd">12400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="I2017Q4Nov3_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e803-wk-Fact-08F9F1383706DEAF8042C7EB69C04B5D"
      unitRef="usd">1200000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <vcyt:LiquidityRequirementMinimum
      contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_SiliconValleyBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e807-wk-Fact-0AFDAF5EA1C986BAADA4C7EB6A01339D"
      unitRef="usd">40000000.0</vcyt:LiquidityRequirementMinimum>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-199C35F6A9DBD86B38D7C7EB6A29855B-0-wk-Fact-F4062C063F459F9072BAC7EB6A055CE5">&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;End-of-term debt obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net debt obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e947-wk-Fact-656030E1C19893B5C0FCC7EB69E30964"
      unitRef="usd">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e966-wk-Fact-D66870793B5BFBA7F6FDC7EB69E39288"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <vcyt:DebtInstrumentEndOfTermPaymentInterestAmount
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e981-wk-Fact-8C0C0A24AEC28188B8DB7C9C9FF3E1A9"
      unitRef="usd">594000</vcyt:DebtInstrumentEndOfTermPaymentInterestAmount>
    <vcyt:DebtInstrumentEndOfTermPaymentInterestAmount
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e1000-wk-Fact-CB140B71A67A19CB10267C9CA119D14D"
      unitRef="usd">365000</vcyt:DebtInstrumentEndOfTermPaymentInterestAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e1020-wk-Fact-EA6CA2A962559AA63495C7EB69E3166C"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e1039-wk-Fact-0385952551FDD181AEC6C7EB69E32423"
      unitRef="usd">83000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e1065-wk-Fact-81970322869A90FDCE06C7EB69E29A34"
      unitRef="usd">694000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e1084-wk-Fact-617081BA1FA222FBAD15C7EB69E37024"
      unitRef="usd">25282000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d32804889e1103-wk-Fact-D9F03DB053646D415EABC7EB69F94023"
      unitRef="usd">1300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <vcyt:NumberOfTermLoans
      contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e1130-wk-Fact-AA7D0176D28362880CFDC7EB69C045C2"
      unitRef="term_loan">2</vcyt:NumberOfTermLoans>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e1134-wk-Fact-8FA06A5DC38D68E8EFE8C7EB69FF1670"
      unitRef="usd">40000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="D2016Q1Mar30-Mar30_us-gaap_DebtInstrumentAxis_vcyt_InitialTermLoanMember_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d32804889e1138-wk-Fact-9B4B33BD0A94FF7956BAC7EB69C2D1CA"
      unitRef="usd">25000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="D2016Q1Mar30-Mar30_us-gaap_DebtInstrumentAxis_vcyt_InitialTermLoanMember_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d32804889e1142-wk-Fact-8481C0E88C112A0609BAC7EB69FF5DA8"
      unitRef="usd">5000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e1152-wk-Fact-9EE076F910CF6F27238BC7EB69C3E6DC"
      unitRef="number">0.120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <vcyt:DebtInstrumentNumberOfInstallments
      contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e1156-wk-Fact-E53A9BF1522B5D2241DBC7EB69C44977"
      unitRef="installment">8</vcyt:DebtInstrumentNumberOfInstallments>
    <vcyt:TermOfDebtWithEqualQuarterlyInstallments
      contextRef="FD2019Q4YTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      id="d32804889e1160-wk-Fact-E462754B554516CC86C3C7EB69C23199">P2Y</vcyt:TermOfDebtWithEqualQuarterlyInstallments>
    <vcyt:DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne
      contextRef="FD2019Q4YTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="3"
      id="d32804889e1164-wk-Fact-275B4ECBA8DF08AAA9B8C7EB69C4F630"
      unitRef="number">0.240</vcyt:DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne>
    <vcyt:DebtInstrumentFixedRatePercentagePaidInCash
      contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e1168-wk-Fact-93F50FE39B48D2148A4CC7EB69C33D3A"
      unitRef="number">0.090</vcyt:DebtInstrumentFixedRatePercentagePaidInCash>
    <vcyt:DebtInstrumentInterestPaidInKindPercentage
      contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="3"
      id="d32804889e1173-wk-Fact-E2BB353C958A51E00FE4C7EB69C24504"
      unitRef="number">0.030</vcyt:DebtInstrumentInterestPaidInKindPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d32804889e1177-wk-Fact-9EE076F910CF6F27238BC7EB69C3E6DC"
      unitRef="number">0.120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaidInKindInterest
      contextRef="FD2016Q2QTD_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-3"
      id="d32804889e1181-wk-Fact-2A28690522B11B7E8C53C7EB69FE217D"
      unitRef="usd">385000</us-gaap:PaidInKindInterest>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="D2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d32804889e1191-wk-Fact-1E843413AF00182C4165C7EB69C00574"
      unitRef="usd">27300000</us-gaap:RepaymentsOfLongTermDebt>
    <vcyt:PaymentOfEndOfTermObligation
      contextRef="D2017Q4Nov3_us-gaap_LineOfCreditFacilityAxis_vcyt_VisiumMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d32804889e1195-wk-Fact-1351F4C4F224131CF9D8C7EB69C1008F"
      unitRef="usd">1500000</vcyt:PaymentOfEndOfTermObligation>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-227C645AB5C7A4803C97C7EB6A29DDC8-0-wk-Fact-AF79593C3A371893669AC7EB69FE3ADE">&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest expense was recognized as follows (in thousands of dollars):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nominal debt interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization and write-off of debt discount and issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;End-of-term debt obligation interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt prepayment penalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,536&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest on capital lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;677&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,963&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32804889e1391-wk-Fact-DA70F0E93D397E7E3E57C7EB69C6187C"
      unitRef="usd">332000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32804889e1410-wk-Fact-E5579B6B54553D50CD5CC7EB69C5C5A8"
      unitRef="usd">1568000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32804889e1429-wk-Fact-E397AACD0A14A450ACA6C7EB69C7DAD8"
      unitRef="usd">2838000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32804889e1445-wk-Fact-B9E80BBF080688E97EECC7EB69C52F74"
      unitRef="usd">107000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32804889e1464-wk-Fact-096EFD9A63FCADEBB827C7EB69C72602"
      unitRef="usd">57000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32804889e1483-wk-Fact-62A4761FC211620A6E5FC7EB69C94B57"
      unitRef="usd">472000</us-gaap:AmortizationOfDebtDiscountPremium>
    <vcyt:DebtInstrumentEndOfTermInterestObligationAmount
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32804889e1504-wk-Fact-2AA68FC65F838D6B10DD7C9142B4346A"
      unitRef="usd">229000</vcyt:DebtInstrumentEndOfTermInterestObligationAmount>
    <vcyt:DebtInstrumentEndOfTermInterestObligationAmount
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32804889e1523-wk-Fact-F2BE154BD710F1E7FE617C9142A7C457"
      unitRef="usd">312000</vcyt:DebtInstrumentEndOfTermInterestObligationAmount>
    <vcyt:DebtInstrumentEndOfTermInterestObligationAmount
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32804889e1542-wk-Fact-7BFE1176C0006AD2328E7C9142A15A6F"
      unitRef="usd">53000</vcyt:DebtInstrumentEndOfTermInterestObligationAmount>
    <vcyt:PrepaymentPenalty
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32804889e1563-wk-Fact-BA8C5C3804DCE6F2BC77C7EB69C6254C"
      unitRef="usd">0</vcyt:PrepaymentPenalty>
    <vcyt:PrepaymentPenalty
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32804889e1582-wk-Fact-88D42661B8D8CBCC54F7C7EB69C47A0E"
      unitRef="usd">0</vcyt:PrepaymentPenalty>
    <vcyt:PrepaymentPenalty
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32804889e1601-wk-Fact-54CCCB312B9C8632AB40C7EB69C9E769"
      unitRef="usd">1536000</vcyt:PrepaymentPenalty>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32804889e1622-wk-Fact-C175AF5A578158838BA7C7EB69C4BD0C"
      unitRef="usd">9000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32804889e1641-wk-Fact-A8DBD6604FB7DB172752C7EB69C5D267"
      unitRef="usd">26000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32804889e1660-wk-Fact-6CEEFA1E61E2F69B333AC7EB69C8F452"
      unitRef="usd">42000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32804889e1686-wk-Fact-23F7CD23D2F02C042CE7C7EB69C72155"
      unitRef="usd">677000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32804889e1705-wk-Fact-E4075190162DE36B941AC7EB69C5A5C4"
      unitRef="usd">1963000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32804889e1724-wk-Fact-5E36DD8E5B21D078FAC5C7EB69C8B409"
      unitRef="usd">4941000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A1A4D4053FCC4C704852C7EB6A2CCE44-0-wk-Fact-9FDF23EE12BCD0270FB0C7EB69F3CC9F">Stockholders' Equity&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's Restated Certificate of Incorporation authorizes the Company to issue &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;125,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock with a par value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.001&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The holder of each share of common stock shall have &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; vote for each share of stock. The common stockholders are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all series of convertible preferred stock outstanding. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; dividends have been declared as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options and restricted stock units issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,562,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,235,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options and restricted stock units available for grant under stock option plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,954,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,571,658&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock available for the Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;173,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;309,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,690,456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,116,335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On May 7, 2019, the Company issued and sold&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,325,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock in a registered public offering, including&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;825,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares issued and sold upon the underwriters&#x2019; exercise in full of their option to purchase additional shares, at a price to the public of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share. The Company's net proceeds from the offering were approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$137.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2018, the Company issued and sold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,750,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock in a registered public offering, including &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;750,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares issued and sold upon the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The Company's net proceeds from the offering were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$55.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting commissions and offering expenses of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="d32803588e731-wk-Fact-EE464A49BDE3BB98ECC4C7EB69EAA9A7"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="d32803588e735-wk-Fact-950FDA869E35200EDC84C7EB69F1AB64"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <vcyt:VotingRightsForEachShareOfStock
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32803588e739-wk-Fact-454FAD01F36DDD1397A5C7EB69FBA8EA"
      unitRef="vote">1</vcyt:VotingRightsForEachShareOfStock>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="FI2019Q4"
      decimals="INF"
      id="d32803588e743-wk-Fact-E06F47DCB56072998119C7EB69F224D7"
      unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-10CC5E0D26A3E299614AC7EB6A2C49D6-0-wk-Fact-55CF2BA4EACC03E1F862C7EB69F3D119">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options and restricted stock units issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,562,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,235,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options and restricted stock units available for grant under stock option plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,954,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,571,658&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock available for the Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;173,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;309,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,690,456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,116,335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vcyt:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="INF"
      id="d32803588e854-wk-Fact-7147AADB2ED4AC369D95C7EB6A1BC4DF"
      unitRef="shares">5562484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="INF"
      id="d32803588e868-wk-Fact-17D38D8E7EFB61AB8F88C7EB6A1B2078"
      unitRef="shares">6235258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="INF"
      id="d32803588e883-wk-Fact-EC583663A6FCDC2D03E9C7EB6A0E5E14"
      unitRef="shares">1954804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="INF"
      id="d32803588e897-wk-Fact-1F4E405EF5FD4B86779AC7EB6A183371"
      unitRef="shares">1571658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d32803588e912-wk-Fact-CDAA2434153C67383374C7EB6A1A4736"
      unitRef="shares">173168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d32803588e926-wk-Fact-CF0B958D78CBD852D0BBC7EB6A13B5C6"
      unitRef="shares">309419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2019Q4"
      decimals="INF"
      id="d32803588e941-wk-Fact-632D7DAC613E0C14812FC7EB6A1B0FD0"
      unitRef="shares">7690456</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q4"
      decimals="INF"
      id="d32803588e955-wk-Fact-AE4E6E5DF1B8709E8A24C7EB6A163292"
      unitRef="shares">8116335</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q2May07"
      decimals="INF"
      id="d32803588e973-wk-Fact-F14E1E0B042CCA31097DE85431FEF51E"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q2May07_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d32803588e977-wk-Fact-0E23D053462F0B1BD33FE854BC8230FF"
      unitRef="shares">825000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I2019Q2May07"
      decimals="2"
      id="d32803588e981-wk-Fact-C5495141AE56C4F84FE5E8560BFEC7AB"
      unitRef="usdPerShare">23.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2019Q2May07"
      decimals="-5"
      id="d32803588e985-wk-Fact-32A66B66A05C2F6E9B02E856AFDE1696"
      unitRef="usd">137800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D2019Q2May07"
      decimals="-5"
      id="d32803588e989-wk-Fact-FCB7C8C8939E7C7D70E7E8578B2E4899"
      unitRef="usd">9200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2018Q3July"
      decimals="INF"
      id="d32803588e999-wk-Fact-E03D35475575CEB2BA4EC7EB69EE0E68"
      unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d32803588e1003-wk-Fact-66772D250B09C00E1F31C7EB69E81A37"
      unitRef="shares">750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="I2018Q3Jul31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d32803588e1007-wk-Fact-C31ACACBF781E231E595C7EB69EC4877"
      unitRef="usdPerShare">10.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="d32803588e1011-wk-Fact-93A7CE4FB86A6B46EB0AC7EB69EAF469"
      unitRef="usd">55000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D2018Q3July_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="d32803588e1015-wk-Fact-32A5C4030FEB0AE81407C7EB69E81F6D"
      unitRef="usd">3900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B1D2423FA4FC81D31B2BC7EB6A2D32CE-0-wk-Fact-56246CEAB561C2D20280C7EB6A095352">Stock Incentive Plans&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2008, the Company adopted the 2008 Stock Plan (the "2008 Plan"). The 2008 Plan provides for the granting of options to purchase common stock and common stock to employees, directors and consultants of the Company. The Company may grant incentive stock options ("ISOs"), non-statutory stock options ("NSOs") or restricted stock under the 2008 Plan. ISOs may only be granted to Company employees (including directors who are also considered employees). NSOs and restricted stock may be granted to Company employees, directors and consultants. Options may be granted for terms of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to a person who owns stock representing more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the voting power of all classes of stock of the Company, the term shall be for no more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the date of grant. The exercise price of options granted must be at a price no less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to an employee who at the time of grant of such option owns stock representing more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the voting power of all classes of stock of the Company, the exercise price shall not be less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the estimated fair value of the shares on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2013, the Company adopted the 2013 Stock Incentive Plan (the "2013 Plan"). The 2013 Plan was subsequently approved by the Company's stockholders and became effective on November&#160;4, 2013, immediately before the closing of the Company's initial public offering ("IPO"). Following the effectiveness of the 2013 Plan, no additional options were granted under the 2008 Plan. An aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,700,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares were initially reserved for issuance under the 2013 Plan. In addition, to the extent that any awards outstanding or subject to vesting restrictions under the 2008 Plan are subsequently forfeited or terminated for any &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;reason before being exercised or settled, the shares of common stock reserved for issuance pursuant to such awards as of the closing of the IPO will become available for issuance under the 2013 Plan. The remaining shares available for grant under the 2008 Plan became available for issuance under the 2013 Plan upon the closing of the IPO. On the first day of each year from 2014 to 2023, the 2013 Plan authorizes an annual increase of the lesser of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of outstanding shares on the last day of the immediately preceding fiscal year or a lesser amount as determined by the Company's Board of Directors. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,954,799&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares were available for future issuance under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the 2013 Plan, stock options, restricted shares, stock units, including restricted stock units and stock appreciation rights may be granted to employees, consultants, and outside directors of the Company. Options granted may be either ISOs or NSOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options are governed by stock option agreements between the Company and recipients of stock options. ISOs and NSOs may be granted under the 2013 Plan at an exercise price of not less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the Board of Directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of ISOs may not exceed ten years from the date of grant. Stock option agreements may provide for accelerated exercisability in the event of an optionee's death, disability, or retirement or other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock units are governed by stock unit agreements between the Company and recipients of stock units. Stock units may be granted under the 2013 Plan and the number of stock units awarded are determined by the Compensation Committee of the Board of Directors. Stock units vest and expire as determined by the Compensation Committee.  Stock unit agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Any outside director who was not previously an employee and who first joins the Company's Board of Directors on or after the effective date of the 2013 Plan will be automatically granted an initial NSO to purchase &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock upon first becoming a member of the Board of Directors.  The shares subject to the initial option will vest and become exercisable one-third (1/3) each of the first, second and third annual anniversaries of the date of grant.  On the first business day after each regularly scheduled annual meeting of stockholders, each outside director who was not elected to the Board of Directors for the first time at such meeting and who will continue serving as a member of the Board of Directors thereafter will be automatically granted an option to purchase &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, provided that the outside director has served on the Board of Directors for at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Each annual option will vest and become exercisable on the first anniversary of the date of grant, or immediately prior to the next regular annual meeting of the Company's stockholders following the date of grant if the meeting occurs prior to the first anniversary date. The options granted to outside directors will have a per share exercise price equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the fair market value of the underlying shares on the date of grant and will become fully vested in the event of a change of control. In addition, such options will terminate on the earlier of (i)&#160;the day before the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;10&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;th anniversary of the date of grant or (ii)&#160;the date &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; after the termination of the outside director's service for any reason.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes activity under the Company's stock incentive plans (aggregate intrinsic value in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Available&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;for Grant&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Stock Options&lt;br/&gt;Outstanding and Unvested Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life of Stock Options&lt;br/&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance&#x2014;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,571,658&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,235,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additional shares authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,634,528&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted - stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(969,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;969,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted - restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(505,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;505,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(180,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,846,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(122,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tax portion of restricted stock units vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance&#x2014;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,954,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,562,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options vested and exercisable&#x2014;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,651,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options vested and expected to vest&#x2014;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,442,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The aggregate intrinsic value was calculated as the difference between the exercise price of the options to purchase common stock and the fair market value of the Company's common stock, which was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.92&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.58&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share as of December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted average fair value of options to purchase common stock granted was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.62&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.49&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended December&#160;31, 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The aggregate estimated grant date fair value of employee options to purchase common stock vested during the years ended December&#160;31, 2019, 2018 and 2017 was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The intrinsic value of stock options exercised was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$31.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended December&#160;31, 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted average fair value of restricted stock units granted was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$21.90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.17&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended December 31, 2019 and 2018, respectively.  The intrinsic value of restricted stock units vested was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2,720,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$184,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended December 31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2015, the Company's stockholders approved the Company's ESPP. The ESPP provides eligible employees with an opportunity to purchase common stock from the Company and to pay for their purchases through payroll deductions. The ESPP will be implemented through a series of offerings of purchase rights to eligible employees. Under the ESPP, the Compensation Committee of the Company's Board of Directors may specify offerings with a duration of not more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and may specify shorter purchase periods within each offering. During each purchase period, payroll deductions will accumulate, without interest. On the last day of the purchase period, accumulated payroll deductions will be used to purchase common stock for employees participating in the offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The purchase price will be specified pursuant to the offering, but cannot, under the terms of the ESPP, be less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the fair market value per share of the Company's common stock on either the offering date or on the purchase date, whichever is less.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's Board of Directors has determined that the purchase periods initially shall have a duration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, that the first purchase period began on August&#160;3, 2015 and that the purchase price will be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the fair market value per share &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of the Company's common stock on either the offering date or the purchase date, whichever is less. The length of the purchase period applicable to U.S. employees and the purchase price may not be changed without the approval of the independent members of the Compensation Committee of the Company's Board of Directors. The Compensation Committee has determined that if the fair market value of a share of the Company's common stock on any purchase date within a particular offering period is less than the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;No employee is permitted to accrue, under the ESPP, a right to purchase stock of the Company having a value in excess of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the fair market value of such stock (determined at the time the right is granted) for each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock-based compensation expense related to stock options, restricted stock units and the ESPP for the years ended December&#160;31, 2019, 2018 and 2017, and are included in the consolidated statements of operations and comprehensive loss as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of testing revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,856&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling and marketing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,899&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,736&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of December&#160;31, 2019, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation expense related to unvested stock options and restricted stock units, which is expected to be recognized over an estimated weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.20 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated grant-date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;52.90 - 53.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;50.40 - 52.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;50.40 - 52.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.90 - 2.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.40 - 3.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.80 - 2.33%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of non-employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;43.60 - 50.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;50.40 - 51.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.25 - 6.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;6.80 - 7.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.84 - 2.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.16 - 2.37%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; non-employee stock options outstanding as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated grant date fair value of the ESPP shares was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;53.38 - 71.77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;42.88 - 47.74%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;37.00 - 43.86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.50 - 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.50 - 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.50 - 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.88 - 2.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.64 - 2.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.65 - 1.22%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member"
      id="d32811342e734-wk-Fact-22C8C326C7EA8CBE36D2C7EB69D4D682">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock
      contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member"
      decimals="INF"
      id="d32811342e738-wk-Fact-3C9DCE72C15835027D4DC7EB6A00FB65"
      unitRef="number">0.10</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock
      contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member"
      id="d32811342e742-wk-Fact-D9A19009EC11AAEDDE36C7EB69F29AC4">P5Y</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member"
      decimals="INF"
      id="d32811342e746-wk-Fact-676430472D86DF363F3FC7EB69D451CD"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock
      contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member"
      decimals="INF"
      id="d32811342e750-wk-Fact-3C9DCE72C15835027D4DC7EB6A00FB65"
      unitRef="number">0.10</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock>
    <vcyt:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock
      contextRef="D2008Q1Feb01-Feb29_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockPlan2008Member"
      decimals="INF"
      id="d32811342e755-wk-Fact-EE99BCFCFAC8FB5B9721C7EB6A0FFA4B"
      unitRef="number">1.10</vcyt:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock>
    <vcyt:CommonStockCapitalAdditionalSharesReservedForFutureIssuance
      contextRef="I2013Q4Oct31_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="INF"
      id="d32811342e764-wk-Fact-96C0F8D26973FF633F06C7EB69D50D23"
      unitRef="shares">1700000</vcyt:CommonStockCapitalAdditionalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="INF"
      id="d32811342e771-wk-Fact-06FFFAAAC65037E5C9E2C7EB69F6C4C6"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q4_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="INF"
      id="d32811342e779-wk-Fact-8BE506586061BDFE8A2EC7EB69F113A8"
      unitRef="shares">1954799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_vcyt_IncentiveStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="INF"
      id="d32811342e794-wk-Fact-14C6CC78D499EF2A8B88C7EB69F5FE85"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants
      contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember_us-gaap_AwardTypeAxis_vcyt_NonStatutoryStockOptionsMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="INF"
      id="d32811342e808-wk-Fact-328E8A98ABE7B14AEF2FC7EB6A1B6674"
      unitRef="shares">35000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants
      contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="INF"
      id="d32811342e812-wk-Fact-03E1DB18D87EA6D2D345C7EB69F7FD3B"
      unitRef="shares">10000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      id="d32811342e816-wk-Fact-D1699ABE02FF2CA4E381C7EB69DAD366">P6M</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      decimals="INF"
      id="d32811342e820-wk-Fact-2F1C68E8CF724C810A13C7EB6A030700"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_vcyt_OutsideDirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vcyt_StockIncentivePlan2013Member"
      id="d32811342e829-wk-Fact-361E0CF6D133883BA6A1C7EB69E675FA">P12M</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-76278BF2E9044BE52F35C7EB6A2DF2BB-0-wk-Fact-0E68927A64CEFECDB943C7EB69FDAB9F">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes activity under the Company's stock incentive plans (aggregate intrinsic value in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Available&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;for Grant&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Stock Options&lt;br/&gt;Outstanding and Unvested Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life of Stock Options&lt;br/&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance&#x2014;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,571,658&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,235,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additional shares authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,634,528&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted - stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(969,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;969,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted - restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(505,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;505,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(180,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,846,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(122,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tax portion of restricted stock units vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance&#x2014;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,954,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,562,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options vested and exercisable&#x2014;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,651,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options vested and expected to vest&#x2014;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,442,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="INF"
      id="d32811342e964-wk-Fact-1F4E405EF5FD4B86779AC7EB6A183371"
      unitRef="shares">1571658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4"
      decimals="INF"
      id="d32811342e978-wk-Fact-44701CC745B307046BC0C7EB69CDC59C"
      unitRef="shares">6235258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d32811342e997-wk-Fact-ED8D7240B8484DCDCBDEC7EB69CF423D"
      unitRef="usdPerShare">7.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD"
      id="d32811342e1012-wk-Fact-2B8250DE4910E781F4ADE8AC70A52872">P6Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811342e1027-wk-Fact-289489DF41031F44C0D3C7EB6A12C98E"
      unitRef="usd">27340000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32811342e1042-wk-Fact-E8EFB43B49BF1681ED85C7EB69CE3402"
      unitRef="shares">1634528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d32811342e1120-wk-Fact-04F0928E5D2E0A218324C7EB6A0EF231"
      unitRef="shares">969500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d32811342e1135-wk-Fact-04F0928E5D2E0A218324C7EB6A0EF231"
      unitRef="shares">969500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d32811342e1149-wk-Fact-7804C69FF87C5ECD033AC7EB6A0E9D9C"
      unitRef="usdPerShare">21.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d32811342e1199-wk-Fact-B342F1C909C8C4B951EAC7EB6A192477"
      unitRef="shares">505965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d32811342e1214-wk-Fact-B342F1C909C8C4B951EAC7EB6A192477"
      unitRef="shares">505965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32811342e1280-wk-Fact-5A3046DD37C0534C41FFC7EB69D13BC8"
      unitRef="shares">180017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32811342e1294-wk-Fact-5A3046DD37C0534C41FFC7EB69D13BC8"
      unitRef="shares">180017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d32811342e1309-wk-Fact-DB5904730DA01414669DC7EB69CE30FC"
      unitRef="usdPerShare">9.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32811342e1373-wk-Fact-A8018B56FEDDC463CC9DC7EB69D4775D"
      unitRef="shares">1846222</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d32811342e1388-wk-Fact-C8407BB35184E482E470C7EB6A0CD487"
      unitRef="usdPerShare">7.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d32811342e1452-wk-Fact-36F8DA0225D0433F13C4C7EB69D45924"
      unitRef="shares">122000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d32811342e1519-wk-Fact-B026CBFB9EB59C633CBFC7EB6A0AA8EC"
      unitRef="shares">44066</vcyt:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionMember"
      decimals="INF"
      id="d32811342e1599-wk-Fact-EC583663A6FCDC2D03E9C7EB6A0E5E14"
      unitRef="shares">1954804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d32811342e1613-wk-Fact-47C805DBCB1C5B213202C7EB6A11F061"
      unitRef="shares">5562484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d32811342e1632-wk-Fact-459DDF6DFB2BEB8D92DEC7EB6A0FF28A"
      unitRef="usdPerShare">10.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q4YTD"
      id="d32811342e1647-wk-Fact-735D4BAFA14534F9E144C7EB6A0C5093">P6Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811342e1662-wk-Fact-D0850444DCBB67AACE85C7EB69D07CDF"
      unitRef="usd">79760000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d32811342e1774-wk-Fact-BDAA0EF939AD82117367C7EB69CED8B3"
      unitRef="shares">2651858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d32811342e1793-wk-Fact-5E013378BF155645ECABC7EB6A0B09A2"
      unitRef="usdPerShare">8.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q4YTD"
      id="d32811342e1808-wk-Fact-52125299D851754EFED2C7EB69CDA7D9">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811342e1823-wk-Fact-3F53C30C637A4BE55EC4C7EB69D57520"
      unitRef="usd">52469000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d32811342e1852-wk-Fact-D8DBD532EBC62F35729AC7EB69D3EE73"
      unitRef="shares">4442275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d32811342e1871-wk-Fact-FCE09982C18EAAC82590C7EB6A094E01"
      unitRef="usdPerShare">10.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q4YTD"
      id="d32811342e1886-wk-Fact-5DED8C1337CC32A4B1C3C7EB6A0EA9BC">P6Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811342e1901-wk-Fact-7D2BDD4D27E0C2298AE4C7EB69D0069F"
      unitRef="usd">77453000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32811342e1918-wk-Fact-F09A13C9D9DBA6D4E6ABC7EB6A01374B"
      unitRef="usdPerShare">27.92</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d32811342e1922-wk-Fact-686469D00EC7F99D9354E8AC9A0946B7"
      unitRef="usdPerShare">12.58</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d32811342e1932-wk-Fact-7C05B130092EC234A6A3C7EB6A00F9A6"
      unitRef="usdPerShare">11.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d32811342e1936-wk-Fact-E2593EAEB33D83DA8FDBE8ACC41677EC"
      unitRef="usdPerShare">3.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d32811342e1940-wk-Fact-9A921687EBE546640F15C7EB69FD86E2"
      unitRef="usdPerShare">4.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d32811342e1949-wk-Fact-FA1498E11A858616A3BAC7EB69E576AD"
      unitRef="usd">4400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d32811342e1953-wk-Fact-F177C8E46776CF289FD4E8AD0E26918D"
      unitRef="usd">4100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d32811342e1957-wk-Fact-755BE5EB04C35648FDCFC7EB69DED8E4"
      unitRef="usd">3100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d32811342e1966-wk-Fact-CB0CC348A5017F67A155C7EB69F43492"
      unitRef="usd">31300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d32811342e1970-wk-Fact-54ECAE9664378495B855E8AD5C0442BA"
      unitRef="usd">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d32811342e1974-wk-Fact-E33E19C00875B3C259DDC7EB69F9E4D1"
      unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d32811342e1983-wk-Fact-21B9B8A2555BB4725E5AC7EB69FCE5F3"
      unitRef="usdPerShare">21.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d32811342e1987-wk-Fact-E0B57C230B63EE8158A3E8ADEFAF91F9"
      unitRef="usdPerShare">6.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d32811342e1991-wk-Fact-C493DCA0A3A283536814C7EB6A130CB1"
      unitRef="usd">2720000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d32811342e1995-wk-Fact-B9A8F14E7A050FDC4024E8AE1A2177BE"
      unitRef="usd">184000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d32811342e2009-wk-Fact-95AE7CE8F70EE1080106C7EB6A16AD3F">P12M</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d32811342e2019-wk-Fact-3AD572979CE952031D65C7EB69E1FC7E"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d32811342e2028-wk-Fact-219C48DE207BF3D9AA92C7EB69FE3275">P6M</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d32811342e2032-wk-Fact-3AD572979CE952031D65C7EB69E1FC7E"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d32811342e2044-wk-Fact-8C68CF97C17940A6E4FCC7EB69FEA394"
      unitRef="usd">25000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember"
      id="TextSelection-700F551A844844C81E20C7EB6A2D406C-0-wk-Fact-F3908BAA9D33BEF7D9F9C7EB69FCC54E">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock-based compensation expense related to stock options, restricted stock units and the ESPP for the years ended December&#160;31, 2019, 2018 and 2017, and are included in the consolidated statements of operations and comprehensive loss as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of testing revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,856&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling and marketing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,899&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,736&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="d32811342e2224-wk-Fact-8F18F57393D9E440133EC7EB6A0E6F27"
      unitRef="usd">277000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="d32811342e2243-wk-Fact-63C1AB1D876B3D800015C7EB69E4D098"
      unitRef="usd">130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="d32811342e2262-wk-Fact-ACB88209EF2E69F95EFBC7EB69E724B9"
      unitRef="usd">133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d32811342e2278-wk-Fact-5467F84B64B2DE42D5F5C7EB6A1AC405"
      unitRef="usd">1856000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d32811342e2297-wk-Fact-759ECFE23068962AD30BC7EB6A192747"
      unitRef="usd">1018000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d32811342e2316-wk-Fact-F56E6AB66BF49A9DAEFAC7EB69E46E1C"
      unitRef="usd">1495000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="d32811342e2337-wk-Fact-68914B865D7F61CDA9F7C7EB69E9ABB6"
      unitRef="usd">2938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="d32811342e2356-wk-Fact-1AAEF0040260DB43E44DC7EB69E59B80"
      unitRef="usd">1866000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="d32811342e2375-wk-Fact-C283BA7970CF08337F9FC7EB69E92185"
      unitRef="usd">1899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d32811342e2396-wk-Fact-705635915D5AB5E86E3FC7EB69E639F0"
      unitRef="usd">4736000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d32811342e2415-wk-Fact-F2CCBA0501C383BD5421C7EB69E55B31"
      unitRef="usd">2944000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d32811342e2434-wk-Fact-9D7EE486F31EDA88F6B7C7EB6A1E5B4D"
      unitRef="usd">3090000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811342e2460-wk-Fact-FD2D0108AEAC5312EA2EC7EB6A14A127"
      unitRef="usd">9807000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811342e2479-wk-Fact-918B56AB80510B7980B7C7EB69E941CE"
      unitRef="usd">5958000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811342e2498-wk-Fact-AF2B9E94D61AA7CD2752C7EB69E813AD"
      unitRef="usd">6617000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember"
      decimals="-5"
      id="d32811342e2516-wk-Fact-8F236B51758E395DDEEBC7EB69D56098"
      unitRef="usd">18400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember"
      id="d32811342e2520-wk-Fact-75B1F3378C94A6C737FCC7EB69F8B846">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_EmployeeStockOptionExcludingBonusCompensationMember"
      id="TextSelection-D893A0FCD76B967939EAC7EB6A2C8C56-0-wk-Fact-1B11C58216B431133248C7EB69F79E83">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated grant-date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;52.90 - 53.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;50.40 - 52.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;50.40 - 52.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.90 - 2.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.40 - 3.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.80 - 2.33%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      id="TextSelection-646EBE93DD05DE70F384C7EB6A2CABD2-0-wk-Fact-2BABEF0041A75EC9F47DC7EB69DE1FDA">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of non-employee stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;43.60 - 50.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;50.40 - 51.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.25 - 6.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;6.80 - 7.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.84 - 2.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.16 - 2.37%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="TextSelection-D57508DD7AD27039E626C7EB6A2DF4BD-0-wk-Fact-020809F23D4804447258C7EB69D8C306">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; non-employee stock options outstanding as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated grant date fair value of the ESPP shares was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;53.38 - 71.77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;42.88 - 47.74%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;37.00 - 43.86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.50 - 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.50 - 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.50 - 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.88 - 2.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.64 - 2.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.65 - 1.22%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_vcyt_NonEmployeeStockOptionMember"
      decimals="INF"
      id="d32811342e2968-wk-Fact-339F5A903023007CF0B4782CF902A0B9"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:LongTermContractsOrProgramsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B3A9E68887F5DC72F8DDC7EB6A2DB92F-0-wk-Fact-415609B700F88587F305C7EB69E6DF87">Thyroid Cytopathology Partners&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has an agreement with a specialized pathology practice, Thyroid Cytopathology Partners, ("TCP"), to provide testing services to the Company (the "TCP Agreement").&#160; The TCP Agreement is effective through October 31, 2022, and thereafter automatically renews every year unless either party provides notice of intent not to renew at least&#160;12 months&#160;prior to the end of the then-current term. Under the TCP Agreement, the Company pays TCP based on a fixed price per test schedule which is reviewed periodically for changes in market pricing, and the TCP Agreement included a clause allowing TCP to sublease a portion of the Company's facility in Austin, Texas. &#160;The Company does not have an ownership interest in or provide any form of financial or other support to TCP. &#160;The Company previously concluded that TCP represented a variable interest entity as a result of the facility arrangement clause, but that the Company was not the primary beneficiary as it did not have the ability to direct the activities that most significantly impacted TCP's economic performance, and therefore did not consolidate TCP.&#160; On February 14, 2019, the TCP Agreement was amended to remove the facility clause.&#160; Accordingly, the Company believes TCP was no longer a variable interest entity as of that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;TCP's portion of rent and related operating expenses reimbursed to the Company for the shared space at the Austin, Texas facility was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$128,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$114,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and is included other income, net in the Company's consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermContractsOrProgramsDisclosureTextBlock>
    <vcyt:OtherIncomeRentReimbursement
      contextRef="FD2019Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"
      decimals="-3"
      id="d32805237e731-wk-Fact-A4DB47A3963062D31262C7EB6A05A0E0"
      unitRef="usd">11000</vcyt:OtherIncomeRentReimbursement>
    <vcyt:OtherIncomeRentReimbursement
      contextRef="FD2018Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"
      decimals="-3"
      id="d32805237e735-wk-Fact-61E2A181C2A05765A28AC7EB6A064D1C"
      unitRef="usd">128000</vcyt:OtherIncomeRentReimbursement>
    <vcyt:OtherIncomeRentReimbursement
      contextRef="FD2017Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"
      decimals="-3"
      id="d32805237e739-wk-Fact-43382273C24B6317F86EC7EB6A03F8B9"
      unitRef="usd">114000</vcyt:OtherIncomeRentReimbursement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B1D68602D75C1559FA68C7EB6A2D0884-0-wk-Fact-CA880B9A140B00FF573CC7EB6A11CBB7">Income Taxes&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company generated a pretax loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$31.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the United States for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Since inception, the Company has not generated any pretax income or loss outside of the United States. The Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; provision for income taxes during the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company follows FASB ASC No.&#160;740, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes for the Computation and Presentation of its Tax Provision.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company's income tax expense for the periods presented (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December, 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. federal taxes at statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State tax (net of federal benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non deductible officers' compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock based compensation - PSU/RSU/NQSQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Permanent differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Incentive stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(996&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(777&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,552&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Rate differential impact - &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Tax Cuts and Jobs Act&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,474&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,034&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;NanoString intangibles and goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accruals and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(55,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets. The valuation allowance increased &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, increased &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and decreased &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had net operating loss carryforwards of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$236.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$58.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; available to reduce future taxable income, if any, for federal, California and other state income tax purposes, respectively.  The U.S. federal net operating loss carryforwards will begin to expire in 2026 while for state purposes, the net operating losses began to expire in 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had net research and development credit carryforwards of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal credit carryforwards begin to expire in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2028&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. California credits have no expiration date. Other state credit carryforwards begin to expire in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Internal Revenue Code of 1986, as amended, imposes restrictions on the utilization of net operating losses and tax credits in the event of an "ownership change" of a corporation. Accordingly, a company's ability to use net operating losses and tax credits may be limited as prescribed under Internal Revenue Code Section 382 and 383 ("IRC Section 382"). Events which may cause limitations in the amount of the net operating losses or tax credits that the Company may use in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. Utilization of the federal and state net operating losses may be subject to substantial annual limitation due to the ownership change limitations provided by the IRC Section 382 rules and similar state provisions. In the event the Company has any changes in ownership, net operating losses and research and development credit carryovers could be limited and may expire unutilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had unrecognized tax benefits of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, none of which would currently affect the Company's effective tax rate if recognized due to the Company's deferred tax assets being fully offset by a valuation allowance. The Company does not anticipate that the amount of unrecognized tax benefits relating to tax positions existing at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will significantly increase or decrease within the next 12&#160;months.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrecognized tax benefits, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross increases&#x2014;tax position in prior period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross decreases&#x2014;tax position in prior period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross increases&#x2014;current period tax position&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrecognized tax benefits, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;It is the Company's policy to include penalties and interest expense related to income taxes as a component of other income (expense), net, and interest expense, respectively, as necessary. There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; interest expense or penalties related to unrecognized tax benefits recorded through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's major tax jurisdictions are the United States and California. All of the Company's tax years will remain open for examination by the Federal and state tax authorities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from the date of utilization of the net operating loss or research and development credit. The Company does not have any tax audits pending.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d32811328e726-wk-Fact-C36A7880192747F17755C7EB69D8E858"
      unitRef="usd">-12500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d32811328e730-wk-Fact-E4CF2CE782D25D0E8239C7EB6A111B01"
      unitRef="usd">-23000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d32811328e734-wk-Fact-64D7C8BF0BCA6F802959C7EB69D7C3C1"
      unitRef="usd">-31000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32811328e751-wk-Fact-852167221E0A3FB62D61C7EB6A12F420"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5BA0C18CA5B7684F5535C7EB6A2EC126-0-wk-Fact-452088269E1B3C5F5277C7EB6A0D4972">The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company's income tax expense for the periods presented (in thousands of dollars):&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December, 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. federal taxes at statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State tax (net of federal benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non deductible officers' compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock based compensation - PSU/RSU/NQSQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Permanent differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Incentive stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(996&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(777&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,552&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Rate differential impact - &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Tax Cuts and Jobs Act&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,474&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e941-wk-Fact-986F042E18B95D40B2A6C7EB6A1D567F"
      unitRef="usd">-2632000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e961-wk-Fact-3A4A8D4EA567F356B7E9C7EB6A0ED829"
      unitRef="usd">-4825000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e981-wk-Fact-0CCAF611294DFFD6ABFBC7EB6A11775F"
      unitRef="usd">-10541000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e998-wk-Fact-BD4DCF1CB893C059CA9CC7EB6A05B4EE"
      unitRef="usd">-828000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1018-wk-Fact-C220B76AB54D5B74F5E6C7EB6A04D7B4"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1037-wk-Fact-65EA4E3A138960268654C7EB6A13C902"
      unitRef="usd">15000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e1058-wk-Fact-98CA36835D412A9612F7C7EB69E842DF"
      unitRef="usd">439000</vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount>
    <vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1077-wk-Fact-CAEA31A710A0D225A25CC7EB6A1A27F0"
      unitRef="usd">409000</vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount>
    <vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1096-wk-Fact-AF8D931D5C8C38650A72C7EB6A1DA8C9"
      unitRef="usd">0</vcyt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e1117-wk-Fact-474567B1C5D87F56AFEE40422C1EDBC9"
      unitRef="usd">628000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1136-wk-Fact-60C81E477A6D803019F2404242E08420"
      unitRef="usd">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1155-wk-Fact-8556779A3D175AA34A7040424F9625E2"
      unitRef="usd">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e1176-wk-Fact-174129832A9C46FEA187C7EB6A105693"
      unitRef="usd">221000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1195-wk-Fact-B22A595E4A9BC1BC7AE3C7EB69FBC159"
      unitRef="usd">285000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1214-wk-Fact-373E59D35E607861D4DCC7EB6A106AEA"
      unitRef="usd">198000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e1235-wk-Fact-C31BA6CFE4CD13CC6D47C7EB6A0FBB55"
      unitRef="usd">-4994000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1255-wk-Fact-4397EC77E0844D208001C7EB69F7B98C"
      unitRef="usd">-256000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1275-wk-Fact-5C1CD0E776718DD1363CC7EB6A1CD30A"
      unitRef="usd">994000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e1296-wk-Fact-B57C22A0657CEBC28E32C7EB6A10C42A"
      unitRef="usd">996000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1316-wk-Fact-EED66889ADDBE881E6EAC7EB6A1A9AB5"
      unitRef="usd">777000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1336-wk-Fact-BF39F5833C7CD2A527BEC7EB6A1B7E2A"
      unitRef="usd">588000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e1358-wk-Fact-A80268BFD3A24D24C6C4C7EB6A129FBD"
      unitRef="usd">8162000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1377-wk-Fact-92060D846E66F5EB7ACEC7EB69F452C7"
      unitRef="usd">5164000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1396-wk-Fact-08FA150F5AD8F408A1A2C7EB69FD6CE0"
      unitRef="usd">-14552000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e1420-wk-Fact-F16FB7692F11DF74E847C7EB6A1C3401"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1439-wk-Fact-D669E145C68DADDA61C8C7EB6A1FC0E7"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1458-wk-Fact-59F8A60DD2566D003D68C7EB6A1E90A6"
      unitRef="usd">24474000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e1485-wk-Fact-533CE0650954522E5890C7EB6A1CC308"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e1504-wk-Fact-B830F66DE3633110BAE2C7EB6A1E5797"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e1523-wk-Fact-568F44F692A8F05490AEC7EB6A1FC9FA"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CD9944AABE826230B200C7EB6A2D9A92-0-wk-Fact-8B10ABE236EE6AD669F0C7EB69D68AE5">Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands of dollars):&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,034&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;NanoString intangibles and goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accruals and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(55,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e1766-wk-Fact-AB214F76E00700C63A5FC7EB69D7955D"
      unitRef="usd">56506000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e1785-wk-Fact-2B7E385AF48B16002243C7EB6A1E1358"
      unitRef="usd">50410000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e1804-wk-Fact-44C3BE18D7D8F3F66A79C7EB69DDB46F"
      unitRef="usd">47177000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e1820-wk-Fact-818C6AE3391BFF03DBDCC7EB69D65AFF"
      unitRef="usd">5579000</vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e1839-wk-Fact-174C5CE48AB74E664176C7EB69E2E656"
      unitRef="usd">4584000</vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e1858-wk-Fact-BE623EC7E620070FE6C6C7EB6A1D9FCF"
      unitRef="usd">4034000</vcyt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e1879-wk-Fact-7B5C5BC0D4D25F01DBA1C7EB69E33C82"
      unitRef="usd">2246000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e1898-wk-Fact-8244B672FCB09BE872E7C7EB69DB65A1"
      unitRef="usd">1032000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e1917-wk-Fact-A2B650EAFAC39693A52EC7EB69D82DBE"
      unitRef="usd">2068000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e1938-wk-Fact-090F034167B8E56E906A4044DBC81304"
      unitRef="usd">380000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e1957-wk-Fact-3C6FB1C87FE759B7A1C140450AA881C5"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e1976-wk-Fact-61294A21DB3E94BE145D404515E32009"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <vcyt:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e1997-wk-Fact-3F046C474496C6493AD44045E899925B"
      unitRef="usd">3068000</vcyt:DeferredTaxAssetsOperatingLeaseLiability>
    <vcyt:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2016-wk-Fact-3B233324A6A6BB80288B4045F613169A"
      unitRef="usd">0</vcyt:DeferredTaxAssetsOperatingLeaseLiability>
    <vcyt:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2035-wk-Fact-B4D6B51640381774C79B4046027438D9"
      unitRef="usd">0</vcyt:DeferredTaxAssetsOperatingLeaseLiability>
    <vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2056-wk-Fact-165970B9BF63367460E8C7EB69DA91EF"
      unitRef="usd">2610000</vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther>
    <vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2075-wk-Fact-53A6A513CF792E97DC16C7EB69DCE6E0"
      unitRef="usd">2918000</vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther>
    <vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2094-wk-Fact-DB603C3F35FDBD0360D1C7EB69D73F51"
      unitRef="usd">2375000</vcyt:DeferredTaxAssetsAccrualsDeferredRentAndOther>
    <us-gaap:DeferredTaxAssetsGrossNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2115-wk-Fact-88F7DBEAB8FD9D856EA7C7EB69DAF1F6"
      unitRef="usd">70389000</us-gaap:DeferredTaxAssetsGrossNoncurrent>
    <us-gaap:DeferredTaxAssetsGrossNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2134-wk-Fact-53CEDCBCF4B65662354CC7EB6A1F4FDD"
      unitRef="usd">58944000</us-gaap:DeferredTaxAssetsGrossNoncurrent>
    <us-gaap:DeferredTaxAssetsGrossNoncurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2153-wk-Fact-FBD72B36A712DBCA28B4C7EB69DBA5B4"
      unitRef="usd">55654000</us-gaap:DeferredTaxAssetsGrossNoncurrent>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2174-wk-Fact-08A0FC21DDDFAF4C6C93C7EB69D6385C"
      unitRef="usd">65228000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2194-wk-Fact-2F74AC2684305A3A2D76C7EB69DC9907"
      unitRef="usd">55366000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2214-wk-Fact-675582AF20F40013A45AC7EB69D81586"
      unitRef="usd">51657000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2237-wk-Fact-18BF41293B2EABEBDDCEC7EB69DE65E2"
      unitRef="usd">5161000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2256-wk-Fact-7B338E4FE52CCA398DE2C7EB69D867A9"
      unitRef="usd">3578000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2275-wk-Fact-9FCD5BB7A6282B52EF3BC7EB69D8A5EF"
      unitRef="usd">3997000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2355-wk-Fact-0E1019514F3992D3ED86C7EB69D9475A"
      unitRef="usd">471000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2375-wk-Fact-52135B7C2EBB24E9DB00C7EB6A1EF982"
      unitRef="usd">695000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2395-wk-Fact-B5EA34F31EDB749854D0C7EB69D86125"
      unitRef="usd">983000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2417-wk-Fact-494A2B81BDDECF5AA58FC7EB69D94D44"
      unitRef="usd">2597000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2437-wk-Fact-FECE491D112FFA820F97C7EB69DA5755"
      unitRef="usd">2883000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2457-wk-Fact-F54E89ABAC472713B67CC7EB69D81057"
      unitRef="usd">3014000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <vcyt:DeferredTaxLiabilitiesRightofUseAssets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2479-wk-Fact-AFDBA8F884BDFA5B99794046ED20002C"
      unitRef="usd">2093000</vcyt:DeferredTaxLiabilitiesRightofUseAssets>
    <vcyt:DeferredTaxLiabilitiesRightofUseAssets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2499-wk-Fact-F8B88DA31F7BBBCDBA184046FF530883"
      unitRef="usd">0</vcyt:DeferredTaxLiabilitiesRightofUseAssets>
    <vcyt:DeferredTaxLiabilitiesRightofUseAssets
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2518-wk-Fact-251FDE70C26E18E7E84940470C03B068"
      unitRef="usd">0</vcyt:DeferredTaxLiabilitiesRightofUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2539-wk-Fact-57AA608907573F210319C7EB6A1F9B5F"
      unitRef="usd">5161000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2559-wk-Fact-D7B6D3A0C5108B49C375C7EB69DCD445"
      unitRef="usd">3578000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2579-wk-Fact-A4D9F3B64330EF3C943BC7EB69DBC4A3"
      unitRef="usd">3997000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2601-wk-Fact-FEFFC0AE0EBE5575BFCAC7EB6A1CF67D"
      unitRef="usd">5161000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2621-wk-Fact-47D51DA1CA2306A3BDF5C7EB69D9C774"
      unitRef="usd">3578000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2641-wk-Fact-38649C2EC8F4A8186DDDC7EB69E2525A"
      unitRef="usd">3997000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e2668-wk-Fact-301DE6FBD088234187EFC7EB69D7D25E"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2687-wk-Fact-EB10ACD06CCC807E99C2C7EB69DF1666"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e2706-wk-Fact-E15BD12195F682F8B19AC7EB69DA33F0"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d32811328e2726-wk-Fact-16E5B7ACA5DA153CB2DEC7EB6A1D745A"
      unitRef="usd">9900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d32811328e2734-wk-Fact-1535EC4932AA038CC3CEC7EB69D89EFF"
      unitRef="usd">3700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d32811328e2742-wk-Fact-7B6ABA7D2437D2D1DEE0C7EB6A10552B"
      unitRef="usd">-14300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d32811328e2760-wk-Fact-21E16675A737593672B3C7EB6A1B7D29"
      unitRef="usd">236900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_stpr_CA_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="d32811328e2764-wk-Fact-9ECBE79F6BA6ABF35E70C7EB6A1EB625"
      unitRef="usd">58300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_vcyt_OtherStatesNotSeparatelyDisclosedMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="d32811328e2768-wk-Fact-FC96F4468EE7DD6A5530C7EB6A148F68"
      unitRef="usd">45200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d32811328e2781-wk-Fact-C72ACF66AB3E88F6FB0FC7EB6A1CC062"
      unitRef="usd">4900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="d32811328e2785-wk-Fact-A4A60DBC359639BD612DC7EB6A0B9B46"
      unitRef="usd">4700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-5"
      id="d32811328e2817-wk-Fact-746C330B27B56B22FD7A651358C5B8EF"
      unitRef="usd">3300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D9D88CFB59535BE1E2A7C7EB6A2DEEBF-0-wk-Fact-9DD57C9CE41707A4D676C7EB6A14A79A">&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrecognized tax benefits, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross increases&#x2014;tax position in prior period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross decreases&#x2014;tax position in prior period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross increases&#x2014;current period tax position&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrecognized tax benefits, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e2994-wk-Fact-3ED137AF0196091A3173C7EB69DDD018"
      unitRef="usd">2799000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e3013-wk-Fact-F29429FF9C4C194EABA0C7EB69D852AE"
      unitRef="usd">2523000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2016Q4"
      decimals="-3"
      id="d32811328e3032-wk-Fact-9B77080EE02EA01558F7C7EB69DCE7F8"
      unitRef="usd">2222000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e3048-wk-Fact-4EFB2A53EB86263DFD0AC7EB69D91DD8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e3067-wk-Fact-EE5D3CC111215485F059C7EB69D9D211"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e3086-wk-Fact-2E3BF5737C9515440BDEC7EB69FB5163"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e3107-wk-Fact-8CF00C39FB11DAF48274C7EB69D61C7F"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e3126-wk-Fact-69A0F9E6669376D664C9C7EB69DB81AF"
      unitRef="usd">97000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e3146-wk-Fact-9A17E092A8D49B58AE4AC7EB6A01D6E5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e3167-wk-Fact-AA1C4A1A0228891767D0C7EB69DA0049"
      unitRef="usd">479000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e3186-wk-Fact-C130CBBB4C8E161D1133C7EB6A02FC77"
      unitRef="usd">373000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e3205-wk-Fact-D9201A61053DDC249AA7C7EB69DC6E31"
      unitRef="usd">301000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811328e3226-wk-Fact-6ADDFAA0C29C1CEA6E94C7EB69FC5629"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811328e3245-wk-Fact-89378E331EF7D6F96E84C7EB69D8C479"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811328e3264-wk-Fact-197675F877533AE44430C7EB6A02BC9A"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-3"
      id="d32811328e3290-wk-Fact-92B588ECC0BEC4479CE7C7EB69D8A5C4"
      unitRef="usd">3278000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-3"
      id="d32811328e3309-wk-Fact-3ED137AF0196091A3173C7EB69DDD018"
      unitRef="usd">2799000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-3"
      id="d32811328e3328-wk-Fact-F29429FF9C4C194EABA0C7EB69D852AE"
      unitRef="usd">2523000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d32811328e3346-wk-Fact-8FB6A3C25503A0E5CB51C7EB6A15FAFF"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <vcyt:IncomeTaxExaminationPeriod
      contextRef="FD2019Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      id="d32811328e3363-wk-Fact-0D0FDBE5DDA62AEF1CC1C7EB6A1B98F6">P4Y</vcyt:IncomeTaxExaminationPeriod>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0FC4F47AD4B0B2E31F67C7EB6A2EE5C7-0-wk-Fact-F5B943EDFBFE0F7153E4C7EB6A1A4EF4">401(k) Plan&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company sponsors a 401(k) defined contribution plan covering all employees. Employer contributions to the plan were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$509,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$448,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$324,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d32811626e726-wk-Fact-93A3BDAB2B9B442A855BC7EB6A1526AA"
      unitRef="usd">509000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d32811626e730-wk-Fact-F62DD958A0BE66A651CDC7EB6A158048"
      unitRef="usd">448000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d32811626e734-wk-Fact-A5717EDFDE2C503613B7C7EB6A145105"
      unitRef="usd">324000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4BD2CB0BB019D1F87767C7EB6A2E402B-0-wk-Fact-9D6BFF1C5B0A593F8D00C7EB6A087035">Selected Quarterly Financial Data (Unaudited)&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents selected unaudited financial data for each of the eight quarters in the two-year period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company believes this information reflects all recurring adjustments necessary to fairly present this information when read in conjunction with the Company's financial statements and the related notes. Net loss per common share, basic and diluted, for the four quarters of each fiscal year may not sum to the total for the fiscal year because of the different number of shares outstanding during each period. The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period (in thousands of dollars, except for share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,458&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares used to compute net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,168,593&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,586,081&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,588,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,095,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,466&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares used to compute net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,271,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,314,234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,620,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,731,334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F5C6E694203491F78B8DC7EB6A2E0C95-0-wk-Fact-739E49F9DD38AFECFD18C7EB6A00846B">The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period (in thousands of dollars, except for share and per share data):&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,458&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares used to compute net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,168,593&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,586,081&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,588,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,095,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,466&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares used to compute net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,271,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,314,234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,620,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,731,334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d32812916e937-wk-Fact-47BCFE3AE10A6DCF5A63C7EB69D2538E"
      unitRef="usd">29529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d32812916e956-wk-Fact-DC5BCD53490B5084659DC7EB69CB7703"
      unitRef="usd">30136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d32812916e975-wk-Fact-D68061C79BB0B812A5DEC7EB69C108CC"
      unitRef="usd">30973000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4QTD"
      decimals="-3"
      id="d32812916e995-wk-Fact-6A7BB882AF35474CF459C7EB69C82027"
      unitRef="usd">29730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d32812916e1010-wk-Fact-828CF12D48E585FA10A2C7EB69C76A4F"
      unitRef="usd">-1917000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d32812916e1030-wk-Fact-F95C069571B74EE649E4C7EB69CF0408"
      unitRef="usd">-2494000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d32812916e1050-wk-Fact-6EBF060564F11A64768CC7EB69C742C9"
      unitRef="usd">-730000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q4QTD"
      decimals="-3"
      id="d32812916e1071-wk-Fact-0633E040AFF7F0264514C7EB69C8C777"
      unitRef="usd">-7458000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d32812916e1092-wk-Fact-432DB526ED1212239204C7EB69C62D4A"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d32812916e1112-wk-Fact-31F0C7C65E4AE9879E0AC7EB69D2EA24"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d32812916e1132-wk-Fact-BAE1E471E56361563319C7EB69CAD9BF"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q4QTD"
      decimals="2"
      id="d32812916e1153-wk-Fact-64E76552049A82760921C7EB69CA0A73"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d32812916e1174-wk-Fact-834216C3FA64051F3FC2C7EB69CBD8F2"
      unitRef="shares">41168593</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d32812916e1193-wk-Fact-731AD0E99E7C727E24FBC7EB69D660F2"
      unitRef="shares">45586081</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q3QTD"
      decimals="0"
      id="d32812916e1212-wk-Fact-489926AEEE386832BD52C7EB69C6F71C"
      unitRef="shares">48588296</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q4QTD"
      decimals="0"
      id="d32812916e1232-wk-Fact-9F0E2344A8444420CFD5C7EB69D3ADA1"
      unitRef="shares">49095703</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d32812916e1335-wk-Fact-BD63204B41767EFC9A59C7EB69C66608"
      unitRef="usd">20041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d32812916e1354-wk-Fact-76E94D207DFBEBFACF63C7EB69CA55B5"
      unitRef="usd">22751000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d32812916e1373-wk-Fact-3D7F066071A6A548DC51C7EB69CCA5B9"
      unitRef="usd">23466000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d32812916e1393-wk-Fact-2350DB098948676BC150C7EB69C43EC2"
      unitRef="usd">25750000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d32812916e1408-wk-Fact-97F75F4B3F4772305783C7EB69D53661"
      unitRef="usd">-9177000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d32812916e1428-wk-Fact-0C63839638CC0D183ED2C7EB69C822F6"
      unitRef="usd">-6248000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d32812916e1448-wk-Fact-74C7D198BB0B1F49AD4CC7EB69C16716"
      unitRef="usd">-4469000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d32812916e1469-wk-Fact-3B38A50A93428DFD7682C7EB69CB1BD8"
      unitRef="usd">-3105000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q1QTD"
      decimals="2"
      id="d32812916e1490-wk-Fact-312DC66C5DB134B72655C7EB69CF51F6"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d32812916e1510-wk-Fact-8924A7957435BC285253C7EB69CFA7A7"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d32812916e1530-wk-Fact-B13B045DE9047B02C1E1C7EB69CA6361"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4QTD"
      decimals="2"
      id="d32812916e1551-wk-Fact-788093E78B3D774D3DDAC7EB69D4C033"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q1QTD"
      decimals="0"
      id="d32812916e1572-wk-Fact-90705F57D3A9996AF1CFC7EB69C85EF0"
      unitRef="shares">34271254</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="0"
      id="d32812916e1591-wk-Fact-C81658FF0B98CF82EEE0C7EB69C7091E"
      unitRef="shares">34314234</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q3QTD"
      decimals="0"
      id="d32812916e1610-wk-Fact-17E1ED686A3447CDFF32C7EB69D1D67E"
      unitRef="shares">38620036</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q4QTD"
      decimals="0"
      id="d32812916e1630-wk-Fact-F994C446CEC4C2F95261C7EB69CB867F"
      unitRef="shares">40731334</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6962363616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating lease</a></td>
<td class="nump">$ 8,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 12,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets - finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985747040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans Stock Incentive Plans - ESPP (Details) - Employee stock purchase plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum', window );">Maximum offering period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee', window );">Maximum fair market value of shares an employee can purchase per calendar year</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Minimum purchase price as a percentage of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum fair market value of shares an employee can purchase under the plan per calendar year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The purchase period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821273888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Loan and Security Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 03, 2017</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,385,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit | Silicon Valley Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_LiquidityRequirementMinimum', window );">Minimum requirement liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit | Silicon Valley Bank | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Periodic payment terms, balloon payment to be paid</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit | Silicon Valley Bank | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR | Line of credit | Silicon Valley Bank | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR | Line of credit | Silicon Valley Bank | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | LIBOR | Line of credit | Silicon Valley Bank | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | LIBOR | Line of credit | Silicon Valley Bank | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheOneMember', window );">Debt prepayment tranche one | LIBOR | Line of credit | Silicon Valley Bank | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheTwoMember', window );">Debt prepayment tranche two | LIBOR | Line of credit | Silicon Valley Bank | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheThreeMember', window );">Debt prepayment tranche three | LIBOR | Line of credit | Silicon Valley Bank | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentPrepaymentPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment premium waived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentPrepaymentPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_LiquidityRequirementMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity Requirement, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_LiquidityRequirementMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=vcyt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=vcyt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtPrepaymentTrancheAxis=vcyt_DebtPrepaymentTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6801980112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 07, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of shares of common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_VotingRightsForEachShareOfStock', window );">Number of votes for each share of stock (in votes) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options issued and outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,562,484<span></span>
</td>
<td class="nump">6,235,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,690,456<span></span>
</td>
<td class="nump">8,116,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period (in shares)</a></td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in usd per share) | $ / shares</a></td>
<td class="nump">$ 23.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 137,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period (in shares)</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember', window );">Shares of common stock subject to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options issued and outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,562,484<span></span>
</td>
<td class="nump">6,235,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954,804<span></span>
</td>
<td class="nump">1,571,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,168<span></span>
</td>
<td class="nump">309,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_VotingRightsForEachShareOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes for each share of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_VotingRightsForEachShareOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985063872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Thyroid Cytopathology Partners (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Thyroid Cytopathology Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Thyroid Cytopathology Partners</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_OtherIncomeRentReimbursement', window );">Reduction to rent expense for TCP's portion of costs for shared space</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_OtherIncomeRentReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_OtherIncomeRentReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6960944048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Uncertain Tax Positions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of the beginning and ending amount of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning of period</a></td>
<td class="nump">$ 2,799,000<span></span>
</td>
<td class="nump">$ 2,523,000<span></span>
</td>
<td class="nump">$ 2,222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases&#8212;tax position in prior period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases&#8212;tax position in prior period</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases&#8212;current period tax position</a></td>
<td class="nump">479,000<span></span>
</td>
<td class="nump">373,000<span></span>
</td>
<td class="nump">301,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, end of period</a></td>
<td class="nump">3,278,000<span></span>
</td>
<td class="nump">$ 2,799,000<span></span>
</td>
<td class="nump">$ 2,523,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest expense or penalties related to unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820969184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6978430272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Identifiable Acquisition-Related Intangibles (Details) - NanoString<br></strong></div></th>
<th class="th"><div>Dec. 03, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember', window );">Prosigna product technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated Useful life (In Years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Prosigna customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated Useful life (In Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember', window );">nCounter FLEX Dx license</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated Useful life (In Years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember', window );">LymphMark product technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated Useful life (In Years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterFLEXDxLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_AZCollaborationLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807372576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue recognized when cash is received and on an accrual basis</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was as follows (in thousands of dollars):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized on the accrual basis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,058</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Testing revenue recognized on the cash basis</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue concentration risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of the Company's third-party payers as a percentage of total</a></td>
<td class="text">The Company's third-party payers and other customers in excess of 10% of revenue and their related revenue as a percentage of total revenue were as follows:<div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UnitedHealthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Gross receivables concentration risk | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of the Company's third-party payers as a percentage of total</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's significant third-party payers and other customers in excess of 10% of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Johnson and Johnson Services, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UnitedHealthcare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=vcyt_SalesRevenueGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=vcyt_SalesRevenueGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6968604704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments under non-cancelable operating leases</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating leases as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands of dollars):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,401</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total future minimum lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,588</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: short-term lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6824521040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Intangible Assets, Bonus Accruals, and Revenue Recognition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract', window );"><strong>Finite-lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Finite-lived intangible assets, impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAbstract', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,730,000<span></span>
</td>
<td class="nump">$ 30,973,000<span></span>
</td>
<td class="nump">$ 30,136,000<span></span>
</td>
<td class="nump">$ 29,529,000<span></span>
</td>
<td class="nump">$ 25,750,000<span></span>
</td>
<td class="nump">$ 23,466,000<span></span>
</td>
<td class="nump">$ 22,751,000<span></span>
</td>
<td class="nump">$ 20,041,000<span></span>
</td>
<td class="nump">120,368,000<span></span>
</td>
<td class="nump">92,008,000<span></span>
</td>
<td class="nump">71,953,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,127,000)<span></span>
</td>
<td class="num">$ (22,233,000)<span></span>
</td>
<td class="num">$ (26,538,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net income (loss) per common share, basic and diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vcyt_BiopharmaceuticalCompanyMember', window );">Biopharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net income (loss) per common share, basic and diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract', window );"><strong>Finite-lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract', window );"><strong>Finite-lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_TestingMember', window );">Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_RevenueRecognizedOnAccrualBasis', window );">Revenue recognized on an accrual basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,355,000<span></span>
</td>
<td class="nump">$ 91,058,000<span></span>
</td>
<td class="nump">$ 69,274,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_RevenueRecognizedReceivedInCash', window );">Revenue recognized on a cash basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,679,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,355,000<span></span>
</td>
<td class="nump">91,058,000<span></span>
</td>
<td class="nump">71,953,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue | Biopharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_TermContractAgreement', window );">Contract agreement term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_AutomaticRenewalPeriodContractAgreement', window );">Automatic renewal period of contract agreement</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, amount of remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service | Biopharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter', window );">Revenue, quarterly amount of remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenue from Contract with Customer, Product and Service Benchmark | Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_RevenueRecognizedOnAccrualBasisPercentage', window );">Revenue recognized on accrual basis, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_RevenueRecognizedReceivedInCashPercentage', window );">Revenue recognized received in cash, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member', window );">Johnson and Johnson Services, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_TermContractAgreement', window );">Contract agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member', window );">Johnson and Johnson Services, Inc. | Gross receivables concentration risk | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AutomaticRenewalPeriodContractAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Automatic Renewal Period, Contract Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AutomaticRenewalPeriodContractAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_RevenueRecognizedOnAccrualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized during the period on an accrual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_RevenueRecognizedOnAccrualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_RevenueRecognizedOnAccrualBasisPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognized On Accrual Basis, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_RevenueRecognizedOnAccrualBasisPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_RevenueRecognizedReceivedInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized during the period based on cash receipts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_RevenueRecognizedReceivedInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_RevenueRecognizedReceivedInCashPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognized Received In Cash, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_RevenueRecognizedReceivedInCashPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Amount, Per Quarter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_RevenueRemainingPerformanceObligationAmountPerQuarter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_TermContractAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term, Contract Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_TermContractAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vcyt_BiopharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vcyt_BiopharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_TestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_TestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6809731760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of selected quarterly financial data (unaudited)</a></td>
<td class="text">The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period (in thousands of dollars, except for share and per share data):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Ended</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,529</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,494</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used to compute net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,168,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,586,081</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,588,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,095,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,041</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,177</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,248</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,469</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used to compute net loss per common share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,271,254</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,314,234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,620,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,731,334</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807128592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text">Business Combination<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exclusive License to NanoString Diagnostics Platform</span><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 3, 2019, the Company executed an agreement with NanoString for the exclusive global diagnostics license to the nCounter FLEX Analysis System, the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. The strategic transaction positions the Company to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to physicians and their patients via hospital and clinical laboratories throughout the European Union and other parts of the world.  The Company has accounted for this agreement under Accounting Standards Codification 805, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span><span style="font-family:inherit;font-size:10pt;">.  Pursuant to the terms of the agreement, Veracyte paid NanoString </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in Veracyte common stock, and may pay up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, contingent upon the commercial launch of Veracyte diagnostic tests for use on the platform.  This contingency was valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of the acquisition date, recorded as a liability, and will be remeasured to fair value at each reporting date until the contingent consideration is settled.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets acquired are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.95711500974659%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total identifiable intangible assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,668</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable acquisition-related intangibles included in the above table are finite-lived and are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.33723196881091%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:81%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Useful life (In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. This acquisition includes </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of goodwill which the Company believes consists principally of the organized workforce </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">that will help the Company execute its strategic plans in relation to the assets acquired. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. As of December 31, 2019, goodwill is not deductible for tax purposes, however, if contingent consideration is paid at a future date, the portions of contingent consideration paid and allocated to the intangible assets for tax purposes will be tax deductible.  The accounting for this acquisition is preliminary and will be finalized upon completion of the analysis of certain contracts acquired and executed as part of this acquisition along with the impact on goodwill, should there be any.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited pro forma financial information in the table below summarizes the combined revenue for the Company and acquired business from NanoString as though the acquisition had been executed as of January 1, 2018. The pro forma amounts have been adjusted in the table below. NanoString&#8217;s historical books and records did not contain the operating expense information to prepare the financial disclosures required in the pro forma table below. Thus, the pro forma financial disclosures are limited to revenue only. The unaudited pro forma revenue information is for informational purposes only and is not necessarily indicative of the revenue that would have been achieved if the acquisition had taken place as of January 1, 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.99610136452242%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,040</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6722484192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">49,625,341<span></span>
</td>
<td class="nump">40,863,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">49,625,341<span></span>
</td>
<td class="nump">40,863,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820318224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (12,599)<span></span>
</td>
<td class="num">$ (22,999)<span></span>
</td>
<td class="num">$ (31,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
<td class="nump">3,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of property and equipment</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,807<span></span>
</td>
<td class="nump">5,958<span></span>
</td>
<td class="nump">6,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt discount and issuance costs</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty', window );">Interest on end-of-term debt obligation and prepayment penalty</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(6,161)<span></span>
</td>
<td class="num">(452)<span></span>
</td>
<td class="num">(3,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Supplies</a></td>
<td class="num">(3,404)<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
<td class="num">(1,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">154<span></span>
</td>
<td class="num">(517)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities', window );">Right-of-use assets - operating lease and operating lease liability</a></td>
<td class="num">(171)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(760)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent', window );">Accrued liabilities and deferred rent</a></td>
<td class="nump">5,228<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,232)<span></span>
</td>
<td class="num">(13,521)<span></span>
</td>
<td class="num">(23,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,756)<span></span>
</td>
<td class="num">(1,874)<span></span>
</td>
<td class="num">(1,755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(42,733)<span></span>
</td>
<td class="num">(1,874)<span></span>
</td>
<td class="num">(1,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from the issuance of long-term debt, net of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock in a public offering, net of issuance costs</a></td>
<td class="nump">137,848<span></span>
</td>
<td class="nump">55,038<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of long-term debt</a></td>
<td class="num">(24,900)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_PaymentOfEndOfTermObligation', window );">Payment of end-of-term debt obligation and prepayment penalty</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Proceeds from legal settlement regarding short-swing profits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payment of financial lease liability</a></td>
<td class="num">(308)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options and employee stock purchases</a></td>
<td class="nump">14,647<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">127,287<span></span>
</td>
<td class="nump">59,499<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">81,322<span></span>
</td>
<td class="nump">44,104<span></span>
</td>
<td class="num">(25,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">78,598<span></span>
</td>
<td class="nump">34,494<span></span>
</td>
<td class="nump">59,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">159,920<span></span>
</td>
<td class="nump">78,598<span></span>
</td>
<td class="nump">34,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplementary cash flow information of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liability arising from obtaining right-of-use assets - operating lease at beginning of period</a></td>
<td class="nump">14,118<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Shares issued for purchase consideration for a business combination</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration', window );">Deferred purchase consideration for a business combination</a></td>
<td class="nump">6,088<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest on debt</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for tax</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 159,920<span></span>
</td>
<td class="nump">$ 34,494<span></span>
</td>
<td class="nump">$ 59,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, End of Term Payment Interest Amount and Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtinstrumentEndofTermPaymentInterestAmountandPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Assets and Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_IncreaseDecreaseinOperatingLeaseAssetsandLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Acquisition, Deferred Purchase Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_NoncashorPartNoncashAcquisitionDeferredPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_PaymentOfEndOfTermObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of the end-of-term obligation and prepayment penalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_PaymentOfEndOfTermObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983322832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loan and Security Agreement</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 3, 2017, the Company entered into a loan and security agreement (the &#8220;Loan and Security Agreement&#8221;) with Silicon Valley Bank.  The Loan and Security Agreement allows the Company to borrow up to </span><span style="font-family:inherit;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, with a </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> advance term loan (the &#8220;Term Loan Advance&#8221;) and a revolving line of credit of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the &#8220;Revolving Line of Credit&#8221;).  The Term Loan Advance was advanced upon the closing of the Loan and Security Agreement and was used to pay the outstanding balance of the Company&#8217;s existing long-term debt, which was canceled at that date.  The Company had not drawn on the Revolving Line of Credit as of December 31, 2019.  Borrowings under the Loan and Security Agreement mature on October 1, 2022.  Amounts may be borrowed and repaid under the Revolving Line of Credit up until the earliest of full repayment or maturity of the Loan and Security Agreement, termination of the Loan and Security Agreement, or October 1, 2022.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Term Loan Advance bears interest at a variable rate equal to (i) the thirty-day U.S. London Interbank Offer Rate (&#8220;LIBOR&#8221;) plus (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>4.20%</span></span><span style="font-family:inherit;font-size:10pt;">, with a minimum rate of </span><span style="font-family:inherit;font-size:10pt;"><span>5.43%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. Principal amounts outstanding under the Revolving Line of Credit bear interest at a variable rate equal to (i) LIBOR plus (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>3.50%</span></span><span style="font-family:inherit;font-size:10pt;">, with a minimum rate of </span><span style="font-family:inherit;font-size:10pt;"><span>4.70%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum.  The average Term Loan Advance interest rate for the year ended&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>6.70%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may prepay the outstanding principal amount under the Term Loan Advance plus accrued and unpaid interest and, if the Term Loan Advance is repaid in full, a prepayment premium. The prepayment premium will be (i) </span><span style="font-family:inherit;font-size:10pt;"><span>$750,000</span></span><span style="font-family:inherit;font-size:10pt;"> if prepayment is made prior to November 3, 2018, (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>$500,000</span></span><span style="font-family:inherit;font-size:10pt;"> if the prepayment is made after November 3, 2018 but on or before November 3, 2019, or (iii) </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> if the prepayment is made after November 3, 2019.  In January 2019 and May 2019, the Company prepaid&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$12.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the principal amount of the Term Loan Advance. These prepayments did not trigger any prepayment premium because they were partial, not full, repayments of the principal amount. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, a final payment on the Term Loan Advance in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> is due upon the earlier of the maturity date of the Term Loan Advance or its payment in full.  The Loan and Security Agreement contains customary representations, warranties, and events of default such as a material adverse change in our business, operations or financial condition, as well as affirmative and negative covenants. The negative covenants include, among other provisions, covenants that limit or restrict the Company's ability to incur liens, make investments, incur indebtedness, merge with or acquire other entities, dispose of assets, make dividends or other distributions to holders of its equity interests, engage in any new line of business, or enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company&#8217;s obligations under the Loan and Security Agreement are secured by substantially all of its assets (excluding intellectual property), subject to certain customary exceptions.  The Loan and Security Agreement also requires the Company to achieve certain revenue levels tested quarterly on a trailing twelve-month basis.  However, failure to maintain the revenue levels will not be considered a default if the Company maintains liquidity of at least </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.  As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with the loan covenants.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the net debt obligation for borrowings made under the Loan and Security Agreement was as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End-of-term debt obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net debt obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future principal and end-of-term debt obligation payments due under the Loan and Security Agreement are </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2022.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The end-of-term debt obligation accretes over the term of the Loan and Security Agreement until maturity and is included in interest expense in the Company's consolidated statement of operations and comprehensive loss.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit Agreement</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March&#160;2016, the Company entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with Visium Healthcare Partners, LP (&#8220;Visium&#8221;). Under the Credit Agreement, </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> term loans were available to the Company with an aggregate principal amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company drew down the initial </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> term loan (the &#8220;Initial Term Loan&#8221;) on March&#160;30, 2016, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was used to pay the outstanding balance of the Company&#8217;s previous long-term debt, which was canceled at that date. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Term Loans bore interest at a fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per annum and no principal payments were due through March&#160;31, 2020. The Company was obligated to repay the outstanding principal amounts under the Term Loans in </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> equal installments during the final </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> under the Credit Agreement. Prepayment of the outstanding principal amount under the Term Loans prior to March 31, 2018 was subject to a prepayment premium equal to </span><span style="font-family:inherit;font-size:10pt;"><span>24.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding principal balance, less the aggregate amount of all interest payments in cash.  For any quarterly interest payment through and including the 16th interest payment date after the Initial Borrowing Date, so long as no event of default had occurred and was then continuing, the Company could have elected to pay interest in cash on the outstanding principal amounts of the Term Loans at a fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span>9.0%</span></span><span style="font-family:inherit;font-size:10pt;">, with the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:10pt;"> interest paid-in-kind by adding such paid-in-kind interest to the outstanding principal amounts of the Term Loans.  The Company elected to pay interest in-kind for the quarters ended June 30, 2016 and September 30, 2016, totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$385,000</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, upon entering into the Loan and Security Agreement, the Credit Agreement was paid in full and terminated on November 3, 2017, wherein all commitments were terminated, all liens were released and all outstanding principal, interest and fees accrued thereunder were repaid in the aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$27.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, including a prepayment premium of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was recognized as follows (in thousands of dollars):&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nominal debt interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization and write-off of debt discount and issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End-of-term debt obligation interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt prepayment penalty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest on capital lease</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>677</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,963</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983296912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generated a pretax loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$23.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$31.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the United States for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Since inception, the Company has not generated any pretax income or loss outside of the United States. The Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> provision for income taxes during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company follows FASB ASC No.&#160;740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes for the Computation and Presentation of its Tax Provision.</span><span style="font-family:inherit;font-size:10pt;"> The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company's income tax expense for the periods presented (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December, 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal taxes at statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,632</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,825</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State tax (net of federal benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(828</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non deductible officers' compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>409</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock based compensation - PSU/RSU/NQSQ</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incentive stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,994</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(256</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>994</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(996</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(777</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(588</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,164</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,552</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rate differential impact - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Cuts and Jobs Act</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,068</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NanoString intangibles and goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,068</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,918</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55,366</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,997</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(471</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(695</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(983</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,014</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,997</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,161</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,578</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,997</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets. The valuation allowance increased </span><span style="font-family:inherit;font-size:10pt;"><span>$9.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, increased </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and decreased </span><span style="font-family:inherit;font-size:10pt;"><span>$14.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$236.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$58.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$45.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> available to reduce future taxable income, if any, for federal, California and other state income tax purposes, respectively.  The U.S. federal net operating loss carryforwards will begin to expire in 2026 while for state purposes, the net operating losses began to expire in 2028.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had net research and development credit carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal credit carryforwards begin to expire in </span><span style="font-family:inherit;font-size:10pt;">2028</span><span style="font-family:inherit;font-size:10pt;">. California credits have no expiration date. Other state credit carryforwards begin to expire in </span><span style="font-family:inherit;font-size:10pt;">2023</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Internal Revenue Code of 1986, as amended, imposes restrictions on the utilization of net operating losses and tax credits in the event of an "ownership change" of a corporation. Accordingly, a company's ability to use net operating losses and tax credits may be limited as prescribed under Internal Revenue Code Section 382 and 383 ("IRC Section 382"). Events which may cause limitations in the amount of the net operating losses or tax credits that the Company may use in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. Utilization of the federal and state net operating losses may be subject to substantial annual limitation due to the ownership change limitations provided by the IRC Section 382 rules and similar state provisions. In the event the Company has any changes in ownership, net operating losses and research and development credit carryovers could be limited and may expire unutilized.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Uncertain Tax Positions</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had unrecognized tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, none of which would currently affect the Company's effective tax rate if recognized due to the Company's deferred tax assets being fully offset by a valuation allowance. The Company does not anticipate that the amount of unrecognized tax benefits relating to tax positions existing at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> will significantly increase or decrease within the next 12&#160;months.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross increases&#8212;tax position in prior period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross decreases&#8212;tax position in prior period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross increases&#8212;current period tax position</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>479</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statute of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is the Company's policy to include penalties and interest expense related to income taxes as a component of other income (expense), net, and interest expense, respectively, as necessary. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> interest expense or penalties related to unrecognized tax benefits recorded through </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's major tax jurisdictions are the United States and California. All of the Company's tax years will remain open for examination by the Federal and state tax authorities for </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>four years</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from the date of utilization of the net operating loss or research and development credit. The Company does not have any tax audits pending.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001384101-20-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001384101-20-000015-xbrl.zip
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M[P<)OZ>2U-'S*>B3.>L,A6+%XNAGM8.RMU;"B11 J2)6YSA@MFO^[U5RYQ"
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M1BBZ:F@_:@?/3Z' SRKDR&(F:^:)O0.Y@O$QN*NV4HDJL8M#A(YF*4,-#5:
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M=-PV]7UQO=CCJ6?IMM#K5XA7C],F'3),NB_(ON%,POC1&Q#TR(N%%V8._E
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M"S??XR<HXNUP:1-[CV8V\F_-RH6PR-M^HY5P.C*ZU_M.72OT0MK9X?%:JK!
M<,)[Y(_>CKJL<J,=9)H.RTM:)3MOP8*_$WYV->%I"-IX-UPPIN+4_#EQISQ_
MT,:O4;9#H,I!G^4-P&LMWVAD-IAI(CWM_O9,1P0NB?0**DLP<F_"[+"IYE<L
MR+*(.$[32ERLN5E7*'%-3^OVV4TZE\UY][<<XP^HBC&;'[DH!$$;(.<#R+6!
MP;\YB(QCW12@J[P%6T;D!O7,%9ZMJ\,,-$>4XO.FN:7*8+<F'+.FM9W/_ 5^
M5J87MCK;-4GE>63L*O.?]!@*0#7G3.[M*[/]["<;A-]?!I6,5^)>9:5%.;%G
M+UI0J_(UYCF.A0+$66+'1M RV''<VZ;6]A;R*'GHL#D,:RJJO:I3VSPZ%OR[
MN2GT=.QO;9@-=J-J*2@3OD:;*@.8FG$K%PLO.I.R<?"C@N.3T2G22F3Y=IO,
MF=+*XH6=18>5_ ]+1A$/P[CU_?V4]DW$G:[+LJ_%>*%6$\ 8TP+%N[-2[9B0
MY(V)"I='O;>G*\VZDW5R[JR]T&*@.\V"!%.]XB78.)6OS,=9H")8R>9$E4Y;
M<_Z='-^Z!;]F@DYC0VQ1PG%M".,[:=JJ[VOI)J3RCK"UZC-$Z9=$_6]^'?JH
M2-LMY86]/_B)98'L99>3 M6UP5[:%TO^CL/VQ^D=M.^@MS$%U,HBFCCEI66$
MYS^.2Z0[][2B0L.*[LS9#4X]4#Z(%>E:'0WF+6V?D=-5='0/URG.=YT\POM4
M*E[+>/'9*LO#WL7W;!A#R^IS3=#S(\6E@-XF4=KKX'@?J"GM?(/WF. * _ND
MK_:+&]X+.D8J1U)4$TC7B+EU?.L4GGRTH_5T@=-<^.HY'35ZR _'80PC#HQ1
MVSV.5"@OCJRWFON1\#E(YZ:!ZPT)O@<3>I:,M&_X]MX(WV'4(-R##2 QDRLR
M$T<(O"E5I MK1K[^-S;?_U<V;[+#@X;Q$% L>:G=-4T9T73BX,^8_=-[&;^W
MO%=X-$U=WZNP$7@MG'@5DJ+B$$+FYL ;DY>=O+O&2:]Q#H@.H^7V,2CIJS-M
MM>TV!7 _6%#[#&_PZ6P<*)%8!"?XB!]6'B4;L"XIF>>*B4KHF5QP.6?20Q5M
MVU31MD.M[QA+<Q+5!W"#$S+RZ9W\/4HX9=/6?^8R1Y+]2B+?8<;7#N)@7'A>
M;7$42<5Y8LA/QY<C[_C6.OMAUG$R0+-^GBK;SK3;RM"BQA,0F%MFLG>Q=(ME
M,=H.:O%KF=<O>\SE# 1%)PYQ?JFJX FFNW*L4H2I)C.5OP_UZU<]/4@EWE-+
M7F'B"YJ:G!N.-Z$9/WA=L&A Y:P?8QI#0]4-']YRR)**NQ@H0.\UJ*H?$]7X
MPIU<#V6139&Y>^" D)'Z\*#E.9UR\37X[F I]!+^ZD>BQFSC6>+#$D]K[I&G
MDXM"CP,S+&[Z<&G0>0\Y=6^>[^'=HXJ%'IC4WTZ;A+"+&&>$ZN??:EI^]1;9
MH*BL=R0:Z-O>0F4UZW=0&NJ8R- 0%"BY4MNR>J<^M-VN[J6Y:_R\W5+/A:V+
M=\?&U@Z9+M".*=& ;/ZSY\ M],ZO*&,.B%*B;',-H(;(+,+=SQ&@!N_5'V&U
M=;Y+&6]\QY2NIKWOBB3E@A^MXEV1@IY4SB5*@3$9I'9S+U ]!7A,RG5U,5K]
MMRPX]4T"#LT7O=:DB<INO>UP%K@O54KH;&QSKD96[R(\QOHR@KU7"J!?-W7:
M+*L7!M?2B5</>M6ADJ1Z4N>/9;, W'@=*5]K2"O8#_9J)^](4(9VC*Q.9,&,
M#QXP-L6BU87/SX^X1?H&CWHH7.GDN*;%JTW=,$"B5!*@J^PD/$D")5ZASBKG
M.W14LJ,;OLSM(RURJ)M]RD8U'GX]X(6ISQ!:*&,0*E6*L2OY#FN0;/MWY=SB
MCW=!PO3,QLSJ0&%Q)@R"Y2=R'5GWFT>BP*"1]UNIET+?M=9Y^,K?Q]GP&:RF
MQ5Z\K9DUVW7X/DJ7?PZYEF,K_Z/P51XDO5I. 9V0O)/<J6Q/^G1W8>63I+D<
MS<#WYMFN$GPB)GP5W=S32F1$.]PTS6VICQ%H?"#&V=J2[L4TPZ0^4KK7JLUU
M=:63/0G 9ZW-$;D+?Z/\^MFX^[-"3V6'_D0TMB:MB,@5W6:T?/182XE)V+>J
MMQ=>@R2*4TUKX"HO$J7ZFSCJN6--'B(/+Z5K%/LICOT>7_ZMBQOS_^;:5?X^
M2EL<]XF4"T>5-JQRV,(_FU& LZNX&U.FR%V0YV]HOWY*V,=F(9W3.0_,*NH\
M/A)SNQ=U@*M>ZJ]"J*3CTA>(G4O'1++C>HK?5GNS[1]-&=J?X(40G"R5&[VQ
M765H$/X6$B5&\'TS"W(ECQ 4OHX('2QOZL)GUL\?S"4MDDK SA 6V(3:'<_Q
M,,7GVF9<9],^^IU[:79^C._!B(QWL)/^7N9?C-_NWV'L+A2AIKX-O \MC>7O
MXVN??.]]WEM.N[58?UZKG8ZZU=EV56/'NSNE^^!GJLG\OYZ6Q3>\KLC\LF*,
MNIH<9&TU-OG%/I/=Q)NZQ:IL4=7J,_(79!TU:Z\JY**%P'@3)$J"/)LG$$**
MW>VRSJFXDJYR[!;2?!/=I4/^O(KIT%4 "<,_^Y"27S:;U\!=3BC =I3 ;^VC
MG?1][ '$DBJH(0/F<>%N XCG@H.Q1QXN38W3G/[^9^E1&<*:ZN/V2BE4D]0)
MK<5XD9G&PS#-Z/A$]'!').]&N,[B]WX_]AR+,MI/M4H%K^G2U*R7 O_=?0__
M3_"'"^@*4XOI.]ZM.O0ZP6K]!GDZ[A$ALFX_M(9*OB'B3PO:C8>&)-SR\.-D
M$2,*8$GE??D#\O9;CF_,LK^I(NW?/UGTSR'_'/*_?4AU0Q=W*".9UZ^W@/$S
M8C%7<!QGV1*[-W>=0U%B4T"=5IU6&J#)2@)V/ORW-^O\"[I89JE\"U]<[-\[
M(,IKQ>(2"^V7W;L"D5>D-^$-J:/;3ZYNZ8'"+2 (JB;<!I]^@ISXP8\M0?_N
M>P 6]<_N?W;_L_O_/]V1<1A%E#7QDGG<*3B6 C3YJASL8B\0?#Y[R[<NU'QL
M;9)9CFI5'[0%#OZ[K%,=<U2-ET3@FFHC(B@ R^TUTGNW7#5;Q0+%KR8GJWOB
M >%O6$\MP?@@$,E2D=B,)'R* NO)5%,5Z;][*OV?W?_L_I]T<Y)R_CXSCW=%
ML.]H0HB2_**2Y(D6DT/<JFN2R"=#+IV#F(#A<75']6K?_X5[UO^)?^*?^%_'
M):;NX;4[9R8@ND1[4HNN %$VS^O\$2/6L%[4LN*/3YV86M'7VSWC=UC^^E/]
MDAA& >AEL.2.20-4@;0IIK.64*>9/Q)' :+5F2C BYVYWA\/.JYU.#]>WJ(
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M#8\HOOS)]66J4S"Y$)'[V^@(\G/<_WV2[ _SEO_IYVO]?QZ?-'\V.Z,J^2B
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MGB\7,RA*0HKROJV/]6RX!C,9N+N4&C<]9MU""3J!%;XP_1K"1CC)"7E5L;?
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M9T'O?I96:3T/>3MWC@I8@(0B=KI&OQBH07P@=?_5\Z+,B[";I+<(.MQ<"5;
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MDC'I4('=D^J#\N@'\&X&S/_SG&8;'APO";PPU>4+=YYHLA27[IY>P%F>/MB
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M)J&[F:9H9*5(\W14&[>&;F*]-*Q(^L\Z5W0I#?D0N0]OP$:+M;]RPN:-P)O
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MD#RQ3B' A>!9:V[I1=,DC+VPL(K(3):1YV\^P9V_[>>?E-R@%[.$;R5C\_'
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MM^&"XK?;^'L6;WKNBCTF#72%[AK^H(U_ I>AFO\L]"];H09_=JG=7XH)09M
M#NM.X@@.BW241XL]M&8296IILP^I^YD0OP/)D[T]^8NF9.X@UR+9I;^GI\G;
MYS#^OQS^R;*"OD'W%G;0$A< R5/N3P%W\%LD-0(D!W+M^6F(Z$.<]YV"_K.C
M85K%[T9F)5,7 #OCYI?[B!1@=NL#<AQ,N.!+\[OS:WG2R3F0UX7EZS1TPZ^<
MWRUZ7 !^Z2B!/3&_;5E8;>JG583F_7K&Z@:L=WW@8B&NR2KZWG'FE<?[AXL4
MEL,0O=*W4;==E'++$9V-L@.6+YKA \K<YTSNB1Y;@K%KJI)^8EG2-U@S'V%V
MFX6QY)>&33)U5<%Y5NGW?F%5&V2HYC"_Y"91[JAMYL;$E?W&II3\6/2,=:9B
MR<;^3$>W(R1_<X'U2Q@DYZ0I'>ZJ?AT=>1F^=+GU VKD@%:T\L?V@"],C80(
MQV?.,OX<\7MY"/^+UJ,@RAW8KOYI&$/Q5:411VK%=U1?*$9#:7"@%;=MT^/6
MV#+3NI/HX;VRO;)XP<&HC&V2PJT<Q ]4ZO:&SO3+-I#]N"3]77/5A-IKH^.Q
M%P!A%ILIZ-TO_W*LY'R:"F+"5J[$S'Z!3"_.D_1@Q7XL^ZBUI0QSO@>5_&?
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MO<NTF"V(UM?Y?Z41S'XX4UH<C1S91@MD)G)W)@N/^-AD9L0*)'WZ3'(.FKJ
M+.,![,LT\\R&=1 (49;6[<'FSJ]3O:?_J;#,O@!\!,VH</_CFR %,X\[6MQ\
M(5G/SMX-DRJ_70#<1Q#S&S[=BW;D'ZV79P(L1[HFD,GVRQ")AS.K]2;)J,0'
M1\,OIY O($N(VS[>>KA\E&O>UHF^,7BV=OI^BHMJ_3%U!0?7!/$:.T/0\FON
MRK+<R>UB*":9) ZZUH5]-L?]7?!(,O\$RD8Q\?W/3SE'/6]PH^:BR'?]!B%+
M*6?:_D7E,(BO8Z[ $T=VOZ== 1 <\B06;]3>QI2J(1E-IT,*1+&0 BDIH+?G
M;JT3VQ0I<@5WYXQB4O(2E'&;"".=.9[T&NK3<%WN_(Q\%KZA]NM(=F5-\$-*
M"%=Q;EPZ]TQ+V?8443! -6%Y0VZPT1W\'M-$V8=W#/),>*(8[2W9Z^YL-4:7
M9S!L8,2*G4Y8%9!Y;F*D !RM6-ALYYND8V,^J[.@+K?,V^1OQ]R,%1@@[_8I
MP]S@84U><U8>U["0C2JQ^/J1Y,8SRF_T]25$/U3*)!V_5G-T=@'H,:8?3<A+
MT@V(+Q)$$,/-]OT3V7R''OBKZ0?SGABPH^=JCVP6:0GK'12Q^MMVC5WY62[S
M]R-TUZ!>7*X$HZQ-&//U 3XLK5]8J$XG)M '=2*.VRNBLO"1-JL?W5\YBQ-*
M4=CPOH5\RCZV?0@5ZB-9X;V73SLX@<Y7MU.#)JLN$5N4NHFAD05[ZQ0^T +Q
M%SXV2L^8S3=^=6 ;,J%NJNY]>$:W9N 6M)YF-6O!1SUXCPA<!-6?4YV$D+-W
M8*R;51N-''@+GWR#*::G?>^O$_=GO>1$EWU^@6Z8F^O /7D/^_BZ?@]9_'4S
MF0_OXSWE385(U'E?_=X\UC_-NYHRA1R/!UO ?E\ JIXT:G7510: [5?G\WE_
MCJYQ=/J%VW!^]](?*UIG.>_WP 6(![G%-R,7^:=]8:H=XR7?79,47P@ET>Q%
M[!'K".><J)TZG&XK&\'F.,.4+O/AQ!OFZ-!!1VH#Q'1XAW0K-0[3,*(,TXSL
M>MN-2?1#&9&-R8N7ON0D6V4%_VB9HBC.'EJ9([M E]KP0K_\ZD+7!!'N]]XE
MHE?3^[UYH-*7D.^5/1.,:+,+F%D_#3569YFF%[TUBDI$Y@!-R8FPA\!XJ2Q<
M4R>V3'3WXS<3WAYJV4=JL!^KR1CA#:%924Z@EMQ23A0*AWXO- RW0TV?K_2(
M=RVC;]9-*QC9UJ3HDJH\F!,?H$.4?[7M/17_56Z&W=]]]P1,81@.G_$X80MN
M.,B\ /3R_&,$Q>SN5>#6+?<_1M&L4/ ITWS<]!&D"LB6H;,S^^[97E_ '7_)
M$>D1U/;PE%V)J78!%L3THFJC]6%%8_3Y$^G'?_T9T@-W?$N\:_V 4?E:FJ:U
MU=$J)@6)#P%08PQ8R&%SPV\K*+<A>\QBK_1C!\V<6D5WWGP]P$@>/[;LB6Y#
MAA[T.(LA&;8T1DRRD2G&41+H5]0(?83?+_SIKM'2XN69 0CV6ROO1-@,&Z-R
M(](PGM :GGX>L4*Y1V+%2W== %CY$3 ^GDB%TJ09SW9'\4O]HLDDAEOU"G4!
M7]77,BQM=PKE^XXW$"+EHBG-C\S/MC55,!U7)^H6ZXZ0[D3> -&T-MB-9(OQ
M]P+%VVDV-U?68N8^=--G?4H"=D&%%@2H.6Y=%?;SL%>)EM16I"_[A158<L%U
MZ,\([>]1/CW.CIC:^[_:Z0]U$(LWK EU2R:E6086'W^G10,_KIQ^7Q.#-ZX@
MRL=F6D0B-CHP1<$E;.,9><P>;LL_QRL2^$-+4:Q"X@>P@U$H\ !B]CUS88W:
M[F_$<X/8+VU7O.Y'$.$GY@1"IL+H>]Q0@RN"85HUS":VH258U?S4D],_]M#]
MT/K.22D9:=:IJ[4"NF7F-+[\>DO*553Z.O7Y!.?<K9QZKAPDXFA>8U]E7'B_
MU(FWNKG.]8G^JUD3%HZO=+"FQ]CZM$N>N<F+K/!XDE$*@8,O:FENL$C$#M2H
M^T]>""!^U-;T>F!ON9DI;OO%H&+Q7F2)BAQJ;*9Y?XEY]T%!@'95H/K$:J0.
M_BVDNGO*>/\ID 3?]18@1,5DSH,3)W/"!B!R!@:I)"C];*%1^SJ+C6D0BAE3
M#$4B/7PN .$DGAS"@(Z4Z6"0]!\X_7?@!V!Q1R)P"3.\($-.<"J;T432@,O&
MH; NOQ>]BHGGW)WT1:@J3U'ZV<75<5]Q[F7=MO.(M7T)]@$Q=X9$$)K[8<O.
M+5<C>I+ ;-\NV8];* 5'?J)=DP7?%[X H,QR#M'&..XP#[H70L(O59MJZE.5
M[KY0&YIF20>4G9HA7X*=22!<NB4U#I:2H_QU$D\OB2'\56B"/='!1FRPOG3I
M4#AZF-3R&F:OSWV]7;<&?:=S0,S4Q$9]/*HA;03\+SU^_>>D/J$C5YFR;'\L
M6#*$1:F3SV281NU;N>M^=OP\S.?N[/ARQ#2HSW 3ZC2T)2-7TVCB+>8!OE7]
MNVI>9*JQU+8$"BTIXG"1N5O3%:!'J/M!>O1GAFB4KOC[,SFI_:'"=L@1U<]C
MZU_G2]RBIU/]Q;>-G#\@O,E(D1S!1+X!II)/D2OT7='26.Z@U0G1FX/^CZPK
M*^=#,E_#(N0J=A1[J0_3.A=XQQ4L4&"(7%Z'^>*"FDV2RK$B@/,S"\ +<!-#
M2,3S&!/REL./RRS-FP*^F64!+9I]L7?]_$]E)3=!53J_6&&/(#?*MI^*^5@.
M:;^DA=8J_7,2##F6I(KCB%/=.H/=#*7'\H5UHJ%[%X#'J&WP2]P<YEDGWA+(
M\OKAZ9U3HW4!N*FPM-]YP8XWSJ8:0K42;4E7EQS[_6@JEZ/G!G&4#/YQ ;#E
MSS$:.YI:4;,V7C%0&[]JH/L9L $H,%J=(CF^[F!XHJS=)#*0#?K4?S!C8LC(
M8FHA#5TT(GO\^;=\#Q'&_Q/31P6NTU[G>9@4 2!1R/DP6G3[!8!%\CCHBH_[
M6Z^XJ<*S=_$E+Z#/)N#3QVVEHE_@+"@@/:'!&> ?S;7]R>@D G9N&PH^P? B
MS&.[W<%PPGJ;'+A3E-9RP[09Z)C7O^)&)J1#,?K37]:/%!B%#I'+B Y.,^P_
MVALY?C6'A,WL&C',J69RP@MWX')D9[[?]A\)1E^[MGG+*'R+$_ V$/7RD_Q6
MI6B3)&HU:4_G2J(?,-/4CQ)O+U>+7"Z[A]$=V^-I&=M;8>Q0L'WP97\'VOCU
MNJ3A\O3N+'7BSD(-KNX7]PPC$7OKQR=G0\T+ .U<ZV99PNJ2]:3:X>*$'X>7
M F:^E16O@EB!WN/446D)U1M;XWX2R[%T:LAI$.KBHAQPSS'!L']KNJ1MYP*@
MN@;+BK6="MB*</4J;'U,*6DD-286EIRR6?WM=*?T%3^)9K?ZHK]O>>/X\O]S
MUF<6J!WWFOF,^?C'S9'NT9\&K)(HB$-MW]9ZR9N :+D%=<Y1%FN]8=XH ( V
M3GU#Z"]R1NBD &%0VXA#?]V[4?N-!27I,Z30M6$== 'P.!)=K.- ZHL.E*P9
M&,@)::.R*4U<(I T;&7$K=H'VR.>S@/'4%KD3-7*%J%R2X>: %N!(1SYSSW'
M'0_F-0J"].?OGNZI_KA"".U8O.P 9E0PL?ZQ:9^RQ[Z>$%7Z#-'"XW_I+/U6
MKB$P/G<!,I-1FU$PJ^[K[WX_@N4AJZWUGYOD:X1+. W,T@4@! Y?G?,).7YI
M.2_ZP#_L'R9[0OTSH0 RB#6L [=V53<+W]*\: +:[B6970KJPGM]P,MD")0M
MOFI4AEO,'NZ1N+&:]%0$6^T_U;VD)J''0?:9I7Y5W%Z\\7M:G_ZQ"DA6(S?]
M[]XT^9(V0]Y5[9M]=LG?=)69KOZW=;!^[Y-*ZK@YF]6A/@!ON@!@*(EUEK)$
M)4+.&QPB\'C03"OV?4N-\17M#0ZZ496"P!X5R6%+V%!:O,+OGML_I^S?^HL>
M-/S1!2O\,T*A/T[-T@J9C_^0WJ1F_'XZD#>=31/6\86\$&3+<=I#G;KER7V/
MT-%- 4Y6T]]8,-F8E'O\JJ&U/NCU@=IB^Z4KU@]"25?2CYA6G[RV[%NLP,?^
M+M+RK_!N-!S=VR+OUJ5L5QM%;:+O-:L6V,$D?T[L[.XUZV#K.[^4C9\979_G
M0)D#7G)8!\Y44CA(*GCG,,E!AAS\+<2RIN8P@3(6JS>SW/ON0Z%C*='-SXE8
M,,X&K*+)6Z2P@*HW#E5NR \,.#JB<A8PBKO&.=?T0ZCO1^Q6ERS63?,6[),G
MSR/."DP)6<L,>.N.<UXVCT;+8%=OR1(M3[:]EF?DM=<'MQGK><KAEXZ8@^:^
M[^G_%(0K7 ""O:RVBOIR_1LLQ21+-&ZWQ@Q/8N1NKE!X OAQF"Y%"=/MR<LF
MMQGH_H)X<?!&2F;/_5.F*5W+&L&:QX-O"X0D)[B53:.?*$MK5+_-/M5Y"X,%
MN)#3:D"!)RL&6B_H=%XD65UQ?W:P;GC_6VDH"G"0>\1_N27M1)6@XXA%T2*Y
MMG AXZ),26WF[K2*T@@5]TQX$V*?K8#H[<#8DT^0:S,[%=?RE!<M>=A9#!=@
M/T3I$0;AKKAU+(U(U(#3N4VJJI/&-8,;%=34,2%HI3)$UXK8CB+KP$+I3.L,
MOR,4O 33#>W'R7HY1G;JAS:$1IF:$4>-&M$V->?'4IYT&HXJ[P_J!DB/Y80-
M4.F\A)KE71JM/YX?\=JARSQPWH=:]V8DF(5:W-X&_V4X]=UP/2I#, >HX&E!
M=VMV;]+?LX>QC97F!&,=7UQY,/ JZBVCF+9Q:IN-Y/NS.X954#\)I.;QCN.3
M@RB,0@+*H]%3J\S9"5&T_V:0K_FK6GI.3%1^88 AP=L6W_1+^AXCK^MVTN<!
M&Q<? 1$95LK*RA688K"OQRE,NA$G[W .CI;(>+E3XJZ D3J)Z!,K+GIK^?2Z
MX!EHEUYC V[+:=T-XW.4MYST+#$K$Z3<2##I<:CH+2U_SO?Y O".XMFG3Z-/
M3QU9H"N@#_-&.S;F^MU]-EYA<.]RF8",@>DN1!Z"5IE<Y DB1U8C;@V60R9G
MDN)"NV8@X0]2U]?LEH=Z;A8$V\#*,.M4DZUH5%R / MN>'>@T,0TX-NB1+Z!
MI?B:"3GK?W\_GZGW^=+XO="H-?$!JZC0$8G>*%@O[VM12&6+0#]='F1ZCX++
MCA!:TZGZWZSZE^2)JVI?9!2>%+UM?WNAD5;512Q>=:=2A)UKNJ?&,^%M_[/4
MU;A&L1*-##LYS_>Y2-5BH-TDR I]:^[U;CXA4K="Y2]?I[H,^%-TLX$BZ.3N
M&(_5R>*]^3D1WWLG$ :R2<F6G%#H%@MD,?Y0@;HC13]9^B?8GX2R'E2X1)0G
M<&/'\?/&]G#'<>M5YYIKA[GZ6SF7WA*+ RV3E9FF;[KD-[PK13B%L,7<XQH*
MNFL4]_/?CI8U^E_J]G* WKU#%*K-D\2$DY@_ <<[^WQS59ZM<>5AN1?V]-%.
M/J"WNI8Q5-Q@D=*2-["2'$O;V%0;GT\S@5GAEHABZ,B9(G&;'75F[^Q*0RS)
MH3K[>AV5T\I F9I!A3+2B7<_4R_;W ZV>*$ +7Y&F?3YYI\NW8#R)/01I0C^
MRY5]\%L2SK=7(@GZ0L]V^'26+P#^(1QNS[L"+/#L2XL1E'OS8A _2*36K/6X
M\"%?<^;W !=H&O4,6B\G>L#G:UR>B2DT<YLDBCKV@/&'#53%W"W?QOZ= Z4X
MI%(.-@_/Q(] ;:U W 6@DTX";,=6UIIW[1J>W6IEV/;EH<#Y%XNK,/V-\[4<
M[/P+^5V1\Q7M9L3>,$1(905_K:6N'50+CI&XJN;YJ@I/2],&"2,555#.W\'X
MU%%IW2Z)/M)/>,>3;7,N /P$;JMD_!I;MFZ/4KO%9,G>/(Q_KLJDS?7WSYX'
MQS;72H#!5OQF-MQ[<:#$ &(69<Z2J3$(#K'S*\\ G3HV-X5= /:S>^'XF<W2
M"\ G^A",S*$DS:S.^:[-@PO GY=&0P./?V]L[N0=8 Z M:PGFF%&)SA,*S(#
M8:YULQV8U ]?X+T R%71I=\C==&Z(@W>"/4Z70 @B!##E6?;TLR6?Z9^@X[X
MF+X4P68MK]6$4_JL2A<UJ/NO,'3G$N/.N&.+8@Q2#,:F!M922?U)WO&ZF-F.
MOV,DQ(^M_*(2$SLOL84M:1?CZ79I=5?7^]%W_2N6C'J @N1Z!=5"H9X?&TFF
M<EQ7,").-EPK>X6@-Y .!2L\36<FL)&9Z_ZD2(VT?H(ZF*& 6/BTA'#)<N].
M\#-/4Y^0'ZVG!'L"4ARQ4DIW99)1)+=UE;!-"!@N@@G!IF=@J57VE.N?':3-
MBR9$WH3=F;^]U' JP[U_\TRTTY)W0L&L1*=HFWG,0?J0HWFL5N<GYV?.STM>
M1<W"2V3G[IG4S?-[*:Y%\W5OOXC=]:ORT-U38SI&M0U/'?1T'"B5^$Q@)YR3
M;Z5^@$M6VY*K+@#"]'7SVZ<EV\Z)N%5%H/1A_ 6 [Y1G:3?#U=,&CBW8O'X!
M2",N]AZ /B.KM//P8LMTUJ;J'HLT17,LT94+\"KN['/TDI@[HM$CX]&PTIAC
M]2YP1EY>Z -#QQ7-8&5.0,FS[@J5P@B&NU8&*@"JGP5&:RGYCF")HD%]M;)D
M98KS;S*"KQ<W+<RE83JXS_\/)/C^_D>5"D;^1T=MN($96UGMD$P*LH_B2]N^
MB4V>ZBYI.A&(O?#O&_X8,V6(=N[&X-O\G<G?W35L/A%N>88*(WX2PX/P2- U
M!25<I.%3!Q=RCG9B6,UXEO[J:T70]"=/?<('=Q,N*D+\LFA((VKVB$Y%4_J3
M[T]DJL#GG0T?D&6. @,X7VXRW&I9400J_[8JA-+M.<O7O,%J#*6'PR8.$%W.
M4[7+U&EO<,*_ZD.3Y+3^?O<\B7G9=BX%6I \AUET^@38@$K6;CPZ1P>?GY!:
MZ+NJG!BZ5H]A=0FUHY-]Q)&C_;/S/:]_D [Z!+[EDV55A5>P[DB-;3\[$[9_
M<#P_ 5HRI]\W:IV9-]V:C)TSTZ);+0WT<'_5-A):R!,(3C+=#ZT!T6R)&3N<
M0[O3?+D70M;$HH_;MA1[F)P[@#)X^L"/8AM^@R=)G:M),U[*SJ?),LZ=>MTN
MY5SH_:?NJV@M3-_^&4)T)<J0^50V&.CO::JY5@O_<O[Y_)/P'Z9_\#WNF"=J
MSP)5#E#$7@!FQ9>O(>B3?<EI9?1GF[Z?="\ ,M.J:W2>AO"ZCR@N( :KR=H2
MD%: ."LQ^CV.#>B_-1*1G ,N0U3E=3<HOTK/>WS>14D&UK*I[3\ !2MZ]"87
M?21!_LX.SS:2>\Y% W>QH*,9<BY%M\R]L6ZW8072:RDO+*TZ-N"1^#Y.%9R_
M/GL6$>;2;2.\E%P"SALHZO958&[2'1@5/:XX^>O20S__O/5X%<R(MD=<"Y S
M>4>TFSRVZ;TGYTX]LQ#SC]45>_AG6GGQMMVB;#Y8"TDDPZ+%\PN WS1W?Q#9
M^K4 J>1;"*O(1[6LZ+S$7H-7>B;A&P!.+2@7?9 U\V!4$9R/ L<Q',B&<@W9
M=US26'";( _H=)US)>/-3@+Q1EWA7 M[K@5VLY6I-BD/Q3<^*)H?;??\8.HD
MZ+3+H6,D"R4R&+O-B)L(AFX9W?GO1P:<?<LMH5CX3O@RDE5".I7@3+NI2OMJ
M.ZV(.KN'!#+J5J2#AN.(6&1H*\O&BLZ?)X;39M<@H6?Y&:'>L(+-/[:?A="L
MF>_<4L%&;7P"(I$V6^<4Z/2:#4DZ9;VFM2Y%O5NTA(",LV#&3HN'$>B)"IOH
MZZ7!Q[.JA834#YUU[P*^44W*5/WQJ]/?D4&]RXX@U=V)*(DJWC9,_#L\^]1'
MCA7*@L6-K$90RHD__\%&PNY_:[="_/",:/LY(D*!H<R^T0(]@T(Q4MTUFY!V
M3*1QZ[ST.?< ,K4M;3ZFG05)8$T%&BV.&S(5$36<^#.^6R6)TLF)%E\ /@<T
M% ?PC#?S%!+ G0NW1JWDRDIU.XKLOZPH)SBR3]V3?^EY)7".X<\:>3@TP&J)
MFPMB^L_@JNT\=Z4M;@@/1B4+7/FI<8GRT$7%I-$65:M3D1Y#?RWB (9BPC5Q
M,Y/3-$2.9F/J#&MC)AO'BA>S5BRY"?XKDE5X>%A!4]VH@G79)Z*"ZVZB\,CU
M]F</0G\#S*-6 ,?E3F/8X0B2YC*2SL+"!Z2#*SUW_.V^L'52U<VV;7\%RZ-H
MQA4:/WY+:"-50$&",W'Q&'7\WB9)+R["S<L28N2_Z+@_87RX&,;%-"&)#H-=
M'M\I"]CF%/$/;4K^K7S0(7A5AO=.1L$/1:$9!8$;9KZKBIR?N4,O .4-VV:V
MS1D/HVR^4RR/YTS-A#.:70KF=1&H%K^[ C-.T L %I$S\+-8LL#$$[/^ <VK
MI7S7R/4H]#>R3CITM1E7$'*<H#<R-3_@_ @4I%&L!)R.Y XKQRRSFY,LR4B]
M"\"K,$N++2F&QL[RDL.X)@SOYYN5WWQW(",DWZ59T3 NA@D%$.R9,Y1!:^E#
M=T>"ZU[I)9+0&OWG108GV V?)CT"9"7D7A*=+%'Q=\&IKMK\ 7PU(? *U^=,
MOSC@P%79]RYO3@2/70[<-)O-FH@I9WLV&BP*_063G(7+R]FKI"J-?G)Y[>$1
M:V$ ^SA)VGIIG\''2/.+@E:!TF4'-E^?"9%;OWCEPV>;Y+_</TP/_":6NA](
MTD#?]1R^C?HLK*!E5:CD5-%1:#Y++Q"D&X(-_\LDU%-P)>)<4P^W\_..<.'A
MDI/*@AKW9&4J*U-MI5A=%K7DF(Y4.GDMH1IBMC"X,"-QY,\%_122(=V;%M'H
M9XI1+]E*G5#4IE*NF'"F<&X;WB$88MHQ;LJN5UO3["5TV/<0(?U62D\ZW3<S
MCT=A0ZU,XP'22U"NGK=U1.'5!+=PZP543:KJ?1MUZM5/.$A!Q9^]_?1+K.'R
MS8%4%P"4I2U1E6170_#%-@0\P&Z2_E/,>6-5PTH6\M;J:P\G[SN7G,(AJ/C
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MM[LR)D4>:]H7 &^=EWVP^Y3Q!0;<_M<+0(T$I_:PQ03_](FCHG'(W^ANI0F
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M67?ZW78B\NGMUHD$[</-NEA[4<N)]Y-%P?9>GP;W,5!L1X<2>KJJC1R%G9)
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MAD*XKX_MCXY,GR9^K:U&3*O7N5IADQ.LZVCLR#D@AU/?,IB50'M[VPIA69E
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M>=GP#<FN/46Q=LQL0<,5.J"OGPYX3T;19#0H,M"FZ2,NR#;R&/Y;"B6+]>@
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MLW[D5/+R7+VSZ1^7O0W!@T>#XG]6F[8YJJK#[J<DR1D4Y8Z$J<$#_3FL!^F
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MG,5OWI*L[>_N6HFDRW\,N1F\F38A-9[Q()JP?"UIU3:2<\S,]KJ!_&"YE J
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M6G,A%NQ7U"ME1 SB]SF/X\]NK;]01[LXE, C-'3WIK6W"!/_4=K"V^_YZD!
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M/HGT]L52BJB $4<&$CL5 "!?3FL$G2^M KC_^"80GP)<(]*@K,DK)R%GM52
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M< D^>(YR+OZ5/;'L@2E'+B12 3SWJX;W**Q0-H F>PQ1Y8!S+_4T^]/'@$3
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M"LWM2-RK/<;-&E/]N=L#CF5/$X)>C%=J'R>H7SVMR_S]ZL*ZB8?J6W/V!0S
M:^L8A>]9G=Z1;TMUQNZ50\<M60#X&E5% #>+JU\0ET$JI94*N.0&C$ \'%O#
MB]8EU&BA+FL>ZT:G&UE'?W=:S. "H'[S"G)7@=,:.'$-T0MD =''2L.B;LD@
M\5J8/6/DA5UG^=B9%$VH_)?TW28'7Y!C\LH/;OEO-])OU)?'+1\;&!@X5H..
M![GFFQH#SPR:D!<G":X: N\"N]T]NH.KDS_-WN.N =!: -;8BQ;#1/H=.V?1
M@>\D65WTK,W+JC,%/8@5ZC"VY$>8]P>'F(Z]Z=C%6_ 7Y(PZ'>FZ!L>HF,[T
MZ5]R=P+?_?W1.^O-H?29$5$%;E%!H,5Y&N.E8NZ.KFB7V#L_><P_'% :A74V
M)=[#M%:OQ6QZ"R2IQ-O?J>U8>]BCI2Y8W>OQ=JD.-5+%)IZ@^#=\#'V=-+]Q
M4KI+!1#X8?X\,":O^=9]U<\[.^^&?GZ)8L] /GD&\G_0N)<*2>6H"+<NFOK^
M<<N]*CQG=E0[1_'YF0$*T8:\#L0R;)^;^.R332"O_@C+9N5F\PV!;Q=9HEHM
MF5)/WIC/&^HF2$VKMMH23B)Z'1:%%)E+H-T:&#.*;1P43,-'WY\YER]HYZ1R
ME0KPN]"_8DIJO$Y2Y7SKR/O5IZ 3-1)V8BR4-_179LN=*8?>7!_,?O%B/.2J
M=&W(18_*<JV5C!GD77"AISD'P3)S_6%L+Q7 3%>^K"Z,93D+H@*XQBV5_\Y[
MJ0H2E&M[E]XI9.1M?TZ(SZ-F!^[/O[N2_;\I#%'@A31T:3[I!<[4'#2P Y]%
M-@_$U85)=YM.+!>#5N]K(&OZUZ\@[ B6+5/H +AR-C1)>B9>/@LM/V-BJN*M
M^N:+;WN. M,7Z,G@5_DX"W:UILO.T/WTXQ5RK#5!9E$=#L%^_PO.E*>9$,:_
MI)F,.BO=X 16^3#43GIZOLK-Y@6;+Y!V;X4<ZPM1 <%D6!VR>W?;=X<H2X(/
M4@'VP!!&Z.VLIV8> P_ELWX4]I81-FG?<"[$@75&-7VXHLO>ZP5?Q;2*^S>R
MDY1P@NWZ*0*X0T(\>'9FLD,[SO/:W;+7#$I1#*^>\68B?L/9"+-8\!1G$QZ*
MX*Z]N"B1[YW=I3KU,(-W5ZV^W50"6]SN+)FO$3W['MY_R_EP/Z^H_HK/HVEB
M@_8A,G=,Y[6FT_%.,)>'4UMZD2OV'[W?@+%XF<^WWG9I?EPFSNFDSF@5)7=G
M%_PGH9F'(Z#YMBB,)?+Q4YCW'4O!.PL>K,7*3VL-S<\YS^L[NA5C.RX"M'0S
M(_%CXJ!KIV_&QS?4%[5OV<U=PNVLEA9NWC[3BK9FC_E8FS#U&9PK^(F6[PO@
M9T[;&P=)@_>H-AZQP08N@K;.^%%WQ^$.4"NP5V'?X]+/2[6WG@$^J ,^0/'?
MC[\0\'F( ?0MC(*R%\^T)HH,_'MXLD2TL$F6MN*8V..K)0^@=2=:(,;&_[D5
M]3DX,9.]0.%F=I=F9CH)XWZWXV"%IZIOE,+HJXX!DU,H%[<:RP1;Z& ,&\(#
M1JJA[MSJ"9*332F&9\7K^3-G +5#^S>ZXU*H&2]/_NQH[,HWR]ELIT9KY/>M
M$W'PA_/,Z$7IP^"9VYO;DWJ+X#+8R0#C@O#]6<@-EDLCJE_6R(4!*= C@>H]
M@!>#"L%Z@2S>S ,LO^VCE7PU^,Y9\6Y?>ZTD?^BNNO3 .+<Z4=V45*K0F_W#
MDM]L@S7#P)H"\SBGKU;P?\G+E^<A&/<:-;FHJ=\UOY@5\MXJI4^Z?&PQ\H/Q
M71?6MJ<[?6V@( 9EZ9-,@\;BBM&'3@\Q=Z,VAQ:?!-L)O.J\+W$OSF_!_]KE
MCZ-_M&[5*,+S)7/CWF'#LH?=9]TAXV]PL=C&%E%;K$%D&9IEG0UH.W*X$9B;
M\EIY?;!JMR CER>XT89RE62#.]FAQ1T/M_@\])>QX*TKMJ$Q$?D$LIL^#2 ]
M"]@&/T:^1TVJG!PC\)8.27\_FB&PZ7[]+A)E.*7V0;,L9,2U'#6G,Q-@#L.)
M+[6'4@&V5,"=K%IL]Z?!CLN>-6[+W\3OTSXUI0]T#>;*!04&S,L*#ZZ&$L5@
M<5@"^LH-&WJ-9%$@ H\<0XV0LY)F=Z:A#*G;#O('R$_H<@,_I)WC$]G#[O+A
MNF?,[FT!\ 73>Y=BV3>$SZVJSB\B:,.\^$G"G  5\*G<NU>V]C&N1X6CXE9Z
MNKG8(S-VM"FP#1UPIMVV=[DQQ-U^M4PY6>QG364;P?K5[R<,E]]^8UIO3UVM
MO[)C@RIP)-P8L7YY=!G!(K"X&Q32HO='/]+GULH/L^'M_@=D--)V5GR!)B#'
M:-+A\>9X36 ^_^CRX.?F]Y?OYUWT\*NNB?F@K0@X<OCP9V?P#OF*-@]:*EFE
MB3(JI]XYFV0I&8<_6@EMZ4[Z,!N7ZWY321O7@/(NW#)PWIBR_JJI<,)VLYQ7
MF?UA6S&%%ZZ)0S8A&1K*%WMMYC4J *?OWM0832!OZ* 2I]=E-YWE,-U4P%3M
M<<_8.:\WB4VWC]9(];I_3:;=PM![_#U#-]^R2_NK@+L\V\]X7[K-JBY_]!9[
M'MHG+*;7K0D3WS_/H%D6E/.?EL7-[[#B;\R:G%;,L0[+/,^8[&R:TNY]C-IK
MN-!NP>+!MT=I!I>VH#DHPL_S'#Q:2?S8C5N;1QF0F,57KJR-#6HSS<2\YVU8
M<VV<Y<+:9X0<8;>[F8<GP&TH^81-BR'._BJO6PG/;]OLUVJ78B&E8-H&9CO(
M9=*E+,*;9MQ.6;G9T(PLCW5/.^>*Z^PWU&\ +<# 3#W/927T#,9HX_:(ZWKW
M+V/-?/'=HL+3AA2?Y$(6'7,7@N%_@R>M_M-$W_.S CB+4*K4,'@4_L"=6^Q8
MP']QS'TFYMZ=NZB#L,$TOS8MT9=BO< 8<'GVMF4!B7;$27J'1NX(=:%7X/7R
MS:&-Y11>-+!Y0GT 1T__& MDH-PGH+"P4,>C<T3K,,X!RF6X:,<98KZ^B3!X
MXQ=GH8S F1DW^4*ERWLD9TS^#I:[%Z?$F_L_JXO<D?![Q'-RVB2S,)I5@V?X
M$\L:UVVC#I=Q)KYU'2&G*/U!5LV+*SSZ=,7S34'22B+QMGIKF0O+&(-T^=R/
M?EN*^,'D4?$P_,)Y'(XB0-H&3=:I *9WX7]JAM^"RV(%M7^<%<M)H$]*ZD_H
MXXY&ZSQ\RG_()/F.&-PN?1 CE.K"]T%H7<^OB7;$ ,L65L=;2. T1JOA:>(\
MTQV<N=2A'^E4E@86CFB+N7A&QT@BY)^4NR2V[Z!;>.FY9 <3UPDY9N/JW;^U
MKB]3 5X WXU^^I1?TCU5(@QAY&,3D,FA3_OR"03502Z(^6-'!80XG\>GI*!4
M]\T(4%K#91R0Q*ID5&Z(Q:/\MX^8?D/K>;"%TULK#3CMP:\&I1M(W!OQ0)DF
MQ"!L45$VI='N5V0Q%0!_.=JSWNL&NL34S%[!/3GPX2 2O9)[&#\\S'+DKW*.
M/O[4@1@(#\"_)PM[(A=K/YLBNX6DOI>T[T>@QHK=Q0E"XDVU7*?,6TE1X+5I
M+5[P"3X^>[*_N)4+)15;TJQ-!5RP'9+<*)69^\/@:F#Q*XI'NV\NFR2"%><Z
M5Y%NV<2+:*^G36P&JD#^L>H/OS[Y+J(\D'O%$'&2WCDI%B&9!$,UE5H$58<R
M.QQE7BA!F2^-&OD]DCVVY9TJB[Q6?ZA( M*L>L4GZ^:V]VZ=B%">@%\@%!#3
M: ;$-?[6",_P132S:AR'5L+=MYP^FN(BP*J5QDE,+S#J/&I41B+M%"U,O<*(
MG4/8#V-)TBFOQ^8K/-;6X$A.JWT7OU;O]XP:[E+.S9R]4A%,O)$:CR5E 1=&
MQL?G2QM)S)6M$$:;BC$%N" .%:+%921QZ54U1#.$K';B4DM.<35[R9A6U#\H
M,6FC\^>PH=C< 'V@2 7LC%*,3SP4>!>TS]'[8N/4I=;0=(+'2&&!M>9Q[J-H
MF"W[[EHMCW- +.J9&AE. .+ S6@ B0&&[6=02HDQA[RD3?9^(F'E>G9E/1WU
MV@=X@03&G30#;TP1D,T<NAPJ<4X@M;M []K:XI6)I?AWZD7!U<)Z[E+K"$LT
MGOO]JGD?77S,I.<!<J6$]%?8@P*&J'_E79)'"B98;F [@JMQP)T,XGZCUA#1
MZ@*57S%%2CQONFSA?^$R$^0;I*Q_^]HB+.C-[%8#7=A2*XBI,SHMTG-N F,J
M?X'8 IS7V:JZ847)TS'^DYYU" IYT"]II*CE((;_V'J^A)VG%-N#4WMOE^Q9
M95>H5/RX1)77:E"7O(3<9::.NR>L1ZI_((0'XRWHD&.<H9?_4QB7??$"S<B=
M5B\6CX,1[GD#?=#1<7\[> *%[6]KKQKAZ"#8MGRPCBK,R,M.FBM5/K$Z49"D
M',%U\,R4:Y5X[3^O-<0^N9TC@@F,\/O5VR><OL9R:NS'!@[;QU\W1=3(YBG>
MT6LCHPH..@GV&S!U9)-VQYEV,P2GRQ!<$U>'G)9G^RP%33\9DWU7_=F72_[<
M_1JN>(S-XUYA_(:G$B$M)_J[X)7 )+U.UW/';#,XPG3O0!=@+1!Z33Z?!#\%
M51M+69M8#;3MPK2S:I5TEZE=35#A[\J4ME7V_HM"]ZPM"4Q)BD$RQ>(!^^]5
MZU\ZB@L)GF8A,K8@N#? 0!^'QHD%/'W! KS1IOC%9;)5M#/X.@X5>CX[;98M
MB5[H OJF$<'E#BO;62 :6@7<$7ZKHUU*R[JOE8##M-6L@DOK@!C([L:QV2/O
MQ^?3R\58X!BV&?"Q[9K,G=AUDK0-@0I0'[=EM-QBG'U >HVR?2E?DOX%MVM"
M[-K7FN\7']8@]^#![%Y++4#&\LYRU*TMMJ2Y;/&YJKJOM1<F#12$H[HD:-^:
M1^-HCW7Q[3M7<MJFE*.'X0J8BB7S^K\JUB\L"WI#R'%[$7%<XS.0*\B%[XAK
MN(<#F^92=3!.!SLET7R5M\5*>SP:_^Q,/M5VQQ1MOW<LZY9U?+BS6%8>=-GE
M^<7+:B/.K+K.@$-6YA;^# 9QJ:67+/>V'U7-3;E*6]6S09(3<M?0%Q$ @LFQ
M+^[S(%S.R=R[HOXX6Y9F<?\9Z"!Z4$5KE.M&RG+LAJZ.J6;%;G]'OD%N:*[P
M:&:O8.T_9$7BWWZ!ZU\@<MJ?(==)_'B(JKQMN!N=Z(=A6MLI2_+RBR/)#HD.
MWY$ "!=)\SQ=&F\8#&FZ+XBS]F;&=YH]-4;U?08^?_3VJZ]>?[WODK(]1TQP
MS[$S>QM8E KPR!O:J2&FA"SU1S9:[$50Z&S?8F$[6]940$+D+:S8)5_>CE@J
M@ O#-X9@\^IO+F$9A?,6;43)%ZY^EU*E GAT('52^EM,8CE$8R[O</]R!\F$
MS/%3=/]VO(Q$!V_,G.Z70Y6_&%:,DV!^)-6"CN*-,YI<^,Z@8T'&%_1//6GB
MK++!&#RJTX54N(MMW(=11DBF.-2V.SZV+>9N*>YVKBVG>X+^\W<_?2B$7/ G
MZ4/5YD8"?TJE-]\;PE+K6-)[1>-^Y<CLKRAMR3]YZ+0JS&"-B-P[@>,!O*0I
M-''<M*S:'L/O>5)+48V# \G?$%PDADA@LSDPG*AI<#-_'D'!5S61L4"!CX'7
M%?-'[=*JIV'Z<&6X\GO=6>.##[&;L^>,.<,UZ-]=D_@_3O390N$N/PD@T;.V
M?-@[M8[(Z4<2Q\_CP9\*\O2R5<3<^=(2#-*DLU]FVC]X'1[K>ZM6Q@Y#CZ?=
M,4J=C-?DU:@=^>',EQC(A'8Y^7YPL4IC;RJ[U>"6S&2!6[<A%1#HK;4-RFA@
M6(&(?EXLR*8_]<U^3-F$X:?QH&R&/XD5]UP_@O3(JPG8Q@5?(V6XJSM1U6MW
MB6R>?1,#WN\:XJ4"4H6RFH@J7OO QGQE,-FM[#.2GW65"BB:=-SI!E<C]U6S
M*1DV^HT*H!,JH -MI0,1VF@L5PUS-*2K%7UR])2RL^1*"&[?,)OS(^K;>0:]
MT1_:/1Q78+_W5L%RACQ&\L-H,+0::=V;GOK0N"?0R-W(W-/BG.488G ,[R86
M@IN1OT\X1.B:0;(#\+>WR4"]RH:[5FV1H2P?4YL96O1W?#7ER[:4M;Y^C=U,
M'MP?%=)-%[Q>[ )-US^/?/I9S_^UC8AZ";&MZ>JQVV,=)3-+#TUVLPE)@(T'
M&#E4.T>:>G6*'!LQ(@"8+3UI)W]HO)+KSF.:VQ*])GO",W(A]]_>1>F_2 SG
M'N"#HQ?JI3'EX1/;V/74:F^&M)P5U%"U>#CRSC:"8S+<*P[FWID@,;6V\IQ\
M*CG@0Y\]70A'+<)8-E,D1OE&I*'58KN05,O]GY3-J##%(#CH8RO+AXKU5Z9'
MR"M;:RLG$\0?X4%;-J$&1:="B$>'^P?$(I]&%!5@7VAB8B^J(,=I=ZR**JO@
MP+;O:S<+SM6]V]R$3H<*5B6IKWW9]>9_U],^$CM60P4 X/QXVA;U $.3T]L7
M?IV<L!N&Y'!/$!G:60]A :#+A#>_M[C&76["7IO#M\JN/*<";$ !^,X33/_Z
MRF0[LZ8!1D2IK@QRO$D%B'\'42JL8W$]W->9ZHBJ!E0 #'QPRKNR1T\"XX'A
M$FZ%'+O[CW\G6DX#R<<3D+%Z!@UR?)V1]ZWZT;YD"VW#Y;CD=O)^!J+\<,GA
M;Y:':L4Y=[C<\G;<18ZB&Q4,IMYZ"5Y21U ^?"<FG%($6Q>]IKEU*(M,_L3Y
M4P1MH#&EDRV2"@#R\/F+GZW8]9-F7ILA.F6ZT:6$J#G(V99#)^G;>$V\Z$CL
MRY)'AS9 )?/LL\S8J;EN*D @X30%<C;]PYPR3@7PHTZ!3S;1)>/A#['VHDYN
M.\^BHMM%>-'$C6=D:+^",HX*:$&PS+B;<>P.28[9H-R0)U,K2&.BM;@ *B.0
M"JCO-4*]OG&]YU/NPA))I+L%IT631FY9H3W!')"TW]QLF]B$G> BQF>H@&X<
MZ&)%35(75K R7DTP8E>=]UU!]@C34'WX;W!96_G/,H^:,VZ'%I<UY\JKH'H@
M?FVNWK6M$4 27;);KBK];#<5X'H<+GWA&A7@! K!-9U@?B@@<;$M0/H5423L
M.%*AXA9E7I3ID+8&;4FP:1!K,/GA/#+K<PN>O)1'!50FG.9[V$X-])0@^/U3
MS470967(XRTJ0!"Q3F3[DR(YI."8)4I!>26\.G3G4G DCYG_I *B3?1PP""2
M41Y!1A^E,^0T-X;UDETQ0]9T#Z L(69P04)3-OQER?XWT?CRZZO01UYOR02R
MP73.W@1ZX)&88'J2<9![IP$N(1N=L(KP3<&UOB\Z6@?Y0")\X754 .] 3EH8
M,0#[+ZM,U/EL8G>+^!/[S%4>(IG-F\TM%QW9#Y-?_BU$5 @L<YS>.&*Y@#*9
MNU;EY4Z(UNX6+JE<N$9Y]PM:C!.+H$ =;N7J @J,]E*RSQ!2%Z8&E:T(X:W&
MJH$%B/$"!\:)YQ-=\X\_"D<9$@$.PKI!#ZI'/#3R!SG>9,N7O,HJFE?.E\[!
M7,4+[IAD&C]N3[-_O'E#EME,-@CT\T8,J*J(YN X#1_9"=+U<?RYLS)=S$LY
MLX3P?E[LR6<0T]/II +<(?A!H$D(5F&<L3I9FI6\!FO6]X4JP^T:RU11\8YK
MQOJF:]U/G!W/?'LHY1A;HH[7G]F$WG#-&M.#U6==VN3]/U6I;=56*7G04?'!
MT@HX:V*KW0*9D_P:5)96Q]N,+'>*\^CDJ<SHSRY>Z'58M#K[XOSLS*8^O+E!
M>$C!Y)W88>1?G(2GW[['@2*RXT MU\_@MQW]>I"S>;F@:7#U)KQ-1JC=>FK1
M7K:(B*FW<QA4=D7<QW_8>,0)=3,J>G8:[CM"!3";5R]S\[.N 7'?'1IL]IXH
M(%V[[YR[[%@-F)Y0[6Y_I?S/0QD^>";BW []?M+'_#>H,OVG295V.))%%,&Q
M3J-3X6N\S%I683ERXD$%6"'J&%Q&O0+^1WOO%=7DU[0/QPHJB @H2(D*BDA3
M:18@BM)$1'HG"E(CO;=$18JT" A(C?1.D"HM06G2I!,()1!Z3X! 2/WXO=_)
M>_"N;ZWO6<^[GO_!_V#.[K5GW?>>V7-=LV?FMJHF=$3Y%^.Z%LW,.M[Z; 4#
M2"*SQ]94@Q[,(_C ?KMMR6;-NV]R'UE'/3#) 7JS#)-$,DG$(.U,F.TK@Q7T
M3+_K#1RMB<Y1/9<.IQJA:TK1WNPTG.ON#ND>R=ELUW*D7.[<X<S2SEQ/EWCF
M$4 *KW/:[_]X=/JKU9V\P@1\SGD[/,Y26_&NZ)N/[Q[X"0[YLAIMSP2$S+<;
M:^$%K06QJHU,0$[+?%3*L;5@79TEOPW58+% _R7HEK*P4,;ZXGW[<&C-NU:A
M\LP?.L@#1+(+=1,]2E3@5)3<H9VH,M,L1TQ;!5.=45W[$67.0]AND;JZ&)_K
M'5F&CU>XSW\L7E;,U.;&Q-FH^;XNSKGQ;?8LW5]<7'CGTJ2O36$I"V;+6_.*
MI-#4\^]SY4M_/D,S^FX11C!@^:RBJ2G@UK.@:EHH6-I#>ZC%^WY>Z=W99B"Y
M3"MS8P@%RQ"E76L(@!5!HF"4Q4<<RVH9K?H^D;\>JI44[-H6I84"=SKV7/II
MK)XZ-<3;I3W.18^QWEVS_N%WT=2RH5BK%I=.8;7)KXG*H_YV(7H?-EWPL28+
M>G"!2#X!H>\AIGL&LJE58O(9@[.(*RA S'D^TC;[L[[7]8%IQY+NQ&YE=%-B
MIP.\B)*B1DT#WN+!*K]]:YKJW(@]? M POXV.'A\QK]GL:O'IS_@$+[_GJR(
MXFEPO;!"V!R2 EZ^<!6/50F /[,Y%'KT ?R%J'">;G08=LQ4\FVRSK:T%+UN
MTA7STSX"5?,.+;0U$^>*/  C7*BNZ+H@$7(6A"C^^&)&A5-MB^1T969X%9(J
MNK<0F+F%.D=0B$8&L>"U+*W:*P<S*MO3)7X@FL+7*1<XG*CP5BP)\7G/7,GH
MMX[\T-K=ZPKN:QQ9+%>I(6#CU@?+^V4<]J:,??[#<B9@>7DMJ(#K+6S"D%[&
M0RW:7*#"DI.S<E2YC;' 2_\KY>,"^T1+-9M4N22948NW!E]?G;: \@WA$P(F
MU!OII7&'0N(ZH>#'8I!E#NRY^:=]DIVAU>(??XB)P;SY%N%^7RDPOX/5=82P
M;.^*[7W?B+(=2_--^KN 0RM3L'R;A!(P;249MN[IBT_>O ;YWB6?,@>78M ]
M*L$*?6SJ@^I$!!1A=EAG@:D!7G2Z"'9*3@!;@DQOOD-\WQ-JC8S2&MHBE:F<
MX^?WERI?<HYKO;CX#3/(!'# ["T5'L>*;_,XCY#83ELJG7\-I\_3[/<H)&2G
M=)J[K:_S590N_!#=3(./;WXE9)P*MF-X)!]*UP?ULQ#0K3A.ORXT7B=WRK(S
MG>]'Y=7@Z0IT68 R@BI)#GMKA!KUZKD8T"&XX$V9>TR+"19<]G?+O9/]ZSA[
M$?=3I\(]@+[X)B&=ZWT></_S W0]] I#M,V:/ DT F\07X$#:5XT#E;7"8,(
M#T5CSC0J^HTS.I,)6#6]$K[1C.?53>TW&-IV'Y(1[MC<ZYXG(7,*D2H%K(M<
M1@;8O02ZN2(ER#+MUXPA%RF2?E%9D@AJW>;TDT/C77.GS-33SQ!1PGO>W8R:
MM*QU"CR,=!(UM'WS1\/+>)5QT-,U)3C/@;"UAI48CVUH!R92E:V4X]636<P7
MF@H]TVO3_48S8:Q/^A6UHQU.42P8U"$ :;ZK8ZA']V8WU+@.#KVFRLIJX_<@
ML%_[]?NFKKQS1-C/WM<YP=)-X.) J'B]ZYSKT1:6=YU/P;L+ANZ^L4&!D_AT
M<CAFE>G*B3GNXOV*\1J>PC_L1$<R(8LQ^EJ-@]YG-ES+%FH:0VLUV4K"]*V:
M"<-XD8>)-;5QA9J5='?N>PJ:X:I\C -7Z"-,46N0UL,J2I*-N%9.@#P5I(Q;
M\K?0;'V5QU&^.-@4D%>LU;"S378(D-1T%6]U%XA+URCE._(A;K1M6N\.+46Q
M?VOS :VD@(#^M!Q8N+4M?%>5;^K'S]:[FW'CQFLLB\O>JI[8_AB)ZEJ'>29
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M7%H^8;$1?MU)RRBGQ&FLM@\A%]+^FO#M^5"!E(OEFSY;*9]T<$-ZM>;,P;1
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M#ZCEM ^%(7IX=GT3TYMR>21R*'"R(F[7N*W,.TB&^G@-\PP_'7VW#[Y5S;G
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M!X(YA"'K;.VW:YM;3M"8RW^MPM%BVQPA5+-XQ2[-L]3ITIB\6_6!\456?$Q
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MM+V.[EW]A0E8N3KH3=7PNX1[)'<N"D%9=+S*! R\1W[)KVBH8P+,G67!VUG
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M!KW+.+\J:UPUFD-?S,>XO:Y6[IMQCKS"J+D\4_4CA8^KXG1DWX6+$ZUZ(:S
M0(].9JHZEVU/\)*387Y1FHK@Z,009O2Y.6.MRF1W787+B2H0/(\".P8-.QN(
M(.?=>Z!_;TLB.N:^0/B@KA 0]>91F3HD7:RZ!F^!%/@YIZEE0PZ/T-SR&//!
MX;G3&2\QO5])%)54A9E._'M'\G](P#*@1(NU0S.5WD *BQ_D+XP9,6"+WTE
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M!::'J0BF1NDA\1^%T!3FABUINV[>QBL>+'ZZNIY)<B9?027F=' ^N8,87A-
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M/&!T7MN.H!MG)"!*\4-V!Z['G)2,-IG)_W-_]6S]5W][V?P-&<7KTM[V+PZ
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MW4?/LF2-VQ![OQP@GS(RPRBNB+5536"ATG#7IU6PMZBX=52-S_SB213;08:
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MYU+6]-1Q:8#'.T@LGDM&R/UQ6DZ4_/+,L__ZOU^P#&2C:5]@>NL_XZ 7PH&
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M'[:L*B@EMWWQS$;^&P0#XF.-.!A.<K=O<O3<"P:^G[_9&C6?0#*!^K!G1].
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MZQUH0/=K&I  I7;ID)5@%#W(YF4:L*@XA2:TT8 #R!E;&O!YR)-Z2H=\$MD
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M;IH2W!,%67=??[<!G1_]N]^I^3>#2PIZ"]WTSH!:3BWV:*<8X4V/T  ;^B0
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M'6IQ8-=5GNZ]UA6-D;^I%^#^S]H2QO_(&LX_W7[R[ MT*PD X]V?5G=+MTX
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MZ%:LE@<J2 OFF:7L:_C[VSJ=5I2]_^EN^D87+_;J86NP?4%S_M&K":7YIC.
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M[DNM<'>QYU\Y]#54\M=.$(D.E(JZ)$V'TD8$X$0_*)ZRGWQJ8M6MCM'YF?3
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M]IIO+P% 4T>Q%N<V?04G2M.2X.3 ;]M+U<;\T)Y>L BP9%*_TC'\$=\#9Q*
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MF*_$Q@%IH>S&Q5X3[/2Y96Y1GZA].CE*U3DZM2Q8.@R\8&BX,$+[+#RLP,!
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M) & &0.C(GVOP'IR"(!81B1>TKA>UM7'FXX  )N?RBAX1PQ6?!NX,PO$7B0
M6%M/Q>F'V?(X(8$&^R,:\';ZJ8JUVHQPIJ^-( ^/!7"G0OL.9O$$O-0$1M/@
MY2,(@,:;N%L$P =- H!;%(9SB\":05Y/[W+#%N2V"(#PX4_J\L-%L)U]"/8*
M 7 ;__4+K/L-;(8'%P$D  )DL2H$P(,LO)8= 8#= *+;D!>0RUH$0$?8- '
MC'B2%H$XE=ZE=22: V]RDO"" (!?/I5FW4,6\#^F%VA\JH[=H[ 9-5SC\1TB
M @!T@P!X@=B6@N'IZ5"B)Q?AA^K5!,!<">SO2*CU"P;5GDH\_//IN^"'@?L6
MQ'BH# % !)D_==1^9(WEOZ+"^]S5[QE-N?Z5!(<-Q)]!MF%.AW]@3N_?$[%_
MD?-H7P#OVWGJH, 6@:/O* \QE+ASL,@Y N#OF)/^(Q&EZU?5]]8AN)-X_%D"
MX"OXK]7]:W7_P>I&&^#;P*3S%I,H7@)@0NE7E/OMD&; UY'M_NC4\^!E]M_@
M1Y__4;[]?^0;\G\1V_Y2BO^:U=V!-8/]3O^)I\(:J-@;H*MC)A?NVUY*=S%/
M?7#AXONNY0ML:  B"&>4;V4P5<S7$O+^/JH+G.'F,*$B3CR8*L=6WD\\5K=S
MDH\GMP'2XC@R.]_;PK7Z+*)D/WN>N=#;$ "(#ON2.\=&;K=8YX*U.;Z&[6\V
M> ]B_?_8>^^H)IMV73Q65$I$0#I!09$N(%4DHB\@(B!(#T5$1$! I$,@ @+2
M!00$A(CT+KTG0(!05*1+$4A"KPDE!$@Y^.VO[/?=>ZWS[=_VG+5_WWG_F+6>
M/^:99^YG9JZY[C+WA%&9_45D#KHO/X[W49Q5C]!1*0GLXURRLDY\M#B(:O@>
M\:6W\(7S5&3!WKI/,E8$.\)].O0NEVFGL%7SG)/X^$(H"89J@$=4/[WVA:_3
M7YWJ]GIM[5LE*$#IR&3&"?] O!?Q0D5EQ TM['&X4YUU8O^:K2@K;&= C;^<
MJ$_':X8()KG@X2CP&7?X)Y*?CM:+EM.ELWOK0@*-R ?;',<^L8V.)L?T.8PT
M7:6N^NW 9OU\K.C[46:Y,M/)+A7(OH6\N)/PO/$EH_NF8Y#;=O9'3V%K X]J
M< 6^+,QZ2?>A8/$C N)ONBLL6'RHGV5?_3,:[7]D--I%ZE3J\/#0% -^"/BZ
M5#!I"4?=FK.)HG)GDU>6P70D2W2K"L?@-7&E2Q%?.T^$'(UR;IF+K5<4W!4<
M_0RNS0M;SZK%AX67#+U;NYPT8MSI6>GDW4=5H %R_*5FK#A,2 =M2I;(O+L5
M$,N6"FL=3SF5QRK++X #S:N&A^K$)S*<<0X&H0'B-K]SBTVS]Q',SM, C-6U
M7T>%R5HDEVRH$3X=';:3>:4J<4 M=;*PEZ6@Z['@629I)7<;*R7J2,")P0#N
M@*]4'CSUS2ACWOA*^3OJL.0[G+N\F$_+NF8+[\I4@"Q4OX9T>X9[S5>/==?!
M2/2Z)L@%+LIS8J>%TV8U%^%$R:0*6)*-*.^@BEBM'SQ/.Q?:1>+:*CE_>_W)
M7/+=:;V7)E?1-Y2VS&Q=V]T&DLF-\V2G[^CK!:^('C/)&_77'7L#J'E%W@?8
M870K#3 VVK:?"S]J[C"JY)]>7=B5$\?1DI/]\#H B%5[GJJ+FAX'=D[Q5(_F
M$LAFMAU#M["\RO4A-9]ZPIC1U9H<N/=V[]TLP.T;,<:@$XB3)+:J7F]GV9('
MVK41$VN =SB#(.EU ^:ZZ![ 4E+W4G#?$HR>"B;MM]$WNV'/D#SIWP*)?D^D
M^KCBWK.%L!Z+F=A:L;AFLUJ@%'U+/F$WIRA $_+8%7MI;:50> @N9K..^J'G
MY")LX;#/!:^T0L<RK\23&E%3"F#[(;+B\63&%^6%/49RHB(J4Z<?U!YG\OGJ
M&(67?*URE3HP:M99]I'4-M&6JIV.3N1]+UF5*?"BK*?QG4V1U.S"L:"3=JO)
M1$D@V884(<MH*+E](*ZRJEMH_EZ,D-/CG+*IRW#$)MYW1]97<BSVX EVHWWZ
M!#D@_(G0TR0IY4_OWEE'/7+O?BC/\-A=0'"GM.<-ZGZ9L=KYH6>3+FS^VTMN
M?3D/."/:^AO=-'M313S3-!<WB"6S7J 333#"[=ND:H\9,)^&7+4#VRO?*J-7
M:.[C4]'SA5>N],9M,83RNW85PU^#6!#\T'LDG#]^I67_"S+4J6JF#5)PRCCE
MS3$!YW%(T/<SS:[QK@-PE&XTZ!R"#VHVT'2$(."TZ2 6IZJ<QE#0E!@]\AM(
M*8E;9]V_4\K,BI5ZBJ2+TV@OT=EJS9"I'80Z.<A/CW6:CD(?:R!?O+%Y^#R/
M<X'G6/SSV3PMECXS9DVTYJ4OW#2 ;$R9O5G-Z0>HH00'WT[=)$\J9-IJ%"_M
M 3X+?4:BQU+.B%L]2$.;,:Y@!L;'2CGR!;R_?EF>X8FYHT+B]T!R!ESQAJ/@
M56&H#:8EWZJ:5+[LFB?+G]5?:2'F?WN69($2 2PK&:>L\$F0I@^D^ZQ=L>)J
M4#7,TN6SP:ZNQ'=S"D(/XUXF<C\5M(M1XGE4C9!Q/$L*(V:0% LG[%9W1QIL
MAWQ6JM>SK?>Y1K\+#T7-<70K])JLCEL8JT>I5(JXV^FPO'^<!_0T;GK@S[MS
M;Y8&<* !F$@3NJ2XCYHECL3]D&K*#FK1M?/JLRSIW&'8&W=&T"YBB>PO@)VO
M)NC.H%L-&X>;;'B)2-<R#1ZO$5?AB6</7]A<SP)UIBR1AG4G; X)4 @-L$.0
MIT8'-< F&JEWUM-H .LZV/:][8(A8GEKFZOV70J[!L6J;D6/R/)99/!]0D1T
M\\((.$\'K86+C='%HV<DPYITO5GT1ZM%Z55=6)$B7Y[CBQIK)JTU/J,Y5A6^
M^(2%-8D>W(;>^F9-N$-XKR1JGC<N?FT,F%A_JF?NO/0'YBCG[IT.-W"U@1<C
M7G=F,@+6;ZRC]@96X_1A8I^N=$*-Q$ZPN]^_*E%% T2YW7CU3>-2HX9@QSU;
M57.W08[BI<&L,%1A0<==_:0*X_[KIO:9)6;?HXS$^QU>1 GP"ESB-6N>*EQX
M<" /]1@AVQ<[4,\0BNE=L#_XY1Z?.OLU?^(Q UT/IZ:E<1#339Q0JPJ(K$?"
M$&(@9<"G7*OQ6LSR#Z:OQASC>IYY+]#[^/:QA+Z'C@,J]&1)&N"5%8Z<O!_6
M'BW3;BD0;A>SW^&55G Z*C@>G8X45DESJ"6S4'\HPWGZ8J<XQ0956N[!2NPE
MBS XR^8K0K8G2ZNT:]++!@NB^"39E27.-VNJKW]TTK3(3C"VKPX(^P8ZX3[-
M86]YI"H8;3SM3*!+N1 7KGXE[;6:V'OY8XHK6S;57@9Z5B!]Y^S)\>J#9P$A
MZJE9.M<&G7M&?9%I9ZY\K)3[,Y7ZGZG4_R^D4C\2C9,\91^@C/]!#"F>H.3I
M-&G'7WZNSG1;>+7EI>H.V^9:[2J*8(QYDND^S=3D=&KPB1-5K3V:A67"W=92
MCO^A\\S!F?WUB T4SM'Z$89>H7G06",YJO<Y:4P]>SV[)MX3YJNB64E)(/L0
MN-OEQF,[0.PE<]D*'=79)6*O[-Z:%V8_W,\'Z^PL@ZN +1/(<!##-9?3I <'
MU^]JR^T+XV*6,A2,6$--B-&OT6"%M>];EKUJCF*]S$IO"MSK/35-)>/Z=(7:
M'N3H)Z8MD-*\7.:]O3KZQKY:A4_3*TME1I+$=BA'1Q0^U#W\<CSJHD'<Z<Z9
M8KT[SQX[\1BS -M<QH%F_0FH5'CT]@0OF\V!<D+GQ$*\F UW$O\:FJ<B87)T
M:%M/5ZI$AR=)6\C#/3UM56E,A:]$U]Y'K2JA*K4!8HG^ CIDE;;^5AB[=FTS
MK,5MG>$F@?RE@:5*#8$[M?KJF-,]Q\=5; 4VX&_W1RZ%K>((5ABF\GQ0:(9X
M)17=Z#]MAVB!.741*LX?.^;-_]Z=5W1%1(0&J)9BTGE0V:"96YK>U)@"L\8(
MG&I+Q_5,:,NE(I94T%_!C#3 $R2+?'N^L@]!J/V^8T-' =#%Q3X^L&5/\Y+!
M%?-9D5*9KWX<B,O4+RI"NN$RWEN8LM<7^CW\DJ3-(9/Q14T4HCY;\,F9M[:=
M+]R^ ;,7"Z@#[7ZZ]A[5);:.GN5Y1#F6[P>B-_;*O+Y\F3J8W-.X3WE/%85:
M#KEOD$P#) _[7I4 &WL&F-X(,>D_QMR)U>1<&F^T>FU5N5Z"!4=-'2.HQ*JD
MV7T@>7+?X1NQ%V1Y%OH$RG]*=>_.,3%%MHUK][=$UG*+X[4%$Y,:%Z_,?C<\
MG^,C-^A4,S$W\0!% SR%!39L=""92?+W!R2V#YZZVS_V"VF.5WO"0+@Z5LTM
M=,H75_TL8 !^>@<6E7&DJO\:)$T44N=Q:KUWNC';]KPBZTM#DP6)ZYZR*ZQ&
M9SN'PRIKR8W-"#O#>PTANDZ?X1M.7\IL;6V^-*GB+=&=-,#)[;+CCA4G4K]V
MCK,U5>]%R71P6$G)'XE#,=WL*><QCCS4L4\$J)#!@Y";^-%H]]%OF[VGXZA/
MW^Z[A*>"/TH!,FXXKHB(WE4,<=![7O$6TIS:@'03V3/B:\K27Y>^.QII/U&Y
M[IV\NGN@$/O*F'U\OC*_M!J;MB,LWN8LU5Y\^ZK^9*,,0.L-\%C@5QO*.Y63
M*\@3XE -OEJ?/(N:'$%)(!$:KW _<*O15T*%M)2ZRR7B8%,T;,CZ8V\-EC2R
M:LA31J\ZX(YSL?.#34Q,U^FIL2UD?/J_>$'!_XF(X/\-:+U KS>K^5#K*"*0
MO^69_7#J5W@'?Y;&O^\:PY%_OT+@Y<5?=<;L7^GBP%_B4C[_#Q+C] _?RDN1
M7S59_KS#XO]'=UC8F81,Z+\+$73].2.7BD2(YQWS!/) 7?=/LH_-4C%9JYNP
MYR.U8]/CL97(:L!C2H;N.I=*G] NHZ-_.B7_X/K!_9.Z?U;\?Z7B"?H[/P0O
MO0V,@'2-JUL4:IM[?X:FGI.Y['J3$V:7<! :6]E-09E-V\$<5+Y2AXXD$'W
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M^[)&DIXV]!!PVVK\K9BU!XMTQ,%"-$#W>0]1DV*7O"#Z+H]3-H^*/)Q+RWO
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M#CRJ'G=*@O5B_@Q H:4$1KJBGN!?$/!E=^-QO"9;1J:CFWM<D-NI1WDJK2G
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M%YB=+( !AH-XW)TD-0F(,OP"MB,CFC-8O_96S>[SLV?0Z2O-B"<'>6\X>-8
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M!AA?I %"#G>:^Y+D]S3 FD<WK"V?8$PY2@-L/I*D2L22#/E$:( /5M1[:C1
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M7K#GP.]*M_[URR/+*?Q\:P<:9!/8F!T&'.;2)//15-OF?(Y3=BF<W_;.&KD
M<KHJZBHSX'37["P7%GK[0!5J3[+.64+($D8#J[AA1R:USTV9+;GU[&>D\40=
MK6I,LU8.?*DT<ZZ^U(;82JK^"%6CI$!/X*(Y*$4Z">U$8Z!SNTOT '<0OFZU
M)0@XK\ _LKMV^^ VB1L+;*'_0M_F^Z,L'*J*/=QN\I;.,UUJ8!K("MB\L*5^
MDRX4L-[">N0;.8"22];";W1.G?P&9<$<2++)1ZQF0&03TWGGGIVZ<_WEZ:V3
MSW O?2P_$.C66' ;(3"&[;TF+PPW'2FNQ*$D9['A9*QKPW4$R[-B+\3)^=;[
M;CTQTJZ=CE/<R6TT0%79*CK3$BZW< ]/'HFOY&WO9LL25MS8DK"G ?#W@8SA
MLN"0#.&A[*$9?&E"0:]+D:6]9 7VR^6G=WM>'34L9]F*R=30OW(,9D+YH")!
MYJP;D+6*Y#N'7_:6OU^O9;I!5E0ND7C7MWNO=2SX2'!ZDVOKUR.+*N)07T((
MLI-1!A.+<A)5:R*<Z$RGY-V@ 5Y?]JB^TZU@8' AY9-,IV^,@B!T@V"'0AX7
M<[\A\A6-!493A::6=Z5NNWQ8"A",6?I>CDF_]UB8#B#*."80D^W+OG;$!I_6
M#F?=!AXCJU<--?$6F"[VRZ7AK&H%+PS9G*U,%'D^9?<9=22P4_X^73%9@-2!
MZZ4!SI'24%;GR!P-O-1H1^+<R+77\PG:#;%G[F;5J)/E;DYJHAB.YC8-HF!5
M=FA@^!3S$-1O!D[G;81KDQOX^FFIUIA%L_!>W$XGFAYY;!TGI'SLC0YHE8*S
M.DO2P-6^;@)^(&&W<'1!8E6*DF3B6YV'*3?'SFC7!PJ^><=8M;%X)G6+(OD;
M208;R[1,5<#;M?-JS, B/L@T[9\>&I932FK+-C5^. G-;V=8F^B\<FQ1,@;.
MS1'0,X)0'(+2V2GO/H"$-\EC5R['*YCWW%^/;DL(.FW4TL6_6P*+A%5=1G[P
M'D5-,R%X22]&V_D4AE9']E7]+L1\;9OFN?:./R.Z$_.2O>"A:(N*D/=*!X@9
M.9,AESH=J:5=J%5PF\NBX;CC._T7!1< 3#JG^OSK-RR^EF-%@4'@FL2R"*BQ
M)-$KE&R,>;U]8''(B,]^S= Q3"-IK*O[ :^R!";<Y*U]10,\E>0EW<:6AL](
M1D[Q#KCWQIX]VJ!>^T%+P$SW"@V0=*]4ZZBFWM##"D)H%[J)DAT@1$K "453
M>;U!;5P26?X?OV88Y>1K"WKB56OG[?%C3\2Z6"\K,+9VJK.C@=Q/:0!>Y%-@
M< 87GI?,)YBL.CQJ-BS+**%Z[?PGP3@IRO+<BUOR 3ET#R(6D79L(/RP597H
M0V=V(P#H404-\/(#$YP((^UB8=S>6QTP8!/L@^G3 !D\V752<5#P24W&^8FM
M*X_:_4E=>S&WMX]S[2;91FM)_2_VWCNNR6U;%WX5%1400>DEN@!1$%'I+;$!
M B*]EX@@+0:D=X(%$*0H56I0I)=([P2E"8CTWD$Z@00I@;0;UR[WK+77^?:Y
MYWB_O<ZY_L%/?E/F>,8[WSG&.YY9QCB>>]4P&1!>8#R :+_V/;O3<!&,6  K
M))74GZMHA 14SXU^,C 8+$H?SO7;_':0.\SE%?O+)W*8-,98HN)T#04855;$
M#^#BVC+8.-6)?(W,K2\_THDF*D'S30PM\=^@]_%LLT$E.),=1)^\V<Q1UU4D
ML_EPC@G\^HA(W+(A_Z=Y_WLTPG-DFE5S")8"[)P=* 4=7/9V)(H@.9? #W+K
M)F,SIKSTBSZOT.=F2[?,-D[5:9$B'U3BA7$NLVP-F+O+BT&CCA@XI]U[^IZK
MA1L/8VR3: +T50'JY_T!(9)5:LT)=Y7KA9F(+[NXB%U!H;8R 6;F1>M<3)I(
M\G"6^2(\X,]%-*["*Q#8B9 !5\R1Q:;JNG$U2\LLDR.-GS=5@MP!S/4(#>=K
M<S(H2:HKM'C;1CA-O(--Z[_'RU_2*]&1L/5Q..47@@RO]62-<X--_VPX;!89
M N8BMT*.P$L9M&JECE1)%Z%Q!Q47),+DQJ/JGX6W\B6?_4";"&R)\OIZXS%8
MY;O%.(U(>8$9+M0QA:9'$XUOQM5W:LR(]"55VCZ/C@K2\,D4]LT9M%(MVQ,Q
M*_C,'^0+[BVMN]E$/EL*VZH>>N").1O@V'K\IAA(!$_+1_,T%:Q$RBG5"/9F
M;!Q&E/@+KTZ=]C5S$W=@^%(NBL&\Y:X-RWF9T)Y-WT0<=T6YD-Z@ZEGP)4U0
M1E\1')]Z7<],74_OJCJNKJ#W S?HTAW%YV?"<I&O3V;TXRH3@6W19VB6^G-F
M1*4ZK$83\O#8\NX%FYT...*Z"O+N:QLN.K![T=[S#IK-5Q%*?BWU M37+V+2
M@"Y=B*>^WH\(YG7_"Y[,J^IQ"[B%9+-SB7I6YUDUC5RJ+$$7:'8KA5\R^)7]
M<>@V[M>S74ACALL@U:<KU"7E,S4U'QMF+^+F3=LM)'_/QN/"F?7XWN"EU 6Y
MH'(/&:>21X)#V84/;]FK0FKDD]M3SV7POR_\LK]JLYM<03RW/T4D4]D=-6J9
MI1K=LRD3"H"<(CY#$M4=J%H648#L>/(U"K"630$"+2F EBCQ,048,4"NX< (
M!/'4@G]>TFX\^3 %./3QM]U!V"28\E.?5Q3 -)H"A!1,X?4AV\P4X!.(%*N/
MQK*4QSM85P^RGF]UH>7?/U 3K=+7E.$^18T,#B58E!AF75!5080C$MK4Q4Q5
M>\$3GYW=L[7V#H1&O$NP-#*\A>'WFDEPC\9;40#9^SG6 'UTP\'*2*1'?4VB
M,>0YJE2) BC%[WJUA>S=Q+L3A7OE(;,PQY-*OF6V6=?CPZM:NW=9/BWY Y5U
M>G%[B8-\77&T&XQX1*IP?='[BC[X()=M'/L0U9%<]4G<?E^4!WIAB7'VEFZW
MW^9Y,T).01?04>F1MV#__^E]U;]$WG_; ^US^&N ;WOP1Y6+.?/73=#,OX;W
MFH=B?M!*E$$E!3 $QUZ$K R^_=^__G;MXK^REOSGO8_R:^733PA;QT-$)5Q&
M1 BH<>ID5O!"191^K75-%*/$;;.GYPN23T[XP8:RLY-UY]H_"VOI+5<[PP7'
ME'QA%."X\$X<!7@;R48^<0F"'W#T92$EDP7PT#F]^/!:6*$A#&Q6^[[C<FV<
MW=B5T]>DE*0Y>%97VH43+.XE>GA[I5I=361*MND4;%]'"7_GDH6-H_\0F_NT
M\ IC6ZGV%V(@NQM:*V!ALU/S2'R*S<BN0Z*_]RAVQ[D:]9K_+,+CRQ!(5&^!
M$6]N'!ED&0<-F62GVJS'S0%+._$<D=C")*Z[%PMC:%X$T3RBF8<WR^9T%7<>
M\CC.:CBHIV]PH/\D._?3[4,'P3'J?] 8VR'D9N(@MM7W;6.^XO.^K/1:M?C<
M\6&U\H)S[_KZ;!@X7R#L5U2VM&K 5_%E:6/FGH(J/;7JTP310#!WO.G3)DY+
M3Y^[1E*O>_I'3%O9-2L<@IV98OF?D9EAZ.YM"G""*(8[@),*KV>UK3]*[C%(
M4AYP39$0J+KSE10U_?:!0_*#H$DNISOS7ONRMGR5FL4MQ;G%E2?2 AJ^@K+/
M,&V]_:/&G!V)N '),8TN=&S!-TER;X<@;CIJ 5]E/1 U%K4[C_@\W^5CU^'N
M>6?JU&QWV:HHLZ\N5B#UF;$,/W8!Q9!=6U-V^+:D]GOMGG'9KP'!,,<+ W<=
M3'WM:WK@#K3-T&.9(3,3]\_YB;6'33J8@K:$2X''CZ8= -^"RBP]F9V<M(B9
M&QV<[;GMT[)/:&A>^J<%*/>&_%%CI*417 =>2B3L&4]=_G>U])V:"8<U0H]N
M6Q1Z5LS<#9YF%TVW$S=35NQC6N=C%UPSX#5^<,G4MT&T?:S<1KB3 ISV7-7H
MAQN0V3P:.^C@![<D6H+YXY".GB;<QG<EHWGZ#E2Y$PMJK)UK233B3./GC2R-
M](Q,:36OW7-F[#]Y=%_K#QO78"*Y\'(D$B%LL@ :-;(BRS.;3K%='"TV<38G
MHO:2JS;@,@Y=![&()B[1)SL.]>?P"$OL1F-UFA2GCJW^X]<O3XRIE84CYI8#
MQNMN.@@GYWPYE^$V(\SC1%3$N<R<>_I..6>]JK>,?:NI-KG\&&O%O;,40/6>
ME*BF&@NM<%??J>L\'P/C)&+U8AO<#AVA/4.Z#D1F_&$C;TOQ:.:8W=[N9EF]
M!2DC3F/N@T GSKDS3Z!"8*.= B1TI.[TQ:UA_0QFS>K*7^V(AO$>*.KS%<@^
MCU2J@%U'<#X$U914/<_1JSKK<8;&;J*4&W6N"G<5M%9>CN^8EI-CI+._B>&4
M=X3M;&NG84JK(NWH7*^-URCU56;+F/O-_H?G:/KPH(GN&!P")NM7?(:4%K<1
M/?FKZB\9E5F5?ZW;@WZ3<9D<=9Y @CU%6T9M/D@_B&Y"GBC="#8^EY_J'B\9
M:,VK-'K,1*Z(<Q%S\<C\2I:3IG.6E&MD*!-19J",QZ/5_' )UA3\"\BVM'^K
M1DOD\_SU$3MO+0^NJ*L= W<WT^;O^HW^8%533SW W8#0X$.II.0D\9C-C(Q$
M]I4LF+%?=F6M9__!.#:'O)JNLRRQUX=51F7N^C$J]<SA8].6JY$1\CR9RCX\
MC6:&P_:LN FU^U6D$8''=)+=&>5;\NZ%7_Y(I:S!F.4OHI,I0]OHY:(/82T6
M5TYCE.ES.NN,X7DB,3H#4(SDO'NT:76FOOPD/9;4&I*&XZYF31)\?B^R_86^
MCW3GN.UU+GU31QKZ1F#+<M7DM,'UV>1\T'%?%EC.2F(8F*E[#CU@$35)GG%=
M>CJA++C?%(/9&Z#27>Z@C<0:J<?R$BXS;MCQ>E#O5&-[#9N*I!,IUD &4*RP
MY5C,,IYX&R#=*3A=T4AB5*WKN_A]#0 .WKLQ,78IZ41'(#W'K0#4%QK@VL/I
MQ\;>BXU==)Y)U\N[MQU/V!E'A-OGQNVP23K57A8J'&!ZPW[GQ)'Q>ZZ%3T*!
M1>)9["[U4\"(F7_:".;M$V?/:$T4)]QZUA8V7:1)QQ0]I !+^W=.//V:RY%U
MRBV[DI"^JE@Q80\D?E_OJB7,WI*".)3'!$G6FP\H/+5:Q+5 A+8XE?1>J18'
MZ?0SO3(<R,)8=+@$<P3NS[.I[L@'*V(QZU7GSD0^O#:3Z7\:$;)O\';)_%1Q
M=[\L"NDR:<--IBE[F!NH>1J@O78!)F3HJ3/D[C2]62VMX47H7:< W_?.W5*[
M_[/[+#\WU/_;;*C_B-W&?[J2[@!>VN^![QJ_B*P&EYKX#:8=R_Y!9P2?_'U^
M)?WMTOTUYA^U&7GXKQ/LZE_OW ?P_Z@I7->Z_V$KQX(Z&<I8_OYKZ6]/!_Y7
MM@#^]XG&ZY#]1IU6<H%_#+#R@Z0+_?T\(TN(Z'Y+0>7W>GB_K70B?'7S4<6)
M*ZG(]M+5^,&R8V?Z,Q7USL!7D>NA 'KG%6D4W NI,82.]E( -P@?61P!4R/U
M$R/QW4<V1I5W;0FWR1B+O[7UD I$=W4V(7/7N-!VH(ET#!^A+/!O;<H[I>@)
MC4\4(!QP(+U#N$>61JX/LOV]$?1WA ,U/V%_POYI8+75%H KH;_$=W1QY(]Q
M+5;%Y!T&+GEF0<T5\LYH9O'5 7;_TY[X)^R/@?U<[/5ZCCTCPE'$*>R;T8Y4
MI.L7]O,-&/7Z>A^[&]G:QQ<3@8'O6H&H&N2+8NP0U<A7%( 34I9!7O%7)MK2
M>%#5*O6C:O >_;<V\F \(6</A$MCF*)JU?,=_^/?VM()QM#UK*^(E@ I?ZI.
MRM2GAM']K2WR[_*!B9^@?U+0!*MO1^=.+RT,5[; P"W+ZQ7KQR7G,I0]LE4<
MKU"_RMX+ 1+U_Y.>]R?H?Q7TOHI\RY<KS6"9)^?9.[6**F'9(Z^!ZZTLYJM:
M41P3++J/5Q.!X3^?VC]!_W6@(5P^-NPYK(]RCPC%IC2:WJP+H)6>S>G,Z>#^
M\MC@^.TE6QK8GT[GGZ#_,E")B8HK$E6,E]]0 "N$T**(M=A8WGL@>6M_2)GQ
M9!JU\7=\,AQ'2PQ<ATQ#]H\6ME=.G41\,I_[?L,S+13X\H-(^3\E[>O1% #$
M0%[</DV"DJP0-^_T(N9FT./DM\@\"I ?29WB/^IR(@,#'\D*>?W. 'IN!C%.
MSD2^0^1'+UU(K"#ZBA*0_=V'A7X0E1<O1=2(SI#LZS.HCP;? K7GVU( =VCC
M_H"?&AD\M@2)!?1^T/#1&*A0 $T*L(&XKEO&B"=&8\EZ'O_0I'O _$>-H9\H
M60$QK53B@)Y;@.Z&V]DA<*L4X*!$DAOU6:]2@%K;@S]J&"5+*0#^6R2.;%UM
M^WTQQ.![A;#69$3D-XD^Q7\\8V[J^!SR5=2) AR@ -V*[GHM^*?D&[L@+(AT
M2//(K[F367"T&"W"-5]=[)<\R:>\(6XS/EP*6NKUZ,S:#A[B _9W/KC2.&WV
M;/XGS]QSB%H$35];G&"P&\^EKIE+9>_&)SYVM_K9V7B?>_R\P?4CXVMWU/5[
MN=(Y9K %/S<P1XMNQMWB&#AD0X0U<:.0(.*#?*AERMA@ F4>(9[!-IE?]DF0
M5]ZY/P3WG%^8'TY[&75W.O!ZE\R1FI69&"^KN>$][RU2N%'O76)!7D%*=7H0
MW@>7U @]589FMI/EKQ#UF2%DEM49I0FE!;O2H]IC+;DLDZ==6<:'&OT%\8(X
MY ?(J5KH[,8)SQ?*V++,HFR-R^[HT$F9^U?%E.LEU0.?)$==E[&6:9/9=GR\
M#VI-@O*8C'NN-HWZ%\P\"U5,Y+)YG.1UIW673V="PSRHQMYB.E[^7,%8SM;P
M>#H#N[P2UZD3)H+M\QOFHQD9J34@92U%E@;?U_]LM<^@?:I4JJDK D)'%A38
M"=[)0QU5X498E%<4GQJKQO#>5ROS.")2$^7RY#)L&"SDZ]WMSS(A$-Y9-EF0
M*PZ"^9B 1'<OKPM7=5S^P,]](.J1MX$R=F,6'(B[^6%P\ESWNL;.PXS>ZR[/
MHB:Z9P:UHDY'U#D].0&K?I813%I;_J:XG&VYZ?O@(3^LT-X);JRV/T(^AP[>
MEMFNHU7OO^2ZYUJ35&.[Z'.AGGBQ_=C-K7.U>;,&F&,>V.#9@HCH62C#6SR;
MSNWTLB&,T>>7GZ]]HP](R8+QZM[#?+4N(SIA]5MG*\*)8G,%H!:/1,6=%^43
MUKW#&H>;8&?A;QHM5"ZV>S]A5(V<;4FG '0F#?4"G'=&-X++'(^MW%^Y72CN
MXL*R(-;P'.?$="A5AIV68]750BU%*M>GP$ 4K@%BN7C'XCS*7<M; 2015V%L
M4ICH)=;OP>?"%<(GGW?BF;NX_HFJ627LQI,'@^]"Y49FRXV8![A-N')4'9AN
M@5YBGI9=2;T2^@FOAH/=PK?.2&\7L+?1"7M)N8O-=9:_!E3+92.<N2JW9&@B
M1S1>]9>_N-FSLT5Z^VZJ=F#-O51+T<KA/[(P;O8[+VV7J$'TE:)Z49UMQ/8K
M$@-@\Z.6B]_\UDOW;45N1_D=%M.G )&!%,!E/Q'(^$$;%4?B(G<?$"$%!OWH
M.4S]TSV]<-!Z!QYAC,I!M([YT6ZF'2_]0=L*]LN0%1!I8TDHCOJE!D7Y@]H+
M_Z$E0/A'C2"*^AEJ11&/#L*'B+X=9%R!R&]]^ \KEWUD$$D!>)W(D,]#ZK\>
M1%EP_:T'_S\+/VA:T?:B(3L(.G_>,6A;FK%GO'9-?<30W:*Z9VJ@5+WGSI5M
M#8?NW8MJL+*1F(.PH&&.SUEYY2N[:SG2C-5)P1F9Z?FM;C2WEVZI\4_/M Q$
M>NI$>-!T^K!A5+!))OB\:3]Q3VM#G2;C2^F\6=;1E_5BLN_I.$WS7N>8F__0
MXF).DTZDP>>]Q7/-@IX[@%OD_6:7%6,&.YSH3I<F#$\P$\K/S79TI^0&<\_Q
MEO-H[=A]&?KVK6+:_VFT3@<XY_CK8#;QT5*DD?0[##%7RF/=SP6+:GWOJX'W
M>>/Y=O+4P\38RM@TD9J.1ZK5BY7T^6)3+ ,&Q["B'[I](7BUF92#=&-^MXS&
MX%$K XW-_/EKFZ<M!CQ*#FP5KM>.QNG8RYGBDTWM6IFTM/"G4^I$LZ;]'Q!-
M-^O/P4#LOLJS2.8V1Q3>1=-$'70]2L^LQR^O[5[NQ(TS;<>^W%U8[2KU%1[B
MZT4\%(9!&? O8?L:STOUD/JAD]?Y]7O?T=HS9]E9;:8#VP=O9-6Y3C'7GR1R
MXE=Q*"TL'HTNPGV6+'#)5GEW-?^.YEM,M'=Q N"T>]E3+D+1SK]#EO$CXW%\
M7C.GZ)/%NFJ<0PI_>7P)[+!Z8S-W#?M'W4.;+Q[O7H-X>-COV!A?>J'O X>S
M8/!V+ENU^I9*F6;\;^2R3>)CG9M5% 41\[5>T1/E?A<43QL\\]?^9_;D.T.X
M[=\>3P%8?;7@L] 3J]W+%;TF!068C%')UN.=90/Q\M,!NA$CG:YD'E)R<"#$
MQD]Y9CVET,N[Y<V"!CAK'B3ZQ5J)KD)FY-EQG^GHB $,"\_\9UD'I!/"2UX_
M3G+.M4**^>A<F'?)J<=F4,.\#G:H8M$6:,QS3S,C4'O7KG3N[01\U:$UG,B!
M%YQ%!$+H?$W2!4,PR*;J?I3+X?%')2;&'65ZAA?6K\E(ST54HHRQ$ZDEEC,*
MS%--;"]R5B\;\QMX]#3.O]NDGP]HF,-RM*INBD9"2LWB&Q%'[1(C@QU<,0]0
MA5_+84N9;)([\WP,9<_@NTGR!QL#-,21)2DM63C>&;*P_6CYFZ,#:XEM\G(E
MK$ZR5UNL;S1%976,IW.S^=^U7SP>_31/1XUL8RW,&-XTD_7:$L[>;@PV,XU+
MKA;.L-KM4_=01N $&V1%(TM=(YLXPP9E16*<N]R8W^OZ7II/0DR&SPI7F?FP
M'CH)TVCDI<,.!?N2;C96^R4[VQ?=='+)-BI77#KNKNKT0="%IX$^RB5Q7L1?
M))+#%@RA ,],&G?C$UN#'A#8W_<'!#H^6'QTLTNS(%#ZB\%@ ?[I]!110QS!
MYFGL)2]0:.3I#;^D(&H%MR*\L3PH2YJ:4/U0?5(U5.8!.T$V:IZ,0A4F4H!7
M>Q1 7  "5^+N0IOG*6WUF8D3[ZZ$XBC "'(V/H3,;\M[ID_>QG('<@IO/2^R
M_E5REN9J6XW%>8#KL7(;-U/I+NI>OK!V+$>U\P2/I^^M*[JQM@\)Z]39=-_U
MGQV 9'-%XO&.NY#LK!4*L,JWSVG].PYSC>-';6_;VH%6^?>/6Q=0 >BH .*D
MWW*8@ L_ZA9G1CII!,&XJK<MBB<XII'U+)4)Q6308-X*%+<S=9V8?;#@!UW2
MXJS6V ^F #[[QS.R$:U?D<&;>?_0DG;\1PT@;/GW! 6FID:-':!XIOPQ%'XO
MGC3W:X:8'S*&9;\C*%4I$++\'!&14)CX!XEJYGRO4X"S/I%X1O(3X>)"J2;0
M)EOEKRFOEGX)$/LU:3AR9VL0M09F7S*&UQ&6XSC+2U@*2.W,M+%%8S#+W*]'
M^.K;]Z"Z)"11ZMTJE-GU!8JC$>8V@P'SZ"A5OFXY._#&TW=<M+/M;#K=^U23
M-\W^SWQMNWTY9AF#O6-X%6Q_P8Y;6"?.VM%;L](>7VI\.2+-OII\;Y%V?H,=
MT2A'M"LR4X7KF/86^ K;V62IY1C?G#]V3V3^1GX!%VL+X]GK-$, (^R844MB
MJ,:7=E(!67FY5B'A;@2S>$Z+W;F]#/9OPA5LH%1<A77"ENA:F=,#-P+$4V!K
M*U'.PDKGX3I'17Y$L3,PY_G0J8]E)39PVHSM%G;C:2E<KO'^V3?7[9^TO?%;
MPC&]G$&_</=PV$@>Q'A)"'3*J+C9+ ZWAY:?*S#,C'DW6;.ROX<\ZLDUZ_"8
M(.;KCH^IE^\6M1J0X+FA]H+'?/)0G,;9KQYS+O3"0=JJT9\^++>@/HC -/"-
M!*C*G,9AO#><L5%2DOG%'J= F(9P>N'N<=5@=S?I0U%\%WT&LYH=1XO[FL"2
M \0K&;[GGL[2<THTCLGOOB1E7<K7:V_YQ2^OZC:M_)S$L'\7!>"15YN-9!OU
M-$<\ZYH.9YJ-TW%B*'W?R"7TE2%3P#39LL#GU.*.0WI@DO%J7S>)C[F(Z:-N
M<P=CA[;KGM6$HH.)B*ZHS]B#'J0:E5O-(&/_Z2%LWRG"(\1'%=@T\H2]MU[^
M4*) Q-NN[$9.MFO-$-?>\RMI01S4[T._0>_IFHC>JCT-O368L9Y"3#_&AS?.
M+(S<U=QXJJ.SHV>[=PH[:?,15&03Z ;B(*H.22AH* <ACK79?MRD6[VW4]SY
MTN( ._S2.V9&3;'5KDE.O_R3I-1!.JN@P<M\$:,3-WX1?7!-6E/A0M[F!;T]
MW>18'K%5PU09G!NZD0(<6JT7K XI/-L+-U[\=+.TO3%0?7C/N8E^IQ-NG%\D
M(6ZR)>M2.[/@-GE.ZVNHB?E.\=30?-'<5,E4*^-S$'/]><_6:SC]8)["A$S^
M*,%X^VXN&;V/0C(0A/,3K\7Y3W,2/;;UM#C1QV0)S[Z6T>#0@O@&[X+J3SN[
M0W<R.4*NY07MZ5X:_,#0$X ZB^<BV,#,9?'I#V8VF.PX?25E^\F*M>5G!S!6
M9]:^&&Z8!ISP6E0H,A\BJ/J*]OL+^PH,N*JS^&+L+Z17EU5</&W*WC;!JP'$
M"G+PO13N+CBFU>0CTWQ=A7\_SP,B]W$@B._(JG9R;GL2'*KL/QF'&&S-O& $
M\<TO]FJ )(:Q2_,]?344:HSM&J8 BKBLH'JVSG>>Z+OU?<R#>RU(Q^RS*JR_
MY!H"7G0UTD0G\T5S,WO_EG=I*9C^76Q9ZB]A]I6;Y>5^!T//YY](^T\OIU6"
M0JG_0P;YB@R<[2.JS\+@LJ1HQ(B^C&"L[M;%5WDLM.77.G4M+]0HFB7UO#%@
M@M@HG=!>BW;$RG$*-Z%G2NL9$-US%""F9NK70F/Q'U#[W(C->)_O=<8<\P;)
MRKMBW>36S^@E3@3^$/K3SN@_ZV6[7^?X%>'"N$;E)(^ICC- C1@)?UNK1N92
MFQXBG8#LJ=7]I8BCG2\G!7C32@$N>*")UI&_8EW^"?43ZB?4?Q3*KQ<RJ+)U
MNM.$#&8C=:W FL0WQF#3934RT2T^U[D1386[%""LSXUQS'*Z]INP8-@N S40
M>6FVD4,!,L7]S"LV(57!.^ '%.!:'P5H$" K%VN9"U  A@PLC!P,(F9,4H#O
M)1E_J]; *H*/\!IAN0#=8H 0#T*_^L!99J'84>@1])(3!6@WV_A+<<7?C, ?
M@97W_ 3["?83[/\V&'KI=]M4GH5)!#B1M8+9*U5L+-F2+&! ]2>V_5)3Y>@/
M(84<T2U&IHQ[@;\J!4:9[('&&PG?*5::'0689J8 ?"/9*.H_0;UX"0IP,Y*L
MO8'X7ESY=XJM;*-?D3Y#BKZ)[A]!D@^(;BJ4A^)$\7#1I] M:0HP?VGWKT5*
M?S,(?X@W9OL3[R?>3[Q_%=Z2B"#I)@6H(QW6[H?,;6HT[AF$+5. \L4/AF<?
M(#CA B44X$P>U6?IH2!PQZ?,XW*B8<59;\@==5L4H/ /?5+)_UAO^Q/L)]C_
MHV#=B5"B-_77<.L)!)7:;'#B5AG'?*;S)0G0EM</%\G7#:C<)WO<?Q1YQ"I5
M"<IAQ<K_5X[2L^T]]8F\ !K>BR?1:%  ('Z/=T#1,_YW%.@?G)Y! 3%RW8(4
MF8#H%J< V&.(5YA2@Y!_H%N_]WI_@#;V$^TGVI\,[2SA/KF?]RK6L<E.'C1C
MLM!=L'8O5"TI>U8_;E;EI/2!U]SGM=/#N-?;,$93-!3 ,8\$-BQ%A3"E* TD
MT16,WF*E*K>:;P\\4M"E:5620.R$X6P:0!$XQ>SFN9)TS]1142&N^5Y'3IF7
MS#=4Z^_>/I1\^:O5]C*4#6K2"O,2OV+:[,7MH.=P]@3S-4C(S=QRQDK:T;I]
M=F\]V^R[K/YQ"*_]!;V8Z2M[#Q\-AXD]ZQVHK&PG]2<.DLK6>@@R,^A3R^#+
M/9AM^"FMB@'QU<>OU^%6)[+ZG;HCIC?E!E/\(411?/,L^NE^ZTYP4)E4&?WU
MU"\:J9/3)WJ5NTE*[#9/A#>03T#EP<_ Y\M28_.+\99-?>]#1 K9DWR"^2(O
MF=YC]CR.ESG#T%);JW0D ^0MFSXC%G&Z>7XH[^9N#*%@*)=D\*6U>TM+T2NX
M\?NR.Y<Q@NC5BJ< 8F;BOU[]3*"ZK;DOD-:]Q.6WOR;1^VWBO]_NW-0(_=M]
MG?,TWVL?,"9"'%- VOWUC,M#^N_5/#*7]TL-9,,N)X,$+;/O^P"?:8ON^1AT
MC&8U1P9!X?ATUI09G^>E&B?MXN+V+Z6^? >UJHXX*3_4B"N_4ZXT.[Z8@\J'
MP#<X8.1#>.B[E530$)=B%6>M4^4U-=.<4.C$W&%#I\J\,)[Z-)IV3^C.$U(B
MQJIT(%ZIKS3<0L^T33 82)6YTC9Q^L%-F^K$'>QFC*U@^R3!-S5K14;"OM3Y
MDXIFK**7R:NZBW.B7B;5^K",GC5D"6](KJ?'M.C3AQ+/OP9K1GRN4;Q\ML=<
MR;/_Z:>S'$IREBS+VY$SC*S+_K+8B:"ZM^-<!9?VY#^=LQVA^YX#$XBXOB)\
MOS8TO!U>9N/R+=E,9:!)-T=;OM@97MA99_ )+Z:&+YAS? )B(_,C3_A*])>)
MT.D-++QL%*G%$)I>M29PY_%*RES\\.C142"9V2]O&HT1G@.%^,N7=9<A@X;J
M.8OB+EC!;SC*V;-H7]M[J]4V5^ 9W+0Q*C=W+B/7<\P<VY+!&S[=Q6B/'GG(
M5U[Q,N>2%D=MDXW ^V.M-(]8)HDL.*GF)8CM"T9Z7Q6<;-O)WGET16ED.Q.4
M[V#N)XMK7(>N[!6%![.L#;S+4&_7,JCP\&/:UX?0<%:J&*!4D:6:9*\JGR(S
M$>M>^_WM_OWUT/.HH\3LWU^K50MB?9^0!;YSS:I-L+U.K'_PE.\-K*O+42M<
M9/!LDO25^JR30GZ,G1]V4(%4(PV':5;B/\ M!;8;1Q0S;V@/MT\:)U><=8GX
M6!,9A'@_%$B$8Q<;1^>G0B1@/A/:+7)5\J_G1NADUT=SE0SI=^4)!NG;MDK)
M]KHIJ*]^X\[TO" :9:Z(ILK<) &NO5T28\G9*+ELXB=^M>?5(;_ VY6S?WEW
M>U1I--1P_WRG_T/85=]KI%"P,(]LAR&;OD..<VA&>%S60T,2OFWZ*XOTO,;-
M;F2AO[BO,O24?WMB5YBOF(=;5G.V75$'_?MV;<,7MU]<]!GB?F)V0F%%R,*4
MV\NLOSKY]21/*F\F3T]NEFJ)ZM4*_]7]D37O]9Q9$:[KX4B]P:V)\\)PB$/U
M[;M>:ZW#_;(:+XARL\<F&02;C/4+'KVH>U-4HV)ZR:DR4.&J,GA[#T60(#*6
MD]+D+7+M]C,KW#*:']CM9*:R/RN^K1;88H@;0DEL4VV2?!P/W;F.W0BO=1[-
M)Y_9?)A^ON)1_MU0U&?5AND$_BLG4@+U'BK(:D0G;F(LLZY^>F_DF\IRGWMU
MV79S1!+SP*=LJ&K#(_IFYL>^R2Z6\&+2\GJR,B<N.4[^A+#4;5QPL/SU1X/[
MT!!Q/]5Y X\1C&AZU V%&.Y$XG+W?=PB)AWWH,!-Q"(]Q!*68/@$7CJF=^:^
M]&-@^CU@PY^JH6/^ O=TA\7Q )YWMVF2!2<QB'+*4')PR%^?,?QZ1?0B[FIJ
M[M4FWH9OPV,?=9YJYLBI[/&(S=2RLKZ[7#EN(V(WILC:6S_D065>Z\%*X>7%
ML>"P*^K6AG-7;W=PJ^V^<PF$YF"@_/Y-B%*EG#D1%>*!V:2V,N'F9QWO)ML]
M/J\@_=DL.RS #Q2>O-]"<9,*P:(P],EZ$?MZIB <IE8A?4HRQ=&J^&&HD5YY
M0L9:4]0CC>-7UN\HTTKI]3H,KCAKSICJW6GQ/!ZEI67Z!3JQU$LNL/8/&,7/
M?1P-Q!:7X<R#73Q5#AYU.YK21O,2D$=FF ^6)HGXW$3W;JNY5?5N8$;I7D,?
M\]^1X<!LLVSJ0K!WU=BW3JNAN<<540\/$_-8?'0=3G1+';FGX Q^FN%S(AJ[
M/C?CN-:9AW?^IAMO4%_>(YHX.ZO"T^>C?':,=_W&@0!:GB\R^5G'M4JRY&IV
MB!I27/'S(4K2=S1*'51%I,O25PN7.O$ZA MXT PR/+Y)G\TCL6Z[<*$H=-/J
M0=G]*^CCZ2X'7AZ;MLE\!!O_6%K0<+$U]; _G-Q$KX$YG&6U2#J^2@UA46F(
MAZA1'4V\O8@OQXQ:?-'0>MJW;:YMFL]E(2''N&WP9D$J"D'C;G,H)J4RXQ7F
M>+'RM<DL6@I@LW"E_1$#^,'GB?RX74>#L2UPU*"\8CK>E29_5=8]LA)#HUE]
M6T6ZZ\#S<V][B09IJY\[WJU6.^1W[ :&]ZH:K#Z%LOJRDEX4@L_C]<=:_*5P
M#-LE]@U=<-@Q9M,V#GFUBY')#M./P^8.I0[,0TI;/W0P!I#E^TKK3NG5U3U9
M^"!ZJ^(,_RL9#^VTPJM@S>O3WS ZW"(7ND9R")/!1<$SM36G0CPY#5M6\J;&
M^]2WT2O^:>Q6#$^Y:,+FCA1M:[#9<G(_EC#SN=/[>HNM0H75/T'BFT&+Z"D8
M'>$8WICD9M)<G]IZ-\+DE=PQ?NTYH<[DEWZK'RC @ZF1CKMXLN]UEWS8;K6N
MK.7'-_#[1KS6CYKF7^/"ZX,+;.@OF@IH.Q??'>/V-.=Y<U'DH?55-/^%MN91
MJ9$,O_V*8=*)7J+1#,E=0U05=R(ZMV-2F.O3O-/ZC>300=L1+M@%_2V^1"*9
M]!9B68:_,B.%0P3+JSGEV@U&WXJ_8G[K;&6P#UQ92><;0[/R-267K1W18<NY
M2U5S&XRKWHS/4=;]ZZ[0<VK";5_V.,_QLT]$\E_J*4U.9I8[KG>Y9\=\,+DP
MK"B!@7V:]T$ "G.A>63"J"!^I5ZY3RK^Y')1B*AU1+OHWO*C60G>/8E(.RI-
M.KK"1G<8]:*4*RF(\+(YN^G+8L\UZKSW9&L6'1[<F%ULAMLT>2,C'"YN^8RP
MVN9_UG"Y>*N0YW1-X"W:]<>I)RY?,:T(1TRGN'LC@APW?.5FZU17=2I",H+&
M-(NU3N,YQNIN#]^5EN;;ZV^)/1(OH0Y]E0JZU);%+C0\F,%?_K38,=U?>=@^
M##^:4>':L*IE,J[H)AA/'R*VR&5YKU4>]W@+$NLK1CA*?#BX10%X(@^N2)5,
MV0X-?E.Q/-W+2A#X>,'WC<+IW/?"?=(0:!;5=P9*:7,XE,JXDN1T7V@G:956
M&H9Y6M_(!=UK8[>A'0E7-^9MR>)/Z'QMA1[Q;'W6I%L>KUT>+K<QIK?@#;WG
MPZO($CX]=2+K6:UHEBWNY/V2R/8[5QQC3E7P;]Z]$KUJ(M&^V[W7'GHE2<O#
M[&/H^7?7_NU)FN]W&"*#OI_O#25FDU#R=+..QXFN./A.%=QYL#J%&!]GL/:L
M^>()%\Z\K?9+)R/&_&/W4>\H0&LCHHJD"#&@ $:@[B%KMI/87N>R=3]>Y>0.
M 910._>*:J?Y5#CRJS^/%K2\U""+E$?J:B4?V 6M[I)N4("O%("4@X]5]!_M
M4=Y![4) ^ -D-*)?E$P-M$>1(;H&F(+3"'NJ6CCJE^5GGS]?G_5+K\C%&FF9
M]E,X+'H=H?,'?Q5<^J=^@I]]_I-O'OS;T_M:?S%M (&:VJ:C -$48"=K]C +
M :8(&D6/$Q'3M/LD"J")WH-0 'M_@>_NX ^[Z/WL\F?M$DMU^-F(771:KG$P
MT5\%CQ""E"&JJ,2]@7&;0'Z#V$20^XDWWJ+AMND$ P(RD@A0 "AZA8T""%(
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M[DD#SOE<3H<H@$^_P8(764SJ36C2&YD;,;KPCL/"$VHFZ W^Q*44DG^'\)N
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M)[Z">#B;CU1>$%%UH:/,IEUO&Y2Y2!]::#1D,K>U<#C[K,GULA$VWK,JFII
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M.C[G^W?>JMJ:DV-A&_+>'J"5;<W)_;,V[]KM%8$7NB^4$A7S;!?J&([E(A6
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M>$G0K0<N1F M&I7W/BB9=6QMSLWV(\@,76!( [S+QUY KR9$U@2,074.ZG;
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M@X_)I;J-J)S(##]EJ<)VU)B<**RB71+7.#0.>FDM'PT.GRWH?\-ND93LZ7I
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MHI^S6F>)/[IP82?/B*N>=9AJ1T.WLI'P,#>?8O?FO_WD;,Y%F8Y5V\6-5+'
M51V8&5P.!OB0.&]^)$%?H" R>$=.LX:&[J;NB3D#=.H0NCEE=]ZX>40LJT7D
M7M6/)8=J<\Q%>&FR(Q^(;?T_+59%,N<="*N4X= FM&%[7ZMX:(CL@?SOL?7?
M"?__GW#AH<C_E?#&2:&KR?>+8X$1EV:ZA> &'/[X9.V>%9'HYU?_3O\5S_N!
M=?.6?/HHS4WSS)V4;;BE6,+W 0)1S5>@5N7& .XZGSK'CYK$ ?Q5W)-IY_(N
MJZ[0J5)C==2S0,/1)?;8OD>;&/;H(GM.I^(F==5GYC56?HV24TGE$FM\S4__
MM8K%_[Y*P7A1O-M+)<WBGD)VLC6A1_Q.B!W#<VC#@35BYWZW*,D[0N"K2]+W
M&[FSE+4S+CV0,^^G\+4=+=L1=( S5E#WD0CR@HE<<E.C^41*(F[$D5DWY:8Z
M#;ZCD45MI2M"CW(9S/;(NUXBU]^AW.5V.?,:'YD@@U+&=^7BKRDZ8_A":X/6
M?G_;8^8KE?40S]5LP?"7"@=R1PVGS98$)OD*TB:6@W^$.AJDJE2(K&#D*I>G
M]&M,?(Z#7U]D'C$S 86_ET[_24_Q6C=9U#Z,;@8XW_U,M_U) A+[G,3;.U_J
MU^<2%SUF#_\&W=='?O#D[$UW:/1OFJGF.?RHBPI6',N+$XW1TV1"\'=-3Z?R
M(6Z31*HXV^0](KBG#N1B<Z5?-X?<,8FM+NQGYQ?B@":L:02<4QL+.(7P-"U6
M. 93?*?Q*Q3'U15#7%V"IVL'BJ/7Z^4-<I,IM<'\38GZ,PU*S<5B\Z^D#_>7
MOK%?)ZO$P\<%?NW2XN^I1"_0TT8!M=UG;@P'BDB.U^>XMCK<N\'W[,T;7$!U
M!VW?-PVK;@DZ(2=>VKA1U5AV/=;$&FV.N*+MC:&_(IQ%G]1".-8L6]'R?>NV
M2A##+"AS^MK\S,L:_<D* =EF%>[XSPIWS8OC,@7F$VR\ZTLVOY:;9:HG!.A!
MB:*'S<3LOA,)*Q'E5N+Z*:>[-]A5O_*,$*UOF@P.,^Q_TQ]2XK"Y;VL\:3]\
M]M4FC_$5+[/9!NG]P:"S2)T>$B_N9"+>!^&//4[7Z@&][/LK-(!4H(.\%C[F
M5WG!Y,WP1)0?I0A C]7(F@"T&.:QZ%-=<!D]4WNI;48)?>'6P[!0_\/'\!V?
M&JRAS?:V=TU4@^*3I?X?^M*3AH&07?.1W_J=K-B.J#2-5$; "?[CK$$Z''DW
M\\K9[_'<VPL.G,,L;"82N4Z\#Q"AGYXPL#XDZXRU0A4)!C8&(QH5TN+BW XK
M<AP0H1NJVV5-T@T<23$P:1DA%V\V:SV6NOM5U_SXLF>ENN7ZX/[Q>(=9%#.V
M853DEOH!I8C.*>/=^P^F*9<M/@*+@?U31=(&*+-HB+%\J9ON_:09!L^@@QKR
MK2(GA2ME#:6.ZK)_#,,-/C^U&'(<K3/NM_:G]0<]?OXV]ZMAE9M@&I[>@2"E
MZ*WZQTKT=^UE6#24^93*<8//Q9GT326B() E?= %A?(G=T%@S\^M )CX](=5
M%BQ&Y*PL3MN;V)U^X54E%^+5DFXD%G3WOHF9_@^TMDV!U@OK8;@>U]^FOJ,!
M&MN%\A'*AQ_*S16U;F,A5Z[:ZI QI9B )7#^Q))>!M9?N!9UTA2S$1)AZ5::
MVZ )_9)(>39(!86C@$G!.%[!\NC *?F+XU,R3DI4$,L6T>+!(/&/=O.36_K5
M7XI<_/F%\:V-W3'P>OGRD=<JEQY[%\OGF&/9>X?TE1=YREU:0530 U)LLO2=
M-U]6%>WA"3<NW<N/[KG*_P)[@ZLXE7!<&\&+HQ/<Q V&CI8T_BR,]3?>._X\
M8MV4\]M7L#EGX.FJ&^8-7VT^<C;''J57MQ5S."HDV/% [[Y;' ? 6W;2/4A!
M^D")XF"*;.<;,BO1\TS6'$6M(<YWOZ@%>$E@EV5=4(UWFRE7M;[2.S1YIB^&
MI5"&%CL6]5@3G:(EVG-Q?(\]KAI%8\;H<MWSF<SOBB^WV ^1-QCI58P#88O?
M'AI1CJ.N9UIE4[[@/55C2]O:D(WRU46:5%#(*&X<U7@H$U#WH%[_U YJU#!0
M0::V]S:D.DYER&K .==1XO$1K+?2=FFV>_71,R<[\#$\]O_12-=H<4+#A5)X
MD]170BZN+4 (<FA<2KR82-FTZ6&@$PU.PBHO]Z7;4KCAS[69D?&+J_S[$4O8
MPNB0!]@UNA$=;)6:+_WU>KZUYK1;:2A.H><DD5#&<BT:O&=]0WOO#R%^U65[
MMP1\)U=NR$2KSLI&E:QKEG7VV'&G7D:/!QFA',Y;TV(1X+FE%\[Y3&JYB_W!
M_T9'4?Q@%K(?/RM[G^-ELP#^8/;H[@L%TD+GAYHY-\RJ(Y-\0[^G>CQXM-PT
M"R?3D=BN7.V^ 82J#E\V1$>!1N7I+?+DA!<^W>?(/!F*N.OFRQA'T@V6V(.'
M#%QW7$O&\K0C)82,MIYFY3;],/\L?U#;6BR:M2@-O0"S1ZJP]WM$G&CZ;%%!
M_QM)(JSW4D%<Q0ZE@SV)6?<>@G%_XJH[MX6$I\J3Y.Z<3<V3\E)EW:>[N,<B
MH-(?EV(<3;0Z,GGHA?>1*>[Y_GW>$Q_^J> &35)MH"SYDNSU"OW2>)S(=4Q9
M>H"M+X-0VC/Q6>M<YQ\G.T+.O%=(K941@'2*@G5I_N-@D6&(DRC;TE2MPKD8
M0]W\)=,P\;7=@L^R.[:&-6-MIF\_YLH7"P?T?+RQ*I%@TKR0^93W:;^SV3X'
MQ.8.*.U+",X"I.]Z$71.@AM0(Q7WH;EV(A2!Q.,(@ND$PK8$B#$,9S#X.K;<
ME9]9$L+WE4#LRGARTZ]Q:PG9,.SA?R@I/D,^#.O/"BV+BZ@%3+!9^7A'=HS=
MW@#]=*<;7K^Q1L)L&J)1*UY8#AC>GA5O>!&V) 5C^,FC;AP?X+TK8AB29]\R
M*YLS,6(2LXA^ ;<^>-L'[^^C7'R2?0[PR,<&BM"-KC U:\3_\N0WMKPFQ9O4
M U/+%.H0SGW<5F/0>NU+C*'VM2\25WO+9_U;E0Q*BO]"^>"&)L_K4P2^--1*
MCY#X?"_WAC\J %_ML1@@<)W$@#F\F2H2, ](@"J&@\X<;,T?F1 06X>96T\(
M/X6A03"=X,:!'Z-R,4G"J1EYC6!(Y.+Y.]:541(^9M^7[F@+-]&YVA=:4;'5
M_&N@[2$M1^,Z+2FD'_#1AA%;>L-%;I?, Q'V4$'X,AXJ_7JL=O.K/6"BFY^=
MUFS'&V\E3@59?K@AF%J]!'AA9K,F;.W<[92:\MLK>SS\2FVT?9@^,%5Q<2Q5
MFU9^8"KBN D"@;A5_@-VHI^<_D;@]LHDOE9F<+I8QB6-F.1%S+*=M)CQ'F=-
MZB?Y7NXZIW)NMM>?S3)RH%_"7KPLKRP"T9#405MFDH8K-M6\<;14GO_HV' !
M=^UK4=IDN:EGQ>QGTIM<5LH>6#QC7(/XIW<U5IVMB*=#T1"/Y!J,$9$AE553
MKI$$[K*%+*QZ[H^+I)1'RAQ(^<A.@)B%VZ^>Z8+N-$/_YS1P^[6:^U^2)\PH
M_3$_F/UA:=10_5NT)&;ZPY95>62O*49:][*^)-Y?OI1QA#.AZO'6HZK/99<;
M4>I-$N)+^_X+60]S9BQ_"?E*"%I=M\!!C#PS\Z^9 AYFYNG)UZXO<GE<-7_1
M^)"OY/5_SM,55- C]_S&_.N_4A2WE-=7SPM%*!$*5("I8PV$6FL8.S_P!U<;
M7U5[!GAF>,)SW,^9=M.RD=B<U;)RN?-U/--KNXWTN]NW*[,N6M?ZBZS^"V]K
M_0M,PZZA!^UAYT/KR-(G;[MER=ITM+9;=K&1!ZBH LY"M;Y86P 3C.TR\S)-
MRLN7P.0V8]G3A49O%Z9%2%(F"AMW&PA5J<^1-!'\E''>0J%1NWNY?Z+?=9"@
M_9I@;//KJNIZ/?QX*HQ#NA$&@LOA%IM*Y)W<M>CK6TBH/CG^BB0@!&/ND:K<
MXO%S+<=*0P4EK46?VIBI'H"*JS$KA6CQ,L1$%0N\J?:5[]S ?83;!;P5->>(
MKS)(<E'5&<]]DM2Y/:[T:8TO.'YP-HA@]KXHMM0XWT%7BC\^PT7UX1,;".0:
MONY-Y>NH-19E@4R[R20))38; \,#,$%E<#P:"2*#J:!SY7TH+GN/I[S/HKNC
M<<NB)C'A(?W=*B1+TKE2N,(G)XX)0B>)/1GRL/K>,$\>;I5]'N;)N;8KEL)\
M5=:W"/#K?^;41#I41=@>^P,-F,*&PNTUZ=>K<+_#>[-:%X$P[5ERF!>'K;02
M=#%O0+F]IJN[@0Z#+)7X)$>[J2+"U/Q*VX=$VZ<%;4TQNHRI(,+(G"TWNTGY
MY0.P15X">Q\5E P3_/$5=A,]%S3VF'R5R!MS8-@@E$VY %AC"VEJ\S_ &7JM
MC1-:2/9 Y:\^+;'+^F3SVLV:)\3!WWXOD*Z%D3"V95\(F)CX2=WX?>VD<C-%
MZ.,,1$^A1?J/R)79XNG.6P&C^E=JE=3XTHP#]+7V#LMH8\U+,3,\"LK6R;Y7
M\]4S9@4,]40$>N>BI![LB*T)_>(W+O#3,,MB8$TSR ])(B+K?[%=]D2=[\'N
MQQQ](/9=,_] NC%1X2]^+6K=D#]X=T2LUZ(BH_?WP^2^]2<5>IL%8<64:1B3
MV%30#B>V\ 7E$MEB*FC$*UQ4OP'0(8Z;O>QYRJ-\OK0FN2"? .;HQX['/,VU
MS._TU_9N=A([YFYJ%WOZ4U3'H!$1<GP?7IU!W.O=BRYDVCF[IEM*@N'-X8..
M-BH@X4YN8OMG(^ZUI;;.,J#H0@I-NMK@Y*3[XIVB.^VN^1=O<I_-4D[AT*.Q
M4)1PIXVD!Y510?]B8*6^ETH:F&64K$FJ2!H8M1D8+7\V6FY>\FG>7:G^^W/@
M>M)#KF*^4KX!R:L#-ZSTK[S7%TNSNU)$E-BA(:8?UI-,>@MY[.#:AXGA,#Q/
M@W!S?C$<V2L0\E*+&6 P>GF_0%4I;UG;LKL.2";1WH\9,5")]W#V(PB>\T.Y
M-GD\;GDN3CN$Q.:!&]QV;AW+>FJIG?J*)2B]$1'5?SC;?7%R";.B1%ENGX!X
ME#.'JZVU3"T9?C3Y"(_5YEC:Y.R7ZK1^)O*&8AZ_'G1B^Z]&W"KI>K_?!>VS
M_A@6KV;5]W=2%$TG3,]?NY;28\&D+?8^X2H(M=])!;T<A*[)4,#_=NFO'!54
M$=*?0 59J%-!4N, ))!BMHJC@OZY=I,*^IN-L'G'OO>+PIA-!5U]==HW@Y +
M10A.*FA:]PO:=&N?\)]\\A.$X@>*CV^2Q0"EL**-PO.=,(_WGDX74_;W1XQC
M1BQG@QD5'97T9Q"FE?/N5@+Y/^*Q.\*C][>TY&:P#<0?F9K]C2J+&?+W$L)S
MT:)([/MNEO98/'OO:A(5Q(#0)@GBD#LFQ'7#@D'<7D(0%10MH@(T$+T(R!@E
M-81^K2-E[+3WD3EQ8:Y-I,R"#GPJZX:*'9>R^OI++3& [4_?X,"I7;]W"";F
M_&Q_Q;"1/->/C&F.N$%4P6RE"L%=(!XD.4R!&"DV$J+87M/8WI)(EL(>?'U,
M4HEK9';/U?[PL_TRO!A3?G_ZG;,7^^'*&\B RJL8O S2P^^ERJJ(']HU#,J]
MO(QPG8*H(JP_ ':KO2)JN;V#=WB:K6.\T *#N"PB71.V:3KH*"55)2'=SJ*[
M4::<UO\\,@T!"\0G6Q\V_7/GJBT1"2+KZ8NF;.#&L0$ZN5.M9'$%2,7 6!'Z
M^,)8))V='+UGM_Q$$ :7IY1J.]FTQPX/^$%9-XCMOP \V_YYWZ%1[FR$,(D!
M:QT/"2-008OTX/FJ@55!"(,7"85SVWF)95^4P" OC ]J*N#$<TB#_2N<Z$DM
M7H0UX/R.[/'12*$7S%$3<679\,K:J8B"/R(T2"$8V[VFO?,;[6^;T6Q-ST G
M]P!_4@O.NG]82;5;"+YZA^2UH?S,J2I L<WU<CB#4Z%E$Y$*2E!L;GNQK#3.
M "2LWYZ3Z=0@"',T@9F]_@C(HMA2JYV&RYRJ14[5VA^][/?=B[1Z* N$$D;&
M4\$-J2F#D0@C+)01\<^32A[ F0]=@1P_?#B#.;'T$[ JEQ(AM#E!AC1_G/;>
MN3CW';A5AE FI2[][KI@9(U1+L;+%K33H\+8&OQ%(TK(UL#K=XB+@!_!)+[[
M:JAN++:0W5/@Y,#JYZ2C4YYJ?-/D=O'=[_*PS3_C/J7S=\X?96>_0MUVIR5-
M41A+&$FI9!X_4?[3*.8I<V?#4@%K*&@@(N>LV_S<K@M2N9!H;++(BS\U4S?(
MKH!?$1S]"<VL5)A2 "65#VJ<&&SAGI#LELD&G0FS)MS TZO;D%LX#2\? QA[
MC\LSL&-K9U?N*J;^Z,F@XJ[K24,=H$=:1*#BT)YHGF&NE][Q.' TDK%3<8E9
MESU3JPFW*O!-^U+<7<C,J\S,O@^5=7$VM!M//AO3G@FG.4NQ\ 7O(%=E*-R_
M=.:VE_TK[SZ>I8+<P8OFYJ[2XX<F\<T%YY-S<MYFQGX2X26^];\:4.H<)^;Y
MH8YNW^[N"HI\XT^/_5OE+C<"E.\SO0!,F*Q'FDMN(5?&(K2NS#4)WF:JN@1K
M\+DQYG].Y,[^P">1W[7 :D\WGS7R KP!HP6^P_+E[PJZQ.-: DI 0<.3-PMW
M,_31;6.0AZCYBTWVC$U8D\DVKK1!3VY@+\8Z'67OR-N_:!*'"HP_9UE/)/\M
MG:H_NL=O=>%S/W>DQR.V=NOM?J+*[:!T'< #*RSO/J_N8(]0!Y[,/>P)J/4[
MU3Y-0GO.X\4]#54V"^'(J[_MP<PZI4NE97F53ANS=3OG?,KGX:X#9YD2+T0G
M3&&(ND7.=VZ>2;I\F3W3 L0N"&[BQ4C-_P$"[P$-! 8,-XR)S P,5MX&@N.X
MIV$]RKEWM27=R7/3%[C2))W3[JXHW]<FK??]?2.*66T(&3RYG\9D6+$!9>OD
M]AUN^G:#"HI:Q1M'/TN:J&P?.+RVN7^ELU?PM=B-X\B)W4'RJ-TZ7M&<?."L
M=Z@S=\*B/G="*J*"]K,B(;)R<<A&WY(ON7[;.^_<-T?BUDB#@ZQL/<6!=2KZ
M/MA4!OB?@.(.-8MV%N*=?EN)H,A:I)?7T3[GX5/BVRNIGV%X9)^:\^TO&&E.
MW%MS^0]W6VTL%W7?\O5)^4#;D8^73R&XOX8*6A4X;?F2[I3A#BJH*-&>"NI6
MA%+,OC)$&Q+_'*9,YQ@7']^!A^CI,G=!.(DJNA_A7S[Q:?L38 ( \8F=KIQ,
MWFY0RT,A_Q*BP[#*)R37YD.3.*B'7&I[SI5<]Z N$]S@BQI88(P4/Q&&<>0U
MC58N,3CCZ9(A76#__IMQZBYT005Y<,,+^6?@U/M_MH/6^U)!/Q^=CLN]9'8J
M**.1!C=^+(M0Z([3PVN:X^>2[)GX !2A?$#3BH%9\-)RN43RCN)[H6&%3!X:
MCK+7EVUP4A=@4T@7Y,*@H;\B["Q%8,7A99N?$OK<AI-HEQ6;L*T?0H>^*J@Z
MS]3YX=4; Z_[HA\E<X0G'HOO46)D_"C 5RKHR%#OT&CUA,5N]7^="2VZDU-4
MP+Y=94-[L,)Z0R3Z_[;TKK(!*G?;/TXB+IW22 3C5) 5>EK6S$C;ON/"AI;W
M8M1A5KMOW@76YMDL*\8LDM2W94@7K(<* B36/XW':-%,0GBK-L8(/M8WNZ=_
M3% NY]W5 B/TFJ=0>]#&AY-NI%2,6J=<[>JMTI61H*"EO+';]JTR988*HMI^
MW.&%)^DA5) V3PL5A'!'DDN+_S7\FV!-<*2(&A'[%' [ODM^2-SG@<GID@Y6
M1( )7'\R'W=\WJ"=/;#Q:)'%6Z83Z;MV(Y:%F0-%!7FAS_%Z==%BD0-&6G0V
M?;EL*/SJ2Q&)UOL=B.G)X"UD?#=O 4$T\,Z*^ 3VT9+I>U/8;2KHOQQ(XR\/
M,[-ONB3B4S]102F%K'W^,9TS4SV2).W>K\()_5102S?KII-FFJ!W_OMU\\F#
M3R41?U7U^T.<F$Z*ND]EO4!#CIYL111OJ>SP5F?1$IOR@1@RDPNOC,<$2U9W
MWO*Z*!LY&%C6AWLCZ;C O0%>X'6#DDR]$'^8W],>)?,J88 1[%QD]^6E1),X
M 9YD0IB+[IW8_@(NHBYZ30K$_EJV'!>6E^CZ2?!Q2Z[D_<BAS<\EH&<%N&$)
MD'\6';)  3";^WP_8JB \>L53H0*Z103T5%+^O!M"!U)P]J$54=<6VH0F\JM
MC2^DNU9A>AQ-_+M4GZ4;5\6A[X\%+Z(QZ?K0F A-N ;^2M9OCI](+@K_/!!X
MWSTS%DS,1<CGF;2D6!E]GAS!"G[XX^-WD?SYIE;M^VY=OW@8&"$_207U(HFB
M@\^B2[MGLFT!"0(JA@KBV.:OMQ@3>8GO$L45)B.R!DAT9;&5WP9B'_X2.C/K
M305Y@E^\V&>5ZT=R=IH0&VS?Z%%!%U*3NKD[ ?T@U.5=&T([:>]ED*;(04'"
MWZ<5H<PM')^/S#Z!;4P=GB9KQL957YH)8A?ZYI7K,C3675SL!+A9?GQ[GM$=
M):W8D>C!]8)14I+OXL'E)MW,H&?P5#O5K>BO7Z#[B3<%,ZPD_G7FI&[GH?_R
M-:&/"=I4T)H,R&?"IO!?)WR2QU1#HW-?^_!KD'2DN_VTRK)TX?Q2ADA_)$.2
MFV*>P7!CWE/]QMH_]=V[PQVRF(:0>M_/>\,AX5D?5M]_I(+J:T_;A?/L^(2B
M-KG1#M>I1T">!?17V#D0%B\-.\VX/!HVG?C#[:S\VK/^ZG2_UJKP%_6/PS:\
M_J++]=VZ,.?'D;%^=):&VN@^N9R./H.44Z# _KRWOW'1K.]1I5DISZ3O%R_G
M\G//!PA;TEH,Y^('\&(H 3X#;G_NDMK,&?7K;Q=G/(MG1*ITX!Q =)7G4GJ/
M$Q^ QK\R1ZAGKL3CQFE_FKW\X^A'#BG_J=)P^UF\M&+>SDC6G0@:^&2$EE>'
M-I#>BV:7$:-)36<$$E$@-D1S5CBX9Y&NNIQ/.JN]VN-U3#9Z%(DZTI):'KJN
M1@5Q36<U2KSZWCJ\!F_,S\/X:[D(M41Y7BE#01-"K'P:YJ@@*]*T]R]I7?OT
M?OM%O1N#7U-DDW?\?#)P3G+JT;\G7.H]%TO"OIR.!_L*<JS2$#P=S_"<?)&=
M?$5$AKC[ OA\J]*+1SD[4.C,A97/^M%K?5$<S5<OIND.+99?;I5"OS3S2B@D
MYI#O WEX",G?S0^U -?6:74B#I? ->Y-F'D%W&B7&LD;\,[?OX[U^PEFZA3$
MXJ?@GI_G,/MBOH^[/DX@9%BW9!7$LM4;N\'AMY]>=-7W]1,+3&KPSS4$#QYE
M'V?=>DU<$2DVX"NX/.;Y8Z%9V",$%EO/9"A54SQQG^#>T5]>W*Z%PL!-"#_4
M8KRLH-S2#0PL/$RUB^:COR1/ MC#VM]JS13D%DLC'K3,1,#HX)QXB>2S\6_D
M:B#**WQ?OWMC.6J 74+O87JO<:#FBU59M9MD%[K!01E$10(&]P<SHF;-\C=Z
M%D5B=THL'_6N9H@*D@JM^\IJ;1EMK_:+_EP?"3IP2GH4UBQ[V 5$!+$YYT,O
MQ=SC AS58ZU.T%]1;9029.YR]5#]H5KMV#-P4[7V'N5K+GW):_2+(+E%*?RU
M>P;]@3CDR[]E>26C&/ F1(^PR@*7PIC5&D.F9Q8YIH=XTY"5"X=:D^/ JEK-
MN:4M_A!6W!,'F4P+P\Q2W2X^5R';J!#C_>+^2B--@8](;Q? 1_[;2QICT]D"
M*<4JF.J #A4T]3D0[I!5/Z%8^;A&'#53D*+%M?FL>X[4TK<7)R)V]K5R3LFF
M%87F:SX;-$@&P>M7NG4!,\W53:+;<,&]V3<QQ*U&H]DZ):\MNXNP$'<+(ZIM
M-HOOM;3/ECB_< KW_>T;[/'M==HOIP[.8;4?G980Q^.[6^;U\##L\F"LS^>7
MW.O]J8D1M!,+(2Q5^B4(>:);OU3LIS6<C_%8S[7N!QK-0Q#.8ZLM',P26"8>
MX\B7,)JIS[5X]?$C^'*-5_#8P?;O3^]\.*Z7>TE@6[T1SQ7JAJ+]A+@4V3<Y
M.'BYAQ!HP&J0%9BOOD )HV\+M0@<W:]USMOO[Y6] 9_C:X*7.,?A(7L<NG /
M5Z6?#S:E3&@B#T-]'67V$!VR,;RT(2$AO\,Z.IK#=?;7&<[^[E&#OAZN5,^J
M*?UYF ;;_)N<DNW,.-J2F[G<7>C%MY4C*R?V@HNVS8W[5__<]E;E%DYP -DH
ML<. EWB@->-7 A^Y WB5?5'X=:<9R=PIA6-^L[-\TUIONBQS^F/H&R'SQKT%
M,%:\4+4+><;CV6'%JT%;4E=I:E^X1^'+SDTJZ'PUV?0#P]"7[_G7#7V8VY[_
M)?0I!4,7BP_#IGRCHV#<G3)XF;MUVB4 3Q@ZKKVW5?7JHEZD-]GP0]7ND7+3
MQRO$2)Z+UB/HIM2=.0]B.K8EL5,;AXI=Y0U:#K1K+.PM )&L$Q&TH5@3=E1B
M4X=43YG32=Y MIU$@I_HY,ZESKG;\X 3";S-H??4YUW.>NI>LD;O*_=#?X^_
MQJ5AI?,WS_2XE-G W8P;HV\R\6AX@=F7/B5PWZ1Q!H% ?"!K;A(M%H:!)7)X
M/$'<)ZZDDIA8V;RJD@7 ?$!8;_N!NF7_@:EVJ&:4]=^S%3Y*T]>U6?8'WNM?
M3G:6:;@8B; ^%HA8[+X.S!"U,<^:QGOVXL$<$$/L? V$D\3;5W!AIIM;K9ND
ME??0>V)+0ILDT>?'"D\,B0LZJ@X.JT#67ZPSW,K7D2XI6)EX$WZ7"FK46:Z.
M5C*)A#6Z9G&,!K23(9-DW==J9A.X3E[\ZH6\C.PDH\<MUWMM9*:SMFMYJP$D
M41"7VHO<,26B>_]*8"9J3Y*VO+![;'#S6XXV&ZON F&>YQZ^N]-B\EAV-VMF
MS0INA7?191:E_4D%S?^!'5S?@OU/_0*1%$_*$,P71+=$.($UW&]IYYS??@M;
MA+LO%AU:LKE:GOF]"):2\&A.E:RI];T<\+G[0?CGIJ7#9H"6^2B$HM(VP:=Q
MAPHBIL/E\.S140IEVTL.A1QPDWOV]@U-S78.BB'R/AJ7O:U/>=WQX-1')-J#
M=288]B?<*8/_4%:JXVD,<J?4]8%V2!KMZ;?03'[?3UK%*<I#7$VN44&#!<*3
M/XQ*&%+<@S6.U1[DG\,L?7G][1*+R)5K\]N*>TE4$*-2S+D2A 7@5UD7NW.M
MW2^E4PIA-Y]Y!LOL8W?[P96OY_P;9(N?VKB5M1/GNY,?=<W\9A[*G-5)V1W$
MJ-RMOWJMGJZ52(Z\6_2&88#('[-K#'?4PUIC-!W2J^ FO;EE;F'I)\58<,P?
M](:\[R]9Z"1"\))"]Y]522UG7Y_1 '?:J>U@1P7S.^G&T]Y^$WC]B6V43.T$
M]M69="G[D8ON;Z]+7KS"Q]&4HN/T35.0 B IXMU![2=I5)!;7J\  2>'>=^S
M<ON0"F*C@#WV-88"+V49J?0V^\FW'24%- QV_& 4S!T!UXU_4AU2=N*9/HA@
MXL#M\<"K, _Q8MPO=+XJ)2N)-2?2#C4'*Q\NRQ#B+EREW11:GR.=1:K['E#V
M3YE6F^SU@_;X*EQ6N-@ 2#Z^XV[ .1(\B72')4R4U-5"/BS[DO7@W#X#5C3G
MDRH;)*4[;B_$'OIU-([/H]U-%JWFZZ,"5?KR56R&8+]=].(@EZJJC=^F$>-R
MO?'?1\]$TAP,W/IYZWUW*/)E(:?,<\KPR0?*C3M.\K7!J:P(ICG>T?N('%%6
M8DK/>]/T]8'4G('5 O'[@TRP:&ACAG<9YK J<X#&999"C]! FU]^^P&VG;C*
M5K_4^BE7?M(8\\;WG2+-;V'N7RP%;"?5U7]."@E^O49/N'_Q'IMC:[N*Y8<Z
MT!.9C84)*@D7\YC;U_!9<.8;=UUH3-\?0W?"O8UA6.5ZM'1D61.) <,:&1'F
M8(@#\WV0IC<[R<EDQC4NG'T\2G/0N/BT4'.:MV'!SBC,F\_><<3G;+85]@1'
MAQF8NLUF?,<X9UASN*J39IX&H(&-L^_\\PP;7J"#.'580T1%44'-$.Z2#1CC
MC^E.)1*OP23$IQ)>V*/^!460,F3\+9@<=A]V!H#:>&@)VW4E]S4_+0!WM39,
M[P3'2>_FAL7C8W\WW 4>'M^$?UYDU1N -BG.JLO6.+..JKM]6HV-8"'.5+2T
M)WYI"8/R PM:5[Q"LJ9ZI,TP2&>VUXIU]2,<41]%5<U*C2VO&.>K&E3/&-1'
MB?*:>=YXD:_']?9[$>-@KC6B+J$K3<<@,"TAH_0*XWZ/@=$'W5V'.J,FOE_*
MV]6U2\L-FQUY56&JXNWM!5)>7O!%CUU9L;LRN'AZ)WVWS+2K$WK2NYN5-&*1
M4NL[;H>HD\*#_%N-]B9Q?ZV3FHA"R%X5XL"X#5"#5\I4H659E,.$:_3SSM;S
MW(YT&O0N ER=FL:6* .K]+ZR%TY]QVLX!C];)<AKI$V02%+R2]#GS%K.\V$?
MD*D [(;H:<^YO%L:J#QS[1JH:<].[D70'NL&\;1P;=DW)VLB[7T4M"<14L4;
MQ*M\S*Q9>;@E>_=I$(CY/ A$YZZ/!Q,[(Z2!MQ)DJ=2%;#S+[*X!JQ_^3QQ$
MAABF2X>>&5)L\T4\)#&6,7KP^-':#;VY>C-]K9C" 5L<['] !?DA+ %;8MD<
MG JZ!3ACA0T'<__JCF5;D%+[NHQ'[OP2O7E!S02CK.LJKWB1+J4[AC+T+Q9Q
MXC_8V7?L!7F'9D2K5C$J*#J?@$R"\B65"AB:B)#OS=4@5$0EZ:(*Z(B<</"G
M*<PEAB#>".'VI K&G@P:I^PRN#:VY1.*=4O]1RH.%;-Z#B'Y?B-;O3RNJ4-8
M"N/$.-&X(V4<.1Y6Z;78]\2C^:OMHGW?U(JG0/Y\BJ)N5FBKC%,(:8DP]SR"
MQL;]%9#>UZU(@J:0/4*4,XE3./;(QF6&/C1WA(37DSZ7;".B6Q1AZD$6?F5
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M <C^MV>#:  H/!7$YP3HKF/78P]0('AA7TLW(W&@B]@3A.;UNK%9R +1Q&Y
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M.'.STL(LL'*RTL*R.J:'(J]EU4.I'"N/Z9G(6;4IMZA:T/CGP?Q LN1_55;
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MN]VKN)GF?/@*Y2)&(&S"[M"G+<P4C-R4(&1VKP5 [%IYE"!XGP^=&&'*HA0
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M(-,1<Z:M;X\\/UM.N]@=?.;&'_7ZI^E#Q:6_-.0D^&W?UVVHVPK-6<?=> K
MXA#]62@U;+<Z0;4.U2<_,[O)G8X_IMD:*:\F^@ *'C)[:Z UY'!JILY(-M;'
M>H0=+6X?_TG52%M&X\%KHS5&7L+QNY<91R=DVQ4;'RRCA9D0TMN';XXU-YK
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MQ*/-NZ/\*^[2R?-Q1G::7Y*O0/[\/\BD_[L]4_&W%Q5CJ1:;1Y&KG6QA C&
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MPWJR5PI6K35&9G*U27VS7!_PV,.W/2[H!.7QMDT2FL2%6SY,[_]5O*N!3*6
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MQ!$[8C#)-?-%0XMCZ]K'OQNRGG&]AK.J)"(_,+M(&>(Z40K7*J1*.<#3@KQ
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M'(4W?<KNE&?''._?V-SHX:5^,UK2.;3@37,OO>@>60%=-PYRS?.O[7\T,%O
MR,0[T&XHBNBHXT"&O"ZKL\!4Y6!!K^R)ZF]@7T6>4I/^<D38-:\7BM8>I)EQ
MW$"L]&29E(B\)*:Y]%+P1M0"(W>ODXU R>T1.WAWS,:'I=/C:)"?!GN5.4L^
M+\GO@V4"41))2W518RL!9@.7 7I)B4S<<;!(NHH0,%)(&Y0[IO&[072%E*@]
M:?@I'B:6AQ;8M/B92-CMU3H=N?RN_* ?04PFSX+ZM:W >.#Z/>]=+8,V1V0-
MK"E'(TET&H=N3&6T>]$M0#6!^!E4VVG?T!PH00$%1>'5D)OO,,WW9M@$>2[
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MF8:.)V]@%D>)I!=@5A&WNL\,/2Y^7N>K82_K=&EO0!GZW>%LC(\LSSIS#)E
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M9^PW=%/IR@^%>:?"/%Y/F_U9M\A@LC4+ <N\J"9FJ@W#F,KQ-8R%&H4%9K7
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M=Y>Y589L=IS+?YSA^#$S3/K*4M;>-%15Y!H76 2EC,\(EC/'LI^K7^2@5DY
MGZ1J;9@[A-JES@<PJ5*T@J-V7R*^%:E@,M&LMB]/,+X%)'7Z!;BS)J*%FR(-
M(LHC9\A9H/WP:<A42HW$;'M'O1DA3A\W'JJNRSRLNG1-4<5-82?6D(:'SJ^X
MPOH 2L!6+>TVY5[X!$!LLXAN&]<'@MH9"'^55V^D.:KX#6?M5&-3SAW\ ;)
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M6;>UW87VKT1>0^+TAJ9Z[K.[4JVQ$3\?[A/7?Q* 9N46/2DR6?S,JU4C7%B
M@,K 4>E6 O #/X70R.ID[_ ADS07<D DL[ 79T3H"IGS_''0VN ]6).O:*F@
M"ER!5Z5ICZB4'Y_IC^_HM;&PO7+H8CS]Y5G2?FJLO+@1Y'>\X.X"YB6-MVEQ
M$YE(Z><6P%S(UH$=(@N-S21+'00DS9$IU:P@I,*.Y=/Z]E\A##&VQ:'5,">]
MKH[7\A1B54WE'@(&EM>-0Y6"Z=9?UBPBE!&(NK/."-U_9Q>0:8LO:$<?^<]\
M-VD_GU9<^\5VDF=87\\=XN!6?@\3O9F;IT2LA."2?WLG^NCOW#"R/3^ZZ7'8
M>S;0O$A8WD4P9@ / .$JPC;RR\UYHY\_:4BG)L)I%PZG[*U!&Y0[(>]]NGG;
M>/- U>G#D5_>-:-.' XO.FM_KKRRT_GTF;/Y=M@@R[^L?ABZ_=3 T/K N62O
MD^>J6-W L_,FAN$AGIW2\A_)V<6&N4E)825[97M:/J;_@Y52YC!2K#JDWK$L
MSP$HTFQ6^=0RV3&[2CJ/G,Q6&O777,TUNLB)3(M0><_XN+K;5?:K0X)K2EK5
M#FWN-I7*A>\".O)ZJ#,.U!S^'@R=(>A8M_QBX6:/3BX,3I.Z.62073GGYIWN
MC*YL&3FU<]MA\4@HRO_[*.=/B=__F7R.(8 :I\@2@MH-T29 _U]0F<Z#&Q%/
MG@ID3V@V=U)(V7$,8UPC]F8R3C!]M#XPHZN_XJ3Z_K^_'G7*R:TL_>,F__@+
MFK[LAZ_,VAJ3]L<%V2C3\_F7;&BC&@<O8*<AZD^@NL9!JXZ)A[,_?[W]8?&=
MO\;IJ>,OQL75$5Y)C/9Y5=1,WH)5V-L>),# ;X>&F?2#I)GE(791-Y A_<0L
MXF6?$GN#FDF%/L%#:QUNEGVE?+; G8V[H7O.X);6[]5F 3>L]YT_^Z!_<=8L
M[9U19N?E)]1K] #<22LM)W7F;8B<-ME^_JG>KI._!?GPB!Z9^_XNEI9<J#\=
M45'UNEBV_CW-_;JV*/ALE7^-T9:*,R7GZEUV#.^K,/7XS=CUS_ZR._==Z_4B
M-YWTS%H*V.Y:'*/8^Z%K3D!9>G;HGX7RC[?=M]Y%91\Z2-E.+0Z^>GRW[MB.
M<B?A[L]_VV_[2^)]:J>7]&K.RC'X!G2V#/92%/"#D6D\BX)NJ4(XM^ZQLEV5
M?_<6\-"]JM%4T @@\4Y-/>LM13@,3FE3HXAW"!H+2'57*3L9O:NI1Q_+8FR:
MJW\3U!L(?E+]Y_9N*9*'OZ;XLWC/UBL)60GW-A(+19ZD+#%PEC.*O:3XS8)N
M/#V.!.>9$;'(Q%Q.$MZ!WDO7!]4ODJ!ONY4OU-)&)?Q,&#NQ.%!SF9O7*??1
MK)8A,Y^00M*B*[YM8+$HFG7[*=*IFKE&PG72';8N?BNU2H+L/(IS /F=JXBG
M3A!2* )90O$S]T?446E..]' WQ\ZO"+A=ZF(P[H33X=I(:#9A#]+L@%L&>*R
M-2(8!B\*0S4N<R!A*_XP4%6<NTUM>E>@VH;?='JT#S.V]E>!GJUB'>X-D"E_
M!VT 1ML)]8TL'!EPZ.0#;ID.<N83D"_()+;*#<TZ69@V,*G5?T.OTL9I#QTY
M4#>9TUF@-3QOXTIS*/,=H5IP*$7Y\'=9/I4NDYC:LCFV;(:1@&G80]C!]9*P
MMD$K\F.*&AQC95<( V76O\#>',Q 8:\\@0)J:'M 5FI$YL$1*N5[T+B%V451
MAX*D8XTI1?VP(S(=WB4S#CK5"]N47-J;5!1/K^_;Z/G'MAMM;6IJ/;(2.M*'
MT>:DM)@4 ^XME,XSU.ZV IRBBJ=/[^=O)4P4B+7HYB%-IOGS@EZ0*&37D02D
M^!CLW%%%0E T^OXJ8E-.!F\[[0P0-+==(D8^R#N>O=)I2$RZ_C[.D6+(>P)Q
M9/.IXF?\.8>5+1#!!?R4R=M'.ZIXC#] <U84\$RH0<(E><$!<&.6M!HU8=;!
MON./A%Y)S%=\-?;."V8"[=HU*.WB;5RK,B%*L-1+"PQ\/(4V!N1EDI7P2@3]
M]WNZ5WY5J]B)?-E[5VB2E?#7>]D1=-D.A?G7#)**FV!NDX S1 /E7U%T<Y5F
M8J?PUS,"B2D$#!R 3;8<%A0<@LJD_#NK"&WZ?JIZ>XQ[6?I6G>EENWBZ40A&
M;5'AZ<O8[%8<JMP#LC,BU(WF8OJ=@8:21]0L0:1HQ.@BCW$KER0@9HJWXUS)
M$A)T0,E:.4([QNY2&O;#F*KCI4X3(H-74G%"4^9B0UH9IX.U@1KDF>?6T@??
MV!I^::8\U]JK8#]H.LZJ"C6,5YN]N7.M*T+3U0R!/$<\[0,'*,KX$T4Q%XI6
M]L,NJL>O(F&HAB(9?[9D)0@2R9V@E4=^4X<[:Z!^.0VRDZTBC#NI\FUIB\3U
MT[G#3-BT$O: _&Y6^) -&:E<"TG^^7HAP$\EU'*/5L0RXOG7JXG$_D@,@CHS
M(>YP(*;C=:#+*X?@$_T%*QWH33Q@Z8[2"&8,ED*Q9)#A"<:E--ZD3+ UH75=
MXSM /V%7.<TIP+9V0J5^WHQ .2>>@B4-C:6CI]8L^][]]?#A\(1WLAJUAI/T
MN@?;NT[>^"/HCQA9C?F7G#85B/"*5H[3@E<1B;'0O.1SB0RS$;:'^,7*,7M,
MIA)-FC;\<83^5$I,6,K%)-(4W@ME_&=#$D"<2;.0IL&HZC<DGU'Q9 Q??K^+
MK3O<.S+U2E%,Q\%^"C:#@DS"'\SK6KZUBGA&2.7N!\03PT(60NP=$FU(2* Q
M5KZ'W4%&O'(-'-<?Z6WQTU!=K!LF38D$.&TDH[?X9SR#,#N9?HXTK]K67#4P
MU]A]:M,?3T:]#_HVAID[?RZ5<#I9&LHW& ,31=,J@AQ'O) EY.$5;"6&WLE8
MC_^.I@EA)HPQQY0#@Z8@4C@_8B7!I/)VU0_^TVLZ>)U&$V^NYCJ7C4$9_O6
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M6"^ F<8-^0:HPG9V&@\!(C/@[6"XT,<NY?K"J,*AC;<37(]6 _2&,^I;B"X
M)0%+BPN4L@RGLT?0]R.WPIA,1BAC1,<%9,VB)CCJ4(8\#-0KFTL&A3)&O+!C
M7G,2?U#%[^,7,<G*K9 9R):)V^=3>6M9)Z#&HD['^=LX$V#T1+]-MSI+EYKD
M7#]0KSBYBG >G#\8,;JO?AMRX+2Y1)Q JB>DP<[@O#Q;D4,_0@W_-O7Y*S@J
M1<+I;$:B(,]S YA6DBX>0;O"0/M 6*EQ=CXG9XBF(T4B5:J-Q>(:@6IM32G5
M4C<+RZ7C_38*5&=NPP/IQ=D%AB-$6D5LV-*+I>O01\0ZRJ,J&2=)HG<.J[1(
MFG05L?7-R^6:YDKE2Z&DBA8%[0=_&NH#'Q<I>Z$,(*TTZ5P/;W"'#[)#]8>0
MN/7+)766YCNW8YCBW[P^<&X3KK$R^1M6$4'8!'&#61=%@[IQ5.*ETH!TD3VC
MDYWRK;H'^:WT82ULMO(#Q&]7K@-R4JMI<9'5[][03O&A,"D[5;F^ <HOY<=S
M=X7\;^V=6U13U[K'4T%!,(:+"H(D7LI%N;652(LQJUX@4DHC8J6 DK9XX2)D
M6V G&P(!D:L;J/4(6]T0!1&H0DH)I&),!!+8/:@1PD5"2TARJEQ$UCI@F"4K
M*V=QGG>?]CYCG <?YLM:#^L_YOKF-W__.>;\YO=3 OAJ,N;X0'7G6;J)),^Y
M:OP3-A07:+K!"S6Z)4I=$*=NDC4WRU!JNJ.9I)1)6$C^X1$JT;$K\Y3&(H>*
M1O^(^!;T"A G[?!U3>A=U*,-%OTYJ/>VKS^II%+G79SZ:E(D)9@(M;+=F!7V
MRP O$F0C5O()7X35,V^34&-K$DOV&CV!E;XH+P#:@!X$D#&$G\1MT+9<K9]
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MUTZ/1$S/IF1DT/@) Q]3*M?B@^D5$BQ#_90;8] O811RX"= XY$&END'&L<
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MC:E[2,IC@?2B8BB2))J&IGB2[;DN_B?G5U'GJPCXJH;,*G9N2P.-)8O7!,\
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MLD/36:N6MW%RA[BHK<4MCU5+[+T [Q'$V5#B.\XX5"VP'IQ@U[IF0Y+0-BF
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MH5'M[.T^V=NLY'*.;0MP@R3.O>;=_IO%L[[X?M!A_?'OU[CM>#0*4DP&XKP
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M8_=E('GF>38=XV? -)7W^18H;<KP=/D5MN!!=5*.?;>(#M$WBM@ NS8&7,\
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MO.2^M9RSH)O9>:TY6C86+#NM6(4^1KV,0J['GP@ ;ZQ\=0W.#"<KB^4 :9I
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M[H0)V,BR6?S!,Y1?98N.CY'#T:\7ID),[UC&UN;D,-!FII]ALN/+PO\L 7\
MG/VRN%) I1I3.4?AA]3=I>7FL7!PA IM1G5IT0;'Q06"G NI#Q3QS6T40^VD
M$'>C*+D<LJIY.7#)T>'8 <B8=0M_F.(A>*GA<,%B*B;=@LT[:H=TXPZE#+>F
M9-%P0X7&++E 14.QLEBRLGA41R_@ZCPU1\AY8B8O3@. <T#O+&?"4+A)YD;!
MV:!#Z:H0P4JL3?@\:< VM)]N<=A)1H3K(1[2NZT+=E61H5C?U/Z:],F.U<-
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M3!H7$\#>OQ<\N)D\Y-X&O(-4QLT<:7V[$, BD993$\<11HYB9@,P R^A? E
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M.%V,"K[%NQ'MBU A_)YY&RJN;J$\SF3 "&-006YSO2!Y01/I6&*B4GWE29M
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M0$_>Y!,6!RRM-6\Q^EE)5\Z,<_B,)0M&I]/?NZD)^CVU_ =%RD ^,+D:-&9
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M2X%=Y=8L(FWY "#1.=(UGV;V^0/G0JYS38 @^7%5U311:\.3639DFC>3NKA
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MXJ4-1,]&E#U-F%&EPDBNUL?DO>\4XN/;/>+CHT-\_%S5><4UB$()16:I%M#
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M$&2)DT>??[:=Z1\6O/@IGZNW0Z,K6O=7EO^A#WKP_\>AT?A5H.]^:7HL_Z"
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M;BM8Y[@S4VN7DV*EVEI@S[;G#DM<!TZ3'#@G?<%MB]5=571DK:56L IT^PK
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MP]I8JK03R.TMR<#NU&:'O-/CE0IMPPM3A\.@WWR1K=EH,:VD=KW1>YH7%T7
M?H>9YA*[3DN<:Z\JA8J[7'[?/?_'[8K2(9;K/B5BVOVM'!C!E"1N(Y]INA]%
M32'P=9CT@(88 RMT'(A2K=O&"#&\QQ6Y/]DLJ5L64Y-CCHM]G,K!J>AL5BM=
MMKL-BOIN#XKZH*"H.WA'=L#0<L1Z6P#QI!F)O S4:);F.QP]MR^(0#MM#9P9
MM,#Q,9N^?M9,<#D%J ;(M,M& H,AK6A6IQM+%"=_6LCZ_R<-5MJ23R>3CD/0
MYWG&1;]\>IF/GOWS[)65C'AO?/W/T^?/'G_#E )T7TZET7V2W)HX@->YYG;$
M*"0/G3R3^;5NY+,^^Q[YW0-L=WX2P[%CL\G=AF!L[AF RGDSX4<;5L$IQT5R
MX%+LF&G13[=&PQ+]&]+8DOA,V^OR)<()I)&XAODZ!7<EYO[Y>+S/9AMGSCC"
MP3C0M_[IL5?GVN:]E/EEIMCLX+Y($M*Q,''9 D!DZ3KAKG$#H+D;"AB-1U9$
M%RVV63!RC6\<.\ EC=:TM#(@N&R.FJP<D&M+4XH]\>!]&1;E\G/(-2W0S.NS
MK<I5H]=).$Z09F4?&5WL%Y5\)-TV'/)V08@R'LF1\S& ^-RNXBU)\3S^L.R'
M\&/EC,07V<,3W)B1<C#V&LH24R$SU3R%Y('&V@:H]#G8M],<46FN..UB>=&1
M-\I&3-N&-AU4R6"X7:WMLOP+U1ZCU[9$IJM2SX/&@/):-\$79QUJ'KHD)-8.
M'DF?4,#D9JWO69E8MM&PN [#]&5S+V+\<&#1)3VNLRUKU"O6>>](5H,V,915
MW]F+R\OL.%]>^@Z4[)P)D3(VY#0[%QDKN-.+%JYL<L"0=LA*O=7%H%,9+M5[
M\2-AVT_^Y!*7-I@AII<P8.2&&D[)<':1L;_*+!YODDUI=EAGU/%ZJ'6?BJMH
MY>J-!6=.;(B.#T>_EI>5T-FES+TIL5P3"H5RY"2A42^&BQJF3L=8CR$QR'F9
M3].#*E;/I$,AL(QQWCXK%IU ?3T%FQ3LTV:+W_+8?47[CK&5]*QE*]WB$@ C
M=AZ.#;R5&FJDW;)BV=3T4,A3GE4:1DC]N73BIWB8?@!8T1?_\0*:NA.I/3RM
MLTX.M],+;)NSL&(_P=G\BU!;HJ,! @*U>2] W*/I(Y[Z"3D(9?@3N=\[]IB[
M.?E@Q37(D&F[OL-<PT(=?_?=M^RA_/3LQ:F<BX-B*'R)G[B&=!Z\(OSLI_.Q
M;Y=,$$01&"")[[C[ )&L-:.OWZ$?BS!V0C?%F3TIZ4\6E0K7Z?=,01L9FUJ\
M%8#1Z3>'\CABN0V%%I7GC*84%4,P)4TDSB;/NIJJ!R,CB*E9?TMN8\E<O]S
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M>K"F"YLX.EY,9@^$C6*SV7'OFD2HQ7\.JB&^MK!,:VJ_=^+N#>3M1O5#I;7
ML)^$:9>6:N!:3Z9ZUG]U*^9?J1(:7GPI9#K#>JN!KG$@Y?A]O%+V*(->0-G"
M-^J8PK=719<4[);5HS 97\%QON7@N"*HJEGEXAZR7VKD)%PH*0T'$S.C<3#2
MA]VI EZ3#PP(!6?7%3Y0C!U"]V[.8;+FY9W9^]HO^=N-JI?/&.HI#GT$AN)F
M%IZ!=RN2;@,9#GXU8]E'8.'4L\G3O/VVA3:9SB@HQL'BD@W7-90;["'Q>+/1
MQH$6MI>%2V8;Y=08ZS_6PH';!B$2@1E>UME2H' AJ;Y?5K>DVPEAEHAC7:5A
MG+>PAO=B7ZA"7P]9EO?C%][",OK7SGPRJ..';Z$^/3[97>I3&F A\IVZ)2/Q
MNUGFP,?'W"N]=^\\DW=EWSWZB)ECQ:0)%=D2".W&JOC*65D:+'-H\L+&^1RG
M+M,<CZ2DU[$6].7Q@_'1T5'4E3>^A:P6 D8%-/CEQ^!U.3 ^Q[D,937RHA8=
MDR=R;&7QJ!1/_%F8Y$C#00F/2_Y13-^'#?ICGLL;UN71$2],RS(:+2E[5EPX
M-W1U,YGG4M\2QB-.XR8[_F_-APGJ/FVN#TF6)RD.8;5-T?%*/].8S\+N2"@9
M,Y0#O[5\AGQ=K >H\M@I#GQCW(1);U*L=][W>%R+:L\]XMX0 ^F-.<F#BZ:8
M^?1JH6$Q2)1RCP'2LGQU-#4(V-?1#NL>?TH_S"%D@N90- A)GL<FJ[$!< Z&
M:;-,DP_X$>WVO<CM0VX&'\UPT3%-R 2M%E4G?4,SM-]UB]",*N&G^@_JEO_C
M\/QP]&-(X>R=[=N-ZJG X\9]/YOC+6: 71;-- <57%4[M&Z_<A+Q&$G7!1=1
M#D=/\0\FHN2$G>8&)>1/LHE)$B_MTS&Y90WWI=.5V4Y-90T= %:9 5N3RT>[
MJAS%<GUH>]:VD$8;3B>X_"A/"E<G- KEN!"MN^ZQ&*^^P=/1*(<HJMK1-&RF
M-UR.)? PN*2OZ\MO)G5'6VH]LJNOJB*BR 3[$!H2^HQ%&W # SJ*R/K6:-R%
MPR'>BL1I"1<(REC[7?@!JRNG9%$/_EY,7C,#-2W0CZ66LE.XP.,]+O"C$]-[
MY4I?O M>NUU 3LUK%)Z8*3U?5-+R)57G1L#=$B(G?*".*I@%ZJ/SPA:4K*/P
MFC#<%F(W:%SC_K=6X+J24ZSS95?FQE@_+:"4*<RT</'D7V.IVTP%MEN43'84
ML(_69&;L&?R:Q/OB[K4DPAKY$ LJJ1LA_]#T>-P#G9<4Y59E2,5([#'#PS!E
MEG00I>C)+T\>2&2BA\U$N0;QC'2^=)D*&G_YX&CP>U5]F97:_PR9CJJ\VBPS
M;HX\CGJ))B8^9VX,0)/IL70B.K66W1+CB$_9\YU_^NF<ZVY<,1,%>^&P%/?"
M^DN;AMY8+&[(+&D1E0=&1^U@^[GH!<!I:+1$PMDNEUUPN'%^, N9QR%>CM>X
M\:D/X9N+.\6>E \K-J>8@P':%MT?\_W'>^?_XW,[OOB/4]-;V;(8M)6!,0.N
MZ6MHF8TW>[VVP.(4#+?"[ID*AU:[T;YG#K:^W\VQ^>*-=I[:3]8K[3=*PO9:
M^WW2)@?&Q_(>VNA]9"F8 TZZK*7. U/E\0JS/#]HZ&K"7<6T&<DX]=G&HQ]"
M\SLJC &"U9#EHQ&=2S.*]()]2Y8U=%-BJQ^<;1QRX;J_4>QD:;1G*NRXY;K'
M]X^/'AZ>C%UCE>MILD*R"Y-.6[*OT/^SWIE>&$7122T8X_3-<2H?G3/7&0O$
MPI1:TD-_PT/P=Q]\Q1O'67^>.,CJRJ*9\]ND1T@.LZ%S2XZMFZ^L,_4.5S^6
MJ^_<-M]-X^,#FE#-335(]>2%#=)HEWZ?!LV&2]Q^S$::[I!E:&@=3GJM]TJ
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M1=D%X!H ^,#_3HZHH4^B15^L?7NT?3=58$R/!;",@L8CB26\C"0G:US2G/=
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MUF6X_3/AH@>:]Y_K$*>R!"=1D64LMK-@@LYF49?_8BZ99(VF V*6EXWJSG$
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M0-;$L"*\SY%Y5X)FY!PSW&;^%3@#.">\'5##\Q.RTLEK^JY1A*>F4NJ3$>/
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M >*0+TS24WA"O8CE[=Z%9^Q\N$^?*X47 SU^D<=+D3?'D]?YJF2!.?]RL@^
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M? ?LD/MWD.Y_9_3]>P<8Q0>%47RD'#[\HLN\):2C=UC9G:43;=5TU!;!7BN
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MA(IQX!TEXU(R&F1*.[(6JL$6K"OTRQUOKW@4_E3*#KJAR,\HKAQIF9N[0=_
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M-9FJ@6EB@"$]IBEW$F:NL]Y0^MW6<T? F#%?;/%BS9KIFNUG(P4%DI  )$9
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M!%',$P(LY(;B2I&];:$@X"D84V'8\_$QXD@==6-HC\-=]826J4_'VXMB'*M
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MH];ZEE.A&XA?M3$1<CJBR>K'.69L>G>PS1BK"6X[S&5IG0&7M,INI2Q#DO@
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M@ERGMJFI7NDR)6*FPW5F2TD$L"S-R=U[]^DI\;K.&;7AB\_S-A8OZ$F>A+,
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M\N<EK5XVJER'KZ*R,TP#T71ODP]"'I .BEAB+^95NF$;%(=*2 55HD*Q_H3
MNNP">=:HHTSAB[(Q6;SP=S]QR'-8)SF,6XEN[%,7X$L_6&CE9>F1]Y020]E
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M4@LHAM9*M7%H2C;2162/34A//*4%"9HS*K'N.)OC:/,RC[_"64JKO1QIS5%
M?3VYZ0+& T 100?BHB%H4+2H0,WN1%6M#ZPE/#ZV->Y1HP!]/Z:_[NXY=._8
M'RA78=1FHN$NQ&P*C>ZCO=7J[T)Q 8BK?.4L1*P[<1(0.N<@U:;!.2SL+4HD
M')$7!B?P:?#6-(:WI"K"J/,?*$6CO)S^66$H;!(1Z^(HS%0&U<<%OE>2W==L
MX=7?=8Q;!=3S17U#J+T1KEZ$#5PBZ,7TJEC0BZV1Z-J!<U$L9D"OB#N[;/?%
MN#J]*S1Z0PHIX0DLVFHL0&H33($YJ1T!SVDA[D*4HE7>/&PG04>,@U6L_=FL
MJ+EFY!Z@FF_< EL+'W M.E_)P&""Z8AFRN'*[>"TQL3@_6E?3WQSYBI.GJ1C
MB>P:I@8C69<244HAW9IA"8]35F3C=_;0434GF44#G!.<'M /@Z.XP-5D&H-J
M,J5])'MP6%$1:ZG"BNA&H4&$A0@E=3!J2NYD%L1/$Y F$#Y6L$G<DMOF\9$W
MA AE$4Y@SLOF.^IH)Q1;S1CN;01D#(OB))/)WEM=NQC5U!(28>/H89C2L8]I
MZOXV \^:#)0Y9FPYH7L#=*PQ,.$@L6RD!20"G;+8L0'K,2$\K%C&SXZX=B4Q
MT62+-8L;L1#*MBE*# U=@BN@O[KB 5;$[C:M%B)YHS^7)$\L_.\8-'J\BH0:
M!>=17*A:<#Z:X^UM>UNG*#HD*1^H%Z)K_\> EE(^%W-P&%FW;:X\IVPT30DE
M2DM)PF]HXKYY/=ZNQSD78_AD;(Z/  WA4 E VZGQP38;YC,&_:<DT;<RF,#)
M,(8O>;7N,=3[T,)ZBMXM'$+!!H\0L ^A D;0-+5JQCDOE/IZ(P&64W*<2&V2
MWN8D& W&&9;:.:1?8 ""M:W.<3-N *D4)Y'L.D !@A0RS*415;>2+VBYLGP)
M.-[*7X"/*U %8C\?:3A>-WMG J(8,^EK"0N2>O1U"IRI3!$7ZP;V.1>>H(&%
M*;"!Z];A-8++(SAZFIA)$9:1]A81UY& 20N5QJSC6%6 !-8OMXG^&0Y,QG6Q
MNF/&)\=[6+8L!9X'&Y_3Z'+]#3P^L(:RZ=;L:J_-A75DS5KS!>U)(=L,2S5F
M6" F6GQ]))>:N:$+^]6,E5CPZ4G\31F,RB ;)@9NV5I9M,WV9O,-E^Q@8WS*
M;4- 41C5OM"1B0P\ZI;)X'ZB^4+MG\X?^"O"[SQ/!Y8,K:L;IQ2XLW!JD&CV
M5!BJD3^\B23;>+D&JJY#G:)N>9=%7%)XSH=P'1SKI+^9*GDS+83FD H!Z5QR
M4/Q).'*D]6 (LD]O:[A ,PL;[I*- )4*J;%Y*4&?"9^W?E3(U30&$UHRZV:L
M7Y.I6#UBPDTU, 5U65$MY7L[L6;%J,A.%R'615=E80:6XT(M$A<J. 4:[J08
MO32,PZ?PJV+JDAT^MX;]FZ6+;V!;EDB1Y(^K]9TLU0C3 &,*=.F7$LU>X<==
M";"K^NH:&5G>L#%HQ@-B-87LIZ#9KXR,L$5E9JPI6S/6#JV7'DU5:L/N3KE7
M-)K25 ,"@E[8S[/67CLBL1JS:R5$KTF5&JNQ.3R*>=&7)M$U NK04'FD&/"F
MYTQ>N8.7Z2)3+]7$,@9. J&V ]86@,6X-X2DV.2AQKJNLORKU';H CEB9V<9
M"Y6M>>MBM)<G>2YR (DS=-_)9914D@! S6(^0O0HP[Q?=QS:<=<7170;VO'9
M1&F-<AT2MAZ*.AU% .$9.;K>NNR%MFFY5,\5V(ME2A+[![;*,;&AT'3$T2B7
M]<QK(VMFH1L7DQ312()CV$;);6'-[A8&FI0 CEN-X,B&5LMD =C;!DVZ5\[9
M45_R#J.2]"Y_CX3(%G7#:(:&D$C=8"!A\-LD(%"4#"!Q2(12RH6&8\1O!]]"
MD(P=.AI2$J_*G;&H8$V.,9^%N?O: UL-9@M5S 4(JL3MJ)&8DY>TCQ/'%M$G
M:G"8;#LS[K)U,(A-P1<$BX4T,/+:T*!)XY0).!W0Z8)VI'$MY$;66?J/[+$D
M637>XN$N+=?0ZJB:9P' LLG%<@B\$+L;"R>L)^@TKJ= 8!N/UPY<I!5+A;!1
M[X$8XPFW5U/#2>V/^A8G^=X.)]MTP)AD.)H954@19,ESFM'+B3M4,8D9:Q,>
M#J ZD3UZ8))\H&2*Y,;9@%M"'ECV<<F!GVQA9 :6,S11;$T\'"Q*K,=NA!ML
MM;,F4#VMN<:T;E2<JK%GX'I2T,S>N43[D5ZK4IF3^1^,RQ!M"I:\D'"H8VAV
MTI-V?JZ%O&LP3^*V759)*FD5=#;*,AI])<=T"O^0),%EG--@!8V03EZ2F 0@
M!3ALKC'QN5@!#RB9P">R'ZRAU6OQN6F<J)KW<A7E)CW/T0Y:#L5^Z&T4=+?<
M))X:Y?99.$D1 7:(:VLD7G3\J2=*E>A7U/)@V@H9FTQ$H_R+]4NF4R#F&::X
MB0]&1I"X)V;&WLRK(4AH'"/#)X=^6$+P]Q2F2U3*,3G^?I%!CJ"R,VM$M+E+
M;(:A>.:,K50A3E)C#F;:2@R>#%4?WQ *S;@=++49YD2P7%_&^*VP%JTYZ^)8
M!Z[^?O;I^#AT$<NHV%V/',"2M 4:UP8G47JAS" $)W FIF=;>$>T0!._QD6B
M"6OM'+JH@U&;%N$!^7*Z6W:5I/Q\KAA15AZE<V.H*V(NJJLU1')4ZQ91[%";
M-_:]#".%4^+TV+'K=D/!+J?=<.$\HC7A-0(BO<"4Y%DH;5;0@K*M)O!(C+%(
M\!P?>*6&:$MH&X*((QK#D<4D2BG7*278;?,E6P=.A;I6Y];&N=>PM[?$&V'+
M^K0RH6QM3\HPD@+'XNF1?UO:I#.FIF.DD;203%ZCM?BT0B.8G;&D4-Q,RL*_
MY*G.'$4+I1ME'(\,P $\<9)4W[:#,ZK@-#EY77JL!X:8J6CR4;)*^B(J)V@,
M#Z*T,GX@4"OI%FW;.=,"S[#P69N>#5EK446W.  ]=N:*Y.2J<)R32U4YZ"CX
M/;77W,$1W0X6 F>-F3P:WI='\C!BMA6,>#1.U<F)'&_P243Z,0H>6/_)R:=C
MO:PKD.0@LLE[@L]V;H>?!KW^H8&AR%)N2=7,>T7!>=M^B8KT'U%:H=_3#^'>
M06^;>872-/S2:):A!"<)A7 3%P3Y3?'B@I/\:NR,7W2:2:S2I%\["]5D3*.B
M1L[D(0?K+Y+JPN5J#:^XP.BE%'&:A_(\(0SCHH4Y+[>DWE.'ADW18MMS0?L#
M#8U-O+V4G:B55H_1"D6E@F@8=!AXO:AL5"QH'1<T'1W+GZZ VKA>(05K=L*-
M=+"SYCVZF(V>3"\% @?C(2[TN+@\F&97^&Q]J<-7[E2E:TI**&18EBFFH-9\
M2+.6,JNK;1RU&Y<M$^1GV1C=*NK_%%&C0SWU(:"U&<%V%I]3PF2''YEY?"@/
M4E%K=FA0]Y1)-[MT/_,04\>(H1T5.4^DB[FV4M4 :HR<Q_0AC:1T&L/UV;I\
M0N=.[A _&>3?6TQ-?*/"*=9B>J#N&[SVDU5'GPU(+HFTW]Y\^JQ%FA2HV:9P
MT5K\$M@*4%^4< C> U4.]D*2<Z'H$I,=<(!RQ,1#'4!!R=3B-7"*4E[P.Z>.
M3%RD7L)LFF-UBFHBU8*-A8'3DTMN&S]+MKK@_E*[W;7DLQW0U0BJUM6/6W3M
M*"O#O([68N6L4ZK6)+4SQ2;4UI$Z2_K):;0UQ76L-2=!-<>W[OZ(_^9F;7A'
MBC$T<&!3*BO1Z/9S+*:CQ]CW8I4);N__^:_#G?W=7P>]8(9(K+!?/]$7*GP
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M0'62]%+FZ:)+N,@<9A"'#']IF='EC"<RH59+[+9F$(=*<"NA1.TU/H6U318
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MD7QH@)1T9VA,'S/)AF<)K9FT-[<V8Z%A3_? 4),,R TYD+#9/\.(KS2+9T)
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M[_Q7EG^%5P:C:!Z74;*1O=?]@Q[HE6?5??V2,KS/DZ@.T<U89;:9IRE/4\L
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M[)$3QPK7 3N+A$ V5%K_9&95DB5@"L7P*+8LBQ).55T@(<%)%A%;0/.,#Z:
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M#%H?^!KL#-H(X\G0BE!<T'; '=C^@6M@QBQ"D=[LA;A"8\$DY8^GM -9&+A
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MRO7!Z-YA]2)>37S,:3\3VD"(T1_8&VMU(';_.P79I8MB.,M\X?Q0W31DH"G
MDY66+U"7##AET%$PN<P$;P:>?')BQ@1LHW(&UKY@FM5G;.Z;?&$K8@FU%Z5D
M7:4\^N\G&$*)6*Z30/!FU)WHV9+AV&HPC*FL/.C<&Q/^@3%9;=!@M3ZBU7F
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M0*^ M.]LM>6EXU$W6ZYUHR+0X%85*N:;2D1ZH"\7P% S13FMOC#DUOH3EZ&
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MJJUF]CU,'+^*TISKF=I=_K2F88J3#I[2-'4M-*OU3GW-)@/WPN=>S+D+3I7
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M>OB?6G>,7_GB"E8<X_!!FPX4[NGJ>_2XQ&L!VX]XX!\&Y^34OM4#*9DO**%
M@)4/_/0]NP0@$Z=+&B6'8-?##.'L@]MLCF#)NS( ZF&"\#!>P50 ZB0XKK!L
M5*)^*LUM-"XM'D7YA#W\A # DXG$M0A2L8OSZIZ#=^2'=5W=STGV>(IA+9#@
MR8O@CWAY-K3P$XX  )92WBNT$;QK5E4$&["N;/ANQK9)S X&5<6LO2H\\1G+
M"/CD+;-)("&<]IN),Y(<YOQ?167PJ,#UEDCC"V*X\#W*M^\"B.WW$ !P,KUV
M I<8^G\[ 9./FM#WA\,?;&"S(*-<Y S^+8M?-=VW[$D23,!*6!L8' ];;^F)
M@^-V[^TJ4RD%C)H16'C[]M/T\S-VKXBI#1O?<C9>BT64R9(O2JD-%\*V I$T
MPN1!JUJ!FVU:;9WCEF;EFY(BVIJ0O('?S88!R@37B>>L6^,? @R@:\='>:-F
MB,\=/9]]XOC(Z\F&H??S %?D*OBH93H![  >,1-D- &S@'<MPD":<2AL4O\V
M8SI*TC1Z?!5V7X)+>\SPZ\E#-L-\\R.W?O> 2*=><DL /G.6R)7A:&*@0;=8
M7+6-$NLY2.<"^1V@NEB2=R>91V%Z-5]EJ<#U!+ \L(4G0@ 7]@+D>%.#KZI;
M@>#0 ^4*,8TS!U;L\*!QY(?(3.&4XCQ%3,(H(IX96RGL,6(N#$S<2ZR9XWH^
M77IL67_)A<"JTPB9/+[1#V-TOL2X%;I3[^D8:?*!D[@+?$!N.O<&:6T,^$9M
MY+SI=(];N>_8#.FV"U_G]7=V<]VPA\%-4##1MBSTQ"?LP9,O)MG2:=$-RQ"G
MM7N.#W"'[V=IDD9R?\?6"2URW0;EC@!-'-=-%ZE/3&<J9I[KD4'TIM,#"R6W
MYF-K!6_738-?G:UW<#>>;P"'!\6,#_IW'JF'+,$R.YJ ,O'CR)G!DMX[_HUS
M&\.K?IU'<C</6Z*<#N@\;'ETM36/Q.RW@U_B\XN/IYWQR;#;/AUT3EK#X<5%
MK]<9G;:&K8LS^/M1.^>%?*=AYG!F9_ #ZB8:#LY*]&#=@:WLU@P*M0?+GR_%
MB?Y"UN)[XIKI5_ST8O)OKE7$F!3[X^-N@>YR^&]P,')E7SN>3V"+Q'7H7^,;
M$ 2DE!&S89+$:Z4W%31&4MN0A02P<:O=L4!Y2^8Q2'??AU5;<3I#^H%5(04O
M!+ +>AG0*/H;D,)H]1$N/Q+LMT"EQ &^ DIN4O)PYG2*+\P=?F0 -'Y$*_1#
M4!^BHP0]#KX6?;DWT/)<>)H7L-(+?\<>NXK)9X[?12F'%  J8>0D801<EI@4
MO,EER$\!$'ZXQ(=J/[>]QAV=_7Z_/Q5UZ3#ZP:=,XMK.UA6+Z-J3S)P\*O@<
MJ47=6B=7D:!=6H>70EB?@2&"@H8>=X1["K"@F$I <3TZ !99'@88$OB"(60J
M><G<B^]4Z."\%B%IAO#G0C8AFH1I<M\:W]EJ?[QS6!WP:Q9["DIN&"U#\A&M
M#<4@CER!C,2H#$M2%5TYMOY/> .'%!%_7X#YX/AQ:*6Q8+P#N% ,!Q8?J@B*
MBECYM$14.-73\%P2([!CJ[.(\6Z0[=/4Q3-"G+P)4Q\ S;JLMIM,+#RV/LUP
M5:A3!V%B$?'1^;HHM Q!-TM9,;^9@X81@/X@IGH_)/'AKJGPG5M$3UB#8,W"
M#9>L6@#3\#W ,P1B&-!6Z;S6XC)LY2IR%K2M<FP&I$T\PMF8')EP\%=A)G[-
MR%B<@9;W73M=KRYJ>\YG4J+(?V5[^8MA+Y^QO7R)]O(.PO597"H!^1&&AN('
M=F8JIH3BP!>GUL#N@I'9:K6L>.Y$K-P6/1,.D,\5<&Z!FG;!DV%+_HF'-,H_
MJ?BJ=$G6A6#=_@96+*+X;[^,.NWA!^!X(G(]CJ/.4I!9;%U[8 -(LP1H#HRX
M.<9:#8;![[)1BCH<#-?Q ;505@U0.^_T^>\E!M[QQF/K"PG4,G-%^VIN!/*H
M)5SQ$PR=!%1V^<1V=W@\RH(<I%@"<T'6B/?I;>*'J1=3@#>6P5IE\?-G_2[-
M^%&Q&1]WU-,?P4EV%IL_21]9MV5+CUX)/O?M8;^U(7PN/*EF^-QN;1J?^_W,
MR?HD= ;Y1T]>A]C=XW$%Q-X:5OXR(O(.9?/AJS<MO='+&7H@F#Z'U](XLS-'
M"[D+2!672'^7UD\*\:4'X %R^E_']\6M=>H$/V1FSEVW8H+.30S*,1(7>YV
MG"DIJILC GJ'8[WI&-]:;&_!XTD?U/%>MAJ=M58E_B5? K3;RD7'<:_?]'V_
MR_O.I#4:IY-_L6M(KDCZCQ1K6'^GD_G4+$PRP]]&_;>4[@6G[*$B[KB2E".P
ME\&RAN\D"+-0-@:M'0YG&XS/]<-8:F?W'-:Q=5KT[=UWO,! 4K*TK"]N$B*F
M=%J=SLK*)N31TS$<XIO73N2Q@4_&U+_1G -0'7KOZ*U@Y47)[=$45*,_CR^/
MX3G!%'9$V0P30"!6.ZUO<#,=SN^?3K]\LZVE#_ARZ,%#>L= .QHYT*Q=I M^
M&8"B?]SKOK60)SM@22Y@Q5\+20? !=,$3%"V=3)PK#M'VN3#]TCK-9;;/>[?
ML=P>Y2*8R_V++36R'Z491V&T)1J5 5V&IAH[9&\QO="2"+%V ^14).U0'N!#
MLR5DV(8E5!;PX\_E#D[^!!C+?U"NQ2/$S"LZO]#*Y;06EM@&DJSDK618DX&0
MCAS(.5)Z2AHL'6]J8 YF57JSPFT>DKZ\D)05FW0/E5Z#?RX\PHSON;P;]0,[
MF1@% ?^D-B&U)_T^XSX/DS"GA#5PO!,Q0Q.](!! O2/D?=-OW?L<5E6*#V#-
M.F"'A8=X%!:OX9P:>(]>=>?^59>^;0S0 055:7((0?0V^9:Z6U*( 77^(DM#
M>M/.]'U\&4:I-:L%S/<]C(CPLH@Y(O%-)17GGXUN". R>N5\K+S$.Y*:;N1^
MO>E3TJGR2Y%D71;SF,)[T!TDPQW!;1EN@>"!9:E+,^(H3=CB70*6QOG\,!=+
M4ZS8G8,VZW/(2BY;7T)ZLCY4 @[@RZ58)NH;$#X[J*P^QZKN4[_0'^UXF+4-
MBP@7B(T1MG6/T0M)CC3 12>*T'E.QA#:%-?*X3\5,R?U$]"*T)\7HT@#(HC(
M%S>%<T:/)SLC9:9\EH >@IASM*<N<P?#@IAN\66(<,#/\,FSF4=>WFM!:PC$
M%7] ?()[=<;YZ@_*K6PC8:"*1!D)8'-=>S&_)[N4O*CHMDPLRFF/$[#[9/A@
MPC)6!P6!">#-"^>',#V-MOP9#W("AA=O=R$B@ +G\$>9^Y=3X@&V#%VPY98A
MJX9.'(M$/1X0R0.TF!*L9!8[^N^]2<H@Q!0:L$4 XH6PKI(W\"017#E\$DC?
M@;C12K%Q*A$K_JSVNR)"Y+ 2./[8<?E5K+O <?CH#*?M DN$\W=1J<WT8WVW
M^"ECOWA$)^O"07D6)G-X<G(7%=\WK:QD1 5KR8A6[G./;J,U(OA-]*B_WG&_
MK92I@<IDHEW?\HX5Q$UJDMLWG2EP6)X@U5#=H&)K/KKCX;& ,,":08N( !?@
MZ0ALQ */G/()$.6U.*+ &)HR'AZL#GG,X"JT%C#T!L]F!)J+XCM(44$Y,A$<
M")N2N>EHGB*E?@R"1Z)T&BB"5!&\TD"D>JL*U)38I6I:!8K)+ ;Y .T?= $=
M)'S3,TS'57E4IYC\L-@0JXG);V%,'AV*X01>(^7FPXQWM!\YNC>U)K?(H)&C
MRG05A]VA)-](X%B'P*XEGT#9 23C)FA-@+P$B9W<OK/+>'RF/1C<OG;*T+;X
M$\^0I5V@7VP'0?A<@C/+\J6"710<F OW'W1TJTCXC'R-=Y5XW)F!!N8IRK(P
MC1W2Q4 !AI?"0]Z]KQU('GE0J_<;5^<*]%N*X<D%XV?S<0%F8_AY)MGB!@5\
M,"XP%?GK;P>M _H,RW35YY)=?O<6<(R?067]!EQFI9W!C3=-YO G[$,6DKMX
M+LM8O%=_F&"GLO$#W3-+]U1K=P[6M]3B=PSZ;S^HBXJ_M=?_-*YT5[6?ZO>N
MB@W*:MJ?K(1?/ZAC7[O]Q)9]&VWA(E7/%<7M<0I6"2S^24SUO)RI;JY[W7,C
MQZ; \2#4Z+X"9CP"-,^&*RAB][-A3LV.OEK[E>?$BRJ]/E\<%@W2U MIRN;0
M;'A 0EVU$FDTIC%G3TOO.CG[$N^:W,LO1%&O-Z2L4E>N^T[]==L>=^U.M[/[
MS;Z;9O4-46X/4;:[=K]2Y\J&*ANJ?!!5;F%WRR>0["MWM3S$MI8UF"_\NH>^
MP<D"VZ$B<\K&0U3D+9]I=]CKV,-NE;:MNR.6=D#Z;#L6MNW1L-<@88.$KXN$
MW4J2?GN0<+_\793%.>7,ED,IV=^I_+=-BO8MFY?5[@SM3J6YW*_G*:@ZNF.7
M3<Y=Q<_^V.Z-*XV&:M"S0<\7< E4&ZB\_?Z]2B,O7CY=[:4ZR&:9F%R5]$7'
MU4[6:!9/2?VK34/(9VD+>E]\\F'-9*D*I&NTXY!5/]P24#<$-&9;4/%/; 5A
M<$1)H.[<B:YT7X^164=W[P@0JK[K&34H5 2UC 1VAE(U*<XB!.[P'X>K#[D_
MK5[&FW:^= ]K%0)9_8T9V(6[Y=R-3FXZ"/"7<,:]QJC()4L*YY)3Q\>*C S@
M5)D5B1C+*K &GDJRXL(Y</HW]3+SN-;)DU,Z8,-&;Y6LQR1"*/)BZBUA41EE
M-H"CI)*= #[(MF+G;L!!'[ZGNU+T<E4^JV-$Y'+QXE9V,:S.B61J>SB;(3@G
MMR5+HZI<<YO<BVHFJ(-E)&05:+]2UY=Z)OAN$Y6/&.W:W:SNM83,L<?G \E\
M8%SY8#(W6J-4(O/V@\D<JX%E=5?V '/8S@L3/5/54+^^=&J2HT=,Y.A]Z=QJ
M8F]G?-@N4F$)&8]*:3[F(4I<"YUUX\."<GH$M9W%.I=L+^N83RL[T36<(K>G
M'$MJ&]A [ZC*5 S -DSE!9G*D)E*Q^QXM,I4L$/P@YG*H I3&;TB4W'RD\;,
M&G\1.#YV$ FIV2O!E[KE1^+:"]-8-<YQLIX_O+98ME=@?YNNLF'-1795T&OB
MDEULSP6\;";)H9\'R"2A]EY4QZM&B6V,J_4-Q:*<JSU,C>GEVG,%Y9H,1AB#
M)(QN)0/)\[<5_OE _M$V-:B'J3MEG#EC0M8C*J/WF@UMB8WZ20>VG\-&K0TL
MGUW0E"4(/,)&[74R&K-5KV>/6W3E2L?U,Q\VV-&^>[ C21GCU>N>KNIYN:,'
M_$1->&E"A_RYT+20>U,X_OJ;&W7F!;%,V4B&6OJHDVX.ZP4/:Z@.RQ#=<O:I
M=*+@,W,JPB/)MDP1,#TCY32MYH T*+('>L&%UM+OT MJU;6DF&,];;J6K 1E
M'MRU9)_F**WDAI1EA#Q"EVMWAN8,U8(REVL^CF*BO.NSMFI+^V 7Q])Y@>X&
M*'O^]?(3NU=?H!M=8T>7I6X,IGM;4QL,\\4TO$C_*ET8QKRG\\72#V^%X$[_
MUE=UZ5=?-MP]O_SZU38GLB HUPBC3B_O3_6I3:;N^&6T",1ER9%6U&I)6+GI
MLH9CM)%0+TP/4NOLCS.OS0HYF+W+-T@-I*\(; ^H&I/AK=R>]$W/T'0V3QOF
M##1$>165N^.=#F#N%3:1%TG",UW*R4)-HKD;STT2 T7-"Z<-YE=0WZMB_5#U
M'NRL0WKN2Y[A@VXU6^S-2EY7[(!;]*?:!=>L?(!:74D[5OI)1#1B1R-'Z;,5
MON8"2N68]T#FO4K3/ [KAMDZ#690K<CR6QS?3:=WBB-%>H\EYETDEF<P&>B;
M0B<R^"IRN /<EZSUW(Y-[]Q0WLT]7<ATKSP#IF8[/^>.29$OTGGL==*/5N\W
MKMZ3SF.=UL'Z]'U^1V]7NH$U[VHZJI5(HBH=U<9[T5'MJS(*/J8"E;&O9 !L
M3[GN'K92JUEKI LO!D!8V)J/IE9726U_A19T^]U>Z]71I(TV%<[:V/-2UWJ@
M0[U92E?BRE,*O!M<V1G6T2<WS:FX#8,R1:7!B-W'B.]AXOC[7)^>E8JQA]5T
M]1RV7ZI_1-/X;7-5H1V[N]EFC$W-\BMPYH;$:DQB/7LTK-*IJB&QAL0:$GO0
MCOIVN]\TAFE(K"&Q9Y1B[<%&^P,W)-:06$-BYAWM@=WO[(:F6-.P7>5]_A[B
MDDKZ%,3686>-WV/+^TK^[9=1I]VIPD=JR]EW@(%O.5*U[<ZH2A>R!J4:E&KX
M5(-4#5(U2+6U2+5UPF]OXIJ7JKV-+K? 4@LO6>0*5:OAXI:UB>W;@_%NV*"U
M0MJZ<LHMP\ZV/6XWV-E@9SVQL[K6V.!G@Y\-?C;XN=_X.;0'K<%.8.>NQ3_.
M<H7U6?AC)^WTQOFSU4RO0:H&J1JD:I"J0:H&J?80J5ZT04 -D.Z^_=;?!MCV
MZ,FZLKC'G5P73FX:IMC3YBFHNA:8KSN*OE*VXGWP>4HZ8S5P;(S>1W:K4V5H
M<768O.[Y-VZLACDTS.'AS&%8I>M"PQP:YM PAQUG#I5K_1KFT#"'ACGL-G.H
M7*78,(>&.33,8;>90Z=O]]J-ZI#W3)K]FE_>B;Z!31ZVWUG?<.1L3 UE%U[@
M+=*%,3JU,(9"]M[/_\PC$V:.*^>4KN^NOXD5=]Y9'XMEI'*>;396P;9P+-O"
M26@DP+43>=3O.\(O/&QP!C_SY(#U4[1Q7FY@_;<3I$YDS-U10WALZP8!X^&P
M>YSYTS&&-?!\GDYQVIJ:^:#G(_RN9B-<JMD()]EL!%CC4N!8"N'?'J]#Q%^I
MD;G^O@CP+6GY_FSC#/(MZ+[,9D<3QZ<I,Y=S(1+K)(IP7G!)J<)++W<3,'N.
MD_Q+6'/G6EA!F%C4&I FI]!@9!H(H@$:$T = Z ;G+*QTVCY36#31>N$YS(C
M6_T:A0'\[3(<'SN.N7:C2<Q5]4:;616PY@LQB11O'M@T+>;BY/*4)DD!EIY<
M_FE]#H_IUZ..K:%8Y<#H\FR2XN\L]@Z_ATO/M4:]K(O!H_>!(^>]F!:+H].]
M!<XT3ZR%\T/)5R\_GF@11L)*@,K@59&:Y8-#0YT(10$/_(UP9B<($"M.)W'B
M!'* #_RC1/9$X CS\"J M= $,%_$L<"IZ#19RXNL F'3G'4\9I27::PGS-/;
M(Q1683#-5 8UM_S6EM+94!= UN'*<4&,\[ "5"%PX$E!M4#P"((.3EP"K9 E
M(EU.@MQ;\/#T(,#Q*3P+"W=WY04!00X'068#G-I]'EL&POT$M"N4\PB9.[%G
M=-1N/S/ZO+>^.]&50$!\6N!<MKQ(>C16@7(R]]PYSTO# 7J6HW?+R,,#9!<B
MF8=3N!CX.N  O%,B&2@YSG())X1PH3%.O&9$IJD3$8[2--HISUNRIJA:,>I)
MK )\<=-%ZCMX8$=\=' ],@6:004R!)\ )TX'I= --*5(X%P<@(5P(OPM1L4-
ME@C7XTZPW-!UU #<>Q:888*\%IZ)U8J)Q!5+*K\\$ POD$/!<%9; IMB4699
M( B%#UN "Q.DV%4H$AXB/ A]SO!@D9J4!JDF]]!E1$TB3GU2]%RT=*8K:G>.
MW X/OGWY\^ =DQU-_*F,'6_&V7C*)Z!81M<\&(Q6/A6 <:@D1'+<6?55]K+Y
M9$]8I>.'L*P;+YDSPL9Q"(>;E(!;L2PD@"<MO-T[;C]YY8!R7U:0AXR.N5,<
MAPF8L1&\:&T +R1^:RCG5[HQ&+<V@!PD191,\F'-WLP31)RY1<=RBIYD6)KE
MP?HEF;.4*OF!S@I6Y2W0%HV0J7@@J8$1LIB5D^D"\FT0N#3/X5EVA*$T#$Q*
M^4C,!? =$(%^&,?V'3?3I+LYJ)@@ ?Z+AGC+>=[K;W%Q..*,)T0_8!8N6\A*
MLA!N9BP2C6/WAW,EYXFC!H,=X<7/I9AZI-8N<59A@E>S6P'O,;CJ50I+Q$-
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M<FPCB*2MB[%!U5QJ"L?KATO=FX0]P]+2=*D#@,--3/)[IC8"JO&M1[YX/01
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M)2:R46&4;!W4^(8=5AH/X4SB=*E2(*:A2VUOV-&H);G2 EFZQ+(3+N6]Z#4
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MJIA*C,<0LTBVWS@ A)JD%H^!]H(S0ATRE HNA*G"#D)SXI\(H'XD5P 0 6,
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M.=#2?G3'UN;.\D!<ZUZTOXM\DLUFJ\OPQ6\Q8VVYVD05<!TN!\2$VWQ>EXD
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MA.CCKR4]@/ZMYZNKBRR<[BR_+E?5DR9^S%AN#19G!@74:N>LL5(8)PFS!&
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M'VB;5.U'("7,P.>024F.I(!PYPMO\\UDL2JV;?&BA;[.+P(US;_DY>5]3O4
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MA^D:K6'IU K(!75(*>J A-095?<,U0+<K!,K^?^''?O_/;Q<QQ5^B!+@0Q0
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M]TA0&?"F40#>KFH,!D'Y5,3U7Y$"IQ*-(B<I8>D8L'2O^&K5AB!"B?<:40\
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ME/ T$#RU6K=8RSG%- @IYY$4SC$+*BN/4P=AGWCJ3[GLM8'+\!7((_>>;HO
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M:8#PX4:5 -+G>8;RYQIDB.">RV8BHDAZJ>"=P*V9/[91L*4CFH^8N:G5+9#
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MJJ=GO^6<E[2E)EE8+E5V/V-9,4 X\_DLSZH6Q-79NF]@OM5,QK']E?0"=I>
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MS#(\R%-!1GD,F,1OL!21-K!108>'<&VT29G\X9)#=Y9F*G:"W]O^I1:9A>C
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M:488(F'X<>Q%8;A$&-OI>>[KTO,.1Q%'H><YG;U'#US3C1Q=350]T<W L\T
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M8_'.9^ EE4AM&*T +LROP<:^HR3G5HB#)B_K@CPR3]*)^<+YT\@NSY?/=[=
MNV?D2L<=/*2=@H=.P4.GX*%3\!!&_^P4/*2I[YYH](IY?^K/647"?@OW9!(E
MNA%JKN<GEF<$B:.IFA#$>AQ$LH'+U/W$3@(S=BTK]"/'-T/V537VPR!X'1:J
MCUE#O72H)V/(5'C:K".DT".0Q0 7@?ZP0MQ,;)JP>Q"<Q$3X=#9>L&@R0&PP
MYYS\-.TS:=-4^>6B84TQRI[=!+#1!-NQ<JC'CBJ;G*78E/ZJ+3/'XD/:MP*:
M6C1UD[**=%)[5Z::C<AN 5\9I$))HQ",1G@$. M9U;D2Y;,%+N'AI0+$7#SC
M0N4I]M8L=:="O5FR9'7XLZD('-[SU0K?\6=1R 8[X^*B,9>KSL8+YM@2,3F\
MI)\P,V*:'HN+SWKKH@H&L.QQ,S!B40P0.RP)LK9C,.\V!@<-#(OM-^8S3$*L
MNAI$K2*_[A!9LDE&I@<>?]C6Y!9$*JI';#QMJ=81P''NKKXK%[,))<[!#IZU
MNR=L),(R,,>8&DRK>PWNE:/DTA<9^<*4+\)^>'2,\3C9-67 7>=9&T2+_#$;
MLZHI6 ^V:EF'5%F:?J6GXN_ "(BF/TVG^1A[6M]=EV07R^YJ*1A$]BJVY,ZL
MB+W(WLZ(*'<=$.%KY'*N@0N(CGK,Q$L<KGV59,X>6--9?V)>S[0S-2,#6@KJ
M6U5 >66]_^76!YBM>[&X1.;+^2;%%JQP"<C9,"*L1?0:7Y'HRQJ,PT3@!X>T
M>V!SU(2>1]W]#BL170(IBWDV6^>-P![/9S-ZF,>N$"<45?I6#8@6 RD#N5\)
M0<S+/<;@EB>AXX_976?N^ER518D1"J2I,*"\#5PV3#>R5 "_26"X@6.K223
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MM#J'\;!A:P1RXDV7$'IKL:<MBVR;:U%W0T2ZU_E\3?#IUH4S7V4\.S$25^W
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MM@[,HR:I<4ZL"6%Q"I/?C4%RN\A-.O1Z<:<U3S;RIE<[,7$LJ)]>1>)=K2S
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MGUB'41.W_4KAC%^FR[LTG9>'<9L8)W6JWV]I18!9FF9'TYRJ7\W8"8ZJMAV
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M',?*W:7]^YL._!)8^7$14SA<&_NK@1$\^>C.$\]?^<1SRNO1! @K)B.$(Z0
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M9IW"J%CH+BED\PO.1=Z^D56WDUN=+234UIT-R)?/+666W<@RA^&9F+[]:W[
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M TRVG@T[:I=EO\0%V-WH95W>>5FFL2IX.'HAJ=05K#9:'QEAXI#@D,@PADQ
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MV*7W;S>%BZ1U,0NI1 R)X0I0$$>: .2B2@8J!#D/39?Y0+PZ'T!!#L,%SY)
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MI B:KX0"2PY?X7_G13KJ)"6/NICG[T/'R,]W)[?LI2) ZKPWH9G0L>0:<DF
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M?%EL(E@7V\,<&RHC3 T#7##HLO8JO<F44>UBL[W\!=EF\*9[V#RUJ*ME&]>
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MJX=(CJ^O2Q]]Z9&]&=F\V?G$6K(48AUSB8SDD89E2FND#:O[NK:"['9V_-%
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M0]>$$"@= ::U%H ;:6W!4A3&D+'M+7*VBL+.Y_[THK 7A;TH/$]1R$%=9])
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M'7UXMJN>V_6QWST*3SB0L.^0V@>K>W [<#?/STNJ 9.4PY 38QB195$1J6-
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MYD@"-"W5]NEF8'"WW&T"1+U9S6-.8Q+BF'".,*!<5!5W*69L;;/Z^:>%GQ;
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MT933QIZ^HP_S#?UNO>X_C#[IMDAM..SV.\;K/+UOX7[[TNG^@]3N[DB/X=V
MU/\DPUMC8)!>'UX[PQR/6:'F>(IGMSZ>UTY=/]YCVIS-J.FAJPR$&QX8PW"#
M.0:PX Z!JZZ%SKS-G<RN?Z%XK/^%.@Z=+'+L(_9CW+_WD"/HH N\.667;//Q
M?FX3,^ MKWV8#Z!Q'.3XEUB( -Q@DUG8'=N?C_AX+-?)L<BCJ?7 (A#@.IYG
M.PL^3OC2V$1_&#H3<^@,1!+Y=0SJX2Y)YJ:TD#362]O;T4N;/1+NQ; GWI(;
MGI'CXXO.UX,PR@KN=?%-E'KCX\A@)AWN_>1WXI?%(]8\G_B R/O9<!\>+-]G
MY.+7,(3(1 ;"R N\DX57> _L+1"]7%^<+1,TN(W9%7%/EK><38J?+=_A"=T"
MAL\".M&S*IRI$]>AZ#S]:7D!+"&.Q[T_[HR=Z00?X8+>T\V\]".CCYD%M A7
M,M\8PH5\[]KP#B>?;R=@-5A@X686OQ;S5_/%)Q,SW$\LJB_B4^ 3'EY[B-/Y
M/2;U0'F< 3]XM9JO*$6E5-&T$M!4*;[.*UY\T2NNEY_Q;^^^=.37U$I"/.8G
M3Y[9 .[=36(N?AN$L)<"I?LTLY$B*^/MEW]H!;9<^LP2_-S2H]64-'_0FYA2
M25WS3#J%)'V9H>\==N#>PN9,G?-GX-;UW,>//S(]6;&2/7RIY++G6<[8FIGV
MYD59A^1]%_YT&WL?+W)&%:R7SC22 &99!^M,TO>>4BA1Y^ RODZ2*DF5I$I3
M"6?CB]$>WI(O1J=C-/],*!=(*^D0*VEK,G3<,%I>E)91!BR$,S:.5N)!DK?&
MF;0;LDZ?M(ND6BE)E:1*4L_:+OJC>]LA=WE2;P]NN[V$LD'6V/P-=(L[:DY(
MVYG0&64Q@*1I>70<N-O"[N62IF27GK')\X<[=9A<LORI.TO>(DN;((7TR?63
M-EW:UU22*DF5I$J;[AF;KM4WFL3(DT;WUNCDR-=\,Y\CS7SOMGVWK?1&$I@B
M:TS_!II&P@RZK.M2TJ [,>D>G3"AY$ZI$Q-*4\M.BE#*.DMG7>A*^J1YE_8U
ME:1*4B6IIY!/&,R6/=ON2ZW?[A"C-AC>UKXFE 4^A,53%+MXC"67(O(2)9Z2
M;L:E*C_MB^EACSS3#Z;F@^3>,Y&LDKY4T"<M-DFJ)%62FE12S]5BZW?K1G](
M!GEB] 9#HWVF-3I2KQA*JTU:;:FTVOKN"$;/!-#,#ZAU4&4-R<$IEJZ2OE30
M)RTW2:HD59*:5%+/U7+[8GQO=\B7//F]VV^>:VW%U*N%TFZ3=ELJ[;8O]*?E
M,/$#DO6P>HB2?U,L6R5]J:!/6FV25$FJ)#6II)ZKU69\KW7(']V.,4CH^DN#
M31IL29%-TF [(=W&3_C"'ZY#?<FZ9R)6)7VIH$_::I)42:HD-:FDGJNM-FQW
M:AB8U.E^K^5([S;?3$HM@$2@;XI40VFT2:,ME4;;T'),)H+<GR:(H.F!(DCR
M<(KEJZ0O%?0QB7,3F".;1I^SU]AXL"'UM=#65$WY]10#^N^1=_/;ZGC8"_]X
M?02;TNGBS4>HJL6U^<+7_PC?C-S)XK?__.^;:?!@__;_4$L#!!0    ( *V#
M65![Z7B?#@X  *14   8    =F-Y="TQ,C,Q,C Q.7AE>#$P,34N:'1M[5QM
M4]M($OZ\^RMFR6TVJ;*QA8TQADT5,>R%NMTD%<BF\G$LC>PYI!FM9H3Q_?I[
M>D8RLH$D$"?!(:G=@*QYZ>[IEZ=[VMG_Y?#5\/3]ZR,VL6G"7K]]_N?QD&TT
M6ZUWG6&K=7AZR%Z<_O4GZVZV W::<V6DE5KQI-4Z>KG!-B;69H-6:SJ=;DX[
MFSH?MT[?M&BI;BO1VHC-R$8;SW[>IX^>_?S3_D3P"#]_VO^EV62'.BQ2H2P+
M<\&MB%AAI!JS=Y$P9RQ@S>9\Y%!GLUR.)Y9MM;?:[)W.S^0YKT98:1/Q[.AB
M(D?2[K?\(S9KE;OMCW0T>[8?R7-F["P1OV_$6MEFS%.9S :G,A6&O113]D:G
M7.VY=T;^3PR"=F;WB'K,?+;/F>(IYIK=H-,;=;N]]G8_ZO;B_JB[NQ5O!T$8
M!#LQ[\<;S_9;'/^[6=5?U<Z)5*(Y$<3+(-AJ_WIUNWWZY#I"I9J(7-IK9HQR
M;$<?5[O6]G;O/DI%QJ,(LF]:G0VZV<6>%1>VR1,Y5@,G]_F 1,1VL-W?PIA/
MI_P@ESQ9'N\>IYZ&D4XB+% >(0O:F\'V(D?WC/CKA/XA$FLD$1&+%'4[W2\B
MSK^/WAP,WY\>-1@[?CG<O.?4[K3;;7;RXM6;HS^/7QZQX>EF@YV\/3X]8EO;
M>/'J[>D+=G+PDOWQYN#E\/AD^*K!A@?WG*?'CSI;>[O==K]]=T*_B(.XUP34
M[;F]:,_W0R(+NM.[E>;<2-%?/ \G;+N!"-?N_SBL^WU8_Y9%(CG[CU!*1+,&
M>SW9/-QDG5Z;#;FQ0O&(LX-SH0K!3KAB?P XA=*$FEP6V^T&0>^'@#](T:'@
M.?-2;CP0405WI.B=8#P7K% RUGF:S)A,LUP8 SP]E7;"9KK(&1_)!,@=0)>K
MB(F+#&L)%8J&>Y[Z)<1%* F&6XU?H<417C(=QR+'WTRD6:)GA-<W&?:<Z$S0
MVBR6&&@G@NDLT[D%'79&2XP$"W6:B20A4%]N@Z3@C('.*<_=/A-^3F]IG?]J
MJ9 !,([_6"K2D=^6J(]UH4AN($N$A97G@EG!4T9TC$0B!3[ XB'(S7)]+B-!
ME MU+G.M7(:!I:<3&3IIL)3/0)JRDNS3B0>S8HC,939LG.LIY(;QB<#8,]KX
M3/@IN1P5E  9(IZ8-D488B91^K?(>3BSPHD'\FS0@%R 6_R:)8(;+ULO42*$
M%LBT3ZEHA1.AI,[9WS(4[#7.$(PHVV!OA!$N.E2*]\FPQ.O48YYF>Q^=_ %;
M/!>)SOS)OR=Q@;0,,I!SI8J1R1E(4:8\QUH,[""5XF,2'3$YA")P-?O-T%3/
M"RE$=+DR$S$$98U72*%,D?O)W"ZM,-8\,4Y?4P&"\.?68O%\':N[R\1.)'C1
M"4Z6#G(JDP2LD?[3":?""8J9B2Z2B"EMQ15.G!:F.I+Q#*H_8BYK]>;I%R+V
M<Y%PIVX3F4'*N4XQ+A5.^>@G; 7I4B1$:I@2I(@\F-T"Z*^7P^RO)K:<3LA]
MY*DS6G>0WB))I3CI<I+HJ1E\KU+L!16)<-RPO$%SJ[,:P09DC>\OS2$4Y*DY
M,SSA^8RD_:^@W]A!-H?P ]U7\+().4^.X3S+$AGR$7RNY1>E)5  FR"5 O'P
M#-Z#N\417#(N(_+K/ QU'@%@"1_O*C<,5R&,Q8+23.!X,SZ#O2;,A'@JR' I
M2H)_N"LC4MET]"3WWGJL$U&(L%IN__M&>\,]FXR'U?,GU+G8U<TL-K-1-7DJ
M(SL9](@S*FG9B%Z6O[3<T(7AYP(^*^1)*0$(9>-6E:\%)>WT_*YWT,&E2I@G
M^V8B]SY"Y1<XU+F)0(N!7L;2*;V>6TP((CDT>R24B*6E0 /0H00TM80W#D=4
MBEXB,R'F)C*?2#&&<-B$JS$F70D@FPYF."-P:,4(6%28%!$%UX@$U6#D(X"*
MR!S/)4$D'Z(S3I*4F8M/9(>+4;K;#IZ</07L 1"#4S5:JS):P=]B-%XX] DI
MP"\L6G9<Y(2<L#/$D AOY3!2;,DMH4J%8S1^8V?R+PHH-,$D@!,$P>M4P"EL
MRQG/#Z/V,>#K&_7.'8UZ:UV-&I#6QREG=( 9SG3"$@&Z-PAO,N(S<YM0ABDA
M8#?"[:FS65I4.Y.I7I7Y'*P,K,/PBX02PV4CK1P'TC 5C9":_;"<[\QR.FM@
M.:<+.OE<4VD ,>%0(AY:G1MH)_1YG(MZ^FQ @8Q!.Z6._Q14<UB,2&5^[@L)
M#NI30)Q7$ES]8$A)+-7KK+<WEPQDR/NUT=D$(5'&+KV+1$@U!2SIBA0U(ZJE
M?[#[<0YR1%4-J<C($)3  CY2@I!O2/L]"7Y]ZO,/45IG)).")B/6P]8]E68"
M.S;5..P)D,I.K [/Z@4'"JR0%=X*1=B W '@-* "'D:S):._1L#(3$DX"F>+
MA<8%X#JAXA(I1Q"B<.FH3XW*@DW.)EB 19PJ'G2&2/]#QZ G^](;_E, /Y3G
M$7,)Z,_S,V'9.4\*<3US7LBT-KUW<FT0FX $R-R<3_L$QKR#9.=PGDZ:)4-S
MRAX_"OK]O8J"4MC5Z)*&6.;&0J1*.M 1N#S&L7]9$/.("*,5"UK=_@T+"@Z,
MX[,>B@LTPDF\T_.?_L M'_>^6]_$^_;OZ'V[:^!]CZ_"CC]$!,^2,)FF$J;G
M_%C"IXN^+B>OFWN77!5=Z^6MJ&SNH,Q?T%M:OC(=5]@DG^V*?0XM42EQY@SC
MTJXJQ/)6N;KTB84_\$8MS=K9RJ<2M+U($$4+D2\J9+#37JC8]&]W6^V''Z_1
M)>/7(F"I7>:;=>Y,\FJ9C(]%<Y0+?M;D,11AP),ILH6-M>DL>C"Z\TG&W;_&
MVRR8]LZ*:K%S]^N\=UH PU#-M%8^JCMK<OO.UP)DLR>=IVQ$K7A4FG6I:>6V
M*SQ&P*_!2@Q3O\_PX(Q&$9ZL.?+Z1<;\6O)'J741W;BS_]+H)EA&-]W=.Z*;
M[:^(;NYZ.7X-NB&==6BFII[S%Y4R2TJ*FH1U/+8O"ZES_8XH9Z*!KK"#5(2@
MT:)!-/RJ^)!^(JMC(2_*8LWR&Z4A*J11[(6>"@BN<=>K7B2L=[[3K.,N4V?5
ML]=8$!#!/^0UQM]K$O?SFW>&>3(M4F:GFDV%.#._E0PZGX$L+BV0"?F/Z#'3
MQE"Y[$?^\YUYB-X:>(BC#WB!NQJAN;L1^KZ4,9%39(C<+NY2L8O;(J?@VYB7
MD!,Y=VH-%V\/;/,=96='M<+$4*O89UM(Z(X5M0AY2$"K'*MS>H.G T-[."DP
M]^H@'TE;YGX'5'OS$G+W-&7J1[T:J:9*B2\]D_W3_9#QGH)?+@G(D'%79G/]
MV*YYQGG9^?XIA^>(?,_'4G'ERK&X0M!4T)VQ@1=1S4B:,-'&RV=^>* GRZ5P
M":B\9+Q,'WU!T5-76%*T#[##64"EHLZ>9]S-HDP5,M")ZP<B'SF2OFC':Z+3
ML6,4%&8%%>IRZ;[B0#X?KUZ]/=ZX"27-Z:RMEM?VEU0,,V$N1_Z"S%^651DS
MIZZCU M71)_C5[\*6IT?!LDZU-GL\E(0? I%QUOULUUV;$!$!\XV1#2?9!?/
MM@*^Y=7J<M60:I84M;57.E_K ^1=ZG=;4>?%JJ2UPF:0K?:*>FHTX2R1+3=K
MN7.JNM_<6?G&+^XZHG!4B;! &I7:4M2L92DCD>@I-94<P#>X]A#*/^!#)/7I
MU36#K''F6],([55%HNNZ%^E:3+JJNF*^Z7HK\%W7FW=O)?L,V$78J90=,5!*
MS/M]."_KA45:K<KK#9^_0:N5!I(E\0&$P4U#F9,:,Z>7\H5'UF/A_)JS(5+]
MN9&8N7<C[T-W(WK!>5KOL^%LJ9W1N9K2[S28$>Y2)2\]]+RM:LF'WS-MO2:B
M0"E-D8D<RN1ZCRK7D(NR3<@[9@=@+P7GFR5 7P,9LX/Q+)%IV43;8!XH+RYP
M)=)!8_-"6N_])!7[SJ68NITPLUE37"7&P,Q^'6KU* \4+"*VTGB=\Z32_+EA
M?9!"@@UEHE,WD7GP:[C,AV9!W5RWHJ0K*@BAO&L2%TYSX58K.BZ=;^F:1U3F
M9:_B&' _KUWW. =,@E^#4L#GJ>QBM]UJ=/C=U69JW^GM7 DOJ^V7P;*\HT)&
M1E^>A/)551C*9*N;Q 8@8?CMW."$4[\@M,+EELY<^(BP4JU+$[I'2NL\S3RP
MQ$(D+*;B%1@D",U#Q'[8F;L)3&;$XTZOW>SW=YL[.]O;+A']"_!"('U[+M1_
M09QB3Y;ZB)ZZ:>V=YE:OU^SOMG=6J*6+]?P5=;:N]IL[:TEBW=2NCQ:U_1:F
M+QLJ/=<)4I1!) LD!65OY,K* $O4^J2_$VSV.]N[G9WM7_=& #<B;X8Z27AF
MQ*#ZY8ID+@L(& (JU.\;P<;-]0*_4]"&S#\P:BEA'VEK=;KD[R"1NHCJSW[\
MPD<N'QR4M[JUD_D"3OT$H1#X)9DU;DJ'OB-F6Z;%GFNEI& '4.?<:/4 N'YX
M' \G4L3L:/ZUJ!)E?2SA7[K+>U@AXEL"Q&MO\WLK@H0KA*W?:RS=V=WL[FX%
M_<^-I5L?C:6=6BB]4L:_59BENOB:N*.#>9>FZT%TJ8B(!K>Y!?B"_E=CJSC1
MT\%$1E#+53#\^%'0:^_=*="LT;&>5/</MSI)8K"TL9+\(+M@AOK=V:.V^[,N
M B XM?B=_^_]R%_GTK4RO^3I@SWUAW7BA]P^V)/NM()V:_F?7?GV"<-RP"K1
MTZK*X#<&KX?$ZW=EPT>JO A?_OKZQRUY33@\G-\#OJKN ?U-QWVWW6]BKVMT
ML+=I7FE<W[ER8]_*JLHAW_RJZ4MM>$_ZWG^J'MP_V/GSOON71)_]'U!+ P04
M    " "M@UE0R-,^-6$.  #N5   &    '9C>70M,3(S,3(P,3EX97@Q,#$V
M+FAT;>U<6W/;MA)^;G\%ZI[>9G2CY$LLNYYQXK1)IY=,XYY,'T$2%%&#! N
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M#.1 R(]-C)Z!,&"\$C#V#%<]$_X1(^,: :)%BI 36R<)/(E<-P&/R (A=7"
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MNO;Q<[Y=<7GORDNANSR[7GT7=?4MU'_JA=A7TX)['_AUR[VH?/%_4$L#!!0
M   ( *V#65"ATD")=@@  $D]   7    =F-Y="TQ,C,Q,C Q.7AE>#,Q,BYH
M=&WM6VMSV[82_9S\"M29=NP9R7K82E-9\8PLRU--4]MCJS>W'R$"%#$& 18
M)>O^^KL+4C+U<&+55J(DRDQD$J]=@'MVSX)@ZZ?SJT[_[^LNB5PLR?5?9Q]Z
M';)7KE0^'G4JE?/^.?F]_^<'<GQ8K9&^H<H*)[2BLE+I7NZ1O<BYI%FIC,?C
MP_'1H3;#2O^F@D,=5Z36EA\RQ_9.7[>PZ/3UJU;$*8._KUH_E<OD7 =IS)4C
M@>'4<492*]20?&3<WI$:*9=G+3LZF1@QC!RI5^M5\E&;.S&BTQ9..,E/N_>1
M& C7JF2W(*R22VL--)N<MI@8$>LFDK_?"[5RY9#&0DZ:?1%S2R[YF-SHF*H3
M7V?%_WBS5DW<"6H//4];E"@:0U][=G[1:+QM'YW]UFE4J\>_5;NU=\?U=V?U
MVMOSB^.+QMYIJT+AO^\U_9E*ED+Q<L1Q+LU:O?KSLK@6EJQ25*B(&^%6]!@8
M$(?%4ZD%V;[NLUHX?N_*5(JA:OIU?KY:_G:<B1AHR6"(_ G]\J;VMGIR5#NL
MSRN]X57*Q#Y=9&%) C!2;C:R)M<WO<M.[[K]@5ST+MMP"5=7%Q>]3O?FES?O
MZK5?3VX)7/=[4-3N]ZXN :,WMW^U+_ND?[5MD[GM=E#%_ %7ZS 3TO^]2V[;
M-V?MR^YM^>J_'[I_DW:GCS7U:G6[+> %1/9*Y \N7 2_2G$V*9& &R?""7$1
M=<VMGKZW&:$8V$OS^%UR_Q(ZU ZG\I_>]:B@_??ZN_ZJS![J4?VD1R(ZXL3P
MD>!CB*,N$I90I5(JH3#1QA&MR(4V<2:M5BW_071(_L,-#2:.E[+BG@H.ORP\
MML$DZSN3W(!)GE$+A@A6%T_(G=)CR=F0ES++S$V2:>!=2@/]@Q&H4&"Q$Y(J
M9U(.\H 0>FX(9DI)#'=&@#6'-( B0W0L''$Z:[?40/& 6TO-!)O$](Z#W,*8
M%LH8* ,BI2>5( ,;!,( (85F"KJ#)HP;,HY$$!&;XL]#_S$W/!\$)Q +*X%J
M(GD=H[,WW"8\\ KBN FHIAE,<P3=&!E,BLOPXP'N: >X+PDX3D*AP*01'0\F
M7 *T07.H-H5ZH4(($A13/+@.9,I@3(!)P5Y+ #%AY(0D8.4(4 2NE \(S(W?
M+H@&D#.?.Y:P12JA <!. S:\..OU":B-2"CUV$XQ:?A06 >)IR,4"S.]0<M2
M 5IVJLR2MC\>NHYWZ-H NOISIIAG9C;'3T[IT?WK,!1PNV\/,JEHK#U"#?>P
M #,7 \G1? D'+ ZDL!%VPV8QA$ ,@WC/A VDMBGTP^!HM,SPD1@=< ;%ENP#
M'!@'?&4VW[T/(JJ&G+0A[MRDDMN<ZAW1<JVQSPOZU!HL*SKP8PI,!U6&4)1$
M,$P5@)L!";5:3V2X+#($D3CW16!#"R2P:Z1#"648;LN2ASET-H&E=?'\9;2B
M!SN$OR2VS[D50[1IS_(^#[T2$M" IO;I79 )#CB )Y>4<4N=&A@ 0MA(6!\8
MH157?AS<'7@(J<6P;+BD'HTYN7S 42D/V5@I(+R"+E9+P?S6JDT'5C!!C< )
MB(P">Z*@<*34(BWU[LQZ#NO#J+8<%'(0MK%30L$-!*FD&/UA6EZ)!WH+/3*R
M7.3X<#7@V! "-/3G;.O0M)T8'^PPOD&,/SGD+4']Z<'RR8@'+S$2#(%,K584
M^0&UX 0P"T5T4\.F2 /L"SH04K@)\N-58M'O>%!ZO&4N8ZYI(8OU-.0^GU"2
MF@3P;CV?#P)MF%? Y[-#KH"F2X ]U/ $_0DV@5P]@S;X'9% _-\Z&&TGN(,=
MN#< \>Z(RM3'.K1_'H:0A(H16*Y=D4S.&/P38G=VNSJ_](B&CA!W;9;%#G3J
M'M?@*>R"SEIS3-'#S^\AD<$T^?=.BF<K ?J<X.#;9O[;"4JV ^7+1MS,TI<1
M@[N\>>+H:U;"<HTXBTQ9!T%J$!<%6KIBU%A;!^7X!A3&L@$,]$\*K!:&WG^D
M2P@ APBXT#I7/ #8^0UJ-?^VY2#3*J)VQN$Q=GJ'P)DG%7X]\H _(5+<<9GO
M5B^T+SU[B9[C!.K'6^($-J%#8[=5M@'@/V^KS+_(9%/?47J(;!AHB_A]"'*(
MP#48_5+>/%.10N[LM+$S$NT+8,@X%LYQ_@D:,=! T[&>"=#/#[(/*(>H;9$5
MP%_,X*>NB?^3"E#?NZ%4!7[_^V"W^[7;_?H*<&U+R DA1Q6 1MR,Q0W>0'"
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M%I\JZ'?@]PU=#)!T5.W$1V]TYA^/C[V!?SPY03V=33\,3GSP)W?BY8_C<]_
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MVS;R<_LK4/?:N9N1;,EVTM1V/>,X:>NY-,DD;C/]")*@A(0D& "4K/OUM[L
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M-&D#W*FVR81((=:3.]@M<-UFB8W(FAI_MLZP'[_O/^X=KK:?@=&B[@Z,NU0
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M)."*(2]RIY&$$[-@.FE?SPCCW>D0 <EEU@ ] XA9@Y0S=L3D:['-I+!WVMC
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MG/R]551W14B0.V,P;^/XB]-DP3D0JQQ&9E*B/FFL[<$?"!@U[CD(SW*AH=T
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M3L/!8AR.Y4/+X180W[^^Z&5F#LRC_6SM?6@Y?9X^3V]K"G;>UGO2K@@^L9#
M(:1$",1$DD@1$9"&%>"\@;^F'B>5<ZJ27I@8FDFY0''HEQ_N7Y7T@L7@7,J%
MB\.IP)IG5W^ N1ZD8.K8P??IK"G]+(;5[G"G-(_NG104^.8M:#_,C$0.I];\
M K(LEXI@K@53/0ZVY"DF,  R1N58-O/AN_7;+1MHU?.%"UIP$2+RR<,"28P@
MEV"0,># ,:&>B1Z12O6C(&(HYF0YWOK""=/WMB7Z,LY*Z/LQ6>.=<?TX@Y^+
MK8GSU*ZBLTG]=7]G75L*GJSE9VO]\1</GMP0X-VYWX(2#^0FC"2-&K$V5H55
M )P:(8W @@??Z63 OX+?^PU^9T3!3Q8L_[GLG#R!D?VA[:<PCWJQ[WULRAH\
M1-_<5EFZ_1=^G\P#++?3;_X2?,?X 73?:4K1KX-M7D(*@2DCF#"4@/U(FZ@0
MN#X8@27$#*7<B]3)H!MG5MH='!CA^Z;^4H))\.;F\[3UQ.^C-4=^5G[95+&A
M>R>%CS@H)QFR3 (^O7%(F=@F;6)P^B*G.AU\8?Q#!E"=<69R20X8!/"GOHKO
MZNGTZ(LM)^W>XZ?Z04KG,K?GC9V6?CU0M^FI,$H&9@1'5@/_-7@MB"6"D6FS
M!)GV0NN#OQIS+ @\1]K(K,UWS'#S)8MK,-:E>1';VZ.XMF 44H(D*&5D @6[
M(/ V10Q''3O=N+9/>R@3L$;B9[8XL2VK=DF<5Q]M>_72H[VQ+K>L=NN@L!%+
M;DU$2@"?1;(4F3:AV:4(1B#%4HMA*GZ/>8=J)DB-QM)LQ\LN;1-!CH)U45^U
MN^^;A-+J!D7"S@1-!3@*SB"F4D \P*^&&FZU,%H;?.B;4)DP,Q@'LX:C5W#A
M+BAX'RC<%*+NTD=!A")1!8F"!-9R$+<(M'M",@H=+:R?D'H<.\FSQ94)26,R
M-5NRY0/E>YZ6=PE7%\?U=)$2?[(LH[HVV[QC%X77S%@<- HI6A2)%2BUF84Q
M&1&5C<'X'COE>?;(,D%K1)YN1M87?S-;X(70)5K:;XJVO$A9@3<\;S%]6H4Z
MM55'EK54WU:SV("O?%MHUU9AD52V^-/[6-G)RH/3@_1;,,DTJ'&"0*=3%#AF
M@'),D5?1*9U(U'U$5IZ=MI%QM2]&YTL-?AJ&>9[CO#9E>'/S ANG7)NSDH0E
MR',109P3AS27*24NJ<8]7#W]4QGF(S%T?W"ZRYQ>'S]=VZY(U#&>=$"4<X$(
MC1%1+S5*%GO!L0DB]C#2S4\.H'Z<W!]RELG5=W685B99;P6I+AT6(7D79'OE
M"TL68>PI<@$\8.F%;W<S0R^'D."?'&PC\7A_*%S0_7U[<0?8K>RA$$8F3K1!
M1 CPF#&A;6I00DIRS1D!8X'V4(J$_.0X&XJI^[>SEM6+=S*REFT+92B1TL$R
M$A*,3!$3R/84D+?:"9PDMWTJP)*?*IH^!C=W=@U7$O.DA''KMM[7(EP9K-JU
MJT)*K3PS!LQ'89"F5"$J@ESZ)9%XHOJ45LIS-".'!YB'N8/!J*P>'S:Y%8_@
MFJZ_?V+GOHHCS8]/C]21T5H31LS)\1O#S?$;0D_$V>E9'XN)_Q2:+!=K,V8D
MK&)7ZVM,^V;-K.BDP DKJ[%$E@:+9" :665A;2GP9VP@B;D>(/L!TN<.(FMF
MF)G)=KYU>5G5I_K( R.;>%>'-4[_WM33=<C<U+0PG(!EJ2F**1%DI7=(2&K!
MD2;21):,'.A:GCW(O-ZS_/0P[/#,W!N$7CS8NPV87NP$V*Q#DK@-Y9$$;$X"
M?&3/4.28FP#JAHMARFW\C+ :DJT9S^#[&,/T#+BX(A6C*\*Z]U+(H*RBWB/7
M'B_F7/DV%QO,4B8D#UXX['H<Q=RKR3\XPD9EZYY-M?N]T3ZFVHI."A)3,,R#
MH>$,1M1*CJPQ"C&KL$W6LM2G!$0>@/WXIMHP,[,/,?AV.IVW1PC/T\/[.3I*
MO]6-BR2T<UI&I)V@L"9Q0LHQBX3@@47%A)8'7T-ZK(E>(_0&X^8^<?2V J;8
MR?NYFY3^'!9< \S:$DXK^X!E*RSA;<4O8L%X;8_E4ILT(D**9$"]"'KP=^GL
M$55#,37?D<%E6L>TLVAZJ0F,TILV_1])(322+FCD6)!(Q4 \?*6QZG$*:+_)
MRD-C9T F[AQA73H;Y^FT"N>+[)]S0.W%2UG'&]L427,-4K2]*MUHT/M$(D*)
M6D:'I992]=C_VV_0="@ C,'%?6BB=_'"3C[&V6QR6Y>@H_)YVJPPE'%G-$$R
MJ82HCP$E%R@"+Q:607(DN1[1@;VF&(^I;P;@XSY5S/+ZAL4.P7?HKP/1%KT4
M3D4LVQN$N-0<,689(M9*Q(E38.=19DB/:BORIY!#>?BZEY!3>RKQ_'I!\NFW
MV/AR&D-'\;2R;9$4TXSY@(";''D>!++*<T2((%2:1(+]47.*QY110S$S<[6?
MA[5VEGN9\-?%E0!7UTV\C-6T_+(X$/N8S(P%>'[\L],CG8ZZVWK^/J8U8U_Q
M=*&#PR3(@&PD;74KEI !O8JT==R&P"VE!U_)8-0Y?:D :"\>YC-%%O>>ML*I
MO=\#I,#L'^7L\G@^G0'QS>FW93BS35J _\(G^VVM2;)U;X73VF.)$\+&L?;Z
M$(RX#PY$H/).1R6B[Y/5E@5?O>?\F0F2@X_9*N(LCV4MTX377]?S^-$"%B(5
M23(D<6M6A>@020$CS2T+1J>H^Y04S;15.C0\!N!2SKD_3TL\;YCX^^<*QR1-
M8' AS E%T4K?5CC0T'\,$?ZO$COX0'Z_25HQXWW8D['>6H1W72ZR)+_$2;W8
M-EVR8*WB6-.NB(E:;R(,$,N$')=@>3-MD+$:3&O/78P]+BS/E!8V)!R&9E>V
M>@YQ,FG55A5^L\T?<;;8)]V$C9<;%8H13PTPS5/15D=U%DEG#8J>@0/NJ;?J
MX&O.#PJ,07F5K71,K$ _3MI:-^&JK,KIK-667^)F:&QH60C-);6MC/3MZ<GV
M]DMM;$ T:$=]5)+V2;3*4_=C4'P,S[!LE1C"_P/KMQ5S9W73L435BVV*$*D6
M3AD$?*1(6J&18M@@SY4V0AD9^UQ6D2?&/B@PAF153MORI&RBG_UF9[$I[;I+
M"IX_7- 0H_)8H12#A?ZM0C#6A(CBG@<OB3<]?(L\!3<&MS)[\RC?6;O;@@R;
MM<23)PLBHTD2N",$Y> ?.X(4#!)@':-1DN#H>U0[S)=^FRVDU9^!N4!Q=V"T
M?NQQ;\;(^H:%LLP:$'N(&@K>NL$1<="&( ZCXT0H,*F&2>3X21 S.#OSZ90'
M.QJW1 /?SM/ZN.>:5H7PVC%!,2+>4H2M(0@;L+ 4#I)J1C25/=+'<L4R!AI?
MIECY7B7S6,P:0PKOU_$="53CR9[LNZW/+W1_88=UU/M5GE.1\<H7^.Z]O8AC
MON1A>N=8_1\W,92SHXLF+KAZ$F>@@%_:+Q_LK4]DQOJW9K?9-Z35KGBZD(H)
M;)A"SC '.L%'Q$!A(,)T$"ER;T2G4'"V\7W?J^L6L^C:1:$55DYJB:R3(,=L
M"LA(\-' 47/,^TB 0X=N5_2>X?4J<DCF98MS/2IMV8[@KIKE^R9>E?.K-=C9
MV+:P7$CE*4,Q)H6X N.*$L<0$=;K)!18$CW\F#P[*4.#9@RN[9R!?BNT'Q2A
MO$V&OAOS]]S#VSJ4+R6E;]E-<?SF1!^?TJ.C-_P(G]%C\N:4J6-#SL[ (#)]
M+G_(8TL.A8D,S-O]<$+7BK'/*Y,JL&F5T YY[ T*%&QJ38)8)M";P+COH2OR
M[(,,.L5#L"B71KA-2(WO;H^7=@UZKFD%\LSJR)Q#-,;VR'1B*&CI4,+"!0"L
M,K9'-GB>W8^AM<"P_,K@,K8C?E?;]HJ0C]'/&_#*<GL7'_UE#//)XN#H+H2,
MOW8Z'N![=-X,YI<8TV('0X<>T(D"UQI)QIP7G&(9.@7LQAG18^5T!AA_T1+8
MU*3@' =NG <K6&%$8?D@)IE!/#EGK2+$L#[5*;/(@=VG[MG].X-Q:6CK;V4)
M\BU-OY5]%%30$\X$$?(-I>9$2/GF%$R74WHB,#_M<S8QCR_0>_;'9EDN(^'Q
M$#Y7]M:IB?=W(726#RO:%HK)0(-U*,H 2Z MKQ.M)B@(HQR54K.!BGV,&9<?
M25(,PZ],!L.G=LMO5+O@S);-XE;@W\"2FC>/C\)F>V$& ^AV5^&3_38N/Q^\
MYBB$LNW 3MY6J6YN09]WI'>E3^&7VS*61X_*6.[;W'M&W@/:?H_K9>#:E@5V
MP45+&'(I:$2I#HBSV!:OB]@3QK#M)@%''_?ZVJ_K&Q2)$>^DC B'J)$ "P=Q
M!5)1,,=\B#AZ.DS>_9AR?M"I?";Z!^);/KO@EN#[-;P=/E8U*XB(1,&00)U1
MA;@0"3G:'E]U425#K4FA1SI^'K=AB(E\ 1L#\2PW0AX3O$M]PBU[*E*,QGII
MD.).(2MM1-+"DHQ22QR4#\[TN,HS+X[Z3WHG23,D,_<+L"=WARP+++16].K#
M+8M$UZW!M]-;"G ,VNMTP2]0F"/EI$/"M&6J-.$Q,&,<[7$D-8]GG!F8N1C=
M([2RBNP/[3S4Z?-=5?:7@RI=6A<<:RH%/1(G6!BI-3U^H]MR,Z?\B-(3?';H
MVVB#@V8\YNU!>MW2^9A'V[@4CUL6DDN#=5OXSBN#))4:::XYBE@HD8Q4H8_Z
MRRME1K:U!^+?WC"S*(#^_1ZC;4#SI&F1%(U2,H&,T@3Q&!VRC"=DO0DN@-03
MO,=N?7;CN__,;D)-?P;N#3;?[PV!(1S;IKE)=?/5-J&C(;2IE\)Y$3"F$6E,
M09HG$I$**J"VYA"Q2@C29R-X3V#J->&;T#0H,X<P9F[)@@^W"::/2%IM>G6P
M<;;OM! T)(6=1R%8T2Y< @N7AKO\"6NC&.90U8\&I;WP=F\B"SX\=07JJ_;?
MVQFMPIM8Q53.IA\O;1/?V&D,#Q]HW8)M9-L KRM"%%&UU\UC(@4*6&L4*"SC
M@$E*.G#.^M1&S&NXYQ&"^^'Z_JRWN@Y?RTE[:OYM>_7W1>DF+_N+NW131.*]
M)S I*;F F U@,7ME47O5F($_V4!Z'$7.DZ"7%X/#<G,X3?SXKK<[=^C%7,VN
M[0MZI/B9.CFF)_SX5.JCHR-S!MZQ."5OS@P^ZA%:R).OEU&W#L/"X2"QN$32
M3NZ]G/;>R+N[DCOC8ETG!5$FT,2 6<E%Q+$TB$ER=PFE,<ZF'CLR>2H99 3(
MP+S,I9A6VHQMZL/MA$TF]=<VA76-3NK80^&4<#H0 ;SE&A$602_K&)!FU@EC
M#7P>)C25=1]XP"C#>(S,D CT()_C_N/I-WM55GO(*!D_(^G1R[XMRCU/-PXS
MRUWA=ZQ?F-!+FWG-ZGVA12&E]-8DC*A.!#E*P-*A(H+8HI1JK*WL=KICY'%^
MB!Z$.:CBQ1R^,)BCV5D,;8FJ]OSQ'&B\^=[>SC;<GS[<>PH%XIY(IQ&VUB!/
M/$>).(*HHDQQ;S7KE@2^W].5 ^#E^;WJ>^5RONI"*\>Y.!7?YKS!9$]69 !V
MQ^5+/15)*,LHZ @< D8J:B"/@SFB4_"::,:<[A&.R'5$,QOR!N3CSA;_[?U^
M]U4LENA^3"<8LJ!7YO 8Z+LE6\Y3*GUL'@5/UN;V#_ZB0A.?HF7M508D(,6Y
MA4_I+K2H#>/DX"MH#HFV@V%S+D'79:RKPWBGWWR<MB;5G;#?= YIZ%<5U# 7
M9?!(.C"L54P,11G!@G=!8B,%>(8]KN?.=:QU>%%Y (S>LYY>M3JWU]&K>BFT
MM3Y:RA$L7(<"MAP)QCCBP@D:3'38]3@VE>OP;#;]/! /#Q!/.^U@#=(_K$>C
M0YM'PRA7B'-AD$E2PK2Y($)R[<V:AQ[OVS,&!^7NGM%Y'XW:P0_YWK;P/(7H
MN$3<@I076$=DVUUGRQPATD8J> _)IO)$_3+"JA?K]@R9X\7EY&^K9T'2K>+)
M_3LO+*:4A8@1,1(XQ[Q 6!J,$LQ5H-89@GML7>B?392-R]H# >5I9?UL,;;=
M8GZK^RFP\)Z" X:,< F!) \HI0"?M,-&489)G\B*^5FAUIN+>;<T/@/TFYDM
M6_'\OIXN3LSF. _\>YRU.8'O8[,P+3*^*O_@QM^T.6\N;+4LRK;(AIOZIEQ<
MG'F>WLRG915?O&PRV_LS\/UCG,1V\?WGW#:SV$QNEK>3VLF)G=G/E9V#^1'#
M 9!P.,P8'YR+>K@@<F+5!EG:LWBY7[>\F_;F,[RE>7"K[.*/.:9B!4E[JDZP
M@I3%5\]\NSW2\OBKT^GU]1Z)V3M2,BW0;&6SG[]MW[D%Q]^O=%B>Q%RH[45^
M>?,EAK.Z.9O/YDU\.YW.-_AX6_=5>!,TXV <)LXTHMQ(<#D4;9UAH4E@PK).
M=O8XO%D=^#EJFM;:;=/MW]Q\?V19 NJH3>]9WMM]/I]-9[9J2PK_/K]R*U/X
M1GM782A54GL#',4)16X4PM$:&"2)AA(:X>^'GI<P,J*>7HEW '.0RZ_>>:RW
M(SM/MQ-Q?SD,S,3?H>VZ@/98KRPH<4YRJQ'S7*#@"46,8HX<L<%RK]U0MS3]
M"^G#3T4&E_^YULU@5[3SWMP I\J+JDRE;ZMP^$7--Q /[^M)Z<M#H. V+/VA
MG/X!2)LU9>LU'=MI>Z[L/CP(LWM2S]TLS2?+#K*8@YWH/RGM155/9Z5_< SN
MOJAL>Q7Z?]27U;2NEO\<#.%/CZ*\J:OY?;HY<']Y@W,;:(->-GLEXZN,':Z:
M7Z,-\EQ<W\U<?"%9Z_$4+ J4^ BN27A;M4ODI=2K#<T*GK"6MKU6*+57+@I'
MD S)+S-\/+61'GS"Z.BS5X_*T)WS]YZ1<EXMUVQ[$]Z+16$V-"LP24"[3,@(
M)D%WZH2HMVXY L4BHP=?8'>_D.C-T!QV2"?%\*X$$R5L# UD5%6'8ZVT"__1
M]TU=P4>?K91K-S+'-R\_7=XT=1F.;V;UM9V!;5M?M#>MS2HP<??UWLWL7ZZL
M]H<#S^)O?_K_4$L#!!0    ( *V#65 I0K[-DW,  .C)!0 5    =F-Y="TR
M,#$Y,3(S,5]D968N>&UL[+W;EMLXLB9\/T]1?\UU=>%\V&OWS,*QMV=<3F_;
M537[O^&2):934THQFY1<=C_]@)*H/#@E421X4)9[U6HK)0)$?!$ (@(1@7__
MGU]N%S]\3O-BGBW__B/\&_CQAW0YS6;SY:>___CK^Y_4>_/JU8__\W_\MW__
M_W[ZZ?_H=Z]_L-ET?9LN5S^8/)VLTMD/?\Y7-S_\/DN+/WZXSK/;'W[/\C_F
MGR<__;1M],/FPV*^_./?RO_[."G2'[X4\W\KIC?I[>1U-IVL-N^^6:WN_NWG
MG__\\\^_??F8+_Z6Y9]^1@#@G_>M#CY1_O53]=A/Y5<_0?03AG_[4LQ^_"%0
MN"PV[Z[QDNKQ\M?9:M_@X</TY^V/^T>_Z?I/O'D62BE_WORZ?[28/_=@Z!3^
M_']^>?U^ \E/\V6QFBRGZ8__X[_]\,,6N3Q;I._2ZQ_*?W]]]^I1)X%[D^G7
M5?JW:7;[<_G SXH ^+_?+B;+\-Y-\YL\O?[[CY_#4P$=*"':8O/?OWEP]?4N
M_?N/Q?SV;A&@^+GU &RZFLP71>UQ/'D^TG#T9%'B^?XF35<FN[W+ED%^3P[J
M>*M.AZ:FTWR=SE[/)Q_GB_EJGA8U@6S87;?$S&;S<HI/%J^6UUE^NYGO[>BI
MT6.G)/GY<KY*7\\_I[-7RS!7/\T_+E)5%.FJ':/J]]LM>>O5.D_5;9:OYO]J
MSZZ3W75*S-L\NTOSU5>UG+E_KN=WY=[U)EVUHJA>GYV2]6$21*/A\!^WC37,
M=3%?ID417O-QOMRP^>3H#C?I;E!U&7^R97=##.+ERV4M+ >!>_-&"V>K7KLC
MK51Q9NM%>G7M)_/\M\EB'3YN5S@U#5,I3V=A4CW8J<)O0=V<-2<[TAO[@.35
M+,S.^?6\G)Z;L16;;>Y=NB@5[?L=H?8FT\7+N@.BYI)VJF&D 8;^;^>KVXV^
ML9R9+("U_!1LH_GI(=9HVOT@K\(.-2G_?)T&NZ:FQ#3MKWMRZ@E'[0ZB#7A9
M9(OYK)PR#_?:&@,]T;#K ;Z=Y &EFW0UGTX6C4?[;"\=#/W]*OS_AJU7UV92
MW/A%]N=9&!_MH.,![V9.^'4CD[=W>7J3+HN@Y;_.BL94U.NU8]+>K[+I'S?9
M8I;F1:D)K[XV)>=P3[V3T'AJ-.@V&G'AN[>33^GIX3YY,-( ;/IQ=>K=#Y^)
M^%H3-+CY2GW*TPWV-7>ZTRTC#C%H4VF>%BOWY2Y,T;J;\>F6$8?X.ILLPT+R
M/IVN\R"L3>"LV47$0=]KLQ&&?W9G$0FII]U\^V2D(>PMHU^";K?.MVO8J=$<
M;=3EP&KRM$[;2,-\M0P?TP^3+Z=Y^,RC\0?1QN5Z9C?Q!V_3ZS0/*W/X8V>F
M+QMXPAMW&)^@_4?W97)[GA?JO%[B#[W>NG2P01<#^O(VSS[/BT88'FD=?ZB_
M!BLI#^]8EF_-MMZ5!M);IYM(@W^3KDK;X6V:O[\)RNJI01YXO)O!U 3N>*MN
MAE9ODAQM%&E@5_FGR7)WQA(6.9L6TWQ^5_YU=5WYS4Z-\YP^>AQV3?XWZ"H2
M$>_313H-1N!_KB=YT-D77_=^=CM937Y=3M9A,TUGIP@XLYM^!U^3"<UZZY>4
M>I.V46>Q""D]"&$C*-WTG],R.N+T< \WZ6Y0:AH^!C/IU^4LK&WE[U>;";?Y
ML:[$M.NV0^)::-(-N^N.F,U7>E*D&W]ANBQ:4E.KOX[)>?R5*^[N6M)SLL..
M"8HR>0:;+S67U5,-8P[P+/=TYV[H;U]P#I>/->QL@&?P]$B[6,-;W]Y.\J]7
MU^_GGY;SZ_ETLERIZ31;;X[ZWF:+>9T3VO-ZZ77H6Z?TNWGQQ[NT6.7S4OTH
M3ZR"-JL6B^S/\O#-9[G-UA]7U^O%KH/::T6/8^@5-CN??%IFQ6H^M>GG=)%M
M8K+VGMO?YZN;_Y7=+(MLN?LG*EXM7]XK4$\#"W6V7&\C1">+TC/V+E"P7(?7
M3K/0RSD*0C^O[Q6LU_.PDLW.6*1;]=HK:7&7RD&7S" LZ:/O\VP9/D[/.B[H
MX%6]@E!SEV[05R0R/MQ\S;/YS'Q=97>35= 4LD_EF?AJ&12&4\.NT[:'8=84
MI3.Z.#CH23ZMQKW[^'#H^WR4^7+U\VQ^^_/NF9\GBR<1"P<R7JHDEC);AFX&
M_:!E[$&%SV5D2K;\:99>3]:+5<,A'NRGPP%GMY/YLOUX'W43?;B;WG^Z36\_
MIGG3L3[71^R!WH3^\NGZ8_K3'IJ&PSW2T\%!!Z&9;U6*U^'/W=/EN,Y-I]J^
M(?VR2I>STA4;\QW/K@]17U4GKZF'%]9,2NIC)+6=<CT,YMP4H/V0R@%50UID
MT^>FU69*74^*CYMYM2Y^^C29W/U<;ET_IXM547VSV<Q^ G"70?G?=U\G1X86
M*$]?K=+;_> 6DX_IXN\_AH$DYS1/-"8.> \%)TY13 Q1D!&E* (.8T(?$[\H
MLT>S?,>.;JE_D$=PF)"-XG0$@_J=))@;'58%3IGA$A%)+$4[)(PA2-9!XEXT
M53[](<MG:?[W'V'5<K<JGZ54E!F^7;(UZPFO0%KX8K.I_-MTD17I[.\_KL)Z
M=/]EMER%N>46&\T^["?II_)#+Z)VA%;]]9?)_\URLY@4A?HR;SC?GO:24$(-
M91YK )3CWDM"0 4>DH#U*&Q'=O9OA:\+^<CZ@G$C@\.*T_WXWTQN4_M(2SU/
MI)[K*=$4&4Z-Q(8A8H"'CKH='A8H(I)G]?A.Q>N@#7'6RM:<\_6E*R*BWR5M
M& E[1.7+$+!S!>M;[TCY3?(VK/'IW6KR(9W>+#<.DE\>69X/1.+H\XE'AG#@
M*79::AY6=0UE-5[&->J3\<^9T&=QO1U'LOAX->;O[APDG;W-L]EZNJK+YU/M
M$J2I],)"I!C0A$ONM:C&;ZAJKA:CB^9W9-SZVC#,NEAEMVF^R3HN UMOYG?%
M00FIT2IACJ@ %Q:< 6@ P9B:RM*0@C>7#WRI\A$?M<:KPAM3'C2DN7_M_H_]
M\GH^+7.:CB\(1YHD5!./F.?*0&(!YQ!S7XW:4HL;\YI<*J\C0]:8T>K_-]DB
ML#+;IJC6XO2Q-HD"VFNI '<"8.A->)^NQBV$K^47>I;5]*)9'1&S$=@(_\@?
M9"Z?9Q1LFB:4:L^-1%QCS#BSS!!540RM]A>E#+;WGD7&:P02HJ;3]>UZ4Z'D
M83VI9C)SH+-$*^L,T]Q"3F5 A6!&=JAX:&CS;64(%;-3*8J#X CDZDVZ:B9#
MH6'"D$'>62-4V%PY\8KC:A9YCKB]*)6S4WDY'ZWA9>/7(KU>+U[/KX^=Z]1I
MGC @E0H4"DF@H)!R@/>S0D%W6>IJEW+2&+-[:?GWGY_ %<;[1V=GMO4*'/9P
M>GQ.8<(>3XZK894!#JN'8WM=X]SX=.,$4!?$3QG#A1',"\R5XRKL-%1:YC6L
M,[.Z/C4^2$;],^/C722*,DH)8]@2YRE0$CJP0T%;1MU83HQC,O3@>7%4K$9]
M6GR04OWU0QC]B5/B&JV38#TBC;WUA--@1DIGI-Z!9;C#S8WOWDZ'8TE#UC5X
M?>D[AP$)PSAY.E>C=>*1(" H=Y1PI[TA'CA>T>VD9N,^^XW*V;I2TQJ]OX[T
MC/(\=^Q",XRP;.J%EHF!KV[O\NSS-E/BY!G/D58)DU[CL#0CBQT!4#&/V!Y#
M8/CXW'Q1N9=UA51?$K&S(,MQSSYD5ZN;-#\M$(<;)192B R'6G' B$0,B3V5
M@!HP/H==E_(0#:C>#H&#^;I>I?D>A-,'P,^W2+@2 B-$,++<"*THQ+0R&Q1L
M$<;8F2>N2T&(@U)?4O ^NU[].<G3LO#B[N.#9%J3%34VC=I])%H)J%%  )M
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M51QQHR"5%&JH21T)?7D1 D@SI@0FDC,%!-&"2+U%A5A4\\::P2,$:K.V;83
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M9 >.':NHXL=F;:6Z'=K3VO><6(&@AL)(P2'E1$AB1(6!@*)%C9>+]? / ^T
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MM0CT&6MU-.DF$K=J^/R;X-)1 LX15>_>U/B03Y;3FT-QML<;)-B$[IE@1OM
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M,\Q[2UV?CI>S_*X#B$76!:)]J6O/C7:Z.54^[;,[V3;Q6"K#"23.(.J=5!S
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M6)3I9)_22JE[F\^G:;D!7_?I2:DYF$0I 100WCCJPLKE+1?5!JP,DR-R-;Z
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MR-'F?I_APOW[$)AXD/8E*J^6T^PVW2=OO]Z9X2><%$=:)8)1#"BB& ;T,&8
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M G#O'K9C(+[)EI^WB;&EAZG8%'%X^'L)Y)ML]5_IZA[B!R[&UAEL;=^?0,8
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M.!/F0>YX8)K/,7-(.F2"I_-B?FQ <ZRNZZNM*Q:WAY]_H=;^A6$IF(DAP=P
MJIU*%:BUJV?OF$6=E9L]13";<@? 9:R/W:86NN5FN?M8W*=SK[G;;I.'Y.
M6QS_I^%K;S,\ "=T-$T@QRJ5TQ7 B@?)B2 SNF:2_7,? )_91$HNE)5[5&WV
M6)>S3YCDVI\5/,$* 0XA9T1XA8PRJ,844#:C]AO9.3<UF+,GZ P+!!-M(I+$
M@JA7*3F &IZR.2"2Q'1/:LK>.&,^=,V+Z036]:DX_7'^U_02Z/RN0)PA)$+
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M&T>1>9"".-*C8\^XP<?6VK@VKGP=0)/=4.U=,)3&CX) &?%+NQX$DBE\DM,
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M<[ &4?/@2%<$9Q+*.#B1I@L1Q#T\13!.,>/5[A]M?/_G!P5J*7?0L=3[#5B
M,5"4Q%7>0<V)L:VL[I$DO>2M?WU \)+0*!NCC"!M >&<UA)2J=R8[5T;W? Y
ME/32X.N/R*P=YR\DU/<MBB<TC K*:0KC>5LY*"B!GD7SI@9' -0C^#RL4[RO
MKB]1IS-$(YXOGP'0Y@I]PZ@@#:?&(,\1]$1AK(WC)SF9!8[.V].=18,7%Y2^
M:/V\[)BELWMNI)B(#"?GQXN97R[9W#PR0,"C"0OB\=@1) &TQ+):7A!-Y?DY
M,;-H[SDCLJ(T&BL."58=.-$T+C#G(7=>>Z.!3S<*D2.UK RURYH9UT$Y"",R
M8C39EJ'O=;E9W,9#XJ5:WY>&!B8(@=98++@4\>QK@-6UQ)*;[E<E!B[Y/;R5
MV0>GZ9A13_IZB^+9T,"(DYA9;ZB.HFIIF*G71NXDMV_.Z.RHT(M,R8+;GX$Q
M;\40G0E1KB7(N8(>Q3JE&Q]Z2?YE6^UV%PIZO/YX4-I38K!3<;/UA%'/W<-L
MF6"CIM1T-!\Z*Z#*CL_(*32/VA6VS9IY,22XR"L/4ZJB=$@Q@Q4#M814BNYQ
MAO$,R+X,R(S1:%?K3J7.TN6-QY!\^')<\-*OOEA$=?U6_G.OU\VWM#N\+6@/
MJ(X6=$H=DEP;B15YP 6P.=8!SN\%'QZX\>H$'=:_G?J\.R1R-+#E^:/A6,3$
M8X.D(]AI1[4Y220@)]W=5>,M(_VIT!.5L?1L5[OBYF9;WM0\/4[[<-9JLU2T
M&A]2VKLP)"[#7'(L".0@<MPAXD1<CL&8D8Z6C.BNOFIX@ :/3_]V>[^M5DMS
MOZ^^%?O;:EW=W'\LMOM-N1WR8EW3CYWZPMS_%-M5TMF[S;[<EKN]V^PO]"9N
M.3)@2)SSDE.'O1+.8\&.53U26SMB9]&K^%49ZA2%%I;$A3<$+) 1E"@E#%(I
M(]!S?,( 0F?'+";8&#G/ILNS/8USXC3K>/HY04]E>@]9,<<E\PCR!3]HE]<%
MP2S16CO.L19Q9^="ZQI.YM28-P,Z5C;.1)=J=#!'<X<]F_#K7_!EU]@5KPE>
M:90*,GD(C;8& X(>5@'  9^W8W58Y3_WH0V/ZY^9:;-TR+Y=@DU#K->G_$NU
M_[A=I31276X.!6;C'R_Z_JY^5U"$<.&UQLIPQB3UYE1+*F)"G.Y>+6<XQ\X@
M*F^S168$LG,TX,/^MMR^V\1#5?DIVG*?RM77SW?;77DT[%X/"32-"=8@*+EP
M@@#O%$]5SNLOCYAX))X? 7);Z;DQNGA^/_UU^N5SL2O_X]_^'U!+ P04
M" "M@UE0/HIUZ[T' 0".E0T %0   '9C>70M,C Q.3$R,S%?;&%B+GAM;.R]
M:W/<2'8F_'U_1;[C#],=077C?G'8WD@D$K-RJ$6NI/9XMF.C JQ"D7 7 1I
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M[H;G_>53#?)BO=MOR)<Y>?;;^.5=_,C7Y,OAJYH ;TW_Q#H>74@:&"/\4MZ
MDB M('5 C1^EZL>7;T*,TZH@CU1]DU6?Z8-TR%= .+:B,(21F02F&WL)3LS$
M=Q%T_,2TXI!QNB;\^?IT;8 $"";0@@*_#; FGI]=8F=D8B9-Z#)F9/)NE(H?
M--'$&TCF?)M\MV_RK]GG;+VOVI,8_+T3XH1XCLJ'QWTS',B<X>S.P.,X=$)$
M__-]Q_;-R/>M 23Y/RB6GS,)M G3>$[] 4>'P.!1-Y">^$1_Z;7772[G9YJ(
M\Z8&+2[8XAE$4\59<[J1BH@P925-&OIEC!]S.7\QQVF&&+".59+0HJ?7/Z!+
M*J#G7RBRL&>$9"KJ6#:&'>+ ,/W0Y1FXYL2I>12[I&@B656SAI-M5/JC1))O
MB!(,HI911B/#(T/.$N*ZC/%G$4R4RWOK5(Q,'].'K,^U0*$1^1XRXM@-(@<Z
MV'.2@UEL<ZV+I(W-,T9< 0I1,#-,GF 9P=?$K1+59J5U0O4^TL4MP0),+UE'
M1=QA$D-AGIC.YO##XZY\RC)8;#Z6Q?#5YZ9<_W[]2$6WSVT(/-\+H.TA%%M>
M8OHPC(/!-/:]B/F83I5!W7LX='BIN\.XAP>R7*\I0E#O;_\C6S?T&*_<-[26
M *W1 ,H6.<^%3V6\,QS6S4$YY_YVCPD0B(!@!(=OM"A!!_/M]"R-/',<Z<W!
MM^#I7@'2JB+?Z0[UOMUG57;[!-("9$, R@H49?'N\'5>@XRF#.RR37>8O<[H
M*-4?UFWWS;[*KD[?DZ]9W9X TG/![GR/IAU4>7L>3L:T8D_)H&]:W;US_4=E
M729*VH 4U(_9.M_FQ.0C^47R^6D--MDV+[IC0_KCZ7!]5?9\D#%ZEXX*50=_
M :>&RETJ-;XLG&>)I_9Z2S9*L.%@B'#LNM"P_##V#Z-L&'--X$4^7_/(=I#6
M;D1[)#]V3^OZ/)*?XINI"Y''> :KF3?!X:D;C>;)$GZ%DK$S5PD"ES'-EO+@
M_*15F@U60?G4CVW9IK7U:Y$W]:?/O_8V3=]+@L"R+</V$Q3:&%MA;]/T_,3@
MD18Y2]H3W@9PO<SL*3P^>9&DDDUHIF.13W).".Q$IT4&?B#8ZA]G4J!1KD:T
M2 W'RU E1;Z4.I["28_8/APRAAT70N3#Q(@],XE<,XX#<X"7!";7#=G)0&G6
MO^N3S8'Z]:V$[#_W^==T1U8L-5G D&7.?4K64;=91A9?SY(&6C[(%T76@%U9
MU^"1+)>&CZ*?/>E9'$?<)SEXTQ-R-:=LW,D?'^:Z=:$J"/H.XOCCO(P!8WJW
MU1ZQB?(^T3#4Y:>O/,N-G-B,W"@T#2MVH6<.NP-FB&R?[Q+<-)AX]$CHJIS0
M'C;X(>^'E?K'20<6UDA.,JIH".$L0\H5Z#SY0XTF'61]0PEG</\NQA%>G]4.
M(D*,LXX@<7;;Q'F])G/C_4D2/301Q':81-BU?,?T' A#Q[ 2E-BN[4<FHY (
M?KH^9:" P!'1;!=!7B=FY*V59'(9KZ&L$Z72IXOO1:%3N>LMJK)-WB3I.M_E
MS5.7Q.N[3N*X811'1N(9D6%;CCG8BRW#YEG"BUO1O"9O%U=DE.R@@0&;V-4*
M"2[9=&<:&OFD1Y1!+?ISD: 1"9(G=1DJI,"/4O7CQI%T1%7OILH>TR=Z8/^E
M2HOU?=;F;-J(1-L+/!0EQ%H<.8GM#,8"C-BK 8B;T*Q"[?!]1 9Z:%QI];(D
M,N0,3<.?P,QG9NHXTH"FH5 L\4>02K8,FHN.7\J9D6=J 5DR"IPHE3X]O(+\
MS%*?<0JQ$?AF'(:>$0=.X!HTD;ZSY251Z/'IL8B%2>3X_"W@2ER79)!5C'63
M)Z+%<_+&J\2Z^1,3XH&RMB[*ZZ0JD^17&!A59!G&EB+(4CZ\T&-Y1L3GQ]=%
MUN<#^*%E(]<,0F19$;W@1&?HO<4H-B4GR>QVII#FQ^,<I>E?B++@*84ERZ7H
M7%D/C6HFS 2;2"Z]+)6R<V<]E*J=0#-1*S&-/G# -9?F9VXI^JW DS=GU:+L
MB&OYEV]E;]%S/!C&T$U"/[;B) SB)!XLAI[-U+Y%A9V9M+SY5LH*$ >7HEJN
MAT8U6DZP*=-R#BIEM5P/I6JUG(E:"2T_<,"EY?S,+57+!3QY4\M%V9'0<A+X
M8?QPS,B-'<]W41@FEN]'M$E-;S,(O$!2S3DLS:7G%**T#/$P*JSIFLA4I.H4
MG3I=YR%46MDU$:M8V]D(EE'W(P]\^B[ WV(57L27MS5>F*&W5+ZNFM4G>AVZ
MW6B/?-,U/<LWL>O;CNLXOGU8#1A^'+*H.=\G:E;MS_3EJ9M\G>[ +UE*4T[:
MEX+G (V3HG%YUL<.GPP+$L.2UT!</,EI(%^=YS,\X^ 5I1#C:%Y%$,1<RCP5
MG&_XH!^>AY 90\N&@>&0OSJ.T7^Z#[''E/G$^YESO>5<IS/<1#&^Z1HX4O2N
MJRBKQ/ZV7YP9B#*UD#>>%_7Y.R_D-<M;_TM>Y _[A\-.'R(?ZL6VZ4!LVJZ'
M VOX?!-'3-WE^3]5\YO?@V%_P3DY>?L5UT<'WTO>XU!S49KII7[F^8776HR=
M^5]L0=RE[',AUBCM4]KTB3*^:=HF,F+;-CW:13@P@L&,X8NU1F?^<,VO^J%S
M%P4DU>F<G:[QUW\2IOA4@(LDK=W,!C)>$09IWI:1DBP._T*#,D$>1-2BS^1P
MPR3P#$@^W<?80&9@1 =9\J'+5.-0XN.G50RAVJPBI/&KA@:^I'1CEGJK+PEA
MU Y.]I:G'KP.C.B'$!?,UZG*8E,6;1_%V[3X_7J[S:IL0\U^>!]=?QJ.H9(D
M<6V#+%EP$IFA:4)K.(8*;&0Q9="JM:A99UHHG)>IU##)IC33D\@G/AT^<  (
M>H2=&/W0@IRK A03=R,ZI9;[94B78I_.[V5I8(Q#X.Z(W0=Z"/.%_&8[&XNA
M9R4!=KW \T/LAK8;X\&4D_!U3Q$RH%N^"*9W%%2;C7T%*"ZA]948>\P:II<X
M;LGBYDR7/KW@95R.Q&E<C/I(N/!2;&3Y$-66?J:&#1PB.W)<3-0,6]"*PN&P
M)X@M&\FH"Z.)6?1%:#4FRJ&8QFB@3X7*S+(X>YT;#J7A)'.96L/KQ!MJ(\2)
M2.V+?M)D8>@$09Q8KA' V/>@%P]'3($;F5S%> 4^7K?.]+4:UBTF\>(6K&0Q
MBHI>GC@%Y7DYBYF65"\8&9,1<?H6(B$2#HQ4K!#B0J9L3CLS2FR++KB2R$B<
M!+M!X,1#98S0]J$I6S6'R8AN&<D*\DCTC:=$5D'"Y/$+BC;>.&6%G;+)"N.\
MM1"297%YZB+F!D-5' %>9)2F>YKZN5'B0A,%EF<DIFN%&-N1,=0%"W'D\FV^
MR!J;: )S5FSJ"O3OE^":29IB<5W2QJ[4M(>?V,E4ZY0P3O42XGJY*B;F#H.:
M2?#$=&7J,[%"_/ZW=+?+GJ*T&+JO!!%R? ?;,,&)%5*3OGTP95KL]UY%#6A6
MKQX6Z' !"HSC%H\P:^/B-!EA?(+T"E<B5Y^$2>.X\30%>6(7G81(9+O>=,'I
M5Q19"4<+N,PD[4*I\)GAFT.^,EF-'8CBR#2CP SLT#40QL..6H@\ERG76>+C
M-2OMBV*D JM4$=+8YH&:^>(36DZJM,SSN-:E$NPM8RXGXT"I[$F249!A:F@$
MOFL067(=)["(:IE.=! K#+E6GD(&IE81H=6E&'4B2J*!-4DMF675^!HIS'K"
MR>$2%877A5%-$>*#557:KA'9AA[V]?.?$)HP"",80&1%,#2B(!Q6FQ"C*.:1
M%/Y/U[W^ZP"U1]5\&B) %)N Z.6(<\EW0L],!V\OZ!C1#7'JEB$:$OA+50\1
M;Q_=K^7N:U[</9>HWB:9W"1AXOG8(NKDFR;$<%@Z0<>/N%I.REG2+",'</TY
M/MCV\'A;Z4JQR:8OTQ')IS5'#E_,669JHSO"TX@(J>%W&8*DR)<7;735,21U
M9G?HF6@;B,RC#,?W89#8!EF>N4-Q8&@GCG1C'79+\YS6L;4TU4&LQ#&=%DZ5
MG-'-V"%VE"G>PSENAI>A6HI\83F6$V1(1K5^2;_3._I1657E-RJBZ2/YE^9I
MY>((.0%T3>AY"782&X?1889'4,F*F+#AB33M;.IU!1XZP.!V0 S6/61YB1./
M@KCB31( )0)X!7JLX  6H+>XGTP/+_'(*8_2X5BN6LJ[QB">BOCCZ3_ZOJB;
MJCVUC=(ZKS\_5EFZN2Y.[R*;*V29D0\M9#L)BK"+0^3[O?D(FC;7.9PRHYHU
MM$4&ZA8:* OP=;A:7Q%T?&JICF<VI9R%8CZ5;+?/CABO0$?WYP/=SRH93-\?
MEH6^$7%4'H%E"*-ZMU[I*JN!-S%!;.\N9W5#+=+:>]GF)B-/<]&D=]G*"I 1
M&!&.D>F82>RZ27  X,4F5\D5A68UB^* K17!*U"W\,#C 9^,+LK1+:*,DS$M
MJ8T'UC^UK'=0P<W;K$\@CV,<,@NDDD L42+5.#8JD@JYDY=)O-UFZR;_FIU@
M("M_([!-)X8&-CSD0ML?]@&BR.0K3J76LF:Q/$ "^:ELJM)((:YE95(WS6J5
M\AB!Y8GE*TP*Z:5,1)8NF5*^,:NF/(/,/5B. (Z] <C?'O+]PPIZOF4D?A2X
M-K2]R'.@-ZSQHR2,F$Y<E!C2+(LG/2T>.T2<74*D2!P7P,GYD]2[$RYOIN>2
ML^'*5)R*74. #^6>T%AN3[L#]0\H^)82>=C\I*#;R@@)K\B_4NX6<#U!F2OG
MK5;4\<.>Y].;J:^WM"#(E[X@R"J)HMAW$]NQ7,O$H1<D9G(8.@S(=7(N;$1[
M=L^ B[XPNT-]FPUWTJ XC6Q3V4D8Y%/QY^0]+PXT=4+/Z^2,YO)(\KF,.:>\
M&R\R>)3P(K8$)Q/7O-SDZZ'--[%=1^EN5Y;%\*TRRF[2?+."$<:Q#3W+\BW?
MCR/+CX9<HLBR'"B^&E<(0O<,M$<*#DT *=8K<-NA/7Z[!+<9^2K?R*S9509'
M9/D^4UQD9[9#C&Z&_G==C'KDAV]W,;H9B]$$"WMVCIG7^!K"M@SIU>_FZ,I?
M&Z],FP ?\O_<YYN\>?J4D;]T#9SZ%B.K&">QA3WDX1AZ1A"&+AQ*LT38<YAR
MPZ6-:);>H;U-=40&=GEZRY$:+L\CPQ[ 5!3RJ>0!%3B!=06XNB?)T\>Q[)^*
M1K$EOR"=;(O]$=<O+?15L+6 1;X2-TK%3Q%_D=]A!O]+VNRKO,FS^G2.?U/E
MQ3I_3'?OB[]E:9609VR%##,*$S.,DB"$9N2[&*,>"W)-Q%UA7#T"S>IN&9;%
M7PE8 ]%L\^3Y.>:4_[,ZPD?,5^#YIL(!-\@+0)$#"GWZ4L/<[(XEG&J-UC+F
MQII]?*6.L6Y&617W?;$N'[(OZ?<XK]>[DC8WA;=DSIZNFU5D>0D,B17LAK2/
MKA>'KN=$Y"]!A$/F:\0R)O2]U!TJ0&"!(R[PVX!LXLLR(QR-O)HJF%W&"ZC$
MDU+]<R?R,GTHZSHA'J*R:/)BGQ=WUX]9U4Z1ZRC;EE5V0);5^#L!1.C-B[1Z
M:B_P?"2,D=\D[!%+=\.!^0H;E@D-U[>MA+SYV"?0O0&Q'\;VJLCN:!82VS1G
M3J1,[W38O=.G3O&<=#?DM28AK_EF1;/&CT=,%QPX&3'^@?KU(Z#R (ZN@:-O
MX+9U#AS%F\[!GKMS2$::0\&U!.;-$6#>QV%)(\C,3+PZ BTA.MS30?S],2OJ
M+,J*;)LWJP1A'R(;&[&/7.Q'MAO:A_'2,@.>);:H#<V+Z%Y3Z,B1=<# #[<=
MM!]%AA$!$CGGTQKY$YY+XX&ZZ"WJ],ZCGW/#,H<69'-)ZB?AQ:6YLQ0K[*V5
M=_M6#^%N5WY+B<=QMLVJ*ML0!+"NLP;=D^>-Z&27+;:*R2HX\CUD!I;IN(D/
MW20<8,2!P[7CI]RX?IVJLI2^8INL^]N/=+?IZ^ &2 <_0'J7YD7=@$WO4"MN
M*76)<V*L/D!L4C=K;/@T\  5'+!>@0%M*XTM7IHK/\0O'N)W!3KX4S>,YB-W
M1$2UQ6D9ZJK/O1>MJ+7RR*K'A\S\PS! \_4_992N?)>W"#_?IU46D:=W@\H'
M.D:TW\7?UUE=DU_H!XP>)G8#%P:636 ZAHL39%O^ --PG9!O\V)R>-IW+%JT
M[VXI7+ ^P4MFHA1PJ]O]7!2DXU*QD("RZ?LR(RFD_\<[3R>SX;8#]W-WKEZ?
M)E^!TV=@R+*"545?]^Y\?(XQ0G6 1L:0V9Z%98PQ\[E?+N2=Y!NC^CV4XHYN
MKZ"TJIZV9?4MK38$P.TN6T6^'2#7PY'I$FTV#2N*@L&JY\.09XD@:TOSBN
M#U!\X!E \%L+D;.4GC2Y;/(_):]\:BY%J18E?H.K$6%5Q?(R=%*9-Z6>9U%P
MOQ7NF_NR&OHT1)[C6X;E(XP<V[!#+_)1;PP9AN!V*Y^):79;VW7Q@$NH$XLH
M@YQ[K?K($]YJ9>9-[T[K,V98-EK%J%R&^L@Z<6F;5883<:WI^S<@#SL1,J/
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MT\>"3[B>XSL-QMPS,2;F1F1.+?/+T#[%/I4ZGU7>3;B3QB_%YE/6Y%5;B9B
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MCQ%4S$4)]/$OL$,Q-?6J5+$-QH>S8 RHP:<%!$-B>V+JH(CM3GRYS^B%T#Y
MFT. -ON*[DW0=AE5]DBO99"OR"HU+]M2>?3[:9=*7&Z/1S5Y-W';@-M] XJR
M 4]9 ]H#@Q>OV4^*MS88Z&;=V5 9N05N;"AU;VQ?0SV/ZDO:KZ(0)8GE0AS
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MY$$"Z[+F[<NB@'HV<9R6=3Y5?$8XH9BB P,\\$,/\,=IY?!-PD9T4!W9RQ!
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MXOL1-@T_< RN8NXZ[$^HA-ON5L2NO15QO,S2W\04O=*B,!1L$CEW%/@T\S0
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MWM>C]6:@N&1TGN#QY9(O*8B"I6?R>KTKZWW5#GSI8>X%'KM(T:V&]8N K[N
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MB.SKS&:,65Q5&O")RI-3A']Q.HS.[P/*J9>39)B[M(!DE/EE=#S#/CU=)++
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M3Y.?ZC<36>E10E.N_[@MMSS0=?JO?=$\?"B;G!;U>EO6^RK_DO]H, _9'RM
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MR[/Z;I-5=6G_QTX,6+DZ_;M%A/-=+M;53YZ!?0*(15$<AAXF/N!0 A(A! =
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MO\6 UNMRSZ?K'\1QP?<E-XQV&U;LQ*./NV\=)E%'V-V[[@&6)DD2DE0<0F8
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MJ,F )"$F.O\CE\]T>CU:YN_LFKC+L0U"X;JOKIJ-%?4ZV_Y7GE7#Z[^!EWB
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M;K8F1K!.[I<QCK5Z^.*F%MULLH[IX:Z8FZP:%M;R-2HV.-_NB=RLPL0W3#.
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M/G%YP9+(5%"0+HXYH7[:I">']%:0O&>S.YM-@,K>$/*JW^?F@'(D+6 R*.E
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M$;660T>YT+'-%T//P%PYMA5[%K9-:/A>%+L81\%@+?#]9+5K#S]]:]*J80N
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M)E7SD,@G4HB%+CUW0I]C8T*(Y!E<A@0I\./YG="*F.%9GJ:EU\,.V0KZCIO
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M\V__Z)^K^9K_N&_J(^Q_9FEU760K/S&L)/;=. ECRP^M&)MXP&M:,-*?PZM
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M*\<(G3!V[0@%2>![9H*]817>=UVLXE7*>8!JCM4]#) 6!;UH-B_6549WWDE
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M7K>'RVMB-Z$K&E^[[K&R8@LY5F#29Q$<Q[(=QS.(9<N!,')-'/!D)"KL:<Y
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M:+VN]NFV'O[B*]UU+S;ML<]5@A,_L6+;@)Z?8#^T4'P 8.&8_7"Q6K.:8\F
MK4W\2HI(1MOD"!:))+-Q*[_O,D"].JZZ4+3'D\>78UXFM,S6 F+Q!6G?.&FR
MAUU9I=43V.1WY!]F[<=0E05%67SH*T5!>FC^P\=70_.W Z_=@:D>^WGO\.OD
M,VAQ\BXEJIEMJ8UZO2WK;*-\^V6J(9D#HI+>L,2HJ,:QR="HD#OQU:FJK,?U
MS3X)RXF/0P.'T DC/S']:#!+K#H\=T)+&^.*A?SW1+=P7AG\LG5?W)R*KC=I
MI%/%&A.%=P6. "^]K'1*%]=2DB#32UT^$G7GS24C*9Y81>S5;>A_#+$=#:%]
M%?MQ&)I$0>/8028T/ ?:O773<#U_>*J#3<U4664:A:=O=?#)VC]>9CE\@J:,
M7S9=FY58(7D[4T%U!8Y4HS>IUB)RC-Q-:)UJ]I<A><J]*O7V6<DL;OC!QV)=
M/F2KR G<Q'>\R+=])S*3T+6&U7DSLG$HE<1QVM*<PW5O?:C.X'CY%$S@-%*I
M('\[_+"#=^'L[90KGN1-D.5E")DR;]Y*W:18DCGG^NGX9O4K9Z-\/T$8VQ@Y
MCNV9T/?C" \X0IOC$C MUC4OUIZ<>!V][:W@V*LDZPQ+MQ<GG$\")P[ CB!K
M.P4KV1[R1V'G:Y>+GX>==/7<RJ=6VA:P *K7/X;CL2J9%$BD1^9O*GHHM'FZ
M(1V0+LC2FR"ZFO;$#*.$ (!.3/+WP#,L9 PH3 MZ?"L*JJUK7UD8H+4;%MF
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M__AOPT_('_06JO_QW_Y?4$L#!!0    ( *V#65#O6"8@6:@  #YR"  5
M=F-Y="TR,#$Y,3(S,5]P<F4N>&UL[+UKE]LXDB;\?7]%O;V?:PKWRYSMW8-K
MKW=<E;FVJWMFO_#0$M/)::68K8O+[E__ I*HO$JB!))BRM.GVGDC(,03#X%
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M&'E:AYEE'(>EA"O-J>- :4_X!AW&F$V910>X91@<14_0P8 9&IYMEZ'AV4Q
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M(<0#]'+WMB"V _<YZ12_G16'%[Z#;3.JB+" "P"$Q !Z <(V=R.S@B+E(&6
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M5]'GY>RO^609$V?7E0G64WH\MWV40AO^MKR+U38OS_F+#0*$:H*=!S:L4M
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M@*"<*.P9E9YBIZ0EVW&'13[E\&B0M=5Z(4J+B+^]B!DL8ZBJHF&^] Q(*QA
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M%RDY[P/<!W;$EE<NC.Y,!>>>,:[N5W?X3+^\+_)Y<>XXWO-,(UP'!0$@@&?
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M&+6,6Z8! V1SW(\4-[21HZR/+7;0R-5L)=%X9:A?%[./MT%+C7?=NSK($.;
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M)"4Y"X+CX];>X!%<9V#_V.=M!"&JL>8L;+*YYY0)6]=74)8EV?7P>.OL!XR
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M  &TLP82Z"VE7FQ18!:F1&R\D<">MBG7(MSG)YV[N2E&B_)KD<B[5_K) L!
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M1OCT9BC6%<SG<.0V],]F" --H,5<<B@HM-;AK208TI1R>\<'13PJN_XVF)(
M96]^U)55=P%.4LJI5)!:XXF&Q !O?*Q@+V38W5#:R#O447++UE&]A?M3 %B'
M3_O['CGW-<N$LA8%*15@ G,,/!9P+2T"!%Y:'>U4E3]/>FD/V;ZF[MIT>3<-
M[VZA'JZOK"]QV*+3F%^G=IF%E4TBC# WSE/C@ZD-28T0YTEQ<@.U3UOD7D^H
M][)Z^+R<_36?+(M?BSR.>'6&>+:%9#N:!PCG#9:3?<TRQ012#%,"O&(Q)RY@
MO;H*5 *$I6E$]?ZD;?+6[VT7)C\AH$,,,6T10H)Z#6MY*98IUMX EY5V5/_\
M;J86 3[?6WSNH_-.7F9DC85AB^^L%H)1K\),ZKWF1@G#8*,(DHZE5?-YL9B'
M5>%]F7^.01]E,=^H97PU_1 #'&;Q'M/I^+=J.JM_7"65'#I\;^TS,@ ]B3LA
M2K3BC $IH-K@J)CD%U:BK!U*[9HD>E9&7^:J7L[#WGD^5Z-_+,MYN=+R_A/_
M'2TR9:BDJT1TBZ0' HI@]GCO#//>4G=AY[AGX$75A1[.R;/1*JSR<.# P;:9
MQU(93B!Q!E'OI.( KF062%*E+ZRP4;+F&S I!=^3#W!^RZ?5QT5\/_;7MWK^
M7":!6UV20HTD3A'"M=:K\7%@%: 7%AO0HKZJ]E#M:R;9SKSZ^_;;_UT&8WDV
MNOW^OOA:3 XL8,TZR" "TD 99F8 .26"1"?">E[6,FSK+\MY<O[UK!.U]$[*
MQUNSEV(<7.J.ZB=#@"*'( _X6HL-BDE3&RR,D/!23:Z6"+*+?QU WSL-WTWO
MEXOY"A1T,-AN3ZL,4<Q8,!Z@Q11JI[P3-9J&8YB2>#9DBK7+@5U,2\:[+UZ9
M?'X;9OSXQ05#XVL^B< <*B>YLU$6#%7A%%72,XV@8PIOWU'C;%+M] '6CCC_
MVMJ:*OI+W9X'2W2T*,:O#_WUWS8H,G=ZMYD%2%$D+&/*$FD]H)YOD++2T L+
M#FR#,B_ROWM#_^0MZ-778C8MO]PN/A3WRS#7Y_-BFZ6VFU]-FV;A+0TO+.!,
M.ZL]AX!I44LA@FB7Q:%^%%YUJH/>3+=RFD]'9<SGK*.:#NUC7V^1:>J0MH!@
M:H#76EK':E>W5="G+*X#K(YS_L6U'3WTQ;-XG>P\:'"^RL.=_?_LO6F3&SFN
M+OR/SLM]^<AUCF]X;%_;/1WW$T-=E>72&5GIH\5MSZ]_24FI6B6EQ-R4=D='
MMUV5S"2 AR  @L#WZ4WDPON[5XA8IGLGR]=_==*1;?(SP2JG4B)?LH9-9&AD
M*:DXJ556#\$!:LUL/)6#$457H/YG.2]^_G.R^'>Q\NOY[6E#\/4!@3NI!-4&
M\DB6(I(R8W?4.4_!2-J6]@N,L@5)=):7722#8K%(/5\W]ZQJ7) ^,"0X+##7
M""E#B"&0,(RJ[28:T2PGP7^ 1<GZWZ8;$D2?4#M]Q?K@H* Q2!%0[#6V!"BL
MF3,5E5QE55 ?H&K+%W8-]%S$V8L]T_\N)K?_NYXL5EN%'=E7+I*,?NZJSL1U
M]*E<K^X_3>9^D;3T\J;<S/KSW^5QQS7_S<$K[HQ7A$8;)=U$9EZYB@?8CBTV
MT@08RCX%T/EY1(;6?UOC#GBCWPD$.$",H-9(8K$#V/$J0!#_XW)4Y0!K/?:_
M,_<IO7Y/4%Y)63S[0.65=P0,H65<>P,AL$8+1RVN>&"D<>-2QSWAI]892[YT
MND)H593-%M_*Y?18[O:S)X-3%&D-D=4T5<<$W,/*]?-29#7/'FFF3#[:\F30
M==:G*;_^-9UOA&O*^2JR(3(Z_FDYC5+>W838\O!8$Y8+WA8\1\*PU,Z1"8(I
M5E;2;4ZD8P3AG.N79Y\T?R\6?Y6_!#K;E]3%;E3]J25-OBK_.E33.>-M(:Y5
MZAFE@@HK (2&0[[+U,4V[V+F2(]H+L=D=W+JY!+8]CKJY\F/'BL![.=P5CF
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MV2\.DE(H+>$2VSAE&!U(OM\Z(%4CNT+4+XC*'B67C=T&T7H.E0(H [1&"%H
MA9!>4[>CTD4-DG/<<?5)[9V#M3W!#:?8BI-:(6^P5%(Z%]>6VR\K1Q'HK>#
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MU68F7Z)V^5>9KCE\*/].\0PUFYG99+DLEE'MI .H@[F<[7\Z8&RAPAAQ1Z&
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MG8NL,Z"?8.WC*N[J9C7]/EW]W+#R<_%CI6>OW\%J[N4!*@0DD:GT@##42J)
MM0M%QY6/K)-6ES [,P#:N*RZ1_A^^TFE+V^* \R>;4 4__3^[F-Q4WZ93_]3
M[(YV-\'G\X#?\#>#4QY0S*U0PL*HQZ*LQ8['D@*?DS5\MN(_E/_(1KT\^I5H
MG_O"8XX^5@?_FLS66ZJ7R_77[<^R]HC+/Q2$]40;0BUG+)T0:V&KH(RT7N08
M1F>[DH?6!Q[U^NA!C-T=_-^7LXB%I?O?=91D;R?^V\_7.,%_^F  BC)!K36&
M$"JP8\[N:M<X1IFM%6=I2=V\8.Z[<E4\G 77TB1UWQ&X0<@I[(2DVBNFHE?
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M723]_/[N.7.V9,T264?05_,-P1%/K21$P[BR0?2='!45_5*HG(+X0V_ W#H
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M#A&3#@K"TN7=+77$VBR#9H!Z)D_ )]!R$4<[P\MT'I?*5B.>W)I>/AP=!*
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MHKPIBMME*O61D+VY@G7W*%GM"').C@U(8R -L5CZZ+4*@Q7B>YH%RH'0@")
M34.H:;[VD?JU3JYD_,M&:VZUZ9OYHZR3FDE@IUX3#,?.2RV]=$9"30E3U1%A
MM"RS\G@&5(FE1275-(L[ ]NC^=;>Z@Z-"6D) 6"TP(A:316RENUIQ"@GNCB@
M]GR-PZ@A?O:@H$PY7TYOBUVGFUVUM??G:ZC3[PE:"<VAA8@I2U-_>.[VO. 0
MY<2J!E19I445U3B/.S.N)C\W77=W=%1[N2F7JV/NW;%A 7FJ'?=Q=7%-N;."
MN"HZRYW):M-Q=E&5ZT%3@RSMPS)/I]'I&GQBQ+(Z":AIF;\Z-BAM"(*  B92
MK@-U$%7A-RX==SFQS@&52VG3-&^"L0.Z5%[]_^D$K_@RN8^:7PD$)86 4<VB
MPR2VDC J=;"K _%V*-W4C=YWC:SF_G/[W\^1Y7IVW/.N]X* %71"0(\D\@8I
MP+BW%0<()B-+V6D""F4'?.YJ _EC&0THMUQ-OTY61\/)3Q\,)A*"$3?026@B
M(9ZX78I!M.<9R=D:!GAGKP749/'SXO/T)[T[]_N1FM^^7]T7B]3,,U5:^2,^
MM$B'<ZM*Y1]5. V].8BXK2+**:%2.20D<$;L>0!E3K&+ 1U%M("I?@30[W'K
M'_,HZ=5B>K,J;E]_8DO=V>>P=5\<N#%26V>CG*QS $ (=I=6XB_B$N[RZ*/#
MRI5-*L%.)= O7C^V@]9ZKPT&22 4L!(#G2JP&XMWYTK&:IF5"C6@,Y;.D=H*
M][O"J5XODU.Z-.77OZ;S[;9Q$H6'!Z5>;$!H+:7WBLO$8U11Z;QS(SEE:=.1
M:(JW72'H\V)R6U061E6N[Z%"WTDPU1H?@#!4 8X$X\0:[K11K*)=.9^3"#6@
M8Y<6<=4&FSL,<+[>"+Y^'*3N*P* 3%HJK$3*,<$H@;0R)QR /"<2,J SF!:!
MUA*GN\+:ZSV/-PV73ZJRDV.#Y902H"!W7"-HXS]0[56X5SGNPH#.9%I$5],L
M[@I65>O:N"!>].W>_>HDO&J_(V!L')7,,0F\AE9*6!U:&!__DY6?/J SFQ9Q
MUA:ON\*;GTP7F\SF]W=QB4SF-]/)[,T\,F7]M9:C66M\0 XIX674VYXPR0C#
MLEIKGBJ?57GBUS@W:(//'58S.=;[K;YQ=MZ+ A>*$H<$U9X( P5CDN^Y04E6
M2_5?X]RA589W![]E$;^5(BXVTC,K-U:F^_&MF"]/NYTU1@<KA1$PZG###2>.
M*,AVWI %%).LPMOC/HQHC\O=^0&I&]?GR8_Z:NS0D( ]\Q8[J#TD/#K8REA?
M4<@ER"KM-: +$JV:_8VPMM.48SU9%K>I*'#$^D9LVYJ'&XLR'=)%GR7YR*=M
ML0O>%@!S$'$IG!=::^\AXZ#B"\%Y38A^C6!_^USO"HW/F\'5UV@G1J8" !!K
MCKVW$" -J >HHM?0O*+POT:XOUD.=X6H=\7?CWBQ*.?QCS?%(X^E/L3.?54P
M$D#FE43I!,0+H)V0%4>TQ%GM^WZ-HX"663Z@3-5TOO'DYT^('5U/).*B&:U0
MZN3.8(0%HM19"B%QRC-0:V5TKB_>+\S]9/ZE>#-__,1T?C/]-BM.=4W*>F^0
MG@FB!4I-FC6C3!) (K^HTA@0P;NIXC$$15(;./452>/L[VIK4[?_LUYN2I0O
M?;DX0N&)6G=GO2=X[C#E@@A M6!4LJC2$R\<%XX#.K+\ZXYP4W8GD<Z2+>+7
MWM^IV[)>5X/7'@\(028=X^G^B;<22$_)CC*/)1I97XR6I/X\NR*?T9TIN#W]
MGU:3^>UD<;O\X]OM9%7$YQE )S%5:WQPS$B'F+"(0JXX(C9ZQ6EWT=YXX+/B
M#\,#69[XG^NI%A@\ ,?PJ&9_>Z2R7V/O#L9:Q(FD5!"DDI$#A=KM'-&_03G'
ME0,\-^IGE^U:2ETA^_VWS;7R^9>WQ619?)Q^N5^]O_MCN<T).(+:H^."%9IC
MJ*W6UD3'V@/LD^6-&#0,B[RCS/$@\@)L/.\]U* 4.KM"\,K)[-OIY*]-4==C
M=P2.C0L"24\<Q5I89RS<7/2)M&+J4GM"E.-IC$@'YB.N22GTH^/J8.W B "D
MLA@1!SU6F!@0_^P3?9XY0O#8;O$-1:]=RO_.DM(V&4[%F3OHD5'!6ZRQ$9@B
MS(16Z7I-LH*)Q7%A<9-3C6F !^O]X:PY&?2!M3J:[-7G Y)6(^,)$XQ9(P52
M$"7:*$(6<#JR*W/#P->EW!_0N=/&A1K/P1+B<1-AP*3"VPQ[*>-2)W&'<5!3
MS5FM5=":C?QPWSU=;S]U8O3Z@. EH9Z"Z.<2I"T@/%TBV%$HE:M5 :8-/^RA
MSC9J:]$W(?>7MF\^DSMTLYY.5O^LT57OR*B@G*;0HM1O65 "/8N&5T6G "BK
M8E8S8()M@2E7\J> =#&7>T-3K89[1T8%:3@U!GF.H"<*8VT<W]')+' C.Z5N
M1.(GU=&EW.T,1;N P8N9GSR=.3$R0,"C"06B6^@(D@!:8EE%+XBFVLC1=(GD
MGZ.I40YWAJA-(: +\'1L7&#.0^Z\]D8#G[JQ($<J6AD:VX%**VAJD+\]6DRZ
MF-_<1\?HW^>;34^&!B8(@=98++@4T><SP.J*8LE-3OV0AAK>7+'ME,/J_L!5
M3?I\*^K9T,"(DYA9;ZB.I&IIF*E4,W>2CWWSNQ@ )Y&5Q>?3R#K4(7(R2RF^
MFZN,_UB4R^6)#I&O/QZ4]I08[%14VYXPZKG;SY8)-K)\J.:$5S;.VXY3H!Z5
MOZF;]?1B2' 1DQZF% GID&(&*P8J"JD4.1'B:S"!<M'3,'][VZ7>UDA@.CPH
M4$NY@XXQ$K=Z"S &JMKD.3$V)P_D[//2IV4D'PP?>:V&SZ5L[NRVZ*Y/:ZK7
M^GCN[^^VNW;ZKY_<1(G7N5!UP=N"]H#JZ%"D/$+)M9%8D?TB RRKCL? P]]-
MH.7YS='6)=!QA8\ZQT?/'PW;7IH>&R0=P4X[JLV.(@$YR8E;7L/&F ^C3(YV
MA1$[7?[_W5W!;J,P$+WOUV!L;'-9R3:VM)<VJJI>$>W2%"F-*T,K\?<=(/10
M+<$A0+JY1$3(EOWFS3#VC#W9=NN:*L0=Q[MAMS;<QUYYM4^;Y%.N"#@6+&:8
M$\0"T \=$LW!P0A^0$QE,0LUG0=V>:17";K?O]3.%G]57=FWK'JQ.[NM-YFK
M]B"("4'VH>5D[CZ*)\ 9(&J3'HY8O>,-4J7#0"-.M&*"-I<UQ:B[!X FC!J_
M0E[+:&M?BJ9/3RQOW<;9K<M>2Z#'T\Z6[\Y+;4_K* 57'68.C"*1!D<.>,54
MCXAA\DJB6'/1PJZ(]<4U>/HQ[.45F;6W+T0\H3R.@E@;(GN)H8!<\DAU[V3>
M/C]DKFA,^)\]$#LO*[VOBJI/0O)8*(STD&(>*AX1(;@*19.K;!CN,4 Z.>?J
MY?]'=;V),+ 6F!?DM7R[H3'+6NVRLFSSWSI?HGU3CT1_IG27<IH0*258,BPY
M^,Z,PY\#,E2+*SM).#M?[.HB6&T/[MN _SFU>CQJ=$(WJ1$R;.IF&X243!0.
MR*&<-DW"@ 57=DY_6;)\W[9;3@X7-9?UC:TVKFBRAF6^SV&"!3R.!AQ.[BL5
MA#!NI,1",4KCR*A#)67 A&AYUF5</X^;R]#%QUK.*(3+$M,G9C'2,L6(:&UB
M%FEL!-<&<_J%+"+)JN&OH< %O:J/]63P)\?9VY(AW0V<=X#*75Z\/KZ#?C<.
M\M"2ZEB;-%$ABAG7G 1&"Q9+\O6)("K&YYS:FFDS;S'*S"92NPS8'KL!AQ?-
MSV-6YK]_?0)02P$"% ,4    " "M@UE0#8J[GT.[ 0"O" ( #P
M    @ $     8G5S:6YE<W-O;F4N:G!G4$L! A0#%     @ K8-94.34.+2Z
M9@$ )8D" !$              ( !<+L! &)U<VEN97-S=&AR964N:G!G4$L!
M A0#%     @ K8-94!M?8COK$@$ N% ! !T              ( !62(# &-H
M87)T+3@V.34P83$R8CEC,&4W,S5D83 N:G!G4$L! A0#%     @ K8-94(1^
MQ(#$U@, DG@G !4              ( !?S4$ '9C>70M,3(S,3(P,3EX,3!K
M+FAT;5!+ 0(4 Q0    ( *V#65![Z7B?#@X  *14   8              "
M 78," !V8WET+3$R,S$R,#$Y>&5X,3 Q-2YH=&U02P$"% ,4    " "M@UE0
MR-,^-6$.  #N5   &               @ &Z&@@ =F-Y="TQ,C,Q,C Q.7AE
M>#$P,38N:'1M4$L! A0#%     @ K8-94 I9D'GI @  =0T  !<
M     ( !42D( '9C>70M,3(S,3(P,3EX97@R,3$N:'1M4$L! A0#%     @
MK8-94&JB4;LT!   !10  !<              ( !;RP( '9C>70M,3(S,3(P
M,3EX97@R,S$N:'1M4$L! A0#%     @ K8-94*TNT?YO"    ST  !<
M         ( !V# ( '9C>70M,3(S,3(P,3EX97@S,3$N:'1M4$L! A0#%
M  @ K8-94*'20(EV"   23T  !<              ( !?#D( '9C>70M,3(S
M,3(P,3EX97@S,3(N:'1M4$L! A0#%     @ K8-94#69K]@R!0  ."(  !<
M             ( !)T(( '9C>70M,3(S,3(P,3EX97@S,C$N:'1M4$L! A0#
M%     @ K8-94-?S0ZDW!0  ?"(  !<              ( !CD<( '9C>70M
M,3(S,3(P,3EX97@S,C(N:'1M4$L! A0#%     @ K8-94'53T3^6$0  SGD
M !8              ( !^DP( '9C>70M,3(S,3(P,3EX97@T,BYH=&U02P$"
M% ,4    " "M@UE0.J]P)R06  #']P  $0              @ '$7@@ =F-Y
M="TR,#$Y,3(S,2YX<V102P$"% ,4    " "M@UE0A_<\.,(D  !UD $ %0
M            @ $7=0@ =F-Y="TR,#$Y,3(S,5]C86PN>&UL4$L! A0#%
M  @ K8-94"E"OLV3<P  Z,D% !4              ( !#)H( '9C>70M,C Q
M.3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( *V#65 ^BG7KO0<! (Z5#0 5
M          "  =(-"0!V8WET+3(P,3DQ,C,Q7VQA8BYX;6Q02P$"% ,4
M" "M@UE0[U@F(%FH   ^<@@ %0              @ '"%0H =F-Y="TR,#$Y
B,3(S,5]P<F4N>&UL4$L%!@     2 !( PP0  $Z^"@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821171280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Credit Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>term_loan </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,385,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_PaymentOfEndOfTermObligation', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,536,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=vcyt_VisiumMember', window );">Visium | Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_NumberOfTermLoans', window );">Number of term loans (in term loans) | term_loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 27,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentNumberOfInstallments', window );">Number of installments (in installments) | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_TermOfDebtWithEqualQuarterlyInstallments', window );">Term of debt with equal quarterly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentFixedRatePercentagePaidInCash', window );">Fixed rate percentage paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentInterestPaidInKindPercentage', window );">Interest paid-in-kind percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Conversion of accrued interest to long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,000<span></span>
</td>
<td class="nump">$ 385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_PaymentOfEndOfTermObligation', window );">Prepayment premium</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=vcyt_VisiumMember', window );">Visium | Line of credit | Initial Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentFixedRatePercentagePaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate for which Company may elect to pay interest in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentFixedRatePercentagePaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentInterestPaidInKindPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest rate for which interest is paid-in-kind by adding paid-in-kind interest to the outstanding principal amounts of the Term Loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentInterestPaidInKindPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of installments for payment of the debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of prepayment premium for prepayment made on or prior to March 31, 2018.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentPenaltyPercentageOnPrepaymentPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_NumberOfTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of term loans available to the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_NumberOfTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_PaymentOfEndOfTermObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of the end-of-term obligation and prepayment penalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_PaymentOfEndOfTermObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_TermOfDebtWithEqualQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of debt with equal quarterly installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_TermOfDebtWithEqualQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=vcyt_VisiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=vcyt_VisiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vcyt_InitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vcyt_InitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820932176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Activity Under Stock Option Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional options authorized (in shares)</a></td>
<td class="nump">1,634,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="nump">180,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of the period (in shares)</a></td>
<td class="nump">6,235,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(180,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,846,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">5,562,484<span></span>
</td>
<td class="nump">6,235,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable at the end of the period (in shares)</a></td>
<td class="nump">2,651,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">4,442,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share)</a></td>
<td class="nump">9.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">10.66<span></span>
</td>
<td class="nump">$ 7.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">8.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance</a></td>
<td class="text">6 years 11 months 19 days<span></span>
</td>
<td class="text">6 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable at the end of the period</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at the end of the period</a></td>
<td class="text">6 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance (in dollars)</a></td>
<td class="nump">$ 79,760<span></span>
</td>
<td class="nump">$ 27,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable at the end of the period (in dollars)</a></td>
<td class="nump">52,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest at the end of the period (in dollars)</a></td>
<td class="nump">$ 77,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(969,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">969,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 21.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(505,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion', window );">Tax portion of restricted stock units vested (in shares)</a></td>
<td class="nump">44,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">505,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="num">(122,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest at the end of the period (in dollars)</a></td>
<td class="nump">$ 2,720<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember', window );">Shares of common stock subject to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">1,571,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">1,954,804<span></span>
</td>
<td class="nump">1,571,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of the period (in shares)</a></td>
<td class="nump">6,235,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">5,562,484<span></span>
</td>
<td class="nump">6,235,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares, Tax Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedNumberofSharesTaxPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821455136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Diagnostic Development Agreement with Johnson &amp; Johnson (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DevelopmentPrograms', window );">Development programs | program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ContractAgreementConditionalAccountsReceivable', window );">Accounts receivable, current</a></td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,730,000<span></span>
</td>
<td class="nump">$ 30,973,000<span></span>
</td>
<td class="nump">$ 30,136,000<span></span>
</td>
<td class="nump">$ 29,529,000<span></span>
</td>
<td class="nump">$ 25,750,000<span></span>
</td>
<td class="nump">$ 23,466,000<span></span>
</td>
<td class="nump">$ 22,751,000<span></span>
</td>
<td class="nump">$ 20,041,000<span></span>
</td>
<td class="nump">$ 120,368,000<span></span>
</td>
<td class="nump">$ 92,008,000<span></span>
</td>
<td class="nump">$ 71,953,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member', window );">Johnson and Johnson Services, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ContractAgreementReceivableForServices', window );">Contract agreement receivable for services</a></td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_TermContractAgreement', window );">Contract agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ContractAgreementFeePercentageOfCashCollections', window );">Percent of collections</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vcyt_Perceptav.2andNassaRiskMember', window );">Percepta v.2 and Nassa Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_ProvisionofDataMember', window );">Provision of Data | Johnson and Johnson Services, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_FulfillmentofObligationsMember', window );">Fulfillment of Obligations | Johnson and Johnson Services, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ContractAgreementConditionalAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Agreement, Conditional, Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ContractAgreementConditionalAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ContractAgreementFeePercentageOfCashCollections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Agreement Fee Percentage Of Cash Collections</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ContractAgreementFeePercentageOfCashCollections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ContractAgreementReceivableForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Agreement Receivable For Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ContractAgreementReceivableForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_TermContractAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term, Contract Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_TermContractAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_JohnsonandJohnsonServicesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_Perceptav.2andNassaRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_Perceptav.2andNassaRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_ProvisionofDataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_ProvisionofDataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_FulfillmentofObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_FulfillmentofObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983281216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments (in segments)</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807146320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Thyroid Cytopathology Partners<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ServicesAgreementAbstract', window );"><strong>Thyroid Cytopathology Partners</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock', window );">Thyroid Cytopathology Partners</a></td>
<td class="text">Thyroid Cytopathology Partners<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an agreement with a specialized pathology practice, Thyroid Cytopathology Partners, ("TCP"), to provide testing services to the Company (the "TCP Agreement").&#160; The TCP Agreement is effective through October 31, 2022, and thereafter automatically renews every year unless either party provides notice of intent not to renew at least&#160;12 months&#160;prior to the end of the then-current term. Under the TCP Agreement, the Company pays TCP based on a fixed price per test schedule which is reviewed periodically for changes in market pricing, and the TCP Agreement included a clause allowing TCP to sublease a portion of the Company's facility in Austin, Texas. &#160;The Company does not have an ownership interest in or provide any form of financial or other support to TCP. &#160;The Company previously concluded that TCP represented a variable interest entity as a result of the facility arrangement clause, but that the Company was not the primary beneficiary as it did not have the ability to direct the activities that most significantly impacted TCP's economic performance, and therefore did not consolidate TCP.&#160; On February 14, 2019, the TCP Agreement was amended to remove the facility clause.&#160; Accordingly, the Company believes TCP was no longer a variable interest entity as of that date.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TCP's portion of rent and related operating expenses reimbursed to the Company for the shared space at the Austin, Texas facility was </span><span style="font-family:inherit;font-size:10pt;"><span>$11,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$128,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$114,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and is included other income, net in the Company's consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -URI http://asc.fasb.org/topic&amp;trid=2145070<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197326<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermContractsOrProgramsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ServicesAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ServicesAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983298928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following outstanding common stock equivalents have been excluded from diluted net loss per common share for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> because their inclusion would be anti-dilutive:</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock subject to outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,394,944</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,998,163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,163,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,869</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>712,122</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>384,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,133,190</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,417,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,261,718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811201216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 159,317<span></span>
</td>
<td class="nump">$ 77,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">19,329<span></span>
</td>
<td class="nump">13,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Supplies</a></td>
<td class="nump">6,806<span></span>
</td>
<td class="nump">3,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,235<span></span>
</td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">187,687<span></span>
</td>
<td class="nump">96,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,933<span></span>
</td>
<td class="nump">8,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating lease</a></td>
<td class="nump">8,808<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">65,019<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,725<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">275,212<span></span>
</td>
<td class="nump">120,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,328<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,734<span></span>
</td>
<td class="nump">9,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,469<span></span>
</td>
<td class="nump">13,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">23,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueLeasesNetNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition related contingent consideration</a></td>
<td class="nump">6,088<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">11,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">35,757<span></span>
</td>
<td class="nump">40,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized, 49,625,341 and 40,863,202 shares issued and outstanding as of December 31, 2019 and 2018, respectively</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">486,090<span></span>
</td>
<td class="nump">313,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(246,685)<span></span>
</td>
<td class="num">(234,086)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">239,455<span></span>
</td>
<td class="nump">79,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 275,212<span></span>
</td>
<td class="nump">$ 120,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueLeasesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of deferred lease income, classified as noncurrent. Includes, but is not limited to, amount paid in advance by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueLeasesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807178528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 9,208<span></span>
</td>
<td class="nump">$ 3,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807122640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases its headquarters and laboratory facilities in South San Francisco, California under a non-cancelable lease agreement for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>59,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The lease began in June 2015 and ends in March 2026 and contains extension of lease term and expansion options.  In February 2017, the Company relinquished certain expansion rights for a nominal fee.  The Company had deposits of </span><span style="font-family:inherit;font-size:10pt;"><span>$603,000</span></span><span style="font-family:inherit;font-size:10pt;"> included in long-term assets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the South San Francisco facility.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also leases laboratory and office space in Austin, Texas under a lease that expires in January 2029 and includes options for expansion and early termination in 2025.  The Company provided a cash security deposit for this lease of </span><span style="font-family:inherit;font-size:10pt;"><span>$139,000</span></span><span style="font-family:inherit;font-size:10pt;">,   included in other assets in the Company's balance sheets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined its operating lease liabilities for the two operating leases mentioned above using a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span>7.53%</span></span><span style="font-family:inherit;font-size:10pt;"> based on the rate that the Company would have to pay to borrow on a collateralized basis for a similar lease an amount equal to the lease payments in a similar economic environment.  Operating lease liabilities along with the associated right-of-use assets as of December&#160;31, 2019 are disclosed in the accompanying consolidated balance sheets.  After the adoption of ASC 842, the Company classified its deferred rent for tenant improvements with its operating lease right-of-use assets on the consolidated balance sheets.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating leases as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands of dollars):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,401</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total future minimum lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,588</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: short-term lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes rent expense on a straight-line basis over the non-cancelable lease period. Rent expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Supplies Purchase Commitments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had non-cancelable purchase commitments with suppliers to purchase a minimum quantity of supplies for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$7.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no litigation pending that could have, either individually or in the aggregate, a material impact on the Company's financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6727404672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Loan and Security Agreement (Details) - Line of credit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount', window );">End-of-term debt obligation</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net debt obligation</a></td>
<td class="nump">$ 694<span></span>
</td>
<td class="nump">$ 25,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentEndOfTermPaymentInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, End Of Term Payment, Interest Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentEndOfTermPaymentInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820806832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Stock Option Plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2008</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockPlan2008Member', window );">2008 Plan | ISO | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock', window );">Voting power of person owning stock</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock', window );">Option price as a percentage of estimated fair value of shares on date of grant to a person owning stock representing more than 10% of voting power of all classes of stock</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockPlan2008Member', window );">2008 Plan | ISO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock', window );">Term of options granted to a person owning stock representing more than 10% of voting power of all classes of stock</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockPlan2008Member', window );">2008 Plan | Employee stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Minimum purchase price as a percentage of fair market value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockPlan2008Member', window );">2008 Plan | Employee stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of options granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance', window );">Number of additional shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum annual increase in outstanding shares on the last day of the immediately preceding fiscal year (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 | ISO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Minimum purchase price as a percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 | NSO | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Minimum purchase price as a percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 | NSO | Outside director who was not previously an employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne', window );">Percentage of award vesting after one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants', window );">Shares granted as initial grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 | Employee stock options | Outside director serving as a member of Board of Directors for at least six months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants', window );">Shares granted as annual grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 | Employee stock options | Outside director serving as a member of Board of Directors for at least six months | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares', window );">Period for which director has to serve as board of director to receive grant to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 | Employee stock options | Outside director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Minimum purchase price as a percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 | Employee stock options | Outside director | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination', window );">Expiration period after termination of service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based compensation award, tranche one | Stock Incentive Plan 2013 | ISO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based compensation award, tranche two | Stock Incentive Plan 2013 | ISO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-based compensation award, tranche three | Stock Incentive Plan 2013 | ISO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of additional common shares reserved for future issuance under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_CommonStockCapitalAdditionalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration period of award after termination of service, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodAfterTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted to each individual as an annual grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted to each individual as an initial grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInitialGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Voting power of all classes of stock, as a percent, of person owning stock as threshold for option terms under the entity's stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOfAllClassesOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period for which director has to serve as board of director to receive grant to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForWhichDirectorHasToServeAsBoardOfDirectorToReceiveGrantToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of options granted to persons owning stock representing specified percentage of voting power of all classes of stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfOptionsGrantedToEmployeesWhoOwnedSpecifiedPercentageOfClassOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards after one year from date of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentageYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option price as a percentage of estimated fair value of shares on date of grant to a person owning stock representing specified percentage of voting power of all classes of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfStockPercentageForGrantsToPersonsWhoOwnedSpecifiedPercentageOfClassOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vcyt_StockPlan2008Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vcyt_StockPlan2008Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vcyt_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_NonStatutoryStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_NonStatutoryStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vcyt_OutsideDirectorWhoWasNotPreviouslyEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vcyt_OutsideDirectorServingAsMemberOfBoardOfDirectorsForAtLeastSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vcyt_OutsideDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vcyt_OutsideDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807067584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Data (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 29,730<span></span>
</td>
<td class="nump">$ 30,973<span></span>
</td>
<td class="nump">$ 30,136<span></span>
</td>
<td class="nump">$ 29,529<span></span>
</td>
<td class="nump">$ 25,750<span></span>
</td>
<td class="nump">$ 23,466<span></span>
</td>
<td class="nump">$ 22,751<span></span>
</td>
<td class="nump">$ 20,041<span></span>
</td>
<td class="nump">$ 120,368<span></span>
</td>
<td class="nump">$ 92,008<span></span>
</td>
<td class="nump">$ 71,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (7,458)<span></span>
</td>
<td class="num">$ (730)<span></span>
</td>
<td class="num">$ (2,494)<span></span>
</td>
<td class="num">$ (1,917)<span></span>
</td>
<td class="num">$ (3,105)<span></span>
</td>
<td class="num">$ (4,469)<span></span>
</td>
<td class="num">$ (6,248)<span></span>
</td>
<td class="num">$ (9,177)<span></span>
</td>
<td class="num">$ (12,599)<span></span>
</td>
<td class="num">$ (22,999)<span></span>
</td>
<td class="num">$ (31,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares use to compute net loss per common share, basic and diluted (in shares)</a></td>
<td class="nump">49,095,703<span></span>
</td>
<td class="nump">48,588,296<span></span>
</td>
<td class="nump">45,586,081<span></span>
</td>
<td class="nump">41,168,593<span></span>
</td>
<td class="nump">40,731,334<span></span>
</td>
<td class="nump">38,620,036<span></span>
</td>
<td class="nump">34,314,234<span></span>
</td>
<td class="nump">34,271,254<span></span>
</td>
<td class="nump">46,138,177<span></span>
</td>
<td class="nump">37,020,246<span></span>
</td>
<td class="nump">33,925,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6823887360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense (in dollars)</a></td>
<td class="nump">$ 9,807<span></span>
</td>
<td class="nump">$ 5,958<span></span>
</td>
<td class="nump">$ 6,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense (in dollars)</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense (in dollars)</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense (in dollars)</a></td>
<td class="nump">2,938<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense (in dollars)</a></td>
<td class="nump">4,736<span></span>
</td>
<td class="nump">$ 2,944<span></span>
</td>
<td class="nump">$ 3,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember', window );">Stock-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense (in dollars)</a></td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which unrecognized compensation expense expected to be recognized</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_EmployeeStockOptionExcludingBonusCompensationMember', window );">Stock-based Compensation, employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Weighted-average volatility, low end of range (as a percent)</a></td>
<td class="nump">52.90%<span></span>
</td>
<td class="nump">50.40%<span></span>
</td>
<td class="nump">50.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Weighted-average volatility, high end of range (as a percent)</a></td>
<td class="nump">53.40%<span></span>
</td>
<td class="nump">52.70%<span></span>
</td>
<td class="nump">52.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, low end of range (as a percent)</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, high end of range (as a percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember', window );">Stock-based Compensation, non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Weighted-average volatility, low end of range (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">43.60%<span></span>
</td>
<td class="nump">50.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Weighted-average volatility, high end of range (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">50.50%<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, low end of range (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.84%<span></span>
</td>
<td class="nump">2.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, high end of range (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.87%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Weighted-average volatility, low end of range (as a percent)</a></td>
<td class="nump">53.38%<span></span>
</td>
<td class="nump">42.88%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Weighted-average volatility, high end of range (as a percent)</a></td>
<td class="nump">71.77%<span></span>
</td>
<td class="nump">47.74%<span></span>
</td>
<td class="nump">43.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, low end of range (as a percent)</a></td>
<td class="nump">1.88%<span></span>
</td>
<td class="nump">1.64%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, high end of range (as a percent)</a></td>
<td class="nump">2.56%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">1.22%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock-based Compensation, employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock-based Compensation, non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected term</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock-based Compensation, employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected term</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock-based Compensation, non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected term</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">7 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionExcludingBonusCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_EmployeeStockOptionExcludingBonusCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_EmployeeStockOptionExcludingBonusCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819757056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,506<span></span>
</td>
<td class="nump">$ 50,410<span></span>
</td>
<td class="nump">$ 47,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">5,579<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="nump">4,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">2,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">NanoString intangibles and goodwill</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">3,068<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther', window );">Accruals and other</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossNoncurrent', window );">Gross deferred tax assets</a></td>
<td class="nump">70,389<span></span>
</td>
<td class="nump">58,944<span></span>
</td>
<td class="nump">55,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(65,228)<span></span>
</td>
<td class="num">(55,366)<span></span>
</td>
<td class="num">(51,657)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Net deferred tax assets</a></td>
<td class="nump">5,161<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
<td class="nump">3,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(471)<span></span>
</td>
<td class="num">(695)<span></span>
</td>
<td class="num">(983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">In-process research and development</a></td>
<td class="num">(2,597)<span></span>
</td>
<td class="num">(2,883)<span></span>
</td>
<td class="num">(3,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_DeferredTaxLiabilitiesRightofUseAssets', window );">ROU assets</a></td>
<td class="num">(2,093)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(5,161)<span></span>
</td>
<td class="num">(3,578)<span></span>
</td>
<td class="num">(3,997)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(5,161)<span></span>
</td>
<td class="num">(3,578)<span></span>
</td>
<td class="num">(3,997)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences and carryforwards, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ComponentsOfDeferredTaxAssetsNonCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ComponentsOfDeferredTaxLiabilitiesNonCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-current accruals, deferred rent and other reserves and accruals not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DeferredTaxAssetsAccrualsDeferredRentAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible research and development tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DeferredTaxLiabilitiesRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DeferredTaxLiabilitiesRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6984543120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 5,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">5,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">5,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">5,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">5,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">39,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 65,019<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807225568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Pro forma financial information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue | NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total revenue</a></td>
<td class="nump">$ 11,040<span></span>
</td>
<td class="nump">$ 11,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanoStringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6959212912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP").<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company's cash and cash equivalents are deposited with </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> major financial institution in the United States. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Several of the components of the Company's sample collection kit and test reagents, and its nCounter FLEX DX systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable related to its sales. The Company does not perform evaluations of customers' financial condition and does not require collateral.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash Equivalents</a></td>
<td class="text">Cash Equivalents<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist of amounts invested in a money market account primarily consisting of U.S. Treasury reserves, and overnight reverse repurchase agreements which are tri-party repurchase agreements and are collateralized by U.S. Treasury and agency securities of at&#160;least&#160;102%&#160;of the principal amount. In a tri-party repurchase agreement, a third-party custodian bank functions as an independent intermediary to facilitate transfer of cash and holding the collateral on behalf of the underlying investor for the term of the agreement thereby minimizing risk and exposure to both parties. These overnight reverse repurchase agreements are included within cash equivalents due to their high liquidity and relatively low risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had deposits of </span><span style="font-family:inherit;font-size:10pt;"><span>$603,000</span></span><span style="font-family:inherit;font-size:10pt;"> included in long-term assets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, restricted from withdrawal and held by a bank in the form of collateral for an irrevocable standby letter of credit held as security for the lease of the Company's South San Francisco facility.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company first determines whether a set of assets acquired and liabilities assumed constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.&#160; Contingent consideration obligations incurred in connection with a business combination are recorded at  fair value on the acquisition date and remeasured at each subsequent reporting period until the related contingencies are resolved, with the resulting changes in fair value recorded in earnings. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts for Product Sales</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts for Product Sales </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable regularly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value by analyzing the status of significant past due receivables.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Finite-lived Intangible Assets</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finite-lived Intangible Assets </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets consist of intangible assets acquired as part of business combinations. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 5 to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. The Company tests these finite-lived intangible assets for impairment when events or circumstances indicate a reduction in the fair value below their carrying amounts. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill, derived from the Company's acquisition of Allegro Diagnostics Corp. in September 2014 and the exclusive global diagnostics license to the NanoString nCounter FLEX Analysis System and Prosigna and LymphMark assays in December 2019, is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired. The Company's goodwill evaluation is done annually on October 31 and is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company has determined that it operates in a single segment and has a single reporting unit associated with the development and commercialization of diagnostic products. In the event the Company determines that it is more likely than not the carrying value of the reporting unit is higher than its fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value.  There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Cost of Revenue</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Testing Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company commenced recognizing testing revenue in accordance with the provisions of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">, or ASC 606, starting January 1, 2018.  Prior to January 1, 2018, the Company recognized testing revenue in accordance with the provisions of ASC 954-605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Health Care Entities - Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, or ASC 954. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most of the Company&#8217;s revenue is generated from the provision of testing services. These services are completed upon the delivery of test results to the prescribing physician, at which time the Company bills for the services. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized.  In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method, which requires a cumulative catch-up adjustment as if the Company had recognized revenue under ASC 606 from January 1, 2016.  Prior to January 1, 2018, the Company recognized revenue in accordance with ASC 954 and recognized revenue for tests delivered on an accrual basis when amounts that will ultimately be realized could be reasonably estimated, and on the cash basis when there was insufficient information to estimate revenue accruals.  There was sufficient payment history for the Company to substantially accrue all revenue upon delivery of test results starting July 1, 2016 and the Company continued to recognize revenue in 2017 upon cash receipt for unaccrued tests that were delivered prior to July 1, 2016.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, on July 1, 2016 the Company began recognizing testing revenue from substantially all its tests on the accrual basis of accounting at an amount equal to management&#8217;s best estimate of the cash to ultimately be collected. For tests delivered prior to July 1, 2016, substantially all the related cash had been collected by December 31, 2017. Thus, at January 1, 2018, the cumulative impact of adopting ASC 606 was not material and no adjustment was recorded.  Since the Company commenced recognizing revenue from substantially all of its tests on the accrual basis of accounting commencing on July 1, 2016, and continued to do so after the adoption of ASC 606, the adoption of ASC 606 did not have a material impact on the Company's statement of operations for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.   </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2018 or prior years and recognized additional revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which resulted in a decrease in the Company's loss from operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a decrease in loss per share of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.04</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2018, the Company changed its testing revenue estimates due to actual and anticipated cash collections for tests delivered in 2017 or prior years and recognized additional revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which resulted in a decrease in the Company's loss from operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a decrease in loss per share of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.04</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company began recognizing product revenue in December 2019, when the Company executed an agreement with NanoString for the exclusive global license to the nCounter platform for diagnostic use.  More details on this agreement are in Note 4 - Business Combination.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue from instruments, consumables and in vitro diagnostic kits is recognized generally upon shipment or when the instrument is ready for use by the end customer, which is when title of the product has been transferred to the customer. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. The Company recognizes product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.  Shipping and handling costs incurred for product shipments are charged to the Company's customers and included in product revenue. Revenues are presented net of the taxes that are collected from customers and remitted to governmental authorities. There was no revenue from instrument sales for the years ended December 31, 2019, 2018 or 2017. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Biopharmaceutical and Collaboration Revenue</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company enters into arrangements for research and development and/or commercialization services. Such arrangements may require the Company to deliver various rights, services and/or samples, including intellectual property rights/licenses, R&amp;D services, and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, and/or profit sharing.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods is transferred or services are performed. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of licensed products. Each of these payments may result in collaboration revenues or an offset against research and development expense.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales of data or other services to our customers are classified under biopharmaceutical revenue and collaboration revenue, such as milestones, are classified under collaboration revenue in our consolidated statements of operations and comprehensive loss.  </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Up-front Fees: </span><span style="font-family:inherit;font-size:10pt;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments:</span><span style="font-family:inherit;font-size:10pt;"> At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the collaborative partner&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Services Agreement with Loxo Oncology</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 9, 2018, the Company entered into an agreement with Loxo Oncology, Inc. ("Loxo") whereby the Company agreed to provide certain tissue samples and other services in exchange for agreed-upon fees. During the quarter ended June 30, 2018, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$450,000</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue upon deliveries of tissue samples and the Company received </span><span style="font-family:inherit;font-size:10pt;"><span>$500,000</span></span><span style="font-family:inherit;font-size:10pt;"> for other services, which was recognized ratably during the quarters ended September 30 and December 31, 2018 as the services were  performed. Thereafter, the Company expects to receive approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> per quarter as services are performed and may also recognize revenue related to the deliveries of additional tissue samples as long as the agreement is not terminated.  The agreement has a </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year term with an automatic renewal of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> and  Loxo may terminate the agreement at any time with at least </span><span style="font-family:inherit;font-size:10pt;">90</span><span style="font-family:inherit;font-size:10pt;"> days' notice.   As of December 31, 2019, the agreement had not been terminated.  The Company evaluated the accounting for this agreement under ASC 606 and concluded that the performance obligations thereunder are the deliveries of tissue samples and performance of services, both of which are distinct.  For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$90,000</span></span><span style="font-family:inherit;font-size:10pt;"> for  deliveries of tissue samples and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the performance of services and is classified under biopharmaceutical revenue in the Consolidated Statement of Operations and Comprehensive Loss.  There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> deferred revenue related to this agreement at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Diagnostic Development Agreement with Johnson &amp; Johnson</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 28, 2018, the Company entered into a diagnostics development agreement with Johnson and Johnson Services, Inc. ("JJSI") (i) to cooperate on a program to enable the Company to use JJSI samples and clinical data to develop a next generation </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">bronchial genomic classifier diagnostic for lung cancer diagnosis (&#8220;Percepta v.2") and a nasal genomic classifier diagnostic for lung cancer (&#8220;NasaRISK&#8221;) and (ii) for JJSI to use Veracyte data generated in </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> Veracyte development programs for therapeutic purposes and for purposes of developing a companion diagnostic product used in conjunction with a JJSI therapeutic.  The Company granted a license to JJSI with the right to use data and under the Company's intellectual property rights for JJSI's therapeutic purposes, including the development and commercialization of a companion diagnostic for its products, from the Percepta v.2 and NasaRISK programs.  The license granted to JJSI is not distinct from other performance obligations as JJSI receives benefit only when other performance obligations are met.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, the Company will provide data from its RNA whole-transcriptome sequencing platform to JJSI in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments from JJSI.  The Company is also entitled to additional payments from JJSI of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, conditioned upon the achievement of certain milestones relating to the development and reimbursement of Percepta v.2 and NasaRISK.  For a period of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> commencing with the first commercial sale of Percepta v.2 and NasaRISK, respectively, the Company will make payments to JJSI of </span><span style="font-family:inherit;font-size:10pt;"><span>one percent</span></span><span style="font-family:inherit;font-size:10pt;"> of net cash collections for Percepta v.2 and in the low-single digits of net cash collections for NasaRISK, depending on the number and timing of JJSI samples and associated clinical data the Company receives from JJSI.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The JJSI agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the JJSI agreement and has analogized to ASC 606 for the delivery of data from its RNA whole-transcriptome sequencing platform to JJSI under the collaborative arrangement, which the Company believes is a distinct service for which JJSI meets the definition of a customer. Using the concepts of ASC 606, the Company has identified the delivery of data as its only performance obligation. The Company further determined that the transaction price under the arrangement was the </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments which was allocated to the obligation to deliver data.  The </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in future potential payments is considered variable consideration because the Company determined that the potential payments are contingent upon regulatory and commercialization milestones that are uncertain to occur and, as such, were not included in the transaction price, and will be recognized accordingly as each potential payment becomes probable.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during 2019 for the provision of data and fulfillment of obligations relating to Percepta v.2 and NasaRISK development milestones, respectively.  This revenue is classified under biopharmaceutical revenue and collaboration revenue, respectively, in the consolidated statement of operations and comprehensive loss.  Accounts receivable from JJSI was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.  The cost of biopharmaceutical revenue recognized under the agreement with JJSI is not significant and recorded in research and development in the statement of operations and comprehensive loss.  There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> deferred revenue related to this agreement at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Agreement with AstraZeneca Group</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 23, 2019, the Company entered into an agreement with Acerta Pharma B.V. ("Acerta"), a member of AstraZeneca Group whereby the Company agreed to provide genomic information that will support Acerta&#8217;s development of oncology therapeutics.  Acerta will reimburse the Company for certain development costs and pay milestones to the Company for the achievement of development milestones.   As of December 31, 2019, there was no performance of obligations under the agreement or consideration paid.  The agreement will be accounted for in accordance with the policy on collaborative arrangements, as mentioned in this footnote.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Testing Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of our cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation and amortization, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses include expenses incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products. These expenses consist of compensation expenses, direct research and development expenses such as prototype materials, laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses. We expense all research and development costs in the periods in which they are incurred. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company's assessment of an uncertain tax position begins with the initial determination of the position's sustainability and is measured at the largest amount of benefit that is more-likely-than-not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense for stock options issued to employees is measured based on the grant-date fair value of the award. The fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model.  Stock-based compensation expense for stock units is measured based on the fair value of the award, which is determined based upon the closing price of the Company&#8217;s common stock on the date of the grant.  The Company grants performance-based stock units to certain employees which vest upon the achievement of certain performance conditions, subject to the employees&#8217; continued service with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes compensation costs on a straight-line basis for all employee stock-based compensation awards that are expected to vest over the requisite service period of the awards, which is generally the awards' vesting period. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Following the adoption of ASU No. 2018-07, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting</span> by the Company on October 1, 2018, stock-based compensation expense for equity instruments issued to non-employees is also measured based on the grant-date fair value of the awards using the Black-Scholes option-pricing model.  Prior to this, the fair value of such awards was subject to re-measurement as the underlying equity awards vest.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Common Share</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">. This ASU is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU was effective for interim and annual periods beginning after December 15, 2018.  Additionally, the FASB issued ASU No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements.  The Company elected this transition method and adopted ASC 842 on January 1, 2019 and as a result, recorded operating lease right-of-use ("ROU") assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, including offsetting deferred rent of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, along with the associated operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.1 million</span></span><span style="font-family:inherit;font-size:10pt;">.  On January 1, 2019, the Company had finance lease ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and associated finance lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for leases classified as finance leases prior to the adoption of ASC 842. The adoption of ASC 842 had an immaterial impact on the Company's consolidated statement of operations and comprehensive loss, consolidated statement of stockholders' equity and consolidated statement of cash flows for the year ended December 31, 2019.  In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease classification.  Additional information and disclosures required by this new standard are contained in Note 7,&#160;Commitments and Contingencies.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company does not expect to have a material impact on its financial statements and related disclosures from the adoption of this guidance.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808). </span>Under&#160;this ASU,&#160;transactions in collaborative arrangements are to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. Also, entities are precluded from presenting consideration from transactions with a counterparty that is not a customer together with revenue recognized from ASC 606.  This ASU is effective for all interim and annual reporting periods beginning on or after December 15, 2019, with early adoption permitted.  The Company adopted this ASU in 2019 with no cumulative-effect adjustments or retrospective impact.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^KL!N,W=M_;'P1[%KX=1?=%U!+ P04    " "L@UE0F5R<(Q &  "<)P
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M83#T_JMZ4865MW=B/7:Z:+K/8'=IC"Z'5NRME-EK_YU7W?>U_T7*H0P7\*&
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M^U\C.O!2=E=^A%K_P19#0>W"\9,_FVG,)L-A/_\@MGSCX@]02P,$%     @
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MKN>6DKGX3W %A>%1">:HK/)I)=7@@]4S"TK1XF7:I4G[.-W<\AFV#> S@"^
MNY2'38F2\G<BB#)W=B1NZGTOXA/OCAQ[4T5G:D6Z0_$>O=>2\RQGUT@TQYRF
M&+Z*V2T1#-F7%'PKQ8G_!>?;\/VFPGV"[W]3^(_\ATV"0R(X_+?$K9@_5;)5
M3S6X-DV3)Y4=3)KDE7<9V/OTB.Q7^#3MGX5KI?'D8@.^;.I_8VT E)+=X AU
M^,$60T$3XO$MGMTT9I,1;#__(+9\X_(G4$L#!!0    ( *R#65"Q2N;>M0$
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MR>&X#_$QX*>$T:W.)%1R-N8Q&'=53G=!$"@H?6 0N%W@%I0*1"CC:>:D2\H
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M__='(30WOJ0/)B?/9J(;-A4_:KLLS%IV8TVWT:+M1[9DF!M7?P%02P,$%
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M55(:L*5$-[;AQCX52\"A,F[ZQ<[5=&&FP,A^?@O(\B#E?P%02P,$%     @
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MM?,O&_O?:.W I[*[\B/4^0^V& (:%XY[?S;3F$V&T_W\@\CRC<MW4$L#!!0
M   ( *R#65"(-'H<*@(  ( '   9    >&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;)55T8Z;,!#\%<0'G+$))#D1I.2JJI5:*;JJ[;-#-@&=P=1VPO7O:QM"
M<[E%RKW$]C([L^/8WJR3ZD67 "9XK46C5V%I3/M(B"Y*J+E^D"TT]LM!JIH;
MNU1'HEL%?.^3:D%8%*6DYE43YIF/;56>R9,150-;%>A377/U=P-"=JN0AI?
M<W4LC0N0/&OY$7Z ^=ENE5V1D65?U=#H2C:!@L,J7-/'#4U=@D?\JJ#35_/
M6=E)^>(67_>K,'(5@8#". INAS,\@1".R=;Q9R -1TV7>#V_L'_VYJV9'=?P
M),7O:F_*5;@(@ST<^$F89]E]@<%0$@:#^V]P!F'AKA*K44BA_6]0G+21]<!B
M2ZGY:S]6C1^[@?^2AB>P(8'=))!>R%?^B1N>9TIV@>HWO^7N/Z:/S.Y-X8)^
M*_PW6[RVT7,>TR0C9T<T8#8]AEUAZ(@@EGV48)C$AKU+9WAZC%88^_3X384I
M3C!#"6:>8/:&8'YC$<,L<)$$%4G>$;!TB1.D*$%ZO\TY2C!'+"QO;"(8%N$B
M"U1D@1!,'(8E2K"\WR:-\!,;(36PVR.+@>()G8F;01&*V00%>O+7E'W +7[Z
M:7R/6PR43.C@EX0B-X!-E8I? 9I\P"U^"6AZCUL,-+_1(5</8 WJZ)]^'13R
MU/B^<Q4=V\N:^0?T/[SO3=^Y.E:-#G;2V&?8/Y8'*0W86J('Z[FT[7!<"#@8
M-YW;N>I[0K\PLAWZ'1F;;OX/4$L#!!0    ( *R#65#4(A+.SP$  )P$   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;'54;6_;(!#^*X@?4&R<9%UD
M6VI:39NT25&G=9^)?7Y1P7B X^[?#[#C>1[]$KCS\W)'.-)1JE?= !CT)GBG
M,]P8TQ\)T44#@ND[V4-GOU12"69LJ&JB>P6L]"3!"8VB Q&L[7">^MQ9Y:D<
M#&\[."ND!R&8^GT"+L<,Q_B6>&[KQK@$R=.>U? =S(_^K&Q$%I6R%=#I5G9(
M097AA_AX.CB\![RT,.K5'KE.+E*^NN!+F>'(%00<"N,4F%VN\ B<.R%;QJ]9
M$R^6CKC>W]0_^=YM+Q>FX5'RGVUIF@S?8U1"Q09NGN7X&>9^]AC-S7^%*W +
M=Y58CT)R[7]1,6@CQ:QB2Q'L;5K;SJ_CK'^CA0ET)M -@4Q&OO(G9EB>*CDB
M-9U]S]Q?'!^I/9O")?U1^&^V>&VSUSRA]RFY.J$9<YHP=(6)%P2QZHL%#5F<
MZ']T&J8GP0H33T_6]&0?%M@%!79>8/=/BQ\W+08P210VV0=-]@&!>&,2PKQS
M%(>@R2$@D&Q,0IC=QH2L;H< 5?NYT*B00^=G<I5=1N^!^MOU%S[-[3>FZK;3
MZ"*-O:/^)E52&K"E1'>VX<8^%4O H3)N^\'NU30P4V!D/[\%9'F0\C]02P,$
M%     @ K(-94+%Y50RW 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL=5/;;MP@$/T5Q >$7>Q-5BO;4C91E$JMM$K4]IFUQS8*%P?P.OW[
M '8<-W5?@!G..7-AR 9M7FP+X-";%,KFN'6N.Q!BRQ8DLU>Z ^5O:FTD<]XT
M#;&= 59%DA2$;C;71#*N<)%%W\D4F>Z=X I.!ME>2F;^'$'H(<=;_.%XXDWK
M@H,46<<:> ;WLSL9;Y%9I>(2E.5:(0-UCF^WAV,:\!'PB\-@%V<4*CEK_1*,
M;U6.-R$A$%"ZH,#\=H$[$"((^31>)TT\APS$Y?E#_2'6[FLY,PMW6OSFE6MS
MO,>H@IKUPCWIX1&F>G883<5_APL(#P^9^!BE%C:NJ.RMTW)2\:E(]C;N7,5]
M&&]V^XFV3J 3@<Z$?8Q#QD Q\WOF6)$9/2 S]KYCX8FW!^I[4P9G;$6\\\E;
M[[T42;++R"4(39CCB*$+S'9&$*\^AZ!K(8[T'SI=IR>K&2:1GBSIZ7_BIZL"
M:11(_RKQ^DN):YB;+T'(HJ<23!.GR:)2]RI.\L([#^PMC6_R"1^G_0<S#5<6
MG;7S+QO[7VOMP*>RN?(CU/H/-AL":A>.-_YLQC$;#:>[Z0>1^1L7[U!+ P04
M    " "L@UE0E'X3W+D!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6QM4]N.G# ,_94H'[!A MUN1X"TLU752JTTVJK;YPP8B#87FH1A^_?-
MA:&HY878YOCXV''*69M7.P X]":%LA4>G!N/A-AF ,GLG1Y!^3^=-I(Y[YJ>
MV-$ :V.2%(1FV3V1C"M<ES%V-G6I)R>X@K-!=I*2F=\G$'JN\ '? L^\'UP(
MD+H<60_?P?T8S\9[9&5IN01EN5;(0%?AQ\/Q5 1\!+QPF.W&1J&3B]:OP?G2
M5C@+@D! XP(#\\<5GD"(0.1E_%HX\5HR)&[M&_NGV+OOY<(L/&GQD[=NJ/ #
M1BUT;!+N6<^?8>GG'49+\U_A"L+#@Q)?H]'"QB]J)NNT7%B\%,G>TLE5/.>%
M_Y:VGT"7!+HFT-1+*A25?V2.U:71,S)I]B,+5WPX4C^;)@3C*.(_+][ZZ+7.
M\X>27 /1@CDE#-U@#BN">/:U!-TK<:+_I>?YAWV"?%=C'@GR#0'-\GV"8I>@
MB 3%5D&1_=-DPMQ'C-IMDFQF*L'T<9LL:O2DXB9OHNO"/M)X)W_A:=N_,=-S
M9=%%.W^S<?Z=U@Z\D.S.K]#@']CJ".A<,-][VZ0U2X[3X_*"R/J,ZS]02P,$
M%     @ K(-94$(4$83R @  \PL  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&ULE5;M;ILP%'T5Q ,4;/-9)9$6NG:3-JGJM.VWFS@)*F &3M*]_6QP
M4K O$?L3L#GGGGOM>QPOSKQY:P^,">>]+*IVZ1Z$J.\]K]T<6$G;.UZS2G[9
M\::D0@Z;O=?6#:/;CE06'O;]R"MI7KFK13?WW*P6_"B*O&+/C=,>RY(V?]>L
MX.>EB]S+Q$N^/P@UX:T6-=VS'TS\K)\;.?*N4;9YR:HVYY73L-W2_83NGW!'
MZ!"_<G9N!^^.*N65\S<U^+I=NK[*B!5L(U0(*A\GEK&B4)%D'G]T4/>JJ8C#
M]TOTQZYX6<PK;5G&B]_Y5AR6;N(Z6[:CQT*\\/,7I@L*74=7_XV=6"'A*A.I
ML>%%V_TZFV,K>*FCR%1*^MX_\ZI[GG7\"PTF8$W 5P(B-PE$$\@'(;A)"#0A
MF$L(-2&<2X@T(9I+B#4A-@A>O[K==CU005>+AI^=IN^XFJK&1O>Q;(B-FNSV
MO_LF=ZR5LZ<5"=#".ZE &K/N,7B$P6-,!F'(&/, 88(QYK.-,90>;404CR%/
M-@2ACS">7)#KJF!P57 7@(PR#>$ ! Q N@#!($":&)7VD+B#5'VE010EH5$N
M ".!GT1P-@&836!E$Z5&-H$E@\*4(&-E'VU8'*>ID?.3C2(D21&<<@BF'%HI
MDR R^K+'1 .9B.#0]WU8* *%(D#(J'K=8]+1'MSAB8:(09D8D#$Z8AW;>T#B
M9*J<!-1) !UCK[/$6K<P5LLV(92"0JDM%/I&0:E54(JG5) /GT\^H#/126CB
MB$/SW8S@\P!A( ML'F_8MNIT-R+XX$#VR4%",A$"=CL*_J->V'UHCOV0[;_D
M5L&P_Q!D0+-C-6@H=:MC$>Q!-,.$&;)=&-XH"G8A FQHNB/3H-$QF4X*P2Y$
MD T#. 2&'8;]^>V"88=A!&1A_"ED&C0\19%OGZ+>X.:BKL/?:;//J]9YY4)>
M@KJKRHYSP61(_TYVX$'>P*^#@NV$>HWE>]-?0_N!X+6^8GO7>_[J'U!+ P04
M    " "L@UE0WA.V2=L"  !;#   &0   'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6R55]N.VC 0_94H'[")G8O#"I"XJ&JE5D);M7WV@H%HDSBU#6S_OK83
MTF F-/M";'/F>.:$8P_3"Q=O\LB8\M[+HI(S_ZA4_1P$<GMD)95/O&:5_F;/
M14F5GHI#(&O!Z,X&E46 PS -2II7_GQJUS9B/N4G5>05VPA/GLJ2BC]+5O#+
MS$?^=>$E/QR560CFTYH>V'>F?M0;H6=!Q[++2U;)G%>>8/N9OT#/:QR; (OX
MF;.+[(T]4\HKYV]F\F4W\T.3$2O85AD*JA]GMF)%89AT'K];4K_;TP3VQU?V
M3[9X7<PKE6S%BU_Y3AUG?N9[.[:GIT*]\,MGUA:4^%Y;_5=V9H6&FTST'EM>
M2/OI;4]2\;)ET:F4]+UYYI5]7EK^:Q@<@-L W 7$^&% U 9$70!&#P/B-B!V
M H*F%*O-FBHZGPI^\43S>FMJ?D7H.=;J;\VB%=M^I^61>O4\CY)T&IP-48M9
M-AC<PZ .$6CV;@L,;;'$=^%10FZW6$&8[!:SAC 3.)$(K#6R!%&/ ,<$)HA!
M@M@2Q/T,TM 1J\&D%E,]$BL!MTCN<TP&"%*0( 5R1$Z.#8;T<DS#R'DC(S#K
MQYB;9 F8+ &2Q3!!!A)DXU_I!"28 !DX92XA3.S(!6$21RX(D\+)HA!V:PA0
M#-2+!@R/QDN&0$,O$!XA&@AR++T"01-'MO\PW68,.Q]%]Q0D'*" O8_B#^@&
M>QLE8W0#0 2YND$@[.H&@0;LB>##! &G"8D'*&"+(_(!W6"3HVR,;@"()*YN
M$&C(@O"!@0 7DX%Z,.QB'(Z7!,,NQFB$)!"(N!8$00/7*H;/ PP8-!MP%X8-
MBC]P-V/8H!BZG>\D 4"9ZRX(1-Q+..AU6"43!]N]2F_+3Y4R74IOM>N0%[8'
M=-:7NG-N.K=_-$W;_8V*0UY)[Y4KW?_9+FW/N6(ZQ_!)F_NH._UN4K"],D.B
MQZ)I=YN)XG7;R@?=_XGY7U!+ P04    " "L@UE0::BN"[H%  #$(0  &0
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MK&]P-(LMY ^9=8A2LP[)_E.%).1%0GGADO)!R(N\8$LB"7F14#F0J80;B$C
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MJ07YMJ56_\P.+)-X'8GTL>19U?RWEOM*\%Q9D:'DR7M[3(OF>%3V3S)<0)2
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MTSB@Y"QU-U%]WE_1_4"R=GA^P/@&%O\ 4$L#!!0    ( *R#65 !,,^MB0(
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M#. HRG-, M< #C.4HP(6GH'",T!X!A,PD(!='UT.$N171)=/K&:DI"4-<"L
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MYG"AA.<XXIK*?^MXI0PWBH5+:>#;<*U:>>V'.U&BPLP!G@KP[@'#YBP&^"K
M?S0@4 '!HP&A"@AG <[@76[F%C*89P3W%AGJH8.B[, JY,=U%(OR=.0]OI^4
MK][R((PSYR:(%*88,-X$DTPQ&QWC31%;'1'-$NUT" #_:!QNY.[&,[KQ)($_
M5@& F< W$OB2(!@K2,.9U0$32TP[8%S^F]G543/$[G^(B=3 *#70I";I3.D
MB489(C>9G=Q6!RW("(TR0DU&/#O63:@9]6)OMJM;'03<425.E$1&)9&F) A3
M,T%L)(@?KY[$2)#H"J+9J1>)YC.85,\D36I,DQK2@%F:5#M5L)P&N.;>X'Y8
M8H7"3&H,+.99Z$'@PQHJ%&9B*(J2A3SF[@ \P\8M]!=@[@_ ?[Q&@/FY!?J#
MJ_680H&6F\R0R1FU>?%F_P[)I6JI=<",OS%D7S]CS!"G=)_X$U;RCXG[I$9G
M)H8Q'Y/AC3I,&.[4UX)S_V3)_P)02P,$%     @ K(-94%U4XIZ" @  E@D
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M+\?9&0TM>O\LX.EM*OX!4$L#!!0    ( *R#65 'SO'@6@,  *0.   9
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M.0(FQUSPS3P-!8Z_>"*;$H>.HV1BD<\*C0Z.V4&D,B.FA:%09K.]T!3B^9Q
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M.FC52<DXQ5*9O$*BXX +0Z($!9ZW0Q0WK9O&QG?B:<QZ29H63MP1/:68_\N
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MB9SC2 G7_\[QR@6M#(N44J&W[EG6^MD:_GN8/< W 7X? ,-W P(3$#P:$)J
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M6O]9\UQ<ERYQ;QU/V?$D=8>W6E3ID7_G\D?U6*N6-[#LLX*7329*I^:'I?M
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MW:&^:TA1]1<6;[@UK?X"4$L#!!0    ( *R#65!'L$6#@0,  '$1   9
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M,:=L!$B;K*I6:J5HJ[;7#@P!K8VI[83MV]<V!'%2;[ ]_///-\8XZ;AXEQ6
M<CX8;63J5DJU!X1D7@$C\HFWT.@W)1>,*+T45R1; :2P28PB['D18J1NW"RQ
ML;/($GY3M&[@+!QY8XR(OT>@O$O=G?L(O-772ID RI*67.$'J)_M6>@5&EV*
MFD$C:]XX LK4?=D=3I'16\&O&CHYF3NFDPOG[V;QM4A=SP !A5P9!Z*'.YR
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M"#GY$UT6P36,@"*F@>U$0*=@P@DN=A0!3E8E/1E0/\&M)FI>93=QPY#@]H&
M_F$OZ-* AKWR6LG!?00!C822"0FX0:#D_GZ)X<+'0.%3Z_V^,J#AN^Q:/\-P
M]6.@^NV.MC*@OAGLY?6V76KS_RVM#UG9.*]<R!V<WF?M.1=,BOH/,F&/\GNC
MN\C97JC36)[7[::[O1"\,A\47O=5L_@'4$L#!!0    ( *R#65!!^440? (
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MQ#8"9"(1)YB:1USAQ):XI895!PH'+CCU"@-<Y&"+G/&1&0=<O4#>OVA@Y/L
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MCCK-W4DCKS33:\W]4"/.BLAF<$Y#HC3N) @QZX48:N2UX@%X$3%.@^!LD'/
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MY5MH@Q$DG(3LQ\NK26CL@*$#[AWPE0/C9&&PT;W-8<B"EJPHP4 * BD E#A
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M/!3\(/5KK-Z;?NWK#U+4PTKKCWOUZC]02P,$%     @ K(-94%,&(4K^ 0
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M>3HU>E[%4;#PSCK1P*Q[ADX8,A*>RCZ6H%B)-07A=%Y@ XDHGB,91 BAN$6
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M-"1[(217AOZ].DZ.JJD='TJ^E_HV5O=MW]GU#U(T0]?JC:WSZC]02P,$%
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M(8!0GT)XIA"9MZ)[RP#[-2*$2TB^AKBN9W;A&Q/UE8"_2/2#- *C0* $@H6
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M[.4\CK.AQ;"\-&1][HI_4$L#!!0    ( *R#65 ][40^\@$  -L$   9
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;'U4VXZ;,!#]%<0'K+EXDS0"I$VB
MJI5:*=JJVV<'AHO6QM1VPO;O:QLO2P#M"_:,SSESP>.DY^)5U@#*>V.TE:E?
M*]7M$9)Y#8S(!]Y!JT]*+AA1VA05DIT 4E@2HR@*@@UBI&G]++&^L\@2?E6T
M:>$L/'EEC(A_!Z"\3_W0?W<\-U6MC -E24<J^ 7J=W<6VD*C2M$P:&7#6T]
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M5OXHV'VYO,<I008H<](TV0##6C4R1PZG/S0 MDASP+ FA- 41:2_ )RCYS(
M#NJ6**\"NSS41$N8]2H$D'24Z%M 0]D>;0#[.F!..DNU+^_2\A"B;7"O-@E0
MBOMT9?&C@1<LAXRNU$DH:FJ(4#Q%\TTYX*IUPGIG@">JS(YA/<Y(S=8-@#Z>
M(7S8(:Q(I$(<4@.&.=#:J$3;Y,!X;&9%QKD2$-\A.R7G)LLB2W?=$5[D;&0A
ML$QVY'W$H[Q_A%$EJC;SMV& T8_+=%<_<7<9/N[9I;_4(DQ5 1_Q_)_DDWM1
M\4C 8NZDIA C @*'@;,L@$GL0 -!#@Q74M&Q+=\0+&A2149 ?X)O@A;71Y)[
M6$YRO U!RT+1>E\BA.(N00@W"TNOT(:[NK@COSZ=,9Y2X^X5S 9/N'V[35+C
MSM43Y)$8: IYDQDK*%29F:'#O_0SH#Y2'24M$9PK*<  WV13%0&<'(A@I?>@
M"3<A41%K/! T6&>.UD#,@W,+Y#8^?=H]'ND^V\!]W9&B"J)^(A[A9X /&S(3
M9/FO^_+PS(G@%TYO8(:FUV<IMEA I@(-W$K++"JAX*SQI#DQN"UN85M\0N8%
M#V$,M>P^TP&0O.*E YS:5_>BWB>(>U61 YM)LA+OPP4]K:(_4F$D$GQ?Z:MB
M#7<ZN@>)^Z(N+@ <L'C&-@ 5AI9L@#B]RA] 0/$7J'EK]/>N2^,!#@M$WKK@
MNT_'Z*__(JWY>-84GEXCK.AQMGN(*1X>@8M4DPEM;W0*%MK>OH0/K?TB20C(
M+)^RPI-E(3TO0"R8@^2P?861\,&<NSS= SO($IKOES?O@;=$J.)@R(SLCU?
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M4;SG:-U$CNCO'8K2_F@#\=+R5Z_F$VF%)3C(<_ ];LJ^0/?F >\8RGH5IH<
MA# GM^#' *,)6[.UE29!"\;TCG35K6\F.]@KDBCB"(YY;$'HRI"B%3N,8<:
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M1*Q7%J*WH$M&0MO,"2H5#4DEAOU6ZX.GV3Y0L*'D$ZE5ZRD+AZER:GHSI[D
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MT2ZRH?M3.IRY4/<N@4Z,#@TB$7@52N!#J^(QE[!"KFD7&D6ZC2%OY%DG$SD
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M3@1O.W>9,F<.)E5 X,^?O;E]5V$+,PQR0FEGSVU1&D_]3$]9UXMA!ZK1.UC
M)87G:7HJF;8(>A$[[4JWA_*SWC._T<?[PLL@QA#N7H,3P&5U,RD)QS@V[1&H
M8G2H]#,(Q^%82JE,S:8SWSVWE<- ;\6<!.4[D/2+.R[*V-68E.J;8=\I0#:
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M54(U7ND\3D<K UF/*(=.-"'2$,J+$HQ"A!74&$61#K0XHD^N Z4NF%(C.-U
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MU$0NM L>8J&U1P7;;-182PX5_>[NF2:\LWZ)*C("V(47>&$!0TI2K!7)C%\
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ML9B8?&I9N9)G".O@(L(]3?)/V,]IZ;@Y%9GTF>]D'*62>6J H)!I,A5*;G5
M.;$"BLJ/?N=(/!;I?;)9ZSY,A3D^4>0A1;O;K$^+H=AW@!YFGFZS?]"%5H8'
M))[%9U3 @9US6GOJ1)%33S=(_Q6'28L/>E]2QC3)M&-V%)NLHD#+'FF1K8MJ
M"H8ATC_Q<X.MK0*F=38?3LCN9_.6?1-4%9V.U)5JQ]$$:=9T81$8JS)Y%$GT
M'C.GR#%&&)1ISAD?G#EX-H%$&8C$#P47;"#+#+R[2>M:L(<)+@U*122EUZ$B
MQ,;6"O?LZ18DQOOH%H9_C8(!]AMR(?TMB-]@EW?QJ#5^BSYO-]]1FL"_/ML)
M67@6O!#&67,E=,V?I\9H+&]C>7DKKG)C^56'_@;"(AN'6?#!7!U7MI2,\??J
MGA6BIM:DRCX)4LA"+/K*Z]MSB^B;F,;R5@]P?,W=/M]?7N@!#<DC,CP&T0\=
M2Y"@T&"]BX/)830C1%L &6= )\YT8/.PVL_&S:W%O7!EE49<,JSW9*7Q5QB5
MT"K3=LX5A^-$:,$,$C*ZM&SM<+(T?1Q"K5.[VK#&:*M2N![;[<10M.DTCS,S
MSB98N<:: N_T5H-P,M_IL6(YBD.:\:D\-<;A;KQJP=(N,^\&&Q/!+?$W?HG;
M$;I.#BW+@C0.MX;G0%V65< I/."YFXZR*-%1RRH?*&%6Z!9.%9M*=!/#8;5)
M@UR!#UZTPSW<!(K]RV*_J-%><6-OS/NRP!!]H$*;EJ;61U=^I]E:^P@B;%^I
M_>2TI_K"<ZD%![?&3&H2O5F*LU6G5JGI(4#BC.E;2NJ>_SFK?/:'IPSH $+V
M?+')4*,4VJ WP^=1-RU&GN#%DKG#=5\TVM[Y+7V/HD'T%KD)RBD8>H9EVCSO
MEX5_P=JT3IAZC=I+7:?!2J,.(8?XVR#Z*:',5@[BI3NT U3FE0%^EW>L:JB;
M.O'W673)8#LYLH^:I#?=GO1FY:">OZ*KR#3PY*+I*Y>K^8BU,5=9A=%Y2*AC
MD>FD&G,_ M!86RI_YV1];=Y>W:>IO$_I47I][Q).(R7E+W-9%JDKPO*E=5?D
M-2$O',L,NVY>AM=8?RL5,^(;;QJ\(;A\V=-1\'/+SFB5F?:/GE]S^35\JHL>
M-_1+15CRYAV;_$1\!LK9?]MF5#]ZY@( 7!ZTMY5_4[GWG<8BM4YP!M:>9![-
M<G51%%J(3$^+JHX3O:-;1,ZPA%*_\>\0$&@>41/J$Z"@_)@M7BU.A,5[P)9+
MQ,# ZJFNOI2RVZ2FGI-V/9]9I"CI\[Z:^3W-:!,_\Q<YZEW.7Q,I?]1T$_V
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M"_@C "7%CU<O%%$H"^R#) JEMR'81/%^^C"*@C?28$61.X/=$%@82TM6:$V
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M]?V24V*/U!>G$"2G%@ 7YE5DW;VH^OY8>CX$9GHO.!O_< TZ"MYXP(%/OI/
M6TSND ^T&!R_*(ABZM#+I!->")NZ$O>H.KDH ]^)G>4OFUUSR'O+?0^?U1(7
M*>XIC4="0AR[:3Q]T&'$E.6')>TI;<))A,$GH#GX$.K9A+>!J9UJ!.K$1.+G
M-8A: NNQQSE,BN_:SYLQ:)5]*)C[<GIZ5VA8@D]LLOM2=&+OL _<19HTK^UW
MG@_/?^F==!R!\MA!6=2PE'NC%*;9:XQ-IKS,@)\W'\>05JE.P22(C7Y[L3-'
M)&)EG2P):5-QUO.W$-0?#\#];8/FCMO-5Z(=M0@00;/YBM&,T00MGB(M8Z2Z
M6 HR2I_,M2D>1*A ZM*H8_VZ!ADJI@V5C;DRVA=OY% Q&ZN9-I:J@N6.YPE$
M5BL> :QO;1VQ\8GA)_^!4Y!C?1''9TINME:H+ Q4:@]QYPAYCS;P8<,X:!6'
M'+0HL5M&70=PHU$FV,<L>,RZ3+G.H0<9(59)CK"FU)X!NM6]P12ZN5%2B:)R
M)<>!1[+!=Z[:#@*,L9CP2"YZ3V)9]V"FEUJ]?33>]^*;/E:R_T6(R5(W87;9
MJC79J8E\_;Q!Q"](EE?K]*550A@6*3(8@U$WG2'3&@L;?^%89\*E!S4]%HM>
M1+.7^&[0![F&M%T21(DY/7"%DT<B6 *19U=G-XW>]Z<;F!E$3?*#C#*P0^%O
MEW7MMT1:2S@C)N5_E@FE*8P3?JZ0<B"=TG2JN!GBLL)9AYX_ZM[,$^I7CCJW
MUX[A@_'+.94X]"CK].<L?O)4*P6HY6!U3L&@TP(JBP[!08",:,K%M.@CMAC8
M$9[,W+.=[>%)@6RB<QC &]>;>%"6R;,]8'!D0#MP<(,;9SO9H<TGI,P3C2'^
M 5UD>X3.[T E2..)!_XG>^D:V'D+\MW#;PP0]UZ>I'4C$=0;6MVYW.W.1>\9
M!FU@(;]['A)=8"'#]>7P#OJ!MQ^O21=U^T'M!DF7>G$@S#SD#0,7?G\:HD,.
M^Q]WMVQ EN.0W=O?S/=LY -;/V1/]W<1;.\[D[RFTTE 6GC57J6V.KPG*=%V
M.M4W^'0%TG#D0@T>+*(//G"1 Z^2[F^B^RNJX?T-7/;D)&VGRVBGMMS"J2GM
M\%M,U]*4*_;WSR#+/XT8PZ,;E6?\IW1MAQY6)1_93_D'E6#HZ?6WO4]XO.8!
M%U+R_C\DT/#@2]_P!@U6[%IP]/4N16?'TO?IH/TX]2J:!*CV38S%IQF:'G0<
M;/J1QK1)BR!OPT?VFB79!#-L< "YZY75B2/^D$5X /SVWAT5IR&U_G%231$P
M@GU+<CT$HEP;9S8 L,OIUA$6;.+/XC_K5@(CES2X6!-$=J'^N!5- D!Y TEQ
M43O#,FYGZ+,:1Z#Y'^"I2FHD&HJZ;Q,=[,:#WV;%'$N$DV9^M[>]H+!W"H&
MG9U9L4=H.!E84N//KZ/1 QZ?9]>;K_JZW&(J9[\I$"M6!.2$=0J";WO[_:Q^
M.ZCC,M8%5<J(?!MY-H%7?_ 23&,K$.T1BF8,'\:A*X)5.@+3 Q2*")\LPW F
M+#41V\E(4!;5GXA,KXKT-9U'OEPN8J,*O\1B!N%8H:9!\"T5/ B>Q;H'D=DN
MPW%-8\U"R8((=M-\%IG!+#;7*GP22QZD_!]_)-EN3_6>_D(.*=4C94,<,I3>
MXBP).(LRT9_62E:&B<:5$CNNA]S+#UI8/;0BKC0.:;MWI?RI!U2]YW<[@,.J
MJ=QO-ZT:Z/UN<UOO/E,&ZEF]W:TA/^+PZ_T=U5H C]/&B;Y'R]S[9V<_=E*[
M(3>Z006^I.#P4-P513T.T2[\AF3 1E!%]VS;(,3Y)LQ&.PTK9HQTT8G(L^2+
M&VF([*-4=8;Z4PWQ4S&\^0/$)L2.%T#6G"D0ROWIX@*]<E8??/I+JL 1J ![
MBAG$=%Z.L9+/A>)I)#:9RH+\D3VKKUOUWKJM4T^\Q9H"&.4K:Z"H W*[B61J
M>%0'8[1((0.([=T_O++,D$(K\<7IJZH2T^_VEE2):Q9[*ZI$1/:PF$IDHV+U
M5-)$%J9']151"?;UP.HI>^C*P-7!RXGLMX< 6X0U1D("[2\;$FS\_D(@/4S'
MK0$2J$5!\8_0BI:H_!$8OO9O8:+(1^\BR@H?X=412T</-WYOJ8]@BTQYCP'+
MT9-]U5?(8]^S>SGC![7"6T6?:^*1&\*;B%+M ![YB,4]#JN=$5_A0TIFI/;H
M>ULXH$2&W\">*AD'K)A3'"-BD/0JVF\Y5)BR,$U-VL%[Y]&8_3-[\:V^"1!_
M>B4V\_RPIQ)SK.*Z3#69CGX_(D_YX7R:A?4M 4VV'^^,I1,M\!&1_<!Z(X]C
M<B\3$: _==WN7_\;4$L#!!0    ( *R#65!=_0/W6 (  & ,   -    >&PO
M<W1Y;&5S+GAM;-676VO;,!3'OXI0QFAAQ)<L:;O:AJU0&*RCT#SLK2BV; MT
M\60Y2_KI)UF^Q2/=FG4C>8G/1>=_?K*42 E*M:7X(<=8@0VCO QAKE3QP7'*
M.,<,E5-18*XSJ9 ,*>W*S"D+B5%2FB)&'=]U%PY#A,,HX!6[9:H$L:BX"N&\
M"P%;?R,2',+'L[??*Z&NWP#[G+R;3-RI^WA^/<Z<-:ES"*S.YR2$WN(]=/Y<
M>*_L2'3^$M&IZS['ZX[%%R\4?TY[)'VQ1WK(N9?KTA0[S;)%02IXOWHS: -:
M'3$,UHB&\ 91LI+$5*6($;JU8=\$8D&%!$IO&]W=,Y'RR:8]ZYD=U>@PPH6L
M>]L.]G/5#!\E6L\ $DH[0!_:0!042"DL^:UVZL%U\)<4:.SEMM"$F41;SY_#
MOJ!^Z"8K(1,LNS8>;$-10'%J<"3)<O-4HG!,4BG!M)$0E F.:H:VHC&T;(PI
M?3!?MV_ICO8F!7:,61(7 D/1FGK6C=FOFELC#]6L]E#6/T@7%&0MU*=*3X?7
MOMEX^%[BE&QJ?Y-V %H=%07=?J0DXPS;R?RVH7=@PRA ;1^0"TF>M)[9*K$.
M8 G!&DM%XF'DAT3%$F]4NYTVZ:',_@DRO_9[SC#'$M$AM-[[Q_R6_S.Q.93^
MFKG^61D3OR+D[.+X&<U!? *0BU. /(GEOCQ^R-G5/V9TFO-[<$G8N2)T4;"J
M"%6$-[0Y21)L><P=+81?S060[AS4_4U!RRNTTM?]'7U=F^ 4553=FRG6R1#V
M]A<#[BVZ4<M.(H2]?8<34K&KNF'_GR+Z"5!+ P04    " "L@UE0H1:/WU0%
M   3+0  #P   'AL+W=O<FMB;V]K+GAM;,6:6U/C-A2 _XHF+V4?:!+?8!E@
MAB5+R\QV21O*:T>QE42#+:62#(1?WV.'RS&8,WTYY"F1;,N?95O?.9*/[ZV[
MG5M[*QZJTOB3P2J$]=%PZ/.5JJ3_U:Z5@2T+ZRH9H.B60[]V2A9^I52HRF$T
M&F7#2FHS.#U^;FOJAKA@@\J#M@8JFXH;K>[]Z_:F*"3L<*>NY?QD,!H(60=[
MH<N@W$0&]9NS]5J;Y<E@/! +[7R8->=N]ZRTT95^5$5;\BM[_[MU^M&:(,M9
M[FQ9MD<U&]J#X S^I>9&N:#SSHY!SO^2P'HRR$;0X)WV>JY+'38G@_9_J09P
M%4-T&6T_//]N._'(_9]NM(N%SM7$YG6E3-CVHU-E<W;C5WKM!\+(2IT,SNV=
M<F(JEZK!AK-<%MM+"- YKUS"'6G8X"Z+<</(R6.\+74!9R_$-UE*DRO1]JY'
M@!$!&.T,4.Q-)8*,"<CX$R%G#41S@!=V(:[6RB'(A(!,=@8Y"S9'D"D!F>X0
M\I\(068$9+8SR'/I5PCR@( \X(6\<DMI]&.[04A3B(GRN=/KMFP7"/*0@#SD
MA9S5527=IKV]>FDT'"9-$&=Y;FL3-(+\2D!^Y87\">W^L-Z+*0S=LY5TG;%[
M1 W>(UZR;[771@'9N:WFVK0[8#92+,QFZ8S5#>#:FN8MP7R45\;,8KF0VHD;
M6=9*_*&DK]WV)<9XE%'&[$JI*AVVXTKS]L*8$R!N4B;7J@-)&67,K)2)F@?,
M0HECS&R.QF&W*UL6ROE?Q/=_:PCT,!OEBS&S,%HV<0FO@VE"8S&%5Z-S$RE/
MC)E%<;W:.*OA"=L$NY8!NM N-Q"BNF"@*S$E)8HQLRF@\VREQ+5\Z#[^E!?&
MS&)(1N.]VR_MW<3!,F6$B-D(,U5"?@9AR9\UW$#ERHVX #' J"%+,<'A<D3)
M(6*6 ^G]3I@7D;D'LR-HS!AC4JZ(F%WQ/D 1>Y <E\I_P8B4*2)F4_1%*KV0
ME$(B9H5\%+(\@6),RB81>_I!A 9B#V-27HF8O=($![VWF-)(Q)UP]$0)O9"4
M5R)FK_2&"WV4,:6:F%DUV,B]<)1@8F[!4![L"":F!!,S"X9,TKN8Y/06LV!H
M#R88DY),S"P9&C/%F)1F8NY,A<3,,":EF9@[:2$Q#S FI9F863,TYB'&I,03
M,XNG+T:;J"!UV1TT*>_$S-[I#])Z*!/*.\D.)KW$OIA!TT7=B=(2RD )]_P7
MA=D9VA/*0 FS@3[ G#HKFO8P)F6@A-E 'X;F+>H:8Y)++-QISL>8$'[@^>R$
M,E"RJT1G7YP510>3,E#";""J-^M08TS*0 FS@:C>S//.ZA]EH(390!],>#\/
M\!B3DE#"+"$ZN]W'RY24A5)F"[79[3XH76X#]YG*:]<DDV=+IQ0>-U/*0BFS
MA9XPG^781$D8&6-2%DJ9+?2$>>Y4H<-3%\(1/<]F2EDH9;;0$^:E@8Q2^2"^
M/T!C7O5A4A9*N?.@WDF.GC@N)5?Z/V/!YMTLQ[[8UE]A3$I"Z2[6;MJA'8H:
M+W^EE(12[C3H(TSP.>R,,2D)I9\Q__8.\Z468U(22G<R _?T;.[/\6<HE(0R
M9@G12W<"8U(2RI@EU)DI?'DDC2RAAZ%!C$E)*&.6T!M,^&URBX:C38,Q)B6A
MC%E";S G:J$<>+/E/?-X<32C))0Q2^@-YM_P+CD0D-GV*QZ0,LI"&;.%WF"^
M%D'NLL*I4$9^<<9L(;34W&ORC')/QNT><K(=+Y-FE'NRUCW#=F=_>ERHA3:J
M^ FG\%"?RS*?.M'\;+\=2M)F\7]1E^4YU%T9B&N;^K:-Y^^13_\#4$L#!!0
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M[?!=D@?G-N_SV?07P:O_4$L! A0#%     @ K(-94!\CSP/     $P(   L
M             ( !     %]R96QS+RYR96QS4$L! A0#%     @ K(-94"?H
MAPZ"    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    " "L@UE0Y&'&6.X    K @  $0              @ &9 0
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "L@UE0F5R<(Q &  "<)P
M$P              @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( *R#65"+2TAF@0,  (T1   8              "  ?<(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "L@UE0)9[C01L$  #($P
M&               @ &N#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ K(-94",0K\X_ @  O <  !@              ( !_Q   'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *R#65#5W>S_#P0
M *\2   8              "  703  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "L@UE0];^@*CP%  "0&P  &               @ &Y
M%P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ K(-94& 7
M'\;= 0  9 0  !@              ( !*QT  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( *R#65 9#C5%VP4  *0?   8
M  "  3X?  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "L
M@UE03%H_:; !  #2 P  &               @ %/)0  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ K(-94+I<KM"U 0  T@,  !@
M         ( !-2<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( *R#65"J%".@M0$  -(#   9              "  2 I  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ K(-94(1C%N:S 0  T@,
M !D              ( !#"L  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "L@UE0SK.X;K4!  #2 P  &0              @ 'V+
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *R#65 M>9=D
MM0$  -(#   9              "  >(N  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ K(-94"4#+&"S 0  T@,  !D
M ( !SC   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "L
M@UE0L4KFWK4!  #2 P  &0              @ &X,@  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( *R#65 W=W]$M0$  -(#   9
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M970R,"YX;6Q02P$"% ,4    " "L@UE0>DH0T+,!  #2 P  &0
M    @ $]/@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M *R#65 4O="5E (  $,*   9              "  2=   !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ K(-94&*I;QGX 0  I 4  !D
M             ( !\D(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "L@UE0'9(?;+0!  #2 P  &0              @ $A10  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *R#65"WD'8KTP$
M )P$   9              "  0Q'  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ K(-94 YAI,/B 0   04  !D              ( !
M%DD  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "L@UE0
M<?G"&;,!  #2 P  &0              @ $O2P  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( *R#65"9BAPDQ@$  #<$   9
M      "  1E-  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ K(-94&P$;'>V 0  T@,  !D              ( !%D\  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "L@UE0B#1Z'"H"  " !P
M&0              @ $#40  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( *R#65#4(A+.SP$  )P$   9              "  613  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ K(-94+%Y50RW
M 0  T@,  !D              ( !:E4  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " "L@UE0E'X3W+D!  #2 P  &0
M@ %85P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( *R#
M65!"%!&$\@(  /,+   9              "  4A9  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ K(-94-X3MDG; @  6PP  !D
M         ( !<5P  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " "L@UE0::BN"[H%  #$(0  &0              @ &#7P  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *R#65"_Y?YL00,  ,H.
M   9              "  71E  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ K(-94+F#YC0O @  #P<  !D              ( ![&@
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "L@UE0 3#/
MK8D"  "="   &0              @ %2:P  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( *R#65!6OWB6> (  +X(   9
M  "  1)N  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MK(-94%U4XIZ" @  E@D  !D              ( !P7   'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " "L@UE0ABZG!_4!  !;!@  &0
M            @ %Z<P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( *R#65#>-U&UYP$  *<$   9              "  :9U  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ K(-94 ?.\>!: P
MI X  !D              ( !Q'<  'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " "L@UE0&BR37;X#  "P$@  &0              @ %5
M>P  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *R#65!
M2_?JZ@$  -L$   9              "  4I_  !X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ K(-94%8(\A4- @  .08  !D
M     ( !:X$  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *R#65#%U)UU^0$  &T%   9              "
M 8:/  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ K(-9
M4*3)EY,. P  X0P  !D              ( !MI$  'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " "L@UE00?E%$'P"   W"   &0
M        @ '[E   >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( *R#65#F8)"K;@,   8/   9              "  :Z7  !X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ K(-94$!#(,^Y P  B!,
M !D              ( !4YL  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " "L@UE0DZ95>&\$   M%@  &0              @ %#GP
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( *R#65#,(PXJ
M]0(  &,+   9              "  >FC  !X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ K(-94%,&(4K^ 0  AP4  !D
M ( !%:<  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " "L
M@UE06WC?1.$$  !-'   &0              @ %*J0  >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( *R#65#C]:AD]0$  !L%   9
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M970V-2YX;6Q02P$"% ,4    " "L@UE0@B[$#^(!  #Z!   &0
M    @ $VO0  >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M *R#65 ][40^\@$  -L$   9              "  4^_  !X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ K(-94-7 ? V5 P  R@X  !D
M             ( !>,$  'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " "L@UE0D!;$L;VH  "RD@( %               @ %$Q0  >&PO
M<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "L@UE07?T#]U@"  !@#
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:+GAM;%!+!08     30!-  T5  #>>@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802038720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,825</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,615</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Software, including software developed for internal use</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,435</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>726</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,013</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,080</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,006</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,940</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of finite-lived intangible assets</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-live intangible assets consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Amortization Period (Years)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percepta product technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,067</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna product technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prosigna customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">nCounter FLEX Dx license</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(263</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,617</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LymphMark product technology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>978</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,420</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,019</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.5</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated future aggregate amortization expense as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,094</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,094</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,094</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,588</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,019</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
